Accession_No PMID Target HSP_Name Organism Localization Enzymatic_activity Cellular_activity compound_Name IUPAC_Name SMILES Class Enzymatic_Inhibition Kd Ki IC50 EC50 DC50 RD_Index GI50 Site_of_Interaction Type_of_Enzymatic_Assay Percentage_Cell_ Cellular_assay HSP_client_protein_assay CC50 MIC_MBC Celllines Disease HSPMDB000001 16982771 Hsp70 GRP78 Human Endoplasmic Reticulum Inhibition of ATPase activity Sensitizes human breast cancer cells to etoposide (-)-Epigallocatechin Gallate (EGCG) [(2~{R},3~{R})-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2~{H}-chromen-3-yl] 3,4,5-trihydroxybenzoate C1C(C(OC2=CC(=CC(=C21)O)O)C3=CC(=C(C(=C3)O)O)O)OC(=O)C4=CC(=C(C(=C4)O)O)O Polyphenol 61% inhibition at 10 uM 0.7 NA NA NA NA NA NA Nucleotide binding domain ATPase assay NA FACS NA NA NA MDA-MB-231 and 47D Cancer HSPMDB000002 16982771 Hsp70 GRP78 Human Endoplasmic Reticulum Inhibition of ATPase activity NA (-)-epicatechin (EC) (2~{R},3~{R})-2-(3,4-dihydroxyphenyl)-3,4-dihydro-2~{H}-chromene-3,5,7-triol C1C(C(OC2=CC(=CC(=C21)O)O)C3=CC(=C(C=C3)O)O)O Polyphenol 38% inhibition at 10 uM NA NA NA NA NA NA NA Nucleotide binding domain ATPase assay NA NA NA NA NA NA Cancer HSPMDB000003 16982771 Hsp70 GRP78 Human Endoplasmic Reticulum Inhibition of ATPase activity NA (-)-epicatechin-3-gallate (ECG) [(2~{R},3~{R})-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3,4-dihydro-2~{H}-chromen-3-yl] 3,4,5-trihydroxybenzoate C1C(C(OC2=CC(=CC(=C21)O)O)C3=CC(=C(C=C3)O)O)OC(=O)C4=CC(=C(C(=C4)O)O)O Polyphenol 64% inhibition at 10 uM NA NA NA NA NA NA NA Nucleotide binding domain ATPase assay NA NA NA NA NA NA Cancer HSPMDB000004 16982771 Hsp70 GRP78 Human Endoplasmic Reticulum Inhibition of ATPase activity NA (-)-epigallocatechin (EGC) (2~{R},3~{R})-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2~{H}-chromene-3,5,7-triol C1C(C(OC2=CC(=CC(=C21)O)O)C3=CC(=C(C(=C3)O)O)O)O Polyphenol 58% inhibition at 10 uM NA NA NA NA NA NA NA Nucleotide binding domain ATPase assay NA NA NA NA NA NA Cancer HSPMDB000005 19793966 Hsp70 Hsc70/ DnaJ Human Cytosol and nucleus Inhibition of ATPase activity Decreases total tau levels in cells overexpressing human tau protein Methylene blue (MB) [7-(dimethylamino)phenothiazin-3-ylidene]-dimethylazanium;chloride CN(C)C1=CC2=C(C=C1)N=C3C=CC(=[N+](C)C)C=C3S2.[Cl-] Dihydropyrimidine derivative > 80% NA NA 83 NA NA NA NA NA ATPase assay NA NA NA NA NA HeLa Alzheimers disease HSPMDB000006 19793966 Hsp70 Hsc70/ DnaJ Human Cytosol and nucleus Inhibition of ATPase activity Decreases total tau levels in cells overexpressing human tau protein Azure C (AC) 7-methyliminophenothiazin-10-ium-3-amine;chloride CN=C1C=CC2=[NH+]C3=C(C=C(C=C3)N)SC2=C1.[Cl-] Dihydropyrimidine derivative > 80% NA NA 11 NA NA NA NA NA ATPase assay NA NA NA NA NA HeLa Alzheimers disease HSPMDB000007 19793966 Hsp70 Hsc70/ DnaJ Human Cytosol and nucleus Inhibition of ATPase activity NA Myricetin (MY) 3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)chromen-4-one C1=C(C=C(C(=C1O)O)O)C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O Dihydropyrimidine derivative > 80% NA NA 12 NA NA NA NA NA ATPase assay NA NA NA NA NA NA Alzheimers disease HSPMDB000008 19793966 Hsp70 Hsc70/ DnaJ Human Cytosol and nucleus Activation of ATPase activity Increases total tau levels in cells overexpressing human tau protein 115-7c 4-{5-[(benzyloxy)carbonyl]-4-(2,4-dichlorophenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-1-yl}butanoic acid CC1=C(C(NC(=O)N1CCCC(O)=O)C1=C(Cl)C=C(Cl)C=C1)C(=O)OCC1=CC=CC=C1 Dihydropyrimidine derivative 45% NA NA NA 120 to 150 NA NA NA NA ATPase assay NA NA NA NA NA HeLa Alzheimers disease HSPMDB000009 19793966 Hsp70 Hsc70/ DnaJ Human Cytosol and nucleus Activation of ATPase activity Increases total tau levels in cells overexpressing human tau protein SW02 ethyl 6-(4-bromophenyl)-3-(4-methoxy-4-oxobutyl)-4-methyl-2-oxo-1,6-dihydropyrimidine-5-carboxylate CCOC(=O)C1=C(N(C(=O)NC1C2=CC=C(C=C2)Br)CCCC(=O)OC)C Dihydropyrimidine derivative 45% NA NA NA 120 to 150 NA NA NA NA ATPase assay NA NA NA NA NA HeLa Alzheimers disease HSPMDB000010 17904512 Hsp70 DnaK/DnaJ/GrpE Bacteria Cytosol and membrane Inhibition of ATPase activity NA 116-2F methyl 4-(naphthalen-2-yl)-2-oxo-6-(phenoxymethyl)-1,2,3,4-tetrahydropyrimidine-5-carboxylate COC(=O)C1=C(COC2=CC=CC=C2)NC(=O)NC1C1=CC2=C(C=CC=C2)C=C1 Dihydropyrimidine derivative NA NA NA Between 120 and 200 NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000011 17904512 Hsp70 DnaK/DnaJ/GrpE Bacteria Cytosol and membrane Inhibition of ATPase activity NA 116-4G 6-{5-[(benzyloxy)carbonyl]-4-(4-cyclohexylphenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-1-yl}hexanoic acid CC1=C(C(NC(=O)N1CCCCCC(O)=O)C1=CC=C(C=C1)C1CCCCC1)C(=O)OCC1=CC=CC=C1 Dihydropyrimidine derivative NA NA NA Between 120 and 201 NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000012 17904512 Hsp70 DnaK/DnaJ/GrpE Bacteria Cytosol and membrane Inhibition of ATPase activity NA 116-7G 5-[(6-{5-[(benzyloxy)carbonyl]-4-{[1,1'-biphenyl]-4-yl}-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-1-yl}-N-hexylhexanamido)({[(1E)-butylidene]carbamoyl})methyl]-2-(carboxymethoxy)benzoic acid CCCCCCN(C(C(=O)\N=C\CCC)C1=CC=C(OCC(O)=O)C(=C1)C(O)=O)C(=O)CCCCCN1C(=O)NC(C2=CC=C(C=C2)C2=CC=CC=C2)C(C(=O)OCC2=CC=CC=C2)=C1C Dihydropyrimidine derivative NA NA NA Between 120 and 202 NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000013 17904512 Hsp70 DnaK/DnaJ/GrpE Bacteria Cytosol and membrane Inhibition of ATPase activity NA 116-9e 6-{5-[(benzyloxy)carbonyl]-4-{[1,1'-biphenyl]-4-yl}-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-1-yl}hexanoic acid CC1=C(C(NC(=O)N1CCCCCC(O)=O)C1=CC=C(C=C1)C1=CC=CC=C1)C(=O)OCC1=CC=CC=C1 Dihydropyrimidine derivative NA NA NA Between 120 and 203 NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000014 27155465 Hsp70 DnaK/DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Az 4-[[2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)imidazol-1-yl]methyl]benzamide COC1=CC=C(C=C1)C2=C(N(C(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)CC4=CC=C(C=C4)C(=O)N)C5=CC=C(C=C5)OC Imidazole derivative 53.04% (at 200 uM) NA NA NA NA NA NA NA Nucleotide binding domain ATPase assay NA NA NA NA NA NA NA HSPMDB000015 27155465 Hsp70 DnaK/DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA VER-155008 4-[[(2R,3S,4R,5R)-5-[6-amino-8-[(3,4-dichlorophenyl)methylamino]purin-9-yl]-3,4-dihydroxyoxolan-2-yl]methoxymethyl]benzonitrile C1=CC(=CC=C1COCC2C(C(C(O2)N3C4=C(C(=NC=N4)N)N=C3NCC5=CC(=C(C=C5)Cl)Cl)O)O)C#N Dibenzyl-8-aminoadenosine analogue 43.03% (at 200 uM) NA NA NA NA NA NA NA Nucleotide binding domain ATPase assay NA NA NA NA NA NA NA HSPMDB000016 27155465 Hsp70 DnaK/DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA 370 (E)-N-(3-methyl-1-(3-phenylthioureido)butyl)-3-(3,4,5-trimethoxyphenyl) acrylamide COc1cc(/C=C/C(=O)NC(CC(C)C)NC(=S)Nc2ccccc2)cc(OC)c1OC N,N'-disubstituted thiourea derivative 50.42% (at 200 uM) NA NA NA NA NA NA NA Nucleotide binding domain ATPase assay NA NA NA NA NA NA NA HSPMDB000017 27155465 Hsp70 DnaK/DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA 371 (E)-N-(3-methyl-1-(3-pyridin-3-ylthioureido)butyl)-3-(3,4,5-trimethoxyphenyl) acrylamide COc1cc(/C=C/C(=O)NC(CC(C)C)NC(=S)Nc2cccnc2)cc(OC)c1OC N,N'-disubstituted thiourea derivative 38.46% (at 200 uM) NA NA NA NA NA NA NA Nucleotide binding domain ATPase assay NA NA NA NA NA NA NA HSPMDB000018 27155465 Hsp70 DnaK/DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA 374 (E)-N-(cyclopropyl(3-phenylthioureido)methyl)-3-(3,4,5-trimethoxy-phenyl)acrylamide COc1cc(/C=C/C(=O)NC(NC(=S)Nc2ccccc2)C3CC3)cc(OC)c1OC N,N'-disubstituted thiourea derivative 50.45% (at 200 uM) NA NA NA NA NA NA NA Nucleotide binding domain ATPase assay NA NA NA NA NA NA NA HSPMDB000019 27155465 Hsp70 DnaK/DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA 379 (E)-N-(3,3-dimethyl-1-(3-phenylthioureido)butyl)-3-(3,4,5-trimethoxyphenyl)acrylamide COc1cc(/C=C/C(=O)NC(CC(C)(C)C)NC(=S)Nc2ccccc2)cc(OC)c1OC N,N'-disubstituted thiourea derivative 44.12% (at 200 uM) NA NA NA NA NA NA NA Nucleotide binding domain ATPase assay NA NA NA NA NA NA NA HSPMDB000020 27155465 Hsp70 DnaK/DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA 380 (E)-N-(3,3-dimethyl-1-(3-pyridin-3-ylthioureido)butyl)-3-(3,4,5-trimethoxyphenyl)acrylamide COc1cc(/C=C/C(=O)NC(CC(C)(C)C)NC(=S)Nc2cccnc2)cc(OC)c1OC N,N'-disubstituted thiourea derivative 47.13% (at 200 uM) NA NA NA NA NA NA NA Nucleotide binding domain ATPase assay NA NA NA NA NA NA NA HSPMDB000021 27155465 Hsp70 DnaK/DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA 392 (E)-N-(2,2-dimethyl-1-(3-o-tolylthioureido)propyl)-3-(3,4,5-trimethoxyphenyl)acrylamide COc1cc(/C=C/C(=O)NC(NC(=S)Nc2ccccc2C)C(C)(C)C)cc(OC)c1OC N,N'-disubstituted thiourea derivative 50.5% (at 200 uM) NA NA NA NA NA NA NA Nucleotide binding domain ATPase assay NA NA NA NA NA NA NA HSPMDB000022 27155465 Hsp70 DnaK/DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA 394 N-(3,3-dimethyl-1-(3-o-tolylthioureido)butyl)cinnamamide Cc1ccccc1NC(=S)NC(CC(C)(C)C)NC(=O)C=Cc2ccccc2 N,N'-disubstituted thiourea derivative 40.95% (at 200 uM) NA NA NA NA NA NA NA Nucleotide binding domain ATPase assay NA NA NA NA NA NA NA HSPMDB000023 27155465 Hsp70 DnaK/DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA 397 N-(cyclopropyl(3-o-tolylthioureido)methyl)cinnamamide Cc1ccccc1NC(=S)NC(NC(=O)C=Cc2ccccc2)C3CC3 N,N'-disubstituted thiourea derivative 65.36% (at 200 uM) NA NA NA NA NA NA NA Nucleotide binding domain ATPase assay NA NA NA NA NA NA NA HSPMDB000024 27155465 Hsp70 DnaK/DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA 404 (E)-N-(1-(3-cyclohexylthioureido)-3-methylbutyl)-3-(3,4,5-trimethoxyphenyl)acrylamide COc1cc(/C=C/C(=O)NC(CC(C)C)NC(=S)NC2CCCCC2)cc(OC)c1OC N,N'-disubstituted thiourea derivative 46.23% (at 200 uM) NA NA NA NA NA NA NA Nucleotide binding domain ATPase assay NA NA NA NA NA NA NA HSPMDB000025 27155465 Hsp70 DnaK/DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA 405 (E)-N-(1-(3-cyclohexylthioureido)-2,2-dimethylpropyl)-3-(3,4,5-trimethoxyphenyl)acrylamide COc1cc(/C=C/C(=O)NC(NC(=S)NC2CCCCC2)C(C)(C)C)cc(OC)c1OC N,N'-disubstituted thiourea derivative 35.78% (at 200 uM) NA NA NA NA NA NA NA Nucleotide binding domain ATPase assay NA NA NA NA NA NA NA HSPMDB000026 27155465 Hsp70 DnaK/DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA 407 N-(1-(3-cyclohexylthioureido)-3-methylbutyl)cinnamamide CC(C)CC(NC(=O)C=Cc1ccccc1)NC(=S)NC2CCCCC2 N,N'-disubstituted thiourea derivative 58.37% (at 200 uM) NA NA NA NA NA NA NA Nucleotide binding domain ATPase assay NA NA NA NA NA NA NA HSPMDB000027 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 370 (E)-N-(3-methyl-1-(3-phenylthioureido)butyl)-3-(3,4,5-trimethoxyphenyl) acrylamide COc1cc(/C=C/C(=O)NC(CC(C)C)NC(=S)Nc2ccccc2)cc(OC)c1OC N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 7.3 at 10 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB000028 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 371 (E)-N-(3-methyl-1-(3-pyridin-3-ylthioureido)butyl)-3-(3,4,5-trimethoxyphenyl) acrylamide COc1cc(/C=C/C(=O)NC(CC(C)C)NC(=S)Nc2cccnc2)cc(OC)c1OC N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 9.2 at 10 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB000029 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 372 (E)-N-(2,2-dimethyl-1-(3-phenylthioureido)propyl)-3-(3,4,5-trimethoxyphenyl) acrylamide COc1cc(/C=C/C(=O)NC(NC(=S)Nc2ccccc2)C(C)(C)C)cc(OC)c1OC N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 2.2 at 10 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB000030 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 373 (E)-N-(2,2-dimethyl-1-(3-pyridin-3-ylthioureido)propyl)-3-(3,4,5-trimethoxyphenyl)acrylamide COc1cc(/C=C/C(=O)NC(NC(=S)Nc2cccnc2)C(C)(C)C)cc(OC)c1OC N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 10.3 at 10 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB000031 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 374 (E)-N-(cyclopropyl(3-phenylthioureido)methyl)-3-(3,4,5-trimethoxy-phenyl)acrylamide COc1cc(/C=C/C(=O)NC(NC(=S)Nc2ccccc2)C3CC3)cc(OC)c1OC N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 12.2 at 10 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB000032 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 375 (E)-N-(cyclopropyl(3-pyridin-3-ylthioureido)methyl)-3-(3,4,5-trimethoxyphenyl) acrylamide COc1cc(/C=C/C(=O)NC(NC(=S)Nc2cccnc2)C3CC3)cc(OC)c1OC N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 8.6 at 10 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB000033 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 376 (E)-N-(cyclopropyl(3-pyridin-2-ylthioureido)methyl)-3-(3,4,5-trimethoxyphenyl) acrylamide COc1cc(/C=C/C(=O)NC(NC(=S)Nc2ccccn2)C3CC3)cc(OC)c1OC N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 20.1 at 10 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB000034 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 378 (E)-N-(3-methyl-1-(3-pyridin-2-ylthioureido)butyl)-3-(3,4,5-trimethoxyphenyl)acrylamide COc1cc(/C=C/C(=O)NC(CC(C)C)NC(=S)Nc2ccccn2)cc(OC)c1OC N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 24.9 at 10 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB000035 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 379 (E)-N-(3,3-dimethyl-1-(3-phenylthioureido)butyl)-3-(3,4,5-trimethoxyphenyl)acrylamide COc1cc(/C=C/C(=O)NC(CC(C)(C)C)NC(=S)Nc2ccccc2)cc(OC)c1OC N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 19 at 10 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB000036 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 380 (E)-N-(3,3-dimethyl-1-(3-pyridin-3-ylthioureido)butyl)-3-(3,4,5-trimethoxyphenyl)acrylamide COc1cc(/C=C/C(=O)NC(CC(C)(C)C)NC(=S)Nc2cccnc2)cc(OC)c1OC N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 22.1 at 10 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB000037 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 381 (E)-N-(3,3-dimethyl-1-(3-pyridin-2-ylthioureido)butyl)-3-(3,4,5-trimethoxyphenyl)acrylamide COc1cc(/C=C/C(=O)NC(CC(C)(C)C)NC(=S)Nc2ccccn2)cc(OC)c1OC N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 25.8 at 10 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB000038 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 382 (E)-N-(2-methyl-1-(3-pyridin-2-ylureido)propyl)-3-(3,4,5-trimethoxyphenyl) acrylamide COc1cc(/C=C/C(=O)NC(NC(=O)Nc2ccccn2)C(C)C)cc(OC)c1OC N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 12.4 at 10 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB000039 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 383 (E)-N-(2-methyl-1-(3-phenylureido)propyl)-3-(3,4,5-trimethoxy-phenyl) acrylamide COc1cc(/C=C/C(=O)NC(NC(=O)Nc2ccccc2)C(C)C)cc(OC)c1OC N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 4.8 at 10 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB000040 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 384 N-(cyclopropyl(3-pyridin-2-ylthioureido)methyl)cinnamamide O=C(NC(NC(=S)Nc1ccccn1)C2CC2)C=Cc3ccccc3 N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 2.4 at 10 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB000041 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 386 N-(3-methyl-1-(3-phenylthioureido)butyl)cinnamamide CC(C)CC(NC(=O)C=Cc1ccccc1)NC(=S)Nc2ccccc2 N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 17.7 at 10 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB000042 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 387 N-(3,3-dimethyl-1-(3-phenylthioureido)butyl)cinnamamide CC(C)(C)CC(NC(=O)C=Cc1ccccc1)NC(=S)Nc2ccccc2 N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 11.3 at 10 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB000043 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 388 N-(2,2-dimethyl-1-(3-phenylthioureido)propyl)cinnamamide CC(C)(C)C(NC(=O)C=Cc1ccccc1)NC(=S)Nc2ccccc2 N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 9.6 at 10 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB000044 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 389 N-(cyclopropyl(3-phenylthioureido)methyl)cinnamamide O=C(NC(NC(=S)Nc1ccccc1)C2CC2)C=Cc3ccccc3 N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 3.8 at 10 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB000045 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 390 N-(2-methyl-1-(3-phenylthioureido)propyl)cinnamamide CC(C)C(NC(=O)C=Cc1ccccc1)NC(=S)Nc2ccccc2 N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 9.4 at 10 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB000046 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 391 (E)-N-(3-methyl-1-(3-methylthioureido)butyl)-3-(3,4,5-trimethoxy-phenyl)acrylamide CNC(=S)NC(CC(C)C)NC(=O)\C=C\c1cc(OC)c(OC)c(OC)c1 N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 10.5 at 10 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB000047 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 392 (E)-N-(2,2-dimethyl-1-(3-o-tolylthioureido)propyl)-3-(3,4,5-trimethoxyphenyl)acrylamide COc1cc(/C=C/C(=O)NC(NC(=S)Nc2ccccc2C)C(C)(C)C)cc(OC)c1OC N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 8.2 at 10 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB000048 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 393 (E)-N-(cyclopropyl(3-o-tolylthioureido)methyl)-3-(3,4,5-trimethoxyphenyl)acrylamide COc1cc(/C=C/C(=O)NC(NC(=S)Nc2ccccc2C)C3CC3)cc(OC)c1OC N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 44 at 10 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB000049 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 394 N-(3,3-dimethyl-1-(3-o-tolylthioureido)butyl)cinnamamide Cc1ccccc1NC(=S)NC(CC(C)(C)C)NC(=O)C=Cc2ccccc2 N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 18.2 at 10 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB000050 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 395 N-(3-methyl-1-(3-o-tolylthioureido)butyl)cinnamamide CC(C)CC(NC(=O)C=Cc1ccccc1)NC(=S)Nc2ccccc2C N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 9.8 at 10 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB000051 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 396 N-(2,2-dimethyl-1-(3-o-tolylthioureido)propyl)cinnamamide Cc1ccccc1NC(=S)NC(NC(=O)C=Cc2ccccc2)C(C)(C)C N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 7 at 10 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB000052 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 397 N-(cyclopropyl(3-o-tolylthioureido)methyl)cinnamamide Cc1ccccc1NC(=S)NC(NC(=O)C=Cc2ccccc2)C3CC3 N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 6 at 10 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB000053 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 402 (E)-N-(1-(3-(4-methoxyphenyl)thioureido)-2-methylpropyl)-3-(3,4,5-trimethoxyphenyl)acrylamide COc1ccc(NC(=S)NC(NC(=O)\C=C\c2cc(OC)c(OC)c(OC)c2)C(C)C)cc1 N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 11.5 at 10 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB000054 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 404 (E)-N-(1-(3-cyclohexylthioureido)-3-methylbutyl)-3-(3,4,5-trimethoxyphenyl)acrylamide COc1cc(/C=C/C(=O)NC(CC(C)C)NC(=S)NC2CCCCC2)cc(OC)c1OC N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 16.5 at 10 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB000055 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 405 (E)-N-(1-(3-cyclohexylthioureido)-2,2-dimethylpropyl)-3-(3,4,5-trimethoxyphenyl)acrylamide COc1cc(/C=C/C(=O)NC(NC(=S)NC2CCCCC2)C(C)(C)C)cc(OC)c1OC N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 13.5 at 10 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB000056 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 406 (E)-N-(1-(3-cyclohexylthioureido)-2-methylpropyl)-3-(3,4,5-trimethoxyphenyl)acrylamide COc1cc(/C=C/C(=O)NC(NC(=S)NC2CCCCC2)C(C)C)cc(OC)c1OC N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 15.3 at 10 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB000057 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 407 N-(1-(3-cyclohexylthioureido)-3-methylbutyl)cinnamamide CC(C)CC(NC(=O)C=Cc1ccccc1)NC(=S)NC2CCCCC2 N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 13.5 at 10 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB000058 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 408 N-(1-(3-cyclohexylthioureido)-2-methylpropyl)cinnamamide CC(C)C(NC(=O)C=Cc1ccccc1)NC(=S)NC2CCCCC2 N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 10.3 at 10 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB000059 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 409 N-(1-(3-cyclohexylthioureido)-2,2-dimethylpropyl)cinnamamide CC(C)(C)C(NC(=O)C=Cc1ccccc1)NC(=S)NC2CCCCC2 N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 13 at 10 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB000060 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 370 (E)-N-(3-methyl-1-(3-phenylthioureido)butyl)-3-(3,4,5-trimethoxyphenyl) acrylamide COc1cc(/C=C/C(=O)NC(CC(C)C)NC(=S)Nc2ccccc2)cc(OC)c1OC N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 9.4 at 10 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB000061 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 371 (E)-N-(3-methyl-1-(3-pyridin-3-ylthioureido)butyl)-3-(3,4,5-trimethoxyphenyl) acrylamide COc1cc(/C=C/C(=O)NC(CC(C)C)NC(=S)Nc2cccnc2)cc(OC)c1OC N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 10.5 at 10 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB000062 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 372 (E)-N-(2,2-dimethyl-1-(3-phenylthioureido)propyl)-3-(3,4,5-trimethoxyphenyl) acrylamide COc1cc(/C=C/C(=O)NC(NC(=S)Nc2ccccc2)C(C)(C)C)cc(OC)c1OC N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 2.9 at 10 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB000063 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 373 (E)-N-(2,2-dimethyl-1-(3-pyridin-3-ylthioureido)propyl)-3-(3,4,5-trimethoxyphenyl)acrylamide COc1cc(/C=C/C(=O)NC(NC(=S)Nc2cccnc2)C(C)(C)C)cc(OC)c1OC N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 16 at 10 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB000064 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 374 (E)-N-(cyclopropyl(3-phenylthioureido)methyl)-3-(3,4,5-trimethoxy-phenyl)acrylamide COc1cc(/C=C/C(=O)NC(NC(=S)Nc2ccccc2)C3CC3)cc(OC)c1OC N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 13.7 at 10 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB000065 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 375 (E)-N-(cyclopropyl(3-pyridin-3-ylthioureido)methyl)-3-(3,4,5-trimethoxyphenyl) acrylamide COc1cc(/C=C/C(=O)NC(NC(=S)Nc2cccnc2)C3CC3)cc(OC)c1OC N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 12.3 at 10 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB000066 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 376 (E)-N-(cyclopropyl(3-pyridin-2-ylthioureido)methyl)-3-(3,4,5-trimethoxyphenyl) acrylamide COc1cc(/C=C/C(=O)NC(NC(=S)Nc2ccccn2)C3CC3)cc(OC)c1OC N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 17.4 at 10 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB000067 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 378 (E)-N-(3-methyl-1-(3-pyridin-2-ylthioureido)butyl)-3-(3,4,5-trimethoxyphenyl)acrylamide COc1cc(/C=C/C(=O)NC(CC(C)C)NC(=S)Nc2ccccn2)cc(OC)c1OC N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 38.7 at 10 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB000068 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 379 (E)-N-(3,3-dimethyl-1-(3-phenylthioureido)butyl)-3-(3,4,5-trimethoxyphenyl)acrylamide COc1cc(/C=C/C(=O)NC(CC(C)(C)C)NC(=S)Nc2ccccc2)cc(OC)c1OC N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 40.9 at 10 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB000069 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 380 (E)-N-(3,3-dimethyl-1-(3-pyridin-3-ylthioureido)butyl)-3-(3,4,5-trimethoxyphenyl)acrylamide COc1cc(/C=C/C(=O)NC(CC(C)(C)C)NC(=S)Nc2cccnc2)cc(OC)c1OC N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 19.3 at 10 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB000070 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 381 (E)-N-(3,3-dimethyl-1-(3-pyridin-2-ylthioureido)butyl)-3-(3,4,5-trimethoxyphenyl)acrylamide COc1cc(/C=C/C(=O)NC(CC(C)(C)C)NC(=S)Nc2ccccn2)cc(OC)c1OC N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 31.5 at 10 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB000071 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 382 (E)-N-(2-methyl-1-(3-pyridin-2-ylureido)propyl)-3-(3,4,5-trimethoxyphenyl) acrylamide COc1cc(/C=C/C(=O)NC(NC(=O)Nc2ccccn2)C(C)C)cc(OC)c1OC N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 18.2 at 10 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB000072 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 383 (E)-N-(2-methyl-1-(3-phenylureido)propyl)-3-(3,4,5-trimethoxy-phenyl) acrylamide COc1cc(/C=C/C(=O)NC(NC(=O)Nc2ccccc2)C(C)C)cc(OC)c1OC N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 11.4 at 10 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB000073 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 384 N-(cyclopropyl(3-pyridin-2-ylthioureido)methyl)cinnamamide O=C(NC(NC(=S)Nc1ccccn1)C2CC2)C=Cc3ccccc3 N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 6 at 10 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB000074 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 386 N-(3-methyl-1-(3-phenylthioureido)butyl)cinnamamide CC(C)CC(NC(=O)C=Cc1ccccc1)NC(=S)Nc2ccccc2 N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 13.6 at 10 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB000075 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 387 N-(3,3-dimethyl-1-(3-phenylthioureido)butyl)cinnamamide CC(C)(C)CC(NC(=O)C=Cc1ccccc1)NC(=S)Nc2ccccc2 N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 34.6 at 10 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB000076 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 388 N-(2,2-dimethyl-1-(3-phenylthioureido)propyl)cinnamamide CC(C)(C)C(NC(=O)C=Cc1ccccc1)NC(=S)Nc2ccccc2 N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 11.4 at 10 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB000077 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 389 N-(cyclopropyl(3-phenylthioureido)methyl)cinnamamide O=C(NC(NC(=S)Nc1ccccc1)C2CC2)C=Cc3ccccc3 N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 8.7 at 10 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB000078 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 390 N-(2-methyl-1-(3-phenylthioureido)propyl)cinnamamide CC(C)C(NC(=O)C=Cc1ccccc1)NC(=S)Nc2ccccc2 N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 11.5 at 10 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB000079 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 391 (E)-N-(3-methyl-1-(3-methylthioureido)butyl)-3-(3,4,5-trimethoxy-phenyl)acrylamide CNC(=S)NC(CC(C)C)NC(=O)\C=C\c1cc(OC)c(OC)c(OC)c1 N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 13 at 10 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB000080 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 392 (E)-N-(2,2-dimethyl-1-(3-o-tolylthioureido)propyl)-3-(3,4,5-trimethoxyphenyl)acrylamide COc1cc(/C=C/C(=O)NC(NC(=S)Nc2ccccc2C)C(C)(C)C)cc(OC)c1OC N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 9.9 at 10 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB000081 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 393 (E)-N-(cyclopropyl(3-o-tolylthioureido)methyl)-3-(3,4,5-trimethoxyphenyl)acrylamide COc1cc(/C=C/C(=O)NC(NC(=S)Nc2ccccc2C)C3CC3)cc(OC)c1OC N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 6.8 at 10 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB000082 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 394 N-(3,3-dimethyl-1-(3-o-tolylthioureido)butyl)cinnamamide Cc1ccccc1NC(=S)NC(CC(C)(C)C)NC(=O)C=Cc2ccccc2 N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 18.9 at 10 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB000083 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 395 N-(3-methyl-1-(3-o-tolylthioureido)butyl)cinnamamide CC(C)CC(NC(=O)C=Cc1ccccc1)NC(=S)Nc2ccccc2C N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 12.8 at 10 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB000084 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 396 N-(2,2-dimethyl-1-(3-o-tolylthioureido)propyl)cinnamamide Cc1ccccc1NC(=S)NC(NC(=O)C=Cc2ccccc2)C(C)(C)C N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 9.7 at 10 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB000085 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 397 N-(cyclopropyl(3-o-tolylthioureido)methyl)cinnamamide Cc1ccccc1NC(=S)NC(NC(=O)C=Cc2ccccc2)C3CC3 N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 8.7 at 10 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB000086 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 402 (E)-N-(1-(3-(4-methoxyphenyl)thioureido)-2-methylpropyl)-3-(3,4,5-trimethoxyphenyl)acrylamide COc1ccc(NC(=S)NC(NC(=O)\C=C\c2cc(OC)c(OC)c(OC)c2)C(C)C)cc1 N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 15.4 at 10 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB000087 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 404 (E)-N-(1-(3-cyclohexylthioureido)-3-methylbutyl)-3-(3,4,5-trimethoxyphenyl)acrylamide COc1cc(/C=C/C(=O)NC(CC(C)C)NC(=S)NC2CCCCC2)cc(OC)c1OC N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 38.8 at 10 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB000088 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 405 (E)-N-(1-(3-cyclohexylthioureido)-2,2-dimethylpropyl)-3-(3,4,5-trimethoxyphenyl)acrylamide COc1cc(/C=C/C(=O)NC(NC(=S)NC2CCCCC2)C(C)(C)C)cc(OC)c1OC N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 39.8 at 10 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB000089 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 406 (E)-N-(1-(3-cyclohexylthioureido)-2-methylpropyl)-3-(3,4,5-trimethoxyphenyl)acrylamide COc1cc(/C=C/C(=O)NC(NC(=S)NC2CCCCC2)C(C)C)cc(OC)c1OC N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 22.6 at 10 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB000090 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 407 N-(1-(3-cyclohexylthioureido)-3-methylbutyl)cinnamamide CC(C)CC(NC(=O)C=Cc1ccccc1)NC(=S)NC2CCCCC2 N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 19.8 at 10 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB000091 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 408 N-(1-(3-cyclohexylthioureido)-2-methylpropyl)cinnamamide CC(C)C(NC(=O)C=Cc1ccccc1)NC(=S)NC2CCCCC2 N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 13.3 at 10 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB000092 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 409 N-(1-(3-cyclohexylthioureido)-2,2-dimethylpropyl)cinnamamide CC(C)(C)C(NC(=O)C=Cc1ccccc1)NC(=S)NC2CCCCC2 N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 34.3 at 10 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB000093 29414793 Hsp70 DnaK/DnaJ/GrpE Bacteria Cytosol and membrane Inhibition of ATPase activity (protein-protein interaction) NA C NA NA ChemDiv 100K diversity set library NA NA NA NA <50 NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000094 29414793 Hsp70 DnaK/DnaJ/GrpE Bacteria Cytosol and membrane Inhibition of ATPase activity (protein-protein interaction) NA F 4-{2-[(3,5-dimethyl-1H-pyrazol-4-yl)amino]-1,3-thiazol-4-yl}benzene-1,2-diol CC1=C(NC2=NC(=CS2)C2=CC=C(O)C(O)=C2)C(C)=NN1 2-aminothiazole derivative NA NA NA NA <50 NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000095 29414793 Hsp70 DnaK/DnaJ/GrpE Bacteria Cytosol and membrane Inhibition of ATPase activity (protein-protein interaction) NA I NA NA ChemDiv 100K diversity set library NA NA NA NA <50 NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000096 29414793 Hsp70 DnaK/DnaJ/GrpE Bacteria Cytosol and membrane Inhibition of ATPase activity (protein-protein interaction) NA N NA NA ChemDiv 100K diversity set library NA NA NA NA <50 NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000097 29414793 Hsp70 DnaK/DnaJ/GrpE Bacteria Cytosol and membrane Inhibition of ATPase activity (protein-protein interaction) NA R N-(5-chloro-2-methoxyphenyl)-4-{2-methylimidazo[1,2-a]pyridin-3-yl}-1,3-thiazol-2-amine COC1=CC=C(Cl)C=C1NC1=NC(=CS1)C1=C(C)N=C2C=CC=CN12 2-aminothiazole derivative NA NA NA NA <50 NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000098 29414793 Hsp70 Hsp72/DnaJ2/BAG2 Human Cytosol and nucleus Inhibition of ATPase activity (protein-protein interaction) NA C NA NA ChemDiv 100K diversity set library NA NA NA NA 26.2 NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000099 29414793 Hsp70 Hsp72/DnaJ2/BAG2 Human Cytosol and nucleus Inhibition of ATPase activity (protein-protein interaction) NA F 4-{2-[(3,5-dimethyl-1H-pyrazol-4-yl)amino]-1,3-thiazol-4-yl}benzene-1,2-diol CC1=C(NC2=NC(=CS2)C2=CC=C(O)C(O)=C2)C(C)=NN1 2-aminothiazole derivative NA NA NA NA 28.2 NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000100 29414793 Hsp70 Hsp72/DnaJ2/BAG2 Human Cytosol and nucleus Inhibition of ATPase activity (protein-protein interaction) NA H NA NA ChemDiv 100K diversity set library NA NA NA NA 15.5 NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000101 29414793 Hsp70 Hsp72/DnaJ2/BAG2 Human Cytosol and nucleus Inhibition of ATPase activity (protein-protein interaction) NA I NA NA ChemDiv 100K diversity set library NA NA NA NA 10.9 NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000102 29414793 Hsp70 Hsp72/DnaJ2/BAG2 Human Cytosol and nucleus Inhibition of ATPase activity (protein-protein interaction) NA R N-(5-chloro-2-methoxyphenyl)-4-{2-methylimidazo[1,2-a]pyridin-3-yl}-1,3-thiazol-2-amine COC1=CC=C(Cl)C=C1NC1=NC(=CS1)C1=C(C)N=C2C=CC=CN12 2-aminothiazole derivative NA NA NA NA 9.5 NA NA NA Nucleotide binding domain (allosteric site) ATPase assay NA NA NA NA NA NA NA HSPMDB000103 29414793 Hsp70 Hsp72/DnaJ2/BAG2 Human Cytosol and nucleus Inhibition of ATPase activity (protein-protein interaction) NA IT2-144 N-(2,5-difluorophenyl)-4-{2-methylimidazo[1,2-a]pyridin-3-yl}-1,3-thiazol-2-amine CC1=C(N2C=CC=CC2=N1)C1=CSC(NC2=CC(F)=CC=C2F)=N1 2-aminothiazoles derivative NA NA NA NA 6.9 NA NA NA Nucleotide binding domain (allosteric site) ATPase assay NA NA NA NA NA NA NA HSPMDB000104 29414793 Hsp70 DnaK/DnaJ/GrpE Bacteria Cytosol and membrane Inhibition of ATPase activity (protein-protein interaction) NA IT2-149 N-(2-fluoro-5-methylphenyl)-4-{2-methylimidazo[1,2-a]pyridin-3-yl}-1,3-thiazol-2-amine CC1=C(N2C=CC=CC2=N1)C1=CSC(NC2=CC(C)=CC=C2F)=N1 2-aminothiazoles derivative NA NA NA NA >25 NA NA NA Nucleotide binding domain (allosteric site) ATPase assay NA NA NA NA NA NA NA HSPMDB000105 29414793 Hsp70 Hsp72/DnaJ2/BAG2 Human Cytosol and nucleus Inhibition of ATPase activity (protein-protein interaction) NA IT2-151 N-(5-bromo-2-fluorophenyl)-4-{2-methylimidazo[1,2-a]pyridin-3-yl}-1,3-thiazol-2-amine CC1=C(N2C=CC=CC2=N1)C1=CSC(NC2=CC(Br)=CC=C2F)=N1 2-aminothiazoles derivative NA NA NA NA 4.7 NA NA NA Nucleotide binding domain (allosteric site) ATPase assay NA NA NA NA NA NA NA HSPMDB000106 29414793 Hsp70 Hsp72/DnaJ2/BAG2 Human Cytosol and nucleus Inhibition of ATPase activity (protein-protein interaction) NA IT2-179 N-(2,5-dibromophenyl)-4-{2-methylimidazo[1,2-a]pyridin-3-yl}-1,3-thiazol-2-amine CC1=C(N2C=CC=CC2=N1)C1=CSC(NC2=CC(Br)=CC=C2Br)=N1 2-aminothiazoles derivative NA NA NA NA 3.6 NA NA NA Nucleotide binding domain (allosteric site) ATPase assay NA NA NA NA NA NA NA HSPMDB000107 29414793 Hsp70 DnaK/DnaJ/GrpE Bacteria Cytosol and membrane Inhibition of ATPase activity (protein-protein interaction) NA IT2-158 N-(2,3-difluorophenyl)-4-{2-methylimidazo[1,2-a]pyridin-3-yl}-1,3-thiazol-2-amine CC1=C(N2C=CC=CC2=N1)C1=CSC(NC2=CC=CC(F)=C2F)=N1 2-aminothiazoles derivative NA NA NA NA >25 NA NA NA Nucleotide binding domain (allosteric site) ATPase assay NA NA NA NA NA NA NA HSPMDB000108 29414793 Hsp70 Hsp72/-DnaJ2/BAG2 Human Cytosol and nucleus Inhibition of ATPase activity (protein-protein interaction) NA IT2-159 N-(2,4-difluorophenyl)-4-{2-methylimidazo[1,2-a]pyridin-3-yl}-1,3-thiazol-2-amine CC1=C(N2C=CC=CC2=N1)C1=CSC(NC2=CC=C(F)C=C2F)=N1 2-aminothiazoles derivative NA NA NA NA >50 NA NA NA Nucleotide binding domain (allosteric site) ATPase assay NA NA NA NA NA NA NA HSPMDB000109 29414793 Hsp70 DnaK/DnaJ/GrpE Bacteria Cytosol and membrane Inhibition of ATPase activity (protein-protein interaction) NA IT2-160 N-(2,6-difluorophenyl)-4-{2-methylimidazo[1,2-a]pyridin-3-yl}-1,3-thiazol-2-amine CC1=C(N2C=CC=CC2=N1)C1=CSC(NC2=C(F)C=CC=C2F)=N1 2-aminothiazoles derivative NA NA NA NA >25 NA NA NA Nucleotide binding domain (allosteric site) ATPase assay NA NA NA NA NA NA NA HSPMDB000110 29414793 Hsp70 DnaK/DnaJ/GrpE Bacteria Cytosol and membrane Inhibition of ATPase activity (protein-protein interaction) NA IT2-171 N-benzyl-4-{2-methylimidazo[1,2-a]pyridin-3-yl}-1,3-thiazol-2-amine CC1=C(N2C=CC=CC2=N1)C1=CSC(NCC2=CC=CC=C2)=N1 2-aminothiazoles derivative NA NA NA NA >25 NA NA NA Nucleotide binding domain (allosteric site) ATPase assay NA NA NA NA NA NA NA HSPMDB000111 29414793 Hsp70 Hsp72/DnaJ2/BAG2 Human Cytosol and nucleus Inhibition of ATPase activity (protein-protein interaction) NA IT2-70a 4-{2-methylimidazo[1,2-a]pyridin-3-yl}-1,3-thiazol-2-amine CC1=C(N2C=CC=CC2=N1)C1=CSC(N)=N1 2-aminothiazoles derivative NA NA NA NA >50 NA NA NA Nucleotide binding domain (allosteric site) ATPase assay NA NA NA NA NA NA NA HSPMDB000112 29414793 Hsp70 DnaK/DnaJ/GrpE Bacteria Cytosol and membrane Inhibition of ATPase activity (DnaJ stimulated) NA IT2-21c 1-(3,4-dihydroxyphenyl)-2-(4-{[4-(3,4-dihydroxyphenyl)-1,3-thiazol-2-yl]amino}-3,5-dimethyl-1H-pyrazol-1-yl)ethan-1-one CC1=NN(CC(=O)C2=CC(O)=C(O)C=C2)C(C)=C1NC1=NC(=CS1)C1=CC(O)=C(O)C=C1 IT2-21a derivative 80% Inhibition at 10 uM NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) ATPase assay NA NA NA NA NA NA NA HSPMDB000113 29414793 Hsp70 Hsp72/DnaJ2/BAG2 Human Cytosol and nucleus NA Antiproliferative activity R N-(5-chloro-2-methoxyphenyl)-4-{2-methylimidazo[1,2-a]pyridin-3-yl}-1,3-thiazol-2-amine COC1=CC=C(Cl)C=C1NC1=NC(=CS1)C1=C(C)N=C2C=CC=CN12 2-aminothiazoles derivative NA NA NA NA 5.8 NA NA NA NA NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000114 29414793 Hsp70 Hsp72/DnaJ2/BAG2 Human Cytosol and nucleus NA Antiproliferative activity IT2-144 N-(2,5-difluorophenyl)-4-{2-methylimidazo[1,2-a]pyridin-3-yl}-1,3-thiazol-2-amine CC1=C(N2C=CC=CC2=N1)C1=CSC(NC2=CC(F)=CC=C2F)=N1 2-aminothiazoles derivative NA NA NA NA 2.7 NA NA NA NA NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000115 29414793 Hsp70 Hsp72/DnaJ2/BAG2 Human Cytosol and nucleus NA Antiproliferative activity IT2-151 N-(5-bromo-2-fluorophenyl)-4-{2-methylimidazo[1,2-a]pyridin-3-yl}-1,3-thiazol-2-amine CC1=C(N2C=CC=CC2=N1)C1=CSC(NC2=CC(Br)=CC=C2F)=N1 2-aminothiazoles derivative NA NA NA NA 2.9 NA NA NA NA NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000116 29414793 Hsp70 Hsp72/DnaJ2/BAG2 Human Cytosol and nucleus NA Antiproliferative activity IT2-179 N-(2,5-dibromophenyl)-4-{2-methylimidazo[1,2-a]pyridin-3-yl}-1,3-thiazol-2-amine CC1=C(N2C=CC=CC2=N1)C1=CSC(NC2=CC(Br)=CC=C2Br)=N1 2-aminothiazoles derivative NA NA NA NA 3.1 NA NA NA NA NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000117 29414793 Hsp70 Hsp72/DnaJ2/BAG2 Human Cytosol and nucleus NA Antiproliferative activity IT2-159 N-(2,4-difluorophenyl)-4-{2-methylimidazo[1,2-a]pyridin-3-yl}-1,3-thiazol-2-amine CC1=C(N2C=CC=CC2=N1)C1=CSC(NC2=CC=C(F)C=C2F)=N1 2-aminothiazoles derivative NA NA NA NA 8.5 NA NA NA NA NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000118 29414793 Hsp70 Hsp72/DnaJ2/BAG2 Human Cytosol and nucleus NA Antiproliferative activity IT2-70a 4-{2-methylimidazo[1,2-a]pyridin-3-yl}-1,3-thiazol-2-amine CC1=C(N2C=CC=CC2=N1)C1=CSC(N)=N1 2-aminothiazoles derivative NA NA NA NA > 50 NA NA NA NA NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000119 29414793 Hsp70 Hsp72/DnaJ2/BAG2 Human Cytosol and nucleus NA Antiproliferative activity R N-(5-chloro-2-methoxyphenyl)-4-{2-methylimidazo[1,2-a]pyridin-3-yl}-1,3-thiazol-2-amine COC1=CC=C(Cl)C=C1NC1=NC(=CS1)C1=C(C)N=C2C=CC=CN12 2-aminothiazoles derivative NA NA NA NA 5.3 NA NA NA NA NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000120 29414793 Hsp70 Hsp72/DnaJ2/BAG2 Human Cytosol and nucleus NA Antiproliferative activity IT2-144 N-(2,5-difluorophenyl)-4-{2-methylimidazo[1,2-a]pyridin-3-yl}-1,3-thiazol-2-amine CC1=C(N2C=CC=CC2=N1)C1=CSC(NC2=CC(F)=CC=C2F)=N1 2-aminothiazoles derivative NA NA NA NA > 50 NA NA NA NA NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000121 29414793 Hsp70 Hsp72/DnaJ2/BAG2 Human Cytosol and nucleus NA Antiproliferative activity IT2-151 N-(5-bromo-2-fluorophenyl)-4-{2-methylimidazo[1,2-a]pyridin-3-yl}-1,3-thiazol-2-amine CC1=C(N2C=CC=CC2=N1)C1=CSC(NC2=CC(Br)=CC=C2F)=N1 2-aminothiazoles derivative NA NA NA NA 9.3 NA NA NA NA NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000122 29414793 Hsp70 Hsp72/DnaJ2/BAG2 Human Cytosol and nucleus NA Antiproliferative activity IT2-179 N-(2,5-dibromophenyl)-4-{2-methylimidazo[1,2-a]pyridin-3-yl}-1,3-thiazol-2-amine CC1=C(N2C=CC=CC2=N1)C1=CSC(NC2=CC(Br)=CC=C2Br)=N1 2-aminothiazoles derivative NA NA NA NA > 50 NA NA NA NA NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000123 29414793 Hsp70 Hsp72/DnaJ2/BAG2 Human Cytosol and nucleus NA Antiproliferative activity IT2-159 N-(2,4-difluorophenyl)-4-{2-methylimidazo[1,2-a]pyridin-3-yl}-1,3-thiazol-2-amine CC1=C(N2C=CC=CC2=N1)C1=CSC(NC2=CC=C(F)C=C2F)=N1 2-aminothiazoles derivative NA NA NA NA 5.4 NA NA NA NA NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000124 29414793 Hsp70 Hsp72/DnaJ2/BAG2 Human Cytosol and nucleus NA Antiproliferative activity IT2-70a 4-{2-methylimidazo[1,2-a]pyridin-3-yl}-1,3-thiazol-2-amine CC1=C(N2C=CC=CC2=N1)C1=CSC(N)=N1 2-aminothiazoles derivative NA NA NA NA > 50 NA NA NA NA NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000125 18191466 Hsp70 DnaK/DnaJ/GrpE Bacteria Cytosol and membrane Inhibition of chaperone activity NA 116-5c benzyl 4-{[1,1'-biphenyl]-4-yl}-1-(5-{[(butylcarbamoyl)[4-(2-methoxy-2-oxoethoxy)-3-(methoxycarbonyl)phenyl]methyl](2-phenylethyl)carbamoyl}pentyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate CCCCNC(=O)C(N(CCC1=CC=CC=C1)C(=O)CCCCCN1C(=O)NC(C2=CC=C(C=C2)C2=CC=CC=C2)C(C(=O)OCC2=CC=CC=C2)=C1C)C1=CC=C(OCC(=O)OC)C(=C1)C(=O)OC Dihydropyrimidine derivative NA NA NA NA 3.2 NA NA NA NA Refolding assay (luciferase) NA NA NA NA NA NA NA HSPMDB000126 18191466 Hsp70 DnaK/DnaJ/GrpE Bacteria Cytosol and membrane Inhibition of chaperone activity NA 115-3b 2-[(2-{5-[(benzyloxy)carbonyl]-1-(3-carboxypropyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-4-yl}phenoxy)sulfonyl]-N-hydroxy-N-oxoanilinium CC1=C(C(NC(=O)N1CCCC(O)=O)C1=CC=CC=C1OS(=O)(=O)C1=CC=CC=C1[N+](O)=O)C(=O)OCC1=CC=CC=C1 Dihydropyrimidine derivative NA NA NA NA 3.5 NA NA NA NA Refolding assay (luciferase) NA NA NA NA NA NA NA HSPMDB000127 18191466 Hsp70 DnaK/DnaJ/GrpE Bacteria Cytosol and membrane Inhibition of chaperone activity NA 116-4d N-hydroxy-4-[5-(methoxycarbonyl)-2-oxo-6-(2-phenylethyl)-1,2,3,4-tetrahydropyrimidin-4-yl]-N-oxoanilinium COC(=O)C1=C(CCC2=CC=CC=C2)NC(=O)NC1C1=CC=C(C=C1)[N+](O)=O Dihydropyrimidine derivative NA NA NA NA 8.8 NA NA NA NA Refolding assay (luciferase) NA NA NA NA NA NA NA HSPMDB000128 18191466 Hsp70 DnaK/DnaJ/GrpE Bacteria Cytosol and membrane Inhibition of chaperone activity NA 116-10d benzyl 4-{[1,1'-biphenyl]-4-yl}-1-(5-{[(butylcarbamoyl)[4-hydroxy-3-(methoxycarbonyl)phenyl]methyl](hexyl)carbamoyl}pentyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)C1=CC=C(O)C(=C1)C(=O)OC)C(=O)CCCCCN1C(=O)NC(C2=CC=C(C=C2)C2=CC=CC=C2)C(C(=O)OCC2=CC=CC=C2)=C1C Dihydropyrimidine derivative NA NA NA NA 9 NA NA NA NA Refolding assay (luciferase) NA NA NA NA NA NA NA HSPMDB000129 18191466 Hsp70 DnaK/DnaJ/GrpE Bacteria Cytosol and membrane Inhibition of chaperone activity NA SW03 3-[(3R)-3-[(3S)-3-{4-[4-(4-bromophenyl)-5-(ethoxycarbonyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-1-yl]butanamido}-5-methylhexanamido]-3-phenylpropanamido]propanoic acid CCOC(=O)C1=C(C)N(CCCC(=O)N[C@@H](CC(C)C)CC(=O)N[C@H](CC(=O)NCCC(O)=O)C2=CC=CC=C2)C(=O)NC1C1=CC=C(Br)C=C1 Dihydropyrimidine derivative NA NA NA NA 11 NA NA NA NA Refolding assay (luciferase) NA NA NA NA NA NA NA HSPMDB000130 18191466 Hsp70 DnaK/DnaJ/GrpE Bacteria Cytosol and membrane Inhibition of chaperone activity NA 116-8e benzyl 4-{[1,1'-biphenyl]-4-yl}-1-{5-[({[1,1'-biphenyl]-4-yl}(butylcarbamoyl)methyl)(hexyl)carbamoyl]pentyl}-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)C1=CC=C(C=C1)C1=CC=CC=C1)C(=O)CCCCCN1C(=O)NC(C2=CC=C(C=C2)C2=CC=CC=C2)C(C(=O)OCC2=CC=CC=C2)=C1C Dihydropyrimidine derivative NA NA NA NA 30.4 NA NA NA NA Refolding assay (luciferase) NA NA NA NA NA NA NA HSPMDB000131 15448148 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA 625194 NA NA Dihydropyrimidine derivative Fold change 1 (at 0.1 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000132 15448148 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA 625195 NA NA Dihydropyrimidine derivative Fold change 3 (at 0.1 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000133 15448148 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA 625512 NA NA Dihydropyrimidine derivative Fold change 1.2 (at 0.1 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000134 15448148 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA 625513 NA NA Dihydropyrimidine derivative Fold change 1.1 (at 0.1 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000135 15448148 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA ML2-193 NA NA Dihydropyrimidine derivative Fold change 1.6 (at 0.1 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000136 15448148 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA ML2-194 NA NA Dihydropyrimidine derivative Fold change 1.3 (at 0.1 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000137 15448148 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA ML2-214 NA NA Dihydropyrimidine derivative Fold change -1.1 (at 0.1 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000138 15448148 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA ML2-215 NA NA Dihydropyrimidine derivative Fold change 1.2 (at 0.1 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000139 15448148 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA MAL3-38 NA NA Dihydropyrimidine derivative Fold change 1.8 (at 0.1 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000140 15448148 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA MAL3-40 NA NA Dihydropyrimidine derivative Fold change 1.8 (at 0.1 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000141 15448148 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA MAL3-53 NA NA Dihydropyrimidine derivative Fold change 1.9 (at 0.1 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000142 15448148 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA MAL3-55 NA NA Dihydropyrimidine derivative Fold change -1.5 (at 0.1 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000143 15448148 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA MAL3-87 NA NA Dihydropyrimidine derivative Fold change 1.9 (at 0.1 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000144 15448148 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA MAL3-88 NA NA Dihydropyrimidine derivative Fold change 1.5 (at 0.1 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000145 15448148 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA MAL3-90 NA NA Dihydropyrimidine derivative Fold change 2 (at 0.1 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000146 15448148 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA MAL3-91 NA NA Dihydropyrimidine derivative Fold change 1.8 (at 0.1 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000147 15448148 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA NSC-630668-R/1 6-[5-(ethoxycarbonylcarbamoyl)-2,4-dioxopyrimidin-1-yl]hexyl N-[6-[6-[5-(ethoxycarbonylcarbamoyl)-2,4-dioxopyrimidin-1-yl]hexoxycarbonylamino]hexyl]carbamate CCOC(=O)NC(=O)C1=CN(C(=O)NC1=O)CCCCCCOC(=O)NCCCCCCNC(=O)OCCCCCCN2C=C(C(=O)NC2=O)C(=O)NC(=O)OCC Dihydropyrimidine derivative Fold change 5.8 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000148 15448148 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA 624392 ethyl N-[1-[2-[6-[[2-[5-(ethoxycarbonylcarbamoyl)-2,4-dioxopyrimidin-1-yl]ethyl-(2-hydroxyethyl)carbamoyl]amino]hexylcarbamoyl-(2-hydroxyethyl)amino]ethyl]-2,4-dioxopyrimidine-5-carbonyl]carbamate CCOC(=O)NC(=O)C1=CN(C(=O)NC1=O)CCN(CCO)C(=O)NCCCCCCNC(=O)N(CCN2C=C(C(=O)NC2=O)C(=O)NC(=O)OCC)CCO Dihydropyrimidine derivative Fold change -1.3 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000149 15448148 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA 642393 NA NA Dihydropyrimidine derivative Fold change -1.7 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000150 15448148 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA 624903 NA NA Dihydropyrimidine derivative Fold change -2.2 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000151 15448148 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA 624904 NA NA Dihydropyrimidine derivative Fold change -1.4 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000152 15448148 Hsp70 Ssa1p Yeast Cytosol Activation of ATPase activity (endogenous) NA 624905 NA NA Dihydropyrimidine derivative Fold change 1.2 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000153 15448148 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA 624906 NA NA Dihydropyrimidine derivative Fold change -1.8 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000154 15448148 Hsp70 Ssa1p Yeast Cytosol Activation of ATPase activity (endogenous) NA 624907 NA NA Dihydropyrimidine derivative Fold change 1.2 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000155 15448148 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA 624908 NA NA Dihydropyrimidine derivative Fold change -1.1 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000156 15448148 Hsp70 Ssa1p Yeast Cytosol Activation of ATPase activity (endogenous) NA 625194 NA NA Dihydropyrimidine derivative Fold change 1.8 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000157 15448148 Hsp70 Ssa1p Yeast Cytosol Activation of ATPase activity (endogenous) NA 625195 NA NA Dihydropyrimidine derivative Fold change 1.7 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000158 15448148 Hsp70 Ssa1p Yeast Cytosol Activation of ATPase activity (endogenous) NA 625512 NA NA Dihydropyrimidine derivative Fold change 3.1 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000159 15448148 Hsp70 Ssa1p Yeast Cytosol Activation of ATPase activity (endogenous) NA 625513 NA NA Dihydropyrimidine derivative Fold change 2 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000160 15448148 Hsp70 Ssa1p Yeast Cytosol Activation of ATPase activity (endogenous) NA 632006 NA NA Dihydropyrimidine derivative Fold change 1.4 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000161 15448148 Hsp70 Ssa1p Yeast Cytosol Activation of ATPase activity (endogenous) NA 655302 NA NA Dihydropyrimidine derivative Fold change 1.9 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000162 15448148 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA aad9 NA NA Dihydropyrimidine derivative Fold change -1.7 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000163 15448148 Hsp70 Ssa1p Yeast Cytosol Activation of ATPase activity (endogenous) NA ML2-193 NA NA Dihydropyrimidine derivative Fold change 3.1 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000164 15448148 Hsp70 Ssa1p Yeast Cytosol Activation of ATPase activity (endogenous) NA ML2-194 NA NA Dihydropyrimidine derivative Fold change 2.1 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000165 15448148 Hsp70 Ssa1p Yeast Cytosol Activation of ATPase activity (endogenous) NA ML2-214 NA NA Dihydropyrimidine derivative Fold change 1.7 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000166 15448148 Hsp70 Ssa1p Yeast Cytosol Activation of ATPase activity (endogenous) NA ML2-215 NA NA Dihydropyrimidine derivative Fold change 2.2 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000167 15448148 Hsp70 Ssa1p Yeast Cytosol Activation of ATPase activity (endogenous) NA MAL3-38 NA NA Dihydropyrimidine derivative Fold change 3.1 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000168 15448148 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA MAL3-39 NA NA Dihydropyrimidine derivative Fold change 1 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000169 15448148 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA MAL3-40 NA NA Dihydropyrimidine derivative Fold change 2.7 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000170 15448148 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA MAL3-51 NA NA Dihydropyrimidine derivative Fold change -1.2 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000171 15448148 Hsp70 Ssa1p Yeast Cytosol Activation of ATPase activity (endogenous) NA MAL3-53 NA NA Dihydropyrimidine derivative Fold change 2.5 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000172 15448148 Hsp70 Ssa1p Yeast Cytosol Activation of ATPase activity (endogenous) NA MAL3-54 NA NA Dihydropyrimidine derivative Fold change 1.1 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000173 15448148 Hsp70 Ssa1p Yeast Cytosol Activation of ATPase activity (endogenous) NA MAL3-55 NA NA Dihydropyrimidine derivative Fold change 1.4 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000174 15448148 Hsp70 Ssa1p Yeast Cytosol Activation of ATPase activity (endogenous) NA MAL3-87 NA NA Dihydropyrimidine derivative Fold change 2.3 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000175 15448148 Hsp70 Ssa1p Yeast Cytosol Activation of ATPase activity (endogenous) NA MAL3-88 NA NA Dihydropyrimidine derivative Fold change 1.3 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000176 15448148 Hsp70 Ssa1p Yeast Cytosol Activation of ATPase activity (endogenous) NA MAL3-90 NA NA Dihydropyrimidine derivative Fold change 5.2 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000177 15448148 Hsp70 Ssa1p Yeast Cytosol Activation of ATPase activity (endogenous) NA MAL3-91 NA NA Dihydropyrimidine derivative Fold change 2.9 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000178 15448148 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA MAL3-101 Benzyl 4-([1,1?-biphenyl]-4-yl)-1-(6-((2-(butylamino)-1-(4-(2-methoxy-2-oxoethoxy)-3-(methoxycarbonyl)phenyl)-2-oxoethyl)(hexyl)amino)-6-oxohexyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate O=C(C1=C(C)N(CCCCCC(N(C(C2=CC=C(OCC(OC)=O)C(C(OC)=O)=C2)C(NCCCC)=O)CCCCCC)=O)C(NC1C3=CC=C(C4=CC=CC=C4)C=C3)=O)OCC5=CC=CC=C5 Dihydropyrimidine derivative Fold change 1 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000179 15448148 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA 624392 ethyl N-[1-[2-[6-[[2-[5-(ethoxycarbonylcarbamoyl)-2,4-dioxopyrimidin-1-yl]ethyl-(2-hydroxyethyl)carbamoyl]amino]hexylcarbamoyl-(2-hydroxyethyl)amino]ethyl]-2,4-dioxopyrimidine-5-carbonyl]carbamate CCOC(=O)NC(=O)C1=CN(C(=O)NC1=O)CCN(CCO)C(=O)NCCCCCCNC(=O)N(CCN2C=C(C(=O)NC2=O)C(=O)NC(=O)OCC)CCO Dihydropyrimidine derivative Fold change -1.4 (at 0.6 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000180 15448148 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA 624906 NA NA Dihydropyrimidine derivative Fold change -1.1 (at 0.6 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000181 15448148 Hsp70 Ssa1p Yeast Cytosol Activation of ATPase activity (endogenous) NA 625194 NA NA Dihydropyrimidine derivative Fold change 1.4 (at 0.6 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000182 15448148 Hsp70 Ssa1p Yeast Cytosol Activation of ATPase activity (endogenous) NA 625195 NA NA Dihydropyrimidine derivative Fold change1.3 (at 0.6 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000183 15448148 Hsp70 Ssa1p Yeast Cytosol Activation of ATPase activity (endogenous) NA 625512 NA NA Dihydropyrimidine derivative Fold change 3 (at 0.6 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000184 15448148 Hsp70 Ssa1p Yeast Cytosol Activation of ATPase activity (endogenous) NA 625513 NA NA Dihydropyrimidine derivative Fold change 2.5 (at 0.6 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000185 15448148 Hsp70 Ssa1p Yeast Cytosol Activation of ATPase activity (endogenous) NA 632006 NA NA Dihydropyrimidine derivative Fold change 2 (at 0.6 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000186 15448148 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA 655302 NA NA Dihydropyrimidine derivative Fold change -1.3 (at 0.6 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000187 15448148 Hsp70 Ssa1p Yeast Cytosol Activation of ATPase activity (endogenous) NA ML2-193 NA NA Dihydropyrimidine derivative Fold change 2.3 (at 0.6 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000188 15448148 Hsp70 Ssa1p Yeast Cytosol Activation of ATPase activity (endogenous) NA ML2-194 NA NA Dihydropyrimidine derivative Fold change 1.4 (at 0.6 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000189 15448148 Hsp70 Ssa1p Yeast Cytosol Activation of ATPase activity (endogenous) NA ML2-214 NA NA Dihydropyrimidine derivative Fold change 1.3 (at 0.6 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000190 15448148 Hsp70 Ssa1p Yeast Cytosol Activation of ATPase activity (endogenous) NA ML2-215 NA NA Dihydropyrimidine derivative Fold change 2.1 (at 0.6 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000191 15448148 Hsp70 Ssa1p Yeast Cytosol Activation of ATPase activity (endogenous) NA MAL3-38 NA NA Dihydropyrimidine derivative Fold change 2 (at 0.6 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000192 15448148 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA MAL3-39 NA NA Dihydropyrimidine derivative Foldc hange -1.4 (at 0.6 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000193 15448148 Hsp70 Ssa1p Yeast Cytosol Activation of ATPase activity (endogenous) NA MAL3-40 NA NA Dihydropyrimidine derivative Fold change 3 (at 0.6 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000194 15448148 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA MAL3-51 NA NA Dihydropyrimidine derivative Fold change -1.3 (at 0.6 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000195 15448148 Hsp70 Ssa1p Yeast Cytosol Activation of ATPase activity (endogenous) NA MAL3-53 NA NA Dihydropyrimidine derivative Fold change 4.6 (at 0.6 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000196 15448148 Hsp70 Ssa1p Yeast Cytosol Activation of ATPase activity (endogenous) NA MAL3-54 NA NA Dihydropyrimidine derivative Fold change 1.3 (at 0.6 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000197 15448148 Hsp70 Ssa1p Yeast Cytosol Activation of ATPase activity (endogenous) NA MAL3-55 NA NA Dihydropyrimidine derivative Fold change 2.8 (at 0.6 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000198 15448148 Hsp70 Ssa1p Yeast Cytosol Activation of ATPase activity (endogenous) NA MAL3-87 NA NA Dihydropyrimidine derivative Fold change 2.6 (at 0.6 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000199 15448148 Hsp70 Ssa1p Yeast Cytosol Activation of ATPase activity (endogenous) NA MAL3-88 NA NA Dihydropyrimidine derivative Fold change 2.4 (at 0.6 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000200 15448148 Hsp70 Ssa1p Yeast Cytosol Activation of ATPase activity (endogenous) NA MAL3-90 NA NA Dihydropyrimidine derivative Fold change 6.7 (at 0.6 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000201 15448148 Hsp70 Ssa1p Yeast Cytosol Activation of ATPase activity (endogenous) NA MAL3-91 NA NA Dihydropyrimidine derivative Fold change 5 (at 0.6 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000202 15448148 Hsp70 Ssa1p Yeast Cytosol Activation of ATPase activity (endogenous) NA MAL3-101 Benzyl 4-([1,1?-biphenyl]-4-yl)-1-(6-((2-(butylamino)-1-(4-(2-methoxy-2-oxoethoxy)-3-(methoxycarbonyl)phenyl)-2-oxoethyl)(hexyl)amino)-6-oxohexyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate O=C(C1=C(C)N(CCCCCC(N(C(C2=CC=C(OCC(OC)=O)C(C(OC)=O)=C2)C(NCCCC)=O)CCCCCC)=O)C(NC1C3=CC=C(C4=CC=CC=C4)C=C3)=O)OCC5=CC=CC=C5 Dihydropyrimidine derivative Fold change 1.2 (at 0.6 mM) NA NA NA NA NA NA NA Interface between Hsp70 and Hsp40 ATPase assay NA NA NA NA NA NA NA HSPMDB000203 15448148 Hsp70 Ssa1p and TAg /ydj1P Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA NSC-630668-R/1 6-[5-(ethoxycarbonylcarbamoyl)-2,4-dioxopyrimidin-1-yl]hexyl N-[6-[6-[5-(ethoxycarbonylcarbamoyl)-2,4-dioxopyrimidin-1-yl]hexoxycarbonylamino]hexyl]carbamate CCOC(=O)NC(=O)C1=CN(C(=O)NC1=O)CCCCCCOC(=O)NCCCCCCNC(=O)OCCCCCCN2C=C(C(=O)NC2=O)C(=O)NC(=O)OCC Dihydropyrimidine derivative Fold change -1.5 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000204 15448148 Hsp70 Ssa1p and TAg /ydj1P Yeast Cytosol Activation of ATPase activity (TAg stimulated) NA MAL3-38 NA NA Dihydropyrimidine derivative Fold change 2 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000205 15448148 Hsp70 Ssa1p and TAg /ydj1P Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA MAL3-39 NA NA Dihydropyrimidine derivative Fold change -2.8 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000206 15448148 Hsp70 Ssa1p and TAg /ydj1P Yeast Cytosol Activation of ATPase activity (TAg stimulated) NA MAL3-40 NA NA Dihydropyrimidine derivative Fold change 1.5 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000207 15448148 Hsp70 Ssa1p and TAg /ydj1P Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA MAL3-51 NA NA Dihydropyrimidine derivative Fold change -1.1 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000208 15448148 Hsp70 Ssa1p and TAg /ydj1P Yeast Cytosol Activation of ATPase activity (TAg stimulated) NA MAL3-53 NA NA Dihydropyrimidine derivative Fold change 1.2 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000209 15448148 Hsp70 Ssa1p and TAg /ydj1P Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA MAL3-54 NA NA Dihydropyrimidine derivative Fold change -5.1(at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000210 15448148 Hsp70 Ssa1p and TAg /ydj1P Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA MAL3-55 NA NA Dihydropyrimidine derivative Fold change -1.8 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000211 15448148 Hsp70 Ssa1p and TAg /ydj1P Yeast Cytosol Activation of ATPase activity (TAg stimulated) NA MAL3-87 NA NA Dihydropyrimidine derivative Fold change 1.8 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000212 15448148 Hsp70 Ssa1p and TAg /ydj1P Yeast Cytosol Activation of ATPase activity (TAg stimulated) NA MAL3-88 NA NA Dihydropyrimidine derivative Fold change 1.5 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000213 15448148 Hsp70 Ssa1p and TAg /ydj1P Yeast Cytosol Activation of ATPase activity (TAg stimulated) NA MAL3-90 NA NA Dihydropyrimidine derivative Fold change 4.2 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000214 15448148 Hsp70 Ssa1p and TAg /ydj1P Yeast Cytosol Activation of ATPase activity (TAg stimulated) NA MAL3-91 NA NA Dihydropyrimidine derivative Fold change 1.4 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000215 15448148 Hsp70 Ssa1p and TAg /ydj1P Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA MAL3-101 Benzyl 4-([1,1?-biphenyl]-4-yl)-1-(6-((2-(butylamino)-1-(4-(2-methoxy-2-oxoethoxy)-3-(methoxycarbonyl)phenyl)-2-oxoethyl)(hexyl)amino)-6-oxohexyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate O=C(C1=C(C)N(CCCCCC(N(C(C2=CC=C(OCC(OC)=O)C(C(OC)=O)=C2)C(NCCCC)=O)CCCCCC)=O)C(NC1C3=CC=C(C4=CC=CC=C4)C=C3)=O)OCC5=CC=CC=C5 Dihydropyrimidine derivative Fold change -4 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000216 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA MAL3-101 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 Dihydropyrimidine derivative Fold change 1.7 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000217 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA MAL3-51 N-[4-[[2-(tert-butylamino)-1-(4-iodophenyl)-2-oxoethyl]-(2-morpholin-4-ylethyl)amino]-4-oxobutyl]benzamide CC(C)(C)NC(=O)C(N(CCN1CCOCC1)C(=O)CCCNC(=O)c2ccccc2)c3ccc(I)cc3 Dihydropyrimidine derivative Fold change 1.1 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000218 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA DMT002272 6-[4-methyl-2-oxo-5-phenylmethoxycarbonyl-6-(2-phenylphenyl)-1,6-dihydropyrimidin-3-yl]hexanoic acid CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2ccccc2c3ccccc3)C(=O)OCc4ccccc4 Dihydropyrimidine derivative Fold change 1 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000219 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA DMT003034 6-(6-cyclohexyl-4-methyl-2-oxo-5-phenylmethoxycarbonyl-1,6-dihydropyrimidin-3-yl)hexanoic acid CC1=C(C(NC(=O)N1CCCCCC(O)=O)C2CCCCC2)C(=O)OCc3ccccc3 Dihydropyrimidine derivative Fold change 1 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000220 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA DMT003036 6-[6-(4-tert-butylphenyl)-4-methyl-2-oxo-5-phenylmethoxycarbonyl-1,6-dihydropyrimidin-3-yl]hexanoic acid CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2ccc(cc2)C(C)(C)C)C(=O)OCc3ccccc3 Dihydropyrimidine derivative Fold change 1 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000221 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA DMT003038 6-(6-cyclopropyl-4-methyl-2-oxo-5-phenylmethoxycarbonyl-1,6-dihydropyrimidin-3-yl)hexanoic acid CC1=C(C(NC(=O)N1CCCCCC(O)=O)C2CC2)C(=O)OCc3ccccc3 Dihydropyrimidine derivative Fold change 1.1 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000222 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA DMT003116 6-[6-(4-cyclohexylphenyl)-4-methyl-2-oxo-5-phenylmethoxycarbonyl-1,6-dihydropyrimidin-3-yl]hexanoic acid CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2ccc(cc2)C3CCCCC3)C(=O)OCc4ccccc4 Dihydropyrimidine derivative Fold change 1.1 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000223 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA MAL1-274 6-[6-(4-chlorophenyl)-4-methyl-2-oxo-5-phenylmethoxycarbonyl-1,6-dihydropyrimidin-3-yl]hexanoic acid CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2ccc(Cl)cc2)C(=O)OCc3ccccc3 Dihydropyrimidine derivative Fold change 1.3 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000224 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA MAL2-06A 6-(4-methyl-6-naphthalen-2-yl-2-oxo-5-phenylmethoxycarbonyl-1,6-dihydropyrimidin-3-yl)hexanoic acid CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2ccc3ccccc3c2)C(=O)OCc4ccccc4 Dihydropyrimidine derivative Fold change -1.1 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000225 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA MAL2-10A 6-(4-methyl-2-oxo-6-phenyl-5-phenylmethoxycarbonyl-1,6-dihydropyrimidin-3-yl)hexanoic acid CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2ccccc2)C(=O)OCc3ccccc3 Dihydropyrimidine derivative Fold change 1.5 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000226 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA MAL2-116-17 6-[4-methyl-6-(3-nitrophenyl)-2-oxo-5-phenylmethoxycarbonyl-1,6-dihydropyrimidin-3-yl]hexanoic acid CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2cccc(c2)[N+]([O-])=O)C(=O)OCc3ccccc3 Dihydropyrimidine derivative Fold change -1.1 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000227 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA MAL2-116-20 6-[4-methyl-2-oxo-5-phenylmethoxycarbonyl-6-[4-(trifluoromethyl)phenyl]-1,6-dihydropyrimidin-3-yl]hexanoic acid CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2ccc(cc2)C(F)(F)F)C(=O)OCc3ccccc3 Dihydropyrimidine derivative Fold change 1.2 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000228 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA MAL2-11B 6-[4-methyl-2-oxo-5-phenylmethoxycarbonyl-6-(4-phenylphenyl)-1,6-dihydropyrimidin-3-yl]hexanoic acid CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2ccc(cc2)c3ccccc3)C(=O)OCc4ccccc4 Dihydropyrimidine derivative Fold change 1.1 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000229 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA MAL2-13 6-[4-methyl-6-(4-nitrophenyl)-2-oxo-5-phenylmethoxycarbonyl-1,6-dihydropyrimidin-3-yl]hexanoic acid CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2ccc(cc2)[N+]([O-])=O)C(=O)OCc3ccccc3 Dihydropyrimidine derivative Fold change 1.2 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000230 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA DMT003042 benzyl 3-(6-methoxy-6-oxohexyl)-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate COC(=O)CCCCCN1C(=O)NC(c2ccc(cc2)c3ccccc3)C(=C1C)C(=O)OCc4ccccc4 Dihydropyrimidine derivative Fold change 2.6 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000231 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA DMT003044 benzyl 3-(6-methoxy-6-oxohexyl)-4-methyl-2-oxo-6-phenyl-1,6-dihydropyrimidine-5-carboxylate COC(=O)CCCCCN1C(=O)NC(c2ccccc2)C(=C1C)C(=O)OCc3ccccc3 Dihydropyrimidine derivative Fold change 2.3 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000232 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA DMT003046 benzyl 6-cyclopropyl-3-(6-methoxy-6-oxohexyl)-4-methyl-2-oxo-1,6-dihydropyrimidine-5-carboxylate COC(=O)CCCCCN1C(=O)NC(C2CC2)C(=C1C)C(=O)OCc3ccccc3 Dihydropyrimidine derivative Fold change 1.9 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000233 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA DMT003082 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-[4-(trifluoromethyl)phenyl]-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)C(F)(F)F)C(=C2C)C(=O)OCc4ccccc4 Dihydropyrimidine derivative Fold change 1 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000234 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA DMT003084 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-6-(4-tert-butylphenyl)-4-methyl-2-oxo-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)C(C)(C)C)C(=C2C)C(=O)OCc4ccccc4 Dihydropyrimidine derivative Fold change 1.2 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000235 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA DMT003086 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-6-(3-nitrophenyl)-2-oxo-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3cccc(c3)[N+]([O-])=O)C(=C2C)C(=O)OCc4ccccc4 Dihydropyrimidine derivative Fold change 1.1 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000236 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA DMT003088 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-phenyl-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccccc3)C(=C2C)C(=O)OCc4ccccc4 Dihydropyrimidine derivative Fold change 1.1 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000237 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA DMT003090 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-6-(4-chlorophenyl)-4-methyl-2-oxo-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc(Cl)cc3)C(=C2C)C(=O)OCc4ccccc4 Dihydropyrimidine derivative Fold change 1.3 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000238 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA DMT003092 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-6-(4-nitrophenyl)-2-oxo-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)[N+]([O-])=O)C(=C2C)C(=O)OCc4ccccc4 Dihydropyrimidine derivative Fold change 1 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000239 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA DMT003094 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-6-naphthalen-2-yl-2-oxo-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc4ccccc4c3)C(=C2C)C(=O)OCc5ccccc5 Dihydropyrimidine derivative Fold change 1 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000240 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA DMT003096 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(2-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccccc3c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 Dihydropyrimidine derivative Fold change -1.1 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000241 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA DMT003100 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-6-cyclohexyl-4-methyl-2-oxo-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(C3CCCCC3)C(=C2C)C(=O)OCc4ccccc4 Dihydropyrimidine derivative Fold change 1.2 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000242 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA DMT003132 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-6-cyclopropyl-4-methyl-2-oxo-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(C3CC3)C(=C2C)C(=O)OCc4ccccc4 Dihydropyrimidine derivative Fold change 1.2 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000243 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA DMT003134 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-6-(4-cyclohexylphenyl)-4-methyl-2-oxo-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)C4CCCCC4)C(=C2C)C(=O)OCc5ccccc5 Dihydropyrimidine derivative Fold change 2.2 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000244 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA DMT002218 benzyl 3-[6-[[2-(butylamino)-2-oxo-1-phenylethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccccc1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 Dihydropyrimidine derivative Fold change 3.2 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000245 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA DMT002220 benzyl 3-[6-[[2-(butylamino)-1-(4-hydroxyphenyl)-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(O)cc1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 Dihydropyrimidine derivative Fold change 11.8 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000246 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA DMT002222 benzyl 3-[6-[[2-(butylamino)-2-oxo-1-(4-phenylphenyl)ethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(cc1)c2ccccc2)C(=O)CCCCCN3C(=O)NC(c4ccc(cc4)c5ccccc5)C(=C3C)C(=O)OCc6ccccc6 Dihydropyrimidine derivative Fold change 9.9 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000247 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA DMT002260 benzyl 3-[6-[[2-(butylamino)-1-(3-methoxycarbonylphenyl)-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1cccc(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 Dihydropyrimidine derivative Fold change 3.7 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000248 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA DMT002262 benzyl 3-[6-[[1-(butylamino)-1-oxopropan-2-yl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C)C(=O)NCCCC)C(=O)CCCCCN1C(=O)NC(c2ccc(cc2)c3ccccc3)C(=C1C)C(=O)OCc4ccccc4 Dihydropyrimidine derivative Fold change 1.6 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000249 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA DMT002264 benzyl 3-[6-[[2-(butylamino)-1-cyclohexyl-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C1CCCCC1)C(=O)NCCCC)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 Dihydropyrimidine derivative Fold change 3.2 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000250 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA DMT003058 benzyl 3-[6-[[2-(butylamino)-2-oxo-1-pyridin-2-ylethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccccn1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 Dihydropyrimidine derivative Fold change 4.2 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000251 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA DMT003112 benzyl 3-[6-[[2-(butylamino)-1-(4-hydroxy-3-methoxycarbonylphenyl)-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(O)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 Dihydropyrimidine derivative Fold change 19.1 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000252 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA DMT003114 benzyl 3-[6-[[2-(butylamino)-1-[4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)cc1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 Dihydropyrimidine derivative Fold change 1.1 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000253 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA DMT002286 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-[2-(cyclohexen-1-yl)ethyl]amino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCNC(=O)C(N(CCC1=CCCCC1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5)c6ccc(OCC(=O)OC)c(c6)C(=O)OC Dihydropyrimidine derivative Fold change 6.1 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000254 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA DMT003052 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-(2-methoxyethyl)amino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCNC(=O)C(N(CCOC)C(=O)CCCCCN1C(=O)NC(c2ccc(cc2)c3ccccc3)C(=C1C)C(=O)OCc4ccccc4)c5ccc(OCC(=O)OC)c(c5)C(=O)OC Dihydropyrimidine derivative Fold change 1.5 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000255 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA DMT003102 benzyl 3-[6-[benzyl-[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]amino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCNC(=O)C(N(Cc1ccccc1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5)c6ccc(OCC(=O)OC)c(c6)C(=O)OC Dihydropyrimidine derivative Fold change 1.5 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000256 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA DMT003104 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-(2-phenylethyl)amino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCNC(=O)C(N(CCc1ccccc1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5)c6ccc(OCC(=O)OC)c(c6)C(=O)OC Dihydropyrimidine derivative Fold change 12.3 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000257 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA DMT003106 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-(pyridin-2-ylmethyl)amino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCNC(=O)C(N(Cc1ccccn1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5)c6ccc(OCC(=O)OC)c(c6)C(=O)OC Dihydropyrimidine derivative Fold change 1 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000258 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA DMT003108 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-(2-pyridin-2-ylethyl)amino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCNC(=O)C(N(CCc1ccccn1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5)c6ccc(OCC(=O)OC)c(c6)C(=O)OC Dihydropyrimidine derivative Fold change -1.1 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000259 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA DMT003110 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-[2-(1H-indol-3-yl)ethyl]amino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCNC(=O)C(N(CCc1c[nH]c2ccccc12)C(=O)CCCCCN3C(=O)NC(c4ccc(cc4)c5ccccc5)C(=C3C)C(=O)OCc6ccccc6)c7ccc(OCC(=O)OC)c(c7)C(=O)OC Dihydropyrimidine derivative Fold change 10.3 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000260 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA DMT003020 5-[2-(butylamino)-1-[hexyl-[6-[4-methyl-2-oxo-5-phenylmethoxycarbonyl-6-(4-phenylphenyl)-1,6-dihydropyrimidin-3-yl]hexanoyl]amino]-2-oxoethyl]-2-(carboxymethoxy)benzoic acid CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(O)=O)c(c1)C(O)=O)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 Dihydropyrimidine derivative Fold change 1.1 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000261 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA DMT003024 benzyl 3-[6-[[2-(butylamino)-2-oxo-1-(4-phenylphenyl)ethyl]-(2-morpholin-4-ylethyl)amino]-6-oxohexyl]-4-methyl-6-(4-nitrophenyl)-2-oxo-1,6-dihydropyrimidine-5-carboxylate CCCCNC(=O)C(N(CCN1CCOCC1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)[N+]([O-])=O)C(=C2C)C(=O)OCc4ccccc4)c5ccc(cc5)c6ccccc6 Dihydropyrimidine derivative Fold change 2.3 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000262 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA MAL3-101 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 Dihydropyrimidine derivative Fold change -2.0 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000263 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA MAL3-51 N-[4-[[2-(tert-butylamino)-1-(4-iodophenyl)-2-oxoethyl]-(2-morpholin-4-ylethyl)amino]-4-oxobutyl]benzamide CC(C)(C)NC(=O)C(N(CCN1CCOCC1)C(=O)CCCNC(=O)c2ccccc2)c3ccc(I)cc3 Dihydropyrimidine derivative Fold change -2.0 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000264 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA DMT002272 6-[4-methyl-2-oxo-5-phenylmethoxycarbonyl-6-(2-phenylphenyl)-1,6-dihydropyrimidin-3-yl]hexanoic acid CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2ccccc2c3ccccc3)C(=O)OCc4ccccc4 Dihydropyrimidine derivative Fold change -5.0 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000265 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA DMT003034 6-(6-cyclohexyl-4-methyl-2-oxo-5-phenylmethoxycarbonyl-1,6-dihydropyrimidin-3-yl)hexanoic acid CC1=C(C(NC(=O)N1CCCCCC(O)=O)C2CCCCC2)C(=O)OCc3ccccc3 Dihydropyrimidine derivative Fold change 1.5 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000266 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA DMT003036 6-[6-(4-tert-butylphenyl)-4-methyl-2-oxo-5-phenylmethoxycarbonyl-1,6-dihydropyrimidin-3-yl]hexanoic acid CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2ccc(cc2)C(C)(C)C)C(=O)OCc3ccccc3 Dihydropyrimidine derivative Fold change -3.5 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000267 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA DMT003038 6-(6-cyclopropyl-4-methyl-2-oxo-5-phenylmethoxycarbonyl-1,6-dihydropyrimidin-3-yl)hexanoic acid CC1=C(C(NC(=O)N1CCCCCC(O)=O)C2CC2)C(=O)OCc3ccccc3 Dihydropyrimidine derivative Fold change 1 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000268 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA DMT003116 6-[6-(4-cyclohexylphenyl)-4-methyl-2-oxo-5-phenylmethoxycarbonyl-1,6-dihydropyrimidin-3-yl]hexanoic acid CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2ccc(cc2)C3CCCCC3)C(=O)OCc4ccccc4 Dihydropyrimidine derivative Fold change -2.4 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000269 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA MAL1-274 6-[6-(4-chlorophenyl)-4-methyl-2-oxo-5-phenylmethoxycarbonyl-1,6-dihydropyrimidin-3-yl]hexanoic acid CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2ccc(Cl)cc2)C(=O)OCc3ccccc3 Dihydropyrimidine derivative Fold change -1.6 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000270 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA MAL2-06A 6-(4-methyl-6-naphthalen-2-yl-2-oxo-5-phenylmethoxycarbonyl-1,6-dihydropyrimidin-3-yl)hexanoic acid CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2ccc3ccccc3c2)C(=O)OCc4ccccc4 Dihydropyrimidine derivative Fold change -1.4 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000271 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA MAL2-10A 6-(4-methyl-2-oxo-6-phenyl-5-phenylmethoxycarbonyl-1,6-dihydropyrimidin-3-yl)hexanoic acid CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2ccccc2)C(=O)OCc3ccccc3 Dihydropyrimidine derivative Fold change -1.1 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000272 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA MAL2-116-17 6-[4-methyl-6-(3-nitrophenyl)-2-oxo-5-phenylmethoxycarbonyl-1,6-dihydropyrimidin-3-yl]hexanoic acid CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2cccc(c2)[N+]([O-])=O)C(=O)OCc3ccccc3 Dihydropyrimidine derivative Fold change 1.1 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000273 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA MAL2-116-20 6-[4-methyl-2-oxo-5-phenylmethoxycarbonyl-6-[4-(trifluoromethyl)phenyl]-1,6-dihydropyrimidin-3-yl]hexanoic acid CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2ccc(cc2)C(F)(F)F)C(=O)OCc3ccccc3 Dihydropyrimidine derivative Fold change 1.1 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000274 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA MAL2-11B 6-[4-methyl-2-oxo-5-phenylmethoxycarbonyl-6-(4-phenylphenyl)-1,6-dihydropyrimidin-3-yl]hexanoic acid CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2ccc(cc2)c3ccccc3)C(=O)OCc4ccccc4 Dihydropyrimidine derivative Fold change -3.5 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000275 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA MAL2-13 6-[4-methyl-6-(4-nitrophenyl)-2-oxo-5-phenylmethoxycarbonyl-1,6-dihydropyrimidin-3-yl]hexanoic acid CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2ccc(cc2)[N+]([O-])=O)C(=O)OCc3ccccc3 Dihydropyrimidine derivative Fold change 1.1 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000276 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA DMT003042 benzyl 3-(6-methoxy-6-oxohexyl)-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate COC(=O)CCCCCN1C(=O)NC(c2ccc(cc2)c3ccccc3)C(=C1C)C(=O)OCc4ccccc4 Dihydropyrimidine derivative Fold change -1.2 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000277 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA DMT003044 benzyl 3-(6-methoxy-6-oxohexyl)-4-methyl-2-oxo-6-phenyl-1,6-dihydropyrimidine-5-carboxylate COC(=O)CCCCCN1C(=O)NC(c2ccccc2)C(=C1C)C(=O)OCc3ccccc3 Dihydropyrimidine derivative Fold change -1.7 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000278 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA DMT003046 benzyl 6-cyclopropyl-3-(6-methoxy-6-oxohexyl)-4-methyl-2-oxo-1,6-dihydropyrimidine-5-carboxylate COC(=O)CCCCCN1C(=O)NC(C2CC2)C(=C1C)C(=O)OCc3ccccc3 Dihydropyrimidine derivative Fold change 1 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000279 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA DMT003082 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-[4-(trifluoromethyl)phenyl]-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)C(F)(F)F)C(=C2C)C(=O)OCc4ccccc4 Dihydropyrimidine derivative Fold change -4.8 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000280 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA DMT003084 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-6-(4-tert-butylphenyl)-4-methyl-2-oxo-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)C(C)(C)C)C(=C2C)C(=O)OCc4ccccc4 Dihydropyrimidine derivative Fold change -5.2 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000281 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA DMT003086 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-6-(3-nitrophenyl)-2-oxo-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3cccc(c3)[N+]([O-])=O)C(=C2C)C(=O)OCc4ccccc4 Dihydropyrimidine derivative Fold change -1.5 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000282 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA DMT003088 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-phenyl-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccccc3)C(=C2C)C(=O)OCc4ccccc4 Dihydropyrimidine derivative Fold change -1.1 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000283 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA DMT003090 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-6-(4-chlorophenyl)-4-methyl-2-oxo-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc(Cl)cc3)C(=C2C)C(=O)OCc4ccccc4 Dihydropyrimidine derivative Fold change -5.1 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000284 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA DMT003092 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-6-(4-nitrophenyl)-2-oxo-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)[N+]([O-])=O)C(=C2C)C(=O)OCc4ccccc4 Dihydropyrimidine derivative Fold change -1.1 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000285 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA DMT003094 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-6-naphthalen-2-yl-2-oxo-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc4ccccc4c3)C(=C2C)C(=O)OCc5ccccc5 Dihydropyrimidine derivative Fold change -1.1 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000286 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA DMT003096 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(2-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccccc3c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 Dihydropyrimidine derivative Fold change -4.0 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000287 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA DMT003100 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-6-cyclohexyl-4-methyl-2-oxo-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(C3CCCCC3)C(=C2C)C(=O)OCc4ccccc4 Dihydropyrimidine derivative Fold change -2.1 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000288 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA DMT003132 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-6-cyclopropyl-4-methyl-2-oxo-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(C3CC3)C(=C2C)C(=O)OCc4ccccc4 Dihydropyrimidine derivative Fold change -2.6 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000289 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA DMT003134 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-6-(4-cyclohexylphenyl)-4-methyl-2-oxo-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)C4CCCCC4)C(=C2C)C(=O)OCc5ccccc5 Dihydropyrimidine derivative Fold change -1.6 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000290 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA DMT002218 benzyl 3-[6-[[2-(butylamino)-2-oxo-1-phenylethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccccc1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 Dihydropyrimidine derivative Fold change 1.1 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000291 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA DMT002220 benzyl 3-[6-[[2-(butylamino)-1-(4-hydroxyphenyl)-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(O)cc1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 Dihydropyrimidine derivative Fold change 9.2 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000292 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA DMT002222 benzyl 3-[6-[[2-(butylamino)-2-oxo-1-(4-phenylphenyl)ethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(cc1)c2ccccc2)C(=O)CCCCCN3C(=O)NC(c4ccc(cc4)c5ccccc5)C(=C3C)C(=O)OCc6ccccc6 Dihydropyrimidine derivative Fold change 6 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000293 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA DMT002260 benzyl 3-[6-[[2-(butylamino)-1-(3-methoxycarbonylphenyl)-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1cccc(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 Dihydropyrimidine derivative Fold change -2.0 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000294 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA DMT002262 benzyl 3-[6-[[1-(butylamino)-1-oxopropan-2-yl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C)C(=O)NCCCC)C(=O)CCCCCN1C(=O)NC(c2ccc(cc2)c3ccccc3)C(=C1C)C(=O)OCc4ccccc4 Dihydropyrimidine derivative Fold change 1 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000295 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA DMT002264 benzyl 3-[6-[[2-(butylamino)-1-cyclohexyl-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C1CCCCC1)C(=O)NCCCC)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 Dihydropyrimidine derivative Fold change 1.1 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000296 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA DMT003058 benzyl 3-[6-[[2-(butylamino)-2-oxo-1-pyridin-2-ylethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccccn1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 Dihydropyrimidine derivative Fold change 5.5 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000297 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA DMT003112 benzyl 3-[6-[[2-(butylamino)-1-(4-hydroxy-3-methoxycarbonylphenyl)-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(O)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 Dihydropyrimidine derivative Fold change 2.1 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000298 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA DMT003114 benzyl 3-[6-[[2-(butylamino)-1-[4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)cc1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 Dihydropyrimidine derivative Fold change 1.2 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000299 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA DMT002286 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-[2-(cyclohexen-1-yl)ethyl]amino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCNC(=O)C(N(CCC1=CCCCC1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5)c6ccc(OCC(=O)OC)c(c6)C(=O)OC Dihydropyrimidine derivative Fold change -1.2 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000300 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA DMT003052 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-(2-methoxyethyl)amino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCNC(=O)C(N(CCOC)C(=O)CCCCCN1C(=O)NC(c2ccc(cc2)c3ccccc3)C(=C1C)C(=O)OCc4ccccc4)c5ccc(OCC(=O)OC)c(c5)C(=O)OC Dihydropyrimidine derivative Fold change -1.8 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000301 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA DMT003102 benzyl 3-[6-[benzyl-[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]amino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCNC(=O)C(N(Cc1ccccc1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5)c6ccc(OCC(=O)OC)c(c6)C(=O)OC Dihydropyrimidine derivative Fold change -1.9 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000302 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA DMT003104 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-(2-phenylethyl)amino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCNC(=O)C(N(CCc1ccccc1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5)c6ccc(OCC(=O)OC)c(c6)C(=O)OC Dihydropyrimidine derivative Fold change 1.3 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000303 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA DMT003106 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-(pyridin-2-ylmethyl)amino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCNC(=O)C(N(Cc1ccccn1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5)c6ccc(OCC(=O)OC)c(c6)C(=O)OC Dihydropyrimidine derivative Fold change -1.1 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000304 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA DMT003108 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-(2-pyridin-2-ylethyl)amino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCNC(=O)C(N(CCc1ccccn1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5)c6ccc(OCC(=O)OC)c(c6)C(=O)OC Dihydropyrimidine derivative Fold change -1.1 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000305 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA DMT003110 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-[2-(1H-indol-3-yl)ethyl]amino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCNC(=O)C(N(CCc1c[nH]c2ccccc12)C(=O)CCCCCN3C(=O)NC(c4ccc(cc4)c5ccccc5)C(=C3C)C(=O)OCc6ccccc6)c7ccc(OCC(=O)OC)c(c7)C(=O)OC Dihydropyrimidine derivative Fold change -1.3 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000306 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA DMT003020 5-[2-(butylamino)-1-[hexyl-[6-[4-methyl-2-oxo-5-phenylmethoxycarbonyl-6-(4-phenylphenyl)-1,6-dihydropyrimidin-3-yl]hexanoyl]amino]-2-oxoethyl]-2-(carboxymethoxy)benzoic acid CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(O)=O)c(c1)C(O)=O)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 Dihydropyrimidine derivative Fold change -2.2 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000307 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA DMT003024 benzyl 3-[6-[[2-(butylamino)-2-oxo-1-(4-phenylphenyl)ethyl]-(2-morpholin-4-ylethyl)amino]-6-oxohexyl]-4-methyl-6-(4-nitrophenyl)-2-oxo-1,6-dihydropyrimidine-5-carboxylate CCCCNC(=O)C(N(CCN1CCOCC1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)[N+]([O-])=O)C(=C2C)C(=O)OCc4ccccc4)c5ccc(cc5)c6ccccc6 Dihydropyrimidine derivative Fold change -5.0 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000308 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity MAL3-101 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 Dihydropyrimidine derivative NA NA NA NA NA NA NA 27 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000309 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity MAL3-51 N-[4-[[2-(tert-butylamino)-1-(4-iodophenyl)-2-oxoethyl]-(2-morpholin-4-ylethyl)amino]-4-oxobutyl]benzamide CC(C)(C)NC(=O)C(N(CCN1CCOCC1)C(=O)CCCNC(=O)c2ccccc2)c3ccc(I)cc3 Dihydropyrimidine derivative NA NA NA NA NA NA NA >50 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000310 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT002272 6-[4-methyl-2-oxo-5-phenylmethoxycarbonyl-6-(2-phenylphenyl)-1,6-dihydropyrimidin-3-yl]hexanoic acid CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2ccccc2c3ccccc3)C(=O)OCc4ccccc4 Dihydropyrimidine derivative NA NA NA NA NA NA NA >50 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000311 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT003034 6-(6-cyclohexyl-4-methyl-2-oxo-5-phenylmethoxycarbonyl-1,6-dihydropyrimidin-3-yl)hexanoic acid CC1=C(C(NC(=O)N1CCCCCC(O)=O)C2CCCCC2)C(=O)OCc3ccccc3 Dihydropyrimidine derivative NA NA NA NA NA NA NA >50 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000312 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT003036 6-[6-(4-tert-butylphenyl)-4-methyl-2-oxo-5-phenylmethoxycarbonyl-1,6-dihydropyrimidin-3-yl]hexanoic acid CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2ccc(cc2)C(C)(C)C)C(=O)OCc3ccccc3 Dihydropyrimidine derivative NA NA NA NA NA NA NA >50 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000313 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT003038 6-(6-cyclopropyl-4-methyl-2-oxo-5-phenylmethoxycarbonyl-1,6-dihydropyrimidin-3-yl)hexanoic acid CC1=C(C(NC(=O)N1CCCCCC(O)=O)C2CC2)C(=O)OCc3ccccc3 Dihydropyrimidine derivative NA NA NA NA NA NA NA >50 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000314 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT003116 6-[6-(4-cyclohexylphenyl)-4-methyl-2-oxo-5-phenylmethoxycarbonyl-1,6-dihydropyrimidin-3-yl]hexanoic acid CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2ccc(cc2)C3CCCCC3)C(=O)OCc4ccccc4 Dihydropyrimidine derivative NA NA NA NA NA NA NA >50 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000315 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity MAL1-274 6-[6-(4-chlorophenyl)-4-methyl-2-oxo-5-phenylmethoxycarbonyl-1,6-dihydropyrimidin-3-yl]hexanoic acid CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2ccc(Cl)cc2)C(=O)OCc3ccccc3 Dihydropyrimidine derivative NA NA NA NA NA NA NA >50 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000316 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity MAL2-06A 6-(4-methyl-6-naphthalen-2-yl-2-oxo-5-phenylmethoxycarbonyl-1,6-dihydropyrimidin-3-yl)hexanoic acid CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2ccc3ccccc3c2)C(=O)OCc4ccccc4 Dihydropyrimidine derivative NA NA NA NA NA NA NA >50 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000317 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity MAL2-10A 6-(4-methyl-2-oxo-6-phenyl-5-phenylmethoxycarbonyl-1,6-dihydropyrimidin-3-yl)hexanoic acid CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2ccccc2)C(=O)OCc3ccccc3 Dihydropyrimidine derivative NA NA NA NA NA NA NA >50 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000318 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity MAL2-116-17 6-[4-methyl-6-(3-nitrophenyl)-2-oxo-5-phenylmethoxycarbonyl-1,6-dihydropyrimidin-3-yl]hexanoic acid CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2cccc(c2)[N+]([O-])=O)C(=O)OCc3ccccc3 Dihydropyrimidine derivative NA NA NA NA NA NA NA >50 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000319 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity MAL2-116-20 6-[4-methyl-2-oxo-5-phenylmethoxycarbonyl-6-[4-(trifluoromethyl)phenyl]-1,6-dihydropyrimidin-3-yl]hexanoic acid CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2ccc(cc2)C(F)(F)F)C(=O)OCc3ccccc3 Dihydropyrimidine derivative NA NA NA NA NA NA NA >50 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000320 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity MAL2-11B 6-[4-methyl-2-oxo-5-phenylmethoxycarbonyl-6-(4-phenylphenyl)-1,6-dihydropyrimidin-3-yl]hexanoic acid CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2ccc(cc2)c3ccccc3)C(=O)OCc4ccccc4 Dihydropyrimidine derivative NA NA NA NA NA NA NA >50 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000321 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity MAL2-13 6-[4-methyl-6-(4-nitrophenyl)-2-oxo-5-phenylmethoxycarbonyl-1,6-dihydropyrimidin-3-yl]hexanoic acid CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2ccc(cc2)[N+]([O-])=O)C(=O)OCc3ccccc3 Dihydropyrimidine derivative NA NA NA NA NA NA NA >50 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000322 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT003042 benzyl 3-(6-methoxy-6-oxohexyl)-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate COC(=O)CCCCCN1C(=O)NC(c2ccc(cc2)c3ccccc3)C(=C1C)C(=O)OCc4ccccc4 Dihydropyrimidine derivative NA NA NA NA NA NA NA >50 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000323 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT003044 benzyl 3-(6-methoxy-6-oxohexyl)-4-methyl-2-oxo-6-phenyl-1,6-dihydropyrimidine-5-carboxylate COC(=O)CCCCCN1C(=O)NC(c2ccccc2)C(=C1C)C(=O)OCc3ccccc3 Dihydropyrimidine derivative NA NA NA NA NA NA NA >50 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000324 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT003046 benzyl 6-cyclopropyl-3-(6-methoxy-6-oxohexyl)-4-methyl-2-oxo-1,6-dihydropyrimidine-5-carboxylate COC(=O)CCCCCN1C(=O)NC(C2CC2)C(=C1C)C(=O)OCc3ccccc3 Dihydropyrimidine derivative NA NA NA NA NA NA NA >50 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000325 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT003082 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-[4-(trifluoromethyl)phenyl]-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)C(F)(F)F)C(=C2C)C(=O)OCc4ccccc4 Dihydropyrimidine derivative NA NA NA NA NA NA NA >50 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000326 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT003084 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-6-(4-tert-butylphenyl)-4-methyl-2-oxo-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)C(C)(C)C)C(=C2C)C(=O)OCc4ccccc4 Dihydropyrimidine derivative NA NA NA NA NA NA NA 29 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000327 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT003086 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-6-(3-nitrophenyl)-2-oxo-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3cccc(c3)[N+]([O-])=O)C(=C2C)C(=O)OCc4ccccc4 Dihydropyrimidine derivative NA NA NA NA NA NA NA 6 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000328 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT003088 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-phenyl-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccccc3)C(=C2C)C(=O)OCc4ccccc4 Dihydropyrimidine derivative NA NA NA NA NA NA NA 6.5 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000329 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT003090 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-6-(4-chlorophenyl)-4-methyl-2-oxo-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc(Cl)cc3)C(=C2C)C(=O)OCc4ccccc4 Dihydropyrimidine derivative NA NA NA NA NA NA NA 16 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000330 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT003092 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-6-(4-nitrophenyl)-2-oxo-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)[N+]([O-])=O)C(=C2C)C(=O)OCc4ccccc4 Dihydropyrimidine derivative NA NA NA NA NA NA NA 6.9 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000331 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT003094 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-6-naphthalen-2-yl-2-oxo-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc4ccccc4c3)C(=C2C)C(=O)OCc5ccccc5 Dihydropyrimidine derivative NA NA NA NA NA NA NA 10 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000332 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT003096 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(2-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccccc3c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 Dihydropyrimidine derivative NA NA NA NA NA NA NA 17 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000333 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT003100 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-6-cyclohexyl-4-methyl-2-oxo-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(C3CCCCC3)C(=C2C)C(=O)OCc4ccccc4 Dihydropyrimidine derivative NA NA NA NA NA NA NA 6.3 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000334 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT003132 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-6-cyclopropyl-4-methyl-2-oxo-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(C3CC3)C(=C2C)C(=O)OCc4ccccc4 Dihydropyrimidine derivative NA NA NA NA NA NA NA 6.2 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000335 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT003134 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-6-(4-cyclohexylphenyl)-4-methyl-2-oxo-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)C4CCCCC4)C(=C2C)C(=O)OCc5ccccc5 Dihydropyrimidine derivative NA NA NA NA NA NA NA 42 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000336 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT002218 benzyl 3-[6-[[2-(butylamino)-2-oxo-1-phenylethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccccc1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 Dihydropyrimidine derivative NA NA NA NA NA NA NA >50 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000337 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT002220 benzyl 3-[6-[[2-(butylamino)-1-(4-hydroxyphenyl)-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(O)cc1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 Dihydropyrimidine derivative NA NA NA NA NA NA NA >50 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000338 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT002222 benzyl 3-[6-[[2-(butylamino)-2-oxo-1-(4-phenylphenyl)ethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(cc1)c2ccccc2)C(=O)CCCCCN3C(=O)NC(c4ccc(cc4)c5ccccc5)C(=C3C)C(=O)OCc6ccccc6 Dihydropyrimidine derivative NA NA NA NA NA NA NA >50 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000339 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT002260 benzyl 3-[6-[[2-(butylamino)-1-(3-methoxycarbonylphenyl)-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1cccc(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 Dihydropyrimidine derivative NA NA NA NA NA NA NA >50 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000340 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT002262 benzyl 3-[6-[[1-(butylamino)-1-oxopropan-2-yl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C)C(=O)NCCCC)C(=O)CCCCCN1C(=O)NC(c2ccc(cc2)c3ccccc3)C(=C1C)C(=O)OCc4ccccc4 Dihydropyrimidine derivative NA NA NA NA NA NA NA >50 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000341 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT002264 benzyl 3-[6-[[2-(butylamino)-1-cyclohexyl-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C1CCCCC1)C(=O)NCCCC)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 Dihydropyrimidine derivative NA NA NA NA NA NA NA >50 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000342 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT003058 benzyl 3-[6-[[2-(butylamino)-2-oxo-1-pyridin-2-ylethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccccn1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 Dihydropyrimidine derivative NA NA NA NA NA NA NA >50 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000343 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT003112 benzyl 3-[6-[[2-(butylamino)-1-(4-hydroxy-3-methoxycarbonylphenyl)-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(O)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 Dihydropyrimidine derivative NA NA NA NA NA NA NA >50 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000344 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT003114 benzyl 3-[6-[[2-(butylamino)-1-[4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)cc1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 Dihydropyrimidine derivative NA NA NA NA NA NA NA 48 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000345 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT002286 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-[2-(cyclohexen-1-yl)ethyl]amino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCNC(=O)C(N(CCC1=CCCCC1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5)c6ccc(OCC(=O)OC)c(c6)C(=O)OC Dihydropyrimidine derivative NA NA NA NA NA NA NA 39 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000346 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT003052 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-(2-methoxyethyl)amino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCNC(=O)C(N(CCOC)C(=O)CCCCCN1C(=O)NC(c2ccc(cc2)c3ccccc3)C(=C1C)C(=O)OCc4ccccc4)c5ccc(OCC(=O)OC)c(c5)C(=O)OC Dihydropyrimidine derivative NA NA NA NA NA NA NA 8.8 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000347 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT003102 benzyl 3-[6-[benzyl-[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]amino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCNC(=O)C(N(Cc1ccccc1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5)c6ccc(OCC(=O)OC)c(c6)C(=O)OC Dihydropyrimidine derivative NA NA NA NA NA NA NA 14 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000348 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT003104 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-(2-phenylethyl)amino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCNC(=O)C(N(CCc1ccccc1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5)c6ccc(OCC(=O)OC)c(c6)C(=O)OC Dihydropyrimidine derivative NA NA NA NA NA NA NA 32 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000349 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT003106 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-(pyridin-2-ylmethyl)amino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCNC(=O)C(N(Cc1ccccn1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5)c6ccc(OCC(=O)OC)c(c6)C(=O)OC Dihydropyrimidine derivative NA NA NA NA NA NA NA 7.1 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000350 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT003108 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-(2-pyridin-2-ylethyl)amino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCNC(=O)C(N(CCc1ccccn1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5)c6ccc(OCC(=O)OC)c(c6)C(=O)OC Dihydropyrimidine derivative NA NA NA NA NA NA NA 7.5 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000351 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT003110 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-[2-(1H-indol-3-yl)ethyl]amino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCNC(=O)C(N(CCc1c[nH]c2ccccc12)C(=O)CCCCCN3C(=O)NC(c4ccc(cc4)c5ccccc5)C(=C3C)C(=O)OCc6ccccc6)c7ccc(OCC(=O)OC)c(c7)C(=O)OC Dihydropyrimidine derivative NA NA NA NA NA NA NA >50 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000352 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT003020 5-[2-(butylamino)-1-[hexyl-[6-[4-methyl-2-oxo-5-phenylmethoxycarbonyl-6-(4-phenylphenyl)-1,6-dihydropyrimidin-3-yl]hexanoyl]amino]-2-oxoethyl]-2-(carboxymethoxy)benzoic acid CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(O)=O)c(c1)C(O)=O)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 Dihydropyrimidine derivative NA NA NA NA NA NA NA >50 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000353 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT003024 benzyl 3-[6-[[2-(butylamino)-2-oxo-1-(4-phenylphenyl)ethyl]-(2-morpholin-4-ylethyl)amino]-6-oxohexyl]-4-methyl-6-(4-nitrophenyl)-2-oxo-1,6-dihydropyrimidine-5-carboxylate CCCCNC(=O)C(N(CCN1CCOCC1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)[N+]([O-])=O)C(=C2C)C(=O)OCc4ccccc4)c5ccc(cc5)c6ccccc6 Dihydropyrimidine derivative NA NA NA NA NA NA NA >50 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000354 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity MAL3-101 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 Dihydropyrimidine derivative NA NA NA NA NA NA NA 14.7 NA NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000355 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity MAL3-51 N-[4-[[2-(tert-butylamino)-1-(4-iodophenyl)-2-oxoethyl]-(2-morpholin-4-ylethyl)amino]-4-oxobutyl]benzamide CC(C)(C)NC(=O)C(N(CCN1CCOCC1)C(=O)CCCNC(=O)c2ccccc2)c3ccc(I)cc3 Dihydropyrimidine derivative NA NA NA NA NA NA NA >50 NA NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000356 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT003088 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-phenyl-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccccc3)C(=C2C)C(=O)OCc4ccccc4 Dihydropyrimidine derivative NA NA NA NA NA NA NA 2.4 NA NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000357 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT003132 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-6-cyclopropyl-4-methyl-2-oxo-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(C3CC3)C(=C2C)C(=O)OCc4ccccc4 Dihydropyrimidine derivative NA NA NA NA NA NA NA 6.3 NA NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000358 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT003052 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-(2-methoxyethyl)amino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCNC(=O)C(N(CCOC)C(=O)CCCCCN1C(=O)NC(c2ccc(cc2)c3ccccc3)C(=C1C)C(=O)OCc4ccccc4)c5ccc(OCC(=O)OC)c(c5)C(=O)OC Dihydropyrimidine derivative NA NA NA NA NA NA NA 7.8 NA NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000359 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity MAL3-101 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 Dihydropyrimidine derivative NA NA NA NA NA NA NA >50 NA NA NA MTT viability assay NA NA NA HT29 Cancer HSPMDB000360 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity MAL3-51 N-[4-[[2-(tert-butylamino)-1-(4-iodophenyl)-2-oxoethyl]-(2-morpholin-4-ylethyl)amino]-4-oxobutyl]benzamide CC(C)(C)NC(=O)C(N(CCN1CCOCC1)C(=O)CCCNC(=O)c2ccccc2)c3ccc(I)cc3 Dihydropyrimidine derivative NA NA NA NA NA NA NA >50 NA NA NA MTT viability assay NA NA NA HT29 Cancer HSPMDB000361 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT003088 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-phenyl-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccccc3)C(=C2C)C(=O)OCc4ccccc4 Dihydropyrimidine derivative NA NA NA NA NA NA NA 4.8 NA NA NA MTT viability assay NA NA NA HT29 Cancer HSPMDB000362 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT003132 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-6-cyclopropyl-4-methyl-2-oxo-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(C3CC3)C(=C2C)C(=O)OCc4ccccc4 Dihydropyrimidine derivative NA NA NA NA NA NA NA 5.3 NA NA NA MTT viability assay NA NA NA HT29 Cancer HSPMDB000363 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT003052 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-(2-methoxyethyl)amino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCNC(=O)C(N(CCOC)C(=O)CCCCCN1C(=O)NC(c2ccc(cc2)c3ccccc3)C(=C1C)C(=O)OCc4ccccc4)c5ccc(OCC(=O)OC)c(c5)C(=O)OC Dihydropyrimidine derivative NA NA NA NA NA NA NA 3.1 NA NA NA MTT viability assay NA NA NA HT29 Cancer HSPMDB000364 21426241 Hsp70 PfHsp70-1 Plasmodium falciparum Cytosol and nucleus Inhibition of protein aggregation activity NA Malonganenone A 3-methyl-7-[(2E,6E,11Z)-3,7,11,15-tetramethyl-13-oxohexadeca-2,6,11-trien-1-yl]-6,7-dihydro-3H-purin-6-one CC(C)CC(=O)\C=C(\C)CCC\C(C)=C\CC\C(C)=C\CN1C=NC2=C1C(=O)N=CN2C Marine tetraprenylated alkaloid >90% at 300 uM NA NA NA NA NA NA NA NA Substrate aggregation suppression assay NA NA NA NA NA NA Malaria HSPMDB000365 21426241 Hsp70 PfHsp70-1 Plasmodium falciparum Cytosol and nucleus Inhibition of protein aggregation activity NA Malonganenone B N-methyl-4-(N-methylformamido)-1-[(2E,6E,11Z)-3,7,11,15-tetramethyl-13-oxohexadeca-2,6,11-trien-1-yl]-1H-imidazole-5-carboxamide [H]C(=O)N(C)C1=C(N(C\C=C(/C)CC\C=C(/C)CCC\C(C)=C/C(=O)CC(C)C)C=N1)C(=O)NC Marine tetraprenylated alkaloid >90% at 300 uM NA NA NA NA NA NA NA NA Substrate aggregation suppression assay NA NA NA NA NA NA Malaria HSPMDB000366 21426241 Hsp70 PfHsp70-1 Plasmodium falciparum Cytosol and nucleus Inhibition of protein aggregation activity NA Malonganenone C N-[(2E,6E,11Z)-3,7,11,15-tetramethyl-13-oxohexadeca-2,6,11-trien-1-yl]formamide [H]C(=O)NC\C=C(/C)CC\C=C(/C)CCC\C(C)=C/C(=O)CC(C)C Marine tetraprenylated alkaloid >90% at 300 uM NA NA NA NA NA NA NA NA Substrate aggregation suppression assay NA NA NA NA NA NA Malaria HSPMDB000367 21426241 Hsp70 PfHsp70-1 Plasmodium falciparum Cytosol and nucleus Inhibition of protein aggregation activity NA Lapachol 2-hydroxy-3-(3-methylbut-2-en-1-yl)-1,4-dihydronaphthalene-1,4-dione CC(C)=CCC1=C(O)C(=O)C2=C(C=CC=C2)C1=O 1,4 naphthoquinone >90% at 300 uM NA NA NA NA NA NA NA NA Substrate aggregation suppression assay NA NA NA NA NA NA Malaria HSPMDB000368 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Almond NA NA Flavonoid 95% NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000369 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Vanilla NA NA Flavonoid 92% NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000370 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Chili Powder NA NA Flavonoid 101% NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000371 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Cloves NA NA Flavonoid 59% NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000372 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Chives NA NA Flavonoid 88% NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000373 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Chocolate NA NA Flavonoid 96% NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000374 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Cilantro (leaves) NA NA Flavonoid 91% NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000375 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Cinnamon NA NA Flavonoid 46% NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000376 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Coriander NA NA Flavonoid 98% NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000377 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Cumin NA NA Flavonoid 94% NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000378 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Allspice NA NA Flavonoid 53% NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000379 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Dill weed NA NA Flavonoid 94% NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000380 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Fennel seed NA NA Flavonoid 93% NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000381 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Fenugreek seed NA NA Flavonoid 98% NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000382 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Galangal NA NA Flavonoid 86% NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000383 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Ginger NA NA Flavonoid 94% NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000384 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Lemon (peel) NA NA Flavonoid 99% NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000385 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Mustard NA NA Flavonoid 84% NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000386 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Nutmeg NA NA Flavonoid 89% NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000387 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Orange (peel) NA NA Flavonoid 96% NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000388 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Black Tea NA NA Flavonoid 55% NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000389 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Paprika NA NA Flavonoid 104% NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000390 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Parsley flakes NA NA Flavonoid 96% NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000391 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Pepper (cayenne) NA NA Flavonoid 101% NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000392 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Poppy seed NA NA Flavonoid 98% NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000393 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Red Pepper NA NA Flavonoid 99% NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000394 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA White Tea NA NA Flavonoid 67% NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000395 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Turmeric Root NA NA Flavonoid 101% NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000396 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Anise Seeds NA NA Flavonoid 96% NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000397 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Vanilla Bean NA NA Flavonoid 97% NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000398 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA White pepper NA NA Flavonoid 89% NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000399 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Aloe NA NA Flavonoid 90% NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000400 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Basil leaves NA NA Flavonoid 94% NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000401 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Cocoa NA NA Flavonoid 68% NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000402 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Cardamom NA NA Flavonoid 102% NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000403 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Chili powder NA NA Flavonoid 96% NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000404 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Quercetin 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one OC1=CC2=C(C(O)=C1)C(=O)C(O)=C(O2)C1=CC=C(O)C(O)=C1 Flavonoid 67% at 200 uM NA NA 24.9 NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000405 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA QTE 2-(3,4-dimethoxyphenyl)-3-hydroxy-5,7-dimethoxy-4H-chromen-4-one COC1=CC2=C(C(=O)C(O)=C(O2)C2=CC=C(OC)C(OC)=C2)C(OC)=C1 Flavonoid NA NA NA >200 NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000406 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Rhamnetin 2-(3,4-dihydroxyphenyl)-3,5-dihydroxy-7-methoxy-4H-chromen-4-one COC1=CC2=C(C(O)=C1)C(=O)C(O)=C(O2)C1=CC=C(O)C(O)=C1 Flavonoid 13% at 200 uM NA NA >200 NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000407 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity (DnaJ stimulated) NA Myricetin 3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)-4H-chromen-4-one OC1=CC2=C(C(O)=C1)C(=O)C(O)=C(O2)C1=CC(O)=C(O)C(O)=C1 Flavonoid 75% at 200 uM NA NA 14.5 NA NA NA NA Nucleotide binding domain ATPase assay NA NA NA NA NA NA NA HSPMDB000408 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Kaempferol 3,5,7-trihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one OC1=CC=C(C=C1)C1=C(O)C(=O)C2=C(O1)C=C(O)C=C2O Flavonoid 15% at 200 uM NA NA >200 NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000409 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Morin 2-(2,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one OC1=CC=C(C(O)=C1)C1=C(O)C(=O)C2=C(O1)C=C(O)C=C2O Flavonoid 28% at 200 uM NA NA >200 NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000410 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Hieracin 5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-4H-chromen-4-one OC1=CC2=C(C(O)=C1)C(=O)C=C(O2)C1=CC(O)=C(O)C(O)=C1 Flavonoid 48% at 200 uM NA NA 28.2 NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000411 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Luleolin 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4H-chromen-4-one OC1=CC2=C(C(O)=C1)C(=O)C=C(O2)C1=CC=C(O)C(O)=C1 Flavonoid 54% at 200 uM NA NA 9.4 NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000412 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Taxifolin 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-3,4-dihydro-2H-1-benzopyran-4-one OC1C(OC2=C(C(O)=CC(O)=C2)C1=O)C1=CC(O)=C(O)C=C1 Flavonoid 12% at 200 uM NA NA >200 NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000413 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA (+) Cafechin 2-(3,4-dihydroxyphenyl)-3,4-dihydro-2H-1-benzopyran-3,5,7-triol OC1CC2=C(OC1C1=CC(O)=C(O)C=C1)C=C(O)C=C2O Flavonoid NA NA NA >200 NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000414 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA (-)-Epigallocatechin 2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-1-benzopyran-3,5,7-triol OC1CC2=C(OC1C1=CC(O)=C(O)C(O)=C1)C=C(O)C=C2O Flavonoid 0 at 200 uM NA NA >200 NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000415 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA ECG 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3,4-dihydro-2H-1-benzopyran-3-yl 3,4,5-trihydroxybenzoate OC1=CC2=C(CC(OC(=O)C3=CC(O)=C(O)C(O)=C3)C(O2)C2=CC=C(O)C(O)=C2)C(O)=C1 Flavonoid 70 at 200 uM NA NA 6 NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000416 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA EGCG 5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-1-benzopyran-3-yl 3,4,5-trihydroxybenzoate OC1=CC2=C(CC(OC(=O)C3=CC(O)=C(O)C(O)=C3)C(O2)C2=CC(O)=C(O)C(O)=C2)C(O)=C1 Flavonoid 62 at 200 uM NA NA 12 NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000417 25772468 Hsp70 Hsp70 Human Cytosol Inhibition of ATPase activity NA Apoptozole (Az) 4-[[2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)imidazol-1-yl]methyl]benzamide COC1=CC=C(C=C1)C2=C(N(C(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)CC4=CC=C(C=C4)C(=O)N)C5=CC=C(C=C5)OC Imidazole 32% at 100 uM NA NA NA NA NA NA NA Nucleotide binding domain ATPase assay NA NA NA NA NA NA Cancer HSPMDB000418 25772468 Hsp70 Hsp70 Human Cytosol Inhibition of ATPase activity NA Apoptozole (Az) 4-[[2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)imidazol-1-yl]methyl]benzamide COC1=CC=C(C=C1)C2=C(N(C(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)CC4=CC=C(C=C4)C(=O)N)C5=CC=C(C=C5)OC Imidazole 65% at 200 uM NA NA NA NA NA NA NA Nucleotide binding domain ATPase assay NA NA NA NA NA NA Cancer HSPMDB000419 25772468 Hsp70 Hsp70 Human Cytosol Inhibition of ATPase activity NA 1 N-{2-[2-(2-aminoethoxy)ethoxy]ethyl}-4-({2-[2,4-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)benzamide COC1=CC=C(C=C1)C1=C(N(CC2=CC=C(C=C2)C(=O)NCCOCCOCCN)C(=N1)C1=C(C=C(C=C1)C(F)(F)F)C(F)(F)F)C1=CC=C(OC)C=C1 Imidazole library 17.5% at 100 uM NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA Cancer HSPMDB000420 25772468 Hsp70 Hsp70 Human Cytosol Inhibition of ATPase activity NA 2 N-{2-[2-(2-aminoethoxy)ethoxy]ethyl}-4-{[4,5-bis(4-methoxyphenyl)-2-[3-(trifluoromethyl)phenyl]-1H-imidazol-1-yl]methyl}benzamide COC1=CC=C(C=C1)C1=C(N(CC2=CC=C(C=C2)C(=O)NCCOCCOCCN)C(=N1)C1=CC=CC(=C1)C(F)(F)F)C1=CC=C(OC)C=C1 Imidazole library 12.5% at 100 uM NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA Cancer HSPMDB000421 25772468 Hsp70 Hsp70 Human Cytosol Inhibition of ATPase activity NA 3 N-{2-[2-(2-aminoethoxy)ethoxy]ethyl}-4-{[4,5-bis(4-methoxyphenyl)-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-1-yl]methyl}benzamide COC1=CC=C(C=C1)C1=C(N(CC2=CC=C(C=C2)C(=O)NCCOCCOCCN)C(=N1)C1=CC=C(C=C1)C(F)(F)F)C1=CC=C(OC)C=C1 Imidazole library 15% at 100 uM NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA Cancer HSPMDB000422 25772468 Hsp70 Hsp70 Human Cytosol Inhibition of ATPase activity NA 4 1,3-dimethyl 5-(1-{[4-({2-[2-(2-aminoethoxy)ethoxy]ethyl}carbamoyl)phenyl]methyl}-4,5-bis(4-methoxyphenyl)-1H-imidazol-2-yl)benzene-1,3-dicarboxylate COC(=O)C1=CC(=CC(=C1)C(=O)OC)C1=NC(=C(N1CC1=CC=C(C=C1)C(=O)NCCOCCOCCN)C1=CC=C(OC)C=C1)C1=CC=C(OC)C=C1 Imidazole library 17.5% at 100 uM NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA Cancer HSPMDB000423 25772468 Hsp70 Hsp70 Human Cytosol Inhibition of ATPase activity NA 5 N-{2-[2-(2-aminoethoxy)ethoxy]ethyl}-4-{[2-(3,5-dimethylphenyl)-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl]methyl}benzamide COC1=CC=C(C=C1)C1=C(N(CC2=CC=C(C=C2)C(=O)NCCOCCOCCN)C(=N1)C1=CC(C)=CC(C)=C1)C1=CC=C(OC)C=C1 Imidazole library 12.5% at 100 uM NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA Cancer HSPMDB000424 25772468 Hsp70 Hsp70 Human Cytosol Inhibition of ATPase activity NA 6 N-{2-[2-(2-aminoethoxy)ethoxy]ethyl}-4-{[2-(3,5-dimethoxyphenyl)-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl]methyl}benzamide COC1=CC=C(C=C1)C1=C(N(CC2=CC=C(C=C2)C(=O)NCCOCCOCCN)C(=N1)C1=CC(OC)=CC(OC)=C1)C1=CC=C(OC)C=C1 Imidazole library 10% at 100 uM NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA Cancer HSPMDB000425 25772468 Hsp70 Hsp70 Human Cytosol Inhibition of ATPase activity NA 7 N-{2-[2-(2-aminoethoxy)ethoxy]ethyl}-4-{[4,5-bis(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)-1H-imidazol-1-yl]methyl}benzamide COC1=CC=C(C=C1)C1=C(N(CC2=CC=C(C=C2)C(=O)NCCOCCOCCN)C(=N1)C1=CC(OC)=C(OC)C(OC)=C1)C1=CC=C(OC)C=C1 Imidazole library 5% at 100 uM NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA Cancer HSPMDB000426 25772468 Hsp70 Hsp70 Human Cytosol Inhibition of ATPase activity NA 8 N-{2-[2-(2-aminoethoxy)ethoxy]ethyl}-4-{[4,5-bis(4-chlorophenyl)-2-[3-(difluoromethyl)-5-(trifluoromethyl)phenyl]-1H-imidazol-1-yl]methyl}benzamide NCCOCCOCCNC(=O)C1=CC=C(CN2C(=NC(=C2C2=CC=C(Cl)C=C2)C2=CC=C(Cl)C=C2)C2=CC(=CC(=C2)C(F)(F)F)C(F)F)C=C1 Imidazole library 7.5% at 100 uM NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA Cancer HSPMDB000427 25772468 Hsp70 Hsp70 Human Cytosol Inhibition of ATPase activity NA 9 N-{2-[2-(2-aminoethoxy)ethoxy]ethyl}-4-{[4,5-bis(4-bromophenyl)-2-[3-(difluoromethyl)-5-(trifluoromethyl)phenyl]-1H-imidazol-1-yl]methyl}benzamide NCCOCCOCCNC(=O)C1=CC=C(CN2C(=NC(=C2C2=CC=C(Br)C=C2)C2=CC=C(Br)C=C2)C2=CC(=CC(=C2)C(F)(F)F)C(F)F)C=C1 Imidazole library 10% at 100 uM NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA Cancer HSPMDB000428 25772468 Hsp70 Hsp70 Human Cytosol Inhibition of ATPase activity NA 10 N-{2-[2-(2-aminoethoxy)ethoxy]ethyl}-4-({2-[3-(difluoromethyl)-5-(trifluoromethyl)phenyl]-4,5-bis(4-methylphenyl)-1H-imidazol-1-yl}methyl)benzamide CC1=CC=C(C=C1)C1=C(N(CC2=CC=C(C=C2)C(=O)NCCOCCOCCN)C(=N1)C1=CC(=CC(=C1)C(F)(F)F)C(F)F)C1=CC=C(C)C=C1 Imidazole library 12.5% at 100 uM NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA Cancer HSPMDB000429 25772468 Hsp70 Hsp70 Human Cytosol Inhibition of ATPase activity NA 11 N-{2-[2-(2-aminoethoxy)ethoxy]ethyl}-4-({2-[3-(difluoromethyl)-5-(trifluoromethyl)phenyl]-4,5-bis[4-(dimethylamino)phenyl]-1H-imidazol-1-yl}methyl)benzamide CN(C)C1=CC=C(C=C1)C1=C(N(CC2=CC=C(C=C2)C(=O)NCCOCCOCCN)C(=N1)C1=CC(=CC(=C1)C(F)(F)F)C(F)F)C1=CC=C(C=C1)N(C)C Imidazole library 12.5% at 100 uM NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA Cancer HSPMDB000430 25772468 Hsp70 Hsp70 Human Cytosol Inhibition of ATPase activity NA 12 N-{2-[2-(2-aminoethoxy)ethoxy]ethyl}-4-({2-[3-(difluoromethyl)-5-(trifluoromethyl)phenyl]-4,5-bis(quinolin-6-yl)-1H-imidazol-1-yl}methyl)benzamide NCCOCCOCCNC(=O)C1=CC=C(CN2C(=NC(=C2C2=CC3=C(C=C2)N=CC=C3)C2=CC=C3N=CC=CC3=C2)C2=CC(=CC(=C2)C(F)(F)F)C(F)F)C=C1 Imidazole library 7.5% at 100 uM NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA Cancer HSPMDB000431 25772468 Hsp70 Hsp70 Human Cytosol Inhibition of ATPase activity NA 13 N-{2-[2-(2-aminoethoxy)ethoxy]ethyl}-4-({2-[3-(difluoromethyl)-5-(trifluoromethyl)phenyl]-4,5-bis(naphthalen-2-yl)-1H-imidazol-1-yl}methyl)benzamide NCCOCCOCCNC(=O)C1=CC=C(CN2C(=NC(=C2C2=CC3=C(C=CC=C3)C=C2)C2=CC=C3C=CC=CC3=C2)C2=CC(=CC(=C2)C(F)(F)F)C(F)F)C=C1 Imidazole library 10% at 100 uM NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA Cancer HSPMDB000432 25772468 Hsp70 Hsp70 Human Cytosol Inhibition of ATPase activity NA 14 N-{2-[2-(2-aminoethoxy)ethoxy]ethyl}-4-{[4,5-bis(2H-1,3-benzodioxol-5-yl)-2-[3-(difluoromethyl)-5-(trifluoromethyl)phenyl]-1H-imidazol-1-yl]methyl}benzamide NCCOCCOCCNC(=O)C1=CC=C(CN2C(=NC(=C2C2=CC3=C(OCO3)C=C2)C2=CC=C3OCOC3=C2)C2=CC(=CC(=C2)C(F)(F)F)C(F)F)C=C1 Imidazole library 10% at 100 uM NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA Cancer HSPMDB000433 25772468 Hsp70 Hsp70 Human Cytosol Inhibition of ATPase activity NA 15 4-({2-[3-(difluoromethyl)-5-(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)benzamide COC1=CC=C(C=C1)C1=C(N(CC2=CC=C(C=C2)C(N)=O)C(=N1)C1=CC(=CC(=C1)C(F)(F)F)C(F)F)C1=CC=C(OC)C=C1 Imidazole library 15% at 100 uM NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA Cancer HSPMDB000434 25772468 Hsp70 Hsp70 Human Cytosol NA Antiproliferative activity Apoptozole (Az) 4-[[2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)imidazol-1-yl]methyl]benzamide COC1=CC=C(C=C1)C2=C(N(C(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)CC4=CC=C(C=C4)C(=O)N)C5=CC=C(C=C5)OC Imidazole NA NA NA 7 NA NA NA NA Nucleotide binding domain NA NA MTT viability assay NA NA NA A549 Cancer HSPMDB000435 25772468 Hsp70 Hsp70 Human Cytosol NA Antiproliferative activity Apoptozole (Az) 4-[[2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)imidazol-1-yl]methyl]benzamide COC1=CC=C(C=C1)C2=C(N(C(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)CC4=CC=C(C=C4)C(=O)N)C5=CC=C(C=C5)OC Imidazole NA NA NA 6 NA NA NA NA Nucleotide binding domain NA NA MTT viability assay NA NA NA HeLa Cancer HSPMDB000436 25772468 Hsp70 Hsp70 Human Cytosol NA Antiproliferative activity Apoptozole (Az) 4-[[2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)imidazol-1-yl]methyl]benzamide COC1=CC=C(C=C1)C2=C(N(C(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)CC4=CC=C(C=C4)C(=O)N)C5=CC=C(C=C5)OC Imidazole NA NA NA 6 NA NA NA NA Nucleotide binding domain NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000437 25772468 Hsp70 Hsp70 Human Cytosol NA Antiproliferative activity Apoptozole (Az) 4-[[2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)imidazol-1-yl]methyl]benzamide COC1=CC=C(C=C1)C2=C(N(C(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)CC4=CC=C(C=C4)C(=O)N)C5=CC=C(C=C5)OC Imidazole NA NA NA 5 NA NA NA NA Nucleotide binding domain NA NA MTT viability assay NA NA NA HepG2 Cancer HSPMDB000438 19256508 Hsp70 Hsc70 Human Cytosol Inhibition of ATP binding NA 1 [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate C1=NC2=C(C(=N1)N)N=CN2C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O Adenosine derivative NA NA NA 0.5 NA NA NA NA Nucleotide binding domain Fluorescence polarization (FP) assay NA NA NA NA NA NA NA HSPMDB000439 19256508 Hsp70 Hsc70 Human Cytosol Inhibition of ATP binding NA 2 [(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphono hydrogen phosphate C1=NC2=C(C(=N1)N)N=CN2C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O Adenosine derivative NA NA NA 0.5 NA NA NA NA Nucleotide binding domain Fluorescence polarization (FP) assay NA NA NA NA NA NA NA HSPMDB000440 19256508 Hsp70 Hsc70 Human Cytosol Inhibition of ATP binding NA 3 (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol NC1=C2N=CN([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)C2=NC=N1 Adenosine derivative NA NA NA 560 NA NA NA NA Nucleotide binding domain Fluorescence polarization (FP) assay NA NA NA NA NA NA NA HSPMDB000441 19256508 Hsp70 Hsc70 Human Cytosol Inhibition of ATP binding NA 4 (2R,3R,4S,5R)-2-(6,8-diamino-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol NC1=NC2=C(N)N=CN=C2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O Adenosine derivative NA NA NA 9.4 NA NA NA NA Nucleotide binding domain Fluorescence polarization (FP) assay NA NA NA NA NA NA NA HSPMDB000442 19256508 Hsp70 Hsc70 Human Cytosol Inhibition of ATP binding NA 5 (2R,3R,4S,5R)-2-[6-amino-8-(methylamino)-9H-purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol CNC1=NC2=C(N)N=CN=C2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O Adenosine derivative NA NA NA 17 NA NA NA NA Nucleotide binding domain Fluorescence polarization (FP) assay NA NA NA NA NA NA NA HSPMDB000443 19256508 Hsp70 Hsc70 Human Cytosol Inhibition of ATP binding NA 6 (2R,3R,4S,5R)-2-[6-amino-8-(benzylamino)-9H-purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol NC1=C2N=C(NCC3=CC=CC=C3)N([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)C2=NC=N1 Adenosine derivative NA NA NA 10 NA NA NA NA Nucleotide binding domain Fluorescence polarization (FP) assay NA NA NA NA NA NA NA HSPMDB000444 19256508 Hsp70 Hsc70 Human Cytosol Inhibition of ATP binding NA 7 (2R,3R,4S,5R)-2-[6-Amino-8-(3,4-dichlorobenzylamino)purin-9-yl]-5-hydroxymethyltetrahydrofuran-3,4-diol Nc1ncnc2n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c(NCc4ccc(Cl)c(Cl)c4)nc12 Adenosine derivative NA NA NA 9.1 NA NA NA NA Nucleotide binding domain Fluorescence polarization (FP) assay NA NA NA NA NA NA NA HSPMDB000445 19256508 Hsp70 Hsc70 Human Cytosol Inhibition of ATP binding NA 8 (2R,3R,4S,5R)-2-{6-Amino-8-[(benzo[1,3]dioxol-5-ylmethyl)-amino]-purin-9-yl}-5- hydroxymethyltetrahydrofuran-3,4-diol Nc1ncnc2n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c(NCc4ccc5OCOc5c4)nc12 Adenosine derivative NA NA NA 4.9 NA NA NA NA Nucleotide binding domain Fluorescence polarization (FP) assay NA NA NA NA NA NA NA HSPMDB000446 19256508 Hsp70 Hsc70 Human Cytosol Inhibition of ATP binding NA 9 (2R,3R,4S,5R)-2-{6-Amino-8-[(quinolin-6-ylmethyl)amino]purin-9-yl}-5-hydroxymethyltetrahydrofuran-3,4-diol Nc1ncnc2n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c(NCc4ccc5ncccc5c4)nc12 Adenosine derivative NA NA NA 2.9 NA NA NA NA Nucleotide binding domain Fluorescence polarization (FP) assay NA NA NA NA NA NA NA HSPMDB000447 19256508 Hsp70 Hsc70 Human Cytosol Inhibition of ATP binding NA 10 (2R,3R,4S,5R)-2-[6-Amino-8-(3,4-dichlorobenzylamino)-purin-9-yl]-5-methoxymethyltetrahydrofuran-3,4-diol COC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n2c(NCc3ccc(Cl)c(Cl)c3)nc4c(N)ncnc24 Adenosine derivative NA NA NA 3.2 NA NA NA NA Nucleotide binding domain Fluorescence polarization (FP) assay NA NA NA NA NA NA NA HSPMDB000448 19256508 Hsp70 Hsc70 Human Cytosol Inhibition of ATP binding NA 11 (2R,3R,4S,5R)-2-[6-Amino-8-(3,4-dichlorobenzylamino)-purin-9-yl]-5-benzyloxymethyltetrahydrofuran-3,4-diol Nc1ncnc2n([C@@H]3O[C@H](COCc4ccccc4)[C@@H](O)[C@H]3O)c(NCc5ccc(Cl)c(Cl)c5)nc12 Adenosine derivative NA NA NA 2.4 NA NA NA NA Nucleotide binding domain Fluorescence polarization (FP) assay NA NA NA NA NA NA NA HSPMDB000449 19256508 Hsp70 Hsc70 Human Cytosol Inhibition of ATP binding NA 12 4-{(2R,3S,4R,5R)-5-[6-Amino-8-(3,4-dichlorobenzylamino)purin-9-yl]-3,4- dihydroxytetrahydrofuran-2-ylmethoxymethyl}benzonitrile Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc5ccc(Cl)c(Cl)c5)nc12 Adenosine derivative NA NA NA 0.5 NA NA NA NA Nucleotide binding domain Fluorescence polarization (FP) assay NA NA NA NA NA NA NA HSPMDB000450 19256508 Hsp70 Hsc70 Human Cytosol Inhibition of ATP binding NA 13 4-[(2R,3S,4R,5R)-5-(6-Amino-8-benzylamino-purin-9-yl)-3,4-dihydroxy-tetrahydro-furan-2- ylmethoxymethyl]-benzonitrile Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc5ccccc5)nc12 Adenosine derivative NA NA NA 1.3 NA NA NA NA Nucleotide binding domain Fluorescence polarization (FP) assay NA NA NA NA NA NA NA HSPMDB000451 19256508 Hsp70 Hsc70 Human Cytosol Inhibition of ATP binding NA 14 (2R,3R,4S,5R)-2-[6-Amino-8-(3,4-dichlorobenzylamino)-purin-9-yl]-5-(3,4,5-trifluorobenzyloxymethyl)-tetrahydrofuran-3,4-diol Nc1ncnc2n([C@@H]3O[C@H](COCc4cc(F)c(F)c(F)c4)[C@@H](O)[C@H]3O)c(NCc5ccc(Cl)c(Cl)c5)nc12 Adenosine derivative NA NA NA 1.7 NA NA NA NA Nucleotide binding domain Fluorescence polarization (FP) assay NA NA NA NA NA NA NA HSPMDB000452 19256508 Hsp70 Hsc70 Human Cytosol Inhibition of ATP binding NA 15 4-((2R,3S,4R,5R)-5-{6-Amino-8-[(quinolin-6-ylmethyl)-amino]-purin-9-yl}-3,4-dihydroxytetrahydrofuran-2-ylmethoxymethyl)-benzonitrile Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc5ccc6ncccc6c5)nc12 Adenosine derivative NA NA NA 0.9 NA NA NA NA Nucleotide binding domain Fluorescence polarization (FP) assay NA NA NA NA NA NA NA HSPMDB000453 19256508 Hsp70 Hsc70 Human Cytosol Inhibition of ATP binding NA 16 (2R,3R,4S,5R)-2-{6-Amino-8-[(quinolin-6-ylmethyl)-amino]-purin-9-yl}-5-(4-trifluoromethylbenzyloxymethyl)-tetrahydrofuran-3,4-diol Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C(F)(F)F)[C@@H](O)[C@H]3O)c(NCc5ccc6ncccc6c5)nc12 Adenosine derivative NA NA NA 0.6 NA NA NA NA Nucleotide binding domain Fluorescence polarization (FP) assay NA NA NA NA NA NA NA HSPMDB000454 19256508 Hsp70 Hsc70 Human Cytosol Inhibition of ATP binding NA 17 (2R,3R,4S,5R)-2-{6-Amino-8-[(quinolin-6-ylmethyl)-amino]-purin-9-yl}-5-(3,4,5- trifluorobenzyloxymethyl)-tetrahydrofuran-3,4-diol Nc1ncnc2n([C@@H]3O[C@H](COCc4cc(F)c(F)c(F)c4)[C@@H](O)[C@H]3O)c(NCc5ccc6ncccc6c5)nc12 Adenosine derivative NA NA NA <0.4 NA NA NA NA Nucleotide binding domain Fluorescence polarization (FP) assay NA NA NA NA NA NA NA HSPMDB000455 19256508 Hsp70 Hsc70 Human Cytosol Binding affinity NA 2 [(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphono hydrogen phosphate C1=NC2=C(C(=N1)N)N=CN2C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O Adenosine derivative NA 0.5 NA NA NA NA NA NA Nucleotide binding domain HSP70 Biacore Direct Binding Assay NA NA NA NA NA NA NA HSPMDB000456 19256508 Hsp70 Hsc70 Human Cytosol Binding affinity NA 4 (2R,3R,4S,5R)-2-(6,8-diamino-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol NC1=NC2=C(N)N=CN=C2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O Adenosine derivative NA 11 NA NA NA NA NA NA Nucleotide binding domain HSP70 Biacore Direct Binding Assay NA NA NA NA NA NA NA HSPMDB000457 19256508 Hsp70 Hsc70 Human Cytosol Binding affinity NA 12 4-{(2R,3S,4R,5R)-5-[6-Amino-8-(3,4-dichlorobenzylamino)purin-9-yl]-3,4- dihydroxytetrahydrofuran-2-ylmethoxymethyl}benzonitrile Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc5ccc(Cl)c(Cl)c5)nc12 Adenosine derivative NA 0.3 NA NA NA NA NA NA Nucleotide binding domain HSP70 Biacore Direct Binding Assay NA NA NA NA NA NA NA HSPMDB000458 19256508 Hsp70 Hsc70 Human Cytosol Binding affinity NA 13 4-[(2R,3S,4R,5R)-5-(6-Amino-8-benzylamino-purin-9-yl)-3,4-dihydroxy-tetrahydro-furan-2- ylmethoxymethyl]-benzonitrile Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc5ccccc5)nc12 Adenosine derivative NA 0.2 NA NA NA NA NA NA Nucleotide binding domain HSP70 Biacore Direct Binding Assay NA NA NA NA NA NA NA HSPMDB000459 19256508 Hsp70 Hsc70 Human Cytosol Binding affinity NA 14 (2R,3R,4S,5R)-2-[6-Amino-8-(3,4-dichlorobenzylamino)-purin-9-yl]-5-(3,4,5-trifluorobenzyloxymethyl)-tetrahydrofuran-3,4-diol Nc1ncnc2n([C@@H]3O[C@H](COCc4cc(F)c(F)c(F)c4)[C@@H](O)[C@H]3O)c(NCc5ccc(Cl)c(Cl)c5)nc12 Adenosine derivative NA 4.2 NA NA NA NA NA NA Nucleotide binding domain HSP70 Biacore Direct Binding Assay NA NA NA NA NA NA NA HSPMDB000460 19256508 Hsp70 Hsc70 Human Cytosol Binding affinity NA 15 4-((2R,3S,4R,5R)-5-{6-Amino-8-[(quinolin-6-ylmethyl)-amino]-purin-9-yl}-3,4-dihydroxytetrahydrofuran-2-ylmethoxymethyl)-benzonitrile Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc5ccc6ncccc6c5)nc12 Adenosine derivative NA 0.05 NA NA NA NA NA NA Nucleotide binding domain HSP70 Biacore Direct Binding Assay NA NA NA NA NA NA NA HSPMDB000461 19256508 Hsp70 Hsc70 Human Cytosol Binding affinity NA 16 (2R,3R,4S,5R)-2-{6-Amino-8-[(quinolin-6-ylmethyl)-amino]-purin-9-yl}-5-(4-trifluoromethylbenzyloxymethyl)-tetrahydrofuran-3,4-diol Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C(F)(F)F)[C@@H](O)[C@H]3O)c(NCc5ccc6ncccc6c5)nc12 Adenosine derivative NA 0.06 NA NA NA NA NA NA Nucleotide binding domain HSP70 Biacore Direct Binding Assay NA NA NA NA NA NA NA HSPMDB000462 19256508 Hsp70 Hsc70 Human Cytosol Binding affinity NA 17 (2R,3R,4S,5R)-2-{6-Amino-8-[(quinolin-6-ylmethyl)-amino]-purin-9-yl}-5-(3,4,5- trifluorobenzyloxymethyl)-tetrahydrofuran-3,4-diol Nc1ncnc2n([C@@H]3O[C@H](COCc4cc(F)c(F)c(F)c4)[C@@H](O)[C@H]3O)c(NCc5ccc6ncccc6c5)nc12 Adenosine derivative NA 0.12 NA NA NA NA NA NA Nucleotide binding domain HSP70 Biacore Direct Binding Assay NA NA NA NA NA NA NA HSPMDB000463 19256508 Hsp70 Hsc70 Human Cytosol NA Antiproliferative activity 4 (2R,3R,4S,5R)-2-(6,8-diamino-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol NC1=NC2=C(N)N=CN=C2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O Adenosine derivative NA NA NA NA NA NA NA 0.05 Nucleotide binding domain NA NA MTT viability assay NA NA NA HCT116 NA HSPMDB000464 19256508 Hsp70 Hsc70 Human Cytosol NA Antiproliferative activity 5 (2R,3R,4S,5R)-2-[6-amino-8-(methylamino)-9H-purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol CNC1=NC2=C(N)N=CN=C2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O Adenosine derivative NA NA NA NA NA NA NA 13 Nucleotide binding domain NA NA MTT viability assay NA NA NA HCT116 NA HSPMDB000465 19256508 Hsp70 Hsc70 Human Cytosol NA Antiproliferative activity 6 (2R,3R,4S,5R)-2-[6-amino-8-(benzylamino)-9H-purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol NC1=C2N=C(NCC3=CC=CC=C3)N([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)C2=NC=N1 Adenosine derivative NA NA NA NA NA NA NA >80 Nucleotide binding domain NA NA MTT viability assay NA NA NA HCT116 NA HSPMDB000466 19256508 Hsp70 Hsc70 Human Cytosol NA Antiproliferative activity 7 (2R,3R,4S,5R)-2-[6-Amino-8-(3,4-dichlorobenzylamino)purin-9-yl]-5-hydroxymethyltetrahydrofuran-3,4-diol Nc1ncnc2n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c(NCc4ccc(Cl)c(Cl)c4)nc12 Adenosine derivative NA NA NA NA NA NA NA 26 Nucleotide binding domain NA NA MTT viability assay NA NA NA HCT116 NA HSPMDB000467 19256508 Hsp70 Hsc70 Human Cytosol NA Antiproliferative activity 8 (2R,3R,4S,5R)-2-{6-Amino-8-[(benzo[1,3]dioxol-5-ylmethyl)-amino]-purin-9-yl}-5- hydroxymethyltetrahydrofuran-3,4-diol Nc1ncnc2n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c(NCc4ccc5OCOc5c4)nc12 Adenosine derivative NA NA NA NA NA NA NA >80 Nucleotide binding domain NA NA MTT viability assay NA NA NA HCT116 NA HSPMDB000468 19256508 Hsp70 Hsc70 Human Cytosol NA Antiproliferative activity 9 (2R,3R,4S,5R)-2-{6-Amino-8-[(quinolin-6-ylmethyl)amino]purin-9-yl}-5-hydroxymethyltetrahydrofuran-3,4-diol Nc1ncnc2n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c(NCc4ccc5ncccc5c4)nc12 Adenosine derivative NA NA NA NA NA NA NA >80 Nucleotide binding domain NA NA MTT viability assay NA NA NA HCT116 NA HSPMDB000469 19256508 Hsp70 Hsc70 Human Cytosol NA Antiproliferative activity 10 (2R,3R,4S,5R)-2-[6-Amino-8-(3,4-dichlorobenzylamino)-purin-9-yl]-5-methoxymethyltetrahydrofuran-3,4-diol COC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n2c(NCc3ccc(Cl)c(Cl)c3)nc4c(N)ncnc24 Adenosine derivative NA NA NA NA NA NA NA >80 Nucleotide binding domain NA NA MTT viability assay NA NA NA HCT116 NA HSPMDB000470 19256508 Hsp70 Hsc70 Human Cytosol NA Antiproliferative activity 11 (2R,3R,4S,5R)-2-[6-Amino-8-(3,4-dichlorobenzylamino)-purin-9-yl]-5-benzyloxymethyltetrahydrofuran-3,4-diol Nc1ncnc2n([C@@H]3O[C@H](COCc4ccccc4)[C@@H](O)[C@H]3O)c(NCc5ccc(Cl)c(Cl)c5)nc12 Adenosine derivative NA NA NA NA NA NA NA >80 Nucleotide binding domain NA NA MTT viability assay NA NA NA HCT116 NA HSPMDB000471 19256508 Hsp70 Hsc70 Human Cytosol NA Antiproliferative activity 12 4-{(2R,3S,4R,5R)-5-[6-Amino-8-(3,4-dichlorobenzylamino)purin-9-yl]-3,4- dihydroxytetrahydrofuran-2-ylmethoxymethyl}benzonitrile Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc5ccc(Cl)c(Cl)c5)nc12 Adenosine derivative NA NA NA NA NA NA NA 5 Nucleotide binding domain NA NA MTT viability assay NA NA NA HCT116 NA HSPMDB000472 19256508 Hsp70 Hsc70 Human Cytosol NA Antiproliferative activity 13 4-[(2R,3S,4R,5R)-5-(6-Amino-8-benzylamino-purin-9-yl)-3,4-dihydroxy-tetrahydro-furan-2- ylmethoxymethyl]-benzonitrile Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc5ccccc5)nc12 Adenosine derivative NA NA NA NA NA NA NA > 80 Nucleotide binding domain NA NA MTT viability assay NA NA NA HCT116 NA HSPMDB000473 19256508 Hsp70 Hsc70 Human Cytosol NA Antiproliferative activity 14 (2R,3R,4S,5R)-2-[6-Amino-8-(3,4-dichlorobenzylamino)-purin-9-yl]-5-(3,4,5-trifluorobenzyloxymethyl)-tetrahydrofuran-3,4-diol Nc1ncnc2n([C@@H]3O[C@H](COCc4cc(F)c(F)c(F)c4)[C@@H](O)[C@H]3O)c(NCc5ccc(Cl)c(Cl)c5)nc12 Adenosine derivative NA NA NA NA NA NA NA 13 Nucleotide binding domain NA NA MTT viability assay NA NA NA HCT116 NA HSPMDB000474 19256508 Hsp70 Hsc70 Human Cytosol NA Antiproliferative activity 15 4-((2R,3S,4R,5R)-5-{6-Amino-8-[(quinolin-6-ylmethyl)-amino]-purin-9-yl}-3,4-dihydroxytetrahydrofuran-2-ylmethoxymethyl)-benzonitrile Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc5ccc6ncccc6c5)nc12 Adenosine derivative NA NA NA NA NA NA NA >80 Nucleotide binding domain NA NA MTT viability assay NA NA NA HCT116 NA HSPMDB000475 19256508 Hsp70 Hsc70 Human Cytosol NA Antiproliferative activity 16 (2R,3R,4S,5R)-2-{6-Amino-8-[(quinolin-6-ylmethyl)-amino]-purin-9-yl}-5-(4-trifluoromethylbenzyloxymethyl)-tetrahydrofuran-3,4-diol Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C(F)(F)F)[C@@H](O)[C@H]3O)c(NCc5ccc6ncccc6c5)nc12 Adenosine derivative NA NA NA NA NA NA NA 27 Nucleotide binding domain NA NA MTT viability assay NA NA NA HCT116 NA HSPMDB000476 19256508 Hsp70 Hsc70 Human Cytosol NA Antiproliferative activity 17 (2R,3R,4S,5R)-2-{6-Amino-8-[(quinolin-6-ylmethyl)-amino]-purin-9-yl}-5-(3,4,5- trifluorobenzyloxymethyl)-tetrahydrofuran-3,4-diol Nc1ncnc2n([C@@H]3O[C@H](COCc4cc(F)c(F)c(F)c4)[C@@H](O)[C@H]3O)c(NCc5ccc6ncccc6c5)nc12 Adenosine derivative NA NA NA NA NA NA NA 18 Nucleotide binding domain NA NA MTT viability assay NA NA NA HCT116 NA HSPMDB000477 20012863 Hsp70 Hsp70 Human Cytosol Inhibition of ATP binding NA VER-155008 4-[[(2R,3S,4R,5R)-5-[6-amino-8-[(3,4-dichlorophenyl)methylamino]purin-9-yl]-3,4-dihydroxyoxolan-2-yl]methoxymethyl]benzonitrile C1=CC(=CC=C1COCC2C(C(C(O2)N3C4=C(C(=NC=N4)N)N=C3NCC5=CC(=C(C=C5)Cl)Cl)O)O)C#N Dibenzyl-8-amino adenosine analogue NA NA NA 0.5 NA NA NA NA Nucleotide binding domain Fluorescence polarization (FP) assay NA NA NA NA NA NA NA HSPMDB000478 20012863 Hsp70 Hsc70 Human Cytosol Inhibition of ATP binding NA VER-155008 4-[[(2R,3S,4R,5R)-5-[6-amino-8-[(3,4-dichlorophenyl)methylamino]purin-9-yl]-3,4-dihydroxyoxolan-2-yl]methoxymethyl]benzonitrile C1=CC(=CC=C1COCC2C(C(C(O2)N3C4=C(C(=NC=N4)N)N=C3NCC5=CC(=C(C=C5)Cl)Cl)O)O)C#N Dibenzyl-8-amino adenosine analogue NA NA NA 2.6 NA NA NA NA Nucleotide binding domain Fluorescence polarization (FP) assay NA NA NA NA NA NA NA HSPMDB000479 20012863 Hsp70 Hsp70 Human Cytosol Binding affinity NA VER-155008 4-[[(2R,3S,4R,5R)-5-[6-amino-8-[(3,4-dichlorophenyl)methylamino]purin-9-yl]-3,4-dihydroxyoxolan-2-yl]methoxymethyl]benzonitrile C1=CC(=CC=C1COCC2C(C(C(O2)N3C4=C(C(=NC=N4)N)N=C3NCC5=CC(=C(C=C5)Cl)Cl)O)O)C#N Dibenzyl-8-amino adenosine analogue NA 0.3 NA NA NA NA NA NA Nucleotide binding domain Surface plasmon resonance (SPR) NA NA NA NA NA NA NA HSPMDB000480 20012863 Hsp70 GRP78 Human Endoplasmic reticulum Inhibition of ATP binding NA VER-155008 4-[[(2R,3S,4R,5R)-5-[6-amino-8-[(3,4-dichlorophenyl)methylamino]purin-9-yl]-3,4-dihydroxyoxolan-2-yl]methoxymethyl]benzonitrile C1=CC(=CC=C1COCC2C(C(C(O2)N3C4=C(C(=NC=N4)N)N=C3NCC5=CC(=C(C=C5)Cl)Cl)O)O)C#N Dibenzyl-8-amino adenosine analogue NA NA NA 2.6 NA NA NA NA Nucleotide binding domain Fluorescence polarization (FP) assay NA NA NA NA NA NA NA HSPMDB000481 20012863 Hsp70 Hsp70 Human Cytosol NA Antiproliferative activity VER-155008 4-[[(2R,3S,4R,5R)-5-[6-amino-8-[(3,4-dichlorophenyl)methylamino]purin-9-yl]-3,4-dihydroxyoxolan-2-yl]methoxymethyl]benzonitrile C1=CC(=CC=C1COCC2C(C(C(O2)N3C4=C(C(=NC=N4)N)N=C3NCC5=CC(=C(C=C5)Cl)Cl)O)O)C#N Dibenzyl-8-amino adenosine analogue NA NA NA NA NA NA NA 10.4 Nucleotide binding domain NA NA Cell cycle analysis NA NA NA BT474 NA HSPMDB000482 20012863 Hsp70 Hsp70 Human Cytosol NA Antiproliferative activity VER-155008 4-[[(2R,3S,4R,5R)-5-[6-amino-8-[(3,4-dichlorophenyl)methylamino]purin-9-yl]-3,4-dihydroxyoxolan-2-yl]methoxymethyl]benzonitrile C1=CC(=CC=C1COCC2C(C(C(O2)N3C4=C(C(=NC=N4)N)N=C3NCC5=CC(=C(C=C5)Cl)Cl)O)O)C#N Dibenzyl-8-amino adenosine analogue NA NA NA NA NA NA NA 14.4 Nucleotide binding domain NA NA Cell cycle analysis NA NA NA MDA-MB-468 NA HSPMDB000483 20012863 Hsp70 Hsp70 Human Cytosol NA Antiproliferative activity VER-155008 4-[[(2R,3S,4R,5R)-5-[6-amino-8-[(3,4-dichlorophenyl)methylamino]purin-9-yl]-3,4-dihydroxyoxolan-2-yl]methoxymethyl]benzonitrile C1=CC(=CC=C1COCC2C(C(C(O2)N3C4=C(C(=NC=N4)N)N=C3NCC5=CC(=C(C=C5)Cl)Cl)O)O)C#N Dibenzyl-8-amino adenosine analogue NA NA NA NA NA NA NA 5.3 Nucleotide binding domain NA NA Cell cycle analysis NA NA NA HCT116 NA HSPMDB000484 20012863 Hsp70 Hsp70 Human Cytosol NA Antiproliferative activity VER-155008 4-[[(2R,3S,4R,5R)-5-[6-amino-8-[(3,4-dichlorophenyl)methylamino]purin-9-yl]-3,4-dihydroxyoxolan-2-yl]methoxymethyl]benzonitrile C1=CC(=CC=C1COCC2C(C(C(O2)N3C4=C(C(=NC=N4)N)N=C3NCC5=CC(=C(C=C5)Cl)Cl)O)O)C#N Dibenzyl-8-amino adenosine analogue NA NA NA NA NA NA NA 12.8 Nucleotide binding domain NA NA Cell cycle analysis NA NA NA HT29 NA HSPMDB000485 20012863 Hsp70 Hsc70 (HSPA8) and Hsp70 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity VER-82160 2-amino-4-{2,4-dichloro-5-[2-(diethylamino)ethoxy]phenyl}-N-ethylthieno[2,3-d]pyrimidine-6-carboxamide CCNC(=O)C1=CC2=C(S1)N=C(N)N=C2C1=C(Cl)C=C(Cl)C(OCCN(CC)CC)=C1 Dibenzyl-8-amino adenosine analogue NA NA NA NA NA NA NA 0.073 NA NA NA Cell cycle analysis NA NA NA BT474 NA HSPMDB000486 20012863 Hsp70 Hsc70 (HSPA8) and Hsp70 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity VER-82160 2-amino-4-{2,4-dichloro-5-[2-(diethylamino)ethoxy]phenyl}-N-ethylthieno[2,3-d]pyrimidine-6-carboxamide CCNC(=O)C1=CC2=C(S1)N=C(N)N=C2C1=C(Cl)C=C(Cl)C(OCCN(CC)CC)=C1 Dibenzyl-8-amino adenosine analogue NA NA NA NA NA NA NA 0.123 NA NA NA Cell cycle analysis NA NA NA MDA-MB-468 NA HSPMDB000487 20012863 Hsp70 Hsc70 (HSPA8) and Hsp70 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity VER-82160 2-amino-4-{2,4-dichloro-5-[2-(diethylamino)ethoxy]phenyl}-N-ethylthieno[2,3-d]pyrimidine-6-carboxamide CCNC(=O)C1=CC2=C(S1)N=C(N)N=C2C1=C(Cl)C=C(Cl)C(OCCN(CC)CC)=C1 Dibenzyl-8-amino adenosine analogue NA NA NA NA NA NA NA 0.154 NA NA NA Cell cycle analysis NA NA NA HCT116 NA HSPMDB000488 20026329 Hsp70 Hsp70-Hsp40 Porcine Cytosol Inhibition of chaperone activity NA Gentamycin 2-[4,6-diamino-3-[3-amino-6-[1-(methylamino)ethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol CC(C1CCC(C(O1)OC2C(CC(C(C2O)OC3C(C(C(CO3)(C)O)NC)O)N)N)N)NC Aminoglycoside antibiotic 25.8% at 5 mM NA NA NA NA NA NA NA C-terminal domain Refolding assay (luciferase) NA NA NA NA NA NA NA HSPMDB000489 20026329 Hsp70 Hsp70-Hsp40 Porcine Cytosol Inhibition of chaperone activity NA Gentamycin 2-[4,6-diamino-3-[3-amino-6-[1-(methylamino)ethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol CC(C1CCC(C(O1)OC2C(CC(C(C2O)OC3C(C(C(CO3)(C)O)NC)O)N)N)N)NC Aminoglycoside antibiotic 10.5% at 10 mM NA NA NA NA NA NA NA C-terminal domain Refolding assay (luciferase) NA NA NA NA NA NA NA HSPMDB000490 14966137 Hsp70 Hsp73 Porcine Cytosol Inhibition of chaperone activity NA Gentamycin 2-[4,6-diamino-3-[3-amino-6-[1-(methylamino)ethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol CC(C1CCC(C(O1)OC2C(CC(C(C2O)OC3C(C(C(CO3)(C)O)NC)O)N)N)N)NC Aminoglycoside antibiotic 100% at 500 uM NA NA NA NA NA NA NA C-terminal domain Substrate aggregation suppression assay NA NA NA NA NA NA NA HSPMDB000491 29042222 Hsp70 Hsp70-Dnak Human and Mtb Cytosol Inhibition of ATP binding NA Rickenyl A 4',5,6-trimethoxy-4-(4-methoxyphenyl)-[1,1'-biphenyl]-2,3-diol COC1=CC=C(C=C1)C1=C(O)C(O)=C(C(OC)=C1OC)C1=CC=C(OC)C=C1 NA NA NA NA NA 49 NA NA NA Nucleotide binding domain Microarray based ATP binding test NA NA NA NA NA NA NA HSPMDB000492 29953808 Hsp70 Hsp70 Human Cytosol Inhibition of HSP 70 BAG interaction NA JG-194 3-benzyl-2-((Z)-((E)-5-(3,6-dimethylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2- ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(C)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA 0.46 NA NA NA NA NA Allosteric site Hsp70-BAG interaction assay NA NA NA NA NA NA Cancer HSPMDB000493 29953808 Hsp70 Hsp70 Human Cytosol Inhibition of HSP 70 BAG interaction NA JG-231 3-((5-bromothiophen-2-yl)methyl)-2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3sc(Br)cc3)=C4/Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA 0.11 NA NA NA NA NA Allosteric site Hsp70-BAG interaction assay NA NA NA NA NA NA Cancer HSPMDB000494 29953808 Hsp70 Hsp70 Human Cytosol Inhibition of HSP 70 BAG interaction NA JG-294 2-((Z)-((E)-5-(6-bromo-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((5-(trifluoromethyl)furan-2-yl)methyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3oc(cc3)C(F)(F)F)=C/4Sc5cc(Br)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA 0.35 NA NA NA NA NA Allosteric site Hsp70-BAG interaction assay NA NA NA NA NA NA Cancer HSPMDB000495 29953808 Hsp70 Hsp70 Human Cytosol Inhibition of HSP 70 BAG interaction NA JG-345 2-((Z)-((E)-3-ethyl-5-(6-ethyl-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)methyl)-3-(2-(methoxycarbonyl)benzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)C(/SC1=C\c2scc[n+]2Cc3ccccc3C(=O)OC)=C4\Sc5cc(CC)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA 1.11 NA NA NA NA NA Allosteric site Hsp70-BAG interaction assay NA NA NA NA NA NA Cancer HSPMDB000496 28455613 Hsp70 PfHsp70-1 Plasmodium falciparum Cytosol and nucleus Inhibition of ATPase activity NA Polymixin B N-[4-amino-1-[[1-[[4-amino-1-oxo-1-[[6,9,18-tris(2-aminoethyl)-15-benzyl-3-(1-hydroxyethyl)-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methyloctanamide CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(Cc2ccccc2)NC(=O)C(CCN)NC1=O)C(C)O Lipopeptide anrtibiotic 100% at 25 uM 0.38 NA NA NA NA NA NA Nucleotide binding domain ATPase assay NA NA NA NA NA NA Malaria HSPMDB000497 28455613 Hsp70 PfHsp70-z Plasmodium falciparum Cytosol and nucleus Inhibition of ATPase activity NA Polymixin B N-[4-amino-1-[[1-[[4-amino-1-oxo-1-[[6,9,18-tris(2-aminoethyl)-15-benzyl-3-(1-hydroxyethyl)-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methyloctanamide CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(Cc2ccccc2)NC(=O)C(CCN)NC1=O)C(C)O Lipopeptide anrtibiotic 100% at 25 uM 0.94 NA NA NA NA NA NA Nucleotide binding domain ATPase assay NA NA NA NA NA NA Malaria HSPMDB000498 25500222 Hsp70 Hsp70i Human Cell surface Inhibition of ATP binding Inhibition of tumor growth HS-72 ((S)-N-(1-propyl-1Hbenzo[d]imidazol-2-yl)-1-(pyrazin-2-yl)piperidine-3-carboxamide) CCCn1c(NC(=O)[C@H]2CCCN(C2)c3cnccn3)nc4ccccc14 Purine analogue NA NA NA NA NA NA NA NA Allosteric site Fluorescence linked enzyme chemoproteomic strategy (FLECS) NA NA Her2 degradation assay NA NA HeLa Cancer HSPMDB000499 26839186 Hsp70 Hsp70 Human Cytosol and nucleus Inhibition of chaperone activity NA 9-aminoacridizinium derivative 1 9-amino acridizinium tetrafluoroborate NA 9-aminoacridizinium derivative NA NA NA 45 NA NA NA NA Nucleotide binding domain Refolding assay (luciferase) NA NA NA NA NA NA NA HSPMDB000500 26839186 Hsp70 Hsc70 Human Cytosol and nucleus Inhibition of chaperone activity NA 9-aminoacridizinium derivative 1 9-amino acridizinium tetrafluoroborate NA 9-aminoacridizinium derivative NA NA NA 363 NA NA NA NA Nucleotide binding domain Refolding assay (luciferase) NA NA NA NA NA NA NA HSPMDB000501 26839186 Hsp70 Hsp70 Human Cytosol and nucleus Inhibition of chaperone activity NA alkylamino-substituted acridizinium derivative 2 9-(pyrrolidin-1-yl)-5??-pyrido[1,2-b]isoquinolin-5-ylium bromide [Br-].C1CCN(C1)C1=CC2=CC3=CC=CC=[N+]3C=C2C=C1 9-aminoacridizinium derivative NA NA NA 127 NA NA NA NA NA Refolding assay (luciferase) NA NA NA NA NA NA NA HSPMDB000502 26839186 Hsp70 Hsc70 Human Cytosol and nucleus Inhibition of chaperone activity NA alkylamino-substituted acridizinium derivative 2 9-(pyrrolidin-1-yl)-5??-pyrido[1,2-b]isoquinolin-5-ylium bromide [Br-].C1CCN(C1)C1=CC2=CC3=CC=CC=[N+]3C=C2C=C1 9-aminoacridizinium derivative NA NA NA 34 NA NA NA NA NA Refolding assay (luciferase) NA NA NA NA NA NA NA HSPMDB000503 26839186 Hsp70 Hsp70 Human Cytosol and nucleus Inhibition of chaperone activity NA sulfanyl-substituted derivative 3 9-(methylsulfanyl)acridizinium tetrafluoroborate NA 9-aminoacridizinium derivative NA NA NA 1052 NA NA NA NA NA Refolding assay (luciferase) NA NA NA NA NA NA NA HSPMDB000504 26839186 Hsp70 Hsc70 Human Cytosol and nucleus Inhibition of chaperone activity NA sulfanyl-substituted derivative 3 9-(methylsulfanyl)acridizinium tetrafluoroborate NA 9-aminoacridizinium derivative NA NA NA 931 NA NA NA NA NA Refolding assay (luciferase) NA NA NA NA NA NA NA HSPMDB000505 10086320 Hsp70 Hsc70 Bovine Cytosol and nucleus Activation of ATPase activity NA 15-deoxyspergualin (DSG) N-[(1S)-2-[4-(3-aminopropylamino)butylamino]-1-hydroxy-2-oxoethyl]-7-(diaminomethylideneamino)heptanamide C(CCCN=C(N)N)CCC(=O)NC(C(=O)NCCCCNCCCN)O Natural product 22% increase NA NA NA NA NA NA NA C-terminal domain ATPase assay NA NA NA NA NA NA NA HSPMDB000506 10086320 Hsp70 Ssa1p Yeast Cytosol Activation of ATPase activity NA 15-deoxyspergualin (DSG) N-[(1S)-2-[4-(3-aminopropylamino)butylamino]-1-hydroxy-2-oxoethyl]-7-(diaminomethylideneamino)heptanamide C(CCCN=C(N)N)CCC(=O)NC(C(=O)NCCCCNCCCN)O Natural product 42% increase NA NA NA NA NA NA NA C-terminal domain ATPase assay NA NA NA NA NA NA NA HSPMDB000507 18729127 Hsp70 Hsc70 Human Cytosol and nucleus Binding affinity NA Apoptozole (Az) 4-[[2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)imidazol-1-yl]methyl]benzamide COC1=CC=C(C=C1)C2=C(N(C(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)CC4=CC=C(C=C4)C(=O)N)C5=CC=C(C=C5)OC Imidazole NA 0.21 NA NA NA NA NA NA Nucleotide binding domain Surface plasmon resonance (SPR) NA NA NA NA NA NA NA HSPMDB000508 18729127 Hsp70 Hsp70 Human Cytosol and nucleus Binding affinity NA Apoptozole (Az) 4-[[2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)imidazol-1-yl]methyl]benzamide COC1=CC=C(C=C1)C2=C(N(C(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)CC4=CC=C(C=C4)C(=O)N)C5=CC=C(C=C5)OC Imidazole NA 0.14 NA NA NA NA NA NA Nucleotide binding domain Surface plasmon resonance (SPR) NA NA NA NA NA NA NA HSPMDB000509 23177194 Hsp70 Hsp72 (HSPA1A) Human Cytosol and nucleus Inhibition of ATPase activity NA Methylene Blue [7-(dimethylamino)phenothiazin-3-ylidene]-dimethylazanium;chloride CN(C)C1=CC2=C(C=C1)N=C3C=CC(=[N+](C)C)C=C3S2.[Cl-] Dihydropyrimidine derivative 37.50% NA NA NA NA NA NA NA Irreversibly inhibits by oxidizing Cys306 ATPase assay NA NA NA NA NA NA NA HSPMDB000510 23472668 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus Binding affinity NA MKT-077 2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=C(C=CC=C2)N1C)=C\C1=[N+](C)C=CC=C1 Rhodacyanine NA NA NA 6.4 NA NA NA NA Nucleotide binding domain (allosteric site) Enzyme-linked immunosorbent assay (ELISA) NA NA NA NA NA NA Alzheimers disease HSPMDB000511 23472668 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus Binding affinity NA YM-01 2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=C(C=CC=C2)N1C)=C\C1=[N+](C)C=CC=C1 Rhodacyanine derivative NA NA NA 3.2 NA NA NA NA Nucleotide binding domain (allosteric site) Enzyme-linked immunosorbent assay (ELISA) NA NA NA NA NA NA Alzheimers disease HSPMDB000512 23472668 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus Binding affinity NA YM-08 (2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-2-[(pyridin-2-yl)methylidene]-1,3-thiazolidin-4-one CCN1\C(S\C(C1=O)=C1\SC2=C(C=CC=C2)N1C)=C\C1=NC=CC=C1 Rhodacyanine derivative NA NA NA 0.61 NA NA NA NA Nucleotide binding domain (allosteric site) Enzyme-linked immunosorbent assay (ELISA) NA NA NA NA NA NA Alzheimers disease HSPMDB000513 23472668 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus Binding affinity NA YM-02 3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-2-sulfanylidene-1,3-thiazolidin-4-one CCN1C(=S)S\C(C1=O)=C1\SC2=C(C=CC=C2)N1C Rhodacyanine derivative NA NA NA >50 NA NA NA NA Nucleotide binding domain (allosteric site) Enzyme-linked immunosorbent assay (ELISA) NA NA NA NA NA NA Alzheimers disease HSPMDB000514 23472668 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus Binding affinity NA YM-03 3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-2-(methylsulfanyl)-4-oxo-4,5-dihydro-1,3-thiazol-3-ium CC[N+]1=C(SC)S\C(C1=O)=C1\SC2=C(C=CC=C2)N1C Rhodacyanine derivative NA NA NA >50 NA NA NA NA Nucleotide binding domain (allosteric site) Enzyme-linked immunosorbent assay (ELISA) NA NA NA NA NA NA Alzheimers disease HSPMDB000515 23472668 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus Binding affinity NA YM-04 2-{[(2Z)-3-ethyl-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium iodide [I-].CCN1C(=O)CS\C1=C/C1=[N+](C)C=CC=C1 Rhodacyanine derivative NA NA NA 15 NA NA NA NA Nucleotide binding domain (allosteric site) Enzyme-linked immunosorbent assay (ELISA) NA NA NA NA NA NA Alzheimers disease HSPMDB000516 23472668 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus Binding affinity NA YM-07 (2Z)-3-ethyl-2-[(pyridin-2-yl)methylidene]-1,3-thiazolidin-4-one CCN1C(=O)CS\C1=C/C1=NC=CC=C1 Rhodacyanine derivative NA NA NA 5.8 NA NA NA NA Nucleotide binding domain (allosteric site) Enzyme-linked immunosorbent assay (ELISA) NA NA NA NA NA NA Alzheimers disease HSPMDB000517 23472668 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity MKT-077 2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=C(C=CC=C2)N1C)=C\C1=[N+](C)C=CC=C1 Rhodacyanine NA NA NA NA 2.2 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000518 23472668 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity YM-01 2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=C(C=CC=C2)N1C)=C\C1=[N+](C)C=CC=C1 Rhodacyanine derivative NA NA NA NA 5.2 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000519 23472668 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity YM-08 (2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-2-[(pyridin-2-yl)methylidene]-1,3-thiazolidin-4-one CCN1\C(S\C(C1=O)=C1\SC2=C(C=CC=C2)N1C)=C\C1=NC=CC=C1 Rhodacyanine derivative NA NA NA NA 10.5 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000520 23472668 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity YM-02 3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-2-sulfanylidene-1,3-thiazolidin-4-one CCN1C(=S)S\C(C1=O)=C1\SC2=C(C=CC=C2)N1C Rhodacyanine derivative NA NA NA NA 5.8 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000521 23472668 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity YM-03 3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-2-(methylsulfanyl)-4-oxo-4,5-dihydro-1,3-thiazol-3-ium CC[N+]1=C(SC)S\C(C1=O)=C1\SC2=C(C=CC=C2)N1C Rhodacyanine derivative NA NA NA NA >30 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000522 23472668 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity YM-04 2-{[(2Z)-3-ethyl-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium iodide [I-].CCN1C(=O)CS\C1=C/C1=[N+](C)C=CC=C1 Rhodacyanine derivative NA NA NA NA >30 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000523 23472668 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity YM-07 (2Z)-3-ethyl-2-[(pyridin-2-yl)methylidene]-1,3-thiazolidin-4-one CCN1C(=O)CS\C1=C/C1=NC=CC=C1 Rhodacyanine derivative NA NA NA NA 6.5 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000524 23472668 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity MKT-077 2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=C(C=CC=C2)N1C)=C\C1=[N+](C)C=CC=C1 Rhodacyanine NA NA NA NA 3 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF10A Cancer HSPMDB000525 23472668 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity YM-01 2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=C(C=CC=C2)N1C)=C\C1=[N+](C)C=CC=C1 Rhodacyanine derivative NA NA NA NA 3.3 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF10A Cancer HSPMDB000526 23472668 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity YM-08 (2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-2-[(pyridin-2-yl)methylidene]-1,3-thiazolidin-4-one CCN1\C(S\C(C1=O)=C1\SC2=C(C=CC=C2)N1C)=C\C1=NC=CC=C1 Rhodacyanine derivative NA NA NA NA 7.8 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF10A Cancer HSPMDB000527 23472668 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity YM-02 3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-2-sulfanylidene-1,3-thiazolidin-4-one CCN1C(=S)S\C(C1=O)=C1\SC2=C(C=CC=C2)N1C Rhodacyanine derivative NA NA NA NA 13.8 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF10A Cancer HSPMDB000528 23472668 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity YM-03 3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-2-(methylsulfanyl)-4-oxo-4,5-dihydro-1,3-thiazol-3-ium CC[N+]1=C(SC)S\C(C1=O)=C1\SC2=C(C=CC=C2)N1C Rhodacyanine derivative NA NA NA NA >30 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF10A Cancer HSPMDB000529 23472668 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity YM-04 2-{[(2Z)-3-ethyl-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium iodide [I-].CCN1C(=O)CS\C1=C/C1=[N+](C)C=CC=C1 Rhodacyanine derivative NA NA NA NA >30 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF10A Cancer HSPMDB000530 23472668 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity YM-07 (2Z)-3-ethyl-2-[(pyridin-2-yl)methylidene]-1,3-thiazolidin-4-one CCN1C(=O)CS\C1=C/C1=NC=CC=C1 Rhodacyanine derivative NA NA NA NA >30 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF10A Cancer HSPMDB000531 23472668 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity MKT-077 2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=C(C=CC=C2)N1C)=C\C1=[N+](C)C=CC=C1 Rhodacyanine NA NA NA NA 1.4 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000532 23472668 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity YM-01 2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=C(C=CC=C2)N1C)=C\C1=[N+](C)C=CC=C1 Rhodacyanine derivative NA NA NA NA 2 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000533 23472668 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity YM-08 (2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-2-[(pyridin-2-yl)methylidene]-1,3-thiazolidin-4-one CCN1\C(S\C(C1=O)=C1\SC2=C(C=CC=C2)N1C)=C\C1=NC=CC=C1 Rhodacyanine derivative NA NA NA NA 8.5 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000534 23472668 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity YM-02 3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-2-sulfanylidene-1,3-thiazolidin-4-one CCN1C(=S)S\C(C1=O)=C1\SC2=C(C=CC=C2)N1C Rhodacyanine derivative NA NA NA NA >30 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000535 23472668 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity YM-03 3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-2-(methylsulfanyl)-4-oxo-4,5-dihydro-1,3-thiazol-3-ium CC[N+]1=C(SC)S\C(C1=O)=C1\SC2=C(C=CC=C2)N1C Rhodacyanine derivative NA NA NA NA >30 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000536 23472668 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity YM-04 2-{[(2Z)-3-ethyl-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium iodide [I-].CCN1C(=O)CS\C1=C/C1=[N+](C)C=CC=C1 Rhodacyanine derivative NA NA NA NA >30 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000537 23472668 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity YM-07 (2Z)-3-ethyl-2-[(pyridin-2-yl)methylidene]-1,3-thiazolidin-4-one CCN1C(=O)CS\C1=C/C1=NC=CC=C1 Rhodacyanine derivative NA NA NA NA >30 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000538 23472668 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity MKT-077 2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=C(C=CC=C2)N1C)=C\C1=[N+](C)C=CC=C1 Rhodacyanine NA NA NA NA 8 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA HeLa Cancer HSPMDB000539 23472668 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity YM-01 2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=C(C=CC=C2)N1C)=C\C1=[N+](C)C=CC=C1 Rhodacyanine derivative NA NA NA NA 3.2 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA HeLa Cancer HSPMDB000540 23472668 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity YM-08 (2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-2-[(pyridin-2-yl)methylidene]-1,3-thiazolidin-4-one CCN1\C(S\C(C1=O)=C1\SC2=C(C=CC=C2)N1C)=C\C1=NC=CC=C1 Rhodacyanine derivative NA NA NA NA 15 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA HeLa Cancer HSPMDB000541 23472668 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity YM-02 3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-2-sulfanylidene-1,3-thiazolidin-4-one CCN1C(=S)S\C(C1=O)=C1\SC2=C(C=CC=C2)N1C Rhodacyanine derivative NA NA NA NA >30 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA HeLa Cancer HSPMDB000542 23472668 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity YM-03 3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-2-(methylsulfanyl)-4-oxo-4,5-dihydro-1,3-thiazol-3-ium CC[N+]1=C(SC)S\C(C1=O)=C1\SC2=C(C=CC=C2)N1C Rhodacyanine derivative NA NA NA NA 22 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA HeLa Cancer HSPMDB000543 23472668 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity YM-04 2-{[(2Z)-3-ethyl-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium iodide [I-].CCN1C(=O)CS\C1=C/C1=[N+](C)C=CC=C1 Rhodacyanine derivative NA NA NA NA >30 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA HeLa Cancer HSPMDB000544 23472668 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity YM-07 (2Z)-3-ethyl-2-[(pyridin-2-yl)methylidene]-1,3-thiazolidin-4-one CCN1C(=O)CS\C1=C/C1=NC=CC=C1 Rhodacyanine derivative NA NA NA NA >30 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA HeLa Cancer HSPMDB000545 23607970 Hsp70 Ssa1-Hlj1 Yeast Cytosol Inhibition of ATPase activity NA MKT-077 2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=C(C=CC=C2)N1C)=C\C1=[N+](C)C=CC=C1 Rhodacyanine 10-15% NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) ATPase assay NA NA NA NA NA NA Alzheimers disease HSPMDB000546 23607970 Hsp70 Ssa1-Hlj1 Yeast Cytosol Inhibition of ATPase activity NA YM-01 2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=C(C=CC=C2)N1C)=C\C1=[N+](C)C=CC=C1 Rhodacyanine derivative 10-15% NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) ATPase assay NA NA NA NA NA NA Alzheimers disease HSPMDB000547 19195901 Hsp70 PfHsp70 Plasmodium falciparum Cytosol and nucleus Inhibition of ATPase activity NA DMT3024 benzyl 1-{5-[({[1,1'-biphenyl]-4-yl}(butylcarbamoyl)methyl)[2-(morpholin-4-yl)ethyl]carbamoyl]pentyl}-6-methyl-4-(4-nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate CCCCNC(=O)C(N(CCN1CCOCC1)C(=O)CCCCCN1C(=O)NC(C2=CC=C(C=C2)[N+]([O-])=O)C(C(=O)OCC2=CC=CC=C2)=C1C)C1=CC=C(C=C1)C1=CC=CC=C1 Pyrimidinone amide 0.73 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA Malaria HSPMDB000548 19195901 Hsp70 PfHsp70 Plasmodium falciparum Cytosol and nucleus Inhibition of ATPase activity NA DMT2264 benzyl 4-{[1,1'-biphenyl]-4-yl}-1-(5-{[(butylcarbamoyl)(cyclohexyl)methyl](hexyl)carbamoyl}pentyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate CCCCCCN(C(C1CCCCC1)C(=O)NCCCC)C(=O)CCCCCN1C(=O)NC(C2=CC=C(C=C2)C2=CC=CC=C2)C(C(=O)OCC2=CC=CC=C2)=C1C Pyrimidinone amide 0.74 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA Malaria HSPMDB000549 19195901 Hsp70 PfHsp70 Plasmodium falciparum Cytosol and nucleus Inhibition of ATPase activity NA MAL2-29 6-[5-(ethoxycarbonyl)-6-methyl-4-(3-nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidin-1-yl]hexanoic acid CCOC(=O)C1=C(C)N(CCCCCC(O)=O)C(=O)NC1C1=CC=CC(=C1)[N+]([O-])=O Pyrimidinone amide 1.01 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA Malaria HSPMDB000550 19195901 Hsp70 PfHsp70 Plasmodium falciparum Cytosol and nucleus Inhibition of ATPase activity NA MAL2-39 benzyl 1-butyl-4-(4-methoxyphenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate CCCCN1C(=O)NC(C2=CC=C(OC)C=C2)C(C(=O)OCC2=CC=CC=C2)=C1C Pyrimidinone amide 0.92 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA Malaria HSPMDB000551 19195901 Hsp70 PfHsp70 Plasmodium falciparum Cytosol and nucleus Inhibition of ATPase activity NA MAL2-61 ethyl 1-benzyl-6-methyl-4-{2-[(2-nitrobenzenesulfonyl)oxy]phenyl}-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate CCOC(=O)C1=C(C)N(CC2=CC=CC=C2)C(=O)NC1C1=CC=CC=C1OS(=O)(=O)C1=C(C=CC=C1)[N+]([O-])=O Pyrimidinone amide 0.99 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA Malaria HSPMDB000552 19195901 Hsp70 PfHsp70 Plasmodium falciparum Cytosol and nucleus Inhibition of ATPase activity NA MAL2-213 ethyl 1-[3-({2-[3-(methoxycarbonyl)-2-methyl-5-phenyl-1H-pyrrol-1-yl]ethyl}carbamoyl)propyl]-6-methyl-4-(4-nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate CCOC(=O)C1=C(C)N(CCCC(=O)NCCN2C(C)=C(C=C2C2=CC=CC=C2)C(=O)OC)C(=O)NC1C1=CC=C(C=C1)[N+]([O-])=O Pyrimidinone amide 1.02 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA Malaria HSPMDB000553 19195901 Hsp70 PfHsp70 Plasmodium falciparum Cytosol and nucleus Inhibition of ATPase activity NA MAL2-215 benzyl 4-{[1,1'-biphenyl]-4-yl}-1-[5-({2-[3-(methoxycarbonyl)-2-methyl-5-phenyl-1H-pyrrol-1-yl]ethyl}carbamoyl)pentyl]-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate COC(=O)C1=C(C)N(CCNC(=O)CCCCCN2C(=O)NC(C3=CC=C(C=C3)C3=CC=CC=C3)C(C(=O)OCC3=CC=CC=C3)=C2C)C(=C1)C1=CC=CC=C1 Pyrimidinone amide 1.01 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA Malaria HSPMDB000554 19195901 Hsp70 PfHsp70 Plasmodium falciparum Cytosol and nucleus Inhibition of ATPase activity NA MAL3-39 benzyl 1-{3-[({[1,1'-biphenyl]-4-yl}(tert-butylcarbamoyl)methyl)[2-(morpholin-4-yl)ethyl]carbamoyl]propyl}-6-methyl-4-(4-nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate CC1=C(C(NC(=O)N1CCCC(=O)N(CCN1CCOCC1)C(C(=O)NC(C)(C)C)C1=CC=C(C=C1)C1=CC=CC=C1)C1=CC=C(C=C1)[N+]([O-])=O)C(=O)OCC1=CC=CC=C1 Pyrimidinone amide 0.72 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA Malaria HSPMDB000555 19195901 Hsp70 PfHsp70 Plasmodium falciparum Cytosol and nucleus Inhibition of ATPase activity NA JAB75 methyl 6-benzyl-4-(naphthalen-2-yl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate COC(=O)C1=C(CC2=CC=CC=C2)NC(=O)NC1C1=CC2=C(C=CC=C2)C=C1 Pyrimidinone amide 1 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA Malaria HSPMDB000556 19195901 Hsp70 Ssa1 Yeast Cytosol Inhibition of ATPase activity NA DMT3024 benzyl 1-{5-[({[1,1'-biphenyl]-4-yl}(butylcarbamoyl)methyl)[2-(morpholin-4-yl)ethyl]carbamoyl]pentyl}-6-methyl-4-(4-nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate CCCCNC(=O)C(N(CCN1CCOCC1)C(=O)CCCCCN1C(=O)NC(C2=CC=C(C=C2)[N+]([O-])=O)C(C(=O)OCC2=CC=CC=C2)=C1C)C1=CC=C(C=C1)C1=CC=CC=C1 Pyrimidinone amide 1 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000557 19195901 Hsp70 Ssa1 Yeast Cytosol Inhibition of ATPase activity NA DMT2264 benzyl 4-{[1,1'-biphenyl]-4-yl}-1-(5-{[(butylcarbamoyl)(cyclohexyl)methyl](hexyl)carbamoyl}pentyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate CCCCCCN(C(C1CCCCC1)C(=O)NCCCC)C(=O)CCCCCN1C(=O)NC(C2=CC=C(C=C2)C2=CC=CC=C2)C(C(=O)OCC2=CC=CC=C2)=C1C Pyrimidinone amide 0.97 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000558 19195901 Hsp70 Ssa1 Yeast Cytosol Inhibition of ATPase activity NA MAL2-29 6-[5-(ethoxycarbonyl)-6-methyl-4-(3-nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidin-1-yl]hexanoic acid CCOC(=O)C1=C(C)N(CCCCCC(O)=O)C(=O)NC1C1=CC=CC(=C1)[N+]([O-])=O Pyrimidinone amide 0.93 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000559 19195901 Hsp70 Ssa1 Yeast Cytosol Inhibition of ATPase activity NA MAL2-39 benzyl 1-butyl-4-(4-methoxyphenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate CCCCN1C(=O)NC(C2=CC=C(OC)C=C2)C(C(=O)OCC2=CC=CC=C2)=C1C Pyrimidinone amide 0.95 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000560 19195901 Hsp70 Ssa1 Yeast Cytosol Inhibition of ATPase activity NA MAL2-61 ethyl 1-benzyl-6-methyl-4-{2-[(2-nitrobenzenesulfonyl)oxy]phenyl}-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate CCOC(=O)C1=C(C)N(CC2=CC=CC=C2)C(=O)NC1C1=CC=CC=C1OS(=O)(=O)C1=C(C=CC=C1)[N+]([O-])=O Pyrimidinone amide 1.1 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000561 19195901 Hsp70 Ssa1 Yeast Cytosol Inhibition of ATPase activity NA MAL2-213 ethyl 1-[3-({2-[3-(methoxycarbonyl)-2-methyl-5-phenyl-1H-pyrrol-1-yl]ethyl}carbamoyl)propyl]-6-methyl-4-(4-nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate CCOC(=O)C1=C(C)N(CCCC(=O)NCCN2C(C)=C(C=C2C2=CC=CC=C2)C(=O)OC)C(=O)NC1C1=CC=C(C=C1)[N+]([O-])=O Pyrimidinone amide 0.89 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000562 19195901 Hsp70 Ssa1 Yeast Cytosol Inhibition of ATPase activity NA MAL2-215 benzyl 4-{[1,1'-biphenyl]-4-yl}-1-[5-({2-[3-(methoxycarbonyl)-2-methyl-5-phenyl-1H-pyrrol-1-yl]ethyl}carbamoyl)pentyl]-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate COC(=O)C1=C(C)N(CCNC(=O)CCCCCN2C(=O)NC(C3=CC=C(C=C3)C3=CC=CC=C3)C(C(=O)OCC3=CC=CC=C3)=C2C)C(=C1)C1=CC=CC=C1 Pyrimidinone amide 1.2 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000563 19195901 Hsp70 Ssa1 Yeast Cytosol Inhibition of ATPase activity NA MAL3-39 benzyl 1-{3-[({[1,1'-biphenyl]-4-yl}(tert-butylcarbamoyl)methyl)[2-(morpholin-4-yl)ethyl]carbamoyl]propyl}-6-methyl-4-(4-nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate CC1=C(C(NC(=O)N1CCCC(=O)N(CCN1CCOCC1)C(C(=O)NC(C)(C)C)C1=CC=C(C=C1)C1=CC=CC=C1)C1=CC=C(C=C1)[N+]([O-])=O)C(=O)OCC1=CC=CC=C1 Pyrimidinone amide 0.75 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000564 19195901 Hsp70 Ssa1 Yeast Cytosol Inhibition of ATPase activity NA JAB75 methyl 6-benzyl-4-(naphthalen-2-yl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate COC(=O)C1=C(CC2=CC=CC=C2)NC(=O)NC1C1=CC2=C(C=CC=C2)C=C1 Pyrimidinone amide 1.2 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000565 19195901 Hsp70 Hsp70 (HSPA1A) Human Cytosol and nucleus Inhibition of ATPase activity NA DMT3024 benzyl 1-{5-[({[1,1'-biphenyl]-4-yl}(butylcarbamoyl)methyl)[2-(morpholin-4-yl)ethyl]carbamoyl]pentyl}-6-methyl-4-(4-nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate CCCCNC(=O)C(N(CCN1CCOCC1)C(=O)CCCCCN1C(=O)NC(C2=CC=C(C=C2)[N+]([O-])=O)C(C(=O)OCC2=CC=CC=C2)=C1C)C1=CC=C(C=C1)C1=CC=CC=C1 Pyrimidinone amide 0.74 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000566 19195901 Hsp70 Hsp70 (HSPA1A) Human Cytosol and nucleus Inhibition of ATPase activity NA DMT2264 benzyl 4-{[1,1'-biphenyl]-4-yl}-1-(5-{[(butylcarbamoyl)(cyclohexyl)methyl](hexyl)carbamoyl}pentyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate CCCCCCN(C(C1CCCCC1)C(=O)NCCCC)C(=O)CCCCCN1C(=O)NC(C2=CC=C(C=C2)C2=CC=CC=C2)C(C(=O)OCC2=CC=CC=C2)=C1C Pyrimidinone amide 0.95 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000567 19195901 Hsp70 Hsp70 (HSPA1A) Human Cytosol and nucleus Inhibition of ATPase activity NA MAL2-29 6-[5-(ethoxycarbonyl)-6-methyl-4-(3-nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidin-1-yl]hexanoic acid CCOC(=O)C1=C(C)N(CCCCCC(O)=O)C(=O)NC1C1=CC=CC(=C1)[N+]([O-])=O Pyrimidinone amide 0.85 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000568 19195901 Hsp70 Hsp70 (HSPA1A) Human Cytosol and nucleus Inhibition of ATPase activity NA MAL2-39 benzyl 1-butyl-4-(4-methoxyphenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate CCCCN1C(=O)NC(C2=CC=C(OC)C=C2)C(C(=O)OCC2=CC=CC=C2)=C1C Pyrimidinone amide 0.8 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000569 19195901 Hsp70 Hsp70 (HSPA1A) Human Cytosol and nucleus Inhibition of ATPase activity NA MAL2-61 ethyl 1-benzyl-6-methyl-4-{2-[(2-nitrobenzenesulfonyl)oxy]phenyl}-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate CCOC(=O)C1=C(C)N(CC2=CC=CC=C2)C(=O)NC1C1=CC=CC=C1OS(=O)(=O)C1=C(C=CC=C1)[N+]([O-])=O Pyrimidinone amide 0.74 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000570 19195901 Hsp70 Hsp70 (HSPA1A) Human Cytosol and nucleus Inhibition of ATPase activity NA MAL2-213 ethyl 1-[3-({2-[3-(methoxycarbonyl)-2-methyl-5-phenyl-1H-pyrrol-1-yl]ethyl}carbamoyl)propyl]-6-methyl-4-(4-nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate CCOC(=O)C1=C(C)N(CCCC(=O)NCCN2C(C)=C(C=C2C2=CC=CC=C2)C(=O)OC)C(=O)NC1C1=CC=C(C=C1)[N+]([O-])=O Pyrimidinone amide 0.8 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000571 19195901 Hsp70 Hsp70 (HSPA1A) Human Cytosol and nucleus Inhibition of ATPase activity NA MAL2-215 benzyl 4-{[1,1'-biphenyl]-4-yl}-1-[5-({2-[3-(methoxycarbonyl)-2-methyl-5-phenyl-1H-pyrrol-1-yl]ethyl}carbamoyl)pentyl]-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate COC(=O)C1=C(C)N(CCNC(=O)CCCCCN2C(=O)NC(C3=CC=C(C=C3)C3=CC=CC=C3)C(C(=O)OCC3=CC=CC=C3)=C2C)C(=C1)C1=CC=CC=C1 Pyrimidinone amide 0.72 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000572 19195901 Hsp70 Hsp70 (HSPA1A) Human Cytosol and nucleus Inhibition of ATPase activity NA MAL3-39 benzyl 1-{3-[({[1,1'-biphenyl]-4-yl}(tert-butylcarbamoyl)methyl)[2-(morpholin-4-yl)ethyl]carbamoyl]propyl}-6-methyl-4-(4-nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate CC1=C(C(NC(=O)N1CCCC(=O)N(CCN1CCOCC1)C(C(=O)NC(C)(C)C)C1=CC=C(C=C1)C1=CC=CC=C1)C1=CC=C(C=C1)[N+]([O-])=O)C(=O)OCC1=CC=CC=C1 Pyrimidinone amide 0.82 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000573 19195901 Hsp70 Hsp70 (HSPA1A) Human Cytosol and nucleus Inhibition of ATPase activity NA JAB75 methyl 6-benzyl-4-(naphthalen-2-yl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate COC(=O)C1=C(CC2=CC=CC=C2)NC(=O)NC1C1=CC2=C(C=CC=C2)C=C1 Pyrimidinone amide 0.7 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000574 19195901 Hsp70 PfHsp70 Plasmodium falciparum Cytosol and nucleus NA Antiparasitic activity (inhibition of [3H]hypoxanthine uptake) DMT3024 benzyl 1-{5-[({[1,1'-biphenyl]-4-yl}(butylcarbamoyl)methyl)[2-(morpholin-4-yl)ethyl]carbamoyl]pentyl}-6-methyl-4-(4-nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate CCCCNC(=O)C(N(CCN1CCOCC1)C(=O)CCCCCN1C(=O)NC(C2=CC=C(C=C2)[N+]([O-])=O)C(C(=O)OCC2=CC=CC=C2)=C1C)C1=CC=C(C=C1)C1=CC=CC=C1 Pyrimidinone amide NA NA NA 0.2 NA NA NA NA NA NA NA [3H]hypoxanthine uptake assay NA NA NA P. falciparum Malaria HSPMDB000575 19195901 Hsp70 PfHsp70 Plasmodium falciparum Cytosol and nucleus NA Antiparasitic activity (inhibition of [3H]hypoxanthine uptake) DMT2264 benzyl 4-{[1,1'-biphenyl]-4-yl}-1-(5-{[(butylcarbamoyl)(cyclohexyl)methyl](hexyl)carbamoyl}pentyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate CCCCCCN(C(C1CCCCC1)C(=O)NCCCC)C(=O)CCCCCN1C(=O)NC(C2=CC=C(C=C2)C2=CC=CC=C2)C(C(=O)OCC2=CC=CC=C2)=C1C Pyrimidinone amide NA NA NA 1.1 NA NA NA NA NA NA NA [3H]hypoxanthine uptake assay NA NA NA P. falciparum Malaria HSPMDB000576 19195901 Hsp70 PfHsp70 Plasmodium falciparum Cytosol and nucleus NA Antiparasitic activity (inhibition of [3H]hypoxanthine uptake) MAL2-29 6-[5-(ethoxycarbonyl)-6-methyl-4-(3-nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidin-1-yl]hexanoic acid CCOC(=O)C1=C(C)N(CCCCCC(O)=O)C(=O)NC1C1=CC=CC(=C1)[N+]([O-])=O Pyrimidinone amide NA NA NA 1.6 NA NA NA NA NA NA NA [3H]hypoxanthine uptake assay NA NA NA P. falciparum Malaria HSPMDB000577 19195901 Hsp70 PfHsp70 Plasmodium falciparum Cytosol and nucleus NA Antiparasitic activity (inhibition of [3H]hypoxanthine uptake) MAL2-39 benzyl 1-butyl-4-(4-methoxyphenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate CCCCN1C(=O)NC(C2=CC=C(OC)C=C2)C(C(=O)OCC2=CC=CC=C2)=C1C Pyrimidinone amide NA NA NA 0.2 NA NA NA NA NA NA NA [3H]hypoxanthine uptake assay NA NA NA P. falciparum Malaria HSPMDB000578 19195901 Hsp70 PfHsp70 Plasmodium falciparum Cytosol and nucleus NA Antiparasitic activity (inhibition of [3H]hypoxanthine uptake) MAL2-61 ethyl 1-benzyl-6-methyl-4-{2-[(2-nitrobenzenesulfonyl)oxy]phenyl}-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate CCOC(=O)C1=C(C)N(CC2=CC=CC=C2)C(=O)NC1C1=CC=CC=C1OS(=O)(=O)C1=C(C=CC=C1)[N+]([O-])=O Pyrimidinone amide NA NA NA 0.1 NA NA NA NA NA NA NA [3H]hypoxanthine uptake assay NA NA NA P. falciparum Malaria HSPMDB000579 19195901 Hsp70 PfHsp70 Plasmodium falciparum Cytosol and nucleus NA Antiparasitic activity (inhibition of [3H]hypoxanthine uptake) MAL2-213 ethyl 1-[3-({2-[3-(methoxycarbonyl)-2-methyl-5-phenyl-1H-pyrrol-1-yl]ethyl}carbamoyl)propyl]-6-methyl-4-(4-nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate CCOC(=O)C1=C(C)N(CCCC(=O)NCCN2C(C)=C(C=C2C2=CC=CC=C2)C(=O)OC)C(=O)NC1C1=CC=C(C=C1)[N+]([O-])=O Pyrimidinone amide NA NA NA 0.03 NA NA NA NA NA NA NA [3H]hypoxanthine uptake assay NA NA NA P. falciparum Malaria HSPMDB000580 19195901 Hsp70 PfHsp70 Plasmodium falciparum Cytosol and nucleus NA Antiparasitic activity (inhibition of [3H]hypoxanthine uptake) MAL2-215 benzyl 4-{[1,1'-biphenyl]-4-yl}-1-[5-({2-[3-(methoxycarbonyl)-2-methyl-5-phenyl-1H-pyrrol-1-yl]ethyl}carbamoyl)pentyl]-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate COC(=O)C1=C(C)N(CCNC(=O)CCCCCN2C(=O)NC(C3=CC=C(C=C3)C3=CC=CC=C3)C(C(=O)OCC3=CC=CC=C3)=C2C)C(=C1)C1=CC=CC=C1 Pyrimidinone amide NA NA NA 0.05 NA NA NA NA NA NA NA [3H]hypoxanthine uptake assay NA NA NA P. falciparum Malaria HSPMDB000581 19195901 Hsp70 PfHsp70 Plasmodium falciparum Cytosol and nucleus NA Antiparasitic activity (inhibition of [3H]hypoxanthine uptake) MAL3-39 benzyl 1-{3-[({[1,1'-biphenyl]-4-yl}(tert-butylcarbamoyl)methyl)[2-(morpholin-4-yl)ethyl]carbamoyl]propyl}-6-methyl-4-(4-nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate CC1=C(C(NC(=O)N1CCCC(=O)N(CCN1CCOCC1)C(C(=O)NC(C)(C)C)C1=CC=C(C=C1)C1=CC=CC=C1)C1=CC=C(C=C1)[N+]([O-])=O)C(=O)OCC1=CC=CC=C1 Pyrimidinone amide NA NA NA 0.8 NA NA NA NA NA NA NA [3H]hypoxanthine uptake assay NA NA NA P. falciparum Malaria HSPMDB000582 19195901 Hsp70 PfHsp70 Plasmodium falciparum Cytosol and nucleus NA Antiparasitic activity (inhibition of [3H]hypoxanthine uptake) JAB75 methyl 6-benzyl-4-(naphthalen-2-yl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate COC(=O)C1=C(CC2=CC=CC=C2)NC(=O)NC1C1=CC2=C(C=CC=C2)C=C1 Pyrimidinone amide NA NA NA 0.3 NA NA NA NA NA NA NA [3H]hypoxanthine uptake assay NA NA NA P. falciparum Malaria HSPMDB000583 24265689 Hsp70 Hsp70(1-382) Human Cytosol and nucleus Inhibition of chaperone activity NA VER-155008 4-[[(2R,3S,4R,5R)-5-[6-amino-8-[(3,4-dichlorophenyl)methylamino]purin-9-yl]-3,4-dihydroxyoxolan-2-yl]methoxymethyl]benzonitrile C1=CC(=CC=C1COCC2C(C(C(O2)N3C4=C(C(=NC=N4)N)N=C3NCC5=CC(=C(C=C5)Cl)Cl)O)O)C#N Dibenzyl-8-amino adenosine analogue Significant Inhibition at 20 uM NA NA NA NA NA NA NA Nucleotide binding domain Refolding assay (luciferase) NA NA NA NA NA NA NA HSPMDB000584 24265689 Hsp70 Hsc70 Human Cytosol and nucleus Inhibition of chaperone activity NA VER-155008 4-[[(2R,3S,4R,5R)-5-[6-amino-8-[(3,4-dichlorophenyl)methylamino]purin-9-yl]-3,4-dihydroxyoxolan-2-yl]methoxymethyl]benzonitrile C1=CC(=CC=C1COCC2C(C(C(O2)N3C4=C(C(=NC=N4)N)N=C3NCC5=CC(=C(C=C5)Cl)Cl)O)O)C#N Dibenzyl-8-amino adenosine analogue Significant Inhibition at 20 uM NA NA NA NA NA NA NA Nucleotide binding domain Refolding assay (luciferase) NA NA NA NA NA NA NA HSPMDB000585 24265689 Hsp70 Hsp70(1-382) Human Cytosol and nucleus Inhibition of chaperone activity NA PES 2-phenylethynesulfonamide C1=CC=C(C=C1)C#CS(=O)(=O)N NA Significant Inhibition at 160 uM NA NA NA NA NA NA NA C-terminal domain Refolding assay (luciferase) NA NA NA NA NA NA NA HSPMDB000586 24265689 Hsp70 Hsc70 Human Cytosol and nucleus Inhibition of chaperone activity NA PES 2-phenylethynesulfonamide C1=CC=C(C=C1)C#CS(=O)(=O)N NA Significant Inhibition at 160 uM NA NA NA NA NA NA NA C-terminal domain Refolding assay (luciferase) NA NA NA NA NA NA NA HSPMDB000587 24265689 Hsp70 Hsp70 Human Cytosol and nucleus Inhibition of ATPase activity NA VER-155008 4-[[(2R,3S,4R,5R)-5-[6-amino-8-[(3,4-dichlorophenyl)methylamino]purin-9-yl]-3,4-dihydroxyoxolan-2-yl]methoxymethyl]benzonitrile C1=CC(=CC=C1COCC2C(C(C(O2)N3C4=C(C(=NC=N4)N)N=C3NCC5=CC(=C(C=C5)Cl)Cl)O)O)C#N Dibenzyl-8-amino adenosine analogue NA NA 10 NA NA NA NA NA Nucleotide binding domain ATPase assay NA NA NA NA NA NA NA HSPMDB000588 24265689 Hsp70 Hsp70 and Hdj1 Human Cytosol and nucleus Inhibition of ATPase activity NA VER-155008 4-[[(2R,3S,4R,5R)-5-[6-amino-8-[(3,4-dichlorophenyl)methylamino]purin-9-yl]-3,4-dihydroxyoxolan-2-yl]methoxymethyl]benzonitrile C1=CC(=CC=C1COCC2C(C(C(O2)N3C4=C(C(=NC=N4)N)N=C3NCC5=CC(=C(C=C5)Cl)Cl)O)O)C#N Dibenzyl-8-amino adenosine analogue NA NA 2.87 NA NA NA NA NA Nucleotide binding domain ATPase assay NA NA NA NA NA NA NA HSPMDB000589 18060774 Hsp70 Hsc70 Bovine Cytosol and nucleus Activation of ATPase activity NA 2(SW02) ethyl 6-(4-bromophenyl)-3-(4-methoxy-4-oxobutyl)-4-methyl-2-oxo-1,6-dihydropyrimidine-5-carboxylate CCOC(=O)C1=C(N(C(=O)NC1C2=CC=C(C=C2)Br)CCCC(=O)OC)C Dihydropyrimidine NA NA NA NA 213 NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000590 18060774 Hsp70 Hsc70 Bovine Cytosol and nucleus Inhibition of ATPase activity NA 6 3-[(3S)-3-[(3S)-7-amino-3-{4-[4-(4-bromophenyl)-5-(ethoxycarbonyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-1-yl]butanamido}heptanamido]-5-phenylpentanamido]propanoic acid CCOC(=O)C1=C(C)N(CCCC(=O)N[C@@H](CCCCN)CC(=O)N[C@@H](CCC2=CC=CC=C2)CC(=O)NCCC(O)=O)C(=O)NC1C1=CC=C(Br)C=C1 Dihydropyrimidine NA NA NA NA 105 NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000591 18060774 Hsp70 Hsc70 Bovine Cytosol and nucleus Inhibition of ATPase activity NA 7 3-[(3S)-7-amino-3-[(3S)-3-{4-[4-(4-bromophenyl)-5-(ethoxycarbonyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-1-yl]butanamido}-5-phenylpentanamido]heptanamido]propanoic acid CCOC(=O)C1=C(C)N(CCCC(=O)N[C@@H](CCC2=CC=CC=C2)CC(=O)N[C@@H](CCCCN)CC(=O)NCCC(O)=O)C(=O)NC1C1=CC=C(Br)C=C1 Dihydropyrimidine NA NA NA NA 265 NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000592 18060774 Hsp70 Hsc70 Bovine Cytosol and nucleus Activation of ATPase activity NA 8 3-[(3R,4S)-3-[(3S)-6-amino-3-{4-[4-(4-bromophenyl)-5-(ethoxycarbonyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-1-yl]butanamido}hexanamido]-4-methylhexanamido]propanoic acid CCOC(=O)C1=C(C)N(CCCC(=O)N[C@@H](CCCN)CC(=O)N[C@H](CC(=O)NCCC(O)=O)[C@@H](C)CC)C(=O)NC1C1=CC=C(Br)C=C1 Dihydropyrimidine NA NA NA NA 352 NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000593 18060774 Hsp70 Hsc70 Bovine Cytosol and nucleus Activation of ATPase activity NA 9 3-[(3S)-3-[(3R)-3-{4-[4-(4-bromophenyl)-5-(ethoxycarbonyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-1-yl]butanamido}-4-methylpentanamido]-4-(naphthalen-1-yl)butanamido]propanoic acid CCOC(=O)C1=C(C)N(CCCC(=O)N[C@H](CC(=O)N[C@H](CC(=O)NCCC(O)=O)CC2=C3C=CC=CC3=CC=C2)C(C)C)C(=O)NC1C1=CC=C(Br)C=C1 Dihydropyrimidine NA NA NA NA 255 NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000594 18060774 Hsp70 Hsc70 Bovine Cytosol and nucleus Activation of ATPase activity NA 14 3-[(3S)-3-{4-[4-(4-bromophenyl)-5-(ethoxycarbonyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-1-yl]butanamido}-5-phenylpentanamido]propanoic acid CCOC(=O)C1=C(C)N(CCCC(=O)N[C@@H](CCC2=CC=CC=C2)CC(=O)NCCC(O)=O)C(=O)NC1C1=CC=C(Br)C=C1 Dihydropyrimidine NA NA NA NA 190 NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000595 18060774 Hsp70 Hsc70 Bovine Cytosol and nucleus Activation of ATPase activity NA 15 3-[(3S)-3-{4-[4-(4-bromophenyl)-5-(ethoxycarbonyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-1-yl]butanamido}-4-(naphthalen-1-yl)butanamido]propanoic aci CCOC(=O)C1=C(C)N(CCCC(=O)N[C@H](CC(=O)NCCC(O)=O)CC2=C3C=CC=CC3=CC=C2)C(=O)NC1C1=CC=C(Br)C=C1 Dihydropyrimidine NA NA NA NA 179 NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000596 18060774 Hsp70 Hsc70 Bovine Cytosol and nucleus Inhibition of ATPase activity NA MAL3-101 Benzyl 4-([1,1?-biphenyl]-4-yl)-1-(6-((2-(butylamino)-1-(4-(2-methoxy-2-oxoethoxy)-3-(methoxycarbonyl)phenyl)-2-oxoethyl)(hexyl)amino)-6-oxohexyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate O=C(C1=C(C)N(CCCCCC(N(C(C2=CC=C(OCC(OC)=O)C(C(OC)=O)=C2)C(NCCCC)=O)CCCCCC)=O)C(NC1C3=CC=C(C4=CC=CC=C4)C=C3)=O)OCC5=CC=CC=C5 Dihydropyrimidine NA NA NA NA 74 NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000597 18060774 Hsp70 DnaK Bacteria Cytosol and membrane Inhibition of ATPase activity NA 6 3-[(3S)-3-[(3S)-7-amino-3-{4-[4-(4-bromophenyl)-5-(ethoxycarbonyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-1-yl]butanamido}heptanamido]-5-phenylpentanamido]propanoic acid CCOC(=O)C1=C(C)N(CCCC(=O)N[C@@H](CCCCN)CC(=O)N[C@@H](CCC2=CC=CC=C2)CC(=O)NCCC(O)=O)C(=O)NC1C1=CC=C(Br)C=C1 Dihydropyrimidine NA NA NA NA 107 NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000598 18060774 Hsp70 DnaK Bacteria Cytosol and membrane Inhibition of ATPase activity NA 7 3-[(3S)-7-amino-3-[(3S)-3-{4-[4-(4-bromophenyl)-5-(ethoxycarbonyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-1-yl]butanamido}-5-phenylpentanamido]heptanamido]propanoic acid CCOC(=O)C1=C(C)N(CCCC(=O)N[C@@H](CCC2=CC=CC=C2)CC(=O)N[C@@H](CCCCN)CC(=O)NCCC(O)=O)C(=O)NC1C1=CC=C(Br)C=C1 Dihydropyrimidine NA NA NA NA 325 NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000599 18060774 Hsp70 DnaK Bacteria Cytosol and membrane Activation of ATPase activity NA 15 3-[(3S)-3-{4-[4-(4-bromophenyl)-5-(ethoxycarbonyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-1-yl]butanamido}-4-(naphthalen-1-yl)butanamido]propanoic aci CCOC(=O)C1=C(C)N(CCCC(=O)N[C@H](CC(=O)NCCC(O)=O)CC2=C3C=CC=CC3=CC=C2)C(=O)NC1C1=CC=C(Br)C=C1 Dihydropyrimidine NA NA NA NA 190 NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000600 22546203 Hsp70 Hsp70-DnaJ (RRL) Rabbit Cytosol and nucleus Inhibition of chaperone activity NA 1 pentyl 3a,8b-dihydroxy-2-methyl-4-methylidene-1H,3aH,4H,8bH-indeno[1,2-b]pyrrole-3-carboxylate CCCCCOC(=O)C1=C(C)NC2(O)C3=C(C=CC=C3)C(=C)C12O Phenoxy-N-arylacetamide NA NA NA 4.3 NA NA NA NA NA Refolding assay (luciferase) NA NA NA NA NA NA NA HSPMDB000601 22546203 Hsp70 Hsp70-DnaJ (RRL) Rabbit Cytosol and nucleus Inhibition of chaperone activity NA 2 N-(4-chlorophenyl)-4-(thiophen-2-yl)-1,3-thiazol-2-amine ClC1=CC=C(NC2=NC(=CS2)C2=CC=CS2)C=C1 Phenoxy-N-arylacetamide NA NA NA 4 NA NA NA NA NA Refolding assay (luciferase) NA NA NA NA NA NA NA HSPMDB000602 22546203 Hsp70 Hsp70-DnaJ (RRL) Rabbit Cytosol and nucleus Inhibition of chaperone activity NA 3 7-(2-chlorophenyl)-4-(furan-2-yl)-8-oxa-5,6-diazatricyclo[7.4.0.0²,?]trideca-1(9),4,10,12-tetraene ClC1=C(C=CC=C1)C1OC2=C(C=CC=C2)C2CC(=NN12)C1=CC=CO1 Phenoxy-N-arylacetamide NA NA NA 8.8 NA NA NA NA NA Refolding assay (luciferase) NA NA NA NA NA NA NA HSPMDB000603 22546203 Hsp70 Hsp70-DnaJ (RRL) Rabbit Cytosol and nucleus Inhibition of chaperone activity NA 4 N-(cyclohexa-1,5-dien-1-yl)-4-(thiophen-2-yl)-1,3-thiazol-2-amine C1CC=C(NC2=NC(=CS2)C2=CC=CS2)C=C1 Phenoxy-N-arylacetamide NA NA NA 1.1 NA NA NA NA NA Refolding assay (luciferase) NA NA NA NA NA NA NA HSPMDB000604 22546203 Hsp70 Hsp70-DnaJ (RRL) Rabbit Cytosol and nucleus Inhibition of chaperone activity NA 5 ethyl 3-[2-(2-chlorophenoxy)acetamido]benzoate CCOC(=O)C1=CC=CC(NC(=O)COC2=CC=CC=C2Cl)=C1 Phenoxy-N-arylacetamide NA NA NA 0.81 NA NA NA NA NA Refolding assay (luciferase) NA NA NA NA NA NA NA HSPMDB000605 19694756 Hsp70 DnaK Bacteria Cytosol and membrane Binding affinity NA B12 N-[(2-fluorophenyl)methyl]thiophene-2-carboxamide FC1=CC=CC=C1CNC(=O)C1=CC=CS1 Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA NA 64.1 NA NA NA NA NA NA C-terminal domain Isothermal Titration Calorimetry (ITC) NA NA NA NA NA NA Bacterial infection HSPMDB000606 19694756 Hsp70 DnaK Bacteria Cytosol and membrane Binding affinity NA F6 N-[(3,4-dichlorophenyl)methyl]thiophene-2-carboxamide ClC1=CC=C(CNC(=O)C2=CC=CS2)C=C1Cl Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA NA 7.3 NA NA NA NA NA NA C-terminal domain Isothermal Titration Calorimetry (ITC) NA NA NA NA NA NA Bacterial infection HSPMDB000607 19694756 Hsp70 DnaK Bacteria Cytosol and membrane Binding affinity NA F8 N-[(2-hydroxyphenyl)methyl]thiophene-2-carboxamide OC1=CC=CC=C1CNC(=O)C1=CC=CS1 Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA NA 2.3 NA NA NA NA NA NA C-terminal domain Isothermal Titration Calorimetry (ITC) NA NA NA NA NA NA Bacterial infection HSPMDB000608 19694756 Hsp70 DnaK Bacteria Cytosol and membrane Binding affinity NA F10 2-[4-(thiophene-2-carbonyl)piperazin-1-yl]ethan-1-ol OCCN1CCN(CC1)C(=O)C1=CC=CS1 Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA NA 16.7 NA NA NA NA NA NA C-terminal domain Isothermal Titration Calorimetry (ITC) NA NA NA NA NA NA Bacterial infection HSPMDB000609 19694756 Hsp70 DnaK Bacteria Cytosol and membrane Binding affinity NA B1 N-[1-(4-fluorophenyl)propan-2-yl]thiophene-2-carboxamide CC(CC1=CC=C(F)C=C1)NC(=O)C1=CC=CS1 Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA NA 13.7 NA NA NA NA NA NA C-terminal domain Isothermal Titration Calorimetry (ITC) NA NA NA NA NA NA Bacterial infection HSPMDB000610 19694756 Hsp70 DnaK Bacteria Cytosol and membrane Binding affinity NA B1 N-[1-(4-fluorophenyl)propan-2-yl]thiophene-2-carboxamide CC(CC1=CC=C(F)C=C1)NC(=O)C1=CC=CS1 Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA NA 28 NA NA NA NA NA NA C-terminal domain Isothermal Titration Calorimetry (ITC) NA NA NA NA NA NA Bacterial infection HSPMDB000611 19694756 Hsp70 DnaK Bacteria Cytosol and membrane Binding affinity NA D10 N-[(1-benzothiophen-7-yl)methyl]thiophene-2-carboxamide O=C(NCC1=CC=CC2=C1SC=C2)C1=CC=CS1 Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA NA 0.2 NA NA NA NA NA NA C-terminal domain Isothermal Titration Calorimetry (ITC) NA NA NA NA NA NA Bacterial infection HSPMDB000612 19694756 Hsp70 DnaK Bacteria Cytosol and membrane Binding affinity NA B3 N-[(4-fluorophenyl)methyl]-5-methylfuran-2-carboxamide CC1=CC=C(O1)C(=O)NCC1=CC=C(F)C=C1 Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA NA 47.6 NA NA NA NA NA NA C-terminal domain Isothermal Titration Calorimetry (ITC) NA NA NA NA NA NA Bacterial infection HSPMDB000613 19694756 Hsp70 DnaK Bacteria Cytosol and membrane Binding affinity NA B4 N-[(4-chlorophenyl)methyl]-5-methylfuran-2-carboxamide CC1=CC=C(O1)C(=O)NCC1=CC=C(Cl)C=C1 Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA NA 19.3 NA NA NA NA NA NA C-terminal domain Isothermal Titration Calorimetry (ITC) NA NA NA NA NA NA Bacterial infection HSPMDB000614 19694756 Hsp70 DnaK Bacteria Cytosol and membrane Binding affinity NA F7 N-[(2,6-dichlorophenyl)methyl]thiophene-2-carboxamide ClC1=CC=CC(Cl)=C1CNC(=O)C1=CC=CS1 Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA NA 1.5 NA NA NA NA NA NA C-terminal domain Isothermal Titration Calorimetry (ITC) NA NA NA NA NA NA Bacterial infection HSPMDB000615 19694756 Hsp70 DnaK Bacteria Cytosol and membrane Binding affinity NA F9 N-[(3,5-dichlorophenyl)methyl]thiophene-2-carboxamide ClC1=CC(CNC(=O)C2=CC=CS2)=CC(Cl)=C1 Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA NA 2.8 NA NA NA NA NA NA C-terminal domain Isothermal Titration Calorimetry (ITC) NA NA NA NA NA NA Bacterial infection HSPMDB000616 19694756 Hsp70 DnaK Bacteria Cytosol and membrane Binding affinity NA D5 N-[(naphthalen-1-yl)methyl]thiophene-2-carboxamide O=C(NCC1=CC=CC2=C1C=CC=C2)C1=CC=CS1 Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA NA 1 NA NA NA NA NA NA C-terminal domain Isothermal Titration Calorimetry (ITC) NA NA NA NA NA NA Bacterial infection HSPMDB000617 19694756 Hsp70 DnaK Bacteria Cytosol and membrane Binding affinity NA D5 N-[(naphthalen-1-yl)methyl]thiophene-2-carboxamide O=C(NCC1=CC=CC2=C1C=CC=C2)C1=CC=CS1 Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA NA 1.7 NA NA NA NA NA NA C-terminal domain Isothermal Titration Calorimetry (ITC) NA NA NA NA NA NA Bacterial infection HSPMDB000618 19694756 Hsp70 DnaK Bacteria Cytosol and membrane Binding affinity NA D9 N-(quinazolin-2-yl)thiophene-2-carboxamide O=C(NC1=NC2=C(C=CC=C2)C=N1)C1=CC=CS1 Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA NA 1.5 NA NA NA NA NA NA C-terminal domain Isothermal Titration Calorimetry (ITC) NA NA NA NA NA NA Bacterial infection HSPMDB000619 19694756 Hsp70 DnaK Bacteria Cytosol and membrane Binding affinity NA C5 N-[(2-bromophenyl)methyl]thiophene-2-carboxamide BrC1=CC=CC=C1CNC(=O)C1=CC=CS1 Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA NA 14.3 NA NA NA NA NA NA C-terminal domain Isothermal Titration Calorimetry (ITC) NA NA NA NA NA NA Bacterial infection HSPMDB000620 19694756 Hsp70 DnaK Bacteria Cytosol and membrane Binding affinity NA C5 N-[(2-bromophenyl)methyl]thiophene-2-carboxamide BrC1=CC=CC=C1CNC(=O)C1=CC=CS1 Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA NA 39.3 NA NA NA NA NA NA C-terminal domain Isothermal Titration Calorimetry (ITC) NA NA NA NA NA NA Bacterial infection HSPMDB000621 19694756 Hsp70 DnaK Bacteria Cytosol and membrane NA Antibacterial activity BI-88E3 N-[(4-methylphenyl)methyl]-5-nitrofuran-2-carboxamide CC1=CC=C(CNC(=O)C2=CC=C(O2)[N+]([O-])=O)C=C1 Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA NA NA NA NA NA NA NA NA C-terminal domain NA NA Bacterial growth inhibition assay (OD based) NA NA 250 uM E. coli at 37 C Bacterial infection HSPMDB000622 19694756 Hsp70 DnaK Bacteria Cytosol and membrane NA Antibacterial activity BI-88E3 N-[(4-methylphenyl)methyl]-5-nitrofuran-2-carboxamide CC1=CC=C(CNC(=O)C2=CC=C(O2)[N+]([O-])=O)C=C1 Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA NA NA NA NA NA NA NA NA C-terminal domain NA NA Bacterial growth inhibition assay (OD based) NA NA 250 uM E. coli at 42 C Bacterial infection HSPMDB000623 19694756 Hsp70 DnaK Bacteria Cytosol and membrane NA Antibacterial activity BI-88E3 N-[(4-methylphenyl)methyl]-5-nitrofuran-2-carboxamide CC1=CC=C(CNC(=O)C2=CC=C(O2)[N+]([O-])=O)C=C1 Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA NA NA NA NA NA NA NA NA C-terminal domain NA NA Bacterial growth inhibition assay (OD based) NA NA 400 uM Yersinia pseudotuberculosis at 22 C Bacterial infection HSPMDB000624 19694756 Hsp70 DnaK Bacteria Cytosol and membrane NA Antibacterial activity BI-88E3 N-[(4-methylphenyl)methyl]-5-nitrofuran-2-carboxamide CC1=CC=C(CNC(=O)C2=CC=C(O2)[N+]([O-])=O)C=C1 Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA NA NA NA NA NA NA NA NA C-terminal domain NA NA Bacterial growth inhibition assay (OD based) NA NA 25 uM Yersinia pseudotuberculosis at 37 C Bacterial infection HSPMDB000625 19694756 Hsp70 DnaK Bacteria Cytosol and membrane NA Antibacterial activity BI-88E3 N-[(4-methylphenyl)methyl]-5-nitrofuran-2-carboxamide CC1=CC=C(CNC(=O)C2=CC=C(O2)[N+]([O-])=O)C=C1 Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA NA NA NA NA NA NA NA NA C-terminal domain NA NA Bacterial growth inhibition assay (OD based) NA NA <12 uM Yersinia pseudotuberculosis at 40 C Bacterial infection HSPMDB000626 19694756 Hsp70 DnaK (SBD) Bacteria Cytosol and membrane Binding affinity NA BI-88E3 N-[(4-methylphenyl)methyl]-5-nitrofuran-2-carboxamide CC1=CC=C(CNC(=O)C2=CC=C(O2)[N+]([O-])=O)C=C1 Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA NA 25 NA NA NA NA NA NA C-terminal domain Isothermal Titration Calorimetry (ITC) NA NA NA NA NA NA Bacterial infection HSPMDB000627 19694756 Hsp70 DnaK Bacteria Cytosol and membrane NA Antibacterial activity BI-88D7 N-(1H-indol-5-yl)thiophene-2-carboxamide N1C=CC2=CC(=CC=C12)NC(=O)C=1SC=CC1 Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA NA NA NA NA NA NA NA NA C-terminal domain NA NA Bacterial growth inhibition assay (OD based) NA NA 400 uM E. coli at 37 C Bacterial infection HSPMDB000628 19694756 Hsp70 DnaK Bacteria Cytosol and membrane NA Antibacterial activity BI-88D7 N-(1H-indol-5-yl)thiophene-2-carboxamide N1C=CC2=CC(=CC=C12)NC(=O)C=1SC=CC1 Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA NA NA NA NA NA NA NA NA C-terminal domain NA NA Bacterial growth inhibition assay (OD based) NA NA 400 uM E. coli at 42 C Bacterial infection HSPMDB000629 19694756 Hsp70 DnaK Bacteria Cytosol and membrane NA Antibacterial activity BI-88D7 N-(1H-indol-5-yl)thiophene-2-carboxamide N1C=CC2=CC(=CC=C12)NC(=O)C=1SC=CC1 Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA NA NA NA NA NA NA NA NA C-terminal domain NA NA Bacterial growth inhibition assay (OD based) NA NA 400 uM Yersinia pseudotuberculosis at 37 C Bacterial infection HSPMDB000630 19694756 Hsp70 DnaK Bacteria Cytosol and membrane NA Antibacterial activity BI-88D7 N-(1H-indol-5-yl)thiophene-2-carboxamide N1C=CC2=CC(=CC=C12)NC(=O)C=1SC=CC1 Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA NA NA NA NA NA NA NA NA C-terminal domain NA NA Bacterial growth inhibition assay (OD based) NA NA 400 uM Yersinia pseudotuberculosis at 22 C Bacterial infection HSPMDB000631 19694756 Hsp70 DnaK Bacteria Cytosol and membrane NA Antibacterial activity BI-88D7 N-(1H-indol-5-yl)thiophene-2-carboxamide N1C=CC2=CC(=CC=C12)NC(=O)C=1SC=CC1 Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA NA NA NA NA NA NA NA NA C-terminal domain NA NA Bacterial growth inhibition assay (OD based) NA NA 400 uM Yersinia pseudotuberculosis at 40 C Bacterial infection HSPMDB000632 19694756 Hsp70 DnaK (SBD) Bacteria Cytosol and membrane Binding affinity NA BI-88D7 N-(1H-indol-5-yl)thiophene-2-carboxamide N1C=CC2=CC(=CC=C12)NC(=O)C=1SC=CC1 Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA NA 4.9 NA NA NA NA NA NA C-terminal domain Isothermal Titration Calorimetry (ITC) NA NA NA NA NA NA Bacterial infection HSPMDB000633 19694756 Hsp70 DnaK (FL) Bacteria Cytosol and membrane Binding affinity NA BI-88D7 N-(1H-indol-5-yl)thiophene-2-carboxamide N1C=CC2=CC(=CC=C12)NC(=O)C=1SC=CC1 Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA NA 12.7 NA NA NA NA NA NA C-terminal domain Isothermal Titration Calorimetry (ITC) NA NA NA NA NA NA Bacterial infection HSPMDB000634 20926844 Hsp70 DnaK-DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA 2a ethyl 2-amino-1-phenyl-1H-pyrrolo[2,3-b]quinoxaline-3-carboxylate CCOC(=O)c1c(N)n(c2ccccc2)c3nc4ccccc4nc13 MS2000 (Spectrum) library NA NA NA >500 NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000635 20926844 Hsp70 DnaK-DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA 2b ethyl 2-amino-1-hexyl-1H-pyrrolo[2,3-b]quinoxaline-3-carboxylate CCCCCCn1c(N)c(C(=O)OCC)c2nc3ccccc3nc12 MS2000 (Spectrum) library NA NA NA >500 NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000636 20926844 Hsp70 DnaK-DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA 3a 6-methyl-2-((2-oxo-2-phenylethyl)thio)-4-(trifluoromethyl)nicotinonitrile Cc1cc(c(C#N)c(SCC(=O)c2ccccc2)n1)C(F)(F)F MS2000 (Spectrum) library NA NA NA >500 NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000637 20926844 Hsp70 DnaK-DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA 3b ethyl 6-acetyl-2-amino-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxylate CCOC(=O)c1c(N)sc2CN(CCc12)C(C)=O MS2000 (Spectrum) library NA NA NA >500 NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000638 20926844 Hsp70 DnaK-DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA 3c cyclopentyl (3-(2-methoxy-4-((o-tolylsulfonyl)carbamoyl)benzyl)-1-methyl-1H-indol-5-yl) carbamate COc1cc(ccc1Cc2cn(C)c3ccc(NC(=O)OC4CCCC4)cc23)C(=O)N[S](=O)(=O)c5ccccc5C MS2000 (Spectrum) library NA NA NA 37 NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000639 20926845 Hsp70 DnaK Bacteria Cytosol and membrane Binding affinity NA 3c cyclopentyl (3-(2-methoxy-4-((o-tolylsulfonyl)carbamoyl)benzyl)-1-methyl-1H-indol-5-yl) carbamate COc1cc(ccc1Cc2cn(C)c3ccc(NC(=O)OC4CCCC4)cc23)C(=O)N[S](=O)(=O)c5ccccc5C MS2000 (Spectrum) library NA 13 NA NA NA NA NA NA NA Intrisic Trp fluortescence NA NA NA NA NA NA NA HSPMDB000640 20926844 Hsp70 Hsp72 Human Cytosol and nucleus Inhibition of ATPase activity NA 3c cyclopentyl (3-(2-methoxy-4-((o-tolylsulfonyl)carbamoyl)benzyl)-1-methyl-1H-indol-5-yl) carbamate COc1cc(ccc1Cc2cn(C)c3ccc(NC(=O)OC4CCCC4)cc23)C(=O)N[S](=O)(=O)c5ccccc5C MS2000 (Spectrum) library NA NA NA 71 NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000641 20926844 Hsp70 Hsc70 Bovine Cytosol and nucleus Inhibition of ATPase activity NA 3c cyclopentyl (3-(2-methoxy-4-((o-tolylsulfonyl)carbamoyl)benzyl)-1-methyl-1H-indol-5-yl) carbamate COc1cc(ccc1Cc2cn(C)c3ccc(NC(=O)OC4CCCC4)cc23)C(=O)N[S](=O)(=O)c5ccccc5C MS2000 (Spectrum) library NA NA NA 106 NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000642 21636681 Hsp70 Hsc70 (HSPA8) and Hsp70 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 2-phenylethyenesulfonamide (PES) 2-phenylethynesulfonamide C1=CC=C(C=C1)C#CS(=O)(=O)N NA NA NA NA NA NA NA NA 8 C-terminal domain NA NA MTT viability assay NA NA NA H1299 Cancer HSPMDB000643 21636681 Hsp70 Hsc70 (HSPA8) and Hsp70 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 2-phenylethyenesulfonamide (PES) 2-phenylethynesulfonamide C1=CC=C(C=C1)C#CS(=O)(=O)N NA NA NA NA NA NA NA NA 11 C-terminal domain NA NA MTT viability assay NA NA NA MCF10A Cancer HSPMDB000644 21636681 Hsp70 Hsc70 (HSPA8) and Hsp70 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 2-phenylethyenesulfonamide (PES) 2-phenylethynesulfonamide C1=CC=C(C=C1)C#CS(=O)(=O)N NA NA NA NA NA NA NA NA 5 C-terminal domain NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000645 21636681 Hsp70 Hsc70 (HSPA8) and Hsp70 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 2-phenylethyenesulfonamide (PES) 2-phenylethynesulfonamide C1=CC=C(C=C1)C#CS(=O)(=O)N NA NA NA NA NA NA NA NA 5 C-terminal domain NA NA MTT viability assay NA NA NA MDA-MB-468 Cancer HSPMDB000646 23819499 Hsp70 DnaK Bacteria Cytosol and membrane Binding affinity (ADP-bound DnaK) NA Zafirlukast (Zaf) cyclopentyl N-[3-[[2-methoxy-4-[(2-methylphenyl)sulfonylcarbamoyl]phenyl]methyl]-1-methylindol-5-yl]carbamate CC1=CC=CC=C1S(=O)(=O)NC(=O)C2=CC(=C(C=C2)CC3=CN(C4=C3C=C(C=C4)NC(=O)OC5CCCC5)C)OC Library assembled at the University of Michigan's Center for Chemical Genomics NA 52 NA NA NA NA NA NA Nucleotide binding domain Intrisic Trp fluortescence NA NA NA NA NA NA NA HSPMDB000647 23819499 Hsp70 DnaK Bacteria Cytosol and membrane Binding affinity (ATP-bound DnaK) NA Zafirlukast (Zaf) cyclopentyl N-[3-[[2-methoxy-4-[(2-methylphenyl)sulfonylcarbamoyl]phenyl]methyl]-1-methylindol-5-yl]carbamate CC1=CC=CC=C1S(=O)(=O)NC(=O)C2=CC(=C(C=C2)CC3=CN(C4=C3C=C(C=C4)NC(=O)OC5CCCC5)C)OC Library assembled at the University of Michigan's Center for Chemical Genomics NA >100 NA NA NA NA NA NA Nucleotide binding domain Intrisic Trp fluortescence NA NA NA NA NA NA NA HSPMDB000648 23819499 Hsp70 DnaK-DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity (DnaJ stimulated) NA Zafirlukast (Zaf) cyclopentyl N-[3-[[2-methoxy-4-[(2-methylphenyl)sulfonylcarbamoyl]phenyl]methyl]-1-methylindol-5-yl]carbamate CC1=CC=CC=C1S(=O)(=O)NC(=O)C2=CC(=C(C=C2)CC3=CN(C4=C3C=C(C=C4)NC(=O)OC5CCCC5)C)OC Library assembled at the University of Michigan's Center for Chemical Genomics NA NA NA 37 NA NA NA NA Nucleotide binding domain ATPase assay NA NA NA NA NA NA NA HSPMDB000649 24239008 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus Inhibition of chaperone activity NA YK5 N-(6-amino-2-{[4,6-dimethoxy-2-(4-methylpiperazin-1-yl)pyrimidin-5-yl]sulfanyl}pyrimidin-4-yl)prop-2-enamide COC1=NC(=NC(OC)=C1SC1=NC(N)=CC(NC(=O)C=C)=N1)N1CCN(C)CC1 Structure based design 90% inhibition at 100 uM NA NA NA NA NA NA NA Nucleotide binding domain Refolding assay (luciferase) NA NA NA NA NA NA Cancer HSPMDB000650 27119979 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus Binding affinity NA 1 (Adenosine) 2-(6-amino-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol NC1=NC=NC2=C1N=CN2C1OC(CO)C(O)C1O Adenosine derivative NA 110 NA NA NA NA NA NA Nucleotide binding domain Surface plasmon resonance (SPR) NA NA NA NA NA NA NA HSPMDB000651 27119979 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus Binding affinity NA 2 2-(6-amino-9H-purin-9-yl)-5-methyloxolane-3,4-diol CC1OC(C(O)C1O)N1C=NC2=C1N=CN=C2N Adenosine derivative NA 130 NA NA NA NA NA NA Nucleotide binding domain Surface plasmon resonance (SPR) NA NA NA NA NA NA NA HSPMDB000652 27119979 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus Binding affinity NA 3 2-(6,8-diamino-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol NC1=NC2=C(N=CN=C2N)N1C1OC(CO)C(O)C1O Adenosine derivative NA 7 NA NA NA NA NA NA Nucleotide binding domain Surface plasmon resonance (SPR) NA NA NA NA NA NA NA HSPMDB000653 27119979 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus Binding affinity NA 4 (2R,3R,4S,5R)-2-(6-Amino-8-(methylamino)-9H-purin-9-yl)-5(hydroxymethyl)tetrahydrofuran-3,4-diol CNc1nc2c(N)ncnc2n1[C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O Adenosine derivative NA 17 NA NA NA NA NA NA Nucleotide binding domain Surface plasmon resonance (SPR) NA NA NA NA NA NA NA HSPMDB000654 27119979 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus Binding affinity NA 5 (2R,3R,4S,5R)-2-(6-Amino-8-(dimethylamino)-9H-purin-9-yl)-5(hydroxymethyl)tetrahydrofuran-3,4-diol CN(C)c1nc2c(N)ncnc2n1[C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O Adenosine derivative NA >1000 NA NA NA NA NA NA Nucleotide binding domain Surface plasmon resonance (SPR) NA NA NA NA NA NA NA HSPMDB000655 27119979 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus Binding affinity NA 6 (2R,3R,4S,5R)-2-(6-Amino-8-methoxy-9H-purin-9-yl)-5(hydroxymethyl)tetrahydrofuran-3,4-diol COc1nc2c(N)ncnc2n1[C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O Adenosine derivative NA >1000 NA NA NA NA NA NA Nucleotide binding domain Surface plasmon resonance (SPR) NA NA NA NA NA NA NA HSPMDB000656 27119979 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus Binding affinity NA 7 (2R,3R,4S,5R)-2-(6-Amino-8-(methylamino)-9H-purin-9-yl)-5methyltetrahydrofuran-3,4-diol CNc1nc2c(N)ncnc2n1[C@@H]3O[C@H](C)[C@@H](O)[C@H]3O Adenosine derivative NA 27 NA NA NA NA NA NA Nucleotide binding domain Surface plasmon resonance (SPR) NA NA NA NA NA NA NA HSPMDB000657 27119979 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus Binding affinity NA 8 (2R,3R,4S,5R)-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-5-(hydroxymethyl)oxolane-3,4-diol C1=CN(C2=C1C(=NC=N2)N)C3C(C(C(O3)CO)O)O Adenosine derivative NA 28 NA NA NA NA NA NA Nucleotide binding domain Surface plasmon resonance (SPR) NA NA NA NA NA NA NA HSPMDB000658 27119979 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus Binding affinity NA 9 4-amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrrolo[2,3-d]pyrimidine-5-carbonitrile C1=C(C2=C(N1C3C(C(C(O3)CO)O)O)N=CN=C2N)C#N Adenosine derivative NA 90 NA NA NA NA NA NA Nucleotide binding domain Surface plasmon resonance (SPR) NA NA NA NA NA NA NA HSPMDB000659 27119979 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus Binding affinity NA 10 4-amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrrolo[2,3-d]pyrimidine-5-carboxamide C1=C(C2=C(N1C3C(C(C(O3)CO)O)O)N=CN=C2N)C(=O)N Adenosine derivative NA 3.3 NA NA NA NA NA NA Nucleotide binding domain Surface plasmon resonance (SPR) NA NA NA NA NA NA NA HSPMDB000660 27119979 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus Binding affinity NA 12 4-Amino-7-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-6-(methylamino)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile CNc1n([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c3ncnc(N)c3c1C#N Adenosine derivative NA 3.3 NA NA NA NA NA NA Nucleotide binding domain Surface plasmon resonance (SPR) NA NA NA NA NA NA NA HSPMDB000661 27119979 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus Binding affinity NA 13 4-Amino-7-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-6-(methylamino)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide CNc1n([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c3ncnc(N)c3c1C(N)=O Adenosine derivative NA 30 NA NA NA NA NA NA Nucleotide binding domain Surface plasmon resonance (SPR) NA NA NA NA NA NA NA HSPMDB000662 27119979 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus Binding affinity NA 14 4-Amino-6-(benzylamino)-7-((2R,3R,4S,5R)-3,4-dihydroxy-5(hydroxymethyl)tetrahydrofuran-2-yl)-7H-pyrrolo[2,3-d]pyrimidine5-carbonitrile Nc1ncnc2n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c(NCc4ccccc4)c(C#N)c12 Adenosine derivative NA 2.8 NA NA NA NA NA NA Nucleotide binding domain Surface plasmon resonance (SPR) NA NA NA NA NA NA NA HSPMDB000663 27119979 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus Binding affinity NA 15 (2R,3R,4S,5R)-2-(6-Amino-8-(benzylamino)-9H-purin-9-yl)-5(hydroxymethyl)tetrahydrofuran-3,4-diol Nc1ncnc2n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c(NCc4ccccc4)nc12 Adenosine derivative NA 1.5 NA NA NA NA NA NA Nucleotide binding domain Surface plasmon resonance (SPR) NA NA NA NA NA NA NA HSPMDB000664 27119979 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus Binding affinity NA 17 (2R,3R,4S,5R)-2-(6-Amino-8-((quinolin-6-ylmethyl)amino)-9Hpurin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol Nc1ncnc2n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c(NCc4ccc5ncccc5c4)nc12 Adenosine derivative NA 0.72 NA NA NA NA NA NA Nucleotide binding domain Surface plasmon resonance (SPR) NA NA NA NA NA NA NA HSPMDB000665 27119979 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus Binding affinity NA 18 (2R,3R,4S,5R)-2-(6-Amino-8-((4-chlorobenzyl)amino)-9H-purin-9yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol Nc1ncnc2n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c(NCc4ccc(Cl)cc4)nc12 Adenosine derivative NA 0.28 NA NA NA NA NA NA Nucleotide binding domain Surface plasmon resonance (SPR) NA NA NA NA NA NA NA HSPMDB000666 27119979 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus Binding affinity NA 19 (2R,3R,4S,5R)-2-(6-Amino-8-((4-?uorobenzyl)amino)-9H-purin-9yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol Nc1ncnc2n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c(NCc4ccc(F)cc4)nc12 Adenosine derivative NA 0.46 NA NA NA NA NA NA Nucleotide binding domain Surface plasmon resonance (SPR) NA NA NA NA NA NA NA HSPMDB000667 27119979 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus Binding affinity NA 20 (2R,3R,4S,5R)-2-(6-Amino-8-((4-methylbenzyl)amino)-9H-purin9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol Cc1ccc(CNc2nc3c(N)ncnc3n2[C@@H]4O[C@H](CO)[C@@H](O)[C@H]4O)cc1 Adenosine derivative NA 0.3 NA NA NA NA NA NA Nucleotide binding domain Surface plasmon resonance (SPR) NA NA NA NA NA NA NA HSPMDB000668 27119979 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus Binding affinity NA 21 (2R,3R,4S,5R)-2-(6-Amino-8-((3,4-dichlorobenzyl)amino)-9Hpurin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol Nc1ncnc2n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c(NCc4ccc(Cl)c(Cl)c4)nc12 Adenosine derivative NA 3.5 NA NA NA NA NA NA Nucleotide binding domain Surface plasmon resonance (SPR) NA NA NA NA NA NA NA HSPMDB000669 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity JG-98 3-benzyl-2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.71 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000670 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 1 3-benzyl-2-((Z)-((E)-5-(6-bromo-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(Br)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.44 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000671 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 2 3-benzyl-2-((Z)-((E)-5-(5-bromo-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5ccc(Br)cc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.27 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000672 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 3 3-benzyl-2-((Z)-((E)-3-ethyl-5-(3-methyl-6-nitrobenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(ccc5N4C)[N+]([O-])=O Benzothiazole Rhodacyanines derivative NA NA NA NA >5 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000673 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 4 3-benzyl-2-((Z)-((E)-3-ethyl-5-(3-methyl-5-(methylsulfonyl)benzo[d]thiazol-2(3H)-ylidene)-4- oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5ccc(cc5N4C)[S](C)(=O)=O Benzothiazole Rhodacyanines derivative NA NA NA NA >5 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000674 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 5 3-benzyl-2-((Z)-((E)-3-ethyl-5-(3-methyl-6-(trifluoromethyl)benzo[d]thiazol-2(3H)-ylidene)-4- oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(ccc5N4C)C(F)(F)F Benzothiazole Rhodacyanines derivative NA NA NA NA 0.53 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000675 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 6 3-benzyl-2-((Z)-((E)-3-ethyl-5-(3-methyl-5-(trifluoromethoxy)benzo[d]thiazol-2(3H)-ylidene)- 4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5ccc(OC(F)(F)F)cc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.26 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000676 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 7 3-benzyl-2-((Z)-((E)-3-ethyl-5-(3-methyl-6-(trifluoromethoxy)benzo[d]thiazol-2(3H)-ylidene)- 4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(OC(F)(F)F)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.4 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000677 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 8 3-benzyl-2-((Z)-((E)-5-(3,5-dimethylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2- ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5ccc(C)cc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.21 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000678 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 9(JG-194) 3-benzyl-2-((Z)-((E)-5-(3,6-dimethylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2- ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(C)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.16 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000679 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 10 3-benzyl-2-((Z)-((E)-5-(3,4-dimethylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cccc(C)c5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.25 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000680 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 11 3-benzyl-2-((Z)-((E)-5-(3,7-dimethylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5c(C)cccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.29 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000681 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 12 3-benzyl-2-((Z)-((E)-3-ethyl-5-(6-ethyl-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(CC)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.08 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000682 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 13 3-benzyl-2-((Z)-((E)-3-ethyl-5-(5-methoxy-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazo lidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5ccc(OC)cc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.37 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000683 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 14 3-benzyl-2-((Z)-((E)-3-ethyl-5-(6-methoxy-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(OC)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.13 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000684 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 15 3-benzyl-2-((Z)-((E)-3-ethyl-5-(3-methyl-6-(methylthio)benzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(SC)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.13 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000685 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 16 2-((Z)-((E)-3-allyl-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)methyl)-3-benzylthiazol-3-ium chloride [Cl-].CN1C(\Sc2cc(Cl)ccc12)=C3/SC(=C\c4scc[n+]4Cc5ccccc5)/N(CC=C)C3=O Benzothiazole Rhodacyanines derivative NA NA NA NA 0.17 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000686 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 17 3-benzyl-2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-cyclopropyl-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CN1C(/Sc2cc(Cl)ccc12)=C3\S\C(=C/c4scc[n+]4Cc5ccccc5)N(C6CC6)C3=O Benzothiazole Rhodacyanines derivative NA NA NA NA 0.33 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000687 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 18 3-benzyl-2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-(3-methoxy-3-oxopropyl)-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].COC(=O)CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.66 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000688 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 19 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(2-fluorobenzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3F)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.16 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000689 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 20 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2- ylidene)methyl)-3-(3-fluorobenzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3cccc(F)c3)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.48 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000690 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 21 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(4-fluorobenzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccc(F)cc3)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.61 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000691 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 22 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(2-chlorobenzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3Cl)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.19 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000692 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 23 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(3-chlorobenzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3cccc(Cl)c3)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.26 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000693 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 24 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(4-chlorobenzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccc(Cl)cc3)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 1.45 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000694 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 25 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2- ylidene)methyl)-3-(2-(trifluoromethyl)benzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3C(F)(F)F)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.13 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000695 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 26 3-(2-bromobenzyl)-2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4- oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3Br)=C4/Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.19 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000696 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 27 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(2-(methoxycarbonyl)benzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3C(=O)OC)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.17 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000697 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 28 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(2-methylbenzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3C)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.19 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000698 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 29 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(2-methoxybenzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3OC)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.4 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000699 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 30 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(2-((trifluoromethyl)thio)benzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3SC(F)(F)F)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.13 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000700 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 31 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(2-(trifluoromethoxy)benzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3OC(F)(F)F)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.22 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000701 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 32(JG-258) 3-benzyl-2-((Z)-((E)-3'-ethyl-3-methyl-4'-oxo-3',4,4',5-tetrahydro-2'H,3H-[2,5'-bithiazolylidene]- 2'-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/SCCN4C Benzothiazole Rhodacyanines derivative NA NA NA NA >5 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000702 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity JG-98 3-benzyl-2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.39 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000703 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 1 3-benzyl-2-((Z)-((E)-5-(6-bromo-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(Br)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.33 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000704 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 2 3-benzyl-2-((Z)-((E)-5-(5-bromo-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5ccc(Br)cc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.11 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000705 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 3 3-benzyl-2-((Z)-((E)-3-ethyl-5-(3-methyl-6-nitrobenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(ccc5N4C)[N+]([O-])=O Benzothiazole Rhodacyanines derivative NA NA NA NA 4.8 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000706 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 4 3-benzyl-2-((Z)-((E)-3-ethyl-5-(3-methyl-5-(methylsulfonyl)benzo[d]thiazol-2(3H)-ylidene)-4- oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5ccc(cc5N4C)[S](C)(=O)=O Benzothiazole Rhodacyanines derivative NA NA NA NA >20 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000707 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 5 3-benzyl-2-((Z)-((E)-3-ethyl-5-(3-methyl-6-(trifluoromethyl)benzo[d]thiazol-2(3H)-ylidene)-4- oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(ccc5N4C)C(F)(F)F Benzothiazole Rhodacyanines derivative NA NA NA NA 0.36 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000708 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 6 3-benzyl-2-((Z)-((E)-3-ethyl-5-(3-methyl-5-(trifluoromethoxy)benzo[d]thiazol-2(3H)-ylidene)- 4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5ccc(OC(F)(F)F)cc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 1.2 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000709 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 7 3-benzyl-2-((Z)-((E)-3-ethyl-5-(3-methyl-6-(trifluoromethoxy)benzo[d]thiazol-2(3H)-ylidene)- 4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(OC(F)(F)F)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.8 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000710 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 8 3-benzyl-2-((Z)-((E)-5-(3,5-dimethylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2- ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5ccc(C)cc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.078 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000711 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 9(JG-194) 3-benzyl-2-((Z)-((E)-5-(3,6-dimethylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2- ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(C)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.15 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000712 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 10 3-benzyl-2-((Z)-((E)-5-(3,4-dimethylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cccc(C)c5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.21 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000713 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 11 3-benzyl-2-((Z)-((E)-5-(3,7-dimethylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5c(C)cccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.25 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000714 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 12 3-benzyl-2-((Z)-((E)-3-ethyl-5-(6-ethyl-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(CC)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.14 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000715 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 13 3-benzyl-2-((Z)-((E)-3-ethyl-5-(5-methoxy-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazo lidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5ccc(OC)cc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.36 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000716 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 14 3-benzyl-2-((Z)-((E)-3-ethyl-5-(6-methoxy-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(OC)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.16 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000717 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 15 3-benzyl-2-((Z)-((E)-3-ethyl-5-(3-methyl-6-(methylthio)benzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(SC)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.12 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000718 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 16 2-((Z)-((E)-3-allyl-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)methyl)-3-benzylthiazol-3-ium chloride [Cl-].CN1C(\Sc2cc(Cl)ccc12)=C3/SC(=C\c4scc[n+]4Cc5ccccc5)/N(CC=C)C3=O Benzothiazole Rhodacyanines derivative NA NA NA NA 0.1 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000719 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 17 3-benzyl-2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-cyclopropyl-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CN1C(/Sc2cc(Cl)ccc12)=C3\S\C(=C/c4scc[n+]4Cc5ccccc5)N(C6CC6)C3=O Benzothiazole Rhodacyanines derivative NA NA NA NA 0.56 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000720 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 18 3-benzyl-2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-(3-methoxy-3-oxopropyl)-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].COC(=O)CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.24 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000721 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 19 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(2-fluorobenzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3F)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.29 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000722 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 20 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2- ylidene)methyl)-3-(3-fluorobenzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3cccc(F)c3)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 1 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000723 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 21 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(4-fluorobenzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccc(F)cc3)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 1.1 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000724 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 22 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(2-chlorobenzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3Cl)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.18 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000725 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 23 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(3-chlorobenzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3cccc(Cl)c3)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.51 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000726 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 24 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(4-chlorobenzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccc(Cl)cc3)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.41 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000727 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 25 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2- ylidene)methyl)-3-(2-(trifluoromethyl)benzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3C(F)(F)F)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.13 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000728 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 26 3-(2-bromobenzyl)-2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4- oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3Br)=C4/Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.2 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000729 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 27 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(2-(methoxycarbonyl)benzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3C(=O)OC)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.17 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000730 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 28 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(2-methylbenzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3C)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.2 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000731 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 29 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(2-methoxybenzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3OC)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.12 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000732 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 30 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(2-((trifluoromethyl)thio)benzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3SC(F)(F)F)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.16 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000733 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 31 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(2-(trifluoromethoxy)benzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3OC(F)(F)F)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.12 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000734 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 32(JG-258) 3-benzyl-2-((Z)-((E)-3'-ethyl-3-methyl-4'-oxo-3',4,4',5-tetrahydro-2'H,3H-[2,5'-bithiazolylidene]- 2'-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/SCCN4C Benzothiazole Rhodacyanines derivative NA NA NA NA >20 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000735 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity JG-98 3-benzyl-2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 4.2 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000736 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 1 3-benzyl-2-((Z)-((E)-5-(6-bromo-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(Br)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 6.1 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000737 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 2 3-benzyl-2-((Z)-((E)-5-(5-bromo-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5ccc(Br)cc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.66 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000738 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 3 3-benzyl-2-((Z)-((E)-3-ethyl-5-(3-methyl-6-nitrobenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(ccc5N4C)[N+]([O-])=O Benzothiazole Rhodacyanines derivative NA NA NA NA 2.8 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000739 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 4 3-benzyl-2-((Z)-((E)-3-ethyl-5-(3-methyl-5-(methylsulfonyl)benzo[d]thiazol-2(3H)-ylidene)-4- oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5ccc(cc5N4C)[S](C)(=O)=O Benzothiazole Rhodacyanines derivative NA NA NA NA 2.5 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000740 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 5 3-benzyl-2-((Z)-((E)-3-ethyl-5-(3-methyl-6-(trifluoromethyl)benzo[d]thiazol-2(3H)-ylidene)-4- oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(ccc5N4C)C(F)(F)F Benzothiazole Rhodacyanines derivative NA NA NA NA 2.4 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000741 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 6 3-benzyl-2-((Z)-((E)-3-ethyl-5-(3-methyl-5-(trifluoromethoxy)benzo[d]thiazol-2(3H)-ylidene)- 4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5ccc(OC(F)(F)F)cc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.34 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000742 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 7 3-benzyl-2-((Z)-((E)-3-ethyl-5-(3-methyl-6-(trifluoromethoxy)benzo[d]thiazol-2(3H)-ylidene)- 4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(OC(F)(F)F)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 1.2 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000743 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 8 3-benzyl-2-((Z)-((E)-5-(3,5-dimethylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2- ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5ccc(C)cc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 1.3 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000744 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 9(JG-194) 3-benzyl-2-((Z)-((E)-5-(3,6-dimethylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2- ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(C)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 1.9 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000745 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 10 3-benzyl-2-((Z)-((E)-5-(3,4-dimethylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cccc(C)c5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 2.3 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000746 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 11 3-benzyl-2-((Z)-((E)-5-(3,7-dimethylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5c(C)cccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 1.6 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000747 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 12 3-benzyl-2-((Z)-((E)-3-ethyl-5-(6-ethyl-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(CC)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 1 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000748 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 13 3-benzyl-2-((Z)-((E)-3-ethyl-5-(5-methoxy-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazo lidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5ccc(OC)cc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 1 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000749 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 14 3-benzyl-2-((Z)-((E)-3-ethyl-5-(6-methoxy-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(OC)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 2 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000750 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 15 3-benzyl-2-((Z)-((E)-3-ethyl-5-(3-methyl-6-(methylthio)benzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(SC)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 1.7 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000751 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 16 2-((Z)-((E)-3-allyl-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)methyl)-3-benzylthiazol-3-ium chloride [Cl-].CN1C(\Sc2cc(Cl)ccc12)=C3/SC(=C\c4scc[n+]4Cc5ccccc5)/N(CC=C)C3=O Benzothiazole Rhodacyanines derivative NA NA NA NA 2.4 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000752 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 17 3-benzyl-2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-cyclopropyl-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CN1C(/Sc2cc(Cl)ccc12)=C3\S\C(=C/c4scc[n+]4Cc5ccccc5)N(C6CC6)C3=O Benzothiazole Rhodacyanines derivative NA NA NA NA 3.4 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000753 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 18 3-benzyl-2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-(3-methoxy-3-oxopropyl)-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].COC(=O)CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 4.9 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000754 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 19 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(2-fluorobenzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3F)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 1.2 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000755 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 20 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2- ylidene)methyl)-3-(3-fluorobenzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3cccc(F)c3)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 1 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000756 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 21 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(4-fluorobenzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccc(F)cc3)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 1.9 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000757 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 22 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(2-chlorobenzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3Cl)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.7 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000758 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 23 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(3-chlorobenzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3cccc(Cl)c3)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.69 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000759 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 24 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(4-chlorobenzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccc(Cl)cc3)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 3.1 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000760 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 25 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2- ylidene)methyl)-3-(2-(trifluoromethyl)benzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3C(F)(F)F)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 1.2 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000761 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 26 3-(2-bromobenzyl)-2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4- oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3Br)=C4/Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 1.6 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000762 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 27 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(2-(methoxycarbonyl)benzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3C(=O)OC)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 2.9 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000763 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 28 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(2-methylbenzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3C)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 1.6 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000764 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 29 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(2-methoxybenzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3OC)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 1.5 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000765 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 30 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(2-((trifluoromethyl)thio)benzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3SC(F)(F)F)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 3.7 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000766 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 31 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(2-(trifluoromethoxy)benzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3OC(F)(F)F)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 2.7 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000767 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 32(JG-258) 3-benzyl-2-((Z)-((E)-3'-ethyl-3-methyl-4'-oxo-3',4,4',5-tetrahydro-2'H,3H-[2,5'-bithiazolylidene]- 2'-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/SCCN4C Benzothiazole Rhodacyanines derivative NA NA NA NA >20 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000768 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 33 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(2,6-dichlorobenzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3c(Cl)cccc3Cl)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.16 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000769 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 34 3-((2-bromopyridin-3-yl)methyl)-2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(/S/C(C1=O)=C2/Sc3cc(Cl)ccc3N2C)=C/c4scc[n+]4Cc5cccnc5Br Benzothiazole Rhodacyanines derivative NA NA NA NA 1.5 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000770 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 35 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((2-chloropyridin-4-yl)methyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccnc(Cl)c3)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA >5 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000771 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 36 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((5-(trifluoromethyl)furan-2-yl)methyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3oc(cc3)C(F)(F)F)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.21 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000772 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 37 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((5-(methoxycarbonyl)furan-2-yl)methyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3oc(cc3)C(=O)OC)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 1.5 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000773 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 38 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((3-(methoxycarbonyl)furan-2-yl)methyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3occc3C(=O)OC)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.81 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000774 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 39 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(thiophen-3-ylmethyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3cscc3)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.73 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000775 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 40 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((2-(methoxycarbonyl)thiophen-3-yl)methyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccsc3C(=O)OC)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.16 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000776 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 41 3-((2-bromothiophen-3-yl)methyl)-2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccsc3Br)=C4/Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.52 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000777 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 42(JG-231) 3-((5-bromothiophen-2-yl)methyl)-2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3sc(Br)cc3)=C4/Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.12 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000778 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 43 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((2,5-dimethylthiophen-3-yl)methyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3cc(C)sc3C)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.098 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000779 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 44 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((2-methylthiazol-4-yl)methyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3csc(C)n3)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.96 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000780 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 45 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((2-chlorothiazol-5-yl)methyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3sc(Cl)nc3)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA >5 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000781 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 46 3-((2-acetamidothiazol-4-yl)methyl)-2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3csc(NC(C)=O)n3)=C4/Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA >5 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000782 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 47 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((3,5-dimethylisoxazol-4-yl)methyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3c(C)onc3C)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA >5 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000783 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 33 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(2,6-dichlorobenzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3c(Cl)cccc3Cl)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.16 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000784 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 34 3-((2-bromopyridin-3-yl)methyl)-2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(/S/C(C1=O)=C2/Sc3cc(Cl)ccc3N2C)=C/c4scc[n+]4Cc5cccnc5Br Benzothiazole Rhodacyanines derivative NA NA NA NA 1.6 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000785 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 35 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((2-chloropyridin-4-yl)methyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccnc(Cl)c3)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 7.2 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000786 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 36 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((5-(trifluoromethyl)furan-2-yl)methyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3oc(cc3)C(F)(F)F)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.12 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000787 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 37 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((5-(methoxycarbonyl)furan-2-yl)methyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3oc(cc3)C(=O)OC)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.97 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000788 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 38 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((3-(methoxycarbonyl)furan-2-yl)methyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3occc3C(=O)OC)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.13 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000789 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 39 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(thiophen-3-ylmethyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3cscc3)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.11 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000790 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 40 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((2-(methoxycarbonyl)thiophen-3-yl)methyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccsc3C(=O)OC)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.22 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000791 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 41 3-((2-bromothiophen-3-yl)methyl)-2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccsc3Br)=C4/Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.2 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000792 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 42(JG-231) 3-((5-bromothiophen-2-yl)methyl)-2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3sc(Br)cc3)=C4/Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.25 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000793 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 43 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((2,5-dimethylthiophen-3-yl)methyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3cc(C)sc3C)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.08 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000794 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 44 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((2-methylthiazol-4-yl)methyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3csc(C)n3)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.74 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000795 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 45 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((2-chlorothiazol-5-yl)methyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3sc(Cl)nc3)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 2.3 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000796 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 46 3-((2-acetamidothiazol-4-yl)methyl)-2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3csc(NC(C)=O)n3)=C4/Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA >20 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000797 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 47 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((3,5-dimethylisoxazol-4-yl)methyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3c(C)onc3C)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 10 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000798 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 33 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(2,6-dichlorobenzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3c(Cl)cccc3Cl)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 1.4 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000799 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 34 3-((2-bromopyridin-3-yl)methyl)-2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(/S/C(C1=O)=C2/Sc3cc(Cl)ccc3N2C)=C/c4scc[n+]4Cc5cccnc5Br Benzothiazole Rhodacyanines derivative NA NA NA NA 1.7 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000800 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 35 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((2-chloropyridin-4-yl)methyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccnc(Cl)c3)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA >5 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000801 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 36 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((5-(trifluoromethyl)furan-2-yl)methyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3oc(cc3)C(F)(F)F)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 5.5 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000802 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 37 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((5-(methoxycarbonyl)furan-2-yl)methyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3oc(cc3)C(=O)OC)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 2 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000803 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 38 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((3-(methoxycarbonyl)furan-2-yl)methyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3occc3C(=O)OC)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 2.7 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000804 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 39 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(thiophen-3-ylmethyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3cscc3)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 4.4 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000805 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 40 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((2-(methoxycarbonyl)thiophen-3-yl)methyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccsc3C(=O)OC)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 3.2 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000806 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 41 3-((2-bromothiophen-3-yl)methyl)-2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccsc3Br)=C4/Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 1.3 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000807 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 42(JG-231) 3-((5-bromothiophen-2-yl)methyl)-2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3sc(Br)cc3)=C4/Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 2.5 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000808 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 43 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((2,5-dimethylthiophen-3-yl)methyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3cc(C)sc3C)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 4.2 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000809 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 44 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((2-methylthiazol-4-yl)methyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3csc(C)n3)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 4.9 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000810 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 45 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((2-chlorothiazol-5-yl)methyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3sc(Cl)nc3)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 8.9 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000811 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 46 3-((2-acetamidothiazol-4-yl)methyl)-2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3csc(NC(C)=O)n3)=C4/Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 4.2 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000812 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 47 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((3,5-dimethylisoxazol-4-yl)methyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3c(C)onc3C)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 7.6 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000813 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 48 2-((Z)-((E)-5-(3,5-dimethylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene) methyl)-3-(2-(trifluoromethoxy)benzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3OC(F)(F)F)=C/4Sc5ccc(C)cc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.089 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000814 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 49 2-((Z)-((E)-5-(3,6-dimethylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene) methyl)-3-(2-(trifluoromethoxy)benzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3OC(F)(F)F)=C/4Sc5cc(C)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.064 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000815 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 50 2-((Z)-((E)-3-ethyl-5-(5-methoxy-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2- ylidene)methyl)-3-(2-(trifluoromethoxy)benzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)C(/SC1=C\c2scc[n+]2Cc3ccccc3OC(F)(F)F)=C4\Sc5ccc(OC)cc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.16 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000816 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 51 2-((Z)-((E)-3-ethyl-5-(6-methoxy-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2- ylidene)methyl)-3-(2-(trifluoromethoxy)benzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)C(/SC1=C\c2scc[n+]2Cc3ccccc3OC(F)(F)F)=C4\Sc5cc(OC)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.07 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000817 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 52 2-((Z)-((E)-3-ethyl-5-(6-isopropyl-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2- ylidene)methyl)-3-(2-(trifluoromethoxy)benzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)C(/SC1=C\c2scc[n+]2Cc3ccccc3OC(F)(F)F)=C4\Sc5cc(ccc5N4C)C(C)C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.09 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000818 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 53 3-(2-chlorobenzyl)-2-((Z)-((E)-3-ethyl-5-(6-methoxy-3-methylbenzo[d]thiazol-2(3H)-ylidene)- 4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3Cl)=C4/Sc5cc(OC)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.048 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000819 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 54 3-(2-chlorobenzyl)-2-((Z)-((E)-3-ethyl-5-(3-methyl-6-(methylthio)benzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3Cl)=C4/Sc5cc(SC)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.15 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000820 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 55 2-((Z)-((E)-3-ethyl-5-(6-methoxy-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2- ylidene)methyl)-3-(2-methoxybenzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)C(/SC1=C\c2scc[n+]2Cc3ccccc3OC)=C4\Sc5cc(OC)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.076 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000821 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 56 2-((Z)-((E)-5-(3,6-dimethylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene) methyl)-3-(2-methoxybenzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3OC)=C/4Sc5cc(C)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.071 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000822 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 57(JG-345) 2-((Z)-((E)-3-ethyl-5-(6-ethyl-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)methyl)-3-(2-(methoxycarbonyl)benzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)C(/SC1=C\c2scc[n+]2Cc3ccccc3C(=O)OC)=C4\Sc5cc(CC)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.049 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000823 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 58 3-(2,6-dichlorobenzyl)-2-((Z)-((E)-5-(3,5-dimethylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4- oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3c(Cl)cccc3Cl)=C4/Sc5ccc(C)cc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.088 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000824 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 59 3-(2,6-dichlorobenzyl)-2-((Z)-((E)-3-ethyl-5-(6-ethyl-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4- oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3c(Cl)cccc3Cl)=C4/Sc5cc(CC)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.093 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000825 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 60(JG-294) 2-((Z)-((E)-5-(6-bromo-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((5-(trifluoromethyl)furan-2-yl)methyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3oc(cc3)C(F)(F)F)=C/4Sc5cc(Br)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.1 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000826 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 61 2-((Z)-((E)-3-ethyl-5-(6-ethyl-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)methyl)-3-((5-(trifluoromethyl)furan-2-yl)methyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)C(/SC1=C\c2scc[n+]2Cc3oc(cc3)C(F)(F)F)=C4\Sc5cc(CC)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.11 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000827 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 48 2-((Z)-((E)-5-(3,5-dimethylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene) methyl)-3-(2-(trifluoromethoxy)benzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3OC(F)(F)F)=C/4Sc5ccc(C)cc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.18 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000828 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 49 2-((Z)-((E)-5-(3,6-dimethylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene) methyl)-3-(2-(trifluoromethoxy)benzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3OC(F)(F)F)=C/4Sc5cc(C)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.077 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000829 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 50 2-((Z)-((E)-3-ethyl-5-(5-methoxy-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2- ylidene)methyl)-3-(2-(trifluoromethoxy)benzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)C(/SC1=C\c2scc[n+]2Cc3ccccc3OC(F)(F)F)=C4\Sc5ccc(OC)cc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.16 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000830 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 51 2-((Z)-((E)-3-ethyl-5-(6-methoxy-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2- ylidene)methyl)-3-(2-(trifluoromethoxy)benzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)C(/SC1=C\c2scc[n+]2Cc3ccccc3OC(F)(F)F)=C4\Sc5cc(OC)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.053 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000831 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 52 2-((Z)-((E)-3-ethyl-5-(6-isopropyl-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2- ylidene)methyl)-3-(2-(trifluoromethoxy)benzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)C(/SC1=C\c2scc[n+]2Cc3ccccc3OC(F)(F)F)=C4\Sc5cc(ccc5N4C)C(C)C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.21 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000832 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 53 3-(2-chlorobenzyl)-2-((Z)-((E)-3-ethyl-5-(6-methoxy-3-methylbenzo[d]thiazol-2(3H)-ylidene)- 4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3Cl)=C4/Sc5cc(OC)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.033 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000833 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 54 3-(2-chlorobenzyl)-2-((Z)-((E)-3-ethyl-5-(3-methyl-6-(methylthio)benzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3Cl)=C4/Sc5cc(SC)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.13 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000834 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 55 2-((Z)-((E)-3-ethyl-5-(6-methoxy-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2- ylidene)methyl)-3-(2-methoxybenzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)C(/SC1=C\c2scc[n+]2Cc3ccccc3OC)=C4\Sc5cc(OC)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.062 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000835 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 56 2-((Z)-((E)-5-(3,6-dimethylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene) methyl)-3-(2-methoxybenzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3OC)=C/4Sc5cc(C)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.082 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000836 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 57(JG-345) 2-((Z)-((E)-3-ethyl-5-(6-ethyl-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)methyl)-3-(2-(methoxycarbonyl)benzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)C(/SC1=C\c2scc[n+]2Cc3ccccc3C(=O)OC)=C4\Sc5cc(CC)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.046 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000837 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 58 3-(2,6-dichlorobenzyl)-2-((Z)-((E)-5-(3,5-dimethylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4- oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3c(Cl)cccc3Cl)=C4/Sc5ccc(C)cc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.054 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000838 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 59 3-(2,6-dichlorobenzyl)-2-((Z)-((E)-3-ethyl-5-(6-ethyl-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4- oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3c(Cl)cccc3Cl)=C4/Sc5cc(CC)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.1 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000839 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 60(JG-294) 2-((Z)-((E)-5-(6-bromo-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((5-(trifluoromethyl)furan-2-yl)methyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3oc(cc3)C(F)(F)F)=C/4Sc5cc(Br)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.18 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000840 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 61 2-((Z)-((E)-3-ethyl-5-(6-ethyl-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)methyl)-3-((5-(trifluoromethyl)furan-2-yl)methyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)C(/SC1=C\c2scc[n+]2Cc3oc(cc3)C(F)(F)F)=C4\Sc5cc(CC)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.1 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000841 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 48 2-((Z)-((E)-5-(3,5-dimethylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene) methyl)-3-(2-(trifluoromethoxy)benzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3OC(F)(F)F)=C/4Sc5ccc(C)cc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 1.4 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000842 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 49 2-((Z)-((E)-5-(3,6-dimethylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene) methyl)-3-(2-(trifluoromethoxy)benzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3OC(F)(F)F)=C/4Sc5cc(C)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.75 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000843 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 50 2-((Z)-((E)-3-ethyl-5-(5-methoxy-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2- ylidene)methyl)-3-(2-(trifluoromethoxy)benzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)C(/SC1=C\c2scc[n+]2Cc3ccccc3OC(F)(F)F)=C4\Sc5ccc(OC)cc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 2.2 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000844 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 51 2-((Z)-((E)-3-ethyl-5-(6-methoxy-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2- ylidene)methyl)-3-(2-(trifluoromethoxy)benzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)C(/SC1=C\c2scc[n+]2Cc3ccccc3OC(F)(F)F)=C4\Sc5cc(OC)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.7 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000845 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 52 2-((Z)-((E)-3-ethyl-5-(6-isopropyl-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2- ylidene)methyl)-3-(2-(trifluoromethoxy)benzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)C(/SC1=C\c2scc[n+]2Cc3ccccc3OC(F)(F)F)=C4\Sc5cc(ccc5N4C)C(C)C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.48 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000846 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 53 3-(2-chlorobenzyl)-2-((Z)-((E)-3-ethyl-5-(6-methoxy-3-methylbenzo[d]thiazol-2(3H)-ylidene)- 4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3Cl)=C4/Sc5cc(OC)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.66 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000847 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 54 3-(2-chlorobenzyl)-2-((Z)-((E)-3-ethyl-5-(3-methyl-6-(methylthio)benzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3Cl)=C4/Sc5cc(SC)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.75 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000848 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 55 2-((Z)-((E)-3-ethyl-5-(6-methoxy-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2- ylidene)methyl)-3-(2-methoxybenzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)C(/SC1=C\c2scc[n+]2Cc3ccccc3OC)=C4\Sc5cc(OC)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.77 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000849 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 56 2-((Z)-((E)-5-(3,6-dimethylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene) methyl)-3-(2-methoxybenzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3OC)=C/4Sc5cc(C)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.96 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000850 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 57(JG-345) 2-((Z)-((E)-3-ethyl-5-(6-ethyl-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)methyl)-3-(2-(methoxycarbonyl)benzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)C(/SC1=C\c2scc[n+]2Cc3ccccc3C(=O)OC)=C4\Sc5cc(CC)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 1 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000851 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 58 3-(2,6-dichlorobenzyl)-2-((Z)-((E)-5-(3,5-dimethylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4- oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3c(Cl)cccc3Cl)=C4/Sc5ccc(C)cc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.55 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000852 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 59 3-(2,6-dichlorobenzyl)-2-((Z)-((E)-3-ethyl-5-(6-ethyl-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4- oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3c(Cl)cccc3Cl)=C4/Sc5cc(CC)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.3 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000853 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 60(JG-294) 2-((Z)-((E)-5-(6-bromo-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((5-(trifluoromethyl)furan-2-yl)methyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3oc(cc3)C(F)(F)F)=C/4Sc5cc(Br)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 3.5 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000854 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 61 2-((Z)-((E)-3-ethyl-5-(6-ethyl-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)methyl)-3-((5-(trifluoromethyl)furan-2-yl)methyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)C(/SC1=C\c2scc[n+]2Cc3oc(cc3)C(F)(F)F)=C4\Sc5cc(CC)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 1.4 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000855 24548207 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 17a N-(6-Amino-2-((4,6-dimethoxy-2-(4-methylpiperazin-1-yl)pyrimidin-5-yl)thio)pyrimidin-4-yl)acrylamide COc1nc(nc(OC)c1Sc2nc(N)cc(NC(=O)C=C)n2)N3CCN(C)CC3 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 0.9 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA Kasumi-1 Cancer HSPMDB000856 24548207 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 17b N-(6-Amino-2-((4,6-dimethoxy-2-morpholinopyrimidin-5-yl)thio)pyrimidin-4-yl)acrylamide COc1nc(nc(OC)c1Sc2nc(N)cc(NC(=O)C=C)n2)N3CCOCC3 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 12.5 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA Kasumi-1 Cancer HSPMDB000857 24548207 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 17c N-(6-Amino-2-((4,6-dimethoxy-2-(piperidin-1-yl)pyrimidin-5-yl)thio)pyrimidin-4-yl)acrylamide COc1nc(nc(OC)c1Sc2nc(N)cc(NC(=O)C=C)n2)N3CCCCC3 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 17.1 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA Kasumi-1 Cancer HSPMDB000858 24548207 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 20a N-(6-Amino-2-((4,6-diethoxy-2-(4-methylpiperazin-1-yl)pyrimidin-5-yl)thio)pyrimidin-4-yl)acrylamide CCOc1nc(nc(OCC)c1Sc2nc(N)cc(NC(=O)C=C)n2)N3CCN(C)CC3 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 0.89 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA Kasumi-1 Cancer HSPMDB000859 24548207 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 20b N-(6-Amino-2-((4,6-diethoxy-2-morpholinopyrimidin-5-yl)thio)pyrimidin-4-yl)acrylamide CCOc1nc(nc(OCC)c1Sc2nc(N)cc(NC(=O)C=C)n2)N3CCOCC3 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 2.2 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA Kasumi-1 Cancer HSPMDB000860 24548207 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 20c N-(6-Amino-2-((4,6-diethoxy-2-(piperidin-1-yl)pyrimidin-5-yl)thio)pyrimidin-4-yl)acrylamide CCOc1nc(nc(OCC)c1Sc2nc(N)cc(NC(=O)C=C)n2)N3CCCCC3 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 4.5 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA Kasumi-1 Cancer HSPMDB000861 24548207 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 27a N-(2-((4,6-Dimethoxy-2-(4-methylpiperazin-1-yl)pyrimidin-5-yl)thio)pyrimidin-4-yl)acrylamide COc1nc(nc(OC)c1Sc2nccc(NC(=O)C=C)n2)N3CCN(C)CC3 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 1.25 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA Kasumi-1 Cancer HSPMDB000862 24548207 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 27b N-(2-((4,6-Dimethoxy-2-morpholinopyrimidin-5-yl)thio)pyrimidin-4-yl)acrylamide COc1nc(nc(OC)c1Sc2nccc(NC(=O)C=C)n2)N3CCOCC3 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 2 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA Kasumi-1 Cancer HSPMDB000863 24548207 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 27c N-(2-((4,6-Dimethoxy-2-(piperidin-1-yl)pyrimidin-5-yl)thio)pyrimidin-4-yl)acrylamide COc1nc(nc(OC)c1Sc2nccc(NC(=O)C=C)n2)N3CCCCC3 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 3.15 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA Kasumi-1 Cancer HSPMDB000864 24548207 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 27d N-(2-((4,6-Dimethoxy-2-(pyrrolidin-1-yl)pyrimidin-5-yl)thio)pyrimidin-4-yl)acrylamide COc1nc(nc(OC)c1Sc2nccc(NC(=O)C=C)n2)N3CCCC3 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 46.1 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA Kasumi-1 Cancer HSPMDB000865 24548207 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 28 4-(5-((4-Acrylamidopyrimidin-2-yl)thio)-4,6-dimethoxypyrimidin2-yl)-1-methylpiperazine 1-Oxide COc1nc(nc(OC)c1Sc2nccc(NC(=O)C=C)n2)N3CC[N+](C)([O-])CC3 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA >100 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA Kasumi-1 Cancer HSPMDB000866 24548207 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 31 N-(6-Amino-2-((2-amino-4,6-dimethoxypyrimidin-5-yl)thio)pyrimidin-4-yl)acrylamide COc1nc(N)nc(OC)c1Sc2nc(N)cc(NC(=O)C=C)n2 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 3.9 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA Kasumi-1 Cancer HSPMDB000867 24548207 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 36a N-(3-((4,6-Dimethoxy-2-(4-methylpiperazin-1-yl)pyrimidin-5-yl)thio)phenyl)acrylamide COc1nc(nc(OC)c1Sc2cccc(NC(=O)C=C)c2)N3CCN(C)CC3 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 7.8 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA Kasumi-1 Cancer HSPMDB000868 24548207 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 37 N-(3-((4,6-Dimethoxy-2-morpholinopyrimidin-5-yl)thio)phenyl)acrylamide COc1nc(nc(OC)c1Sc2cccc(NC(=O)C=C)c2)N3CCOCC3 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 46.5 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA Kasumi-1 Cancer HSPMDB000869 24548207 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 43 N-(2-((4,6-Dimethyl-2-morpholinopyrimidin-5-yl)thio)pyrimidin4-yl)acrylamide Cc1nc(nc(C)c1Sc2nccc(NC(=O)C=C)n2)N3CCOCC3 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 14.4 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA Kasumi-1 Cancer HSPMDB000870 24548207 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 44a N-(6-Amino-2-(2-(4-(2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)ethyl)piperazin-1-yl)-4,6- dimethoxypyrimidin-5-ylthio)pyrimidin-4-yl)acrylamide COc1nc(nc(OC)c1Sc2nc(N)cc(NC(=O)C=C)n2)N3CCN(CCOCCOCCOCCO)CC3 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 3.8 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA Kasumi-1 Cancer HSPMDB000871 24548207 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 45a N-(6-Amino-2-(4-(2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)ethoxy)-6-methoxy-2-(4- methylpiperazin-1-yl)pyrimidin-5-ylthio)pyrimidin-4-yl)acrylamide COc1nc(nc(OCCOCCOCCOCCO)c1Sc2nc(N)cc(NC(=O)C=C)n2)N3CCN(C)CC3 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 76.5 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA Kasumi-1 Cancer HSPMDB000872 24548207 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 17a N-(6-Amino-2-((4,6-dimethoxy-2-(4-methylpiperazin-1-yl)pyrimidin-5-yl)thio)pyrimidin-4-yl)acrylamide COc1nc(nc(OC)c1Sc2nc(N)cc(NC(=O)C=C)n2)N3CCN(C)CC3 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 0.8 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA SK-BR-3 Cancer HSPMDB000873 24548207 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 17c N-(6-Amino-2-((4,6-dimethoxy-2-(piperidin-1-yl)pyrimidin-5-yl)thio)pyrimidin-4-yl)acrylamide COc1nc(nc(OC)c1Sc2nc(N)cc(NC(=O)C=C)n2)N3CCCCC3 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 9 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA SK-BR-3 Cancer HSPMDB000874 24548207 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 20a N-(6-Amino-2-((4,6-diethoxy-2-(4-methylpiperazin-1-yl)pyrimidin-5-yl)thio)pyrimidin-4-yl)acrylamide CCOc1nc(nc(OCC)c1Sc2nc(N)cc(NC(=O)C=C)n2)N3CCN(C)CC3 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 1.1 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA SK-BR-3 Cancer HSPMDB000875 24548207 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 20c N-(6-Amino-2-((4,6-diethoxy-2-(piperidin-1-yl)pyrimidin-5-yl)thio)pyrimidin-4-yl)acrylamide CCOc1nc(nc(OCC)c1Sc2nc(N)cc(NC(=O)C=C)n2)N3CCCCC3 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 7 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA SK-BR-3 Cancer HSPMDB000876 24548207 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 27a N-(2-((4,6-Dimethoxy-2-(4-methylpiperazin-1-yl)pyrimidin-5-yl)thio)pyrimidin-4-yl)acrylamide COc1nc(nc(OC)c1Sc2nccc(NC(=O)C=C)n2)N3CCN(C)CC3 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 1.2 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA SK-BR-3 Cancer HSPMDB000877 24548207 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 27d N-(2-((4,6-Dimethoxy-2-(pyrrolidin-1-yl)pyrimidin-5-yl)thio)pyrimidin-4-yl)acrylamide COc1nc(nc(OC)c1Sc2nccc(NC(=O)C=C)n2)N3CCCC3 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 5 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA SK-BR-3 Cancer HSPMDB000878 24548207 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 31 N-(6-Amino-2-((2-amino-4,6-dimethoxypyrimidin-5-yl)thio)pyrimidin-4-yl)acrylamide COc1nc(N)nc(OC)c1Sc2nc(N)cc(NC(=O)C=C)n2 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 3.2 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA SK-BR-3 Cancer HSPMDB000879 24548207 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 37 N-(3-((4,6-Dimethoxy-2-morpholinopyrimidin-5-yl)thio)phenyl)acrylamide COc1nc(nc(OC)c1Sc2cccc(NC(=O)C=C)c2)N3CCOCC3 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 16.5 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA SK-BR-3 Cancer HSPMDB000880 24548207 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 42a N-(2-((4,6-Dimethyl-2-(4-methylpiperazin-1-yl)pyrimidin-5-yl)thio)pyrimidin-4-yl)acrylamide CN1CCN(CC1)c2nc(C)c(Sc3nccc(NC(=O)C=C)n3)c(C)n2 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 1.8 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA SK-BR-3 Cancer HSPMDB000881 24548207 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 42c N-(2-((4,6-Dimethyl-2-(4-methylpiperazin-1-yl)pyrimidin-5-yl)thio)pyrimidin-4-yl)methacrylamide  CC1=NC(=NC(=C1SC1=NC=CC(=N1)NC(C(=C)C)=O)C)N1CCN(CC1)C 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 16.7 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA SK-BR-3 Cancer HSPMDB000882 24548207 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 44a N-(6-Amino-2-(2-(4-(2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)ethyl)piperazin-1-yl)-4,6- dimethoxypyrimidin-5-ylthio)pyrimidin-4-yl)acrylamide COc1nc(nc(OC)c1Sc2nc(N)cc(NC(=O)C=C)n2)N3CCN(CCOCCOCCOCCO)CC3 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 7.5 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA SK-BR-3 Cancer HSPMDB000883 24548207 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 45a N-(6-Amino-2-(4-(2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)ethoxy)-6-methoxy-2-(4- methylpiperazin-1-yl)pyrimidin-5-ylthio)pyrimidin-4-yl)acrylamide COc1nc(nc(OCCOCCOCCOCCO)c1Sc2nc(N)cc(NC(=O)C=C)n2)N3CCN(C)CC3 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 50 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA SK-BR-3 Cancer HSPMDB000884 24548239 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 1a N-(6-amino-2-{[4,6-diethoxy-2-(4-methylpiperazin-1-yl)pyrimidin-5-yl]sulfanyl}pyrimidin-4-yl)prop-2-enamide CCOC1=NC(=NC(OCC)=C1SC1=NC(N)=CC(NC(=O)C=C)=N1)N1CCN(C)CC1 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 0.89 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA Kasumi-1 Cancer HSPMDB000885 24548239 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 3a N-(6-Amino-2-((4,6-diethoxy-2-(4-methylpiperazin-1-yl)-pyrimidin-5-yl)thio)pyrimidin-4-yl)propionamide NC1=CC(=NC(=N1)SC=1C(=NC(=NC1OCC)N1CCN(CC1)C)OCC)NC(CC)=O 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 51.4 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA Kasumi-1 Cancer HSPMDB000886 24548239 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 1b N-(2-{[4,6-dimethoxy-2-(4-methylpiperazin-1-yl)pyrimidin-5-yl]sulfanyl}pyrimidin-4-yl)prop-2-enamide COC1=NC(=NC(OC)=C1SC1=NC=CC(NC(=O)C=C)=N1)N1CCN(C)CC1 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 1.25 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA Kasumi-1 Cancer HSPMDB000887 24548239 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 1c N-(3-{[4,6-dimethoxy-2-(4-methylpiperazin-1-yl)pyrimidin-5-yl]sulfanyl}phenyl)prop-2-enamide COC1=NC(=NC(OC)=C1SC1=CC=CC(NC(=O)C=C)=C1)N1CCN(C)CC1 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 7.8 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA Kasumi-1 Cancer HSPMDB000888 24548239 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 4e N-(2-((4,6-Dimethyl-2-(4-methylpiperazin-1-yl)pyrimidin-5-yl)-thio)pyrimidin-4-yl)cyclopropanecarboxamide CC1=NC(=NC(=C1SC1=NC=CC(=N1)NC(=O)C1CC1)C)N1CCN(CC1)C 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 60.5 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA Kasumi-1 Cancer HSPMDB000889 24548239 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 7c 2-cyclobutyl-N-(3-{[4,6-dimethoxy-2-(4-methylpiperazin-1-yl)pyrimidin-5-yl]sulfanyl}phenyl)acetamide COC1=NC(=NC(OC)=C1SC1=CC=CC(NC(=O)CC2CCC2)=C1)N1CCN(C)CC1 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 47.2 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA Kasumi-1 Cancer HSPMDB000890 24548239 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 7e N-(3-{[4,6-dimethoxy-2-(4-methylpiperazin-1-yl)pyrimidin-5-yl]sulfanyl}phenyl)-2-phenylacetamide COC1=NC(=NC(OC)=C1SC1=CC=CC(NC(=O)CC2=CC=CC=C2)=C1)N1CCN(C)CC1 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 8.1 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA Kasumi-1 Cancer HSPMDB000891 24548239 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 4d N-(2-((4,6-Dimethyl-2-(4-methylpiperazin-1-yl)pyrimidin-5-yl)-thio)pyrimidin-4-yl)furan-2-carboxamide CN1CCN(CC1)c2nc(C)c(Sc3nccc(NC(=O)c4occc4)n3)c(C)n2 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 30.3 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA Kasumi-1 Cancer HSPMDB000892 24548239 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 7f 2-Amino-N-(3-((4,6-dimethoxy-2-(4-methylpiperazin-1-yl)-pyrimidin-5-yl)thio)phenyl)acetamide COc1nc(nc(OC)c1Sc2cccc(NC(=O)CN)c2)N3CCN(C)CC3 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 22.5 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA Kasumi-1 Cancer HSPMDB000893 24548239 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 9 N-(6-Amino-2-((4,6-dimethoxy-2-(4-methylpiperazin-1-yl)-pyrimidin-5-yl)thio)pyrimidin-4-yl)-3-(dimethylamino)propanamide COc1nc(nc(OC)c1Sc2nc(N)cc(NC(=O)CCN(C)C)n2)N3CCN(C)CC3 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 14.7 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA Kasumi-1 Cancer HSPMDB000894 24548239 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 7h 2-Amino-N-(3-((4-methoxy-2-(4-methylpiperazin-1-yl)pyrimidin-5-yl)thio)phenyl)acetamide COc1nc(ncc1Sc2cccc(NC(=O)CN)c2)N3CCN(C)CC3 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 25.2 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA Kasumi-1 Cancer HSPMDB000895 24548239 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 14b N-(2-((2-Methoxy-6-(4-methylpiperazin-1-yl)pyridin-3-yl)thio)-pyrimidin-4-yl)cyclopropanecarboxamide COc1nc(ccc1Sc2nccc(NC(=O)C3CC3)n2)N4CCN(C)CC4 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 58.5 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA Kasumi-1 Cancer HSPMDB000896 24548239 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 16b N-(3-((2-Methoxy-6-(4-methylpiperazin-1-yl)pyridin-3-yl)thio)-phenyl)cyclopropanecarboxamide COc1nc(ccc1Sc2cccc(NC(=O)C3CC3)c2)N4CCN(C)CC4 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 36.4 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA Kasumi-1 Cancer HSPMDB000897 24548239 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 16c N-(3-((2-Methoxy-6-(4-methylpiperazin-1-yl)pyridin-3-yl)thio)-phenyl)benzamide COc1nc(ccc1Sc2cccc(NC(=O)c3ccccc3)c2)N4CCN(C)CC4 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 4.7 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA Kasumi-1 Cancer HSPMDB000898 24548239 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 16d 2-Amino-N-(3-((2-methoxy-6-(4-methylpiperazin-1-yl)pyridin-3-yl)thio)phenyl)acetamide COc1nc(ccc1Sc2cccc(NC(=O)CN)c2)N3CCN(C)CC3 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 19.1 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA Kasumi-1 Cancer HSPMDB000899 24548239 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 27a N-(3-((4-(Benzyloxy)-2-(4-methylpiperazin-1-yl)pyrimidin-5-yl)-thio)phenyl)acetamide CN1CCN(CC1)c2ncc(Sc3cccc(NC(C)=O)c3)c(OCc4ccccc4)n2 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 5.2 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA Kasumi-1 Cancer HSPMDB000900 24548239 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 27b N-(3-((4-(Benzyloxy)-2-(4-methylpiperazin-1-yl)pyrimidin-5-yl)-thio)phenyl)benzamide CN1CCN(CC1)c2ncc(Sc3cccc(NC(=O)c4ccccc4)c3)c(OCc5ccccc5)n2 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 3.1 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA Kasumi-1 Cancer HSPMDB000901 24548239 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 27c 2-Amino-N-(3-((4-(benzyloxy)-2-(4-methylpiperazin-1-yl)-pyrimidin-5-yl)thio)phenyl)acetamide CN1CCN(CC1)c2ncc(Sc3cccc(NC(=O)CN)c3)c(OCc4ccccc4)n2 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 2.3 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA Kasumi-1 Cancer HSPMDB000902 24548239 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 27d 2-Amino-N-(3-((4-(benzyloxy)-2-(4-methylpiperazin-1-yl)-pyrimidin-5-yl)thio)phenyl)propanamide CC(N)C(=O)Nc1cccc(Sc2cnc(nc2OCc3ccccc3)N4CCN(C)CC4)c1 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 4.8r Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA Kasumi-1 Cancer HSPMDB000903 24548239 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 27e 2-Amino-N-(3-((4-(benzyloxy)-2-(4-methylpiperazin-1-yl)-pyrimidin-5-yl)thio)phenyl)-3-methylbutanamide CC(C)C(N)C(=O)Nc1cccc(Sc2cnc(nc2OCc3ccccc3)N4CCN(C)CC4)c1 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 3.1 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA Kasumi-1 Cancer HSPMDB000904 24548239 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 27f N-(3-((4-(Benzyloxy)-2-(4-methylpiperazin-1-yl)pyrimidin-5-yl)-thio)phenyl)pyrrolidine-2-carboxamide CN1CCN(CC1)c2ncc(Sc3cccc(NC(=O)C4CCCN4)c3)c(OCc5ccccc5)n2 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 2.9 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA Kasumi-1 Cancer HSPMDB000905 24548239 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 27g 2-Amino-N-(3-((2-(4-methylpiperazin-1-yl)-4-phenylpyrimidin-5-yl)thio)phenyl)acetamide CN1CCN(CC1)c2ncc(Sc3cccc(NC(=O)CN)c3)c(n2)c4ccccc4 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 20.8 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA Kasumi-1 Cancer HSPMDB000906 24548239 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 27h 2-amino-N-(3-{[2-(4-methylpiperazin-1-yl)-4-[(pyridin-4-yl)methoxy]pyrimidin-5-yl]sulfanyl}phenyl)acetamide CN1CCN(CC1)C1=NC=C(SC2=CC=CC(NC(=O)CN)=C2)C(OCC2=CC=NC=C2)=N1 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 10.7 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA Kasumi-1 Cancer HSPMDB000907 27035072 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 6 (apoptozole) 4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)benzamide COc1ccc(cc1)c2nc(n(Cc3ccc(cc3)C(N)=O)c2c4ccc(OC)cc4)c5cc(cc(c5)C(F)(F)F)C(F)(F)F Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline NA NA NA NA NA NA NA 7 Nucleotide binding domain NA NA Resazurin based viability assay NA NA NA HCT116 Cancer HSPMDB000908 27035072 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 7a 2-Phenyl-1H-phenanthro[9,10-d]imidazole [nH]1c(nc2c1c3ccccc3c4ccccc24)c5ccccc5 Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline NA NA NA NA NA NA NA 7.6 NA NA NA Resazurin based viability assay NA NA NA HCT116 Cancer HSPMDB000909 27035072 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 7b 2-(4-Fluorophenyl)-1H-phenanthro[9,10-d]imidazole Fc1ccc(cc1)c2[nH]c3c4ccccc4c5ccccc5c3n2 Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline NA NA NA NA NA NA NA 6.7 NA NA NA Resazurin based viability assay NA NA NA HCT116 Cancer HSPMDB000910 27035072 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 7c 2-(4-Methoxyphenyl)-1H-phenanthro[9,10-d]imidazole COc1ccc(cc1)c2[nH]c3c4ccccc4c5ccccc5c3n2 Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline NA NA NA NA NA NA NA 3 NA NA NA Resazurin based viability assay NA NA NA HCT116 Cancer HSPMDB000911 27035072 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 7d 2-(3,5-Bis(trifluoromethyl)phenyl)-1H-phenanthro[9,10-d]imidazole FC(F)(F)c1cc(cc(c1)C(F)(F)F)c2[nH]c3c4ccccc4c5ccccc5c3n2 Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline NA NA NA NA NA NA NA 7.3 NA NA NA Resazurin based viability assay NA NA NA HCT116 Cancer HSPMDB000912 27035072 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 12 6,9-Dimethoxy-2-phenyl-1H-phenanthro[9,10-d]imidazole COc1ccc2c3[nH]c(nc3c4ccc(OC)cc4c2c1)c5ccccc5 Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline NA NA NA NA NA NA NA 7.8 NA NA NA Resazurin based viability assay NA NA NA HCT116 Cancer HSPMDB000913 27035072 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 13 2-(3,5-Bis(trifluoromethyl)phenyl)-6,9-dimethoxy-1H-phenanthro[9,10-d]imidazole COc1ccc2c3[nH]c(nc3c4ccc(OC)cc4c2c1)c5cc(cc(c5)C(F)(F)F)C(F)(F)F Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline NA NA NA NA NA NA NA 11.2 NA NA NA Resazurin based viability assay NA NA NA HCT116 Cancer HSPMDB000914 27035072 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 14 2-(4-Methoxyphenyl)-4,5-diphenyl-1H-imidazole COc1ccc(cc1)c2[nH]c(c3ccccc3)c(n2)c4ccccc4 Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline NA NA NA NA NA NA NA >20 NA NA NA Resazurin based viability assay NA NA NA HCT116 Cancer HSPMDB000915 27035072 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 15 2,4,5-Tri(4-methoxyphenyl)-1H-imidazole COc1ccc(cc1)c2[nH]c(c3ccc(OC)cc3)c(n2)c4ccc(OC)cc4 Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline NA NA NA NA NA NA NA 7.8 NA NA NA Resazurin based viability assay NA NA NA HCT116 Cancer HSPMDB000916 27035072 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 16 2,4,5-Tri(4-fluorophenyl)-1H-imidazole Fc1ccc(cc1)c2[nH]c(c3ccc(F)cc3)c(n2)c4ccc(F)cc4 Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline NA NA NA NA NA NA NA 9.5 NA NA NA Resazurin based viability assay NA NA NA HCT116 Cancer HSPMDB000917 27035072 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 18 1-Methyl-2-phenyl-1H-phenanthro[9,10-d]imidazole Cn1c(nc2c3ccccc3c4ccccc4c12)c5ccccc5 Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline NA NA NA NA NA NA NA 9.4 NA NA NA Resazurin based viability assay NA NA NA HCT116 Cancer HSPMDB000918 27035072 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 19 1-Benzyl-2-phenyl-1H-phenanthro[9,10-d]imidazole C(n1c(nc2c3ccccc3c4ccccc4c12)c5ccccc5)c6ccccc6 Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline NA NA NA NA NA NA NA 6.8 NA NA NA Resazurin based viability assay NA NA NA HCT116 Cancer HSPMDB000919 27035072 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 20 1-Benzyl-2-(3,5-bis(trifluoromethyl)phenyl)-1H-phenanthro-[9,10-d]imidazole FC(F)(F)c1cc(cc(c1)C(F)(F)F)c2nc3c4ccccc4c5ccccc5c3n2Cc6ccccc6 Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline NA NA NA NA NA NA NA >20 NA NA NA Resazurin based viability assay NA NA NA HCT116 Cancer HSPMDB000920 27035072 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 21 1-(4-Carboxamidobenzyl)-2-phenyl-1H-phenanthro[9,10-d]imidazole NC(=O)C1=CC=C(CN2C(=NC3=C2C2=C(C=CC=C2)C2=C3C=CC=C2)C2=CC=CC=C2)C=C1 Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline NA NA NA NA NA NA NA >20 NA NA NA Resazurin based viability assay NA NA NA HCT116 Cancer HSPMDB000921 27035072 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 22 1-(4-Carboxamidobenzyl)-2-(4-fluorophenyl)-1H-phenanthro-[9,10-d]imidazole NC(=O)C1=CC=C(CN2C(=NC3=C2C2=C(C=CC=C2)C2=C3C=CC=C2)C2=CC=C(F)C=C2)C=C1 Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline NA NA NA NA NA NA NA 5.9 NA NA NA Resazurin based viability assay NA NA NA HCT116 Cancer HSPMDB000922 27035072 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 23 1-(4-Carboxamidobenzyl)-2-(4-methoxyphenyl)-1H-phenanthro-[9,10-d]imidazole COC1=CC=C(C=C1)C1=NC2=C(N1CC1=CC=C(C=C1)C(N)=O)C1=C(C=CC=C1)C1=C2C=CC=C1 Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline NA NA NA NA NA NA NA 5.5 NA NA NA Resazurin based viability assay NA NA NA HCT116 Cancer HSPMDB000923 27035072 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 24 1-(4-Carboxamidobenzyl)-2-(3,5-bis(trifluoromethyl)phenyl)-1H-phenanthro[9,10-d]-imidazole NC(=O)C1=CC=C(CN2C(=NC3=C2C2=C(C=CC=C2)C2=C3C=CC=C2)C2=CC(=CC(=C2)C(F)(F)F)C(F)(F)F)C=C1 Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline NA NA NA NA NA NA NA >20 NA NA NA Resazurin based viability assay NA NA NA HCT116 Cancer HSPMDB000924 27035072 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 25 1-(4-Carboxamidobenzyl)-6,9-dimethoxy-2-phenyl-1H-phenanthro[9,10-d]imidazole COC1=CC2=C(C=C1)C1=C(N(CC3=CC=C(C=C3)C(N)=O)C(=N1)C1=CC=CC=C1)C1=C2C=C(OC)C=C1 Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline NA NA NA NA NA NA NA 3.4 NA NA NA Resazurin based viability assay NA NA NA HCT116 Cancer HSPMDB000925 27035072 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 28 2-Phenyl-1H-imidazo[4,5-f][1,10]phenanthroline [nH]1c(nc2c1c3cccnc3c4ncccc24)c5ccccc5 Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline NA NA NA NA NA NA NA 0.09 NA NA NA Resazurin based viability assay NA NA NA HCT116 Cancer HSPMDB000926 27035072 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 30 1-Methyl-2-phenyl-1H-imidazo[4,5-f ][1,10]phenanthroline Cn1c(nc2c3cccnc3c4ncccc4c12)c5ccccc5 Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline NA NA NA NA NA NA NA 2.6 NA NA NA Resazurin based viability assay NA NA NA HCT116 Cancer HSPMDB000927 27035072 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 31 1-Benzyl-2-(3,5-bis(trifluoromethyl)phenyl)-1H-imidazo[4,5-f ]-[1,10]phenanthroline FC(F)(F)c1cc(cc(c1)C(F)(F)F)c2nc3c4cccnc4c5ncccc5c3n2Cc6ccccc6 Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline NA NA NA NA NA NA NA 0.5 NA NA NA Resazurin based viability assay NA NA NA HCT116 Cancer HSPMDB000928 27035072 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 32 1-(4-Carboxamidobenzyl)-2-(3,5-bis(trifluoromethyl)phenyl)-1H-imidazo[4,5-f][1,10]-phenanthroline NC(=O)C1=CC=C(CN2C(=NC3=C2C2=C(N=CC=C2)C2=C3C=CC=N2)C2=CC(=CC(=C2)C(F)(F)F)C(F)(F)F)C=C1 Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline NA NA NA NA NA NA NA 0.7 NA NA NA Resazurin based viability assay NA NA NA HCT116 Cancer HSPMDB000929 27035072 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 7a 2-Phenyl-1H-phenanthro[9,10-d]imidazole [nH]1c(nc2c1c3ccccc3c4ccccc24)c5ccccc5 Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline NA NA NA NA NA NA NA >5 NA NA NA Resazurin based viability assay NA NA NA MCF7 Cancer HSPMDB000930 27035072 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 7c 2-(4-Methoxyphenyl)-1H-phenanthro[9,10-d]imidazole COc1ccc(cc1)c2[nH]c3c4ccccc4c5ccccc5c3n2 Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline NA NA NA NA NA NA NA 4 NA NA NA Resazurin based viability assay NA NA NA MCF7 Cancer HSPMDB000931 27035072 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 16 2,4,5-Tri(4-fluorophenyl)-1H-imidazole Fc1ccc(cc1)c2[nH]c(c3ccc(F)cc3)c(n2)c4ccc(F)cc4 Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline NA NA NA NA NA NA NA >10 NA NA NA Resazurin based viability assay NA NA NA MCF7 Cancer HSPMDB000932 27035072 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 22 1-(4-Carboxamidobenzyl)-2-(4-fluorophenyl)-1H-phenanthro-[9,10-d]imidazole NC(=O)C1=CC=C(CN2C(=NC3=C2C2=C(C=CC=C2)C2=C3C=CC=C2)C2=CC=C(F)C=C2)C=C1 Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline NA NA NA NA NA NA NA >10 NA NA NA Resazurin based viability assay NA NA NA MCF7 Cancer HSPMDB000933 27035072 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 23 1-(4-Carboxamidobenzyl)-2-(4-methoxyphenyl)-1H-phenanthro-[9,10-d]imidazole COC1=CC=C(C=C1)C1=NC2=C(N1CC1=CC=C(C=C1)C(N)=O)C1=C(C=CC=C1)C1=C2C=CC=C1 Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline NA NA NA NA NA NA NA >10 NA NA NA Resazurin based viability assay NA NA NA MCF7 Cancer HSPMDB000934 27035072 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 25 1-(4-Carboxamidobenzyl)-6,9-dimethoxy-2-phenyl-1H-phenanthro[9,10-d]imidazole COC1=CC2=C(C=C1)C1=C(N(CC3=CC=C(C=C3)C(N)=O)C(=N1)C1=CC=CC=C1)C1=C2C=C(OC)C=C1 Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline NA NA NA NA NA NA NA >10 NA NA NA Resazurin based viability assay NA NA NA MCF7 Cancer HSPMDB000935 27035072 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 28 2-Phenyl-1H-imidazo[4,5-f][1,10]phenanthroline [nH]1c(nc2c1c3cccnc3c4ncccc24)c5ccccc5 Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline NA NA NA NA NA NA NA 0.69 NA NA NA Resazurin based viability assay NA NA NA MCF7 Cancer HSPMDB000936 27035072 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 31 1-Benzyl-2-(3,5-bis(trifluoromethyl)phenyl)-1H-imidazo[4,5-f ]-[1,10]phenanthroline FC(F)(F)c1cc(cc(c1)C(F)(F)F)c2nc3c4cccnc4c5ncccc5c3n2Cc6ccccc6 Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline NA NA NA NA NA NA NA 2.8 NA NA NA Resazurin based viability assay NA NA NA MCF7 Cancer HSPMDB000937 27035072 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 32 1-(4-Carboxamidobenzyl)-2-(3,5-bis(trifluoromethyl)phenyl)-1H-imidazo[4,5-f][1,10]-phenanthroline NC(=O)C1=CC=C(CN2C(=NC3=C2C2=C(N=CC=C2)C2=C3C=CC=N2)C2=CC(=CC(=C2)C(F)(F)F)C(F)(F)F)C=C1 Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline NA NA NA NA NA NA NA 2.3 NA NA NA Resazurin based viability assay NA NA NA MCF7 Cancer HSPMDB000938 27035072 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 22 1-(4-Carboxamidobenzyl)-2-(4-fluorophenyl)-1H-phenanthro-[9,10-d]imidazole NC(=O)C1=CC=C(CN2C(=NC3=C2C2=C(C=CC=C2)C2=C3C=CC=C2)C2=CC=C(F)C=C2)C=C1 Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline NA NA NA NA NA NA NA >5 NA NA NA Resazurin based viability assay NA NA NA WM266.4 Cancer HSPMDB000939 27035072 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 23 1-(4-Carboxamidobenzyl)-2-(4-methoxyphenyl)-1H-phenanthro-[9,10-d]imidazole COC1=CC=C(C=C1)C1=NC2=C(N1CC1=CC=C(C=C1)C(N)=O)C1=C(C=CC=C1)C1=C2C=CC=C1 Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline NA NA NA NA NA NA NA >5 NA NA NA Resazurin based viability assay NA NA NA WM266.4 Cancer HSPMDB000940 27035072 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 25 1-(4-Carboxamidobenzyl)-6,9-dimethoxy-2-phenyl-1H-phenanthro[9,10-d]imidazole COC1=CC2=C(C=C1)C1=C(N(CC3=CC=C(C=C3)C(N)=O)C(=N1)C1=CC=CC=C1)C1=C2C=C(OC)C=C1 Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline NA NA NA NA NA NA NA >5 NA NA NA Resazurin based viability assay NA NA NA WM266.4 Cancer HSPMDB000941 27035072 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 28 2-Phenyl-1H-imidazo[4,5-f][1,10]phenanthroline [nH]1c(nc2c1c3cccnc3c4ncccc24)c5ccccc5 Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline NA NA NA NA NA NA NA 0.32 NA NA NA Resazurin based viability assay NA NA NA WM266.4 Cancer HSPMDB000942 27035072 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 31 1-Benzyl-2-(3,5-bis(trifluoromethyl)phenyl)-1H-imidazo[4,5-f ]-[1,10]phenanthroline FC(F)(F)c1cc(cc(c1)C(F)(F)F)c2nc3c4cccnc4c5ncccc5c3n2Cc6ccccc6 Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline NA NA NA NA NA NA NA 2.9 NA NA NA Resazurin based viability assay NA NA NA WM266.4 Cancer HSPMDB000943 27035072 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 32 1-(4-Carboxamidobenzyl)-2-(3,5-bis(trifluoromethyl)phenyl)-1H-imidazo[4,5-f][1,10]-phenanthroline NC(=O)C1=CC=C(CN2C(=NC3=C2C2=C(N=CC=C2)C2=C3C=CC=N2)C2=CC(=CC(=C2)C(F)(F)F)C(F)(F)F)C=C1 Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline NA NA NA NA NA NA NA 2.5 NA NA NA Resazurin based viability assay NA NA NA WM266.4 Cancer HSPMDB000944 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity MKT-077 1-ethyl-2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}pyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC=C2N1C)=C\C1=[N+](CC)C=CC=C1 Rhodacyanine NA NA NA NA 1.4 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000945 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity YM-01 2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC=C2N1C)=C\C1=[N+](C)C=CC=C1 Rhodacyanine derivative NA NA NA NA 2 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000946 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 1 2-{[(2Z)-3-ethyl-5-[(2E)-4-fluoro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC(F)=C2N1C)=C\C1=[N+](C)C=CC=C1 Rhodacyanine derivative NA NA NA NA 4 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000947 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 2 2-{[(2Z)-3-ethyl-5-[(2E)-5-fluoro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=C(F)C=C2N1C)=C\C1=[N+](C)C=CC=C1 Rhodacyanine derivative NA NA NA NA 7.7 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000948 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 3 2-{[(2Z)-3-ethyl-5-[(2E)-6-fluoro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC(F)=CC=C2N1C)=C\C1=[N+](C)C=CC=C1 Rhodacyanine derivative NA NA NA NA 5.6 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000949 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 4 2-{[(2Z)-3-ethyl-5-[(2E)-7-fluoro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=C(F)C=CC=C2N1C)=C\C1=[N+](C)C=CC=C1 Rhodacyanine derivative NA NA NA NA 6.2 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000950 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 5 1-ethyl-2-{[(2Z)-3-ethyl-5-[(2E)-4-fluoro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}pyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC(F)=C2N1C)=C\C1=[N+](CC)C=CC=C1 Rhodacyanine derivative NA NA NA NA 3.8 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000951 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 6 1-ethyl-2-{[(2Z)-3-ethyl-5-[(2E)-5-fluoro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}pyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=C(F)C=C2N1C)=C\C1=[N+](CC)C=CC=C1 Rhodacyanine derivative NA NA NA NA 13 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000952 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 7 1-ethyl-2-{[(2Z)-3-ethyl-5-[(2E)-6-fluoro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}pyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC(F)=CC=C2N1C)=C\C1=[N+](CC)C=CC=C1 Rhodacyanine derivative NA NA NA NA 8.3 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000953 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 8 1-ethyl-2-{[(2Z)-3-ethyl-5-[(2E)-7-fluoro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}pyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=C(F)C=CC=C2N1C)=C\C1=[N+](CC)C=CC=C1 Rhodacyanine derivative NA NA NA NA 2.8 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000954 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 9 2-{[(2Z)-5-[(2E)-4-chloro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-3-ethyl-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC(Cl)=C2N1C)=C\C1=[N+](C)C=CC=C1 Rhodacyanine derivative NA NA NA NA 4.4 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000955 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 10 2-{[(2Z)-5-[(2E)-5-chloro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-3-ethyl-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=C(Cl)C=C2N1C)=C\C1=[N+](C)C=CC=C1 Rhodacyanine derivative NA NA NA NA 4.6 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000956 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 11 2-{[(2Z)-5-[(2E)-6-chloro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-3-ethyl-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC(Cl)=CC=C2N1C)=C\C1=[N+](C)C=CC=C1 Rhodacyanine derivative NA NA NA NA 8.3 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000957 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 12 2-{[(2Z)-5-[(2E)-7-chloro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-3-ethyl-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=C(Cl)C=CC=C2N1C)=C\C1=[N+](C)C=CC=C1 Rhodacyanine derivative NA NA NA NA 4.1 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000958 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 13 2-{[(2Z)-3-ethyl-5-[(2E)-5-methoxy-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=C(OC)C=C2N1C)=C\C1=[N+](C)C=CC=C1 Rhodacyanine derivative NA NA NA NA 2.8 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000959 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 14 2-{[(2Z)-3-ethyl-5-[(2E)-6-methoxy-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC(OC)=CC=C2N1C)=C\C1=[N+](C)C=CC=C1 Rhodacyanine derivative NA NA NA NA 4 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000960 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 15 2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-5-(trifluoromethyl)-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=C(C=C2N1C)C(F)(F)F)=C\C1=[N+](C)C=CC=C1 Rhodacyanine derivative NA NA NA NA 21 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000961 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 16 2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-6-(trifluoromethyl)-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC(=CC=C2N1C)C(F)(F)F)=C\C1=[N+](C)C=CC=C1 Rhodacyanine derivative NA NA NA NA 19 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000962 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 17 1-methyl-2-{[(2Z)-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-3-(prop-2-en-1-yl)-1,3-thiazolidin-2-ylidene]methyl}pyridin-1-ium chloride [Cl-].CN1\C(SC2=CC=CC=C12)=C1/S\C(=C/C2=[N+](C)C=CC=C2)N(CC=C)C1=O Rhodacyanine derivative NA NA NA NA 3.6 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000963 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 18 2-{[(2Z)-3-benzyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CN1\C(SC2=CC=CC=C12)=C1/S\C(=C/C2=[N+](C)C=CC=C2)N(CC2=CC=CC=C2)C1=O Rhodacyanine derivative NA NA NA NA 1.8 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000964 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 19 2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-propylpyridin-1-ium chloride [Cl-].CCC[N+]1=C(\C=C2/S\C(C(=O)N2CC)=C2\SC3=CC=CC=C3N2C)C=CC=C1 Rhodacyanine derivative NA NA NA NA 1.6 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000965 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 20 1-benzyl-2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}pyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC=C2N1C)=C\C1=[N+](CC2=CC=CC=C2)C=CC=C1 Rhodacyanine derivative NA NA NA NA 1 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000966 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 21 2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-(2-hydroxyethyl)pyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC=C2N1C)=C\C1=[N+](CCO)C=CC=C1 Rhodacyanine derivative NA NA NA NA 24 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000967 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 22 4-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC=C2N1C)=C\C1=CC=[N+](C)C=C1 Rhodacyanine derivative NA NA NA NA 1.7 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000968 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 23 2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyrimidin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC=C2N1C)=C\C1=[N+](C)C=CC=N1 Rhodacyanine derivative NA NA NA NA 5.8 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000969 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 24 2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-3-methyl-1,3-thiazol-3-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC=C2N1C)=C\C1=[N+](C)C=CS1 Rhodacyanine derivative NA NA NA NA 5.1 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000970 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 25 3-ethyl-2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1,3-thiazol-3-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC=C2N1C)=C\C1=[N+](CC)C=CS1 Rhodacyanine derivative NA NA NA NA 2.2 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000971 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 26 3-benzyl-2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1,3-thiazol-3-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC=C2N1C)=C\C1=[N+](CC2=CC=CC=C2)C=CS1 Rhodacyanine derivative NA NA NA NA 0.5 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000972 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 27(JG-83) 3-benzyl-2-{[(2Z)-3-ethyl-5-[(2E)-4-fluoro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1,3-thiazol-3-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC(F)=C2N1C)=C\C1=[N+](CC2=CC=CC=C2)C=CS1 Rhodacyanine derivative NA NA NA NA 0.4 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000973 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 28(JG-84) 3-benzyl-2-{[(2Z)-5-[(2E)-4-chloro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-3-ethyl-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1,3-thiazol-3-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC(Cl)=C2N1C)=C\C1=[N+](CC2=CC=CC=C2)C=CS1 Rhodacyanine derivative NA NA NA NA 0.4 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000974 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 29 3-benzyl-2-{[(2Z)-5-[(2E)-5-chloro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-3-ethyl-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1,3-thiazol-3-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=C(Cl)C=C2N1C)=C\C1=[N+](CC2=CC=CC=C2)C=CS1 Rhodacyanine derivative NA NA NA NA 0.6 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000975 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 30(JG-98) 3-benzyl-2-{[(2Z)-5-[(2E)-6-chloro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-3-ethyl-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1,3-thiazol-3-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC(Cl)=CC=C2N1C)=C\C1=[N+](CC2=CC=CC=C2)C=CS1 Rhodacyanine derivative NA NA NA NA 0.4 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000976 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 31 3-benzyl-2-{[(2Z)-5-[(2E)-7-chloro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-3-ethyl-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1,3-thiazol-3-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=C(Cl)C=CC=C2N1C)=C\C1=[N+](CC2=CC=CC=C2)C=CS1 Rhodacyanine derivative NA NA NA NA 0.5 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000977 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity MKT-077 1-ethyl-2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}pyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC=C2N1C)=C\C1=[N+](CC)C=CC=C1 Rhodacyanine derivative NA NA NA NA 2.2 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000978 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity YM-01 2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC=C2N1C)=C\C1=[N+](C)C=CC=C1 Rhodacyanine derivative NA NA NA NA 5.2 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000979 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 1 2-{[(2Z)-3-ethyl-5-[(2E)-4-fluoro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC(F)=C2N1C)=C\C1=[N+](C)C=CC=C1 Rhodacyanine derivative NA NA NA NA 2.2 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000980 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 2 2-{[(2Z)-3-ethyl-5-[(2E)-5-fluoro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=C(F)C=C2N1C)=C\C1=[N+](C)C=CC=C1 Rhodacyanine derivative NA NA NA NA 18 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000981 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 3 2-{[(2Z)-3-ethyl-5-[(2E)-6-fluoro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC(F)=CC=C2N1C)=C\C1=[N+](C)C=CC=C1 Rhodacyanine derivative NA NA NA NA 6.2 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000982 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 4 2-{[(2Z)-3-ethyl-5-[(2E)-7-fluoro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=C(F)C=CC=C2N1C)=C\C1=[N+](C)C=CC=C1 Rhodacyanine derivative NA NA NA NA 8.5 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000983 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 5 1-ethyl-2-{[(2Z)-3-ethyl-5-[(2E)-4-fluoro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}pyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC(F)=C2N1C)=C\C1=[N+](CC)C=CC=C1 Rhodacyanine derivative NA NA NA NA 1 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000984 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 6 1-ethyl-2-{[(2Z)-3-ethyl-5-[(2E)-5-fluoro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}pyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=C(F)C=C2N1C)=C\C1=[N+](CC)C=CC=C1 Rhodacyanine derivative NA NA NA NA 2.4 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000985 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 7 1-ethyl-2-{[(2Z)-3-ethyl-5-[(2E)-6-fluoro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}pyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC(F)=CC=C2N1C)=C\C1=[N+](CC)C=CC=C1 Rhodacyanine derivative NA NA NA NA 0.9 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000986 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 8 1-ethyl-2-{[(2Z)-3-ethyl-5-[(2E)-7-fluoro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}pyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=C(F)C=CC=C2N1C)=C\C1=[N+](CC)C=CC=C1 Rhodacyanine derivative NA NA NA NA 0.8 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000987 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 9 2-{[(2Z)-5-[(2E)-4-chloro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-3-ethyl-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC(Cl)=C2N1C)=C\C1=[N+](C)C=CC=C1 Rhodacyanine derivative NA NA NA NA 7.8 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000988 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 10 2-{[(2Z)-5-[(2E)-5-chloro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-3-ethyl-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=C(Cl)C=C2N1C)=C\C1=[N+](C)C=CC=C1 Rhodacyanine derivative NA NA NA NA 28 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000989 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 11 2-{[(2Z)-5-[(2E)-6-chloro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-3-ethyl-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC(Cl)=CC=C2N1C)=C\C1=[N+](C)C=CC=C1 Rhodacyanine derivative NA NA NA NA 9.5 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000990 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 12 2-{[(2Z)-5-[(2E)-7-chloro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-3-ethyl-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=C(Cl)C=CC=C2N1C)=C\C1=[N+](C)C=CC=C1 Rhodacyanine derivative NA NA NA NA 5.2 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000991 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 13 2-{[(2Z)-3-ethyl-5-[(2E)-5-methoxy-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=C(OC)C=C2N1C)=C\C1=[N+](C)C=CC=C1 Rhodacyanine derivative NA NA NA NA 14 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000992 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 14 2-{[(2Z)-3-ethyl-5-[(2E)-6-methoxy-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC(OC)=CC=C2N1C)=C\C1=[N+](C)C=CC=C1 Rhodacyanine derivative NA NA NA NA 11 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000993 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 15 2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-5-(trifluoromethyl)-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=C(C=C2N1C)C(F)(F)F)=C\C1=[N+](C)C=CC=C1 Rhodacyanine derivative NA NA NA NA >30 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000994 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 16 2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-6-(trifluoromethyl)-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC(=CC=C2N1C)C(F)(F)F)=C\C1=[N+](C)C=CC=C1 Rhodacyanine derivative NA NA NA NA >30 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000995 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 17 1-methyl-2-{[(2Z)-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-3-(prop-2-en-1-yl)-1,3-thiazolidin-2-ylidene]methyl}pyridin-1-ium chloride [Cl-].CN1\C(SC2=CC=CC=C12)=C1/S\C(=C/C2=[N+](C)C=CC=C2)N(CC=C)C1=O Rhodacyanine derivative NA NA NA NA 8.4 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000996 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 18 2-{[(2Z)-3-benzyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CN1\C(SC2=CC=CC=C12)=C1/S\C(=C/C2=[N+](C)C=CC=C2)N(CC2=CC=CC=C2)C1=O Rhodacyanine derivative NA NA NA NA 2.9 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000997 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 19 2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-propylpyridin-1-ium chloride [Cl-].CCC[N+]1=C(\C=C2/S\C(C(=O)N2CC)=C2\SC3=CC=CC=C3N2C)C=CC=C1 Rhodacyanine derivative NA NA NA NA 2.8 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000998 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 20 1-benzyl-2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}pyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC=C2N1C)=C\C1=[N+](CC2=CC=CC=C2)C=CC=C1 Rhodacyanine derivative NA NA NA NA 1.5 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000999 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 21 2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-(2-hydroxyethyl)pyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC=C2N1C)=C\C1=[N+](CCO)C=CC=C1 Rhodacyanine derivative NA NA NA NA 6.9 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB001000 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 22 4-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC=C2N1C)=C\C1=CC=[N+](C)C=C1 Rhodacyanine derivative NA NA NA NA 19 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB001001 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 23 2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyrimidin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC=C2N1C)=C\C1=[N+](C)C=CC=N1 Rhodacyanine derivative NA NA NA NA 9.1 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB001002 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 24 2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-3-methyl-1,3-thiazol-3-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC=C2N1C)=C\C1=[N+](C)C=CS1 Rhodacyanine derivative NA NA NA NA 0.7 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB001003 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 25 3-ethyl-2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1,3-thiazol-3-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC=C2N1C)=C\C1=[N+](CC)C=CS1 Rhodacyanine derivative NA NA NA NA 0.8 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB001004 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 26 3-benzyl-2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1,3-thiazol-3-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC=C2N1C)=C\C1=[N+](CC2=CC=CC=C2)C=CS1 Rhodacyanine derivative NA NA NA NA 0.6 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB001005 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 27(JG-83) 3-benzyl-2-{[(2Z)-3-ethyl-5-[(2E)-4-fluoro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1,3-thiazol-3-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC(F)=C2N1C)=C\C1=[N+](CC2=CC=CC=C2)C=CS1 Rhodacyanine derivative NA NA NA NA 1 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB001006 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 28(JG-84) 3-benzyl-2-{[(2Z)-5-[(2E)-4-chloro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-3-ethyl-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1,3-thiazol-3-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC(Cl)=C2N1C)=C\C1=[N+](CC2=CC=CC=C2)C=CS1 Rhodacyanine derivative NA NA NA NA 0.8 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB001007 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 29 3-benzyl-2-{[(2Z)-5-[(2E)-5-chloro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-3-ethyl-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1,3-thiazol-3-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=C(Cl)C=C2N1C)=C\C1=[N+](CC2=CC=CC=C2)C=CS1 Rhodacyanine derivative NA NA NA NA 0.8 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB001008 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 30(JG-98) 3-benzyl-2-{[(2Z)-5-[(2E)-6-chloro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-3-ethyl-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1,3-thiazol-3-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC(Cl)=CC=C2N1C)=C\C1=[N+](CC2=CC=CC=C2)C=CS1 Rhodacyanine derivative NA NA NA NA 0.7 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB001009 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 31 3-benzyl-2-{[(2Z)-5-[(2E)-7-chloro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-3-ethyl-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1,3-thiazol-3-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=C(Cl)C=CC=C2N1C)=C\C1=[N+](CC2=CC=CC=C2)C=CS1 Rhodacyanine derivative NA NA NA NA 1 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB001010 25148104 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 2-phenylethyenesulfonamide (PES) 2-phenylethynesulfonamide C1=CC=C(C=C1)C#CS(=O)(=O)N NA NA NA NA NA NA NA NA NA C-terminal domain NA 90% at 10 uM MTT viability assay NA NA NA A875 Cancer HSPMDB001011 25148104 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity PET-16 triphenyl(phenylethynyl)phosphonium bromide [Br-].C1(=CC=CC=C1)[P+](C#CC1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1 2-phenylethyenesulfonamide (PES) derivative NA NA NA NA NA NA NA NA C-terminal domain NA 100% at 10 um MTT viability assay NA NA NA A875 Cancer HSPMDB001012 25148104 Hsp70 Hsp72 (HSPA1A) Human Cytosol and nucleus Binding affinity NA 2-phenylethyenesulfonamide (PES) 2-phenylethynesulfonamide C1=CC=C(C=C1)C#CS(=O)(=O)N NA NA 5.7 NA NA NA NA NA NA C-terminal domain Isothermal Titration Calorimetry (ITC) NA NA NA NA NA NA Cancer HSPMDB001013 25148104 Hsp70 Hsp72 (HSPA1A) Human Cytosol and nucleus Binding affinity NA PET-16 triphenyl(phenylethynyl)phosphonium bromide [Br-].C1(=CC=CC=C1)[P+](C#CC1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1 2-phenylethyenesulfonamide (PES) derivative NA 3.8 NA NA NA NA NA NA C-terminal domain Isothermal Titration Calorimetry (ITC) NA NA NA NA NA NA Cancer HSPMDB001014 25148104 Hsp70 DnaK Bacteria Cytosol and membrane Binding affinity NA PES 2-phenylethynesulfonamide C1=CC=C(C=C1)C#CS(=O)(=O)N NA NA 6.8 NA NA NA NA NA NA C-terminal domain Isothermal Titration Calorimetry (ITC) NA NA NA NA NA NA Bacterial infection HSPMDB001015 25148104 Hsp70 DnaK Bacteria Cytosol and membrane Binding affinity NA PET-16 triphenyl(phenylethynyl)phosphonium bromide [Br-].C1(=CC=CC=C1)[P+](C#CC1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1 2-phenylethyenesulfonamide (PES) derivative NA 6 NA NA NA NA NA NA C-terminal domain Isothermal Titration Calorimetry (ITC) NA NA NA NA NA NA Bacterial infection HSPMDB001016 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity Lapatinib 2-phenylethynesulfonamide C1=CC=C(C=C1)C#CS(=O)(=O)N Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 75.6 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001017 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 1 N-(3-Chlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3cccc(Cl)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 14.4 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001018 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 2 2-(((1-((2-Ethoxythiazol-5-yl)methyl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile CCOc1sc(CN2CCC(CC2)N(C)Cc3ccccc3C#N)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 17.6 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001019 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 3 N-(3,4-dichlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 62.9 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001020 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 4 4-(((1-((2-Ethoxythiazol-5-yl)methyl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile CCOc1sc(CN2CCC(CC2)N(C)Cc3ccc(cc3)C#N)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 61.7 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001021 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 5 N-(2-chloro-6-fluorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3c(F)cccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 54.4 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001022 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 6 N-(2-chlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3ccccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 10.1 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001023 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 7 1-((2-Ethoxythiazol-5-yl)methyl)-N-(4-fluorobenzyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3ccc(F)cc3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 36.4 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001024 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 8 N-(2,4-dichlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3ccc(Cl)cc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 70.3 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001025 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 9 N-(2,6-dichlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3c(Cl)cccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 38.2 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001026 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 10 N-(2,5-dichlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 5.6 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001027 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 11 N-methyl-N-(2-methylbenzyl)-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3ccccc3C)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 15.5 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001028 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 12 N-methyl-N-(4-methylbenzyl)-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(C)cc3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 68.3 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001029 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 13 N-(3-fluorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3cccc(F)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 26.3 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001030 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 14 N-(3-chlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3cccc(Cl)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 44.9 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001031 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 15 N-(4-fluorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(F)cc3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 54.4 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001032 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 16 N-(3,4-dichlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 62.6 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001033 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 17 N-(2-chloro-6-fluorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl) piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3c(F)cccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 49.5 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001034 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 18 N-(2,6-dichlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3c(Cl)cccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 54.9 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001035 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 19 N-(2,4-dichlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(Cl)cc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 70 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001036 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 20 N-(2,5-dichlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 42.3 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001037 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 21 2-(((1-((2-Chlorothiazol-5-yl)methyl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile CN(Cc1ccccc1C#N)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA -4.1 Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001038 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 22 4-(((1-((2-Chlorothiazol-5-yl)methyl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile CN(Cc1ccc(cc1)C#N)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 69.3 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001039 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 23 1-((2-Chlorothiazol-5-yl)methyl)-N-(4-fluorobenzyl)-N-methylpiperidin-4-amine CN(Cc1ccc(F)cc1)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 7.1 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001040 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 24 1-((2-Chlorothiazol-5-yl)methyl)-N-(3,4-dichlorobenzyl)-N-methylpiperidin-4-amine CN(Cc1ccc(Cl)c(Cl)c1)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 45.4 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001041 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 25 N-(3-chlorobenzyl)-1-((2-chlorothiazol-5-yl)methyl)-N-methylpiperidin-4-amine CN(Cc1cccc(Cl)c1)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 7.1 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001042 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 26 N-(2-chloro-6-fluorobenzyl)-1-((2-chlorothiazol-5-yl)methyl)-N-methylpiperidin-4-amine CN(Cc1c(F)cccc1Cl)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 10.6 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001043 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 27 1-((2-Chlorothiazol-5-yl)methyl)-N-(2,4-dichlorobenzyl)-N-methylpiperidin-4-amine CN(Cc1ccc(Cl)cc1Cl)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 64.1 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001044 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 28 1-((2-Chlorothiazol-5-yl)methyl)-N-methyl-N-(2-methylbenzyl)piperidin-4-amine CN(Cc1ccccc1C)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 1.5 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001045 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 29 1-((2-Chlorothiazol-5-yl)methyl)-N-methyl-N-(4-methylbenzyl)piperidin-4-amine CN(Cc1ccc(C)cc1)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 14.2 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001046 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 30 1-((2-Chlorothiazol-5-yl)methyl)-N-(3-fluorobenzyl)-N-methylpiperidin-4-amine CN(Cc1cccc(F)c1)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 2.4 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001047 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 31 1-((2-Chlorothiazol-5-yl)methyl)-N-(2,6-dichlorobenzyl)-N-methylpiperidin-4-amine CN(Cc1c(Cl)cccc1Cl)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 70 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001048 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 32 1-((2-Chlorothiazol-5-yl)methyl)-N-(3,4-dichlorobenzyl)piperidin-4-amine Clc1sc(CN2CCC(CC2)NCc3ccc(Cl)c(Cl)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 11 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001049 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 33 1-((2-Chlorothiazol-5-yl)methyl)-N-(4-fluorobenzyl)piperidin-4-amine Fc1ccc(CNC2CCN(CC2)Cc3sc(Cl)nc3)cc1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 70 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001050 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 34 N-(3-chlorobenzyl)-1-((2-chlorothiazol-5-yl)methyl)piperidin-4-amine Clc1sc(CN2CCC(CC2)NCc3cccc(Cl)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 3.8 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001051 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 35 N-(4-fluorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(F)cc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 40.5 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001052 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 36 4-((Methyl(1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-yl)amino)methyl) benzonitrile CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(cc3)C#N Piperidine derivative NA NA NA 1.41 NA NA NA NA Nucleotide binding domain (allosteric site) NA 75.5 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001053 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 37 N-(2-chloro-6-fluorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3c(F)cccc3Cl Piperidine derivative NA NA NA 1.04 NA NA NA NA Nucleotide binding domain (allosteric site) NA 75.5 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001054 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 38 N-(3,4-dichlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 39.5 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001055 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 39 N-(3-chlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3cccc(Cl)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 35.1 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001056 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 40 N-(2,4-dichlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(Cl)cc3Cl Piperidine derivative NA NA NA 1.62 NA NA NA NA Nucleotide binding domain (allosteric site) NA 74.2 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001057 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 41 2-((Methyl(1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-yl)amino)methyl) benzonitrile CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccccc3C#N Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 74.2 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001058 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 42 N-methyl-N-(4-methylbenzyl)-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(C)cc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 69.2 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001059 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 47 N-(2-chlorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 36.7 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001060 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 44 N-(2,5-dichlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 61 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001061 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 45 N-(3-fluorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3cccc(F)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 67.1 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001062 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 46 N-(2-chlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccccc3Cl Piperidine derivative NA NA NA 1.99 NA NA NA NA Nucleotide binding domain (allosteric site) NA 21.3 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001063 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 43 N-(2,6-dichlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3c(Cl)cccc3Cl Piperidine derivative NA NA NA 0.78 NA NA NA NA Nucleotide binding domain (allosteric site) NA 73.1 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001064 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 48 4-(((1-(2-Methoxypyrimidin-4-yl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(cc3)C#N Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 60.4 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001065 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 49 2-(((1-(2-Methoxypyrimidin-4-yl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccccc3C#N Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 71.6 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001066 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 50 1-(2-Methoxypyrimidin-4-yl)-N-methyl-N-(4-methylbenzyl)piperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(C)cc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 61.5 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001067 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 51 N-(2,5-dichlorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 27.5 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001068 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 52 N-(3,4-dichlorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 52.9 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001069 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 53 N-(2-chloro-6-fluorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3c(F)cccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 65.4 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001070 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 54 N-(3-chlorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3cccc(Cl)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 36.2 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001071 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 55 N-(3-fluorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3cccc(F)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 9.9 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001072 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 56 N-(4-fluorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(F)cc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 12.5 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001073 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 57 N-(2-chlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 27.7 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001074 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 58 1-(6-Methoxypyrimidin-4-yl)-N-methyl-N-(4-methylbenzyl)piperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccc(C)cc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 5 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001075 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 59 N-(2,6-dichlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3c(Cl)cccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 53.6 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001076 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 60 N-(3,4-dichlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 9.8 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001077 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 61 N-(4-fluorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccc(F)cc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 7.8 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001078 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 62 N-(3-chlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3cccc(Cl)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 11.9 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001079 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 63 N-(2-chloro-6-fluorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3c(F)cccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 45.9 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001080 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 64 2-(((1-(6-Methoxypyrimidin-4-yl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccccc3C#N Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 65.8 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001081 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 65 4-(((1-(6-Methoxypyrimidin-4-yl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccc(cc3)C#N Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 25.1 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001082 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 66 N-(2,5-dichlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 45.9 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001083 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 67 N-(2,5-dichlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 5.4 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001084 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity Lapatinib N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 18 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001085 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 1 N-(3-Chlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3cccc(Cl)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 12.5 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001086 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 2 2-(((1-((2-Ethoxythiazol-5-yl)methyl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile CCOc1sc(CN2CCC(CC2)N(C)Cc3ccccc3C#N)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 19.4 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001087 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 3 N-(3,4-dichlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 67.4 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001088 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 4 4-(((1-((2-Ethoxythiazol-5-yl)methyl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile CCOc1sc(CN2CCC(CC2)N(C)Cc3ccc(cc3)C#N)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 66.1 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001089 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 5 N-(2-chloro-6-fluorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3c(F)cccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 50.5 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001090 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 6 N-(2-chlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3ccccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 13.3 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001091 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 7 1-((2-Ethoxythiazol-5-yl)methyl)-N-(4-fluorobenzyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3ccc(F)cc3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 20.7 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001092 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 8 N-(2,4-dichlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3ccc(Cl)cc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 65.9 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001093 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 9 N-(2,6-dichlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3c(Cl)cccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 25.6 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001094 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 10 N-(2,5-dichlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 9.6 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001095 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 11 N-methyl-N-(2-methylbenzyl)-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3ccccc3C)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 1.4 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001096 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 12 N-methyl-N-(4-methylbenzyl)-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(C)cc3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 66.7 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001097 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 13 N-(3-fluorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3cccc(F)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 19.8 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001098 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 14 N-(3-chlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3cccc(Cl)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 36.1 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001099 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 15 N-(4-fluorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(F)cc3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 50.5 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001100 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 16 N-(3,4-dichlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 67.1 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001101 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 17 N-(2-chloro-6-fluorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl) piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3c(F)cccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 59.9 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001102 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 18 N-(2,6-dichlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3c(Cl)cccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 54.9 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001103 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 19 N-(2,4-dichlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(Cl)cc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 66.3 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001104 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 20 N-(2,5-dichlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 34.4 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001105 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 21 2-(((1-((2-Chlorothiazol-5-yl)methyl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile CN(Cc1ccccc1C#N)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 4 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001106 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 22 4-(((1-((2-Chlorothiazol-5-yl)methyl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile CN(Cc1ccc(cc1)C#N)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 68.7 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001107 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 23 1-((2-Chlorothiazol-5-yl)methyl)-N-(4-fluorobenzyl)-N-methylpiperidin-4-amine CN(Cc1ccc(F)cc1)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 9 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001108 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 24 1-((2-Chlorothiazol-5-yl)methyl)-N-(3,4-dichlorobenzyl)-N-methylpiperidin-4-amine CN(Cc1ccc(Cl)c(Cl)c1)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 53.4 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001109 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 25 N-(3-chlorobenzyl)-1-((2-chlorothiazol-5-yl)methyl)-N-methylpiperidin-4-amine CN(Cc1cccc(Cl)c1)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 8.4 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001110 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 26 N-(2-chloro-6-fluorobenzyl)-1-((2-chlorothiazol-5-yl)methyl)-N-methylpiperidin-4-amine CN(Cc1c(F)cccc1Cl)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 3.2 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001111 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 27 1-((2-Chlorothiazol-5-yl)methyl)-N-(2,4-dichlorobenzyl)-N-methylpiperidin-4-amine CN(Cc1ccc(Cl)cc1Cl)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 61.8 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001112 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 28 1-((2-Chlorothiazol-5-yl)methyl)-N-methyl-N-(2-methylbenzyl)piperidin-4-amine CN(Cc1ccccc1C)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 4 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001113 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 29 1-((2-Chlorothiazol-5-yl)methyl)-N-methyl-N-(4-methylbenzyl)piperidin-4-amine CN(Cc1ccc(C)cc1)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 16 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001114 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 30 1-((2-Chlorothiazol-5-yl)methyl)-N-(3-fluorobenzyl)-N-methylpiperidin-4-amine CN(Cc1cccc(F)c1)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 5.7 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001115 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 31 1-((2-Chlorothiazol-5-yl)methyl)-N-(2,6-dichlorobenzyl)-N-methylpiperidin-4-amine CN(Cc1c(Cl)cccc1Cl)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 66.3 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001116 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 32 1-((2-Chlorothiazol-5-yl)methyl)-N-(3,4-dichlorobenzyl)piperidin-4-amine Clc1sc(CN2CCC(CC2)NCc3ccc(Cl)c(Cl)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 10.6 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001117 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 33 1-((2-Chlorothiazol-5-yl)methyl)-N-(4-fluorobenzyl)piperidin-4-amine Fc1ccc(CNC2CCN(CC2)Cc3sc(Cl)nc3)cc1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 66.3 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001118 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 34 N-(3-chlorobenzyl)-1-((2-chlorothiazol-5-yl)methyl)piperidin-4-amine Clc1sc(CN2CCC(CC2)NCc3cccc(Cl)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 7.2 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001119 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 35 N-(4-fluorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(F)cc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 44.7 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001120 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 36 4-((Methyl(1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-yl)amino)methyl) benzonitrile CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(cc3)C#N Piperidine derivative NA NA NA 1.47 NA NA NA NA Nucleotide binding domain (allosteric site) NA 76.2 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001121 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 37 N-(2-chloro-6-fluorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3c(F)cccc3Cl Piperidine derivative NA NA NA 0.94 NA NA NA NA Nucleotide binding domain (allosteric site) NA 70.7 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001122 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 38 N-(3,4-dichlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 29.9 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001123 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 39 N-(3-chlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3cccc(Cl)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 25.1 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001124 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 40 N-(2,4-dichlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(Cl)cc3Cl Piperidine derivative NA NA NA 1.68 NA NA NA NA Nucleotide binding domain (allosteric site) NA 68.1 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001125 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 41 2-((Methyl(1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-yl)amino)methyl) benzonitrile CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccccc3C#N Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 68.1 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001126 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 42 N-methyl-N-(4-methylbenzyl)-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(C)cc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 65.8 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001127 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 47 N-(2-chlorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 28.6 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001128 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 44 N-(2,5-dichlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 56.9 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001129 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 45 N-(3-fluorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3cccc(F)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 63.9 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001130 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 46 N-(2-chlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccccc3Cl Piperidine derivative NA NA NA 1.7 NA NA NA NA Nucleotide binding domain (allosteric site) NA 17.5 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001131 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 43 N-(2,6-dichlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3c(Cl)cccc3Cl Piperidine derivative NA NA NA 0.7 NA NA NA NA Nucleotide binding domain (allosteric site) NA 70 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001132 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 48 4-(((1-(2-Methoxypyrimidin-4-yl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(cc3)C#N Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 58.1 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001133 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 49 2-(((1-(2-Methoxypyrimidin-4-yl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccccc3C#N Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 72.7 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001134 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 50 1-(2-Methoxypyrimidin-4-yl)-N-methyl-N-(4-methylbenzyl)piperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(C)cc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 58.8 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001135 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 51 N-(2,5-dichlorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 22.7 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001136 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 52 N-(3,4-dichlorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 35.8 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001137 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 53 N-(2-chloro-6-fluorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3c(F)cccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 62.4 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001138 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 54 N-(3-chlorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3cccc(Cl)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 26.2 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001139 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 55 N-(3-fluorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3cccc(F)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 10.5 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001140 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 56 N-(4-fluorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(F)cc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 14.6 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001141 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 57 N-(2-chlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 18.9 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001142 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 58 1-(6-Methoxypyrimidin-4-yl)-N-methyl-N-(4-methylbenzyl)piperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccc(C)cc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 8 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001143 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 59 N-(2,6-dichlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3c(Cl)cccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 52.5 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001144 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 60 N-(3,4-dichlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 9.2 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001145 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 61 N-(4-fluorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccc(F)cc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 8.1 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001146 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 62 N-(3-chlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3cccc(Cl)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 9.4 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001147 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 63 N-(2-chloro-6-fluorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3c(F)cccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 48.5 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001148 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 64 2-(((1-(6-Methoxypyrimidin-4-yl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccccc3C#N Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 62.2 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001149 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 65 4-(((1-(6-Methoxypyrimidin-4-yl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccc(cc3)C#N Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 16.9 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001150 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 66 N-(2,5-dichlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 32.1 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001151 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 67 N-(2,5-dichlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 5.6 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001152 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity Lapatinib N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 40.2 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001153 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 1 N-(3-Chlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3cccc(Cl)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 14.2 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001154 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 2 2-(((1-((2-Ethoxythiazol-5-yl)methyl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile CCOc1sc(CN2CCC(CC2)N(C)Cc3ccccc3C#N)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 12.3 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001155 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 3 N-(3,4-dichlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 35.8 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001156 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 4 4-(((1-((2-Ethoxythiazol-5-yl)methyl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile CCOc1sc(CN2CCC(CC2)N(C)Cc3ccc(cc3)C#N)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 51.3 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001157 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 5 N-(2-chloro-6-fluorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3c(F)cccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 32.8 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001158 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 6 N-(2-chlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3ccccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 33.3 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001159 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 7 1-((2-Ethoxythiazol-5-yl)methyl)-N-(4-fluorobenzyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3ccc(F)cc3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 24.2 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001160 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 8 N-(2,4-dichlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3ccc(Cl)cc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 49.2 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001161 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 9 N-(2,6-dichlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3c(Cl)cccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 24.5 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001162 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 10 N-(2,5-dichlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 25.3 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001163 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 11 N-methyl-N-(2-methylbenzyl)-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3ccccc3C)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 31.7 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001164 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 12 N-methyl-N-(4-methylbenzyl)-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(C)cc3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 38.3 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001165 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 13 N-(3-fluorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3cccc(F)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 31.7 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001166 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 14 N-(3-chlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3cccc(Cl)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 31.1 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001167 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 15 N-(4-fluorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(F)cc3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 32.8 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001168 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 16 N-(3,4-dichlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 42.1 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001169 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 17 N-(2-chloro-6-fluorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl) piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3c(F)cccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 47.2 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001170 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 18 N-(2,6-dichlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3c(Cl)cccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 45.2 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001171 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 19 N-(2,4-dichlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(Cl)cc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 36.3 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001172 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 20 N-(2,5-dichlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 25.4 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001173 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 21 2-(((1-((2-Chlorothiazol-5-yl)methyl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile CN(Cc1ccccc1C#N)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA -8.5 Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001174 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 22 4-(((1-((2-Chlorothiazol-5-yl)methyl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile CN(Cc1ccc(cc1)C#N)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 35.6 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001175 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 23 1-((2-Chlorothiazol-5-yl)methyl)-N-(4-fluorobenzyl)-N-methylpiperidin-4-amine CN(Cc1ccc(F)cc1)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA -1.3 Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001176 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 24 1-((2-Chlorothiazol-5-yl)methyl)-N-(3,4-dichlorobenzyl)-N-methylpiperidin-4-amine CN(Cc1ccc(Cl)c(Cl)c1)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 42.9 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001177 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 25 N-(3-chlorobenzyl)-1-((2-chlorothiazol-5-yl)methyl)-N-methylpiperidin-4-amine CN(Cc1cccc(Cl)c1)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 9.7 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001178 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 26 N-(2-chloro-6-fluorobenzyl)-1-((2-chlorothiazol-5-yl)methyl)-N-methylpiperidin-4-amine CN(Cc1c(F)cccc1Cl)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 10.4 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001179 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 27 1-((2-Chlorothiazol-5-yl)methyl)-N-(2,4-dichlorobenzyl)-N-methylpiperidin-4-amine CN(Cc1ccc(Cl)cc1Cl)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 30.1 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001180 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 28 1-((2-Chlorothiazol-5-yl)methyl)-N-methyl-N-(2-methylbenzyl)piperidin-4-amine CN(Cc1ccccc1C)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 4.4 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001181 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 29 1-((2-Chlorothiazol-5-yl)methyl)-N-methyl-N-(4-methylbenzyl)piperidin-4-amine CN(Cc1ccc(C)cc1)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 10.9 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001182 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 30 1-((2-Chlorothiazol-5-yl)methyl)-N-(3-fluorobenzyl)-N-methylpiperidin-4-amine CN(Cc1cccc(F)c1)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 3.2 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001183 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 31 1-((2-Chlorothiazol-5-yl)methyl)-N-(2,6-dichlorobenzyl)-N-methylpiperidin-4-amine CN(Cc1c(Cl)cccc1Cl)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 36.3 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001184 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 32 1-((2-Chlorothiazol-5-yl)methyl)-N-(3,4-dichlorobenzyl)piperidin-4-amine Clc1sc(CN2CCC(CC2)NCc3ccc(Cl)c(Cl)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 13.9 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001185 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 33 1-((2-Chlorothiazol-5-yl)methyl)-N-(4-fluorobenzyl)piperidin-4-amine Fc1ccc(CNC2CCN(CC2)Cc3sc(Cl)nc3)cc1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 36.3 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001186 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 34 N-(3-chlorobenzyl)-1-((2-chlorothiazol-5-yl)methyl)piperidin-4-amine Clc1sc(CN2CCC(CC2)NCc3cccc(Cl)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 3.2 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001187 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 35 N-(4-fluorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(F)cc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 46 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001188 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 36 4-((Methyl(1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-yl)amino)methyl) benzonitrile CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(cc3)C#N Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 46.9 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001189 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 37 N-(2-chloro-6-fluorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3c(F)cccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 55.9 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001190 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 38 N-(3,4-dichlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 29.5 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001191 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 39 N-(3-chlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3cccc(Cl)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 39.1 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001192 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 40 N-(2,4-dichlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(Cl)cc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 64.1 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001193 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 41 2-((Methyl(1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-yl)amino)methyl) benzonitrile CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccccc3C#N Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 64.1 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001194 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 42 N-methyl-N-(4-methylbenzyl)-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(C)cc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 55.7 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001195 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 47 N-(2-chlorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 45.1 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001196 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 44 N-(2,5-dichlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 45.7 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001197 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 45 N-(3-fluorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3cccc(F)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 50.4 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001198 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 46 N-(2-chlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 36.2 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001199 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 43 N-(2,6-dichlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3c(Cl)cccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 53.2 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001200 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 48 4-(((1-(2-Methoxypyrimidin-4-yl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(cc3)C#N Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 27.7 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001201 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 49 2-(((1-(2-Methoxypyrimidin-4-yl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccccc3C#N Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 53.3 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001202 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 50 1-(2-Methoxypyrimidin-4-yl)-N-methyl-N-(4-methylbenzyl)piperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(C)cc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 30.1 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001203 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 51 N-(2,5-dichlorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 22 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001204 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 52 N-(3,4-dichlorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 41.7 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001205 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 53 N-(2-chloro-6-fluorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3c(F)cccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 48.3 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001206 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 54 N-(3-chlorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3cccc(Cl)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 23.2 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001207 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 55 N-(3-fluorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3cccc(F)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 8.5 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001208 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 56 N-(4-fluorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(F)cc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 12.8 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001209 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 57 N-(2-chlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 20.3 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001210 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 58 1-(6-Methoxypyrimidin-4-yl)-N-methyl-N-(4-methylbenzyl)piperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccc(C)cc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 10.6 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001211 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 59 N-(2,6-dichlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3c(Cl)cccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 30.8 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001212 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 60 N-(3,4-dichlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 6.5 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001213 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 61 N-(4-fluorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccc(F)cc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 4.9 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001214 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 62 N-(3-chlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3cccc(Cl)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 25.6 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001215 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 63 N-(2-chloro-6-fluorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3c(F)cccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 39.6 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001216 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 64 2-(((1-(6-Methoxypyrimidin-4-yl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccccc3C#N Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 42.7 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001217 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 65 4-(((1-(6-Methoxypyrimidin-4-yl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccc(cc3)C#N Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 20.3 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001218 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 66 N-(2,5-dichlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 27.6 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001219 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 67 N-(2,5-dichlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 8.4 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001220 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity Lapatinib N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 79 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001221 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 1 N-(3-Chlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3cccc(Cl)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 16.7 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001222 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 2 2-(((1-((2-Ethoxythiazol-5-yl)methyl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile CCOc1sc(CN2CCC(CC2)N(C)Cc3ccccc3C#N)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 13.6 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001223 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 3 N-(3,4-dichlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 41.2 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001224 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 4 4-(((1-((2-Ethoxythiazol-5-yl)methyl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile CCOc1sc(CN2CCC(CC2)N(C)Cc3ccc(cc3)C#N)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 45.5 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001225 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 5 N-(2-chloro-6-fluorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3c(F)cccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 40.9 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001226 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 6 N-(2-chlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3ccccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 12.6 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001227 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 7 1-((2-Ethoxythiazol-5-yl)methyl)-N-(4-fluorobenzyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3ccc(F)cc3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 26 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001228 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 8 N-(2,4-dichlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3ccc(Cl)cc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 41.6 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001229 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 9 N-(2,6-dichlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3c(Cl)cccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 17.9 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001230 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 10 N-(2,5-dichlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 9.4 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001231 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 11 N-methyl-N-(2-methylbenzyl)-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3ccccc3C)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 21.9 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001232 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 12 N-methyl-N-(4-methylbenzyl)-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(C)cc3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 49.6 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001233 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 13 N-(3-fluorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3cccc(F)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 19.5 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001234 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 14 N-(3-chlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3cccc(Cl)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 26.7 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001235 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 15 N-(4-fluorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(F)cc3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 40.9 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001236 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 16 N-(3,4-dichlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 42.4 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001237 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 17 N-(2-chloro-6-fluorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl) piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3c(F)cccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 9.2 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001238 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 18 N-(2,6-dichlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3c(Cl)cccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 24.3 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001239 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 19 N-(2,4-dichlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(Cl)cc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 37.8 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001240 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 20 N-(2,5-dichlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 23.3 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001241 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 21 2-(((1-((2-Chlorothiazol-5-yl)methyl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile CN(Cc1ccccc1C#N)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 7.3 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001242 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 22 4-(((1-((2-Chlorothiazol-5-yl)methyl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile CN(Cc1ccc(cc1)C#N)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 41.5 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001243 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 23 1-((2-Chlorothiazol-5-yl)methyl)-N-(4-fluorobenzyl)-N-methylpiperidin-4-amine CN(Cc1ccc(F)cc1)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 18.6 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001244 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 24 1-((2-Chlorothiazol-5-yl)methyl)-N-(3,4-dichlorobenzyl)-N-methylpiperidin-4-amine CN(Cc1ccc(Cl)c(Cl)c1)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 34.3 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001245 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 25 N-(3-chlorobenzyl)-1-((2-chlorothiazol-5-yl)methyl)-N-methylpiperidin-4-amine CN(Cc1cccc(Cl)c1)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 15.5 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001246 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 26 N-(2-chloro-6-fluorobenzyl)-1-((2-chlorothiazol-5-yl)methyl)-N-methylpiperidin-4-amine CN(Cc1c(F)cccc1Cl)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 9.8 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001247 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 27 1-((2-Chlorothiazol-5-yl)methyl)-N-(2,4-dichlorobenzyl)-N-methylpiperidin-4-amine CN(Cc1ccc(Cl)cc1Cl)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 47.1 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001248 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 28 1-((2-Chlorothiazol-5-yl)methyl)-N-methyl-N-(2-methylbenzyl)piperidin-4-amine CN(Cc1ccccc1C)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 9.7 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001249 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 29 1-((2-Chlorothiazol-5-yl)methyl)-N-methyl-N-(4-methylbenzyl)piperidin-4-amine CN(Cc1ccc(C)cc1)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 26.2 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001250 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 30 1-((2-Chlorothiazol-5-yl)methyl)-N-(3-fluorobenzyl)-N-methylpiperidin-4-amine CN(Cc1cccc(F)c1)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 4.2 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001251 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 31 1-((2-Chlorothiazol-5-yl)methyl)-N-(2,6-dichlorobenzyl)-N-methylpiperidin-4-amine CN(Cc1c(Cl)cccc1Cl)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 37.8 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001252 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 32 1-((2-Chlorothiazol-5-yl)methyl)-N-(3,4-dichlorobenzyl)piperidin-4-amine Clc1sc(CN2CCC(CC2)NCc3ccc(Cl)c(Cl)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 26.3 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001253 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 33 1-((2-Chlorothiazol-5-yl)methyl)-N-(4-fluorobenzyl)piperidin-4-amine Fc1ccc(CNC2CCN(CC2)Cc3sc(Cl)nc3)cc1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 37.8 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001254 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 34 N-(3-chlorobenzyl)-1-((2-chlorothiazol-5-yl)methyl)piperidin-4-amine Clc1sc(CN2CCC(CC2)NCc3cccc(Cl)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 17.9 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001255 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 35 N-(4-fluorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(F)cc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 31.5 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001256 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 36 4-((Methyl(1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-yl)amino)methyl) benzonitrile CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(cc3)C#N Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 83.4 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001257 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 37 N-(2-chloro-6-fluorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3c(F)cccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 78.9 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001258 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 38 N-(3,4-dichlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 30.1 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001259 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 39 N-(3-chlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3cccc(Cl)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 26.4 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001260 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 40 N-(2,4-dichlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(Cl)cc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 87.6 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001261 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 41 2-((Methyl(1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-yl)amino)methyl) benzonitrile CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccccc3C#N Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 87.6 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001262 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 42 N-methyl-N-(4-methylbenzyl)-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(C)cc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 38.9 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001263 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 47 N-(2-chlorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 41.4 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001264 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 44 N-(2,5-dichlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 19.3 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001265 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 45 N-(3-fluorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3cccc(F)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 32.6 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001266 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 46 N-(2-chlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 22.2 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001267 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 43 N-(2,6-dichlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3c(Cl)cccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 85.9 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001268 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 48 4-(((1-(2-Methoxypyrimidin-4-yl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(cc3)C#N Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 31.7 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001269 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 49 2-(((1-(2-Methoxypyrimidin-4-yl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccccc3C#N Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 86.5 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001270 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 50 1-(2-Methoxypyrimidin-4-yl)-N-methyl-N-(4-methylbenzyl)piperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(C)cc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 19.7 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001271 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 51 N-(2,5-dichlorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 24.7 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001272 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 52 N-(3,4-dichlorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 27.7 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001273 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 53 N-(2-chloro-6-fluorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3c(F)cccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 27.7 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001274 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 54 N-(3-chlorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3cccc(Cl)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 18.5 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001275 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 55 N-(3-fluorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3cccc(F)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 9.2 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001276 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 56 N-(4-fluorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(F)cc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 14.4 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001277 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 57 N-(2-chlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 13.5 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001278 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 58 1-(6-Methoxypyrimidin-4-yl)-N-methyl-N-(4-methylbenzyl)piperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccc(C)cc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 20.6 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001279 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 59 N-(2,6-dichlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3c(Cl)cccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 22.8 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001280 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 60 N-(3,4-dichlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 16.1 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001281 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 61 N-(4-fluorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccc(F)cc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 7.6 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001282 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 62 N-(3-chlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3cccc(Cl)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 12.6 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001283 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 63 N-(2-chloro-6-fluorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3c(F)cccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 15.5 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001284 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 64 2-(((1-(6-Methoxypyrimidin-4-yl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccccc3C#N Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 23.3 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001285 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 65 4-(((1-(6-Methoxypyrimidin-4-yl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccc(cc3)C#N Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 17.3 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001286 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 66 N-(2,5-dichlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 29.2 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001287 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 67 N-(2,5-dichlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 5.2 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001288 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity Lapatinib N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 10.4 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001289 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 1 N-(3-Chlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3cccc(Cl)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 5.2 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001290 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 2 2-(((1-((2-Ethoxythiazol-5-yl)methyl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile CCOc1sc(CN2CCC(CC2)N(C)Cc3ccccc3C#N)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 7.2 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001291 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 3 N-(3,4-dichlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 13.1 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001292 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 4 4-(((1-((2-Ethoxythiazol-5-yl)methyl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile CCOc1sc(CN2CCC(CC2)N(C)Cc3ccc(cc3)C#N)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 6.7 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001293 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 5 N-(2-chloro-6-fluorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3c(F)cccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 11.7 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001294 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 6 N-(2-chlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3ccccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 0.6 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001295 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 7 1-((2-Ethoxythiazol-5-yl)methyl)-N-(4-fluorobenzyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3ccc(F)cc3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 25.1 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001296 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 8 N-(2,4-dichlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3ccc(Cl)cc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 12 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001297 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 9 N-(2,6-dichlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3c(Cl)cccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 5.1 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001298 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 10 N-(2,5-dichlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 5.2 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001299 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 11 N-methyl-N-(2-methylbenzyl)-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3ccccc3C)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 6.9 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001300 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 12 N-methyl-N-(4-methylbenzyl)-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(C)cc3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 12.1 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001301 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 13 N-(3-fluorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3cccc(F)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 2.1 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001302 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 14 N-(3-chlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3cccc(Cl)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 7.3 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001303 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 15 N-(4-fluorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(F)cc3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 11.7 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001304 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 16 N-(3,4-dichlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 10.1 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001305 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 17 N-(2-chloro-6-fluorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl) piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3c(F)cccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 4.5 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001306 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 18 N-(2,6-dichlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3c(Cl)cccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 26.8 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001307 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 19 N-(2,4-dichlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(Cl)cc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 40.4 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001308 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 20 N-(2,5-dichlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 11.4 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001309 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 21 2-(((1-((2-Chlorothiazol-5-yl)methyl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile CN(Cc1ccccc1C#N)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 4.2 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001310 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 22 4-(((1-((2-Chlorothiazol-5-yl)methyl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile CN(Cc1ccc(cc1)C#N)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 7.5 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001311 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 23 1-((2-Chlorothiazol-5-yl)methyl)-N-(4-fluorobenzyl)-N-methylpiperidin-4-amine CN(Cc1ccc(F)cc1)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA -0.1 Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001312 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 24 1-((2-Chlorothiazol-5-yl)methyl)-N-(3,4-dichlorobenzyl)-N-methylpiperidin-4-amine CN(Cc1ccc(Cl)c(Cl)c1)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 5.3 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001313 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 25 N-(3-chlorobenzyl)-1-((2-chlorothiazol-5-yl)methyl)-N-methylpiperidin-4-amine CN(Cc1cccc(Cl)c1)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 8.5 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001314 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 26 N-(2-chloro-6-fluorobenzyl)-1-((2-chlorothiazol-5-yl)methyl)-N-methylpiperidin-4-amine CN(Cc1c(F)cccc1Cl)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 1.5 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001315 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 27 1-((2-Chlorothiazol-5-yl)methyl)-N-(2,4-dichlorobenzyl)-N-methylpiperidin-4-amine CN(Cc1ccc(Cl)cc1Cl)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 11.4 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001316 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 28 1-((2-Chlorothiazol-5-yl)methyl)-N-methyl-N-(2-methylbenzyl)piperidin-4-amine CN(Cc1ccccc1C)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 5.1 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001317 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 29 1-((2-Chlorothiazol-5-yl)methyl)-N-methyl-N-(4-methylbenzyl)piperidin-4-amine CN(Cc1ccc(C)cc1)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 8.4 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001318 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 30 1-((2-Chlorothiazol-5-yl)methyl)-N-(3-fluorobenzyl)-N-methylpiperidin-4-amine CN(Cc1cccc(F)c1)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 1.3 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001319 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 31 1-((2-Chlorothiazol-5-yl)methyl)-N-(2,6-dichlorobenzyl)-N-methylpiperidin-4-amine CN(Cc1c(Cl)cccc1Cl)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 40.4 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001320 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 32 1-((2-Chlorothiazol-5-yl)methyl)-N-(3,4-dichlorobenzyl)piperidin-4-amine Clc1sc(CN2CCC(CC2)NCc3ccc(Cl)c(Cl)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 25.1 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001321 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 33 1-((2-Chlorothiazol-5-yl)methyl)-N-(4-fluorobenzyl)piperidin-4-amine Fc1ccc(CNC2CCN(CC2)Cc3sc(Cl)nc3)cc1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 40.4 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001322 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 34 N-(3-chlorobenzyl)-1-((2-chlorothiazol-5-yl)methyl)piperidin-4-amine Clc1sc(CN2CCC(CC2)NCc3cccc(Cl)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 4.1 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001323 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 35 N-(4-fluorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(F)cc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 30.9 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001324 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 36 4-((Methyl(1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-yl)amino)methyl) benzonitrile CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(cc3)C#N Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 86.1 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001325 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 37 N-(2-chloro-6-fluorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3c(F)cccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 78.3 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001326 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 38 N-(3,4-dichlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 12.9 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001327 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 39 N-(3-chlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3cccc(Cl)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 24.4 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001328 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 40 N-(2,4-dichlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(Cl)cc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 80.7 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001329 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 41 2-((Methyl(1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-yl)amino)methyl) benzonitrile CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccccc3C#N Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 80.7 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001330 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 42 N-methyl-N-(4-methylbenzyl)-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(C)cc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 42 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001331 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 47 N-(2-chlorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 35.8 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001332 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 44 N-(2,5-dichlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 29.4 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001333 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 45 N-(3-fluorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3cccc(F)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 35.2 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001334 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 46 N-(2-chlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 34.2 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001335 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 43 N-(2,6-dichlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3c(Cl)cccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 71 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001336 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 48 4-(((1-(2-Methoxypyrimidin-4-yl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(cc3)C#N Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 16.6 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001337 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 49 2-(((1-(2-Methoxypyrimidin-4-yl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccccc3C#N Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 74.3 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001338 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 50 1-(2-Methoxypyrimidin-4-yl)-N-methyl-N-(4-methylbenzyl)piperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(C)cc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 13.5 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001339 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 51 N-(2,5-dichlorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 11.7 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001340 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 52 N-(3,4-dichlorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 16.8 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001341 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 53 N-(2-chloro-6-fluorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3c(F)cccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 17.2 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001342 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 54 N-(3-chlorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3cccc(Cl)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 15.1 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001343 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 55 N-(3-fluorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3cccc(F)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 3.9 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001344 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 56 N-(4-fluorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(F)cc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 9 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001345 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 57 N-(2-chlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 29 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001346 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 58 1-(6-Methoxypyrimidin-4-yl)-N-methyl-N-(4-methylbenzyl)piperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccc(C)cc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 22 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001347 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 59 N-(2,6-dichlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3c(Cl)cccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 19.2 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001348 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 60 N-(3,4-dichlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 28 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001349 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 61 N-(4-fluorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccc(F)cc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 5.7 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001350 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 62 N-(3-chlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3cccc(Cl)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 24.8 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001351 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 63 N-(2-chloro-6-fluorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3c(F)cccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 16.6 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001352 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 64 2-(((1-(6-Methoxypyrimidin-4-yl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccccc3C#N Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 16.8 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001353 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 65 4-(((1-(6-Methoxypyrimidin-4-yl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccc(cc3)C#N Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 8.8 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001354 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 66 N-(2,5-dichlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 9.4 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001355 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 67 N-(2,5-dichlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 30.1 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001356 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity Lapatinib N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 42.6 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001357 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 1 N-(3-Chlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3cccc(Cl)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 41.2 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001358 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 2 2-(((1-((2-Ethoxythiazol-5-yl)methyl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile CCOc1sc(CN2CCC(CC2)N(C)Cc3ccccc3C#N)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 43.8 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001359 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 3 N-(3,4-dichlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 71.6 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001360 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 4 4-(((1-((2-Ethoxythiazol-5-yl)methyl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile CCOc1sc(CN2CCC(CC2)N(C)Cc3ccc(cc3)C#N)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 70.5 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001361 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 5 N-(2-chloro-6-fluorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3c(F)cccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 67.4 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001362 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 6 N-(2-chlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3ccccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 36.4 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001363 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 7 1-((2-Ethoxythiazol-5-yl)methyl)-N-(4-fluorobenzyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3ccc(F)cc3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 52.9 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001364 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 8 N-(2,4-dichlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3ccc(Cl)cc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 71.3 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001365 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 9 N-(2,6-dichlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3c(Cl)cccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 51.5 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001366 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 10 N-(2,5-dichlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 23.9 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001367 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 11 N-methyl-N-(2-methylbenzyl)-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3ccccc3C)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 35.1 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001368 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 12 N-methyl-N-(4-methylbenzyl)-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(C)cc3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 67.1 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001369 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 13 N-(3-fluorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3cccc(F)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 44.2 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001370 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 14 N-(3-chlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3cccc(Cl)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 62.3 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001371 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 15 N-(4-fluorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(F)cc3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 67.4 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001372 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 16 N-(3,4-dichlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 69.9 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001373 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 17 N-(2-chloro-6-fluorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl) piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3c(F)cccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 65.3 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001374 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 18 N-(2,6-dichlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3c(Cl)cccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 63.7 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001375 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 19 N-(2,4-dichlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(Cl)cc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 72.4 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001376 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 20 N-(2,5-dichlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 59.4 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001377 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 21 2-(((1-((2-Chlorothiazol-5-yl)methyl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile CN(Cc1ccccc1C#N)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 8.2 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001378 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 22 4-(((1-((2-Chlorothiazol-5-yl)methyl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile CN(Cc1ccc(cc1)C#N)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 68.5 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001379 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 23 1-((2-Chlorothiazol-5-yl)methyl)-N-(4-fluorobenzyl)-N-methylpiperidin-4-amine CN(Cc1ccc(F)cc1)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 11 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001380 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 24 1-((2-Chlorothiazol-5-yl)methyl)-N-(3,4-dichlorobenzyl)-N-methylpiperidin-4-amine CN(Cc1ccc(Cl)c(Cl)c1)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 63.8 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001381 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 25 N-(3-chlorobenzyl)-1-((2-chlorothiazol-5-yl)methyl)-N-methylpiperidin-4-amine CN(Cc1cccc(Cl)c1)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 12.6 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001382 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 26 N-(2-chloro-6-fluorobenzyl)-1-((2-chlorothiazol-5-yl)methyl)-N-methylpiperidin-4-amine CN(Cc1c(F)cccc1Cl)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 22.4 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001383 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 27 1-((2-Chlorothiazol-5-yl)methyl)-N-(2,4-dichlorobenzyl)-N-methylpiperidin-4-amine CN(Cc1ccc(Cl)cc1Cl)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 60.8 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001384 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 28 1-((2-Chlorothiazol-5-yl)methyl)-N-methyl-N-(2-methylbenzyl)piperidin-4-amine CN(Cc1ccccc1C)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 3.5 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001385 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 29 1-((2-Chlorothiazol-5-yl)methyl)-N-methyl-N-(4-methylbenzyl)piperidin-4-amine CN(Cc1ccc(C)cc1)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 29.6 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001386 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 30 1-((2-Chlorothiazol-5-yl)methyl)-N-(3-fluorobenzyl)-N-methylpiperidin-4-amine CN(Cc1cccc(F)c1)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 4.4 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001387 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 31 1-((2-Chlorothiazol-5-yl)methyl)-N-(2,6-dichlorobenzyl)-N-methylpiperidin-4-amine CN(Cc1c(Cl)cccc1Cl)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 72.4 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001388 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 32 1-((2-Chlorothiazol-5-yl)methyl)-N-(3,4-dichlorobenzyl)piperidin-4-amine Clc1sc(CN2CCC(CC2)NCc3ccc(Cl)c(Cl)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 32.9 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001389 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 33 1-((2-Chlorothiazol-5-yl)methyl)-N-(4-fluorobenzyl)piperidin-4-amine Fc1ccc(CNC2CCN(CC2)Cc3sc(Cl)nc3)cc1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 72.4 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001390 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 34 N-(3-chlorobenzyl)-1-((2-chlorothiazol-5-yl)methyl)piperidin-4-amine Clc1sc(CN2CCC(CC2)NCc3cccc(Cl)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 2.4 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001391 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 35 N-(4-fluorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(F)cc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 82.3 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001392 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 36 4-((Methyl(1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-yl)amino)methyl) benzonitrile CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(cc3)C#N Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 82.4 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001393 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 37 N-(2-chloro-6-fluorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3c(F)cccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 84.2 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001394 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 38 N-(3,4-dichlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 60 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001395 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 39 N-(3-chlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3cccc(Cl)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 65.7 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001396 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 40 N-(2,4-dichlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(Cl)cc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 68.7 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001397 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 41 2-((Methyl(1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-yl)amino)methyl) benzonitrile CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccccc3C#N Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 68.7 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001398 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 42 N-methyl-N-(4-methylbenzyl)-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(C)cc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 66.6 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001399 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 47 N-(2-chlorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 60.8 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001400 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 44 N-(2,5-dichlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 69.3 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001401 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 45 N-(3-fluorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3cccc(F)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 66.2 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001402 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 46 N-(2-chlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 45.3 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001403 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 43 N-(2,6-dichlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3c(Cl)cccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 79.2 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001404 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 48 4-(((1-(2-Methoxypyrimidin-4-yl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(cc3)C#N Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 66.2 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001405 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 49 2-(((1-(2-Methoxypyrimidin-4-yl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccccc3C#N Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 79.5 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001406 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 50 1-(2-Methoxypyrimidin-4-yl)-N-methyl-N-(4-methylbenzyl)piperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(C)cc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 68.9 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001407 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 51 N-(2,5-dichlorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 50.6 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001408 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 52 N-(3,4-dichlorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 60.2 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001409 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 53 N-(2-chloro-6-fluorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3c(F)cccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 64.7 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001410 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 54 N-(3-chlorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3cccc(Cl)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 56.7 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001411 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 55 N-(3-fluorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3cccc(F)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 27.9 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001412 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 56 N-(4-fluorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(F)cc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 40.4 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001413 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 57 N-(2-chlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 46.7 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001414 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 58 1-(6-Methoxypyrimidin-4-yl)-N-methyl-N-(4-methylbenzyl)piperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccc(C)cc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 13.4 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001415 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 59 N-(2,6-dichlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3c(Cl)cccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 65.1 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001416 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 60 N-(3,4-dichlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 12.7 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001417 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 61 N-(4-fluorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccc(F)cc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 5 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001418 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 62 N-(3-chlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3cccc(Cl)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 23.8 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001419 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 63 N-(2-chloro-6-fluorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3c(F)cccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 59.4 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001420 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 64 2-(((1-(6-Methoxypyrimidin-4-yl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccccc3C#N Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 66.1 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001421 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 65 4-(((1-(6-Methoxypyrimidin-4-yl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccc(cc3)C#N Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 46.1 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001422 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 66 N-(2,5-dichlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 61.1 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001423 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 67 N-(2,5-dichlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 9.4 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001424 25935385 Hsp70 Hsp70 Human Cytosol Binding affinity NA VER-155008 4-[[(2R,3S,4R,5R)-5-[6-amino-8-[(3,4-dichlorophenyl)methylamino]purin-9-yl]-3,4-dihydroxyoxolan-2-yl]methoxymethyl]benzonitrile Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc5ccc(Cl)c(Cl)c5)nc12 Piperidine derivative NA 0.206 NA NA NA NA NA NA Nucleotide binding domain (allosteric site) Surface plasmon resonance (SPR) NA NA NA NA NA NA Cancer HSPMDB001425 25935385 Hsp70 Hsp70 Human Cytosol Binding affinity NA 12 N-methyl-N-(4-methylbenzyl)-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(C)cc3)cn1 Piperidine derivative NA 0.1999 NA NA NA NA NA NA Nucleotide binding domain (allosteric site) Surface plasmon resonance (SPR) NA NA NA NA NA NA Cancer HSPMDB001426 25935385 Hsp70 Hsp70 Human Cytosol Binding affinity NA 14 N-(3-chlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3cccc(Cl)c3)cn1 Piperidine derivative NA 2.454 NA NA NA NA NA NA Nucleotide binding domain (allosteric site) Surface plasmon resonance (SPR) NA NA NA NA NA NA Cancer HSPMDB001427 25935385 Hsp70 Hsp70 Human Cytosol Binding affinity NA 35 N-(4-fluorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(F)cc3 Piperidine derivative NA 2.045 NA NA NA NA NA NA Nucleotide binding domain (allosteric site) Surface plasmon resonance (SPR) NA NA NA NA NA NA Cancer HSPMDB001428 25935385 Hsp70 Hsp70 Human Cytosol Binding affinity NA 36 4-((Methyl(1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-yl)amino)methyl) benzonitrile CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(cc3)C#N Piperidine derivative NA 0.2463 NA NA NA NA NA NA Nucleotide binding domain (allosteric site) Surface plasmon resonance (SPR) NA NA NA NA NA NA Cancer HSPMDB001429 25935385 Hsp70 Hsp70 Human Cytosol Binding affinity NA 56 N-(4-fluorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(F)cc3 Piperidine derivative NA 2.811 NA NA NA NA NA NA Nucleotide binding domain (allosteric site) Surface plasmon resonance (SPR) NA NA NA NA NA NA Cancer HSPMDB001430 25935385 Hsp70 DnaK:DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA 4 4-(((1-((2-Ethoxythiazol-5-yl)methyl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile CCOc1sc(CN2CCC(CC2)N(C)Cc3ccc(cc3)C#N)cn1 Piperidine derivative 5.49% at 200 uM NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) ATPase assay NA NA NA NA NA NA Bacterial infection HSPMDB001431 25935385 Hsp70 DnaK:DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA 8 N-(2,4-dichlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3ccc(Cl)cc3Cl)cn1 Piperidine derivative 4.5% at 200 uM NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) ATPase assay NA NA NA NA NA NA Bacterial infection HSPMDB001432 25935385 Hsp70 DnaK:DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA 12 N-methyl-N-(4-methylbenzyl)-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(C)cc3)cn1 Piperidine derivative 10.59% at 200 uM NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) ATPase assay NA NA NA NA NA NA Bacterial infection HSPMDB001433 25935385 Hsp70 DnaK:DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA 16 N-(3,4-dichlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3)cn1 Piperidine derivative 10.74% at 200 uM NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) ATPase assay NA NA NA NA NA NA Bacterial infection HSPMDB001434 25935385 Hsp70 DnaK:DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA 19 N-(2,4-dichlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(Cl)cc3Cl)cn1 Piperidine derivative 6.21% at 200 uM NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) ATPase assay NA NA NA NA NA NA Bacterial infection HSPMDB001435 25935385 Hsp70 DnaK:DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA 22 4-(((1-((2-Chlorothiazol-5-yl)methyl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile CN(Cc1ccc(cc1)C#N)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative 11.28% at 200 uM NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) ATPase assay NA NA NA NA NA NA Bacterial infection HSPMDB001436 25935385 Hsp70 DnaK:DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA 35 N-(4-fluorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(F)cc3 Piperidine derivative 7.73% at 200 uM NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) ATPase assay NA NA NA NA NA NA Bacterial infection HSPMDB001437 25935385 Hsp70 DnaK:DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA 36 4-((Methyl(1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-yl)amino)methyl) benzonitrile CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(cc3)C#N Piperidine derivative 8.14% at 200 uM NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) ATPase assay NA NA NA NA NA NA Bacterial infection HSPMDB001438 25935385 Hsp70 DnaK:DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA 37 N-(2-chloro-6-fluorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3c(F)cccc3Cl Piperidine derivative 20.39% at 200 uM NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) ATPase assay NA NA NA NA NA NA Bacterial infection HSPMDB001439 25935385 Hsp70 DnaK:DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA 40 N-(2,4-dichlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(Cl)cc3Cl Piperidine derivative 8.28% at 200 uM NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) ATPase assay NA NA NA NA NA NA Bacterial infection HSPMDB001440 25935385 Hsp70 DnaK:DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA 41 2-((Methyl(1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-yl)amino)methyl) benzonitrile CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccccc3C#N Piperidine derivative 16.67% at 200 uM NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) ATPase assay NA NA NA NA NA NA Bacterial infection HSPMDB001441 25935385 Hsp70 DnaK:DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA 43 N-(2,6-dichlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3c(Cl)cccc3Cl Piperidine derivative 12.81% at 200 uM NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) ATPase assay NA NA NA NA NA NA Bacterial infection HSPMDB001442 25935385 Hsp70 DnaK:DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA 46 N-(2-chlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccccc3Cl Piperidine derivative 11.63% at 200 uM NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) ATPase assay NA NA NA NA NA NA Bacterial infection HSPMDB001443 25935385 Hsp70 DnaK:DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA 47 N-(2-chlorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccccc3Cl Piperidine derivative 6.11% at 200 uM NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) ATPase assay NA NA NA NA NA NA Bacterial infection HSPMDB001444 28615625 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity Az 4-[[2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)imidazol-1-yl]methyl]benzamide COc1ccc(cc1)c2nc(n(Cc3ccc(cc3)C(N)=O)c2c4ccc(OC)cc4)c5cc(cc(c5)C(F)(F)F)C(F)(F)F Piperidine derivative NA NA NA 2.8 NA NA NA NA Nucleotide binding domain NA NA MTT viability assay NA NA NA HL60 Cancer HSPMDB001445 28615625 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity Az-GA (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-({2-[2-(2-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}ethoxy)ethoxy]ethyl}amino)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate CO[C@H]1C[C@H](C)CC2=C(NCCOCCOCCNC(=O)C3=CC=C(CN4C(=NC(=C4C4=CC=C(OC)C=C4)C4=CC=C(OC)C=C4)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C=C3)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O Hybrid of HSP70 and HSP90 inhibitor NA NA NA 0.73 NA NA NA NA Nucleotide binding domain NA NA MTT viability assay NA NA NA HL60 Cancer HSPMDB001446 28615625 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity Az-O3-GD (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-(16-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}-5,9,13-trioxa-1-azahexadecan-1-yl)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate CO[C@H]1C[C@H](C)CC2=C(NCCCOCCCOCCCOCCCNC(=O)C3=CC=C(CN4C(=NC(=C4C4=CC=C(OC)C=C4)C4=CC=C(OC)C=C4)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C=C3)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O Hybrid of HSP70 and HSP90 inhibitor NA NA NA 0.74 NA NA NA NA Nucleotide binding domain NA NA MTT viability assay NA NA NA HL60 Cancer HSPMDB001447 28615625 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity Az-amide-GD (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-[13-({2-[2-(2-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}ethoxy)ethoxy]ethyl}carbamoyl)-4,8,12-trioxa-1-azatridecan-1-yl]-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate CO[C@H]1C[C@H](C)CC2=C(NCCOCCCOCCCOCC(=O)NCCOCCOCCNC(=O)C3=CC=C(CN4C(=NC(=C4C4=CC=C(OC)C=C4)C4=CC=C(OC)C=C4)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C=C3)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O Hybrid of HSP70 and HSP90 inhibitor NA NA NA >10 NA NA NA NA Nucleotide binding domain NA NA MTT viability assay NA NA NA HL60 Cancer HSPMDB001448 28615625 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity Az-O3-Imatinib 4-{[4-(2-{[(2-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}ethoxy)methoxy]methoxy}ethyl)piperazin-1-yl]methyl}-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide COC1=CC=C(C=C1)C1=C(N(CC2=CC=C(C=C2)C(=O)NCCOCOCOCCN2CCN(CC3=CC=C(C=C3)C(=O)NC3=CC(NC4=NC(=CC=N4)C4=CC=CN=C4)=C(C)C=C3)CC2)C(=N1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)C1=CC=C(OC)C=C1 Hybrid of HSP70 and HSP90 inhibitor NA NA NA >10 NA NA NA NA Nucleotide binding domain NA NA MTT viability assay NA NA NA HL60 Cancer HSPMDB001449 28615625 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity Az-O4-Imatinib 4-{[4-(11-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}-3,5,7,9-tetraoxaundecan-1-yl)piperazin-1-yl]methyl}-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide COC1=CC=C(C=C1)C1=C(N(CC2=CC=C(C=C2)C(=O)NCCOCOCOCOCCN2CCN(CC3=CC=C(C=C3)C(=O)NC3=CC(NC4=NC(=CC=N4)C4=CC=CN=C4)=C(C)C=C3)CC2)C(=N1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)C1=CC=C(OC)C=C1 Hybrid of HSP70 and HSP90 inhibitor NA NA NA >10 NA NA NA NA Nucleotide binding domain NA NA MTT viability assay NA NA NA HL60 Cancer HSPMDB001450 28615625 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity Az 4-[[2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)imidazol-1-yl]methyl]benzamide COc1ccc(cc1)c2nc(n(Cc3ccc(cc3)C(N)=O)c2c4ccc(OC)cc4)c5cc(cc(c5)C(F)(F)F)C(F)(F)F Imidazole derivative NA NA NA 3.3 NA NA NA NA Nucleotide binding domain NA NA MTT viability assay NA NA NA KG-1 Cancer HSPMDB001451 28615625 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity Az-GA (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-({2-[2-(2-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}ethoxy)ethoxy]ethyl}amino)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate CO[C@H]1C[C@H](C)CC2=C(NCCOCCOCCNC(=O)C3=CC=C(CN4C(=NC(=C4C4=CC=C(OC)C=C4)C4=CC=C(OC)C=C4)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C=C3)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O Hybrid of HSP70 and HSP90 inhibitor NA NA NA 0.91 NA NA NA NA Nucleotide binding domain NA NA MTT viability assay NA NA NA KG-1 Cancer HSPMDB001452 28615625 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity Az-O3-GD (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-(16-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}-5,9,13-trioxa-1-azahexadecan-1-yl)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate CO[C@H]1C[C@H](C)CC2=C(NCCCOCCCOCCCOCCCNC(=O)C3=CC=C(CN4C(=NC(=C4C4=CC=C(OC)C=C4)C4=CC=C(OC)C=C4)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C=C3)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O Hybrid of HSP70 and HSP90 inhibitor NA NA NA 1.31 NA NA NA NA Nucleotide binding domain NA NA MTT viability assay NA NA NA KG-1 Cancer HSPMDB001453 28615625 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity Az-amide-GD (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-[13-({2-[2-(2-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}ethoxy)ethoxy]ethyl}carbamoyl)-4,8,12-trioxa-1-azatridecan-1-yl]-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate CO[C@H]1C[C@H](C)CC2=C(NCCOCCCOCCCOCC(=O)NCCOCCOCCNC(=O)C3=CC=C(CN4C(=NC(=C4C4=CC=C(OC)C=C4)C4=CC=C(OC)C=C4)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C=C3)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O Hybrid of HSP70 and HSP90 inhibitor NA NA NA >10 NA NA NA NA Nucleotide binding domain NA NA MTT viability assay NA NA NA KG-1 Cancer HSPMDB001454 28615625 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity Az-O3-Imatinib 4-{[4-(2-{[(2-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}ethoxy)methoxy]methoxy}ethyl)piperazin-1-yl]methyl}-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide COC1=CC=C(C=C1)C1=C(N(CC2=CC=C(C=C2)C(=O)NCCOCOCOCCN2CCN(CC3=CC=C(C=C3)C(=O)NC3=CC(NC4=NC(=CC=N4)C4=CC=CN=C4)=C(C)C=C3)CC2)C(=N1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)C1=CC=C(OC)C=C1 Hybrid of HSP70 and HSP90 inhibitor NA NA NA >10 NA NA NA NA Nucleotide binding domain NA NA MTT viability assay NA NA NA KG-1 Cancer HSPMDB001455 28615625 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity Az-O4-Imatinib 4-{[4-(11-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}-3,5,7,9-tetraoxaundecan-1-yl)piperazin-1-yl]methyl}-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide COC1=CC=C(C=C1)C1=C(N(CC2=CC=C(C=C2)C(=O)NCCOCOCOCOCCN2CCN(CC3=CC=C(C=C3)C(=O)NC3=CC(NC4=NC(=CC=N4)C4=CC=CN=C4)=C(C)C=C3)CC2)C(=N1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)C1=CC=C(OC)C=C1 Hybrid of HSP70 and HSP90 inhibitor NA NA NA >10 NA NA NA NA Nucleotide binding domain NA NA MTT viability assay NA NA NA KG-1 Cancer HSPMDB001456 28615625 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity Az 4-[[2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)imidazol-1-yl]methyl]benzamide COc1ccc(cc1)c2nc(n(Cc3ccc(cc3)C(N)=O)c2c4ccc(OC)cc4)c5cc(cc(c5)C(F)(F)F)C(F)(F)F Imidazole derivative NA NA NA 3.7 NA NA NA NA Nucleotide binding domain NA NA MTT viability assay NA NA NA THP1 Cancer HSPMDB001457 28615625 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity Az-GA (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-({2-[2-(2-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}ethoxy)ethoxy]ethyl}amino)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate CO[C@H]1C[C@H](C)CC2=C(NCCOCCOCCNC(=O)C3=CC=C(CN4C(=NC(=C4C4=CC=C(OC)C=C4)C4=CC=C(OC)C=C4)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C=C3)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O Hybrid of HSP70 and HSP90 inhibitor NA NA NA 0.36 NA NA NA NA Nucleotide binding domain NA NA MTT viability assay NA NA NA THP1 Cancer HSPMDB001458 28615625 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity Az-O3-GD (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-(16-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}-5,9,13-trioxa-1-azahexadecan-1-yl)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate CO[C@H]1C[C@H](C)CC2=C(NCCCOCCCOCCCOCCCNC(=O)C3=CC=C(CN4C(=NC(=C4C4=CC=C(OC)C=C4)C4=CC=C(OC)C=C4)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C=C3)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O Hybrid of HSP70 and HSP90 inhibitor NA NA NA 0.62 NA NA NA NA Nucleotide binding domain NA NA MTT viability assay NA NA NA THP1 Cancer HSPMDB001459 28615625 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity Az-amide-GD (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-[13-({2-[2-(2-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}ethoxy)ethoxy]ethyl}carbamoyl)-4,8,12-trioxa-1-azatridecan-1-yl]-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate CO[C@H]1C[C@H](C)CC2=C(NCCOCCCOCCCOCC(=O)NCCOCCOCCNC(=O)C3=CC=C(CN4C(=NC(=C4C4=CC=C(OC)C=C4)C4=CC=C(OC)C=C4)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C=C3)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O Hybrid of HSP70 and HSP90 inhibitor NA NA NA >10 NA NA NA NA Nucleotide binding domain NA NA MTT viability assay NA NA NA THP1 Cancer HSPMDB001460 28615625 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity Az-O3-Imatinib 4-{[4-(2-{[(2-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}ethoxy)methoxy]methoxy}ethyl)piperazin-1-yl]methyl}-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide COC1=CC=C(C=C1)C1=C(N(CC2=CC=C(C=C2)C(=O)NCCOCOCOCCN2CCN(CC3=CC=C(C=C3)C(=O)NC3=CC(NC4=NC(=CC=N4)C4=CC=CN=C4)=C(C)C=C3)CC2)C(=N1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)C1=CC=C(OC)C=C1 Hybrid of HSP70 and HSP90 inhibitor NA NA NA >10 NA NA NA NA Nucleotide binding domain NA NA MTT viability assay NA NA NA THP1 Cancer HSPMDB001461 28615625 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity Az-O4-Imatinib 4-{[4-(11-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}-3,5,7,9-tetraoxaundecan-1-yl)piperazin-1-yl]methyl}-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide COC1=CC=C(C=C1)C1=C(N(CC2=CC=C(C=C2)C(=O)NCCOCOCOCOCCN2CCN(CC3=CC=C(C=C3)C(=O)NC3=CC(NC4=NC(=CC=N4)C4=CC=CN=C4)=C(C)C=C3)CC2)C(=N1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)C1=CC=C(OC)C=C1 Hybrid of HSP70 and HSP90 inhibitor NA NA NA >10 NA NA NA NA Nucleotide binding domain NA NA MTT viability assay NA NA NA THP1 Cancer HSPMDB001462 28615625 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity Az 4-[[2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)imidazol-1-yl]methyl]benzamide COc1ccc(cc1)c2nc(n(Cc3ccc(cc3)C(N)=O)c2c4ccc(OC)cc4)c5cc(cc(c5)C(F)(F)F)C(F)(F)F Imidazole derivative NA NA NA 4.7 NA NA NA NA Nucleotide binding domain NA NA MTT viability assay NA NA NA U937 Cancer HSPMDB001463 28615625 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity Az-GA (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-({2-[2-(2-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}ethoxy)ethoxy]ethyl}amino)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate CO[C@H]1C[C@H](C)CC2=C(NCCOCCOCCNC(=O)C3=CC=C(CN4C(=NC(=C4C4=CC=C(OC)C=C4)C4=CC=C(OC)C=C4)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C=C3)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O Hybrid of HSP70 and HSP90 inhibitor NA NA NA 1.12 NA NA NA NA Nucleotide binding domain NA NA MTT viability assay NA NA NA U937 Cancer HSPMDB001464 28615625 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity Az-O3-GD (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-(16-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}-5,9,13-trioxa-1-azahexadecan-1-yl)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate CO[C@H]1C[C@H](C)CC2=C(NCCCOCCCOCCCOCCCNC(=O)C3=CC=C(CN4C(=NC(=C4C4=CC=C(OC)C=C4)C4=CC=C(OC)C=C4)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C=C3)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O Hybrid of HSP70 and HSP90 inhibitor NA NA NA 1.12 NA NA NA NA Nucleotide binding domain NA NA MTT viability assay NA NA NA U937 Cancer HSPMDB001465 28615625 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity Az-amide-GD (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-[13-({2-[2-(2-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}ethoxy)ethoxy]ethyl}carbamoyl)-4,8,12-trioxa-1-azatridecan-1-yl]-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate CO[C@H]1C[C@H](C)CC2=C(NCCOCCCOCCCOCC(=O)NCCOCCOCCNC(=O)C3=CC=C(CN4C(=NC(=C4C4=CC=C(OC)C=C4)C4=CC=C(OC)C=C4)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C=C3)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O Hybrid of HSP70 and HSP90 inhibitor NA NA NA >10 NA NA NA NA Nucleotide binding domain NA NA MTT viability assay NA NA NA U937 Cancer HSPMDB001466 28615625 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity Az-O3-Imatinib 4-{[4-(2-{[(2-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}ethoxy)methoxy]methoxy}ethyl)piperazin-1-yl]methyl}-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide COC1=CC=C(C=C1)C1=C(N(CC2=CC=C(C=C2)C(=O)NCCOCOCOCCN2CCN(CC3=CC=C(C=C3)C(=O)NC3=CC(NC4=NC(=CC=N4)C4=CC=CN=C4)=C(C)C=C3)CC2)C(=N1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)C1=CC=C(OC)C=C1 Hybrid of HSP70 and HSP90 inhibitor NA NA NA >10 NA NA NA NA Nucleotide binding domain NA NA MTT viability assay NA NA NA U937 Cancer HSPMDB001467 28615625 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity Az-O4-Imatinib 4-{[4-(11-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}-3,5,7,9-tetraoxaundecan-1-yl)piperazin-1-yl]methyl}-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide COC1=CC=C(C=C1)C1=C(N(CC2=CC=C(C=C2)C(=O)NCCOCOCOCOCCN2CCN(CC3=CC=C(C=C3)C(=O)NC3=CC(NC4=NC(=CC=N4)C4=CC=CN=C4)=C(C)C=C3)CC2)C(=N1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)C1=CC=C(OC)C=C1 Hybrid of HSP70 and HSP90 inhibitor NA NA NA >10 NA NA NA NA Nucleotide binding domain NA NA MTT viability assay NA NA NA U937 Cancer HSPMDB001468 28615625 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity Az 4-[[2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)imidazol-1-yl]methyl]benzamide COc1ccc(cc1)c2nc(n(Cc3ccc(cc3)C(N)=O)c2c4ccc(OC)cc4)c5cc(cc(c5)C(F)(F)F)C(F)(F)F Imidazole derivative NA NA NA 3.1 NA NA NA NA Nucleotide binding domain NA NA MTT viability assay NA NA NA Jurkat Cancer HSPMDB001469 28615625 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity Az-GA (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-({2-[2-(2-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}ethoxy)ethoxy]ethyl}amino)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate CO[C@H]1C[C@H](C)CC2=C(NCCOCCOCCNC(=O)C3=CC=C(CN4C(=NC(=C4C4=CC=C(OC)C=C4)C4=CC=C(OC)C=C4)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C=C3)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O Hybrid of HSP70 and HSP90 inhibitor NA NA NA 0.89 NA NA NA NA Nucleotide binding domain NA NA MTT viability assay NA NA NA Jurkat Cancer HSPMDB001470 28615625 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity Az-O3-GD (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-(16-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}-5,9,13-trioxa-1-azahexadecan-1-yl)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate CO[C@H]1C[C@H](C)CC2=C(NCCCOCCCOCCCOCCCNC(=O)C3=CC=C(CN4C(=NC(=C4C4=CC=C(OC)C=C4)C4=CC=C(OC)C=C4)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C=C3)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O Hybrid of HSP70 and HSP90 inhibitor NA NA NA 0.57 NA NA NA NA Nucleotide binding domain NA NA MTT viability assay NA NA NA Jurkat Cancer HSPMDB001471 28615625 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity Az-amide-GD (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-[13-({2-[2-(2-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}ethoxy)ethoxy]ethyl}carbamoyl)-4,8,12-trioxa-1-azatridecan-1-yl]-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate CO[C@H]1C[C@H](C)CC2=C(NCCOCCCOCCCOCC(=O)NCCOCCOCCNC(=O)C3=CC=C(CN4C(=NC(=C4C4=CC=C(OC)C=C4)C4=CC=C(OC)C=C4)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C=C3)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O Hybrid of HSP70 and HSP90 inhibitor NA NA NA >10 NA NA NA NA Nucleotide binding domain NA NA MTT viability assay NA NA NA Jurkat Cancer HSPMDB001472 28615625 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity Az-O3-Imatinib 4-{[4-(2-{[(2-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}ethoxy)methoxy]methoxy}ethyl)piperazin-1-yl]methyl}-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide COC1=CC=C(C=C1)C1=C(N(CC2=CC=C(C=C2)C(=O)NCCOCOCOCCN2CCN(CC3=CC=C(C=C3)C(=O)NC3=CC(NC4=NC(=CC=N4)C4=CC=CN=C4)=C(C)C=C3)CC2)C(=N1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)C1=CC=C(OC)C=C1 Hybrid of HSP70 and HSP90 inhibitor NA NA NA >10 NA NA NA NA Nucleotide binding domain NA NA MTT viability assay NA NA NA Jurkat Cancer HSPMDB001473 28615625 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity Az-O4-Imatinib 4-{[4-(11-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}-3,5,7,9-tetraoxaundecan-1-yl)piperazin-1-yl]methyl}-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide COC1=CC=C(C=C1)C1=C(N(CC2=CC=C(C=C2)C(=O)NCCOCOCOCOCCN2CCN(CC3=CC=C(C=C3)C(=O)NC3=CC(NC4=NC(=CC=N4)C4=CC=CN=C4)=C(C)C=C3)CC2)C(=N1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)C1=CC=C(OC)C=C1 Hybrid of HSP70 and HSP90 inhibitor NA NA NA >10 NA NA NA NA Nucleotide binding domain NA NA MTT viability assay NA NA NA Jurkat Cancer HSPMDB001474 28615625 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity Az 4-[[2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)imidazol-1-yl]methyl]benzamide COc1ccc(cc1)c2nc(n(Cc3ccc(cc3)C(N)=O)c2c4ccc(OC)cc4)c5cc(cc(c5)C(F)(F)F)C(F)(F)F Imidazole derivative NA NA NA 3.6 NA NA NA NA Nucleotide binding domain NA NA MTT viability assay NA NA NA K562 Cancer HSPMDB001475 28615625 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity Az-GA (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-({2-[2-(2-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}ethoxy)ethoxy]ethyl}amino)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate CO[C@H]1C[C@H](C)CC2=C(NCCOCCOCCNC(=O)C3=CC=C(CN4C(=NC(=C4C4=CC=C(OC)C=C4)C4=CC=C(OC)C=C4)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C=C3)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O Hybrid of HSP70 and HSP90 inhibitor NA NA NA 0.63 NA NA NA NA Nucleotide binding domain NA NA MTT viability assay NA NA NA K562 Cancer HSPMDB001476 28615625 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity Az-O3-GD (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-(16-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}-5,9,13-trioxa-1-azahexadecan-1-yl)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate CO[C@H]1C[C@H](C)CC2=C(NCCCOCCCOCCCOCCCNC(=O)C3=CC=C(CN4C(=NC(=C4C4=CC=C(OC)C=C4)C4=CC=C(OC)C=C4)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C=C3)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O Hybrid of HSP70 and HSP90 inhibitor NA NA NA 0.72 NA NA NA NA Nucleotide binding domain NA NA MTT viability assay NA NA NA K562 Cancer HSPMDB001477 28615625 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity Az-amide-GD (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-[13-({2-[2-(2-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}ethoxy)ethoxy]ethyl}carbamoyl)-4,8,12-trioxa-1-azatridecan-1-yl]-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate CO[C@H]1C[C@H](C)CC2=C(NCCOCCCOCCCOCC(=O)NCCOCCOCCNC(=O)C3=CC=C(CN4C(=NC(=C4C4=CC=C(OC)C=C4)C4=CC=C(OC)C=C4)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C=C3)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O Hybrid of HSP70 and HSP90 inhibitor NA NA NA >10 NA NA NA NA Nucleotide binding domain NA NA MTT viability assay NA NA NA K562 Cancer HSPMDB001478 28615625 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity Az-O3-Imatinib 4-{[4-(2-{[(2-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}ethoxy)methoxy]methoxy}ethyl)piperazin-1-yl]methyl}-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide COC1=CC=C(C=C1)C1=C(N(CC2=CC=C(C=C2)C(=O)NCCOCOCOCCN2CCN(CC3=CC=C(C=C3)C(=O)NC3=CC(NC4=NC(=CC=N4)C4=CC=CN=C4)=C(C)C=C3)CC2)C(=N1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)C1=CC=C(OC)C=C1 Hybrid of HSP70 and HSP90 inhibitor NA NA NA 4.3 NA NA NA NA Nucleotide binding domain NA NA MTT viability assay NA NA NA K562 Cancer HSPMDB001479 28615625 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity Az-O4-Imatinib 4-{[4-(11-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}-3,5,7,9-tetraoxaundecan-1-yl)piperazin-1-yl]methyl}-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide COC1=CC=C(C=C1)C1=C(N(CC2=CC=C(C=C2)C(=O)NCCOCOCOCOCCN2CCN(CC3=CC=C(C=C3)C(=O)NC3=CC(NC4=NC(=CC=N4)C4=CC=CN=C4)=C(C)C=C3)CC2)C(=N1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)C1=CC=C(OC)C=C1 Hybrid of HSP70 and HSP90 inhibitor NA NA NA 4.5 NA NA NA NA Nucleotide binding domain NA NA MTT viability assay NA NA NA K562 Cancer HSPMDB001480 20481474 Hsp70 DnaK (Full length) Bacteria Cytosol and membrane Activation of ATPase activity NA 115-7c 4-{5-[(benzyloxy)carbonyl]-4-(2,4-dichlorophenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-1-yl}butanoic acid CC1=C(C(NC(=O)N1CCCC(O)=O)C1=C(Cl)C=C(Cl)C=C1)C(=O)OCC1=CC=CC=C1 Dihydropyrimidine derivative 50% at 100 uM 220 NA NA NA NA NA NA Nucleotide binding domain ATPase assay NA NA NA NA NA NA NA HSPMDB001481 20481474 Hsp70 DnaK (NBD) Bacteria Cytosol and membrane Activation of ATPase activity NA 115-7c 4-{5-[(benzyloxy)carbonyl]-4-(2,4-dichlorophenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-1-yl}butanoic acid CC1=C(C(NC(=O)N1CCCC(O)=O)C1=C(Cl)C=C(Cl)C=C1)C(=O)OCC1=CC=CC=C1 Dihydropyrimidine derivative 2 fold at 100 uM 211 NA NA NA NA NA NA Nucleotide binding domain ATPase assay NA NA NA NA NA NA NA HSPMDB001482 20481474 Hsp70 DnaK Bacteria Cytosol and membrane Activation of chaperone activity NA 115-7c 4-{5-[(benzyloxy)carbonyl]-4-(2,4-dichlorophenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-1-yl}butanoic acid CC1=C(C(NC(=O)N1CCCC(O)=O)C1=C(Cl)C=C(Cl)C=C1)C(=O)OCC1=CC=CC=C1 Dihydropyrimidine derivative 2 fold at 1 uM NA NA NA NA NA NA NA Nucleotide binding domain Refolding assay (luciferase) NA NA NA NA NA NA NA HSPMDB001483 20481474 Hsp70 DnaK-DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity (DnaJ stimulated) NA 116-9e 6-{5-[(benzyloxy)carbonyl]-4-{[1,1'-biphenyl]-4-yl}-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-1-yl}hexanoic acid CC1=C(C(NC(=O)N1CCCCCC(O)=O)C1=CC=C(C=C1)C1=CC=CC=C1)C(=O)OCC1=CC=CC=C1 Dihydropyrimidine derivative 80% NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB010219 11036084 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA NSC-630668-R/1 6-[5-(ethoxycarbonylcarbamoyl)-2,4-dioxopyrimidin-1-yl]hexyl N-[6-[6-[5-(ethoxycarbonylcarbamoyl)-2,4-dioxopyrimidin-1-yl]hexoxycarbonylamino]hexyl]carbamate C(C)OC(=O)NC(=O)C=1C(NC(N(C1)CCCCCCOC(=O)NCCCCCCNC(OCCCCCCN1C(NC(C(=C1)C(NC(=O)OCC)=O)=O)=O)=O)=O)=O DSG analogs 48% NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB010220 11036084 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (DnaJ stimulated) NA NSC-630668-R/1 6-[5-(ethoxycarbonylcarbamoyl)-2,4-dioxopyrimidin-1-yl]hexyl N-[6-[6-[5-(ethoxycarbonylcarbamoyl)-2,4-dioxopyrimidin-1-yl]hexoxycarbonylamino]hexyl]carbamate C(C)OC(=O)NC(=O)C=1C(NC(N(C1)CCCCCCOC(=O)NCCCCCCNC(OCCCCCCN1C(NC(C(=C1)C(NC(=O)OCC)=O)=O)=O)=O)=O)=O DSG analogs 51% NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB010221 8939938 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity NA N-ethylmaleimide 1-ethylpyrrole-2,5-dione CCN1C(=O)C=CC1=O NA 100% after 60 min NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB010222 30452489 Hsp70 Hsp70-HDJ2 Human Cytosol NA Antiproliferative activity 116-9e in combination with Hydroxyurea 6-{5-[(benzyloxy)carbonyl]-4-{[1,1'-biphenyl]-4-yl}-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-1-yl}hexanoic acid CC1=C(C(NC(=O)N1CCCCCC(O)=O)C1=CC=C(C=C1)C1=CC=CC=C1)C(=O)OCC1=CC=CC=C1 Dihydropyrimidine derivative NA NA NA NA NA NA NA NA NA NA 60% at 40uM 116-9e and 100 uM Hydroxyurea Luminescence based viability assay NA NA NA HAP1 cells Cancer HSPMDB010223 30452489 Hsp70 Hsp70-HDJ2 Human Cytosol NA Antiproliferative activity 116-9e in combination with Triapine 6-{5-[(benzyloxy)carbonyl]-4-{[1,1'-biphenyl]-4-yl}-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-1-yl}hexanoic acid CC1=C(C(NC(=O)N1CCCCCC(O)=O)C1=CC=C(C=C1)C1=CC=CC=C1)C(=O)OCC1=CC=CC=C1 Dihydropyrimidine derivative NA NA NA NA NA NA NA NA NA NA 99% at 40uM 116-9e and 100 uM Triapine Luminescence based viability assay NA NA NA HAP1 cells Cancer


Accession_No PMID Target HSP_Name Organism Localization Enzymatic_activity Cellular_activity compound_Name IUPAC_Name SMILES Class Enzymatic_Inhibition Kd Ki IC50 EC50 DC50 RD_Index GI50 Site_of_Interaction Type_of_Enzymatic_Assay Percentage_Cell_ Cellular_assay HSP_client_protein_assay CC50 MIC_MBC Celllines Disease HSPMDB000001 16982771 Hsp70 GRP78 Human Endoplasmic Reticulum Inhibition of ATPase activity Sensitizes human breast cancer cells to etoposide (-)-Epigallocatechin Gallate (EGCG) [(2~{R},3~{R})-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2~{H}-chromen-3-yl] 3,4,5-trihydroxybenzoate C1C(C(OC2=CC(=CC(=C21)O)O)C3=CC(=C(C(=C3)O)O)O)OC(=O)C4=CC(=C(C(=C4)O)O)O Polyphenol 61% inhibition at 10 uM 0.7 NA NA NA NA NA NA Nucleotide binding domain ATPase assay NA FACS NA NA NA MDA-MB-231 and 47D Cancer HSPMDB000002 16982771 Hsp70 GRP78 Human Endoplasmic Reticulum Inhibition of ATPase activity NA (-)-epicatechin (EC) (2~{R},3~{R})-2-(3,4-dihydroxyphenyl)-3,4-dihydro-2~{H}-chromene-3,5,7-triol C1C(C(OC2=CC(=CC(=C21)O)O)C3=CC(=C(C=C3)O)O)O Polyphenol 38% inhibition at 10 uM NA NA NA NA NA NA NA Nucleotide binding domain ATPase assay NA NA NA NA NA NA Cancer HSPMDB000003 16982771 Hsp70 GRP78 Human Endoplasmic Reticulum Inhibition of ATPase activity NA (-)-epicatechin-3-gallate (ECG) [(2~{R},3~{R})-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3,4-dihydro-2~{H}-chromen-3-yl] 3,4,5-trihydroxybenzoate C1C(C(OC2=CC(=CC(=C21)O)O)C3=CC(=C(C=C3)O)O)OC(=O)C4=CC(=C(C(=C4)O)O)O Polyphenol 64% inhibition at 10 uM NA NA NA NA NA NA NA Nucleotide binding domain ATPase assay NA NA NA NA NA NA Cancer HSPMDB000004 16982771 Hsp70 GRP78 Human Endoplasmic Reticulum Inhibition of ATPase activity NA (-)-epigallocatechin (EGC) (2~{R},3~{R})-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2~{H}-chromene-3,5,7-triol C1C(C(OC2=CC(=CC(=C21)O)O)C3=CC(=C(C(=C3)O)O)O)O Polyphenol 58% inhibition at 10 uM NA NA NA NA NA NA NA Nucleotide binding domain ATPase assay NA NA NA NA NA NA Cancer HSPMDB000005 19793966 Hsp70 Hsc70/ DnaJ Human Cytosol and nucleus Inhibition of ATPase activity Decreases total tau levels in cells overexpressing human tau protein Methylene blue (MB) [7-(dimethylamino)phenothiazin-3-ylidene]-dimethylazanium;chloride CN(C)C1=CC2=C(C=C1)N=C3C=CC(=[N+](C)C)C=C3S2.[Cl-] Dihydropyrimidine derivative > 80% NA NA 83 NA NA NA NA NA ATPase assay NA NA NA NA NA HeLa Alzheimers disease HSPMDB000006 19793966 Hsp70 Hsc70/ DnaJ Human Cytosol and nucleus Inhibition of ATPase activity Decreases total tau levels in cells overexpressing human tau protein Azure C (AC) 7-methyliminophenothiazin-10-ium-3-amine;chloride CN=C1C=CC2=[NH+]C3=C(C=C(C=C3)N)SC2=C1.[Cl-] Dihydropyrimidine derivative > 80% NA NA 11 NA NA NA NA NA ATPase assay NA NA NA NA NA HeLa Alzheimers disease HSPMDB000007 19793966 Hsp70 Hsc70/ DnaJ Human Cytosol and nucleus Inhibition of ATPase activity NA Myricetin (MY) 3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)chromen-4-one C1=C(C=C(C(=C1O)O)O)C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O Dihydropyrimidine derivative > 80% NA NA 12 NA NA NA NA NA ATPase assay NA NA NA NA NA NA Alzheimers disease HSPMDB000008 19793966 Hsp70 Hsc70/ DnaJ Human Cytosol and nucleus Activation of ATPase activity Increases total tau levels in cells overexpressing human tau protein 115-7c 4-{5-[(benzyloxy)carbonyl]-4-(2,4-dichlorophenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-1-yl}butanoic acid CC1=C(C(NC(=O)N1CCCC(O)=O)C1=C(Cl)C=C(Cl)C=C1)C(=O)OCC1=CC=CC=C1 Dihydropyrimidine derivative 45% NA NA NA 120 to 150 NA NA NA NA ATPase assay NA NA NA NA NA HeLa Alzheimers disease HSPMDB000009 19793966 Hsp70 Hsc70/ DnaJ Human Cytosol and nucleus Activation of ATPase activity Increases total tau levels in cells overexpressing human tau protein SW02 ethyl 6-(4-bromophenyl)-3-(4-methoxy-4-oxobutyl)-4-methyl-2-oxo-1,6-dihydropyrimidine-5-carboxylate CCOC(=O)C1=C(N(C(=O)NC1C2=CC=C(C=C2)Br)CCCC(=O)OC)C Dihydropyrimidine derivative 45% NA NA NA 120 to 150 NA NA NA NA ATPase assay NA NA NA NA NA HeLa Alzheimers disease HSPMDB000010 17904512 Hsp70 DnaK/DnaJ/GrpE Bacteria Cytosol and membrane Inhibition of ATPase activity NA 116-2F methyl 4-(naphthalen-2-yl)-2-oxo-6-(phenoxymethyl)-1,2,3,4-tetrahydropyrimidine-5-carboxylate COC(=O)C1=C(COC2=CC=CC=C2)NC(=O)NC1C1=CC2=C(C=CC=C2)C=C1 Dihydropyrimidine derivative NA NA NA Between 120 and 200 NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000011 17904512 Hsp70 DnaK/DnaJ/GrpE Bacteria Cytosol and membrane Inhibition of ATPase activity NA 116-4G 6-{5-[(benzyloxy)carbonyl]-4-(4-cyclohexylphenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-1-yl}hexanoic acid CC1=C(C(NC(=O)N1CCCCCC(O)=O)C1=CC=C(C=C1)C1CCCCC1)C(=O)OCC1=CC=CC=C1 Dihydropyrimidine derivative NA NA NA Between 120 and 201 NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000012 17904512 Hsp70 DnaK/DnaJ/GrpE Bacteria Cytosol and membrane Inhibition of ATPase activity NA 116-7G 5-[(6-{5-[(benzyloxy)carbonyl]-4-{[1,1'-biphenyl]-4-yl}-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-1-yl}-N-hexylhexanamido)({[(1E)-butylidene]carbamoyl})methyl]-2-(carboxymethoxy)benzoic acid CCCCCCN(C(C(=O)\N=C\CCC)C1=CC=C(OCC(O)=O)C(=C1)C(O)=O)C(=O)CCCCCN1C(=O)NC(C2=CC=C(C=C2)C2=CC=CC=C2)C(C(=O)OCC2=CC=CC=C2)=C1C Dihydropyrimidine derivative NA NA NA Between 120 and 202 NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000013 17904512 Hsp70 DnaK/DnaJ/GrpE Bacteria Cytosol and membrane Inhibition of ATPase activity NA 116-9e 6-{5-[(benzyloxy)carbonyl]-4-{[1,1'-biphenyl]-4-yl}-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-1-yl}hexanoic acid CC1=C(C(NC(=O)N1CCCCCC(O)=O)C1=CC=C(C=C1)C1=CC=CC=C1)C(=O)OCC1=CC=CC=C1 Dihydropyrimidine derivative NA NA NA Between 120 and 203 NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000014 27155465 Hsp70 DnaK/DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Az 4-[[2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)imidazol-1-yl]methyl]benzamide COC1=CC=C(C=C1)C2=C(N(C(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)CC4=CC=C(C=C4)C(=O)N)C5=CC=C(C=C5)OC Imidazole derivative 53.04% (at 200 uM) NA NA NA NA NA NA NA Nucleotide binding domain ATPase assay NA NA NA NA NA NA NA HSPMDB000015 27155465 Hsp70 DnaK/DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA VER-155008 4-[[(2R,3S,4R,5R)-5-[6-amino-8-[(3,4-dichlorophenyl)methylamino]purin-9-yl]-3,4-dihydroxyoxolan-2-yl]methoxymethyl]benzonitrile C1=CC(=CC=C1COCC2C(C(C(O2)N3C4=C(C(=NC=N4)N)N=C3NCC5=CC(=C(C=C5)Cl)Cl)O)O)C#N Dibenzyl-8-aminoadenosine analogue 43.03% (at 200 uM) NA NA NA NA NA NA NA Nucleotide binding domain ATPase assay NA NA NA NA NA NA NA HSPMDB000016 27155465 Hsp70 DnaK/DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA 370 (E)-N-(3-methyl-1-(3-phenylthioureido)butyl)-3-(3,4,5-trimethoxyphenyl) acrylamide COc1cc(/C=C/C(=O)NC(CC(C)C)NC(=S)Nc2ccccc2)cc(OC)c1OC N,N'-disubstituted thiourea derivative 50.42% (at 200 uM) NA NA NA NA NA NA NA Nucleotide binding domain ATPase assay NA NA NA NA NA NA NA HSPMDB000017 27155465 Hsp70 DnaK/DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA 371 (E)-N-(3-methyl-1-(3-pyridin-3-ylthioureido)butyl)-3-(3,4,5-trimethoxyphenyl) acrylamide COc1cc(/C=C/C(=O)NC(CC(C)C)NC(=S)Nc2cccnc2)cc(OC)c1OC N,N'-disubstituted thiourea derivative 38.46% (at 200 uM) NA NA NA NA NA NA NA Nucleotide binding domain ATPase assay NA NA NA NA NA NA NA HSPMDB000018 27155465 Hsp70 DnaK/DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA 374 (E)-N-(cyclopropyl(3-phenylthioureido)methyl)-3-(3,4,5-trimethoxy-phenyl)acrylamide COc1cc(/C=C/C(=O)NC(NC(=S)Nc2ccccc2)C3CC3)cc(OC)c1OC N,N'-disubstituted thiourea derivative 50.45% (at 200 uM) NA NA NA NA NA NA NA Nucleotide binding domain ATPase assay NA NA NA NA NA NA NA HSPMDB000019 27155465 Hsp70 DnaK/DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA 379 (E)-N-(3,3-dimethyl-1-(3-phenylthioureido)butyl)-3-(3,4,5-trimethoxyphenyl)acrylamide COc1cc(/C=C/C(=O)NC(CC(C)(C)C)NC(=S)Nc2ccccc2)cc(OC)c1OC N,N'-disubstituted thiourea derivative 44.12% (at 200 uM) NA NA NA NA NA NA NA Nucleotide binding domain ATPase assay NA NA NA NA NA NA NA HSPMDB000020 27155465 Hsp70 DnaK/DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA 380 (E)-N-(3,3-dimethyl-1-(3-pyridin-3-ylthioureido)butyl)-3-(3,4,5-trimethoxyphenyl)acrylamide COc1cc(/C=C/C(=O)NC(CC(C)(C)C)NC(=S)Nc2cccnc2)cc(OC)c1OC N,N'-disubstituted thiourea derivative 47.13% (at 200 uM) NA NA NA NA NA NA NA Nucleotide binding domain ATPase assay NA NA NA NA NA NA NA HSPMDB000021 27155465 Hsp70 DnaK/DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA 392 (E)-N-(2,2-dimethyl-1-(3-o-tolylthioureido)propyl)-3-(3,4,5-trimethoxyphenyl)acrylamide COc1cc(/C=C/C(=O)NC(NC(=S)Nc2ccccc2C)C(C)(C)C)cc(OC)c1OC N,N'-disubstituted thiourea derivative 50.5% (at 200 uM) NA NA NA NA NA NA NA Nucleotide binding domain ATPase assay NA NA NA NA NA NA NA HSPMDB000022 27155465 Hsp70 DnaK/DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA 394 N-(3,3-dimethyl-1-(3-o-tolylthioureido)butyl)cinnamamide Cc1ccccc1NC(=S)NC(CC(C)(C)C)NC(=O)C=Cc2ccccc2 N,N'-disubstituted thiourea derivative 40.95% (at 200 uM) NA NA NA NA NA NA NA Nucleotide binding domain ATPase assay NA NA NA NA NA NA NA HSPMDB000023 27155465 Hsp70 DnaK/DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA 397 N-(cyclopropyl(3-o-tolylthioureido)methyl)cinnamamide Cc1ccccc1NC(=S)NC(NC(=O)C=Cc2ccccc2)C3CC3 N,N'-disubstituted thiourea derivative 65.36% (at 200 uM) NA NA NA NA NA NA NA Nucleotide binding domain ATPase assay NA NA NA NA NA NA NA HSPMDB000024 27155465 Hsp70 DnaK/DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA 404 (E)-N-(1-(3-cyclohexylthioureido)-3-methylbutyl)-3-(3,4,5-trimethoxyphenyl)acrylamide COc1cc(/C=C/C(=O)NC(CC(C)C)NC(=S)NC2CCCCC2)cc(OC)c1OC N,N'-disubstituted thiourea derivative 46.23% (at 200 uM) NA NA NA NA NA NA NA Nucleotide binding domain ATPase assay NA NA NA NA NA NA NA HSPMDB000025 27155465 Hsp70 DnaK/DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA 405 (E)-N-(1-(3-cyclohexylthioureido)-2,2-dimethylpropyl)-3-(3,4,5-trimethoxyphenyl)acrylamide COc1cc(/C=C/C(=O)NC(NC(=S)NC2CCCCC2)C(C)(C)C)cc(OC)c1OC N,N'-disubstituted thiourea derivative 35.78% (at 200 uM) NA NA NA NA NA NA NA Nucleotide binding domain ATPase assay NA NA NA NA NA NA NA HSPMDB000026 27155465 Hsp70 DnaK/DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA 407 N-(1-(3-cyclohexylthioureido)-3-methylbutyl)cinnamamide CC(C)CC(NC(=O)C=Cc1ccccc1)NC(=S)NC2CCCCC2 N,N'-disubstituted thiourea derivative 58.37% (at 200 uM) NA NA NA NA NA NA NA Nucleotide binding domain ATPase assay NA NA NA NA NA NA NA HSPMDB000027 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 370 (E)-N-(3-methyl-1-(3-phenylthioureido)butyl)-3-(3,4,5-trimethoxyphenyl) acrylamide COc1cc(/C=C/C(=O)NC(CC(C)C)NC(=S)Nc2ccccc2)cc(OC)c1OC N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 7.3 at 10 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB000028 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 371 (E)-N-(3-methyl-1-(3-pyridin-3-ylthioureido)butyl)-3-(3,4,5-trimethoxyphenyl) acrylamide COc1cc(/C=C/C(=O)NC(CC(C)C)NC(=S)Nc2cccnc2)cc(OC)c1OC N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 9.2 at 10 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB000029 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 372 (E)-N-(2,2-dimethyl-1-(3-phenylthioureido)propyl)-3-(3,4,5-trimethoxyphenyl) acrylamide COc1cc(/C=C/C(=O)NC(NC(=S)Nc2ccccc2)C(C)(C)C)cc(OC)c1OC N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 2.2 at 10 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB000030 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 373 (E)-N-(2,2-dimethyl-1-(3-pyridin-3-ylthioureido)propyl)-3-(3,4,5-trimethoxyphenyl)acrylamide COc1cc(/C=C/C(=O)NC(NC(=S)Nc2cccnc2)C(C)(C)C)cc(OC)c1OC N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 10.3 at 10 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB000031 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 374 (E)-N-(cyclopropyl(3-phenylthioureido)methyl)-3-(3,4,5-trimethoxy-phenyl)acrylamide COc1cc(/C=C/C(=O)NC(NC(=S)Nc2ccccc2)C3CC3)cc(OC)c1OC N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 12.2 at 10 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB000032 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 375 (E)-N-(cyclopropyl(3-pyridin-3-ylthioureido)methyl)-3-(3,4,5-trimethoxyphenyl) acrylamide COc1cc(/C=C/C(=O)NC(NC(=S)Nc2cccnc2)C3CC3)cc(OC)c1OC N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 8.6 at 10 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB000033 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 376 (E)-N-(cyclopropyl(3-pyridin-2-ylthioureido)methyl)-3-(3,4,5-trimethoxyphenyl) acrylamide COc1cc(/C=C/C(=O)NC(NC(=S)Nc2ccccn2)C3CC3)cc(OC)c1OC N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 20.1 at 10 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB000034 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 378 (E)-N-(3-methyl-1-(3-pyridin-2-ylthioureido)butyl)-3-(3,4,5-trimethoxyphenyl)acrylamide COc1cc(/C=C/C(=O)NC(CC(C)C)NC(=S)Nc2ccccn2)cc(OC)c1OC N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 24.9 at 10 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB000035 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 379 (E)-N-(3,3-dimethyl-1-(3-phenylthioureido)butyl)-3-(3,4,5-trimethoxyphenyl)acrylamide COc1cc(/C=C/C(=O)NC(CC(C)(C)C)NC(=S)Nc2ccccc2)cc(OC)c1OC N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 19 at 10 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB000036 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 380 (E)-N-(3,3-dimethyl-1-(3-pyridin-3-ylthioureido)butyl)-3-(3,4,5-trimethoxyphenyl)acrylamide COc1cc(/C=C/C(=O)NC(CC(C)(C)C)NC(=S)Nc2cccnc2)cc(OC)c1OC N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 22.1 at 10 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB000037 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 381 (E)-N-(3,3-dimethyl-1-(3-pyridin-2-ylthioureido)butyl)-3-(3,4,5-trimethoxyphenyl)acrylamide COc1cc(/C=C/C(=O)NC(CC(C)(C)C)NC(=S)Nc2ccccn2)cc(OC)c1OC N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 25.8 at 10 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB000038 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 382 (E)-N-(2-methyl-1-(3-pyridin-2-ylureido)propyl)-3-(3,4,5-trimethoxyphenyl) acrylamide COc1cc(/C=C/C(=O)NC(NC(=O)Nc2ccccn2)C(C)C)cc(OC)c1OC N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 12.4 at 10 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB000039 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 383 (E)-N-(2-methyl-1-(3-phenylureido)propyl)-3-(3,4,5-trimethoxy-phenyl) acrylamide COc1cc(/C=C/C(=O)NC(NC(=O)Nc2ccccc2)C(C)C)cc(OC)c1OC N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 4.8 at 10 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB000040 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 384 N-(cyclopropyl(3-pyridin-2-ylthioureido)methyl)cinnamamide O=C(NC(NC(=S)Nc1ccccn1)C2CC2)C=Cc3ccccc3 N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 2.4 at 10 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB000041 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 386 N-(3-methyl-1-(3-phenylthioureido)butyl)cinnamamide CC(C)CC(NC(=O)C=Cc1ccccc1)NC(=S)Nc2ccccc2 N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 17.7 at 10 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB000042 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 387 N-(3,3-dimethyl-1-(3-phenylthioureido)butyl)cinnamamide CC(C)(C)CC(NC(=O)C=Cc1ccccc1)NC(=S)Nc2ccccc2 N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 11.3 at 10 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB000043 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 388 N-(2,2-dimethyl-1-(3-phenylthioureido)propyl)cinnamamide CC(C)(C)C(NC(=O)C=Cc1ccccc1)NC(=S)Nc2ccccc2 N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 9.6 at 10 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB000044 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 389 N-(cyclopropyl(3-phenylthioureido)methyl)cinnamamide O=C(NC(NC(=S)Nc1ccccc1)C2CC2)C=Cc3ccccc3 N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 3.8 at 10 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB000045 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 390 N-(2-methyl-1-(3-phenylthioureido)propyl)cinnamamide CC(C)C(NC(=O)C=Cc1ccccc1)NC(=S)Nc2ccccc2 N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 9.4 at 10 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB000046 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 391 (E)-N-(3-methyl-1-(3-methylthioureido)butyl)-3-(3,4,5-trimethoxy-phenyl)acrylamide CNC(=S)NC(CC(C)C)NC(=O)\C=C\c1cc(OC)c(OC)c(OC)c1 N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 10.5 at 10 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB000047 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 392 (E)-N-(2,2-dimethyl-1-(3-o-tolylthioureido)propyl)-3-(3,4,5-trimethoxyphenyl)acrylamide COc1cc(/C=C/C(=O)NC(NC(=S)Nc2ccccc2C)C(C)(C)C)cc(OC)c1OC N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 8.2 at 10 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB000048 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 393 (E)-N-(cyclopropyl(3-o-tolylthioureido)methyl)-3-(3,4,5-trimethoxyphenyl)acrylamide COc1cc(/C=C/C(=O)NC(NC(=S)Nc2ccccc2C)C3CC3)cc(OC)c1OC N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 44 at 10 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB000049 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 394 N-(3,3-dimethyl-1-(3-o-tolylthioureido)butyl)cinnamamide Cc1ccccc1NC(=S)NC(CC(C)(C)C)NC(=O)C=Cc2ccccc2 N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 18.2 at 10 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB000050 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 395 N-(3-methyl-1-(3-o-tolylthioureido)butyl)cinnamamide CC(C)CC(NC(=O)C=Cc1ccccc1)NC(=S)Nc2ccccc2C N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 9.8 at 10 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB000051 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 396 N-(2,2-dimethyl-1-(3-o-tolylthioureido)propyl)cinnamamide Cc1ccccc1NC(=S)NC(NC(=O)C=Cc2ccccc2)C(C)(C)C N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 7 at 10 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB000052 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 397 N-(cyclopropyl(3-o-tolylthioureido)methyl)cinnamamide Cc1ccccc1NC(=S)NC(NC(=O)C=Cc2ccccc2)C3CC3 N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 6 at 10 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB000053 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 402 (E)-N-(1-(3-(4-methoxyphenyl)thioureido)-2-methylpropyl)-3-(3,4,5-trimethoxyphenyl)acrylamide COc1ccc(NC(=S)NC(NC(=O)\C=C\c2cc(OC)c(OC)c(OC)c2)C(C)C)cc1 N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 11.5 at 10 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB000054 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 404 (E)-N-(1-(3-cyclohexylthioureido)-3-methylbutyl)-3-(3,4,5-trimethoxyphenyl)acrylamide COc1cc(/C=C/C(=O)NC(CC(C)C)NC(=S)NC2CCCCC2)cc(OC)c1OC N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 16.5 at 10 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB000055 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 405 (E)-N-(1-(3-cyclohexylthioureido)-2,2-dimethylpropyl)-3-(3,4,5-trimethoxyphenyl)acrylamide COc1cc(/C=C/C(=O)NC(NC(=S)NC2CCCCC2)C(C)(C)C)cc(OC)c1OC N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 13.5 at 10 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB000056 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 406 (E)-N-(1-(3-cyclohexylthioureido)-2-methylpropyl)-3-(3,4,5-trimethoxyphenyl)acrylamide COc1cc(/C=C/C(=O)NC(NC(=S)NC2CCCCC2)C(C)C)cc(OC)c1OC N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 15.3 at 10 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB000057 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 407 N-(1-(3-cyclohexylthioureido)-3-methylbutyl)cinnamamide CC(C)CC(NC(=O)C=Cc1ccccc1)NC(=S)NC2CCCCC2 N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 13.5 at 10 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB000058 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 408 N-(1-(3-cyclohexylthioureido)-2-methylpropyl)cinnamamide CC(C)C(NC(=O)C=Cc1ccccc1)NC(=S)NC2CCCCC2 N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 10.3 at 10 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB000059 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 409 N-(1-(3-cyclohexylthioureido)-2,2-dimethylpropyl)cinnamamide CC(C)(C)C(NC(=O)C=Cc1ccccc1)NC(=S)NC2CCCCC2 N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 13 at 10 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB000060 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 370 (E)-N-(3-methyl-1-(3-phenylthioureido)butyl)-3-(3,4,5-trimethoxyphenyl) acrylamide COc1cc(/C=C/C(=O)NC(CC(C)C)NC(=S)Nc2ccccc2)cc(OC)c1OC N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 9.4 at 10 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB000061 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 371 (E)-N-(3-methyl-1-(3-pyridin-3-ylthioureido)butyl)-3-(3,4,5-trimethoxyphenyl) acrylamide COc1cc(/C=C/C(=O)NC(CC(C)C)NC(=S)Nc2cccnc2)cc(OC)c1OC N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 10.5 at 10 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB000062 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 372 (E)-N-(2,2-dimethyl-1-(3-phenylthioureido)propyl)-3-(3,4,5-trimethoxyphenyl) acrylamide COc1cc(/C=C/C(=O)NC(NC(=S)Nc2ccccc2)C(C)(C)C)cc(OC)c1OC N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 2.9 at 10 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB000063 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 373 (E)-N-(2,2-dimethyl-1-(3-pyridin-3-ylthioureido)propyl)-3-(3,4,5-trimethoxyphenyl)acrylamide COc1cc(/C=C/C(=O)NC(NC(=S)Nc2cccnc2)C(C)(C)C)cc(OC)c1OC N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 16 at 10 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB000064 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 374 (E)-N-(cyclopropyl(3-phenylthioureido)methyl)-3-(3,4,5-trimethoxy-phenyl)acrylamide COc1cc(/C=C/C(=O)NC(NC(=S)Nc2ccccc2)C3CC3)cc(OC)c1OC N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 13.7 at 10 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB000065 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 375 (E)-N-(cyclopropyl(3-pyridin-3-ylthioureido)methyl)-3-(3,4,5-trimethoxyphenyl) acrylamide COc1cc(/C=C/C(=O)NC(NC(=S)Nc2cccnc2)C3CC3)cc(OC)c1OC N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 12.3 at 10 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB000066 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 376 (E)-N-(cyclopropyl(3-pyridin-2-ylthioureido)methyl)-3-(3,4,5-trimethoxyphenyl) acrylamide COc1cc(/C=C/C(=O)NC(NC(=S)Nc2ccccn2)C3CC3)cc(OC)c1OC N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 17.4 at 10 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB000067 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 378 (E)-N-(3-methyl-1-(3-pyridin-2-ylthioureido)butyl)-3-(3,4,5-trimethoxyphenyl)acrylamide COc1cc(/C=C/C(=O)NC(CC(C)C)NC(=S)Nc2ccccn2)cc(OC)c1OC N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 38.7 at 10 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB000068 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 379 (E)-N-(3,3-dimethyl-1-(3-phenylthioureido)butyl)-3-(3,4,5-trimethoxyphenyl)acrylamide COc1cc(/C=C/C(=O)NC(CC(C)(C)C)NC(=S)Nc2ccccc2)cc(OC)c1OC N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 40.9 at 10 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB000069 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 380 (E)-N-(3,3-dimethyl-1-(3-pyridin-3-ylthioureido)butyl)-3-(3,4,5-trimethoxyphenyl)acrylamide COc1cc(/C=C/C(=O)NC(CC(C)(C)C)NC(=S)Nc2cccnc2)cc(OC)c1OC N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 19.3 at 10 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB000070 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 381 (E)-N-(3,3-dimethyl-1-(3-pyridin-2-ylthioureido)butyl)-3-(3,4,5-trimethoxyphenyl)acrylamide COc1cc(/C=C/C(=O)NC(CC(C)(C)C)NC(=S)Nc2ccccn2)cc(OC)c1OC N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 31.5 at 10 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB000071 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 382 (E)-N-(2-methyl-1-(3-pyridin-2-ylureido)propyl)-3-(3,4,5-trimethoxyphenyl) acrylamide COc1cc(/C=C/C(=O)NC(NC(=O)Nc2ccccn2)C(C)C)cc(OC)c1OC N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 18.2 at 10 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB000072 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 383 (E)-N-(2-methyl-1-(3-phenylureido)propyl)-3-(3,4,5-trimethoxy-phenyl) acrylamide COc1cc(/C=C/C(=O)NC(NC(=O)Nc2ccccc2)C(C)C)cc(OC)c1OC N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 11.4 at 10 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB000073 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 384 N-(cyclopropyl(3-pyridin-2-ylthioureido)methyl)cinnamamide O=C(NC(NC(=S)Nc1ccccn1)C2CC2)C=Cc3ccccc3 N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 6 at 10 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB000074 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 386 N-(3-methyl-1-(3-phenylthioureido)butyl)cinnamamide CC(C)CC(NC(=O)C=Cc1ccccc1)NC(=S)Nc2ccccc2 N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 13.6 at 10 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB000075 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 387 N-(3,3-dimethyl-1-(3-phenylthioureido)butyl)cinnamamide CC(C)(C)CC(NC(=O)C=Cc1ccccc1)NC(=S)Nc2ccccc2 N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 34.6 at 10 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB000076 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 388 N-(2,2-dimethyl-1-(3-phenylthioureido)propyl)cinnamamide CC(C)(C)C(NC(=O)C=Cc1ccccc1)NC(=S)Nc2ccccc2 N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 11.4 at 10 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB000077 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 389 N-(cyclopropyl(3-phenylthioureido)methyl)cinnamamide O=C(NC(NC(=S)Nc1ccccc1)C2CC2)C=Cc3ccccc3 N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 8.7 at 10 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB000078 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 390 N-(2-methyl-1-(3-phenylthioureido)propyl)cinnamamide CC(C)C(NC(=O)C=Cc1ccccc1)NC(=S)Nc2ccccc2 N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 11.5 at 10 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB000079 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 391 (E)-N-(3-methyl-1-(3-methylthioureido)butyl)-3-(3,4,5-trimethoxy-phenyl)acrylamide CNC(=S)NC(CC(C)C)NC(=O)\C=C\c1cc(OC)c(OC)c(OC)c1 N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 13 at 10 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB000080 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 392 (E)-N-(2,2-dimethyl-1-(3-o-tolylthioureido)propyl)-3-(3,4,5-trimethoxyphenyl)acrylamide COc1cc(/C=C/C(=O)NC(NC(=S)Nc2ccccc2C)C(C)(C)C)cc(OC)c1OC N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 9.9 at 10 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB000081 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 393 (E)-N-(cyclopropyl(3-o-tolylthioureido)methyl)-3-(3,4,5-trimethoxyphenyl)acrylamide COc1cc(/C=C/C(=O)NC(NC(=S)Nc2ccccc2C)C3CC3)cc(OC)c1OC N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 6.8 at 10 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB000082 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 394 N-(3,3-dimethyl-1-(3-o-tolylthioureido)butyl)cinnamamide Cc1ccccc1NC(=S)NC(CC(C)(C)C)NC(=O)C=Cc2ccccc2 N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 18.9 at 10 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB000083 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 395 N-(3-methyl-1-(3-o-tolylthioureido)butyl)cinnamamide CC(C)CC(NC(=O)C=Cc1ccccc1)NC(=S)Nc2ccccc2C N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 12.8 at 10 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB000084 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 396 N-(2,2-dimethyl-1-(3-o-tolylthioureido)propyl)cinnamamide Cc1ccccc1NC(=S)NC(NC(=O)C=Cc2ccccc2)C(C)(C)C N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 9.7 at 10 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB000085 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 397 N-(cyclopropyl(3-o-tolylthioureido)methyl)cinnamamide Cc1ccccc1NC(=S)NC(NC(=O)C=Cc2ccccc2)C3CC3 N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 8.7 at 10 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB000086 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 402 (E)-N-(1-(3-(4-methoxyphenyl)thioureido)-2-methylpropyl)-3-(3,4,5-trimethoxyphenyl)acrylamide COc1ccc(NC(=S)NC(NC(=O)\C=C\c2cc(OC)c(OC)c(OC)c2)C(C)C)cc1 N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 15.4 at 10 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB000087 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 404 (E)-N-(1-(3-cyclohexylthioureido)-3-methylbutyl)-3-(3,4,5-trimethoxyphenyl)acrylamide COc1cc(/C=C/C(=O)NC(CC(C)C)NC(=S)NC2CCCCC2)cc(OC)c1OC N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 38.8 at 10 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB000088 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 405 (E)-N-(1-(3-cyclohexylthioureido)-2,2-dimethylpropyl)-3-(3,4,5-trimethoxyphenyl)acrylamide COc1cc(/C=C/C(=O)NC(NC(=S)NC2CCCCC2)C(C)(C)C)cc(OC)c1OC N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 39.8 at 10 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB000089 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 406 (E)-N-(1-(3-cyclohexylthioureido)-2-methylpropyl)-3-(3,4,5-trimethoxyphenyl)acrylamide COc1cc(/C=C/C(=O)NC(NC(=S)NC2CCCCC2)C(C)C)cc(OC)c1OC N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 22.6 at 10 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB000090 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 407 N-(1-(3-cyclohexylthioureido)-3-methylbutyl)cinnamamide CC(C)CC(NC(=O)C=Cc1ccccc1)NC(=S)NC2CCCCC2 N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 19.8 at 10 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB000091 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 408 N-(1-(3-cyclohexylthioureido)-2-methylpropyl)cinnamamide CC(C)C(NC(=O)C=Cc1ccccc1)NC(=S)NC2CCCCC2 N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 13.3 at 10 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB000092 27155465 Hsp70 Hsp70-2 Human Cytosol and cytoskeleton NA Antiproliferative activity 409 N-(1-(3-cyclohexylthioureido)-2,2-dimethylpropyl)cinnamamide CC(C)(C)C(NC(=O)C=Cc1ccccc1)NC(=S)NC2CCCCC2 N,N'-disubstituted thiourea derivative NA NA NA NA NA NA NA NA Nucleotide binding domain NA 34.3 at 10 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB000093 29414793 Hsp70 DnaK/DnaJ/GrpE Bacteria Cytosol and membrane Inhibition of ATPase activity (protein-protein interaction) NA C NA NA ChemDiv 100K diversity set library NA NA NA NA <50 NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000094 29414793 Hsp70 DnaK/DnaJ/GrpE Bacteria Cytosol and membrane Inhibition of ATPase activity (protein-protein interaction) NA F 4-{2-[(3,5-dimethyl-1H-pyrazol-4-yl)amino]-1,3-thiazol-4-yl}benzene-1,2-diol CC1=C(NC2=NC(=CS2)C2=CC=C(O)C(O)=C2)C(C)=NN1 2-aminothiazole derivative NA NA NA NA <50 NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000095 29414793 Hsp70 DnaK/DnaJ/GrpE Bacteria Cytosol and membrane Inhibition of ATPase activity (protein-protein interaction) NA I NA NA ChemDiv 100K diversity set library NA NA NA NA <50 NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000096 29414793 Hsp70 DnaK/DnaJ/GrpE Bacteria Cytosol and membrane Inhibition of ATPase activity (protein-protein interaction) NA N NA NA ChemDiv 100K diversity set library NA NA NA NA <50 NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000097 29414793 Hsp70 DnaK/DnaJ/GrpE Bacteria Cytosol and membrane Inhibition of ATPase activity (protein-protein interaction) NA R N-(5-chloro-2-methoxyphenyl)-4-{2-methylimidazo[1,2-a]pyridin-3-yl}-1,3-thiazol-2-amine COC1=CC=C(Cl)C=C1NC1=NC(=CS1)C1=C(C)N=C2C=CC=CN12 2-aminothiazole derivative NA NA NA NA <50 NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000098 29414793 Hsp70 Hsp72/DnaJ2/BAG2 Human Cytosol and nucleus Inhibition of ATPase activity (protein-protein interaction) NA C NA NA ChemDiv 100K diversity set library NA NA NA NA 26.2 NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000099 29414793 Hsp70 Hsp72/DnaJ2/BAG2 Human Cytosol and nucleus Inhibition of ATPase activity (protein-protein interaction) NA F 4-{2-[(3,5-dimethyl-1H-pyrazol-4-yl)amino]-1,3-thiazol-4-yl}benzene-1,2-diol CC1=C(NC2=NC(=CS2)C2=CC=C(O)C(O)=C2)C(C)=NN1 2-aminothiazole derivative NA NA NA NA 28.2 NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000100 29414793 Hsp70 Hsp72/DnaJ2/BAG2 Human Cytosol and nucleus Inhibition of ATPase activity (protein-protein interaction) NA H NA NA ChemDiv 100K diversity set library NA NA NA NA 15.5 NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000101 29414793 Hsp70 Hsp72/DnaJ2/BAG2 Human Cytosol and nucleus Inhibition of ATPase activity (protein-protein interaction) NA I NA NA ChemDiv 100K diversity set library NA NA NA NA 10.9 NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000102 29414793 Hsp70 Hsp72/DnaJ2/BAG2 Human Cytosol and nucleus Inhibition of ATPase activity (protein-protein interaction) NA R N-(5-chloro-2-methoxyphenyl)-4-{2-methylimidazo[1,2-a]pyridin-3-yl}-1,3-thiazol-2-amine COC1=CC=C(Cl)C=C1NC1=NC(=CS1)C1=C(C)N=C2C=CC=CN12 2-aminothiazole derivative NA NA NA NA 9.5 NA NA NA Nucleotide binding domain (allosteric site) ATPase assay NA NA NA NA NA NA NA HSPMDB000103 29414793 Hsp70 Hsp72/DnaJ2/BAG2 Human Cytosol and nucleus Inhibition of ATPase activity (protein-protein interaction) NA IT2-144 N-(2,5-difluorophenyl)-4-{2-methylimidazo[1,2-a]pyridin-3-yl}-1,3-thiazol-2-amine CC1=C(N2C=CC=CC2=N1)C1=CSC(NC2=CC(F)=CC=C2F)=N1 2-aminothiazoles derivative NA NA NA NA 6.9 NA NA NA Nucleotide binding domain (allosteric site) ATPase assay NA NA NA NA NA NA NA HSPMDB000104 29414793 Hsp70 DnaK/DnaJ/GrpE Bacteria Cytosol and membrane Inhibition of ATPase activity (protein-protein interaction) NA IT2-149 N-(2-fluoro-5-methylphenyl)-4-{2-methylimidazo[1,2-a]pyridin-3-yl}-1,3-thiazol-2-amine CC1=C(N2C=CC=CC2=N1)C1=CSC(NC2=CC(C)=CC=C2F)=N1 2-aminothiazoles derivative NA NA NA NA >25 NA NA NA Nucleotide binding domain (allosteric site) ATPase assay NA NA NA NA NA NA NA HSPMDB000105 29414793 Hsp70 Hsp72/DnaJ2/BAG2 Human Cytosol and nucleus Inhibition of ATPase activity (protein-protein interaction) NA IT2-151 N-(5-bromo-2-fluorophenyl)-4-{2-methylimidazo[1,2-a]pyridin-3-yl}-1,3-thiazol-2-amine CC1=C(N2C=CC=CC2=N1)C1=CSC(NC2=CC(Br)=CC=C2F)=N1 2-aminothiazoles derivative NA NA NA NA 4.7 NA NA NA Nucleotide binding domain (allosteric site) ATPase assay NA NA NA NA NA NA NA HSPMDB000106 29414793 Hsp70 Hsp72/DnaJ2/BAG2 Human Cytosol and nucleus Inhibition of ATPase activity (protein-protein interaction) NA IT2-179 N-(2,5-dibromophenyl)-4-{2-methylimidazo[1,2-a]pyridin-3-yl}-1,3-thiazol-2-amine CC1=C(N2C=CC=CC2=N1)C1=CSC(NC2=CC(Br)=CC=C2Br)=N1 2-aminothiazoles derivative NA NA NA NA 3.6 NA NA NA Nucleotide binding domain (allosteric site) ATPase assay NA NA NA NA NA NA NA HSPMDB000107 29414793 Hsp70 DnaK/DnaJ/GrpE Bacteria Cytosol and membrane Inhibition of ATPase activity (protein-protein interaction) NA IT2-158 N-(2,3-difluorophenyl)-4-{2-methylimidazo[1,2-a]pyridin-3-yl}-1,3-thiazol-2-amine CC1=C(N2C=CC=CC2=N1)C1=CSC(NC2=CC=CC(F)=C2F)=N1 2-aminothiazoles derivative NA NA NA NA >25 NA NA NA Nucleotide binding domain (allosteric site) ATPase assay NA NA NA NA NA NA NA HSPMDB000108 29414793 Hsp70 Hsp72/-DnaJ2/BAG2 Human Cytosol and nucleus Inhibition of ATPase activity (protein-protein interaction) NA IT2-159 N-(2,4-difluorophenyl)-4-{2-methylimidazo[1,2-a]pyridin-3-yl}-1,3-thiazol-2-amine CC1=C(N2C=CC=CC2=N1)C1=CSC(NC2=CC=C(F)C=C2F)=N1 2-aminothiazoles derivative NA NA NA NA >50 NA NA NA Nucleotide binding domain (allosteric site) ATPase assay NA NA NA NA NA NA NA HSPMDB000109 29414793 Hsp70 DnaK/DnaJ/GrpE Bacteria Cytosol and membrane Inhibition of ATPase activity (protein-protein interaction) NA IT2-160 N-(2,6-difluorophenyl)-4-{2-methylimidazo[1,2-a]pyridin-3-yl}-1,3-thiazol-2-amine CC1=C(N2C=CC=CC2=N1)C1=CSC(NC2=C(F)C=CC=C2F)=N1 2-aminothiazoles derivative NA NA NA NA >25 NA NA NA Nucleotide binding domain (allosteric site) ATPase assay NA NA NA NA NA NA NA HSPMDB000110 29414793 Hsp70 DnaK/DnaJ/GrpE Bacteria Cytosol and membrane Inhibition of ATPase activity (protein-protein interaction) NA IT2-171 N-benzyl-4-{2-methylimidazo[1,2-a]pyridin-3-yl}-1,3-thiazol-2-amine CC1=C(N2C=CC=CC2=N1)C1=CSC(NCC2=CC=CC=C2)=N1 2-aminothiazoles derivative NA NA NA NA >25 NA NA NA Nucleotide binding domain (allosteric site) ATPase assay NA NA NA NA NA NA NA HSPMDB000111 29414793 Hsp70 Hsp72/DnaJ2/BAG2 Human Cytosol and nucleus Inhibition of ATPase activity (protein-protein interaction) NA IT2-70a 4-{2-methylimidazo[1,2-a]pyridin-3-yl}-1,3-thiazol-2-amine CC1=C(N2C=CC=CC2=N1)C1=CSC(N)=N1 2-aminothiazoles derivative NA NA NA NA >50 NA NA NA Nucleotide binding domain (allosteric site) ATPase assay NA NA NA NA NA NA NA HSPMDB000112 29414793 Hsp70 DnaK/DnaJ/GrpE Bacteria Cytosol and membrane Inhibition of ATPase activity (DnaJ stimulated) NA IT2-21c 1-(3,4-dihydroxyphenyl)-2-(4-{[4-(3,4-dihydroxyphenyl)-1,3-thiazol-2-yl]amino}-3,5-dimethyl-1H-pyrazol-1-yl)ethan-1-one CC1=NN(CC(=O)C2=CC(O)=C(O)C=C2)C(C)=C1NC1=NC(=CS1)C1=CC(O)=C(O)C=C1 IT2-21a derivative 80% Inhibition at 10 uM NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) ATPase assay NA NA NA NA NA NA NA HSPMDB000113 29414793 Hsp70 Hsp72/DnaJ2/BAG2 Human Cytosol and nucleus NA Antiproliferative activity R N-(5-chloro-2-methoxyphenyl)-4-{2-methylimidazo[1,2-a]pyridin-3-yl}-1,3-thiazol-2-amine COC1=CC=C(Cl)C=C1NC1=NC(=CS1)C1=C(C)N=C2C=CC=CN12 2-aminothiazoles derivative NA NA NA NA 5.8 NA NA NA NA NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000114 29414793 Hsp70 Hsp72/DnaJ2/BAG2 Human Cytosol and nucleus NA Antiproliferative activity IT2-144 N-(2,5-difluorophenyl)-4-{2-methylimidazo[1,2-a]pyridin-3-yl}-1,3-thiazol-2-amine CC1=C(N2C=CC=CC2=N1)C1=CSC(NC2=CC(F)=CC=C2F)=N1 2-aminothiazoles derivative NA NA NA NA 2.7 NA NA NA NA NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000115 29414793 Hsp70 Hsp72/DnaJ2/BAG2 Human Cytosol and nucleus NA Antiproliferative activity IT2-151 N-(5-bromo-2-fluorophenyl)-4-{2-methylimidazo[1,2-a]pyridin-3-yl}-1,3-thiazol-2-amine CC1=C(N2C=CC=CC2=N1)C1=CSC(NC2=CC(Br)=CC=C2F)=N1 2-aminothiazoles derivative NA NA NA NA 2.9 NA NA NA NA NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000116 29414793 Hsp70 Hsp72/DnaJ2/BAG2 Human Cytosol and nucleus NA Antiproliferative activity IT2-179 N-(2,5-dibromophenyl)-4-{2-methylimidazo[1,2-a]pyridin-3-yl}-1,3-thiazol-2-amine CC1=C(N2C=CC=CC2=N1)C1=CSC(NC2=CC(Br)=CC=C2Br)=N1 2-aminothiazoles derivative NA NA NA NA 3.1 NA NA NA NA NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000117 29414793 Hsp70 Hsp72/DnaJ2/BAG2 Human Cytosol and nucleus NA Antiproliferative activity IT2-159 N-(2,4-difluorophenyl)-4-{2-methylimidazo[1,2-a]pyridin-3-yl}-1,3-thiazol-2-amine CC1=C(N2C=CC=CC2=N1)C1=CSC(NC2=CC=C(F)C=C2F)=N1 2-aminothiazoles derivative NA NA NA NA 8.5 NA NA NA NA NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000118 29414793 Hsp70 Hsp72/DnaJ2/BAG2 Human Cytosol and nucleus NA Antiproliferative activity IT2-70a 4-{2-methylimidazo[1,2-a]pyridin-3-yl}-1,3-thiazol-2-amine CC1=C(N2C=CC=CC2=N1)C1=CSC(N)=N1 2-aminothiazoles derivative NA NA NA NA > 50 NA NA NA NA NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000119 29414793 Hsp70 Hsp72/DnaJ2/BAG2 Human Cytosol and nucleus NA Antiproliferative activity R N-(5-chloro-2-methoxyphenyl)-4-{2-methylimidazo[1,2-a]pyridin-3-yl}-1,3-thiazol-2-amine COC1=CC=C(Cl)C=C1NC1=NC(=CS1)C1=C(C)N=C2C=CC=CN12 2-aminothiazoles derivative NA NA NA NA 5.3 NA NA NA NA NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000120 29414793 Hsp70 Hsp72/DnaJ2/BAG2 Human Cytosol and nucleus NA Antiproliferative activity IT2-144 N-(2,5-difluorophenyl)-4-{2-methylimidazo[1,2-a]pyridin-3-yl}-1,3-thiazol-2-amine CC1=C(N2C=CC=CC2=N1)C1=CSC(NC2=CC(F)=CC=C2F)=N1 2-aminothiazoles derivative NA NA NA NA > 50 NA NA NA NA NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000121 29414793 Hsp70 Hsp72/DnaJ2/BAG2 Human Cytosol and nucleus NA Antiproliferative activity IT2-151 N-(5-bromo-2-fluorophenyl)-4-{2-methylimidazo[1,2-a]pyridin-3-yl}-1,3-thiazol-2-amine CC1=C(N2C=CC=CC2=N1)C1=CSC(NC2=CC(Br)=CC=C2F)=N1 2-aminothiazoles derivative NA NA NA NA 9.3 NA NA NA NA NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000122 29414793 Hsp70 Hsp72/DnaJ2/BAG2 Human Cytosol and nucleus NA Antiproliferative activity IT2-179 N-(2,5-dibromophenyl)-4-{2-methylimidazo[1,2-a]pyridin-3-yl}-1,3-thiazol-2-amine CC1=C(N2C=CC=CC2=N1)C1=CSC(NC2=CC(Br)=CC=C2Br)=N1 2-aminothiazoles derivative NA NA NA NA > 50 NA NA NA NA NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000123 29414793 Hsp70 Hsp72/DnaJ2/BAG2 Human Cytosol and nucleus NA Antiproliferative activity IT2-159 N-(2,4-difluorophenyl)-4-{2-methylimidazo[1,2-a]pyridin-3-yl}-1,3-thiazol-2-amine CC1=C(N2C=CC=CC2=N1)C1=CSC(NC2=CC=C(F)C=C2F)=N1 2-aminothiazoles derivative NA NA NA NA 5.4 NA NA NA NA NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000124 29414793 Hsp70 Hsp72/DnaJ2/BAG2 Human Cytosol and nucleus NA Antiproliferative activity IT2-70a 4-{2-methylimidazo[1,2-a]pyridin-3-yl}-1,3-thiazol-2-amine CC1=C(N2C=CC=CC2=N1)C1=CSC(N)=N1 2-aminothiazoles derivative NA NA NA NA > 50 NA NA NA NA NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000125 18191466 Hsp70 DnaK/DnaJ/GrpE Bacteria Cytosol and membrane Inhibition of chaperone activity NA 116-5c benzyl 4-{[1,1'-biphenyl]-4-yl}-1-(5-{[(butylcarbamoyl)[4-(2-methoxy-2-oxoethoxy)-3-(methoxycarbonyl)phenyl]methyl](2-phenylethyl)carbamoyl}pentyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate CCCCNC(=O)C(N(CCC1=CC=CC=C1)C(=O)CCCCCN1C(=O)NC(C2=CC=C(C=C2)C2=CC=CC=C2)C(C(=O)OCC2=CC=CC=C2)=C1C)C1=CC=C(OCC(=O)OC)C(=C1)C(=O)OC Dihydropyrimidine derivative NA NA NA NA 3.2 NA NA NA NA Refolding assay (luciferase) NA NA NA NA NA NA NA HSPMDB000126 18191466 Hsp70 DnaK/DnaJ/GrpE Bacteria Cytosol and membrane Inhibition of chaperone activity NA 115-3b 2-[(2-{5-[(benzyloxy)carbonyl]-1-(3-carboxypropyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-4-yl}phenoxy)sulfonyl]-N-hydroxy-N-oxoanilinium CC1=C(C(NC(=O)N1CCCC(O)=O)C1=CC=CC=C1OS(=O)(=O)C1=CC=CC=C1[N+](O)=O)C(=O)OCC1=CC=CC=C1 Dihydropyrimidine derivative NA NA NA NA 3.5 NA NA NA NA Refolding assay (luciferase) NA NA NA NA NA NA NA HSPMDB000127 18191466 Hsp70 DnaK/DnaJ/GrpE Bacteria Cytosol and membrane Inhibition of chaperone activity NA 116-4d N-hydroxy-4-[5-(methoxycarbonyl)-2-oxo-6-(2-phenylethyl)-1,2,3,4-tetrahydropyrimidin-4-yl]-N-oxoanilinium COC(=O)C1=C(CCC2=CC=CC=C2)NC(=O)NC1C1=CC=C(C=C1)[N+](O)=O Dihydropyrimidine derivative NA NA NA NA 8.8 NA NA NA NA Refolding assay (luciferase) NA NA NA NA NA NA NA HSPMDB000128 18191466 Hsp70 DnaK/DnaJ/GrpE Bacteria Cytosol and membrane Inhibition of chaperone activity NA 116-10d benzyl 4-{[1,1'-biphenyl]-4-yl}-1-(5-{[(butylcarbamoyl)[4-hydroxy-3-(methoxycarbonyl)phenyl]methyl](hexyl)carbamoyl}pentyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)C1=CC=C(O)C(=C1)C(=O)OC)C(=O)CCCCCN1C(=O)NC(C2=CC=C(C=C2)C2=CC=CC=C2)C(C(=O)OCC2=CC=CC=C2)=C1C Dihydropyrimidine derivative NA NA NA NA 9 NA NA NA NA Refolding assay (luciferase) NA NA NA NA NA NA NA HSPMDB000129 18191466 Hsp70 DnaK/DnaJ/GrpE Bacteria Cytosol and membrane Inhibition of chaperone activity NA SW03 3-[(3R)-3-[(3S)-3-{4-[4-(4-bromophenyl)-5-(ethoxycarbonyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-1-yl]butanamido}-5-methylhexanamido]-3-phenylpropanamido]propanoic acid CCOC(=O)C1=C(C)N(CCCC(=O)N[C@@H](CC(C)C)CC(=O)N[C@H](CC(=O)NCCC(O)=O)C2=CC=CC=C2)C(=O)NC1C1=CC=C(Br)C=C1 Dihydropyrimidine derivative NA NA NA NA 11 NA NA NA NA Refolding assay (luciferase) NA NA NA NA NA NA NA HSPMDB000130 18191466 Hsp70 DnaK/DnaJ/GrpE Bacteria Cytosol and membrane Inhibition of chaperone activity NA 116-8e benzyl 4-{[1,1'-biphenyl]-4-yl}-1-{5-[({[1,1'-biphenyl]-4-yl}(butylcarbamoyl)methyl)(hexyl)carbamoyl]pentyl}-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)C1=CC=C(C=C1)C1=CC=CC=C1)C(=O)CCCCCN1C(=O)NC(C2=CC=C(C=C2)C2=CC=CC=C2)C(C(=O)OCC2=CC=CC=C2)=C1C Dihydropyrimidine derivative NA NA NA NA 30.4 NA NA NA NA Refolding assay (luciferase) NA NA NA NA NA NA NA HSPMDB000131 15448148 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA 625194 NA NA Dihydropyrimidine derivative Fold change 1 (at 0.1 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000132 15448148 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA 625195 NA NA Dihydropyrimidine derivative Fold change 3 (at 0.1 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000133 15448148 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA 625512 NA NA Dihydropyrimidine derivative Fold change 1.2 (at 0.1 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000134 15448148 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA 625513 NA NA Dihydropyrimidine derivative Fold change 1.1 (at 0.1 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000135 15448148 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA ML2-193 NA NA Dihydropyrimidine derivative Fold change 1.6 (at 0.1 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000136 15448148 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA ML2-194 NA NA Dihydropyrimidine derivative Fold change 1.3 (at 0.1 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000137 15448148 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA ML2-214 NA NA Dihydropyrimidine derivative Fold change -1.1 (at 0.1 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000138 15448148 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA ML2-215 NA NA Dihydropyrimidine derivative Fold change 1.2 (at 0.1 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000139 15448148 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA MAL3-38 NA NA Dihydropyrimidine derivative Fold change 1.8 (at 0.1 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000140 15448148 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA MAL3-40 NA NA Dihydropyrimidine derivative Fold change 1.8 (at 0.1 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000141 15448148 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA MAL3-53 NA NA Dihydropyrimidine derivative Fold change 1.9 (at 0.1 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000142 15448148 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA MAL3-55 NA NA Dihydropyrimidine derivative Fold change -1.5 (at 0.1 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000143 15448148 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA MAL3-87 NA NA Dihydropyrimidine derivative Fold change 1.9 (at 0.1 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000144 15448148 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA MAL3-88 NA NA Dihydropyrimidine derivative Fold change 1.5 (at 0.1 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000145 15448148 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA MAL3-90 NA NA Dihydropyrimidine derivative Fold change 2 (at 0.1 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000146 15448148 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA MAL3-91 NA NA Dihydropyrimidine derivative Fold change 1.8 (at 0.1 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000147 15448148 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA NSC-630668-R/1 6-[5-(ethoxycarbonylcarbamoyl)-2,4-dioxopyrimidin-1-yl]hexyl N-[6-[6-[5-(ethoxycarbonylcarbamoyl)-2,4-dioxopyrimidin-1-yl]hexoxycarbonylamino]hexyl]carbamate CCOC(=O)NC(=O)C1=CN(C(=O)NC1=O)CCCCCCOC(=O)NCCCCCCNC(=O)OCCCCCCN2C=C(C(=O)NC2=O)C(=O)NC(=O)OCC Dihydropyrimidine derivative Fold change 5.8 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000148 15448148 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA 624392 ethyl N-[1-[2-[6-[[2-[5-(ethoxycarbonylcarbamoyl)-2,4-dioxopyrimidin-1-yl]ethyl-(2-hydroxyethyl)carbamoyl]amino]hexylcarbamoyl-(2-hydroxyethyl)amino]ethyl]-2,4-dioxopyrimidine-5-carbonyl]carbamate CCOC(=O)NC(=O)C1=CN(C(=O)NC1=O)CCN(CCO)C(=O)NCCCCCCNC(=O)N(CCN2C=C(C(=O)NC2=O)C(=O)NC(=O)OCC)CCO Dihydropyrimidine derivative Fold change -1.3 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000149 15448148 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA 642393 NA NA Dihydropyrimidine derivative Fold change -1.7 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000150 15448148 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA 624903 NA NA Dihydropyrimidine derivative Fold change -2.2 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000151 15448148 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA 624904 NA NA Dihydropyrimidine derivative Fold change -1.4 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000152 15448148 Hsp70 Ssa1p Yeast Cytosol Activation of ATPase activity (endogenous) NA 624905 NA NA Dihydropyrimidine derivative Fold change 1.2 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000153 15448148 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA 624906 NA NA Dihydropyrimidine derivative Fold change -1.8 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000154 15448148 Hsp70 Ssa1p Yeast Cytosol Activation of ATPase activity (endogenous) NA 624907 NA NA Dihydropyrimidine derivative Fold change 1.2 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000155 15448148 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA 624908 NA NA Dihydropyrimidine derivative Fold change -1.1 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000156 15448148 Hsp70 Ssa1p Yeast Cytosol Activation of ATPase activity (endogenous) NA 625194 NA NA Dihydropyrimidine derivative Fold change 1.8 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000157 15448148 Hsp70 Ssa1p Yeast Cytosol Activation of ATPase activity (endogenous) NA 625195 NA NA Dihydropyrimidine derivative Fold change 1.7 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000158 15448148 Hsp70 Ssa1p Yeast Cytosol Activation of ATPase activity (endogenous) NA 625512 NA NA Dihydropyrimidine derivative Fold change 3.1 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000159 15448148 Hsp70 Ssa1p Yeast Cytosol Activation of ATPase activity (endogenous) NA 625513 NA NA Dihydropyrimidine derivative Fold change 2 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000160 15448148 Hsp70 Ssa1p Yeast Cytosol Activation of ATPase activity (endogenous) NA 632006 NA NA Dihydropyrimidine derivative Fold change 1.4 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000161 15448148 Hsp70 Ssa1p Yeast Cytosol Activation of ATPase activity (endogenous) NA 655302 NA NA Dihydropyrimidine derivative Fold change 1.9 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000162 15448148 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA aad9 NA NA Dihydropyrimidine derivative Fold change -1.7 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000163 15448148 Hsp70 Ssa1p Yeast Cytosol Activation of ATPase activity (endogenous) NA ML2-193 NA NA Dihydropyrimidine derivative Fold change 3.1 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000164 15448148 Hsp70 Ssa1p Yeast Cytosol Activation of ATPase activity (endogenous) NA ML2-194 NA NA Dihydropyrimidine derivative Fold change 2.1 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000165 15448148 Hsp70 Ssa1p Yeast Cytosol Activation of ATPase activity (endogenous) NA ML2-214 NA NA Dihydropyrimidine derivative Fold change 1.7 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000166 15448148 Hsp70 Ssa1p Yeast Cytosol Activation of ATPase activity (endogenous) NA ML2-215 NA NA Dihydropyrimidine derivative Fold change 2.2 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000167 15448148 Hsp70 Ssa1p Yeast Cytosol Activation of ATPase activity (endogenous) NA MAL3-38 NA NA Dihydropyrimidine derivative Fold change 3.1 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000168 15448148 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA MAL3-39 NA NA Dihydropyrimidine derivative Fold change 1 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000169 15448148 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA MAL3-40 NA NA Dihydropyrimidine derivative Fold change 2.7 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000170 15448148 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA MAL3-51 NA NA Dihydropyrimidine derivative Fold change -1.2 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000171 15448148 Hsp70 Ssa1p Yeast Cytosol Activation of ATPase activity (endogenous) NA MAL3-53 NA NA Dihydropyrimidine derivative Fold change 2.5 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000172 15448148 Hsp70 Ssa1p Yeast Cytosol Activation of ATPase activity (endogenous) NA MAL3-54 NA NA Dihydropyrimidine derivative Fold change 1.1 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000173 15448148 Hsp70 Ssa1p Yeast Cytosol Activation of ATPase activity (endogenous) NA MAL3-55 NA NA Dihydropyrimidine derivative Fold change 1.4 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000174 15448148 Hsp70 Ssa1p Yeast Cytosol Activation of ATPase activity (endogenous) NA MAL3-87 NA NA Dihydropyrimidine derivative Fold change 2.3 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000175 15448148 Hsp70 Ssa1p Yeast Cytosol Activation of ATPase activity (endogenous) NA MAL3-88 NA NA Dihydropyrimidine derivative Fold change 1.3 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000176 15448148 Hsp70 Ssa1p Yeast Cytosol Activation of ATPase activity (endogenous) NA MAL3-90 NA NA Dihydropyrimidine derivative Fold change 5.2 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000177 15448148 Hsp70 Ssa1p Yeast Cytosol Activation of ATPase activity (endogenous) NA MAL3-91 NA NA Dihydropyrimidine derivative Fold change 2.9 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000178 15448148 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA MAL3-101 Benzyl 4-([1,1?-biphenyl]-4-yl)-1-(6-((2-(butylamino)-1-(4-(2-methoxy-2-oxoethoxy)-3-(methoxycarbonyl)phenyl)-2-oxoethyl)(hexyl)amino)-6-oxohexyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate O=C(C1=C(C)N(CCCCCC(N(C(C2=CC=C(OCC(OC)=O)C(C(OC)=O)=C2)C(NCCCC)=O)CCCCCC)=O)C(NC1C3=CC=C(C4=CC=CC=C4)C=C3)=O)OCC5=CC=CC=C5 Dihydropyrimidine derivative Fold change 1 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000179 15448148 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA 624392 ethyl N-[1-[2-[6-[[2-[5-(ethoxycarbonylcarbamoyl)-2,4-dioxopyrimidin-1-yl]ethyl-(2-hydroxyethyl)carbamoyl]amino]hexylcarbamoyl-(2-hydroxyethyl)amino]ethyl]-2,4-dioxopyrimidine-5-carbonyl]carbamate CCOC(=O)NC(=O)C1=CN(C(=O)NC1=O)CCN(CCO)C(=O)NCCCCCCNC(=O)N(CCN2C=C(C(=O)NC2=O)C(=O)NC(=O)OCC)CCO Dihydropyrimidine derivative Fold change -1.4 (at 0.6 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000180 15448148 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA 624906 NA NA Dihydropyrimidine derivative Fold change -1.1 (at 0.6 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000181 15448148 Hsp70 Ssa1p Yeast Cytosol Activation of ATPase activity (endogenous) NA 625194 NA NA Dihydropyrimidine derivative Fold change 1.4 (at 0.6 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000182 15448148 Hsp70 Ssa1p Yeast Cytosol Activation of ATPase activity (endogenous) NA 625195 NA NA Dihydropyrimidine derivative Fold change1.3 (at 0.6 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000183 15448148 Hsp70 Ssa1p Yeast Cytosol Activation of ATPase activity (endogenous) NA 625512 NA NA Dihydropyrimidine derivative Fold change 3 (at 0.6 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000184 15448148 Hsp70 Ssa1p Yeast Cytosol Activation of ATPase activity (endogenous) NA 625513 NA NA Dihydropyrimidine derivative Fold change 2.5 (at 0.6 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000185 15448148 Hsp70 Ssa1p Yeast Cytosol Activation of ATPase activity (endogenous) NA 632006 NA NA Dihydropyrimidine derivative Fold change 2 (at 0.6 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000186 15448148 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA 655302 NA NA Dihydropyrimidine derivative Fold change -1.3 (at 0.6 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000187 15448148 Hsp70 Ssa1p Yeast Cytosol Activation of ATPase activity (endogenous) NA ML2-193 NA NA Dihydropyrimidine derivative Fold change 2.3 (at 0.6 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000188 15448148 Hsp70 Ssa1p Yeast Cytosol Activation of ATPase activity (endogenous) NA ML2-194 NA NA Dihydropyrimidine derivative Fold change 1.4 (at 0.6 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000189 15448148 Hsp70 Ssa1p Yeast Cytosol Activation of ATPase activity (endogenous) NA ML2-214 NA NA Dihydropyrimidine derivative Fold change 1.3 (at 0.6 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000190 15448148 Hsp70 Ssa1p Yeast Cytosol Activation of ATPase activity (endogenous) NA ML2-215 NA NA Dihydropyrimidine derivative Fold change 2.1 (at 0.6 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000191 15448148 Hsp70 Ssa1p Yeast Cytosol Activation of ATPase activity (endogenous) NA MAL3-38 NA NA Dihydropyrimidine derivative Fold change 2 (at 0.6 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000192 15448148 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA MAL3-39 NA NA Dihydropyrimidine derivative Foldc hange -1.4 (at 0.6 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000193 15448148 Hsp70 Ssa1p Yeast Cytosol Activation of ATPase activity (endogenous) NA MAL3-40 NA NA Dihydropyrimidine derivative Fold change 3 (at 0.6 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000194 15448148 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA MAL3-51 NA NA Dihydropyrimidine derivative Fold change -1.3 (at 0.6 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000195 15448148 Hsp70 Ssa1p Yeast Cytosol Activation of ATPase activity (endogenous) NA MAL3-53 NA NA Dihydropyrimidine derivative Fold change 4.6 (at 0.6 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000196 15448148 Hsp70 Ssa1p Yeast Cytosol Activation of ATPase activity (endogenous) NA MAL3-54 NA NA Dihydropyrimidine derivative Fold change 1.3 (at 0.6 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000197 15448148 Hsp70 Ssa1p Yeast Cytosol Activation of ATPase activity (endogenous) NA MAL3-55 NA NA Dihydropyrimidine derivative Fold change 2.8 (at 0.6 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000198 15448148 Hsp70 Ssa1p Yeast Cytosol Activation of ATPase activity (endogenous) NA MAL3-87 NA NA Dihydropyrimidine derivative Fold change 2.6 (at 0.6 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000199 15448148 Hsp70 Ssa1p Yeast Cytosol Activation of ATPase activity (endogenous) NA MAL3-88 NA NA Dihydropyrimidine derivative Fold change 2.4 (at 0.6 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000200 15448148 Hsp70 Ssa1p Yeast Cytosol Activation of ATPase activity (endogenous) NA MAL3-90 NA NA Dihydropyrimidine derivative Fold change 6.7 (at 0.6 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000201 15448148 Hsp70 Ssa1p Yeast Cytosol Activation of ATPase activity (endogenous) NA MAL3-91 NA NA Dihydropyrimidine derivative Fold change 5 (at 0.6 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000202 15448148 Hsp70 Ssa1p Yeast Cytosol Activation of ATPase activity (endogenous) NA MAL3-101 Benzyl 4-([1,1?-biphenyl]-4-yl)-1-(6-((2-(butylamino)-1-(4-(2-methoxy-2-oxoethoxy)-3-(methoxycarbonyl)phenyl)-2-oxoethyl)(hexyl)amino)-6-oxohexyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate O=C(C1=C(C)N(CCCCCC(N(C(C2=CC=C(OCC(OC)=O)C(C(OC)=O)=C2)C(NCCCC)=O)CCCCCC)=O)C(NC1C3=CC=C(C4=CC=CC=C4)C=C3)=O)OCC5=CC=CC=C5 Dihydropyrimidine derivative Fold change 1.2 (at 0.6 mM) NA NA NA NA NA NA NA Interface between Hsp70 and Hsp40 ATPase assay NA NA NA NA NA NA NA HSPMDB000203 15448148 Hsp70 Ssa1p and TAg /ydj1P Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA NSC-630668-R/1 6-[5-(ethoxycarbonylcarbamoyl)-2,4-dioxopyrimidin-1-yl]hexyl N-[6-[6-[5-(ethoxycarbonylcarbamoyl)-2,4-dioxopyrimidin-1-yl]hexoxycarbonylamino]hexyl]carbamate CCOC(=O)NC(=O)C1=CN(C(=O)NC1=O)CCCCCCOC(=O)NCCCCCCNC(=O)OCCCCCCN2C=C(C(=O)NC2=O)C(=O)NC(=O)OCC Dihydropyrimidine derivative Fold change -1.5 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000204 15448148 Hsp70 Ssa1p and TAg /ydj1P Yeast Cytosol Activation of ATPase activity (TAg stimulated) NA MAL3-38 NA NA Dihydropyrimidine derivative Fold change 2 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000205 15448148 Hsp70 Ssa1p and TAg /ydj1P Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA MAL3-39 NA NA Dihydropyrimidine derivative Fold change -2.8 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000206 15448148 Hsp70 Ssa1p and TAg /ydj1P Yeast Cytosol Activation of ATPase activity (TAg stimulated) NA MAL3-40 NA NA Dihydropyrimidine derivative Fold change 1.5 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000207 15448148 Hsp70 Ssa1p and TAg /ydj1P Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA MAL3-51 NA NA Dihydropyrimidine derivative Fold change -1.1 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000208 15448148 Hsp70 Ssa1p and TAg /ydj1P Yeast Cytosol Activation of ATPase activity (TAg stimulated) NA MAL3-53 NA NA Dihydropyrimidine derivative Fold change 1.2 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000209 15448148 Hsp70 Ssa1p and TAg /ydj1P Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA MAL3-54 NA NA Dihydropyrimidine derivative Fold change -5.1(at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000210 15448148 Hsp70 Ssa1p and TAg /ydj1P Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA MAL3-55 NA NA Dihydropyrimidine derivative Fold change -1.8 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000211 15448148 Hsp70 Ssa1p and TAg /ydj1P Yeast Cytosol Activation of ATPase activity (TAg stimulated) NA MAL3-87 NA NA Dihydropyrimidine derivative Fold change 1.8 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000212 15448148 Hsp70 Ssa1p and TAg /ydj1P Yeast Cytosol Activation of ATPase activity (TAg stimulated) NA MAL3-88 NA NA Dihydropyrimidine derivative Fold change 1.5 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000213 15448148 Hsp70 Ssa1p and TAg /ydj1P Yeast Cytosol Activation of ATPase activity (TAg stimulated) NA MAL3-90 NA NA Dihydropyrimidine derivative Fold change 4.2 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000214 15448148 Hsp70 Ssa1p and TAg /ydj1P Yeast Cytosol Activation of ATPase activity (TAg stimulated) NA MAL3-91 NA NA Dihydropyrimidine derivative Fold change 1.4 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000215 15448148 Hsp70 Ssa1p and TAg /ydj1P Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA MAL3-101 Benzyl 4-([1,1?-biphenyl]-4-yl)-1-(6-((2-(butylamino)-1-(4-(2-methoxy-2-oxoethoxy)-3-(methoxycarbonyl)phenyl)-2-oxoethyl)(hexyl)amino)-6-oxohexyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate O=C(C1=C(C)N(CCCCCC(N(C(C2=CC=C(OCC(OC)=O)C(C(OC)=O)=C2)C(NCCCC)=O)CCCCCC)=O)C(NC1C3=CC=C(C4=CC=CC=C4)C=C3)=O)OCC5=CC=CC=C5 Dihydropyrimidine derivative Fold change -4 (at 0.3 mM) NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000216 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA MAL3-101 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 Dihydropyrimidine derivative Fold change 1.7 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000217 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA MAL3-51 N-[4-[[2-(tert-butylamino)-1-(4-iodophenyl)-2-oxoethyl]-(2-morpholin-4-ylethyl)amino]-4-oxobutyl]benzamide CC(C)(C)NC(=O)C(N(CCN1CCOCC1)C(=O)CCCNC(=O)c2ccccc2)c3ccc(I)cc3 Dihydropyrimidine derivative Fold change 1.1 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000218 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA DMT002272 6-[4-methyl-2-oxo-5-phenylmethoxycarbonyl-6-(2-phenylphenyl)-1,6-dihydropyrimidin-3-yl]hexanoic acid CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2ccccc2c3ccccc3)C(=O)OCc4ccccc4 Dihydropyrimidine derivative Fold change 1 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000219 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA DMT003034 6-(6-cyclohexyl-4-methyl-2-oxo-5-phenylmethoxycarbonyl-1,6-dihydropyrimidin-3-yl)hexanoic acid CC1=C(C(NC(=O)N1CCCCCC(O)=O)C2CCCCC2)C(=O)OCc3ccccc3 Dihydropyrimidine derivative Fold change 1 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000220 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA DMT003036 6-[6-(4-tert-butylphenyl)-4-methyl-2-oxo-5-phenylmethoxycarbonyl-1,6-dihydropyrimidin-3-yl]hexanoic acid CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2ccc(cc2)C(C)(C)C)C(=O)OCc3ccccc3 Dihydropyrimidine derivative Fold change 1 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000221 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA DMT003038 6-(6-cyclopropyl-4-methyl-2-oxo-5-phenylmethoxycarbonyl-1,6-dihydropyrimidin-3-yl)hexanoic acid CC1=C(C(NC(=O)N1CCCCCC(O)=O)C2CC2)C(=O)OCc3ccccc3 Dihydropyrimidine derivative Fold change 1.1 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000222 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA DMT003116 6-[6-(4-cyclohexylphenyl)-4-methyl-2-oxo-5-phenylmethoxycarbonyl-1,6-dihydropyrimidin-3-yl]hexanoic acid CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2ccc(cc2)C3CCCCC3)C(=O)OCc4ccccc4 Dihydropyrimidine derivative Fold change 1.1 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000223 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA MAL1-274 6-[6-(4-chlorophenyl)-4-methyl-2-oxo-5-phenylmethoxycarbonyl-1,6-dihydropyrimidin-3-yl]hexanoic acid CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2ccc(Cl)cc2)C(=O)OCc3ccccc3 Dihydropyrimidine derivative Fold change 1.3 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000224 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA MAL2-06A 6-(4-methyl-6-naphthalen-2-yl-2-oxo-5-phenylmethoxycarbonyl-1,6-dihydropyrimidin-3-yl)hexanoic acid CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2ccc3ccccc3c2)C(=O)OCc4ccccc4 Dihydropyrimidine derivative Fold change -1.1 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000225 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA MAL2-10A 6-(4-methyl-2-oxo-6-phenyl-5-phenylmethoxycarbonyl-1,6-dihydropyrimidin-3-yl)hexanoic acid CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2ccccc2)C(=O)OCc3ccccc3 Dihydropyrimidine derivative Fold change 1.5 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000226 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA MAL2-116-17 6-[4-methyl-6-(3-nitrophenyl)-2-oxo-5-phenylmethoxycarbonyl-1,6-dihydropyrimidin-3-yl]hexanoic acid CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2cccc(c2)[N+]([O-])=O)C(=O)OCc3ccccc3 Dihydropyrimidine derivative Fold change -1.1 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000227 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA MAL2-116-20 6-[4-methyl-2-oxo-5-phenylmethoxycarbonyl-6-[4-(trifluoromethyl)phenyl]-1,6-dihydropyrimidin-3-yl]hexanoic acid CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2ccc(cc2)C(F)(F)F)C(=O)OCc3ccccc3 Dihydropyrimidine derivative Fold change 1.2 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000228 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA MAL2-11B 6-[4-methyl-2-oxo-5-phenylmethoxycarbonyl-6-(4-phenylphenyl)-1,6-dihydropyrimidin-3-yl]hexanoic acid CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2ccc(cc2)c3ccccc3)C(=O)OCc4ccccc4 Dihydropyrimidine derivative Fold change 1.1 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000229 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA MAL2-13 6-[4-methyl-6-(4-nitrophenyl)-2-oxo-5-phenylmethoxycarbonyl-1,6-dihydropyrimidin-3-yl]hexanoic acid CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2ccc(cc2)[N+]([O-])=O)C(=O)OCc3ccccc3 Dihydropyrimidine derivative Fold change 1.2 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000230 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA DMT003042 benzyl 3-(6-methoxy-6-oxohexyl)-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate COC(=O)CCCCCN1C(=O)NC(c2ccc(cc2)c3ccccc3)C(=C1C)C(=O)OCc4ccccc4 Dihydropyrimidine derivative Fold change 2.6 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000231 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA DMT003044 benzyl 3-(6-methoxy-6-oxohexyl)-4-methyl-2-oxo-6-phenyl-1,6-dihydropyrimidine-5-carboxylate COC(=O)CCCCCN1C(=O)NC(c2ccccc2)C(=C1C)C(=O)OCc3ccccc3 Dihydropyrimidine derivative Fold change 2.3 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000232 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA DMT003046 benzyl 6-cyclopropyl-3-(6-methoxy-6-oxohexyl)-4-methyl-2-oxo-1,6-dihydropyrimidine-5-carboxylate COC(=O)CCCCCN1C(=O)NC(C2CC2)C(=C1C)C(=O)OCc3ccccc3 Dihydropyrimidine derivative Fold change 1.9 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000233 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA DMT003082 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-[4-(trifluoromethyl)phenyl]-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)C(F)(F)F)C(=C2C)C(=O)OCc4ccccc4 Dihydropyrimidine derivative Fold change 1 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000234 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA DMT003084 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-6-(4-tert-butylphenyl)-4-methyl-2-oxo-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)C(C)(C)C)C(=C2C)C(=O)OCc4ccccc4 Dihydropyrimidine derivative Fold change 1.2 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000235 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA DMT003086 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-6-(3-nitrophenyl)-2-oxo-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3cccc(c3)[N+]([O-])=O)C(=C2C)C(=O)OCc4ccccc4 Dihydropyrimidine derivative Fold change 1.1 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000236 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA DMT003088 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-phenyl-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccccc3)C(=C2C)C(=O)OCc4ccccc4 Dihydropyrimidine derivative Fold change 1.1 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000237 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA DMT003090 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-6-(4-chlorophenyl)-4-methyl-2-oxo-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc(Cl)cc3)C(=C2C)C(=O)OCc4ccccc4 Dihydropyrimidine derivative Fold change 1.3 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000238 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA DMT003092 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-6-(4-nitrophenyl)-2-oxo-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)[N+]([O-])=O)C(=C2C)C(=O)OCc4ccccc4 Dihydropyrimidine derivative Fold change 1 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000239 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA DMT003094 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-6-naphthalen-2-yl-2-oxo-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc4ccccc4c3)C(=C2C)C(=O)OCc5ccccc5 Dihydropyrimidine derivative Fold change 1 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000240 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA DMT003096 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(2-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccccc3c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 Dihydropyrimidine derivative Fold change -1.1 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000241 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA DMT003100 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-6-cyclohexyl-4-methyl-2-oxo-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(C3CCCCC3)C(=C2C)C(=O)OCc4ccccc4 Dihydropyrimidine derivative Fold change 1.2 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000242 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA DMT003132 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-6-cyclopropyl-4-methyl-2-oxo-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(C3CC3)C(=C2C)C(=O)OCc4ccccc4 Dihydropyrimidine derivative Fold change 1.2 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000243 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA DMT003134 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-6-(4-cyclohexylphenyl)-4-methyl-2-oxo-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)C4CCCCC4)C(=C2C)C(=O)OCc5ccccc5 Dihydropyrimidine derivative Fold change 2.2 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000244 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA DMT002218 benzyl 3-[6-[[2-(butylamino)-2-oxo-1-phenylethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccccc1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 Dihydropyrimidine derivative Fold change 3.2 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000245 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA DMT002220 benzyl 3-[6-[[2-(butylamino)-1-(4-hydroxyphenyl)-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(O)cc1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 Dihydropyrimidine derivative Fold change 11.8 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000246 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA DMT002222 benzyl 3-[6-[[2-(butylamino)-2-oxo-1-(4-phenylphenyl)ethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(cc1)c2ccccc2)C(=O)CCCCCN3C(=O)NC(c4ccc(cc4)c5ccccc5)C(=C3C)C(=O)OCc6ccccc6 Dihydropyrimidine derivative Fold change 9.9 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000247 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA DMT002260 benzyl 3-[6-[[2-(butylamino)-1-(3-methoxycarbonylphenyl)-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1cccc(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 Dihydropyrimidine derivative Fold change 3.7 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000248 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA DMT002262 benzyl 3-[6-[[1-(butylamino)-1-oxopropan-2-yl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C)C(=O)NCCCC)C(=O)CCCCCN1C(=O)NC(c2ccc(cc2)c3ccccc3)C(=C1C)C(=O)OCc4ccccc4 Dihydropyrimidine derivative Fold change 1.6 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000249 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA DMT002264 benzyl 3-[6-[[2-(butylamino)-1-cyclohexyl-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C1CCCCC1)C(=O)NCCCC)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 Dihydropyrimidine derivative Fold change 3.2 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000250 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA DMT003058 benzyl 3-[6-[[2-(butylamino)-2-oxo-1-pyridin-2-ylethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccccn1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 Dihydropyrimidine derivative Fold change 4.2 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000251 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA DMT003112 benzyl 3-[6-[[2-(butylamino)-1-(4-hydroxy-3-methoxycarbonylphenyl)-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(O)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 Dihydropyrimidine derivative Fold change 19.1 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000252 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA DMT003114 benzyl 3-[6-[[2-(butylamino)-1-[4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)cc1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 Dihydropyrimidine derivative Fold change 1.1 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000253 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA DMT002286 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-[2-(cyclohexen-1-yl)ethyl]amino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCNC(=O)C(N(CCC1=CCCCC1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5)c6ccc(OCC(=O)OC)c(c6)C(=O)OC Dihydropyrimidine derivative Fold change 6.1 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000254 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA DMT003052 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-(2-methoxyethyl)amino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCNC(=O)C(N(CCOC)C(=O)CCCCCN1C(=O)NC(c2ccc(cc2)c3ccccc3)C(=C1C)C(=O)OCc4ccccc4)c5ccc(OCC(=O)OC)c(c5)C(=O)OC Dihydropyrimidine derivative Fold change 1.5 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000255 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA DMT003102 benzyl 3-[6-[benzyl-[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]amino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCNC(=O)C(N(Cc1ccccc1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5)c6ccc(OCC(=O)OC)c(c6)C(=O)OC Dihydropyrimidine derivative Fold change 1.5 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000256 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA DMT003104 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-(2-phenylethyl)amino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCNC(=O)C(N(CCc1ccccc1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5)c6ccc(OCC(=O)OC)c(c6)C(=O)OC Dihydropyrimidine derivative Fold change 12.3 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000257 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA DMT003106 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-(pyridin-2-ylmethyl)amino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCNC(=O)C(N(Cc1ccccn1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5)c6ccc(OCC(=O)OC)c(c6)C(=O)OC Dihydropyrimidine derivative Fold change 1 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000258 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA DMT003108 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-(2-pyridin-2-ylethyl)amino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCNC(=O)C(N(CCc1ccccn1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5)c6ccc(OCC(=O)OC)c(c6)C(=O)OC Dihydropyrimidine derivative Fold change -1.1 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000259 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA DMT003110 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-[2-(1H-indol-3-yl)ethyl]amino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCNC(=O)C(N(CCc1c[nH]c2ccccc12)C(=O)CCCCCN3C(=O)NC(c4ccc(cc4)c5ccccc5)C(=C3C)C(=O)OCc6ccccc6)c7ccc(OCC(=O)OC)c(c7)C(=O)OC Dihydropyrimidine derivative Fold change 10.3 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000260 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA DMT003020 5-[2-(butylamino)-1-[hexyl-[6-[4-methyl-2-oxo-5-phenylmethoxycarbonyl-6-(4-phenylphenyl)-1,6-dihydropyrimidin-3-yl]hexanoyl]amino]-2-oxoethyl]-2-(carboxymethoxy)benzoic acid CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(O)=O)c(c1)C(O)=O)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 Dihydropyrimidine derivative Fold change 1.1 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000261 18164205 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA DMT003024 benzyl 3-[6-[[2-(butylamino)-2-oxo-1-(4-phenylphenyl)ethyl]-(2-morpholin-4-ylethyl)amino]-6-oxohexyl]-4-methyl-6-(4-nitrophenyl)-2-oxo-1,6-dihydropyrimidine-5-carboxylate CCCCNC(=O)C(N(CCN1CCOCC1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)[N+]([O-])=O)C(=C2C)C(=O)OCc4ccccc4)c5ccc(cc5)c6ccccc6 Dihydropyrimidine derivative Fold change 2.3 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000262 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA MAL3-101 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 Dihydropyrimidine derivative Fold change -2.0 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000263 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA MAL3-51 N-[4-[[2-(tert-butylamino)-1-(4-iodophenyl)-2-oxoethyl]-(2-morpholin-4-ylethyl)amino]-4-oxobutyl]benzamide CC(C)(C)NC(=O)C(N(CCN1CCOCC1)C(=O)CCCNC(=O)c2ccccc2)c3ccc(I)cc3 Dihydropyrimidine derivative Fold change -2.0 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000264 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA DMT002272 6-[4-methyl-2-oxo-5-phenylmethoxycarbonyl-6-(2-phenylphenyl)-1,6-dihydropyrimidin-3-yl]hexanoic acid CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2ccccc2c3ccccc3)C(=O)OCc4ccccc4 Dihydropyrimidine derivative Fold change -5.0 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000265 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA DMT003034 6-(6-cyclohexyl-4-methyl-2-oxo-5-phenylmethoxycarbonyl-1,6-dihydropyrimidin-3-yl)hexanoic acid CC1=C(C(NC(=O)N1CCCCCC(O)=O)C2CCCCC2)C(=O)OCc3ccccc3 Dihydropyrimidine derivative Fold change 1.5 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000266 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA DMT003036 6-[6-(4-tert-butylphenyl)-4-methyl-2-oxo-5-phenylmethoxycarbonyl-1,6-dihydropyrimidin-3-yl]hexanoic acid CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2ccc(cc2)C(C)(C)C)C(=O)OCc3ccccc3 Dihydropyrimidine derivative Fold change -3.5 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000267 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA DMT003038 6-(6-cyclopropyl-4-methyl-2-oxo-5-phenylmethoxycarbonyl-1,6-dihydropyrimidin-3-yl)hexanoic acid CC1=C(C(NC(=O)N1CCCCCC(O)=O)C2CC2)C(=O)OCc3ccccc3 Dihydropyrimidine derivative Fold change 1 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000268 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA DMT003116 6-[6-(4-cyclohexylphenyl)-4-methyl-2-oxo-5-phenylmethoxycarbonyl-1,6-dihydropyrimidin-3-yl]hexanoic acid CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2ccc(cc2)C3CCCCC3)C(=O)OCc4ccccc4 Dihydropyrimidine derivative Fold change -2.4 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000269 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA MAL1-274 6-[6-(4-chlorophenyl)-4-methyl-2-oxo-5-phenylmethoxycarbonyl-1,6-dihydropyrimidin-3-yl]hexanoic acid CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2ccc(Cl)cc2)C(=O)OCc3ccccc3 Dihydropyrimidine derivative Fold change -1.6 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000270 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA MAL2-06A 6-(4-methyl-6-naphthalen-2-yl-2-oxo-5-phenylmethoxycarbonyl-1,6-dihydropyrimidin-3-yl)hexanoic acid CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2ccc3ccccc3c2)C(=O)OCc4ccccc4 Dihydropyrimidine derivative Fold change -1.4 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000271 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA MAL2-10A 6-(4-methyl-2-oxo-6-phenyl-5-phenylmethoxycarbonyl-1,6-dihydropyrimidin-3-yl)hexanoic acid CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2ccccc2)C(=O)OCc3ccccc3 Dihydropyrimidine derivative Fold change -1.1 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000272 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA MAL2-116-17 6-[4-methyl-6-(3-nitrophenyl)-2-oxo-5-phenylmethoxycarbonyl-1,6-dihydropyrimidin-3-yl]hexanoic acid CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2cccc(c2)[N+]([O-])=O)C(=O)OCc3ccccc3 Dihydropyrimidine derivative Fold change 1.1 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000273 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA MAL2-116-20 6-[4-methyl-2-oxo-5-phenylmethoxycarbonyl-6-[4-(trifluoromethyl)phenyl]-1,6-dihydropyrimidin-3-yl]hexanoic acid CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2ccc(cc2)C(F)(F)F)C(=O)OCc3ccccc3 Dihydropyrimidine derivative Fold change 1.1 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000274 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA MAL2-11B 6-[4-methyl-2-oxo-5-phenylmethoxycarbonyl-6-(4-phenylphenyl)-1,6-dihydropyrimidin-3-yl]hexanoic acid CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2ccc(cc2)c3ccccc3)C(=O)OCc4ccccc4 Dihydropyrimidine derivative Fold change -3.5 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000275 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA MAL2-13 6-[4-methyl-6-(4-nitrophenyl)-2-oxo-5-phenylmethoxycarbonyl-1,6-dihydropyrimidin-3-yl]hexanoic acid CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2ccc(cc2)[N+]([O-])=O)C(=O)OCc3ccccc3 Dihydropyrimidine derivative Fold change 1.1 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000276 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA DMT003042 benzyl 3-(6-methoxy-6-oxohexyl)-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate COC(=O)CCCCCN1C(=O)NC(c2ccc(cc2)c3ccccc3)C(=C1C)C(=O)OCc4ccccc4 Dihydropyrimidine derivative Fold change -1.2 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000277 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA DMT003044 benzyl 3-(6-methoxy-6-oxohexyl)-4-methyl-2-oxo-6-phenyl-1,6-dihydropyrimidine-5-carboxylate COC(=O)CCCCCN1C(=O)NC(c2ccccc2)C(=C1C)C(=O)OCc3ccccc3 Dihydropyrimidine derivative Fold change -1.7 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000278 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA DMT003046 benzyl 6-cyclopropyl-3-(6-methoxy-6-oxohexyl)-4-methyl-2-oxo-1,6-dihydropyrimidine-5-carboxylate COC(=O)CCCCCN1C(=O)NC(C2CC2)C(=C1C)C(=O)OCc3ccccc3 Dihydropyrimidine derivative Fold change 1 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000279 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA DMT003082 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-[4-(trifluoromethyl)phenyl]-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)C(F)(F)F)C(=C2C)C(=O)OCc4ccccc4 Dihydropyrimidine derivative Fold change -4.8 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000280 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA DMT003084 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-6-(4-tert-butylphenyl)-4-methyl-2-oxo-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)C(C)(C)C)C(=C2C)C(=O)OCc4ccccc4 Dihydropyrimidine derivative Fold change -5.2 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000281 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA DMT003086 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-6-(3-nitrophenyl)-2-oxo-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3cccc(c3)[N+]([O-])=O)C(=C2C)C(=O)OCc4ccccc4 Dihydropyrimidine derivative Fold change -1.5 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000282 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA DMT003088 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-phenyl-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccccc3)C(=C2C)C(=O)OCc4ccccc4 Dihydropyrimidine derivative Fold change -1.1 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000283 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA DMT003090 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-6-(4-chlorophenyl)-4-methyl-2-oxo-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc(Cl)cc3)C(=C2C)C(=O)OCc4ccccc4 Dihydropyrimidine derivative Fold change -5.1 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000284 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA DMT003092 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-6-(4-nitrophenyl)-2-oxo-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)[N+]([O-])=O)C(=C2C)C(=O)OCc4ccccc4 Dihydropyrimidine derivative Fold change -1.1 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000285 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA DMT003094 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-6-naphthalen-2-yl-2-oxo-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc4ccccc4c3)C(=C2C)C(=O)OCc5ccccc5 Dihydropyrimidine derivative Fold change -1.1 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000286 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA DMT003096 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(2-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccccc3c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 Dihydropyrimidine derivative Fold change -4.0 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000287 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA DMT003100 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-6-cyclohexyl-4-methyl-2-oxo-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(C3CCCCC3)C(=C2C)C(=O)OCc4ccccc4 Dihydropyrimidine derivative Fold change -2.1 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000288 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA DMT003132 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-6-cyclopropyl-4-methyl-2-oxo-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(C3CC3)C(=C2C)C(=O)OCc4ccccc4 Dihydropyrimidine derivative Fold change -2.6 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000289 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA DMT003134 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-6-(4-cyclohexylphenyl)-4-methyl-2-oxo-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)C4CCCCC4)C(=C2C)C(=O)OCc5ccccc5 Dihydropyrimidine derivative Fold change -1.6 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000290 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA DMT002218 benzyl 3-[6-[[2-(butylamino)-2-oxo-1-phenylethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccccc1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 Dihydropyrimidine derivative Fold change 1.1 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000291 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA DMT002220 benzyl 3-[6-[[2-(butylamino)-1-(4-hydroxyphenyl)-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(O)cc1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 Dihydropyrimidine derivative Fold change 9.2 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000292 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA DMT002222 benzyl 3-[6-[[2-(butylamino)-2-oxo-1-(4-phenylphenyl)ethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(cc1)c2ccccc2)C(=O)CCCCCN3C(=O)NC(c4ccc(cc4)c5ccccc5)C(=C3C)C(=O)OCc6ccccc6 Dihydropyrimidine derivative Fold change 6 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000293 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA DMT002260 benzyl 3-[6-[[2-(butylamino)-1-(3-methoxycarbonylphenyl)-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1cccc(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 Dihydropyrimidine derivative Fold change -2.0 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000294 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA DMT002262 benzyl 3-[6-[[1-(butylamino)-1-oxopropan-2-yl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C)C(=O)NCCCC)C(=O)CCCCCN1C(=O)NC(c2ccc(cc2)c3ccccc3)C(=C1C)C(=O)OCc4ccccc4 Dihydropyrimidine derivative Fold change 1 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000295 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA DMT002264 benzyl 3-[6-[[2-(butylamino)-1-cyclohexyl-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C1CCCCC1)C(=O)NCCCC)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 Dihydropyrimidine derivative Fold change 1.1 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000296 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA DMT003058 benzyl 3-[6-[[2-(butylamino)-2-oxo-1-pyridin-2-ylethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccccn1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 Dihydropyrimidine derivative Fold change 5.5 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000297 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA DMT003112 benzyl 3-[6-[[2-(butylamino)-1-(4-hydroxy-3-methoxycarbonylphenyl)-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(O)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 Dihydropyrimidine derivative Fold change 2.1 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000298 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA DMT003114 benzyl 3-[6-[[2-(butylamino)-1-[4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)cc1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 Dihydropyrimidine derivative Fold change 1.2 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000299 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA DMT002286 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-[2-(cyclohexen-1-yl)ethyl]amino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCNC(=O)C(N(CCC1=CCCCC1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5)c6ccc(OCC(=O)OC)c(c6)C(=O)OC Dihydropyrimidine derivative Fold change -1.2 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000300 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA DMT003052 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-(2-methoxyethyl)amino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCNC(=O)C(N(CCOC)C(=O)CCCCCN1C(=O)NC(c2ccc(cc2)c3ccccc3)C(=C1C)C(=O)OCc4ccccc4)c5ccc(OCC(=O)OC)c(c5)C(=O)OC Dihydropyrimidine derivative Fold change -1.8 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000301 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA DMT003102 benzyl 3-[6-[benzyl-[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]amino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCNC(=O)C(N(Cc1ccccc1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5)c6ccc(OCC(=O)OC)c(c6)C(=O)OC Dihydropyrimidine derivative Fold change -1.9 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000302 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA DMT003104 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-(2-phenylethyl)amino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCNC(=O)C(N(CCc1ccccc1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5)c6ccc(OCC(=O)OC)c(c6)C(=O)OC Dihydropyrimidine derivative Fold change 1.3 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000303 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA DMT003106 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-(pyridin-2-ylmethyl)amino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCNC(=O)C(N(Cc1ccccn1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5)c6ccc(OCC(=O)OC)c(c6)C(=O)OC Dihydropyrimidine derivative Fold change -1.1 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000304 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA DMT003108 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-(2-pyridin-2-ylethyl)amino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCNC(=O)C(N(CCc1ccccn1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5)c6ccc(OCC(=O)OC)c(c6)C(=O)OC Dihydropyrimidine derivative Fold change -1.1 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000305 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA DMT003110 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-[2-(1H-indol-3-yl)ethyl]amino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCNC(=O)C(N(CCc1c[nH]c2ccccc12)C(=O)CCCCCN3C(=O)NC(c4ccc(cc4)c5ccccc5)C(=C3C)C(=O)OCc6ccccc6)c7ccc(OCC(=O)OC)c(c7)C(=O)OC Dihydropyrimidine derivative Fold change -1.3 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000306 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA DMT003020 5-[2-(butylamino)-1-[hexyl-[6-[4-methyl-2-oxo-5-phenylmethoxycarbonyl-6-(4-phenylphenyl)-1,6-dihydropyrimidin-3-yl]hexanoyl]amino]-2-oxoethyl]-2-(carboxymethoxy)benzoic acid CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(O)=O)c(c1)C(O)=O)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 Dihydropyrimidine derivative Fold change -2.2 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000307 18164205 Hsp70 Ssa1p and TAg Yeast Cytosol Inhibition of ATPase activity (TAg stimulated) NA DMT003024 benzyl 3-[6-[[2-(butylamino)-2-oxo-1-(4-phenylphenyl)ethyl]-(2-morpholin-4-ylethyl)amino]-6-oxohexyl]-4-methyl-6-(4-nitrophenyl)-2-oxo-1,6-dihydropyrimidine-5-carboxylate CCCCNC(=O)C(N(CCN1CCOCC1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)[N+]([O-])=O)C(=C2C)C(=O)OCc4ccccc4)c5ccc(cc5)c6ccccc6 Dihydropyrimidine derivative Fold change -5.0 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000308 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity MAL3-101 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 Dihydropyrimidine derivative NA NA NA NA NA NA NA 27 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000309 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity MAL3-51 N-[4-[[2-(tert-butylamino)-1-(4-iodophenyl)-2-oxoethyl]-(2-morpholin-4-ylethyl)amino]-4-oxobutyl]benzamide CC(C)(C)NC(=O)C(N(CCN1CCOCC1)C(=O)CCCNC(=O)c2ccccc2)c3ccc(I)cc3 Dihydropyrimidine derivative NA NA NA NA NA NA NA >50 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000310 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT002272 6-[4-methyl-2-oxo-5-phenylmethoxycarbonyl-6-(2-phenylphenyl)-1,6-dihydropyrimidin-3-yl]hexanoic acid CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2ccccc2c3ccccc3)C(=O)OCc4ccccc4 Dihydropyrimidine derivative NA NA NA NA NA NA NA >50 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000311 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT003034 6-(6-cyclohexyl-4-methyl-2-oxo-5-phenylmethoxycarbonyl-1,6-dihydropyrimidin-3-yl)hexanoic acid CC1=C(C(NC(=O)N1CCCCCC(O)=O)C2CCCCC2)C(=O)OCc3ccccc3 Dihydropyrimidine derivative NA NA NA NA NA NA NA >50 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000312 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT003036 6-[6-(4-tert-butylphenyl)-4-methyl-2-oxo-5-phenylmethoxycarbonyl-1,6-dihydropyrimidin-3-yl]hexanoic acid CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2ccc(cc2)C(C)(C)C)C(=O)OCc3ccccc3 Dihydropyrimidine derivative NA NA NA NA NA NA NA >50 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000313 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT003038 6-(6-cyclopropyl-4-methyl-2-oxo-5-phenylmethoxycarbonyl-1,6-dihydropyrimidin-3-yl)hexanoic acid CC1=C(C(NC(=O)N1CCCCCC(O)=O)C2CC2)C(=O)OCc3ccccc3 Dihydropyrimidine derivative NA NA NA NA NA NA NA >50 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000314 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT003116 6-[6-(4-cyclohexylphenyl)-4-methyl-2-oxo-5-phenylmethoxycarbonyl-1,6-dihydropyrimidin-3-yl]hexanoic acid CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2ccc(cc2)C3CCCCC3)C(=O)OCc4ccccc4 Dihydropyrimidine derivative NA NA NA NA NA NA NA >50 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000315 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity MAL1-274 6-[6-(4-chlorophenyl)-4-methyl-2-oxo-5-phenylmethoxycarbonyl-1,6-dihydropyrimidin-3-yl]hexanoic acid CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2ccc(Cl)cc2)C(=O)OCc3ccccc3 Dihydropyrimidine derivative NA NA NA NA NA NA NA >50 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000316 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity MAL2-06A 6-(4-methyl-6-naphthalen-2-yl-2-oxo-5-phenylmethoxycarbonyl-1,6-dihydropyrimidin-3-yl)hexanoic acid CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2ccc3ccccc3c2)C(=O)OCc4ccccc4 Dihydropyrimidine derivative NA NA NA NA NA NA NA >50 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000317 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity MAL2-10A 6-(4-methyl-2-oxo-6-phenyl-5-phenylmethoxycarbonyl-1,6-dihydropyrimidin-3-yl)hexanoic acid CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2ccccc2)C(=O)OCc3ccccc3 Dihydropyrimidine derivative NA NA NA NA NA NA NA >50 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000318 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity MAL2-116-17 6-[4-methyl-6-(3-nitrophenyl)-2-oxo-5-phenylmethoxycarbonyl-1,6-dihydropyrimidin-3-yl]hexanoic acid CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2cccc(c2)[N+]([O-])=O)C(=O)OCc3ccccc3 Dihydropyrimidine derivative NA NA NA NA NA NA NA >50 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000319 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity MAL2-116-20 6-[4-methyl-2-oxo-5-phenylmethoxycarbonyl-6-[4-(trifluoromethyl)phenyl]-1,6-dihydropyrimidin-3-yl]hexanoic acid CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2ccc(cc2)C(F)(F)F)C(=O)OCc3ccccc3 Dihydropyrimidine derivative NA NA NA NA NA NA NA >50 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000320 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity MAL2-11B 6-[4-methyl-2-oxo-5-phenylmethoxycarbonyl-6-(4-phenylphenyl)-1,6-dihydropyrimidin-3-yl]hexanoic acid CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2ccc(cc2)c3ccccc3)C(=O)OCc4ccccc4 Dihydropyrimidine derivative NA NA NA NA NA NA NA >50 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000321 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity MAL2-13 6-[4-methyl-6-(4-nitrophenyl)-2-oxo-5-phenylmethoxycarbonyl-1,6-dihydropyrimidin-3-yl]hexanoic acid CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2ccc(cc2)[N+]([O-])=O)C(=O)OCc3ccccc3 Dihydropyrimidine derivative NA NA NA NA NA NA NA >50 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000322 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT003042 benzyl 3-(6-methoxy-6-oxohexyl)-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate COC(=O)CCCCCN1C(=O)NC(c2ccc(cc2)c3ccccc3)C(=C1C)C(=O)OCc4ccccc4 Dihydropyrimidine derivative NA NA NA NA NA NA NA >50 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000323 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT003044 benzyl 3-(6-methoxy-6-oxohexyl)-4-methyl-2-oxo-6-phenyl-1,6-dihydropyrimidine-5-carboxylate COC(=O)CCCCCN1C(=O)NC(c2ccccc2)C(=C1C)C(=O)OCc3ccccc3 Dihydropyrimidine derivative NA NA NA NA NA NA NA >50 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000324 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT003046 benzyl 6-cyclopropyl-3-(6-methoxy-6-oxohexyl)-4-methyl-2-oxo-1,6-dihydropyrimidine-5-carboxylate COC(=O)CCCCCN1C(=O)NC(C2CC2)C(=C1C)C(=O)OCc3ccccc3 Dihydropyrimidine derivative NA NA NA NA NA NA NA >50 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000325 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT003082 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-[4-(trifluoromethyl)phenyl]-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)C(F)(F)F)C(=C2C)C(=O)OCc4ccccc4 Dihydropyrimidine derivative NA NA NA NA NA NA NA >50 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000326 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT003084 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-6-(4-tert-butylphenyl)-4-methyl-2-oxo-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)C(C)(C)C)C(=C2C)C(=O)OCc4ccccc4 Dihydropyrimidine derivative NA NA NA NA NA NA NA 29 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000327 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT003086 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-6-(3-nitrophenyl)-2-oxo-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3cccc(c3)[N+]([O-])=O)C(=C2C)C(=O)OCc4ccccc4 Dihydropyrimidine derivative NA NA NA NA NA NA NA 6 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000328 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT003088 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-phenyl-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccccc3)C(=C2C)C(=O)OCc4ccccc4 Dihydropyrimidine derivative NA NA NA NA NA NA NA 6.5 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000329 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT003090 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-6-(4-chlorophenyl)-4-methyl-2-oxo-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc(Cl)cc3)C(=C2C)C(=O)OCc4ccccc4 Dihydropyrimidine derivative NA NA NA NA NA NA NA 16 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000330 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT003092 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-6-(4-nitrophenyl)-2-oxo-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)[N+]([O-])=O)C(=C2C)C(=O)OCc4ccccc4 Dihydropyrimidine derivative NA NA NA NA NA NA NA 6.9 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000331 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT003094 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-6-naphthalen-2-yl-2-oxo-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc4ccccc4c3)C(=C2C)C(=O)OCc5ccccc5 Dihydropyrimidine derivative NA NA NA NA NA NA NA 10 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000332 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT003096 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(2-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccccc3c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 Dihydropyrimidine derivative NA NA NA NA NA NA NA 17 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000333 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT003100 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-6-cyclohexyl-4-methyl-2-oxo-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(C3CCCCC3)C(=C2C)C(=O)OCc4ccccc4 Dihydropyrimidine derivative NA NA NA NA NA NA NA 6.3 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000334 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT003132 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-6-cyclopropyl-4-methyl-2-oxo-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(C3CC3)C(=C2C)C(=O)OCc4ccccc4 Dihydropyrimidine derivative NA NA NA NA NA NA NA 6.2 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000335 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT003134 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-6-(4-cyclohexylphenyl)-4-methyl-2-oxo-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)C4CCCCC4)C(=C2C)C(=O)OCc5ccccc5 Dihydropyrimidine derivative NA NA NA NA NA NA NA 42 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000336 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT002218 benzyl 3-[6-[[2-(butylamino)-2-oxo-1-phenylethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccccc1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 Dihydropyrimidine derivative NA NA NA NA NA NA NA >50 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000337 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT002220 benzyl 3-[6-[[2-(butylamino)-1-(4-hydroxyphenyl)-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(O)cc1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 Dihydropyrimidine derivative NA NA NA NA NA NA NA >50 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000338 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT002222 benzyl 3-[6-[[2-(butylamino)-2-oxo-1-(4-phenylphenyl)ethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(cc1)c2ccccc2)C(=O)CCCCCN3C(=O)NC(c4ccc(cc4)c5ccccc5)C(=C3C)C(=O)OCc6ccccc6 Dihydropyrimidine derivative NA NA NA NA NA NA NA >50 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000339 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT002260 benzyl 3-[6-[[2-(butylamino)-1-(3-methoxycarbonylphenyl)-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1cccc(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 Dihydropyrimidine derivative NA NA NA NA NA NA NA >50 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000340 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT002262 benzyl 3-[6-[[1-(butylamino)-1-oxopropan-2-yl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C)C(=O)NCCCC)C(=O)CCCCCN1C(=O)NC(c2ccc(cc2)c3ccccc3)C(=C1C)C(=O)OCc4ccccc4 Dihydropyrimidine derivative NA NA NA NA NA NA NA >50 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000341 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT002264 benzyl 3-[6-[[2-(butylamino)-1-cyclohexyl-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C1CCCCC1)C(=O)NCCCC)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 Dihydropyrimidine derivative NA NA NA NA NA NA NA >50 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000342 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT003058 benzyl 3-[6-[[2-(butylamino)-2-oxo-1-pyridin-2-ylethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccccn1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 Dihydropyrimidine derivative NA NA NA NA NA NA NA >50 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000343 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT003112 benzyl 3-[6-[[2-(butylamino)-1-(4-hydroxy-3-methoxycarbonylphenyl)-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(O)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 Dihydropyrimidine derivative NA NA NA NA NA NA NA >50 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000344 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT003114 benzyl 3-[6-[[2-(butylamino)-1-[4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)cc1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 Dihydropyrimidine derivative NA NA NA NA NA NA NA 48 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000345 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT002286 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-[2-(cyclohexen-1-yl)ethyl]amino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCNC(=O)C(N(CCC1=CCCCC1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5)c6ccc(OCC(=O)OC)c(c6)C(=O)OC Dihydropyrimidine derivative NA NA NA NA NA NA NA 39 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000346 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT003052 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-(2-methoxyethyl)amino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCNC(=O)C(N(CCOC)C(=O)CCCCCN1C(=O)NC(c2ccc(cc2)c3ccccc3)C(=C1C)C(=O)OCc4ccccc4)c5ccc(OCC(=O)OC)c(c5)C(=O)OC Dihydropyrimidine derivative NA NA NA NA NA NA NA 8.8 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000347 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT003102 benzyl 3-[6-[benzyl-[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]amino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCNC(=O)C(N(Cc1ccccc1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5)c6ccc(OCC(=O)OC)c(c6)C(=O)OC Dihydropyrimidine derivative NA NA NA NA NA NA NA 14 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000348 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT003104 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-(2-phenylethyl)amino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCNC(=O)C(N(CCc1ccccc1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5)c6ccc(OCC(=O)OC)c(c6)C(=O)OC Dihydropyrimidine derivative NA NA NA NA NA NA NA 32 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000349 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT003106 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-(pyridin-2-ylmethyl)amino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCNC(=O)C(N(Cc1ccccn1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5)c6ccc(OCC(=O)OC)c(c6)C(=O)OC Dihydropyrimidine derivative NA NA NA NA NA NA NA 7.1 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000350 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT003108 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-(2-pyridin-2-ylethyl)amino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCNC(=O)C(N(CCc1ccccn1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5)c6ccc(OCC(=O)OC)c(c6)C(=O)OC Dihydropyrimidine derivative NA NA NA NA NA NA NA 7.5 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000351 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT003110 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-[2-(1H-indol-3-yl)ethyl]amino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCNC(=O)C(N(CCc1c[nH]c2ccccc12)C(=O)CCCCCN3C(=O)NC(c4ccc(cc4)c5ccccc5)C(=C3C)C(=O)OCc6ccccc6)c7ccc(OCC(=O)OC)c(c7)C(=O)OC Dihydropyrimidine derivative NA NA NA NA NA NA NA >50 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000352 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT003020 5-[2-(butylamino)-1-[hexyl-[6-[4-methyl-2-oxo-5-phenylmethoxycarbonyl-6-(4-phenylphenyl)-1,6-dihydropyrimidin-3-yl]hexanoyl]amino]-2-oxoethyl]-2-(carboxymethoxy)benzoic acid CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(O)=O)c(c1)C(O)=O)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 Dihydropyrimidine derivative NA NA NA NA NA NA NA >50 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000353 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT003024 benzyl 3-[6-[[2-(butylamino)-2-oxo-1-(4-phenylphenyl)ethyl]-(2-morpholin-4-ylethyl)amino]-6-oxohexyl]-4-methyl-6-(4-nitrophenyl)-2-oxo-1,6-dihydropyrimidine-5-carboxylate CCCCNC(=O)C(N(CCN1CCOCC1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)[N+]([O-])=O)C(=C2C)C(=O)OCc4ccccc4)c5ccc(cc5)c6ccccc6 Dihydropyrimidine derivative NA NA NA NA NA NA NA >50 NA NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000354 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity MAL3-101 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 Dihydropyrimidine derivative NA NA NA NA NA NA NA 14.7 NA NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000355 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity MAL3-51 N-[4-[[2-(tert-butylamino)-1-(4-iodophenyl)-2-oxoethyl]-(2-morpholin-4-ylethyl)amino]-4-oxobutyl]benzamide CC(C)(C)NC(=O)C(N(CCN1CCOCC1)C(=O)CCCNC(=O)c2ccccc2)c3ccc(I)cc3 Dihydropyrimidine derivative NA NA NA NA NA NA NA >50 NA NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000356 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT003088 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-phenyl-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccccc3)C(=C2C)C(=O)OCc4ccccc4 Dihydropyrimidine derivative NA NA NA NA NA NA NA 2.4 NA NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000357 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT003132 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-6-cyclopropyl-4-methyl-2-oxo-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(C3CC3)C(=C2C)C(=O)OCc4ccccc4 Dihydropyrimidine derivative NA NA NA NA NA NA NA 6.3 NA NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000358 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT003052 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-(2-methoxyethyl)amino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCNC(=O)C(N(CCOC)C(=O)CCCCCN1C(=O)NC(c2ccc(cc2)c3ccccc3)C(=C1C)C(=O)OCc4ccccc4)c5ccc(OCC(=O)OC)c(c5)C(=O)OC Dihydropyrimidine derivative NA NA NA NA NA NA NA 7.8 NA NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000359 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity MAL3-101 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 Dihydropyrimidine derivative NA NA NA NA NA NA NA >50 NA NA NA MTT viability assay NA NA NA HT29 Cancer HSPMDB000360 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity MAL3-51 N-[4-[[2-(tert-butylamino)-1-(4-iodophenyl)-2-oxoethyl]-(2-morpholin-4-ylethyl)amino]-4-oxobutyl]benzamide CC(C)(C)NC(=O)C(N(CCN1CCOCC1)C(=O)CCCNC(=O)c2ccccc2)c3ccc(I)cc3 Dihydropyrimidine derivative NA NA NA NA NA NA NA >50 NA NA NA MTT viability assay NA NA NA HT29 Cancer HSPMDB000361 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT003088 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-phenyl-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccccc3)C(=C2C)C(=O)OCc4ccccc4 Dihydropyrimidine derivative NA NA NA NA NA NA NA 4.8 NA NA NA MTT viability assay NA NA NA HT29 Cancer HSPMDB000362 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT003132 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-6-cyclopropyl-4-methyl-2-oxo-1,6-dihydropyrimidine-5-carboxylate CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(C3CC3)C(=C2C)C(=O)OCc4ccccc4 Dihydropyrimidine derivative NA NA NA NA NA NA NA 5.3 NA NA NA MTT viability assay NA NA NA HT29 Cancer HSPMDB000363 18164205 Hsp70 Hsp70 Human Cytosol and nucleus NA Antiproliferative activity DMT003052 benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-(2-methoxyethyl)amino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate CCCCNC(=O)C(N(CCOC)C(=O)CCCCCN1C(=O)NC(c2ccc(cc2)c3ccccc3)C(=C1C)C(=O)OCc4ccccc4)c5ccc(OCC(=O)OC)c(c5)C(=O)OC Dihydropyrimidine derivative NA NA NA NA NA NA NA 3.1 NA NA NA MTT viability assay NA NA NA HT29 Cancer HSPMDB000364 21426241 Hsp70 PfHsp70-1 Plasmodium falciparum Cytosol and nucleus Inhibition of protein aggregation activity NA Malonganenone A 3-methyl-7-[(2E,6E,11Z)-3,7,11,15-tetramethyl-13-oxohexadeca-2,6,11-trien-1-yl]-6,7-dihydro-3H-purin-6-one CC(C)CC(=O)\C=C(\C)CCC\C(C)=C\CC\C(C)=C\CN1C=NC2=C1C(=O)N=CN2C Marine tetraprenylated alkaloid >90% at 300 uM NA NA NA NA NA NA NA NA Substrate aggregation suppression assay NA NA NA NA NA NA Malaria HSPMDB000365 21426241 Hsp70 PfHsp70-1 Plasmodium falciparum Cytosol and nucleus Inhibition of protein aggregation activity NA Malonganenone B N-methyl-4-(N-methylformamido)-1-[(2E,6E,11Z)-3,7,11,15-tetramethyl-13-oxohexadeca-2,6,11-trien-1-yl]-1H-imidazole-5-carboxamide [H]C(=O)N(C)C1=C(N(C\C=C(/C)CC\C=C(/C)CCC\C(C)=C/C(=O)CC(C)C)C=N1)C(=O)NC Marine tetraprenylated alkaloid >90% at 300 uM NA NA NA NA NA NA NA NA Substrate aggregation suppression assay NA NA NA NA NA NA Malaria HSPMDB000366 21426241 Hsp70 PfHsp70-1 Plasmodium falciparum Cytosol and nucleus Inhibition of protein aggregation activity NA Malonganenone C N-[(2E,6E,11Z)-3,7,11,15-tetramethyl-13-oxohexadeca-2,6,11-trien-1-yl]formamide [H]C(=O)NC\C=C(/C)CC\C=C(/C)CCC\C(C)=C/C(=O)CC(C)C Marine tetraprenylated alkaloid >90% at 300 uM NA NA NA NA NA NA NA NA Substrate aggregation suppression assay NA NA NA NA NA NA Malaria HSPMDB000367 21426241 Hsp70 PfHsp70-1 Plasmodium falciparum Cytosol and nucleus Inhibition of protein aggregation activity NA Lapachol 2-hydroxy-3-(3-methylbut-2-en-1-yl)-1,4-dihydronaphthalene-1,4-dione CC(C)=CCC1=C(O)C(=O)C2=C(C=CC=C2)C1=O 1,4 naphthoquinone >90% at 300 uM NA NA NA NA NA NA NA NA Substrate aggregation suppression assay NA NA NA NA NA NA Malaria HSPMDB000368 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Almond NA NA Flavonoid 95% NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000369 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Vanilla NA NA Flavonoid 92% NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000370 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Chili Powder NA NA Flavonoid 101% NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000371 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Cloves NA NA Flavonoid 59% NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000372 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Chives NA NA Flavonoid 88% NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000373 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Chocolate NA NA Flavonoid 96% NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000374 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Cilantro (leaves) NA NA Flavonoid 91% NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000375 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Cinnamon NA NA Flavonoid 46% NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000376 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Coriander NA NA Flavonoid 98% NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000377 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Cumin NA NA Flavonoid 94% NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000378 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Allspice NA NA Flavonoid 53% NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000379 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Dill weed NA NA Flavonoid 94% NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000380 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Fennel seed NA NA Flavonoid 93% NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000381 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Fenugreek seed NA NA Flavonoid 98% NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000382 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Galangal NA NA Flavonoid 86% NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000383 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Ginger NA NA Flavonoid 94% NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000384 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Lemon (peel) NA NA Flavonoid 99% NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000385 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Mustard NA NA Flavonoid 84% NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000386 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Nutmeg NA NA Flavonoid 89% NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000387 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Orange (peel) NA NA Flavonoid 96% NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000388 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Black Tea NA NA Flavonoid 55% NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000389 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Paprika NA NA Flavonoid 104% NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000390 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Parsley flakes NA NA Flavonoid 96% NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000391 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Pepper (cayenne) NA NA Flavonoid 101% NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000392 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Poppy seed NA NA Flavonoid 98% NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000393 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Red Pepper NA NA Flavonoid 99% NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000394 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA White Tea NA NA Flavonoid 67% NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000395 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Turmeric Root NA NA Flavonoid 101% NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000396 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Anise Seeds NA NA Flavonoid 96% NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000397 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Vanilla Bean NA NA Flavonoid 97% NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000398 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA White pepper NA NA Flavonoid 89% NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000399 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Aloe NA NA Flavonoid 90% NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000400 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Basil leaves NA NA Flavonoid 94% NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000401 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Cocoa NA NA Flavonoid 68% NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000402 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Cardamom NA NA Flavonoid 102% NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000403 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Chili powder NA NA Flavonoid 96% NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000404 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Quercetin 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one OC1=CC2=C(C(O)=C1)C(=O)C(O)=C(O2)C1=CC=C(O)C(O)=C1 Flavonoid 67% at 200 uM NA NA 24.9 NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000405 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA QTE 2-(3,4-dimethoxyphenyl)-3-hydroxy-5,7-dimethoxy-4H-chromen-4-one COC1=CC2=C(C(=O)C(O)=C(O2)C2=CC=C(OC)C(OC)=C2)C(OC)=C1 Flavonoid NA NA NA >200 NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000406 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Rhamnetin 2-(3,4-dihydroxyphenyl)-3,5-dihydroxy-7-methoxy-4H-chromen-4-one COC1=CC2=C(C(O)=C1)C(=O)C(O)=C(O2)C1=CC=C(O)C(O)=C1 Flavonoid 13% at 200 uM NA NA >200 NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000407 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity (DnaJ stimulated) NA Myricetin 3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)-4H-chromen-4-one OC1=CC2=C(C(O)=C1)C(=O)C(O)=C(O2)C1=CC(O)=C(O)C(O)=C1 Flavonoid 75% at 200 uM NA NA 14.5 NA NA NA NA Nucleotide binding domain ATPase assay NA NA NA NA NA NA NA HSPMDB000408 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Kaempferol 3,5,7-trihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one OC1=CC=C(C=C1)C1=C(O)C(=O)C2=C(O1)C=C(O)C=C2O Flavonoid 15% at 200 uM NA NA >200 NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000409 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Morin 2-(2,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one OC1=CC=C(C(O)=C1)C1=C(O)C(=O)C2=C(O1)C=C(O)C=C2O Flavonoid 28% at 200 uM NA NA >200 NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000410 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Hieracin 5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-4H-chromen-4-one OC1=CC2=C(C(O)=C1)C(=O)C=C(O2)C1=CC(O)=C(O)C(O)=C1 Flavonoid 48% at 200 uM NA NA 28.2 NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000411 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Luleolin 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4H-chromen-4-one OC1=CC2=C(C(O)=C1)C(=O)C=C(O2)C1=CC=C(O)C(O)=C1 Flavonoid 54% at 200 uM NA NA 9.4 NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000412 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA Taxifolin 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-3,4-dihydro-2H-1-benzopyran-4-one OC1C(OC2=C(C(O)=CC(O)=C2)C1=O)C1=CC(O)=C(O)C=C1 Flavonoid 12% at 200 uM NA NA >200 NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000413 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA (+) Cafechin 2-(3,4-dihydroxyphenyl)-3,4-dihydro-2H-1-benzopyran-3,5,7-triol OC1CC2=C(OC1C1=CC(O)=C(O)C=C1)C=C(O)C=C2O Flavonoid NA NA NA >200 NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000414 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA (-)-Epigallocatechin 2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-1-benzopyran-3,5,7-triol OC1CC2=C(OC1C1=CC(O)=C(O)C(O)=C1)C=C(O)C=C2O Flavonoid 0 at 200 uM NA NA >200 NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000415 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA ECG 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3,4-dihydro-2H-1-benzopyran-3-yl 3,4,5-trihydroxybenzoate OC1=CC2=C(CC(OC(=O)C3=CC(O)=C(O)C(O)=C3)C(O2)C2=CC=C(O)C(O)=C2)C(O)=C1 Flavonoid 70 at 200 uM NA NA 6 NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000416 21338918 Hsp70 DnaK/ DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA EGCG 5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-1-benzopyran-3-yl 3,4,5-trihydroxybenzoate OC1=CC2=C(CC(OC(=O)C3=CC(O)=C(O)C(O)=C3)C(O2)C2=CC(O)=C(O)C(O)=C2)C(O)=C1 Flavonoid 62 at 200 uM NA NA 12 NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000417 25772468 Hsp70 Hsp70 Human Cytosol Inhibition of ATPase activity NA Apoptozole (Az) 4-[[2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)imidazol-1-yl]methyl]benzamide COC1=CC=C(C=C1)C2=C(N(C(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)CC4=CC=C(C=C4)C(=O)N)C5=CC=C(C=C5)OC Imidazole 32% at 100 uM NA NA NA NA NA NA NA Nucleotide binding domain ATPase assay NA NA NA NA NA NA Cancer HSPMDB000418 25772468 Hsp70 Hsp70 Human Cytosol Inhibition of ATPase activity NA Apoptozole (Az) 4-[[2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)imidazol-1-yl]methyl]benzamide COC1=CC=C(C=C1)C2=C(N(C(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)CC4=CC=C(C=C4)C(=O)N)C5=CC=C(C=C5)OC Imidazole 65% at 200 uM NA NA NA NA NA NA NA Nucleotide binding domain ATPase assay NA NA NA NA NA NA Cancer HSPMDB000419 25772468 Hsp70 Hsp70 Human Cytosol Inhibition of ATPase activity NA 1 N-{2-[2-(2-aminoethoxy)ethoxy]ethyl}-4-({2-[2,4-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)benzamide COC1=CC=C(C=C1)C1=C(N(CC2=CC=C(C=C2)C(=O)NCCOCCOCCN)C(=N1)C1=C(C=C(C=C1)C(F)(F)F)C(F)(F)F)C1=CC=C(OC)C=C1 Imidazole library 17.5% at 100 uM NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA Cancer HSPMDB000420 25772468 Hsp70 Hsp70 Human Cytosol Inhibition of ATPase activity NA 2 N-{2-[2-(2-aminoethoxy)ethoxy]ethyl}-4-{[4,5-bis(4-methoxyphenyl)-2-[3-(trifluoromethyl)phenyl]-1H-imidazol-1-yl]methyl}benzamide COC1=CC=C(C=C1)C1=C(N(CC2=CC=C(C=C2)C(=O)NCCOCCOCCN)C(=N1)C1=CC=CC(=C1)C(F)(F)F)C1=CC=C(OC)C=C1 Imidazole library 12.5% at 100 uM NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA Cancer HSPMDB000421 25772468 Hsp70 Hsp70 Human Cytosol Inhibition of ATPase activity NA 3 N-{2-[2-(2-aminoethoxy)ethoxy]ethyl}-4-{[4,5-bis(4-methoxyphenyl)-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-1-yl]methyl}benzamide COC1=CC=C(C=C1)C1=C(N(CC2=CC=C(C=C2)C(=O)NCCOCCOCCN)C(=N1)C1=CC=C(C=C1)C(F)(F)F)C1=CC=C(OC)C=C1 Imidazole library 15% at 100 uM NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA Cancer HSPMDB000422 25772468 Hsp70 Hsp70 Human Cytosol Inhibition of ATPase activity NA 4 1,3-dimethyl 5-(1-{[4-({2-[2-(2-aminoethoxy)ethoxy]ethyl}carbamoyl)phenyl]methyl}-4,5-bis(4-methoxyphenyl)-1H-imidazol-2-yl)benzene-1,3-dicarboxylate COC(=O)C1=CC(=CC(=C1)C(=O)OC)C1=NC(=C(N1CC1=CC=C(C=C1)C(=O)NCCOCCOCCN)C1=CC=C(OC)C=C1)C1=CC=C(OC)C=C1 Imidazole library 17.5% at 100 uM NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA Cancer HSPMDB000423 25772468 Hsp70 Hsp70 Human Cytosol Inhibition of ATPase activity NA 5 N-{2-[2-(2-aminoethoxy)ethoxy]ethyl}-4-{[2-(3,5-dimethylphenyl)-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl]methyl}benzamide COC1=CC=C(C=C1)C1=C(N(CC2=CC=C(C=C2)C(=O)NCCOCCOCCN)C(=N1)C1=CC(C)=CC(C)=C1)C1=CC=C(OC)C=C1 Imidazole library 12.5% at 100 uM NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA Cancer HSPMDB000424 25772468 Hsp70 Hsp70 Human Cytosol Inhibition of ATPase activity NA 6 N-{2-[2-(2-aminoethoxy)ethoxy]ethyl}-4-{[2-(3,5-dimethoxyphenyl)-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl]methyl}benzamide COC1=CC=C(C=C1)C1=C(N(CC2=CC=C(C=C2)C(=O)NCCOCCOCCN)C(=N1)C1=CC(OC)=CC(OC)=C1)C1=CC=C(OC)C=C1 Imidazole library 10% at 100 uM NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA Cancer HSPMDB000425 25772468 Hsp70 Hsp70 Human Cytosol Inhibition of ATPase activity NA 7 N-{2-[2-(2-aminoethoxy)ethoxy]ethyl}-4-{[4,5-bis(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)-1H-imidazol-1-yl]methyl}benzamide COC1=CC=C(C=C1)C1=C(N(CC2=CC=C(C=C2)C(=O)NCCOCCOCCN)C(=N1)C1=CC(OC)=C(OC)C(OC)=C1)C1=CC=C(OC)C=C1 Imidazole library 5% at 100 uM NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA Cancer HSPMDB000426 25772468 Hsp70 Hsp70 Human Cytosol Inhibition of ATPase activity NA 8 N-{2-[2-(2-aminoethoxy)ethoxy]ethyl}-4-{[4,5-bis(4-chlorophenyl)-2-[3-(difluoromethyl)-5-(trifluoromethyl)phenyl]-1H-imidazol-1-yl]methyl}benzamide NCCOCCOCCNC(=O)C1=CC=C(CN2C(=NC(=C2C2=CC=C(Cl)C=C2)C2=CC=C(Cl)C=C2)C2=CC(=CC(=C2)C(F)(F)F)C(F)F)C=C1 Imidazole library 7.5% at 100 uM NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA Cancer HSPMDB000427 25772468 Hsp70 Hsp70 Human Cytosol Inhibition of ATPase activity NA 9 N-{2-[2-(2-aminoethoxy)ethoxy]ethyl}-4-{[4,5-bis(4-bromophenyl)-2-[3-(difluoromethyl)-5-(trifluoromethyl)phenyl]-1H-imidazol-1-yl]methyl}benzamide NCCOCCOCCNC(=O)C1=CC=C(CN2C(=NC(=C2C2=CC=C(Br)C=C2)C2=CC=C(Br)C=C2)C2=CC(=CC(=C2)C(F)(F)F)C(F)F)C=C1 Imidazole library 10% at 100 uM NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA Cancer HSPMDB000428 25772468 Hsp70 Hsp70 Human Cytosol Inhibition of ATPase activity NA 10 N-{2-[2-(2-aminoethoxy)ethoxy]ethyl}-4-({2-[3-(difluoromethyl)-5-(trifluoromethyl)phenyl]-4,5-bis(4-methylphenyl)-1H-imidazol-1-yl}methyl)benzamide CC1=CC=C(C=C1)C1=C(N(CC2=CC=C(C=C2)C(=O)NCCOCCOCCN)C(=N1)C1=CC(=CC(=C1)C(F)(F)F)C(F)F)C1=CC=C(C)C=C1 Imidazole library 12.5% at 100 uM NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA Cancer HSPMDB000429 25772468 Hsp70 Hsp70 Human Cytosol Inhibition of ATPase activity NA 11 N-{2-[2-(2-aminoethoxy)ethoxy]ethyl}-4-({2-[3-(difluoromethyl)-5-(trifluoromethyl)phenyl]-4,5-bis[4-(dimethylamino)phenyl]-1H-imidazol-1-yl}methyl)benzamide CN(C)C1=CC=C(C=C1)C1=C(N(CC2=CC=C(C=C2)C(=O)NCCOCCOCCN)C(=N1)C1=CC(=CC(=C1)C(F)(F)F)C(F)F)C1=CC=C(C=C1)N(C)C Imidazole library 12.5% at 100 uM NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA Cancer HSPMDB000430 25772468 Hsp70 Hsp70 Human Cytosol Inhibition of ATPase activity NA 12 N-{2-[2-(2-aminoethoxy)ethoxy]ethyl}-4-({2-[3-(difluoromethyl)-5-(trifluoromethyl)phenyl]-4,5-bis(quinolin-6-yl)-1H-imidazol-1-yl}methyl)benzamide NCCOCCOCCNC(=O)C1=CC=C(CN2C(=NC(=C2C2=CC3=C(C=C2)N=CC=C3)C2=CC=C3N=CC=CC3=C2)C2=CC(=CC(=C2)C(F)(F)F)C(F)F)C=C1 Imidazole library 7.5% at 100 uM NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA Cancer HSPMDB000431 25772468 Hsp70 Hsp70 Human Cytosol Inhibition of ATPase activity NA 13 N-{2-[2-(2-aminoethoxy)ethoxy]ethyl}-4-({2-[3-(difluoromethyl)-5-(trifluoromethyl)phenyl]-4,5-bis(naphthalen-2-yl)-1H-imidazol-1-yl}methyl)benzamide NCCOCCOCCNC(=O)C1=CC=C(CN2C(=NC(=C2C2=CC3=C(C=CC=C3)C=C2)C2=CC=C3C=CC=CC3=C2)C2=CC(=CC(=C2)C(F)(F)F)C(F)F)C=C1 Imidazole library 10% at 100 uM NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA Cancer HSPMDB000432 25772468 Hsp70 Hsp70 Human Cytosol Inhibition of ATPase activity NA 14 N-{2-[2-(2-aminoethoxy)ethoxy]ethyl}-4-{[4,5-bis(2H-1,3-benzodioxol-5-yl)-2-[3-(difluoromethyl)-5-(trifluoromethyl)phenyl]-1H-imidazol-1-yl]methyl}benzamide NCCOCCOCCNC(=O)C1=CC=C(CN2C(=NC(=C2C2=CC3=C(OCO3)C=C2)C2=CC=C3OCOC3=C2)C2=CC(=CC(=C2)C(F)(F)F)C(F)F)C=C1 Imidazole library 10% at 100 uM NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA Cancer HSPMDB000433 25772468 Hsp70 Hsp70 Human Cytosol Inhibition of ATPase activity NA 15 4-({2-[3-(difluoromethyl)-5-(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)benzamide COC1=CC=C(C=C1)C1=C(N(CC2=CC=C(C=C2)C(N)=O)C(=N1)C1=CC(=CC(=C1)C(F)(F)F)C(F)F)C1=CC=C(OC)C=C1 Imidazole library 15% at 100 uM NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA Cancer HSPMDB000434 25772468 Hsp70 Hsp70 Human Cytosol NA Antiproliferative activity Apoptozole (Az) 4-[[2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)imidazol-1-yl]methyl]benzamide COC1=CC=C(C=C1)C2=C(N(C(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)CC4=CC=C(C=C4)C(=O)N)C5=CC=C(C=C5)OC Imidazole NA NA NA 7 NA NA NA NA Nucleotide binding domain NA NA MTT viability assay NA NA NA A549 Cancer HSPMDB000435 25772468 Hsp70 Hsp70 Human Cytosol NA Antiproliferative activity Apoptozole (Az) 4-[[2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)imidazol-1-yl]methyl]benzamide COC1=CC=C(C=C1)C2=C(N(C(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)CC4=CC=C(C=C4)C(=O)N)C5=CC=C(C=C5)OC Imidazole NA NA NA 6 NA NA NA NA Nucleotide binding domain NA NA MTT viability assay NA NA NA HeLa Cancer HSPMDB000436 25772468 Hsp70 Hsp70 Human Cytosol NA Antiproliferative activity Apoptozole (Az) 4-[[2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)imidazol-1-yl]methyl]benzamide COC1=CC=C(C=C1)C2=C(N(C(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)CC4=CC=C(C=C4)C(=O)N)C5=CC=C(C=C5)OC Imidazole NA NA NA 6 NA NA NA NA Nucleotide binding domain NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000437 25772468 Hsp70 Hsp70 Human Cytosol NA Antiproliferative activity Apoptozole (Az) 4-[[2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)imidazol-1-yl]methyl]benzamide COC1=CC=C(C=C1)C2=C(N(C(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)CC4=CC=C(C=C4)C(=O)N)C5=CC=C(C=C5)OC Imidazole NA NA NA 5 NA NA NA NA Nucleotide binding domain NA NA MTT viability assay NA NA NA HepG2 Cancer HSPMDB000438 19256508 Hsp70 Hsc70 Human Cytosol Inhibition of ATP binding NA 1 [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate C1=NC2=C(C(=N1)N)N=CN2C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O Adenosine derivative NA NA NA 0.5 NA NA NA NA Nucleotide binding domain Fluorescence polarization (FP) assay NA NA NA NA NA NA NA HSPMDB000439 19256508 Hsp70 Hsc70 Human Cytosol Inhibition of ATP binding NA 2 [(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphono hydrogen phosphate C1=NC2=C(C(=N1)N)N=CN2C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O Adenosine derivative NA NA NA 0.5 NA NA NA NA Nucleotide binding domain Fluorescence polarization (FP) assay NA NA NA NA NA NA NA HSPMDB000440 19256508 Hsp70 Hsc70 Human Cytosol Inhibition of ATP binding NA 3 (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol NC1=C2N=CN([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)C2=NC=N1 Adenosine derivative NA NA NA 560 NA NA NA NA Nucleotide binding domain Fluorescence polarization (FP) assay NA NA NA NA NA NA NA HSPMDB000441 19256508 Hsp70 Hsc70 Human Cytosol Inhibition of ATP binding NA 4 (2R,3R,4S,5R)-2-(6,8-diamino-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol NC1=NC2=C(N)N=CN=C2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O Adenosine derivative NA NA NA 9.4 NA NA NA NA Nucleotide binding domain Fluorescence polarization (FP) assay NA NA NA NA NA NA NA HSPMDB000442 19256508 Hsp70 Hsc70 Human Cytosol Inhibition of ATP binding NA 5 (2R,3R,4S,5R)-2-[6-amino-8-(methylamino)-9H-purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol CNC1=NC2=C(N)N=CN=C2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O Adenosine derivative NA NA NA 17 NA NA NA NA Nucleotide binding domain Fluorescence polarization (FP) assay NA NA NA NA NA NA NA HSPMDB000443 19256508 Hsp70 Hsc70 Human Cytosol Inhibition of ATP binding NA 6 (2R,3R,4S,5R)-2-[6-amino-8-(benzylamino)-9H-purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol NC1=C2N=C(NCC3=CC=CC=C3)N([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)C2=NC=N1 Adenosine derivative NA NA NA 10 NA NA NA NA Nucleotide binding domain Fluorescence polarization (FP) assay NA NA NA NA NA NA NA HSPMDB000444 19256508 Hsp70 Hsc70 Human Cytosol Inhibition of ATP binding NA 7 (2R,3R,4S,5R)-2-[6-Amino-8-(3,4-dichlorobenzylamino)purin-9-yl]-5-hydroxymethyltetrahydrofuran-3,4-diol Nc1ncnc2n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c(NCc4ccc(Cl)c(Cl)c4)nc12 Adenosine derivative NA NA NA 9.1 NA NA NA NA Nucleotide binding domain Fluorescence polarization (FP) assay NA NA NA NA NA NA NA HSPMDB000445 19256508 Hsp70 Hsc70 Human Cytosol Inhibition of ATP binding NA 8 (2R,3R,4S,5R)-2-{6-Amino-8-[(benzo[1,3]dioxol-5-ylmethyl)-amino]-purin-9-yl}-5- hydroxymethyltetrahydrofuran-3,4-diol Nc1ncnc2n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c(NCc4ccc5OCOc5c4)nc12 Adenosine derivative NA NA NA 4.9 NA NA NA NA Nucleotide binding domain Fluorescence polarization (FP) assay NA NA NA NA NA NA NA HSPMDB000446 19256508 Hsp70 Hsc70 Human Cytosol Inhibition of ATP binding NA 9 (2R,3R,4S,5R)-2-{6-Amino-8-[(quinolin-6-ylmethyl)amino]purin-9-yl}-5-hydroxymethyltetrahydrofuran-3,4-diol Nc1ncnc2n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c(NCc4ccc5ncccc5c4)nc12 Adenosine derivative NA NA NA 2.9 NA NA NA NA Nucleotide binding domain Fluorescence polarization (FP) assay NA NA NA NA NA NA NA HSPMDB000447 19256508 Hsp70 Hsc70 Human Cytosol Inhibition of ATP binding NA 10 (2R,3R,4S,5R)-2-[6-Amino-8-(3,4-dichlorobenzylamino)-purin-9-yl]-5-methoxymethyltetrahydrofuran-3,4-diol COC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n2c(NCc3ccc(Cl)c(Cl)c3)nc4c(N)ncnc24 Adenosine derivative NA NA NA 3.2 NA NA NA NA Nucleotide binding domain Fluorescence polarization (FP) assay NA NA NA NA NA NA NA HSPMDB000448 19256508 Hsp70 Hsc70 Human Cytosol Inhibition of ATP binding NA 11 (2R,3R,4S,5R)-2-[6-Amino-8-(3,4-dichlorobenzylamino)-purin-9-yl]-5-benzyloxymethyltetrahydrofuran-3,4-diol Nc1ncnc2n([C@@H]3O[C@H](COCc4ccccc4)[C@@H](O)[C@H]3O)c(NCc5ccc(Cl)c(Cl)c5)nc12 Adenosine derivative NA NA NA 2.4 NA NA NA NA Nucleotide binding domain Fluorescence polarization (FP) assay NA NA NA NA NA NA NA HSPMDB000449 19256508 Hsp70 Hsc70 Human Cytosol Inhibition of ATP binding NA 12 4-{(2R,3S,4R,5R)-5-[6-Amino-8-(3,4-dichlorobenzylamino)purin-9-yl]-3,4- dihydroxytetrahydrofuran-2-ylmethoxymethyl}benzonitrile Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc5ccc(Cl)c(Cl)c5)nc12 Adenosine derivative NA NA NA 0.5 NA NA NA NA Nucleotide binding domain Fluorescence polarization (FP) assay NA NA NA NA NA NA NA HSPMDB000450 19256508 Hsp70 Hsc70 Human Cytosol Inhibition of ATP binding NA 13 4-[(2R,3S,4R,5R)-5-(6-Amino-8-benzylamino-purin-9-yl)-3,4-dihydroxy-tetrahydro-furan-2- ylmethoxymethyl]-benzonitrile Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc5ccccc5)nc12 Adenosine derivative NA NA NA 1.3 NA NA NA NA Nucleotide binding domain Fluorescence polarization (FP) assay NA NA NA NA NA NA NA HSPMDB000451 19256508 Hsp70 Hsc70 Human Cytosol Inhibition of ATP binding NA 14 (2R,3R,4S,5R)-2-[6-Amino-8-(3,4-dichlorobenzylamino)-purin-9-yl]-5-(3,4,5-trifluorobenzyloxymethyl)-tetrahydrofuran-3,4-diol Nc1ncnc2n([C@@H]3O[C@H](COCc4cc(F)c(F)c(F)c4)[C@@H](O)[C@H]3O)c(NCc5ccc(Cl)c(Cl)c5)nc12 Adenosine derivative NA NA NA 1.7 NA NA NA NA Nucleotide binding domain Fluorescence polarization (FP) assay NA NA NA NA NA NA NA HSPMDB000452 19256508 Hsp70 Hsc70 Human Cytosol Inhibition of ATP binding NA 15 4-((2R,3S,4R,5R)-5-{6-Amino-8-[(quinolin-6-ylmethyl)-amino]-purin-9-yl}-3,4-dihydroxytetrahydrofuran-2-ylmethoxymethyl)-benzonitrile Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc5ccc6ncccc6c5)nc12 Adenosine derivative NA NA NA 0.9 NA NA NA NA Nucleotide binding domain Fluorescence polarization (FP) assay NA NA NA NA NA NA NA HSPMDB000453 19256508 Hsp70 Hsc70 Human Cytosol Inhibition of ATP binding NA 16 (2R,3R,4S,5R)-2-{6-Amino-8-[(quinolin-6-ylmethyl)-amino]-purin-9-yl}-5-(4-trifluoromethylbenzyloxymethyl)-tetrahydrofuran-3,4-diol Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C(F)(F)F)[C@@H](O)[C@H]3O)c(NCc5ccc6ncccc6c5)nc12 Adenosine derivative NA NA NA 0.6 NA NA NA NA Nucleotide binding domain Fluorescence polarization (FP) assay NA NA NA NA NA NA NA HSPMDB000454 19256508 Hsp70 Hsc70 Human Cytosol Inhibition of ATP binding NA 17 (2R,3R,4S,5R)-2-{6-Amino-8-[(quinolin-6-ylmethyl)-amino]-purin-9-yl}-5-(3,4,5- trifluorobenzyloxymethyl)-tetrahydrofuran-3,4-diol Nc1ncnc2n([C@@H]3O[C@H](COCc4cc(F)c(F)c(F)c4)[C@@H](O)[C@H]3O)c(NCc5ccc6ncccc6c5)nc12 Adenosine derivative NA NA NA <0.4 NA NA NA NA Nucleotide binding domain Fluorescence polarization (FP) assay NA NA NA NA NA NA NA HSPMDB000455 19256508 Hsp70 Hsc70 Human Cytosol Binding affinity NA 2 [(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphono hydrogen phosphate C1=NC2=C(C(=N1)N)N=CN2C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O Adenosine derivative NA 0.5 NA NA NA NA NA NA Nucleotide binding domain HSP70 Biacore Direct Binding Assay NA NA NA NA NA NA NA HSPMDB000456 19256508 Hsp70 Hsc70 Human Cytosol Binding affinity NA 4 (2R,3R,4S,5R)-2-(6,8-diamino-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol NC1=NC2=C(N)N=CN=C2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O Adenosine derivative NA 11 NA NA NA NA NA NA Nucleotide binding domain HSP70 Biacore Direct Binding Assay NA NA NA NA NA NA NA HSPMDB000457 19256508 Hsp70 Hsc70 Human Cytosol Binding affinity NA 12 4-{(2R,3S,4R,5R)-5-[6-Amino-8-(3,4-dichlorobenzylamino)purin-9-yl]-3,4- dihydroxytetrahydrofuran-2-ylmethoxymethyl}benzonitrile Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc5ccc(Cl)c(Cl)c5)nc12 Adenosine derivative NA 0.3 NA NA NA NA NA NA Nucleotide binding domain HSP70 Biacore Direct Binding Assay NA NA NA NA NA NA NA HSPMDB000458 19256508 Hsp70 Hsc70 Human Cytosol Binding affinity NA 13 4-[(2R,3S,4R,5R)-5-(6-Amino-8-benzylamino-purin-9-yl)-3,4-dihydroxy-tetrahydro-furan-2- ylmethoxymethyl]-benzonitrile Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc5ccccc5)nc12 Adenosine derivative NA 0.2 NA NA NA NA NA NA Nucleotide binding domain HSP70 Biacore Direct Binding Assay NA NA NA NA NA NA NA HSPMDB000459 19256508 Hsp70 Hsc70 Human Cytosol Binding affinity NA 14 (2R,3R,4S,5R)-2-[6-Amino-8-(3,4-dichlorobenzylamino)-purin-9-yl]-5-(3,4,5-trifluorobenzyloxymethyl)-tetrahydrofuran-3,4-diol Nc1ncnc2n([C@@H]3O[C@H](COCc4cc(F)c(F)c(F)c4)[C@@H](O)[C@H]3O)c(NCc5ccc(Cl)c(Cl)c5)nc12 Adenosine derivative NA 4.2 NA NA NA NA NA NA Nucleotide binding domain HSP70 Biacore Direct Binding Assay NA NA NA NA NA NA NA HSPMDB000460 19256508 Hsp70 Hsc70 Human Cytosol Binding affinity NA 15 4-((2R,3S,4R,5R)-5-{6-Amino-8-[(quinolin-6-ylmethyl)-amino]-purin-9-yl}-3,4-dihydroxytetrahydrofuran-2-ylmethoxymethyl)-benzonitrile Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc5ccc6ncccc6c5)nc12 Adenosine derivative NA 0.05 NA NA NA NA NA NA Nucleotide binding domain HSP70 Biacore Direct Binding Assay NA NA NA NA NA NA NA HSPMDB000461 19256508 Hsp70 Hsc70 Human Cytosol Binding affinity NA 16 (2R,3R,4S,5R)-2-{6-Amino-8-[(quinolin-6-ylmethyl)-amino]-purin-9-yl}-5-(4-trifluoromethylbenzyloxymethyl)-tetrahydrofuran-3,4-diol Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C(F)(F)F)[C@@H](O)[C@H]3O)c(NCc5ccc6ncccc6c5)nc12 Adenosine derivative NA 0.06 NA NA NA NA NA NA Nucleotide binding domain HSP70 Biacore Direct Binding Assay NA NA NA NA NA NA NA HSPMDB000462 19256508 Hsp70 Hsc70 Human Cytosol Binding affinity NA 17 (2R,3R,4S,5R)-2-{6-Amino-8-[(quinolin-6-ylmethyl)-amino]-purin-9-yl}-5-(3,4,5- trifluorobenzyloxymethyl)-tetrahydrofuran-3,4-diol Nc1ncnc2n([C@@H]3O[C@H](COCc4cc(F)c(F)c(F)c4)[C@@H](O)[C@H]3O)c(NCc5ccc6ncccc6c5)nc12 Adenosine derivative NA 0.12 NA NA NA NA NA NA Nucleotide binding domain HSP70 Biacore Direct Binding Assay NA NA NA NA NA NA NA HSPMDB000463 19256508 Hsp70 Hsc70 Human Cytosol NA Antiproliferative activity 4 (2R,3R,4S,5R)-2-(6,8-diamino-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol NC1=NC2=C(N)N=CN=C2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O Adenosine derivative NA NA NA NA NA NA NA 0.05 Nucleotide binding domain NA NA MTT viability assay NA NA NA HCT116 NA HSPMDB000464 19256508 Hsp70 Hsc70 Human Cytosol NA Antiproliferative activity 5 (2R,3R,4S,5R)-2-[6-amino-8-(methylamino)-9H-purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol CNC1=NC2=C(N)N=CN=C2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O Adenosine derivative NA NA NA NA NA NA NA 13 Nucleotide binding domain NA NA MTT viability assay NA NA NA HCT116 NA HSPMDB000465 19256508 Hsp70 Hsc70 Human Cytosol NA Antiproliferative activity 6 (2R,3R,4S,5R)-2-[6-amino-8-(benzylamino)-9H-purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol NC1=C2N=C(NCC3=CC=CC=C3)N([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)C2=NC=N1 Adenosine derivative NA NA NA NA NA NA NA >80 Nucleotide binding domain NA NA MTT viability assay NA NA NA HCT116 NA HSPMDB000466 19256508 Hsp70 Hsc70 Human Cytosol NA Antiproliferative activity 7 (2R,3R,4S,5R)-2-[6-Amino-8-(3,4-dichlorobenzylamino)purin-9-yl]-5-hydroxymethyltetrahydrofuran-3,4-diol Nc1ncnc2n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c(NCc4ccc(Cl)c(Cl)c4)nc12 Adenosine derivative NA NA NA NA NA NA NA 26 Nucleotide binding domain NA NA MTT viability assay NA NA NA HCT116 NA HSPMDB000467 19256508 Hsp70 Hsc70 Human Cytosol NA Antiproliferative activity 8 (2R,3R,4S,5R)-2-{6-Amino-8-[(benzo[1,3]dioxol-5-ylmethyl)-amino]-purin-9-yl}-5- hydroxymethyltetrahydrofuran-3,4-diol Nc1ncnc2n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c(NCc4ccc5OCOc5c4)nc12 Adenosine derivative NA NA NA NA NA NA NA >80 Nucleotide binding domain NA NA MTT viability assay NA NA NA HCT116 NA HSPMDB000468 19256508 Hsp70 Hsc70 Human Cytosol NA Antiproliferative activity 9 (2R,3R,4S,5R)-2-{6-Amino-8-[(quinolin-6-ylmethyl)amino]purin-9-yl}-5-hydroxymethyltetrahydrofuran-3,4-diol Nc1ncnc2n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c(NCc4ccc5ncccc5c4)nc12 Adenosine derivative NA NA NA NA NA NA NA >80 Nucleotide binding domain NA NA MTT viability assay NA NA NA HCT116 NA HSPMDB000469 19256508 Hsp70 Hsc70 Human Cytosol NA Antiproliferative activity 10 (2R,3R,4S,5R)-2-[6-Amino-8-(3,4-dichlorobenzylamino)-purin-9-yl]-5-methoxymethyltetrahydrofuran-3,4-diol COC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n2c(NCc3ccc(Cl)c(Cl)c3)nc4c(N)ncnc24 Adenosine derivative NA NA NA NA NA NA NA >80 Nucleotide binding domain NA NA MTT viability assay NA NA NA HCT116 NA HSPMDB000470 19256508 Hsp70 Hsc70 Human Cytosol NA Antiproliferative activity 11 (2R,3R,4S,5R)-2-[6-Amino-8-(3,4-dichlorobenzylamino)-purin-9-yl]-5-benzyloxymethyltetrahydrofuran-3,4-diol Nc1ncnc2n([C@@H]3O[C@H](COCc4ccccc4)[C@@H](O)[C@H]3O)c(NCc5ccc(Cl)c(Cl)c5)nc12 Adenosine derivative NA NA NA NA NA NA NA >80 Nucleotide binding domain NA NA MTT viability assay NA NA NA HCT116 NA HSPMDB000471 19256508 Hsp70 Hsc70 Human Cytosol NA Antiproliferative activity 12 4-{(2R,3S,4R,5R)-5-[6-Amino-8-(3,4-dichlorobenzylamino)purin-9-yl]-3,4- dihydroxytetrahydrofuran-2-ylmethoxymethyl}benzonitrile Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc5ccc(Cl)c(Cl)c5)nc12 Adenosine derivative NA NA NA NA NA NA NA 5 Nucleotide binding domain NA NA MTT viability assay NA NA NA HCT116 NA HSPMDB000472 19256508 Hsp70 Hsc70 Human Cytosol NA Antiproliferative activity 13 4-[(2R,3S,4R,5R)-5-(6-Amino-8-benzylamino-purin-9-yl)-3,4-dihydroxy-tetrahydro-furan-2- ylmethoxymethyl]-benzonitrile Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc5ccccc5)nc12 Adenosine derivative NA NA NA NA NA NA NA > 80 Nucleotide binding domain NA NA MTT viability assay NA NA NA HCT116 NA HSPMDB000473 19256508 Hsp70 Hsc70 Human Cytosol NA Antiproliferative activity 14 (2R,3R,4S,5R)-2-[6-Amino-8-(3,4-dichlorobenzylamino)-purin-9-yl]-5-(3,4,5-trifluorobenzyloxymethyl)-tetrahydrofuran-3,4-diol Nc1ncnc2n([C@@H]3O[C@H](COCc4cc(F)c(F)c(F)c4)[C@@H](O)[C@H]3O)c(NCc5ccc(Cl)c(Cl)c5)nc12 Adenosine derivative NA NA NA NA NA NA NA 13 Nucleotide binding domain NA NA MTT viability assay NA NA NA HCT116 NA HSPMDB000474 19256508 Hsp70 Hsc70 Human Cytosol NA Antiproliferative activity 15 4-((2R,3S,4R,5R)-5-{6-Amino-8-[(quinolin-6-ylmethyl)-amino]-purin-9-yl}-3,4-dihydroxytetrahydrofuran-2-ylmethoxymethyl)-benzonitrile Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc5ccc6ncccc6c5)nc12 Adenosine derivative NA NA NA NA NA NA NA >80 Nucleotide binding domain NA NA MTT viability assay NA NA NA HCT116 NA HSPMDB000475 19256508 Hsp70 Hsc70 Human Cytosol NA Antiproliferative activity 16 (2R,3R,4S,5R)-2-{6-Amino-8-[(quinolin-6-ylmethyl)-amino]-purin-9-yl}-5-(4-trifluoromethylbenzyloxymethyl)-tetrahydrofuran-3,4-diol Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C(F)(F)F)[C@@H](O)[C@H]3O)c(NCc5ccc6ncccc6c5)nc12 Adenosine derivative NA NA NA NA NA NA NA 27 Nucleotide binding domain NA NA MTT viability assay NA NA NA HCT116 NA HSPMDB000476 19256508 Hsp70 Hsc70 Human Cytosol NA Antiproliferative activity 17 (2R,3R,4S,5R)-2-{6-Amino-8-[(quinolin-6-ylmethyl)-amino]-purin-9-yl}-5-(3,4,5- trifluorobenzyloxymethyl)-tetrahydrofuran-3,4-diol Nc1ncnc2n([C@@H]3O[C@H](COCc4cc(F)c(F)c(F)c4)[C@@H](O)[C@H]3O)c(NCc5ccc6ncccc6c5)nc12 Adenosine derivative NA NA NA NA NA NA NA 18 Nucleotide binding domain NA NA MTT viability assay NA NA NA HCT116 NA HSPMDB000477 20012863 Hsp70 Hsp70 Human Cytosol Inhibition of ATP binding NA VER-155008 4-[[(2R,3S,4R,5R)-5-[6-amino-8-[(3,4-dichlorophenyl)methylamino]purin-9-yl]-3,4-dihydroxyoxolan-2-yl]methoxymethyl]benzonitrile C1=CC(=CC=C1COCC2C(C(C(O2)N3C4=C(C(=NC=N4)N)N=C3NCC5=CC(=C(C=C5)Cl)Cl)O)O)C#N Dibenzyl-8-amino adenosine analogue NA NA NA 0.5 NA NA NA NA Nucleotide binding domain Fluorescence polarization (FP) assay NA NA NA NA NA NA NA HSPMDB000478 20012863 Hsp70 Hsc70 Human Cytosol Inhibition of ATP binding NA VER-155008 4-[[(2R,3S,4R,5R)-5-[6-amino-8-[(3,4-dichlorophenyl)methylamino]purin-9-yl]-3,4-dihydroxyoxolan-2-yl]methoxymethyl]benzonitrile C1=CC(=CC=C1COCC2C(C(C(O2)N3C4=C(C(=NC=N4)N)N=C3NCC5=CC(=C(C=C5)Cl)Cl)O)O)C#N Dibenzyl-8-amino adenosine analogue NA NA NA 2.6 NA NA NA NA Nucleotide binding domain Fluorescence polarization (FP) assay NA NA NA NA NA NA NA HSPMDB000479 20012863 Hsp70 Hsp70 Human Cytosol Binding affinity NA VER-155008 4-[[(2R,3S,4R,5R)-5-[6-amino-8-[(3,4-dichlorophenyl)methylamino]purin-9-yl]-3,4-dihydroxyoxolan-2-yl]methoxymethyl]benzonitrile C1=CC(=CC=C1COCC2C(C(C(O2)N3C4=C(C(=NC=N4)N)N=C3NCC5=CC(=C(C=C5)Cl)Cl)O)O)C#N Dibenzyl-8-amino adenosine analogue NA 0.3 NA NA NA NA NA NA Nucleotide binding domain Surface plasmon resonance (SPR) NA NA NA NA NA NA NA HSPMDB000480 20012863 Hsp70 GRP78 Human Endoplasmic reticulum Inhibition of ATP binding NA VER-155008 4-[[(2R,3S,4R,5R)-5-[6-amino-8-[(3,4-dichlorophenyl)methylamino]purin-9-yl]-3,4-dihydroxyoxolan-2-yl]methoxymethyl]benzonitrile C1=CC(=CC=C1COCC2C(C(C(O2)N3C4=C(C(=NC=N4)N)N=C3NCC5=CC(=C(C=C5)Cl)Cl)O)O)C#N Dibenzyl-8-amino adenosine analogue NA NA NA 2.6 NA NA NA NA Nucleotide binding domain Fluorescence polarization (FP) assay NA NA NA NA NA NA NA HSPMDB000481 20012863 Hsp70 Hsp70 Human Cytosol NA Antiproliferative activity VER-155008 4-[[(2R,3S,4R,5R)-5-[6-amino-8-[(3,4-dichlorophenyl)methylamino]purin-9-yl]-3,4-dihydroxyoxolan-2-yl]methoxymethyl]benzonitrile C1=CC(=CC=C1COCC2C(C(C(O2)N3C4=C(C(=NC=N4)N)N=C3NCC5=CC(=C(C=C5)Cl)Cl)O)O)C#N Dibenzyl-8-amino adenosine analogue NA NA NA NA NA NA NA 10.4 Nucleotide binding domain NA NA Cell cycle analysis NA NA NA BT474 NA HSPMDB000482 20012863 Hsp70 Hsp70 Human Cytosol NA Antiproliferative activity VER-155008 4-[[(2R,3S,4R,5R)-5-[6-amino-8-[(3,4-dichlorophenyl)methylamino]purin-9-yl]-3,4-dihydroxyoxolan-2-yl]methoxymethyl]benzonitrile C1=CC(=CC=C1COCC2C(C(C(O2)N3C4=C(C(=NC=N4)N)N=C3NCC5=CC(=C(C=C5)Cl)Cl)O)O)C#N Dibenzyl-8-amino adenosine analogue NA NA NA NA NA NA NA 14.4 Nucleotide binding domain NA NA Cell cycle analysis NA NA NA MDA-MB-468 NA HSPMDB000483 20012863 Hsp70 Hsp70 Human Cytosol NA Antiproliferative activity VER-155008 4-[[(2R,3S,4R,5R)-5-[6-amino-8-[(3,4-dichlorophenyl)methylamino]purin-9-yl]-3,4-dihydroxyoxolan-2-yl]methoxymethyl]benzonitrile C1=CC(=CC=C1COCC2C(C(C(O2)N3C4=C(C(=NC=N4)N)N=C3NCC5=CC(=C(C=C5)Cl)Cl)O)O)C#N Dibenzyl-8-amino adenosine analogue NA NA NA NA NA NA NA 5.3 Nucleotide binding domain NA NA Cell cycle analysis NA NA NA HCT116 NA HSPMDB000484 20012863 Hsp70 Hsp70 Human Cytosol NA Antiproliferative activity VER-155008 4-[[(2R,3S,4R,5R)-5-[6-amino-8-[(3,4-dichlorophenyl)methylamino]purin-9-yl]-3,4-dihydroxyoxolan-2-yl]methoxymethyl]benzonitrile C1=CC(=CC=C1COCC2C(C(C(O2)N3C4=C(C(=NC=N4)N)N=C3NCC5=CC(=C(C=C5)Cl)Cl)O)O)C#N Dibenzyl-8-amino adenosine analogue NA NA NA NA NA NA NA 12.8 Nucleotide binding domain NA NA Cell cycle analysis NA NA NA HT29 NA HSPMDB000485 20012863 Hsp70 Hsc70 (HSPA8) and Hsp70 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity VER-82160 2-amino-4-{2,4-dichloro-5-[2-(diethylamino)ethoxy]phenyl}-N-ethylthieno[2,3-d]pyrimidine-6-carboxamide CCNC(=O)C1=CC2=C(S1)N=C(N)N=C2C1=C(Cl)C=C(Cl)C(OCCN(CC)CC)=C1 Dibenzyl-8-amino adenosine analogue NA NA NA NA NA NA NA 0.073 NA NA NA Cell cycle analysis NA NA NA BT474 NA HSPMDB000486 20012863 Hsp70 Hsc70 (HSPA8) and Hsp70 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity VER-82160 2-amino-4-{2,4-dichloro-5-[2-(diethylamino)ethoxy]phenyl}-N-ethylthieno[2,3-d]pyrimidine-6-carboxamide CCNC(=O)C1=CC2=C(S1)N=C(N)N=C2C1=C(Cl)C=C(Cl)C(OCCN(CC)CC)=C1 Dibenzyl-8-amino adenosine analogue NA NA NA NA NA NA NA 0.123 NA NA NA Cell cycle analysis NA NA NA MDA-MB-468 NA HSPMDB000487 20012863 Hsp70 Hsc70 (HSPA8) and Hsp70 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity VER-82160 2-amino-4-{2,4-dichloro-5-[2-(diethylamino)ethoxy]phenyl}-N-ethylthieno[2,3-d]pyrimidine-6-carboxamide CCNC(=O)C1=CC2=C(S1)N=C(N)N=C2C1=C(Cl)C=C(Cl)C(OCCN(CC)CC)=C1 Dibenzyl-8-amino adenosine analogue NA NA NA NA NA NA NA 0.154 NA NA NA Cell cycle analysis NA NA NA HCT116 NA HSPMDB000488 20026329 Hsp70 Hsp70-Hsp40 Porcine Cytosol Inhibition of chaperone activity NA Gentamycin 2-[4,6-diamino-3-[3-amino-6-[1-(methylamino)ethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol CC(C1CCC(C(O1)OC2C(CC(C(C2O)OC3C(C(C(CO3)(C)O)NC)O)N)N)N)NC Aminoglycoside antibiotic 25.8% at 5 mM NA NA NA NA NA NA NA C-terminal domain Refolding assay (luciferase) NA NA NA NA NA NA NA HSPMDB000489 20026329 Hsp70 Hsp70-Hsp40 Porcine Cytosol Inhibition of chaperone activity NA Gentamycin 2-[4,6-diamino-3-[3-amino-6-[1-(methylamino)ethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol CC(C1CCC(C(O1)OC2C(CC(C(C2O)OC3C(C(C(CO3)(C)O)NC)O)N)N)N)NC Aminoglycoside antibiotic 10.5% at 10 mM NA NA NA NA NA NA NA C-terminal domain Refolding assay (luciferase) NA NA NA NA NA NA NA HSPMDB000490 14966137 Hsp70 Hsp73 Porcine Cytosol Inhibition of chaperone activity NA Gentamycin 2-[4,6-diamino-3-[3-amino-6-[1-(methylamino)ethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol CC(C1CCC(C(O1)OC2C(CC(C(C2O)OC3C(C(C(CO3)(C)O)NC)O)N)N)N)NC Aminoglycoside antibiotic 100% at 500 uM NA NA NA NA NA NA NA C-terminal domain Substrate aggregation suppression assay NA NA NA NA NA NA NA HSPMDB000491 29042222 Hsp70 Hsp70-Dnak Human and Mtb Cytosol Inhibition of ATP binding NA Rickenyl A 4',5,6-trimethoxy-4-(4-methoxyphenyl)-[1,1'-biphenyl]-2,3-diol COC1=CC=C(C=C1)C1=C(O)C(O)=C(C(OC)=C1OC)C1=CC=C(OC)C=C1 NA NA NA NA NA 49 NA NA NA Nucleotide binding domain Microarray based ATP binding test NA NA NA NA NA NA NA HSPMDB000492 29953808 Hsp70 Hsp70 Human Cytosol Inhibition of HSP 70 BAG interaction NA JG-194 3-benzyl-2-((Z)-((E)-5-(3,6-dimethylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2- ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(C)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA 0.46 NA NA NA NA NA Allosteric site Hsp70-BAG interaction assay NA NA NA NA NA NA Cancer HSPMDB000493 29953808 Hsp70 Hsp70 Human Cytosol Inhibition of HSP 70 BAG interaction NA JG-231 3-((5-bromothiophen-2-yl)methyl)-2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3sc(Br)cc3)=C4/Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA 0.11 NA NA NA NA NA Allosteric site Hsp70-BAG interaction assay NA NA NA NA NA NA Cancer HSPMDB000494 29953808 Hsp70 Hsp70 Human Cytosol Inhibition of HSP 70 BAG interaction NA JG-294 2-((Z)-((E)-5-(6-bromo-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((5-(trifluoromethyl)furan-2-yl)methyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3oc(cc3)C(F)(F)F)=C/4Sc5cc(Br)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA 0.35 NA NA NA NA NA Allosteric site Hsp70-BAG interaction assay NA NA NA NA NA NA Cancer HSPMDB000495 29953808 Hsp70 Hsp70 Human Cytosol Inhibition of HSP 70 BAG interaction NA JG-345 2-((Z)-((E)-3-ethyl-5-(6-ethyl-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)methyl)-3-(2-(methoxycarbonyl)benzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)C(/SC1=C\c2scc[n+]2Cc3ccccc3C(=O)OC)=C4\Sc5cc(CC)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA 1.11 NA NA NA NA NA Allosteric site Hsp70-BAG interaction assay NA NA NA NA NA NA Cancer HSPMDB000496 28455613 Hsp70 PfHsp70-1 Plasmodium falciparum Cytosol and nucleus Inhibition of ATPase activity NA Polymixin B N-[4-amino-1-[[1-[[4-amino-1-oxo-1-[[6,9,18-tris(2-aminoethyl)-15-benzyl-3-(1-hydroxyethyl)-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methyloctanamide CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(Cc2ccccc2)NC(=O)C(CCN)NC1=O)C(C)O Lipopeptide anrtibiotic 100% at 25 uM 0.38 NA NA NA NA NA NA Nucleotide binding domain ATPase assay NA NA NA NA NA NA Malaria HSPMDB000497 28455613 Hsp70 PfHsp70-z Plasmodium falciparum Cytosol and nucleus Inhibition of ATPase activity NA Polymixin B N-[4-amino-1-[[1-[[4-amino-1-oxo-1-[[6,9,18-tris(2-aminoethyl)-15-benzyl-3-(1-hydroxyethyl)-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methyloctanamide CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(Cc2ccccc2)NC(=O)C(CCN)NC1=O)C(C)O Lipopeptide anrtibiotic 100% at 25 uM 0.94 NA NA NA NA NA NA Nucleotide binding domain ATPase assay NA NA NA NA NA NA Malaria HSPMDB000498 25500222 Hsp70 Hsp70i Human Cell surface Inhibition of ATP binding Inhibition of tumor growth HS-72 ((S)-N-(1-propyl-1Hbenzo[d]imidazol-2-yl)-1-(pyrazin-2-yl)piperidine-3-carboxamide) CCCn1c(NC(=O)[C@H]2CCCN(C2)c3cnccn3)nc4ccccc14 Purine analogue NA NA NA NA NA NA NA NA Allosteric site Fluorescence linked enzyme chemoproteomic strategy (FLECS) NA NA Her2 degradation assay NA NA HeLa Cancer HSPMDB000499 26839186 Hsp70 Hsp70 Human Cytosol and nucleus Inhibition of chaperone activity NA 9-aminoacridizinium derivative 1 9-amino acridizinium tetrafluoroborate NA 9-aminoacridizinium derivative NA NA NA 45 NA NA NA NA Nucleotide binding domain Refolding assay (luciferase) NA NA NA NA NA NA NA HSPMDB000500 26839186 Hsp70 Hsc70 Human Cytosol and nucleus Inhibition of chaperone activity NA 9-aminoacridizinium derivative 1 9-amino acridizinium tetrafluoroborate NA 9-aminoacridizinium derivative NA NA NA 363 NA NA NA NA Nucleotide binding domain Refolding assay (luciferase) NA NA NA NA NA NA NA HSPMDB000501 26839186 Hsp70 Hsp70 Human Cytosol and nucleus Inhibition of chaperone activity NA alkylamino-substituted acridizinium derivative 2 9-(pyrrolidin-1-yl)-5??-pyrido[1,2-b]isoquinolin-5-ylium bromide [Br-].C1CCN(C1)C1=CC2=CC3=CC=CC=[N+]3C=C2C=C1 9-aminoacridizinium derivative NA NA NA 127 NA NA NA NA NA Refolding assay (luciferase) NA NA NA NA NA NA NA HSPMDB000502 26839186 Hsp70 Hsc70 Human Cytosol and nucleus Inhibition of chaperone activity NA alkylamino-substituted acridizinium derivative 2 9-(pyrrolidin-1-yl)-5??-pyrido[1,2-b]isoquinolin-5-ylium bromide [Br-].C1CCN(C1)C1=CC2=CC3=CC=CC=[N+]3C=C2C=C1 9-aminoacridizinium derivative NA NA NA 34 NA NA NA NA NA Refolding assay (luciferase) NA NA NA NA NA NA NA HSPMDB000503 26839186 Hsp70 Hsp70 Human Cytosol and nucleus Inhibition of chaperone activity NA sulfanyl-substituted derivative 3 9-(methylsulfanyl)acridizinium tetrafluoroborate NA 9-aminoacridizinium derivative NA NA NA 1052 NA NA NA NA NA Refolding assay (luciferase) NA NA NA NA NA NA NA HSPMDB000504 26839186 Hsp70 Hsc70 Human Cytosol and nucleus Inhibition of chaperone activity NA sulfanyl-substituted derivative 3 9-(methylsulfanyl)acridizinium tetrafluoroborate NA 9-aminoacridizinium derivative NA NA NA 931 NA NA NA NA NA Refolding assay (luciferase) NA NA NA NA NA NA NA HSPMDB000505 10086320 Hsp70 Hsc70 Bovine Cytosol and nucleus Activation of ATPase activity NA 15-deoxyspergualin (DSG) N-[(1S)-2-[4-(3-aminopropylamino)butylamino]-1-hydroxy-2-oxoethyl]-7-(diaminomethylideneamino)heptanamide C(CCCN=C(N)N)CCC(=O)NC(C(=O)NCCCCNCCCN)O Natural product 22% increase NA NA NA NA NA NA NA C-terminal domain ATPase assay NA NA NA NA NA NA NA HSPMDB000506 10086320 Hsp70 Ssa1p Yeast Cytosol Activation of ATPase activity NA 15-deoxyspergualin (DSG) N-[(1S)-2-[4-(3-aminopropylamino)butylamino]-1-hydroxy-2-oxoethyl]-7-(diaminomethylideneamino)heptanamide C(CCCN=C(N)N)CCC(=O)NC(C(=O)NCCCCNCCCN)O Natural product 42% increase NA NA NA NA NA NA NA C-terminal domain ATPase assay NA NA NA NA NA NA NA HSPMDB000507 18729127 Hsp70 Hsc70 Human Cytosol and nucleus Binding affinity NA Apoptozole (Az) 4-[[2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)imidazol-1-yl]methyl]benzamide COC1=CC=C(C=C1)C2=C(N(C(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)CC4=CC=C(C=C4)C(=O)N)C5=CC=C(C=C5)OC Imidazole NA 0.21 NA NA NA NA NA NA Nucleotide binding domain Surface plasmon resonance (SPR) NA NA NA NA NA NA NA HSPMDB000508 18729127 Hsp70 Hsp70 Human Cytosol and nucleus Binding affinity NA Apoptozole (Az) 4-[[2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)imidazol-1-yl]methyl]benzamide COC1=CC=C(C=C1)C2=C(N(C(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)CC4=CC=C(C=C4)C(=O)N)C5=CC=C(C=C5)OC Imidazole NA 0.14 NA NA NA NA NA NA Nucleotide binding domain Surface plasmon resonance (SPR) NA NA NA NA NA NA NA HSPMDB000509 23177194 Hsp70 Hsp72 (HSPA1A) Human Cytosol and nucleus Inhibition of ATPase activity NA Methylene Blue [7-(dimethylamino)phenothiazin-3-ylidene]-dimethylazanium;chloride CN(C)C1=CC2=C(C=C1)N=C3C=CC(=[N+](C)C)C=C3S2.[Cl-] Dihydropyrimidine derivative 37.50% NA NA NA NA NA NA NA Irreversibly inhibits by oxidizing Cys306 ATPase assay NA NA NA NA NA NA NA HSPMDB000510 23472668 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus Binding affinity NA MKT-077 2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=C(C=CC=C2)N1C)=C\C1=[N+](C)C=CC=C1 Rhodacyanine NA NA NA 6.4 NA NA NA NA Nucleotide binding domain (allosteric site) Enzyme-linked immunosorbent assay (ELISA) NA NA NA NA NA NA Alzheimers disease HSPMDB000511 23472668 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus Binding affinity NA YM-01 2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=C(C=CC=C2)N1C)=C\C1=[N+](C)C=CC=C1 Rhodacyanine derivative NA NA NA 3.2 NA NA NA NA Nucleotide binding domain (allosteric site) Enzyme-linked immunosorbent assay (ELISA) NA NA NA NA NA NA Alzheimers disease HSPMDB000512 23472668 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus Binding affinity NA YM-08 (2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-2-[(pyridin-2-yl)methylidene]-1,3-thiazolidin-4-one CCN1\C(S\C(C1=O)=C1\SC2=C(C=CC=C2)N1C)=C\C1=NC=CC=C1 Rhodacyanine derivative NA NA NA 0.61 NA NA NA NA Nucleotide binding domain (allosteric site) Enzyme-linked immunosorbent assay (ELISA) NA NA NA NA NA NA Alzheimers disease HSPMDB000513 23472668 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus Binding affinity NA YM-02 3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-2-sulfanylidene-1,3-thiazolidin-4-one CCN1C(=S)S\C(C1=O)=C1\SC2=C(C=CC=C2)N1C Rhodacyanine derivative NA NA NA >50 NA NA NA NA Nucleotide binding domain (allosteric site) Enzyme-linked immunosorbent assay (ELISA) NA NA NA NA NA NA Alzheimers disease HSPMDB000514 23472668 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus Binding affinity NA YM-03 3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-2-(methylsulfanyl)-4-oxo-4,5-dihydro-1,3-thiazol-3-ium CC[N+]1=C(SC)S\C(C1=O)=C1\SC2=C(C=CC=C2)N1C Rhodacyanine derivative NA NA NA >50 NA NA NA NA Nucleotide binding domain (allosteric site) Enzyme-linked immunosorbent assay (ELISA) NA NA NA NA NA NA Alzheimers disease HSPMDB000515 23472668 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus Binding affinity NA YM-04 2-{[(2Z)-3-ethyl-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium iodide [I-].CCN1C(=O)CS\C1=C/C1=[N+](C)C=CC=C1 Rhodacyanine derivative NA NA NA 15 NA NA NA NA Nucleotide binding domain (allosteric site) Enzyme-linked immunosorbent assay (ELISA) NA NA NA NA NA NA Alzheimers disease HSPMDB000516 23472668 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus Binding affinity NA YM-07 (2Z)-3-ethyl-2-[(pyridin-2-yl)methylidene]-1,3-thiazolidin-4-one CCN1C(=O)CS\C1=C/C1=NC=CC=C1 Rhodacyanine derivative NA NA NA 5.8 NA NA NA NA Nucleotide binding domain (allosteric site) Enzyme-linked immunosorbent assay (ELISA) NA NA NA NA NA NA Alzheimers disease HSPMDB000517 23472668 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity MKT-077 2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=C(C=CC=C2)N1C)=C\C1=[N+](C)C=CC=C1 Rhodacyanine NA NA NA NA 2.2 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000518 23472668 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity YM-01 2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=C(C=CC=C2)N1C)=C\C1=[N+](C)C=CC=C1 Rhodacyanine derivative NA NA NA NA 5.2 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000519 23472668 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity YM-08 (2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-2-[(pyridin-2-yl)methylidene]-1,3-thiazolidin-4-one CCN1\C(S\C(C1=O)=C1\SC2=C(C=CC=C2)N1C)=C\C1=NC=CC=C1 Rhodacyanine derivative NA NA NA NA 10.5 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000520 23472668 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity YM-02 3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-2-sulfanylidene-1,3-thiazolidin-4-one CCN1C(=S)S\C(C1=O)=C1\SC2=C(C=CC=C2)N1C Rhodacyanine derivative NA NA NA NA 5.8 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000521 23472668 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity YM-03 3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-2-(methylsulfanyl)-4-oxo-4,5-dihydro-1,3-thiazol-3-ium CC[N+]1=C(SC)S\C(C1=O)=C1\SC2=C(C=CC=C2)N1C Rhodacyanine derivative NA NA NA NA >30 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000522 23472668 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity YM-04 2-{[(2Z)-3-ethyl-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium iodide [I-].CCN1C(=O)CS\C1=C/C1=[N+](C)C=CC=C1 Rhodacyanine derivative NA NA NA NA >30 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000523 23472668 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity YM-07 (2Z)-3-ethyl-2-[(pyridin-2-yl)methylidene]-1,3-thiazolidin-4-one CCN1C(=O)CS\C1=C/C1=NC=CC=C1 Rhodacyanine derivative NA NA NA NA 6.5 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000524 23472668 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity MKT-077 2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=C(C=CC=C2)N1C)=C\C1=[N+](C)C=CC=C1 Rhodacyanine NA NA NA NA 3 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF10A Cancer HSPMDB000525 23472668 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity YM-01 2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=C(C=CC=C2)N1C)=C\C1=[N+](C)C=CC=C1 Rhodacyanine derivative NA NA NA NA 3.3 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF10A Cancer HSPMDB000526 23472668 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity YM-08 (2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-2-[(pyridin-2-yl)methylidene]-1,3-thiazolidin-4-one CCN1\C(S\C(C1=O)=C1\SC2=C(C=CC=C2)N1C)=C\C1=NC=CC=C1 Rhodacyanine derivative NA NA NA NA 7.8 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF10A Cancer HSPMDB000527 23472668 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity YM-02 3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-2-sulfanylidene-1,3-thiazolidin-4-one CCN1C(=S)S\C(C1=O)=C1\SC2=C(C=CC=C2)N1C Rhodacyanine derivative NA NA NA NA 13.8 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF10A Cancer HSPMDB000528 23472668 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity YM-03 3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-2-(methylsulfanyl)-4-oxo-4,5-dihydro-1,3-thiazol-3-ium CC[N+]1=C(SC)S\C(C1=O)=C1\SC2=C(C=CC=C2)N1C Rhodacyanine derivative NA NA NA NA >30 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF10A Cancer HSPMDB000529 23472668 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity YM-04 2-{[(2Z)-3-ethyl-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium iodide [I-].CCN1C(=O)CS\C1=C/C1=[N+](C)C=CC=C1 Rhodacyanine derivative NA NA NA NA >30 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF10A Cancer HSPMDB000530 23472668 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity YM-07 (2Z)-3-ethyl-2-[(pyridin-2-yl)methylidene]-1,3-thiazolidin-4-one CCN1C(=O)CS\C1=C/C1=NC=CC=C1 Rhodacyanine derivative NA NA NA NA >30 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF10A Cancer HSPMDB000531 23472668 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity MKT-077 2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=C(C=CC=C2)N1C)=C\C1=[N+](C)C=CC=C1 Rhodacyanine NA NA NA NA 1.4 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000532 23472668 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity YM-01 2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=C(C=CC=C2)N1C)=C\C1=[N+](C)C=CC=C1 Rhodacyanine derivative NA NA NA NA 2 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000533 23472668 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity YM-08 (2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-2-[(pyridin-2-yl)methylidene]-1,3-thiazolidin-4-one CCN1\C(S\C(C1=O)=C1\SC2=C(C=CC=C2)N1C)=C\C1=NC=CC=C1 Rhodacyanine derivative NA NA NA NA 8.5 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000534 23472668 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity YM-02 3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-2-sulfanylidene-1,3-thiazolidin-4-one CCN1C(=S)S\C(C1=O)=C1\SC2=C(C=CC=C2)N1C Rhodacyanine derivative NA NA NA NA >30 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000535 23472668 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity YM-03 3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-2-(methylsulfanyl)-4-oxo-4,5-dihydro-1,3-thiazol-3-ium CC[N+]1=C(SC)S\C(C1=O)=C1\SC2=C(C=CC=C2)N1C Rhodacyanine derivative NA NA NA NA >30 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000536 23472668 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity YM-04 2-{[(2Z)-3-ethyl-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium iodide [I-].CCN1C(=O)CS\C1=C/C1=[N+](C)C=CC=C1 Rhodacyanine derivative NA NA NA NA >30 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000537 23472668 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity YM-07 (2Z)-3-ethyl-2-[(pyridin-2-yl)methylidene]-1,3-thiazolidin-4-one CCN1C(=O)CS\C1=C/C1=NC=CC=C1 Rhodacyanine derivative NA NA NA NA >30 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000538 23472668 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity MKT-077 2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=C(C=CC=C2)N1C)=C\C1=[N+](C)C=CC=C1 Rhodacyanine NA NA NA NA 8 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA HeLa Cancer HSPMDB000539 23472668 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity YM-01 2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=C(C=CC=C2)N1C)=C\C1=[N+](C)C=CC=C1 Rhodacyanine derivative NA NA NA NA 3.2 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA HeLa Cancer HSPMDB000540 23472668 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity YM-08 (2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-2-[(pyridin-2-yl)methylidene]-1,3-thiazolidin-4-one CCN1\C(S\C(C1=O)=C1\SC2=C(C=CC=C2)N1C)=C\C1=NC=CC=C1 Rhodacyanine derivative NA NA NA NA 15 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA HeLa Cancer HSPMDB000541 23472668 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity YM-02 3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-2-sulfanylidene-1,3-thiazolidin-4-one CCN1C(=S)S\C(C1=O)=C1\SC2=C(C=CC=C2)N1C Rhodacyanine derivative NA NA NA NA >30 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA HeLa Cancer HSPMDB000542 23472668 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity YM-03 3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-2-(methylsulfanyl)-4-oxo-4,5-dihydro-1,3-thiazol-3-ium CC[N+]1=C(SC)S\C(C1=O)=C1\SC2=C(C=CC=C2)N1C Rhodacyanine derivative NA NA NA NA 22 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA HeLa Cancer HSPMDB000543 23472668 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity YM-04 2-{[(2Z)-3-ethyl-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium iodide [I-].CCN1C(=O)CS\C1=C/C1=[N+](C)C=CC=C1 Rhodacyanine derivative NA NA NA NA >30 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA HeLa Cancer HSPMDB000544 23472668 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity YM-07 (2Z)-3-ethyl-2-[(pyridin-2-yl)methylidene]-1,3-thiazolidin-4-one CCN1C(=O)CS\C1=C/C1=NC=CC=C1 Rhodacyanine derivative NA NA NA NA >30 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA HeLa Cancer HSPMDB000545 23607970 Hsp70 Ssa1-Hlj1 Yeast Cytosol Inhibition of ATPase activity NA MKT-077 2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=C(C=CC=C2)N1C)=C\C1=[N+](C)C=CC=C1 Rhodacyanine 10-15% NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) ATPase assay NA NA NA NA NA NA Alzheimers disease HSPMDB000546 23607970 Hsp70 Ssa1-Hlj1 Yeast Cytosol Inhibition of ATPase activity NA YM-01 2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=C(C=CC=C2)N1C)=C\C1=[N+](C)C=CC=C1 Rhodacyanine derivative 10-15% NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) ATPase assay NA NA NA NA NA NA Alzheimers disease HSPMDB000547 19195901 Hsp70 PfHsp70 Plasmodium falciparum Cytosol and nucleus Inhibition of ATPase activity NA DMT3024 benzyl 1-{5-[({[1,1'-biphenyl]-4-yl}(butylcarbamoyl)methyl)[2-(morpholin-4-yl)ethyl]carbamoyl]pentyl}-6-methyl-4-(4-nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate CCCCNC(=O)C(N(CCN1CCOCC1)C(=O)CCCCCN1C(=O)NC(C2=CC=C(C=C2)[N+]([O-])=O)C(C(=O)OCC2=CC=CC=C2)=C1C)C1=CC=C(C=C1)C1=CC=CC=C1 Pyrimidinone amide 0.73 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA Malaria HSPMDB000548 19195901 Hsp70 PfHsp70 Plasmodium falciparum Cytosol and nucleus Inhibition of ATPase activity NA DMT2264 benzyl 4-{[1,1'-biphenyl]-4-yl}-1-(5-{[(butylcarbamoyl)(cyclohexyl)methyl](hexyl)carbamoyl}pentyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate CCCCCCN(C(C1CCCCC1)C(=O)NCCCC)C(=O)CCCCCN1C(=O)NC(C2=CC=C(C=C2)C2=CC=CC=C2)C(C(=O)OCC2=CC=CC=C2)=C1C Pyrimidinone amide 0.74 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA Malaria HSPMDB000549 19195901 Hsp70 PfHsp70 Plasmodium falciparum Cytosol and nucleus Inhibition of ATPase activity NA MAL2-29 6-[5-(ethoxycarbonyl)-6-methyl-4-(3-nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidin-1-yl]hexanoic acid CCOC(=O)C1=C(C)N(CCCCCC(O)=O)C(=O)NC1C1=CC=CC(=C1)[N+]([O-])=O Pyrimidinone amide 1.01 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA Malaria HSPMDB000550 19195901 Hsp70 PfHsp70 Plasmodium falciparum Cytosol and nucleus Inhibition of ATPase activity NA MAL2-39 benzyl 1-butyl-4-(4-methoxyphenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate CCCCN1C(=O)NC(C2=CC=C(OC)C=C2)C(C(=O)OCC2=CC=CC=C2)=C1C Pyrimidinone amide 0.92 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA Malaria HSPMDB000551 19195901 Hsp70 PfHsp70 Plasmodium falciparum Cytosol and nucleus Inhibition of ATPase activity NA MAL2-61 ethyl 1-benzyl-6-methyl-4-{2-[(2-nitrobenzenesulfonyl)oxy]phenyl}-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate CCOC(=O)C1=C(C)N(CC2=CC=CC=C2)C(=O)NC1C1=CC=CC=C1OS(=O)(=O)C1=C(C=CC=C1)[N+]([O-])=O Pyrimidinone amide 0.99 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA Malaria HSPMDB000552 19195901 Hsp70 PfHsp70 Plasmodium falciparum Cytosol and nucleus Inhibition of ATPase activity NA MAL2-213 ethyl 1-[3-({2-[3-(methoxycarbonyl)-2-methyl-5-phenyl-1H-pyrrol-1-yl]ethyl}carbamoyl)propyl]-6-methyl-4-(4-nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate CCOC(=O)C1=C(C)N(CCCC(=O)NCCN2C(C)=C(C=C2C2=CC=CC=C2)C(=O)OC)C(=O)NC1C1=CC=C(C=C1)[N+]([O-])=O Pyrimidinone amide 1.02 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA Malaria HSPMDB000553 19195901 Hsp70 PfHsp70 Plasmodium falciparum Cytosol and nucleus Inhibition of ATPase activity NA MAL2-215 benzyl 4-{[1,1'-biphenyl]-4-yl}-1-[5-({2-[3-(methoxycarbonyl)-2-methyl-5-phenyl-1H-pyrrol-1-yl]ethyl}carbamoyl)pentyl]-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate COC(=O)C1=C(C)N(CCNC(=O)CCCCCN2C(=O)NC(C3=CC=C(C=C3)C3=CC=CC=C3)C(C(=O)OCC3=CC=CC=C3)=C2C)C(=C1)C1=CC=CC=C1 Pyrimidinone amide 1.01 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA Malaria HSPMDB000554 19195901 Hsp70 PfHsp70 Plasmodium falciparum Cytosol and nucleus Inhibition of ATPase activity NA MAL3-39 benzyl 1-{3-[({[1,1'-biphenyl]-4-yl}(tert-butylcarbamoyl)methyl)[2-(morpholin-4-yl)ethyl]carbamoyl]propyl}-6-methyl-4-(4-nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate CC1=C(C(NC(=O)N1CCCC(=O)N(CCN1CCOCC1)C(C(=O)NC(C)(C)C)C1=CC=C(C=C1)C1=CC=CC=C1)C1=CC=C(C=C1)[N+]([O-])=O)C(=O)OCC1=CC=CC=C1 Pyrimidinone amide 0.72 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA Malaria HSPMDB000555 19195901 Hsp70 PfHsp70 Plasmodium falciparum Cytosol and nucleus Inhibition of ATPase activity NA JAB75 methyl 6-benzyl-4-(naphthalen-2-yl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate COC(=O)C1=C(CC2=CC=CC=C2)NC(=O)NC1C1=CC2=C(C=CC=C2)C=C1 Pyrimidinone amide 1 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA Malaria HSPMDB000556 19195901 Hsp70 Ssa1 Yeast Cytosol Inhibition of ATPase activity NA DMT3024 benzyl 1-{5-[({[1,1'-biphenyl]-4-yl}(butylcarbamoyl)methyl)[2-(morpholin-4-yl)ethyl]carbamoyl]pentyl}-6-methyl-4-(4-nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate CCCCNC(=O)C(N(CCN1CCOCC1)C(=O)CCCCCN1C(=O)NC(C2=CC=C(C=C2)[N+]([O-])=O)C(C(=O)OCC2=CC=CC=C2)=C1C)C1=CC=C(C=C1)C1=CC=CC=C1 Pyrimidinone amide 1 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000557 19195901 Hsp70 Ssa1 Yeast Cytosol Inhibition of ATPase activity NA DMT2264 benzyl 4-{[1,1'-biphenyl]-4-yl}-1-(5-{[(butylcarbamoyl)(cyclohexyl)methyl](hexyl)carbamoyl}pentyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate CCCCCCN(C(C1CCCCC1)C(=O)NCCCC)C(=O)CCCCCN1C(=O)NC(C2=CC=C(C=C2)C2=CC=CC=C2)C(C(=O)OCC2=CC=CC=C2)=C1C Pyrimidinone amide 0.97 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000558 19195901 Hsp70 Ssa1 Yeast Cytosol Inhibition of ATPase activity NA MAL2-29 6-[5-(ethoxycarbonyl)-6-methyl-4-(3-nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidin-1-yl]hexanoic acid CCOC(=O)C1=C(C)N(CCCCCC(O)=O)C(=O)NC1C1=CC=CC(=C1)[N+]([O-])=O Pyrimidinone amide 0.93 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000559 19195901 Hsp70 Ssa1 Yeast Cytosol Inhibition of ATPase activity NA MAL2-39 benzyl 1-butyl-4-(4-methoxyphenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate CCCCN1C(=O)NC(C2=CC=C(OC)C=C2)C(C(=O)OCC2=CC=CC=C2)=C1C Pyrimidinone amide 0.95 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000560 19195901 Hsp70 Ssa1 Yeast Cytosol Inhibition of ATPase activity NA MAL2-61 ethyl 1-benzyl-6-methyl-4-{2-[(2-nitrobenzenesulfonyl)oxy]phenyl}-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate CCOC(=O)C1=C(C)N(CC2=CC=CC=C2)C(=O)NC1C1=CC=CC=C1OS(=O)(=O)C1=C(C=CC=C1)[N+]([O-])=O Pyrimidinone amide 1.1 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000561 19195901 Hsp70 Ssa1 Yeast Cytosol Inhibition of ATPase activity NA MAL2-213 ethyl 1-[3-({2-[3-(methoxycarbonyl)-2-methyl-5-phenyl-1H-pyrrol-1-yl]ethyl}carbamoyl)propyl]-6-methyl-4-(4-nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate CCOC(=O)C1=C(C)N(CCCC(=O)NCCN2C(C)=C(C=C2C2=CC=CC=C2)C(=O)OC)C(=O)NC1C1=CC=C(C=C1)[N+]([O-])=O Pyrimidinone amide 0.89 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000562 19195901 Hsp70 Ssa1 Yeast Cytosol Inhibition of ATPase activity NA MAL2-215 benzyl 4-{[1,1'-biphenyl]-4-yl}-1-[5-({2-[3-(methoxycarbonyl)-2-methyl-5-phenyl-1H-pyrrol-1-yl]ethyl}carbamoyl)pentyl]-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate COC(=O)C1=C(C)N(CCNC(=O)CCCCCN2C(=O)NC(C3=CC=C(C=C3)C3=CC=CC=C3)C(C(=O)OCC3=CC=CC=C3)=C2C)C(=C1)C1=CC=CC=C1 Pyrimidinone amide 1.2 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000563 19195901 Hsp70 Ssa1 Yeast Cytosol Inhibition of ATPase activity NA MAL3-39 benzyl 1-{3-[({[1,1'-biphenyl]-4-yl}(tert-butylcarbamoyl)methyl)[2-(morpholin-4-yl)ethyl]carbamoyl]propyl}-6-methyl-4-(4-nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate CC1=C(C(NC(=O)N1CCCC(=O)N(CCN1CCOCC1)C(C(=O)NC(C)(C)C)C1=CC=C(C=C1)C1=CC=CC=C1)C1=CC=C(C=C1)[N+]([O-])=O)C(=O)OCC1=CC=CC=C1 Pyrimidinone amide 0.75 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000564 19195901 Hsp70 Ssa1 Yeast Cytosol Inhibition of ATPase activity NA JAB75 methyl 6-benzyl-4-(naphthalen-2-yl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate COC(=O)C1=C(CC2=CC=CC=C2)NC(=O)NC1C1=CC2=C(C=CC=C2)C=C1 Pyrimidinone amide 1.2 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000565 19195901 Hsp70 Hsp70 (HSPA1A) Human Cytosol and nucleus Inhibition of ATPase activity NA DMT3024 benzyl 1-{5-[({[1,1'-biphenyl]-4-yl}(butylcarbamoyl)methyl)[2-(morpholin-4-yl)ethyl]carbamoyl]pentyl}-6-methyl-4-(4-nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate CCCCNC(=O)C(N(CCN1CCOCC1)C(=O)CCCCCN1C(=O)NC(C2=CC=C(C=C2)[N+]([O-])=O)C(C(=O)OCC2=CC=CC=C2)=C1C)C1=CC=C(C=C1)C1=CC=CC=C1 Pyrimidinone amide 0.74 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000566 19195901 Hsp70 Hsp70 (HSPA1A) Human Cytosol and nucleus Inhibition of ATPase activity NA DMT2264 benzyl 4-{[1,1'-biphenyl]-4-yl}-1-(5-{[(butylcarbamoyl)(cyclohexyl)methyl](hexyl)carbamoyl}pentyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate CCCCCCN(C(C1CCCCC1)C(=O)NCCCC)C(=O)CCCCCN1C(=O)NC(C2=CC=C(C=C2)C2=CC=CC=C2)C(C(=O)OCC2=CC=CC=C2)=C1C Pyrimidinone amide 0.95 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000567 19195901 Hsp70 Hsp70 (HSPA1A) Human Cytosol and nucleus Inhibition of ATPase activity NA MAL2-29 6-[5-(ethoxycarbonyl)-6-methyl-4-(3-nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidin-1-yl]hexanoic acid CCOC(=O)C1=C(C)N(CCCCCC(O)=O)C(=O)NC1C1=CC=CC(=C1)[N+]([O-])=O Pyrimidinone amide 0.85 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000568 19195901 Hsp70 Hsp70 (HSPA1A) Human Cytosol and nucleus Inhibition of ATPase activity NA MAL2-39 benzyl 1-butyl-4-(4-methoxyphenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate CCCCN1C(=O)NC(C2=CC=C(OC)C=C2)C(C(=O)OCC2=CC=CC=C2)=C1C Pyrimidinone amide 0.8 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000569 19195901 Hsp70 Hsp70 (HSPA1A) Human Cytosol and nucleus Inhibition of ATPase activity NA MAL2-61 ethyl 1-benzyl-6-methyl-4-{2-[(2-nitrobenzenesulfonyl)oxy]phenyl}-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate CCOC(=O)C1=C(C)N(CC2=CC=CC=C2)C(=O)NC1C1=CC=CC=C1OS(=O)(=O)C1=C(C=CC=C1)[N+]([O-])=O Pyrimidinone amide 0.74 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000570 19195901 Hsp70 Hsp70 (HSPA1A) Human Cytosol and nucleus Inhibition of ATPase activity NA MAL2-213 ethyl 1-[3-({2-[3-(methoxycarbonyl)-2-methyl-5-phenyl-1H-pyrrol-1-yl]ethyl}carbamoyl)propyl]-6-methyl-4-(4-nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate CCOC(=O)C1=C(C)N(CCCC(=O)NCCN2C(C)=C(C=C2C2=CC=CC=C2)C(=O)OC)C(=O)NC1C1=CC=C(C=C1)[N+]([O-])=O Pyrimidinone amide 0.8 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000571 19195901 Hsp70 Hsp70 (HSPA1A) Human Cytosol and nucleus Inhibition of ATPase activity NA MAL2-215 benzyl 4-{[1,1'-biphenyl]-4-yl}-1-[5-({2-[3-(methoxycarbonyl)-2-methyl-5-phenyl-1H-pyrrol-1-yl]ethyl}carbamoyl)pentyl]-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate COC(=O)C1=C(C)N(CCNC(=O)CCCCCN2C(=O)NC(C3=CC=C(C=C3)C3=CC=CC=C3)C(C(=O)OCC3=CC=CC=C3)=C2C)C(=C1)C1=CC=CC=C1 Pyrimidinone amide 0.72 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000572 19195901 Hsp70 Hsp70 (HSPA1A) Human Cytosol and nucleus Inhibition of ATPase activity NA MAL3-39 benzyl 1-{3-[({[1,1'-biphenyl]-4-yl}(tert-butylcarbamoyl)methyl)[2-(morpholin-4-yl)ethyl]carbamoyl]propyl}-6-methyl-4-(4-nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate CC1=C(C(NC(=O)N1CCCC(=O)N(CCN1CCOCC1)C(C(=O)NC(C)(C)C)C1=CC=C(C=C1)C1=CC=CC=C1)C1=CC=C(C=C1)[N+]([O-])=O)C(=O)OCC1=CC=CC=C1 Pyrimidinone amide 0.82 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000573 19195901 Hsp70 Hsp70 (HSPA1A) Human Cytosol and nucleus Inhibition of ATPase activity NA JAB75 methyl 6-benzyl-4-(naphthalen-2-yl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate COC(=O)C1=C(CC2=CC=CC=C2)NC(=O)NC1C1=CC2=C(C=CC=C2)C=C1 Pyrimidinone amide 0.7 NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000574 19195901 Hsp70 PfHsp70 Plasmodium falciparum Cytosol and nucleus NA Antiparasitic activity (inhibition of [3H]hypoxanthine uptake) DMT3024 benzyl 1-{5-[({[1,1'-biphenyl]-4-yl}(butylcarbamoyl)methyl)[2-(morpholin-4-yl)ethyl]carbamoyl]pentyl}-6-methyl-4-(4-nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate CCCCNC(=O)C(N(CCN1CCOCC1)C(=O)CCCCCN1C(=O)NC(C2=CC=C(C=C2)[N+]([O-])=O)C(C(=O)OCC2=CC=CC=C2)=C1C)C1=CC=C(C=C1)C1=CC=CC=C1 Pyrimidinone amide NA NA NA 0.2 NA NA NA NA NA NA NA [3H]hypoxanthine uptake assay NA NA NA P. falciparum Malaria HSPMDB000575 19195901 Hsp70 PfHsp70 Plasmodium falciparum Cytosol and nucleus NA Antiparasitic activity (inhibition of [3H]hypoxanthine uptake) DMT2264 benzyl 4-{[1,1'-biphenyl]-4-yl}-1-(5-{[(butylcarbamoyl)(cyclohexyl)methyl](hexyl)carbamoyl}pentyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate CCCCCCN(C(C1CCCCC1)C(=O)NCCCC)C(=O)CCCCCN1C(=O)NC(C2=CC=C(C=C2)C2=CC=CC=C2)C(C(=O)OCC2=CC=CC=C2)=C1C Pyrimidinone amide NA NA NA 1.1 NA NA NA NA NA NA NA [3H]hypoxanthine uptake assay NA NA NA P. falciparum Malaria HSPMDB000576 19195901 Hsp70 PfHsp70 Plasmodium falciparum Cytosol and nucleus NA Antiparasitic activity (inhibition of [3H]hypoxanthine uptake) MAL2-29 6-[5-(ethoxycarbonyl)-6-methyl-4-(3-nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidin-1-yl]hexanoic acid CCOC(=O)C1=C(C)N(CCCCCC(O)=O)C(=O)NC1C1=CC=CC(=C1)[N+]([O-])=O Pyrimidinone amide NA NA NA 1.6 NA NA NA NA NA NA NA [3H]hypoxanthine uptake assay NA NA NA P. falciparum Malaria HSPMDB000577 19195901 Hsp70 PfHsp70 Plasmodium falciparum Cytosol and nucleus NA Antiparasitic activity (inhibition of [3H]hypoxanthine uptake) MAL2-39 benzyl 1-butyl-4-(4-methoxyphenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate CCCCN1C(=O)NC(C2=CC=C(OC)C=C2)C(C(=O)OCC2=CC=CC=C2)=C1C Pyrimidinone amide NA NA NA 0.2 NA NA NA NA NA NA NA [3H]hypoxanthine uptake assay NA NA NA P. falciparum Malaria HSPMDB000578 19195901 Hsp70 PfHsp70 Plasmodium falciparum Cytosol and nucleus NA Antiparasitic activity (inhibition of [3H]hypoxanthine uptake) MAL2-61 ethyl 1-benzyl-6-methyl-4-{2-[(2-nitrobenzenesulfonyl)oxy]phenyl}-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate CCOC(=O)C1=C(C)N(CC2=CC=CC=C2)C(=O)NC1C1=CC=CC=C1OS(=O)(=O)C1=C(C=CC=C1)[N+]([O-])=O Pyrimidinone amide NA NA NA 0.1 NA NA NA NA NA NA NA [3H]hypoxanthine uptake assay NA NA NA P. falciparum Malaria HSPMDB000579 19195901 Hsp70 PfHsp70 Plasmodium falciparum Cytosol and nucleus NA Antiparasitic activity (inhibition of [3H]hypoxanthine uptake) MAL2-213 ethyl 1-[3-({2-[3-(methoxycarbonyl)-2-methyl-5-phenyl-1H-pyrrol-1-yl]ethyl}carbamoyl)propyl]-6-methyl-4-(4-nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate CCOC(=O)C1=C(C)N(CCCC(=O)NCCN2C(C)=C(C=C2C2=CC=CC=C2)C(=O)OC)C(=O)NC1C1=CC=C(C=C1)[N+]([O-])=O Pyrimidinone amide NA NA NA 0.03 NA NA NA NA NA NA NA [3H]hypoxanthine uptake assay NA NA NA P. falciparum Malaria HSPMDB000580 19195901 Hsp70 PfHsp70 Plasmodium falciparum Cytosol and nucleus NA Antiparasitic activity (inhibition of [3H]hypoxanthine uptake) MAL2-215 benzyl 4-{[1,1'-biphenyl]-4-yl}-1-[5-({2-[3-(methoxycarbonyl)-2-methyl-5-phenyl-1H-pyrrol-1-yl]ethyl}carbamoyl)pentyl]-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate COC(=O)C1=C(C)N(CCNC(=O)CCCCCN2C(=O)NC(C3=CC=C(C=C3)C3=CC=CC=C3)C(C(=O)OCC3=CC=CC=C3)=C2C)C(=C1)C1=CC=CC=C1 Pyrimidinone amide NA NA NA 0.05 NA NA NA NA NA NA NA [3H]hypoxanthine uptake assay NA NA NA P. falciparum Malaria HSPMDB000581 19195901 Hsp70 PfHsp70 Plasmodium falciparum Cytosol and nucleus NA Antiparasitic activity (inhibition of [3H]hypoxanthine uptake) MAL3-39 benzyl 1-{3-[({[1,1'-biphenyl]-4-yl}(tert-butylcarbamoyl)methyl)[2-(morpholin-4-yl)ethyl]carbamoyl]propyl}-6-methyl-4-(4-nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate CC1=C(C(NC(=O)N1CCCC(=O)N(CCN1CCOCC1)C(C(=O)NC(C)(C)C)C1=CC=C(C=C1)C1=CC=CC=C1)C1=CC=C(C=C1)[N+]([O-])=O)C(=O)OCC1=CC=CC=C1 Pyrimidinone amide NA NA NA 0.8 NA NA NA NA NA NA NA [3H]hypoxanthine uptake assay NA NA NA P. falciparum Malaria HSPMDB000582 19195901 Hsp70 PfHsp70 Plasmodium falciparum Cytosol and nucleus NA Antiparasitic activity (inhibition of [3H]hypoxanthine uptake) JAB75 methyl 6-benzyl-4-(naphthalen-2-yl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate COC(=O)C1=C(CC2=CC=CC=C2)NC(=O)NC1C1=CC2=C(C=CC=C2)C=C1 Pyrimidinone amide NA NA NA 0.3 NA NA NA NA NA NA NA [3H]hypoxanthine uptake assay NA NA NA P. falciparum Malaria HSPMDB000583 24265689 Hsp70 Hsp70(1-382) Human Cytosol and nucleus Inhibition of chaperone activity NA VER-155008 4-[[(2R,3S,4R,5R)-5-[6-amino-8-[(3,4-dichlorophenyl)methylamino]purin-9-yl]-3,4-dihydroxyoxolan-2-yl]methoxymethyl]benzonitrile C1=CC(=CC=C1COCC2C(C(C(O2)N3C4=C(C(=NC=N4)N)N=C3NCC5=CC(=C(C=C5)Cl)Cl)O)O)C#N Dibenzyl-8-amino adenosine analogue Significant Inhibition at 20 uM NA NA NA NA NA NA NA Nucleotide binding domain Refolding assay (luciferase) NA NA NA NA NA NA NA HSPMDB000584 24265689 Hsp70 Hsc70 Human Cytosol and nucleus Inhibition of chaperone activity NA VER-155008 4-[[(2R,3S,4R,5R)-5-[6-amino-8-[(3,4-dichlorophenyl)methylamino]purin-9-yl]-3,4-dihydroxyoxolan-2-yl]methoxymethyl]benzonitrile C1=CC(=CC=C1COCC2C(C(C(O2)N3C4=C(C(=NC=N4)N)N=C3NCC5=CC(=C(C=C5)Cl)Cl)O)O)C#N Dibenzyl-8-amino adenosine analogue Significant Inhibition at 20 uM NA NA NA NA NA NA NA Nucleotide binding domain Refolding assay (luciferase) NA NA NA NA NA NA NA HSPMDB000585 24265689 Hsp70 Hsp70(1-382) Human Cytosol and nucleus Inhibition of chaperone activity NA PES 2-phenylethynesulfonamide C1=CC=C(C=C1)C#CS(=O)(=O)N NA Significant Inhibition at 160 uM NA NA NA NA NA NA NA C-terminal domain Refolding assay (luciferase) NA NA NA NA NA NA NA HSPMDB000586 24265689 Hsp70 Hsc70 Human Cytosol and nucleus Inhibition of chaperone activity NA PES 2-phenylethynesulfonamide C1=CC=C(C=C1)C#CS(=O)(=O)N NA Significant Inhibition at 160 uM NA NA NA NA NA NA NA C-terminal domain Refolding assay (luciferase) NA NA NA NA NA NA NA HSPMDB000587 24265689 Hsp70 Hsp70 Human Cytosol and nucleus Inhibition of ATPase activity NA VER-155008 4-[[(2R,3S,4R,5R)-5-[6-amino-8-[(3,4-dichlorophenyl)methylamino]purin-9-yl]-3,4-dihydroxyoxolan-2-yl]methoxymethyl]benzonitrile C1=CC(=CC=C1COCC2C(C(C(O2)N3C4=C(C(=NC=N4)N)N=C3NCC5=CC(=C(C=C5)Cl)Cl)O)O)C#N Dibenzyl-8-amino adenosine analogue NA NA 10 NA NA NA NA NA Nucleotide binding domain ATPase assay NA NA NA NA NA NA NA HSPMDB000588 24265689 Hsp70 Hsp70 and Hdj1 Human Cytosol and nucleus Inhibition of ATPase activity NA VER-155008 4-[[(2R,3S,4R,5R)-5-[6-amino-8-[(3,4-dichlorophenyl)methylamino]purin-9-yl]-3,4-dihydroxyoxolan-2-yl]methoxymethyl]benzonitrile C1=CC(=CC=C1COCC2C(C(C(O2)N3C4=C(C(=NC=N4)N)N=C3NCC5=CC(=C(C=C5)Cl)Cl)O)O)C#N Dibenzyl-8-amino adenosine analogue NA NA 2.87 NA NA NA NA NA Nucleotide binding domain ATPase assay NA NA NA NA NA NA NA HSPMDB000589 18060774 Hsp70 Hsc70 Bovine Cytosol and nucleus Activation of ATPase activity NA 2(SW02) ethyl 6-(4-bromophenyl)-3-(4-methoxy-4-oxobutyl)-4-methyl-2-oxo-1,6-dihydropyrimidine-5-carboxylate CCOC(=O)C1=C(N(C(=O)NC1C2=CC=C(C=C2)Br)CCCC(=O)OC)C Dihydropyrimidine NA NA NA NA 213 NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000590 18060774 Hsp70 Hsc70 Bovine Cytosol and nucleus Inhibition of ATPase activity NA 6 3-[(3S)-3-[(3S)-7-amino-3-{4-[4-(4-bromophenyl)-5-(ethoxycarbonyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-1-yl]butanamido}heptanamido]-5-phenylpentanamido]propanoic acid CCOC(=O)C1=C(C)N(CCCC(=O)N[C@@H](CCCCN)CC(=O)N[C@@H](CCC2=CC=CC=C2)CC(=O)NCCC(O)=O)C(=O)NC1C1=CC=C(Br)C=C1 Dihydropyrimidine NA NA NA NA 105 NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000591 18060774 Hsp70 Hsc70 Bovine Cytosol and nucleus Inhibition of ATPase activity NA 7 3-[(3S)-7-amino-3-[(3S)-3-{4-[4-(4-bromophenyl)-5-(ethoxycarbonyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-1-yl]butanamido}-5-phenylpentanamido]heptanamido]propanoic acid CCOC(=O)C1=C(C)N(CCCC(=O)N[C@@H](CCC2=CC=CC=C2)CC(=O)N[C@@H](CCCCN)CC(=O)NCCC(O)=O)C(=O)NC1C1=CC=C(Br)C=C1 Dihydropyrimidine NA NA NA NA 265 NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000592 18060774 Hsp70 Hsc70 Bovine Cytosol and nucleus Activation of ATPase activity NA 8 3-[(3R,4S)-3-[(3S)-6-amino-3-{4-[4-(4-bromophenyl)-5-(ethoxycarbonyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-1-yl]butanamido}hexanamido]-4-methylhexanamido]propanoic acid CCOC(=O)C1=C(C)N(CCCC(=O)N[C@@H](CCCN)CC(=O)N[C@H](CC(=O)NCCC(O)=O)[C@@H](C)CC)C(=O)NC1C1=CC=C(Br)C=C1 Dihydropyrimidine NA NA NA NA 352 NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000593 18060774 Hsp70 Hsc70 Bovine Cytosol and nucleus Activation of ATPase activity NA 9 3-[(3S)-3-[(3R)-3-{4-[4-(4-bromophenyl)-5-(ethoxycarbonyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-1-yl]butanamido}-4-methylpentanamido]-4-(naphthalen-1-yl)butanamido]propanoic acid CCOC(=O)C1=C(C)N(CCCC(=O)N[C@H](CC(=O)N[C@H](CC(=O)NCCC(O)=O)CC2=C3C=CC=CC3=CC=C2)C(C)C)C(=O)NC1C1=CC=C(Br)C=C1 Dihydropyrimidine NA NA NA NA 255 NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000594 18060774 Hsp70 Hsc70 Bovine Cytosol and nucleus Activation of ATPase activity NA 14 3-[(3S)-3-{4-[4-(4-bromophenyl)-5-(ethoxycarbonyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-1-yl]butanamido}-5-phenylpentanamido]propanoic acid CCOC(=O)C1=C(C)N(CCCC(=O)N[C@@H](CCC2=CC=CC=C2)CC(=O)NCCC(O)=O)C(=O)NC1C1=CC=C(Br)C=C1 Dihydropyrimidine NA NA NA NA 190 NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000595 18060774 Hsp70 Hsc70 Bovine Cytosol and nucleus Activation of ATPase activity NA 15 3-[(3S)-3-{4-[4-(4-bromophenyl)-5-(ethoxycarbonyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-1-yl]butanamido}-4-(naphthalen-1-yl)butanamido]propanoic aci CCOC(=O)C1=C(C)N(CCCC(=O)N[C@H](CC(=O)NCCC(O)=O)CC2=C3C=CC=CC3=CC=C2)C(=O)NC1C1=CC=C(Br)C=C1 Dihydropyrimidine NA NA NA NA 179 NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000596 18060774 Hsp70 Hsc70 Bovine Cytosol and nucleus Inhibition of ATPase activity NA MAL3-101 Benzyl 4-([1,1?-biphenyl]-4-yl)-1-(6-((2-(butylamino)-1-(4-(2-methoxy-2-oxoethoxy)-3-(methoxycarbonyl)phenyl)-2-oxoethyl)(hexyl)amino)-6-oxohexyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate O=C(C1=C(C)N(CCCCCC(N(C(C2=CC=C(OCC(OC)=O)C(C(OC)=O)=C2)C(NCCCC)=O)CCCCCC)=O)C(NC1C3=CC=C(C4=CC=CC=C4)C=C3)=O)OCC5=CC=CC=C5 Dihydropyrimidine NA NA NA NA 74 NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000597 18060774 Hsp70 DnaK Bacteria Cytosol and membrane Inhibition of ATPase activity NA 6 3-[(3S)-3-[(3S)-7-amino-3-{4-[4-(4-bromophenyl)-5-(ethoxycarbonyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-1-yl]butanamido}heptanamido]-5-phenylpentanamido]propanoic acid CCOC(=O)C1=C(C)N(CCCC(=O)N[C@@H](CCCCN)CC(=O)N[C@@H](CCC2=CC=CC=C2)CC(=O)NCCC(O)=O)C(=O)NC1C1=CC=C(Br)C=C1 Dihydropyrimidine NA NA NA NA 107 NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000598 18060774 Hsp70 DnaK Bacteria Cytosol and membrane Inhibition of ATPase activity NA 7 3-[(3S)-7-amino-3-[(3S)-3-{4-[4-(4-bromophenyl)-5-(ethoxycarbonyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-1-yl]butanamido}-5-phenylpentanamido]heptanamido]propanoic acid CCOC(=O)C1=C(C)N(CCCC(=O)N[C@@H](CCC2=CC=CC=C2)CC(=O)N[C@@H](CCCCN)CC(=O)NCCC(O)=O)C(=O)NC1C1=CC=C(Br)C=C1 Dihydropyrimidine NA NA NA NA 325 NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000599 18060774 Hsp70 DnaK Bacteria Cytosol and membrane Activation of ATPase activity NA 15 3-[(3S)-3-{4-[4-(4-bromophenyl)-5-(ethoxycarbonyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-1-yl]butanamido}-4-(naphthalen-1-yl)butanamido]propanoic aci CCOC(=O)C1=C(C)N(CCCC(=O)N[C@H](CC(=O)NCCC(O)=O)CC2=C3C=CC=CC3=CC=C2)C(=O)NC1C1=CC=C(Br)C=C1 Dihydropyrimidine NA NA NA NA 190 NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000600 22546203 Hsp70 Hsp70-DnaJ (RRL) Rabbit Cytosol and nucleus Inhibition of chaperone activity NA 1 pentyl 3a,8b-dihydroxy-2-methyl-4-methylidene-1H,3aH,4H,8bH-indeno[1,2-b]pyrrole-3-carboxylate CCCCCOC(=O)C1=C(C)NC2(O)C3=C(C=CC=C3)C(=C)C12O Phenoxy-N-arylacetamide NA NA NA 4.3 NA NA NA NA NA Refolding assay (luciferase) NA NA NA NA NA NA NA HSPMDB000601 22546203 Hsp70 Hsp70-DnaJ (RRL) Rabbit Cytosol and nucleus Inhibition of chaperone activity NA 2 N-(4-chlorophenyl)-4-(thiophen-2-yl)-1,3-thiazol-2-amine ClC1=CC=C(NC2=NC(=CS2)C2=CC=CS2)C=C1 Phenoxy-N-arylacetamide NA NA NA 4 NA NA NA NA NA Refolding assay (luciferase) NA NA NA NA NA NA NA HSPMDB000602 22546203 Hsp70 Hsp70-DnaJ (RRL) Rabbit Cytosol and nucleus Inhibition of chaperone activity NA 3 7-(2-chlorophenyl)-4-(furan-2-yl)-8-oxa-5,6-diazatricyclo[7.4.0.0²,?]trideca-1(9),4,10,12-tetraene ClC1=C(C=CC=C1)C1OC2=C(C=CC=C2)C2CC(=NN12)C1=CC=CO1 Phenoxy-N-arylacetamide NA NA NA 8.8 NA NA NA NA NA Refolding assay (luciferase) NA NA NA NA NA NA NA HSPMDB000603 22546203 Hsp70 Hsp70-DnaJ (RRL) Rabbit Cytosol and nucleus Inhibition of chaperone activity NA 4 N-(cyclohexa-1,5-dien-1-yl)-4-(thiophen-2-yl)-1,3-thiazol-2-amine C1CC=C(NC2=NC(=CS2)C2=CC=CS2)C=C1 Phenoxy-N-arylacetamide NA NA NA 1.1 NA NA NA NA NA Refolding assay (luciferase) NA NA NA NA NA NA NA HSPMDB000604 22546203 Hsp70 Hsp70-DnaJ (RRL) Rabbit Cytosol and nucleus Inhibition of chaperone activity NA 5 ethyl 3-[2-(2-chlorophenoxy)acetamido]benzoate CCOC(=O)C1=CC=CC(NC(=O)COC2=CC=CC=C2Cl)=C1 Phenoxy-N-arylacetamide NA NA NA 0.81 NA NA NA NA NA Refolding assay (luciferase) NA NA NA NA NA NA NA HSPMDB000605 19694756 Hsp70 DnaK Bacteria Cytosol and membrane Binding affinity NA B12 N-[(2-fluorophenyl)methyl]thiophene-2-carboxamide FC1=CC=CC=C1CNC(=O)C1=CC=CS1 Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA NA 64.1 NA NA NA NA NA NA C-terminal domain Isothermal Titration Calorimetry (ITC) NA NA NA NA NA NA Bacterial infection HSPMDB000606 19694756 Hsp70 DnaK Bacteria Cytosol and membrane Binding affinity NA F6 N-[(3,4-dichlorophenyl)methyl]thiophene-2-carboxamide ClC1=CC=C(CNC(=O)C2=CC=CS2)C=C1Cl Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA NA 7.3 NA NA NA NA NA NA C-terminal domain Isothermal Titration Calorimetry (ITC) NA NA NA NA NA NA Bacterial infection HSPMDB000607 19694756 Hsp70 DnaK Bacteria Cytosol and membrane Binding affinity NA F8 N-[(2-hydroxyphenyl)methyl]thiophene-2-carboxamide OC1=CC=CC=C1CNC(=O)C1=CC=CS1 Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA NA 2.3 NA NA NA NA NA NA C-terminal domain Isothermal Titration Calorimetry (ITC) NA NA NA NA NA NA Bacterial infection HSPMDB000608 19694756 Hsp70 DnaK Bacteria Cytosol and membrane Binding affinity NA F10 2-[4-(thiophene-2-carbonyl)piperazin-1-yl]ethan-1-ol OCCN1CCN(CC1)C(=O)C1=CC=CS1 Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA NA 16.7 NA NA NA NA NA NA C-terminal domain Isothermal Titration Calorimetry (ITC) NA NA NA NA NA NA Bacterial infection HSPMDB000609 19694756 Hsp70 DnaK Bacteria Cytosol and membrane Binding affinity NA B1 N-[1-(4-fluorophenyl)propan-2-yl]thiophene-2-carboxamide CC(CC1=CC=C(F)C=C1)NC(=O)C1=CC=CS1 Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA NA 13.7 NA NA NA NA NA NA C-terminal domain Isothermal Titration Calorimetry (ITC) NA NA NA NA NA NA Bacterial infection HSPMDB000610 19694756 Hsp70 DnaK Bacteria Cytosol and membrane Binding affinity NA B1 N-[1-(4-fluorophenyl)propan-2-yl]thiophene-2-carboxamide CC(CC1=CC=C(F)C=C1)NC(=O)C1=CC=CS1 Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA NA 28 NA NA NA NA NA NA C-terminal domain Isothermal Titration Calorimetry (ITC) NA NA NA NA NA NA Bacterial infection HSPMDB000611 19694756 Hsp70 DnaK Bacteria Cytosol and membrane Binding affinity NA D10 N-[(1-benzothiophen-7-yl)methyl]thiophene-2-carboxamide O=C(NCC1=CC=CC2=C1SC=C2)C1=CC=CS1 Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA NA 0.2 NA NA NA NA NA NA C-terminal domain Isothermal Titration Calorimetry (ITC) NA NA NA NA NA NA Bacterial infection HSPMDB000612 19694756 Hsp70 DnaK Bacteria Cytosol and membrane Binding affinity NA B3 N-[(4-fluorophenyl)methyl]-5-methylfuran-2-carboxamide CC1=CC=C(O1)C(=O)NCC1=CC=C(F)C=C1 Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA NA 47.6 NA NA NA NA NA NA C-terminal domain Isothermal Titration Calorimetry (ITC) NA NA NA NA NA NA Bacterial infection HSPMDB000613 19694756 Hsp70 DnaK Bacteria Cytosol and membrane Binding affinity NA B4 N-[(4-chlorophenyl)methyl]-5-methylfuran-2-carboxamide CC1=CC=C(O1)C(=O)NCC1=CC=C(Cl)C=C1 Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA NA 19.3 NA NA NA NA NA NA C-terminal domain Isothermal Titration Calorimetry (ITC) NA NA NA NA NA NA Bacterial infection HSPMDB000614 19694756 Hsp70 DnaK Bacteria Cytosol and membrane Binding affinity NA F7 N-[(2,6-dichlorophenyl)methyl]thiophene-2-carboxamide ClC1=CC=CC(Cl)=C1CNC(=O)C1=CC=CS1 Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA NA 1.5 NA NA NA NA NA NA C-terminal domain Isothermal Titration Calorimetry (ITC) NA NA NA NA NA NA Bacterial infection HSPMDB000615 19694756 Hsp70 DnaK Bacteria Cytosol and membrane Binding affinity NA F9 N-[(3,5-dichlorophenyl)methyl]thiophene-2-carboxamide ClC1=CC(CNC(=O)C2=CC=CS2)=CC(Cl)=C1 Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA NA 2.8 NA NA NA NA NA NA C-terminal domain Isothermal Titration Calorimetry (ITC) NA NA NA NA NA NA Bacterial infection HSPMDB000616 19694756 Hsp70 DnaK Bacteria Cytosol and membrane Binding affinity NA D5 N-[(naphthalen-1-yl)methyl]thiophene-2-carboxamide O=C(NCC1=CC=CC2=C1C=CC=C2)C1=CC=CS1 Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA NA 1 NA NA NA NA NA NA C-terminal domain Isothermal Titration Calorimetry (ITC) NA NA NA NA NA NA Bacterial infection HSPMDB000617 19694756 Hsp70 DnaK Bacteria Cytosol and membrane Binding affinity NA D5 N-[(naphthalen-1-yl)methyl]thiophene-2-carboxamide O=C(NCC1=CC=CC2=C1C=CC=C2)C1=CC=CS1 Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA NA 1.7 NA NA NA NA NA NA C-terminal domain Isothermal Titration Calorimetry (ITC) NA NA NA NA NA NA Bacterial infection HSPMDB000618 19694756 Hsp70 DnaK Bacteria Cytosol and membrane Binding affinity NA D9 N-(quinazolin-2-yl)thiophene-2-carboxamide O=C(NC1=NC2=C(C=CC=C2)C=N1)C1=CC=CS1 Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA NA 1.5 NA NA NA NA NA NA C-terminal domain Isothermal Titration Calorimetry (ITC) NA NA NA NA NA NA Bacterial infection HSPMDB000619 19694756 Hsp70 DnaK Bacteria Cytosol and membrane Binding affinity NA C5 N-[(2-bromophenyl)methyl]thiophene-2-carboxamide BrC1=CC=CC=C1CNC(=O)C1=CC=CS1 Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA NA 14.3 NA NA NA NA NA NA C-terminal domain Isothermal Titration Calorimetry (ITC) NA NA NA NA NA NA Bacterial infection HSPMDB000620 19694756 Hsp70 DnaK Bacteria Cytosol and membrane Binding affinity NA C5 N-[(2-bromophenyl)methyl]thiophene-2-carboxamide BrC1=CC=CC=C1CNC(=O)C1=CC=CS1 Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA NA 39.3 NA NA NA NA NA NA C-terminal domain Isothermal Titration Calorimetry (ITC) NA NA NA NA NA NA Bacterial infection HSPMDB000621 19694756 Hsp70 DnaK Bacteria Cytosol and membrane NA Antibacterial activity BI-88E3 N-[(4-methylphenyl)methyl]-5-nitrofuran-2-carboxamide CC1=CC=C(CNC(=O)C2=CC=C(O2)[N+]([O-])=O)C=C1 Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA NA NA NA NA NA NA NA NA C-terminal domain NA NA Bacterial growth inhibition assay (OD based) NA NA 250 uM E. coli at 37 C Bacterial infection HSPMDB000622 19694756 Hsp70 DnaK Bacteria Cytosol and membrane NA Antibacterial activity BI-88E3 N-[(4-methylphenyl)methyl]-5-nitrofuran-2-carboxamide CC1=CC=C(CNC(=O)C2=CC=C(O2)[N+]([O-])=O)C=C1 Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA NA NA NA NA NA NA NA NA C-terminal domain NA NA Bacterial growth inhibition assay (OD based) NA NA 250 uM E. coli at 42 C Bacterial infection HSPMDB000623 19694756 Hsp70 DnaK Bacteria Cytosol and membrane NA Antibacterial activity BI-88E3 N-[(4-methylphenyl)methyl]-5-nitrofuran-2-carboxamide CC1=CC=C(CNC(=O)C2=CC=C(O2)[N+]([O-])=O)C=C1 Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA NA NA NA NA NA NA NA NA C-terminal domain NA NA Bacterial growth inhibition assay (OD based) NA NA 400 uM Yersinia pseudotuberculosis at 22 C Bacterial infection HSPMDB000624 19694756 Hsp70 DnaK Bacteria Cytosol and membrane NA Antibacterial activity BI-88E3 N-[(4-methylphenyl)methyl]-5-nitrofuran-2-carboxamide CC1=CC=C(CNC(=O)C2=CC=C(O2)[N+]([O-])=O)C=C1 Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA NA NA NA NA NA NA NA NA C-terminal domain NA NA Bacterial growth inhibition assay (OD based) NA NA 25 uM Yersinia pseudotuberculosis at 37 C Bacterial infection HSPMDB000625 19694756 Hsp70 DnaK Bacteria Cytosol and membrane NA Antibacterial activity BI-88E3 N-[(4-methylphenyl)methyl]-5-nitrofuran-2-carboxamide CC1=CC=C(CNC(=O)C2=CC=C(O2)[N+]([O-])=O)C=C1 Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA NA NA NA NA NA NA NA NA C-terminal domain NA NA Bacterial growth inhibition assay (OD based) NA NA <12 uM Yersinia pseudotuberculosis at 40 C Bacterial infection HSPMDB000626 19694756 Hsp70 DnaK (SBD) Bacteria Cytosol and membrane Binding affinity NA BI-88E3 N-[(4-methylphenyl)methyl]-5-nitrofuran-2-carboxamide CC1=CC=C(CNC(=O)C2=CC=C(O2)[N+]([O-])=O)C=C1 Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA NA 25 NA NA NA NA NA NA C-terminal domain Isothermal Titration Calorimetry (ITC) NA NA NA NA NA NA Bacterial infection HSPMDB000627 19694756 Hsp70 DnaK Bacteria Cytosol and membrane NA Antibacterial activity BI-88D7 N-(1H-indol-5-yl)thiophene-2-carboxamide N1C=CC2=CC(=CC=C12)NC(=O)C=1SC=CC1 Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA NA NA NA NA NA NA NA NA C-terminal domain NA NA Bacterial growth inhibition assay (OD based) NA NA 400 uM E. coli at 37 C Bacterial infection HSPMDB000628 19694756 Hsp70 DnaK Bacteria Cytosol and membrane NA Antibacterial activity BI-88D7 N-(1H-indol-5-yl)thiophene-2-carboxamide N1C=CC2=CC(=CC=C12)NC(=O)C=1SC=CC1 Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA NA NA NA NA NA NA NA NA C-terminal domain NA NA Bacterial growth inhibition assay (OD based) NA NA 400 uM E. coli at 42 C Bacterial infection HSPMDB000629 19694756 Hsp70 DnaK Bacteria Cytosol and membrane NA Antibacterial activity BI-88D7 N-(1H-indol-5-yl)thiophene-2-carboxamide N1C=CC2=CC(=CC=C12)NC(=O)C=1SC=CC1 Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA NA NA NA NA NA NA NA NA C-terminal domain NA NA Bacterial growth inhibition assay (OD based) NA NA 400 uM Yersinia pseudotuberculosis at 37 C Bacterial infection HSPMDB000630 19694756 Hsp70 DnaK Bacteria Cytosol and membrane NA Antibacterial activity BI-88D7 N-(1H-indol-5-yl)thiophene-2-carboxamide N1C=CC2=CC(=CC=C12)NC(=O)C=1SC=CC1 Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA NA NA NA NA NA NA NA NA C-terminal domain NA NA Bacterial growth inhibition assay (OD based) NA NA 400 uM Yersinia pseudotuberculosis at 22 C Bacterial infection HSPMDB000631 19694756 Hsp70 DnaK Bacteria Cytosol and membrane NA Antibacterial activity BI-88D7 N-(1H-indol-5-yl)thiophene-2-carboxamide N1C=CC2=CC(=CC=C12)NC(=O)C=1SC=CC1 Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA NA NA NA NA NA NA NA NA C-terminal domain NA NA Bacterial growth inhibition assay (OD based) NA NA 400 uM Yersinia pseudotuberculosis at 40 C Bacterial infection HSPMDB000632 19694756 Hsp70 DnaK (SBD) Bacteria Cytosol and membrane Binding affinity NA BI-88D7 N-(1H-indol-5-yl)thiophene-2-carboxamide N1C=CC2=CC(=CC=C12)NC(=O)C=1SC=CC1 Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA NA 4.9 NA NA NA NA NA NA C-terminal domain Isothermal Titration Calorimetry (ITC) NA NA NA NA NA NA Bacterial infection HSPMDB000633 19694756 Hsp70 DnaK (FL) Bacteria Cytosol and membrane Binding affinity NA BI-88D7 N-(1H-indol-5-yl)thiophene-2-carboxamide N1C=CC2=CC(=CC=C12)NC(=O)C=1SC=CC1 Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA NA 12.7 NA NA NA NA NA NA C-terminal domain Isothermal Titration Calorimetry (ITC) NA NA NA NA NA NA Bacterial infection HSPMDB000634 20926844 Hsp70 DnaK-DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA 2a ethyl 2-amino-1-phenyl-1H-pyrrolo[2,3-b]quinoxaline-3-carboxylate CCOC(=O)c1c(N)n(c2ccccc2)c3nc4ccccc4nc13 MS2000 (Spectrum) library NA NA NA >500 NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000635 20926844 Hsp70 DnaK-DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA 2b ethyl 2-amino-1-hexyl-1H-pyrrolo[2,3-b]quinoxaline-3-carboxylate CCCCCCn1c(N)c(C(=O)OCC)c2nc3ccccc3nc12 MS2000 (Spectrum) library NA NA NA >500 NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000636 20926844 Hsp70 DnaK-DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA 3a 6-methyl-2-((2-oxo-2-phenylethyl)thio)-4-(trifluoromethyl)nicotinonitrile Cc1cc(c(C#N)c(SCC(=O)c2ccccc2)n1)C(F)(F)F MS2000 (Spectrum) library NA NA NA >500 NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000637 20926844 Hsp70 DnaK-DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA 3b ethyl 6-acetyl-2-amino-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxylate CCOC(=O)c1c(N)sc2CN(CCc12)C(C)=O MS2000 (Spectrum) library NA NA NA >500 NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000638 20926844 Hsp70 DnaK-DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA 3c cyclopentyl (3-(2-methoxy-4-((o-tolylsulfonyl)carbamoyl)benzyl)-1-methyl-1H-indol-5-yl) carbamate COc1cc(ccc1Cc2cn(C)c3ccc(NC(=O)OC4CCCC4)cc23)C(=O)N[S](=O)(=O)c5ccccc5C MS2000 (Spectrum) library NA NA NA 37 NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000639 20926845 Hsp70 DnaK Bacteria Cytosol and membrane Binding affinity NA 3c cyclopentyl (3-(2-methoxy-4-((o-tolylsulfonyl)carbamoyl)benzyl)-1-methyl-1H-indol-5-yl) carbamate COc1cc(ccc1Cc2cn(C)c3ccc(NC(=O)OC4CCCC4)cc23)C(=O)N[S](=O)(=O)c5ccccc5C MS2000 (Spectrum) library NA 13 NA NA NA NA NA NA NA Intrisic Trp fluortescence NA NA NA NA NA NA NA HSPMDB000640 20926844 Hsp70 Hsp72 Human Cytosol and nucleus Inhibition of ATPase activity NA 3c cyclopentyl (3-(2-methoxy-4-((o-tolylsulfonyl)carbamoyl)benzyl)-1-methyl-1H-indol-5-yl) carbamate COc1cc(ccc1Cc2cn(C)c3ccc(NC(=O)OC4CCCC4)cc23)C(=O)N[S](=O)(=O)c5ccccc5C MS2000 (Spectrum) library NA NA NA 71 NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000641 20926844 Hsp70 Hsc70 Bovine Cytosol and nucleus Inhibition of ATPase activity NA 3c cyclopentyl (3-(2-methoxy-4-((o-tolylsulfonyl)carbamoyl)benzyl)-1-methyl-1H-indol-5-yl) carbamate COc1cc(ccc1Cc2cn(C)c3ccc(NC(=O)OC4CCCC4)cc23)C(=O)N[S](=O)(=O)c5ccccc5C MS2000 (Spectrum) library NA NA NA 106 NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB000642 21636681 Hsp70 Hsc70 (HSPA8) and Hsp70 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 2-phenylethyenesulfonamide (PES) 2-phenylethynesulfonamide C1=CC=C(C=C1)C#CS(=O)(=O)N NA NA NA NA NA NA NA NA 8 C-terminal domain NA NA MTT viability assay NA NA NA H1299 Cancer HSPMDB000643 21636681 Hsp70 Hsc70 (HSPA8) and Hsp70 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 2-phenylethyenesulfonamide (PES) 2-phenylethynesulfonamide C1=CC=C(C=C1)C#CS(=O)(=O)N NA NA NA NA NA NA NA NA 11 C-terminal domain NA NA MTT viability assay NA NA NA MCF10A Cancer HSPMDB000644 21636681 Hsp70 Hsc70 (HSPA8) and Hsp70 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 2-phenylethyenesulfonamide (PES) 2-phenylethynesulfonamide C1=CC=C(C=C1)C#CS(=O)(=O)N NA NA NA NA NA NA NA NA 5 C-terminal domain NA NA MTT viability assay NA NA NA SK-BR-3 Cancer HSPMDB000645 21636681 Hsp70 Hsc70 (HSPA8) and Hsp70 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 2-phenylethyenesulfonamide (PES) 2-phenylethynesulfonamide C1=CC=C(C=C1)C#CS(=O)(=O)N NA NA NA NA NA NA NA NA 5 C-terminal domain NA NA MTT viability assay NA NA NA MDA-MB-468 Cancer HSPMDB000646 23819499 Hsp70 DnaK Bacteria Cytosol and membrane Binding affinity (ADP-bound DnaK) NA Zafirlukast (Zaf) cyclopentyl N-[3-[[2-methoxy-4-[(2-methylphenyl)sulfonylcarbamoyl]phenyl]methyl]-1-methylindol-5-yl]carbamate CC1=CC=CC=C1S(=O)(=O)NC(=O)C2=CC(=C(C=C2)CC3=CN(C4=C3C=C(C=C4)NC(=O)OC5CCCC5)C)OC Library assembled at the University of Michigan's Center for Chemical Genomics NA 52 NA NA NA NA NA NA Nucleotide binding domain Intrisic Trp fluortescence NA NA NA NA NA NA NA HSPMDB000647 23819499 Hsp70 DnaK Bacteria Cytosol and membrane Binding affinity (ATP-bound DnaK) NA Zafirlukast (Zaf) cyclopentyl N-[3-[[2-methoxy-4-[(2-methylphenyl)sulfonylcarbamoyl]phenyl]methyl]-1-methylindol-5-yl]carbamate CC1=CC=CC=C1S(=O)(=O)NC(=O)C2=CC(=C(C=C2)CC3=CN(C4=C3C=C(C=C4)NC(=O)OC5CCCC5)C)OC Library assembled at the University of Michigan's Center for Chemical Genomics NA >100 NA NA NA NA NA NA Nucleotide binding domain Intrisic Trp fluortescence NA NA NA NA NA NA NA HSPMDB000648 23819499 Hsp70 DnaK-DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity (DnaJ stimulated) NA Zafirlukast (Zaf) cyclopentyl N-[3-[[2-methoxy-4-[(2-methylphenyl)sulfonylcarbamoyl]phenyl]methyl]-1-methylindol-5-yl]carbamate CC1=CC=CC=C1S(=O)(=O)NC(=O)C2=CC(=C(C=C2)CC3=CN(C4=C3C=C(C=C4)NC(=O)OC5CCCC5)C)OC Library assembled at the University of Michigan's Center for Chemical Genomics NA NA NA 37 NA NA NA NA Nucleotide binding domain ATPase assay NA NA NA NA NA NA NA HSPMDB000649 24239008 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus Inhibition of chaperone activity NA YK5 N-(6-amino-2-{[4,6-dimethoxy-2-(4-methylpiperazin-1-yl)pyrimidin-5-yl]sulfanyl}pyrimidin-4-yl)prop-2-enamide COC1=NC(=NC(OC)=C1SC1=NC(N)=CC(NC(=O)C=C)=N1)N1CCN(C)CC1 Structure based design 90% inhibition at 100 uM NA NA NA NA NA NA NA Nucleotide binding domain Refolding assay (luciferase) NA NA NA NA NA NA Cancer HSPMDB000650 27119979 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus Binding affinity NA 1 (Adenosine) 2-(6-amino-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol NC1=NC=NC2=C1N=CN2C1OC(CO)C(O)C1O Adenosine derivative NA 110 NA NA NA NA NA NA Nucleotide binding domain Surface plasmon resonance (SPR) NA NA NA NA NA NA NA HSPMDB000651 27119979 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus Binding affinity NA 2 2-(6-amino-9H-purin-9-yl)-5-methyloxolane-3,4-diol CC1OC(C(O)C1O)N1C=NC2=C1N=CN=C2N Adenosine derivative NA 130 NA NA NA NA NA NA Nucleotide binding domain Surface plasmon resonance (SPR) NA NA NA NA NA NA NA HSPMDB000652 27119979 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus Binding affinity NA 3 2-(6,8-diamino-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol NC1=NC2=C(N=CN=C2N)N1C1OC(CO)C(O)C1O Adenosine derivative NA 7 NA NA NA NA NA NA Nucleotide binding domain Surface plasmon resonance (SPR) NA NA NA NA NA NA NA HSPMDB000653 27119979 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus Binding affinity NA 4 (2R,3R,4S,5R)-2-(6-Amino-8-(methylamino)-9H-purin-9-yl)-5(hydroxymethyl)tetrahydrofuran-3,4-diol CNc1nc2c(N)ncnc2n1[C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O Adenosine derivative NA 17 NA NA NA NA NA NA Nucleotide binding domain Surface plasmon resonance (SPR) NA NA NA NA NA NA NA HSPMDB000654 27119979 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus Binding affinity NA 5 (2R,3R,4S,5R)-2-(6-Amino-8-(dimethylamino)-9H-purin-9-yl)-5(hydroxymethyl)tetrahydrofuran-3,4-diol CN(C)c1nc2c(N)ncnc2n1[C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O Adenosine derivative NA >1000 NA NA NA NA NA NA Nucleotide binding domain Surface plasmon resonance (SPR) NA NA NA NA NA NA NA HSPMDB000655 27119979 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus Binding affinity NA 6 (2R,3R,4S,5R)-2-(6-Amino-8-methoxy-9H-purin-9-yl)-5(hydroxymethyl)tetrahydrofuran-3,4-diol COc1nc2c(N)ncnc2n1[C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O Adenosine derivative NA >1000 NA NA NA NA NA NA Nucleotide binding domain Surface plasmon resonance (SPR) NA NA NA NA NA NA NA HSPMDB000656 27119979 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus Binding affinity NA 7 (2R,3R,4S,5R)-2-(6-Amino-8-(methylamino)-9H-purin-9-yl)-5methyltetrahydrofuran-3,4-diol CNc1nc2c(N)ncnc2n1[C@@H]3O[C@H](C)[C@@H](O)[C@H]3O Adenosine derivative NA 27 NA NA NA NA NA NA Nucleotide binding domain Surface plasmon resonance (SPR) NA NA NA NA NA NA NA HSPMDB000657 27119979 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus Binding affinity NA 8 (2R,3R,4S,5R)-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-5-(hydroxymethyl)oxolane-3,4-diol C1=CN(C2=C1C(=NC=N2)N)C3C(C(C(O3)CO)O)O Adenosine derivative NA 28 NA NA NA NA NA NA Nucleotide binding domain Surface plasmon resonance (SPR) NA NA NA NA NA NA NA HSPMDB000658 27119979 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus Binding affinity NA 9 4-amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrrolo[2,3-d]pyrimidine-5-carbonitrile C1=C(C2=C(N1C3C(C(C(O3)CO)O)O)N=CN=C2N)C#N Adenosine derivative NA 90 NA NA NA NA NA NA Nucleotide binding domain Surface plasmon resonance (SPR) NA NA NA NA NA NA NA HSPMDB000659 27119979 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus Binding affinity NA 10 4-amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrrolo[2,3-d]pyrimidine-5-carboxamide C1=C(C2=C(N1C3C(C(C(O3)CO)O)O)N=CN=C2N)C(=O)N Adenosine derivative NA 3.3 NA NA NA NA NA NA Nucleotide binding domain Surface plasmon resonance (SPR) NA NA NA NA NA NA NA HSPMDB000660 27119979 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus Binding affinity NA 12 4-Amino-7-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-6-(methylamino)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile CNc1n([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c3ncnc(N)c3c1C#N Adenosine derivative NA 3.3 NA NA NA NA NA NA Nucleotide binding domain Surface plasmon resonance (SPR) NA NA NA NA NA NA NA HSPMDB000661 27119979 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus Binding affinity NA 13 4-Amino-7-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-6-(methylamino)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide CNc1n([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c3ncnc(N)c3c1C(N)=O Adenosine derivative NA 30 NA NA NA NA NA NA Nucleotide binding domain Surface plasmon resonance (SPR) NA NA NA NA NA NA NA HSPMDB000662 27119979 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus Binding affinity NA 14 4-Amino-6-(benzylamino)-7-((2R,3R,4S,5R)-3,4-dihydroxy-5(hydroxymethyl)tetrahydrofuran-2-yl)-7H-pyrrolo[2,3-d]pyrimidine5-carbonitrile Nc1ncnc2n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c(NCc4ccccc4)c(C#N)c12 Adenosine derivative NA 2.8 NA NA NA NA NA NA Nucleotide binding domain Surface plasmon resonance (SPR) NA NA NA NA NA NA NA HSPMDB000663 27119979 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus Binding affinity NA 15 (2R,3R,4S,5R)-2-(6-Amino-8-(benzylamino)-9H-purin-9-yl)-5(hydroxymethyl)tetrahydrofuran-3,4-diol Nc1ncnc2n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c(NCc4ccccc4)nc12 Adenosine derivative NA 1.5 NA NA NA NA NA NA Nucleotide binding domain Surface plasmon resonance (SPR) NA NA NA NA NA NA NA HSPMDB000664 27119979 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus Binding affinity NA 17 (2R,3R,4S,5R)-2-(6-Amino-8-((quinolin-6-ylmethyl)amino)-9Hpurin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol Nc1ncnc2n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c(NCc4ccc5ncccc5c4)nc12 Adenosine derivative NA 0.72 NA NA NA NA NA NA Nucleotide binding domain Surface plasmon resonance (SPR) NA NA NA NA NA NA NA HSPMDB000665 27119979 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus Binding affinity NA 18 (2R,3R,4S,5R)-2-(6-Amino-8-((4-chlorobenzyl)amino)-9H-purin-9yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol Nc1ncnc2n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c(NCc4ccc(Cl)cc4)nc12 Adenosine derivative NA 0.28 NA NA NA NA NA NA Nucleotide binding domain Surface plasmon resonance (SPR) NA NA NA NA NA NA NA HSPMDB000666 27119979 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus Binding affinity NA 19 (2R,3R,4S,5R)-2-(6-Amino-8-((4-?uorobenzyl)amino)-9H-purin-9yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol Nc1ncnc2n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c(NCc4ccc(F)cc4)nc12 Adenosine derivative NA 0.46 NA NA NA NA NA NA Nucleotide binding domain Surface plasmon resonance (SPR) NA NA NA NA NA NA NA HSPMDB000667 27119979 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus Binding affinity NA 20 (2R,3R,4S,5R)-2-(6-Amino-8-((4-methylbenzyl)amino)-9H-purin9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol Cc1ccc(CNc2nc3c(N)ncnc3n2[C@@H]4O[C@H](CO)[C@@H](O)[C@H]4O)cc1 Adenosine derivative NA 0.3 NA NA NA NA NA NA Nucleotide binding domain Surface plasmon resonance (SPR) NA NA NA NA NA NA NA HSPMDB000668 27119979 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus Binding affinity NA 21 (2R,3R,4S,5R)-2-(6-Amino-8-((3,4-dichlorobenzyl)amino)-9Hpurin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol Nc1ncnc2n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c(NCc4ccc(Cl)c(Cl)c4)nc12 Adenosine derivative NA 3.5 NA NA NA NA NA NA Nucleotide binding domain Surface plasmon resonance (SPR) NA NA NA NA NA NA NA HSPMDB000669 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity JG-98 3-benzyl-2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.71 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000670 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 1 3-benzyl-2-((Z)-((E)-5-(6-bromo-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(Br)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.44 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000671 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 2 3-benzyl-2-((Z)-((E)-5-(5-bromo-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5ccc(Br)cc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.27 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000672 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 3 3-benzyl-2-((Z)-((E)-3-ethyl-5-(3-methyl-6-nitrobenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(ccc5N4C)[N+]([O-])=O Benzothiazole Rhodacyanines derivative NA NA NA NA >5 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000673 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 4 3-benzyl-2-((Z)-((E)-3-ethyl-5-(3-methyl-5-(methylsulfonyl)benzo[d]thiazol-2(3H)-ylidene)-4- oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5ccc(cc5N4C)[S](C)(=O)=O Benzothiazole Rhodacyanines derivative NA NA NA NA >5 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000674 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 5 3-benzyl-2-((Z)-((E)-3-ethyl-5-(3-methyl-6-(trifluoromethyl)benzo[d]thiazol-2(3H)-ylidene)-4- oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(ccc5N4C)C(F)(F)F Benzothiazole Rhodacyanines derivative NA NA NA NA 0.53 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000675 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 6 3-benzyl-2-((Z)-((E)-3-ethyl-5-(3-methyl-5-(trifluoromethoxy)benzo[d]thiazol-2(3H)-ylidene)- 4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5ccc(OC(F)(F)F)cc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.26 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000676 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 7 3-benzyl-2-((Z)-((E)-3-ethyl-5-(3-methyl-6-(trifluoromethoxy)benzo[d]thiazol-2(3H)-ylidene)- 4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(OC(F)(F)F)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.4 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000677 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 8 3-benzyl-2-((Z)-((E)-5-(3,5-dimethylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2- ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5ccc(C)cc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.21 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000678 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 9(JG-194) 3-benzyl-2-((Z)-((E)-5-(3,6-dimethylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2- ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(C)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.16 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000679 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 10 3-benzyl-2-((Z)-((E)-5-(3,4-dimethylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cccc(C)c5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.25 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000680 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 11 3-benzyl-2-((Z)-((E)-5-(3,7-dimethylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5c(C)cccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.29 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000681 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 12 3-benzyl-2-((Z)-((E)-3-ethyl-5-(6-ethyl-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(CC)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.08 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000682 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 13 3-benzyl-2-((Z)-((E)-3-ethyl-5-(5-methoxy-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazo lidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5ccc(OC)cc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.37 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000683 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 14 3-benzyl-2-((Z)-((E)-3-ethyl-5-(6-methoxy-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(OC)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.13 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000684 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 15 3-benzyl-2-((Z)-((E)-3-ethyl-5-(3-methyl-6-(methylthio)benzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(SC)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.13 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000685 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 16 2-((Z)-((E)-3-allyl-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)methyl)-3-benzylthiazol-3-ium chloride [Cl-].CN1C(\Sc2cc(Cl)ccc12)=C3/SC(=C\c4scc[n+]4Cc5ccccc5)/N(CC=C)C3=O Benzothiazole Rhodacyanines derivative NA NA NA NA 0.17 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000686 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 17 3-benzyl-2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-cyclopropyl-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CN1C(/Sc2cc(Cl)ccc12)=C3\S\C(=C/c4scc[n+]4Cc5ccccc5)N(C6CC6)C3=O Benzothiazole Rhodacyanines derivative NA NA NA NA 0.33 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000687 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 18 3-benzyl-2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-(3-methoxy-3-oxopropyl)-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].COC(=O)CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.66 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000688 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 19 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(2-fluorobenzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3F)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.16 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000689 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 20 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2- ylidene)methyl)-3-(3-fluorobenzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3cccc(F)c3)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.48 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000690 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 21 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(4-fluorobenzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccc(F)cc3)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.61 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000691 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 22 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(2-chlorobenzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3Cl)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.19 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000692 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 23 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(3-chlorobenzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3cccc(Cl)c3)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.26 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000693 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 24 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(4-chlorobenzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccc(Cl)cc3)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 1.45 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000694 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 25 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2- ylidene)methyl)-3-(2-(trifluoromethyl)benzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3C(F)(F)F)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.13 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000695 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 26 3-(2-bromobenzyl)-2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4- oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3Br)=C4/Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.19 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000696 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 27 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(2-(methoxycarbonyl)benzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3C(=O)OC)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.17 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000697 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 28 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(2-methylbenzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3C)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.19 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000698 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 29 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(2-methoxybenzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3OC)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.4 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000699 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 30 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(2-((trifluoromethyl)thio)benzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3SC(F)(F)F)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.13 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000700 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 31 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(2-(trifluoromethoxy)benzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3OC(F)(F)F)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.22 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000701 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 32(JG-258) 3-benzyl-2-((Z)-((E)-3'-ethyl-3-methyl-4'-oxo-3',4,4',5-tetrahydro-2'H,3H-[2,5'-bithiazolylidene]- 2'-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/SCCN4C Benzothiazole Rhodacyanines derivative NA NA NA NA >5 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000702 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity JG-98 3-benzyl-2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.39 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000703 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 1 3-benzyl-2-((Z)-((E)-5-(6-bromo-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(Br)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.33 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000704 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 2 3-benzyl-2-((Z)-((E)-5-(5-bromo-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5ccc(Br)cc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.11 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000705 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 3 3-benzyl-2-((Z)-((E)-3-ethyl-5-(3-methyl-6-nitrobenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(ccc5N4C)[N+]([O-])=O Benzothiazole Rhodacyanines derivative NA NA NA NA 4.8 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000706 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 4 3-benzyl-2-((Z)-((E)-3-ethyl-5-(3-methyl-5-(methylsulfonyl)benzo[d]thiazol-2(3H)-ylidene)-4- oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5ccc(cc5N4C)[S](C)(=O)=O Benzothiazole Rhodacyanines derivative NA NA NA NA >20 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000707 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 5 3-benzyl-2-((Z)-((E)-3-ethyl-5-(3-methyl-6-(trifluoromethyl)benzo[d]thiazol-2(3H)-ylidene)-4- oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(ccc5N4C)C(F)(F)F Benzothiazole Rhodacyanines derivative NA NA NA NA 0.36 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000708 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 6 3-benzyl-2-((Z)-((E)-3-ethyl-5-(3-methyl-5-(trifluoromethoxy)benzo[d]thiazol-2(3H)-ylidene)- 4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5ccc(OC(F)(F)F)cc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 1.2 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000709 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 7 3-benzyl-2-((Z)-((E)-3-ethyl-5-(3-methyl-6-(trifluoromethoxy)benzo[d]thiazol-2(3H)-ylidene)- 4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(OC(F)(F)F)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.8 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000710 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 8 3-benzyl-2-((Z)-((E)-5-(3,5-dimethylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2- ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5ccc(C)cc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.078 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000711 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 9(JG-194) 3-benzyl-2-((Z)-((E)-5-(3,6-dimethylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2- ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(C)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.15 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000712 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 10 3-benzyl-2-((Z)-((E)-5-(3,4-dimethylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cccc(C)c5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.21 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000713 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 11 3-benzyl-2-((Z)-((E)-5-(3,7-dimethylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5c(C)cccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.25 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000714 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 12 3-benzyl-2-((Z)-((E)-3-ethyl-5-(6-ethyl-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(CC)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.14 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000715 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 13 3-benzyl-2-((Z)-((E)-3-ethyl-5-(5-methoxy-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazo lidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5ccc(OC)cc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.36 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000716 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 14 3-benzyl-2-((Z)-((E)-3-ethyl-5-(6-methoxy-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(OC)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.16 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000717 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 15 3-benzyl-2-((Z)-((E)-3-ethyl-5-(3-methyl-6-(methylthio)benzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(SC)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.12 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000718 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 16 2-((Z)-((E)-3-allyl-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)methyl)-3-benzylthiazol-3-ium chloride [Cl-].CN1C(\Sc2cc(Cl)ccc12)=C3/SC(=C\c4scc[n+]4Cc5ccccc5)/N(CC=C)C3=O Benzothiazole Rhodacyanines derivative NA NA NA NA 0.1 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000719 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 17 3-benzyl-2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-cyclopropyl-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CN1C(/Sc2cc(Cl)ccc12)=C3\S\C(=C/c4scc[n+]4Cc5ccccc5)N(C6CC6)C3=O Benzothiazole Rhodacyanines derivative NA NA NA NA 0.56 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000720 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 18 3-benzyl-2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-(3-methoxy-3-oxopropyl)-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].COC(=O)CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.24 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000721 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 19 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(2-fluorobenzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3F)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.29 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000722 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 20 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2- ylidene)methyl)-3-(3-fluorobenzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3cccc(F)c3)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 1 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000723 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 21 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(4-fluorobenzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccc(F)cc3)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 1.1 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000724 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 22 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(2-chlorobenzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3Cl)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.18 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000725 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 23 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(3-chlorobenzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3cccc(Cl)c3)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.51 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000726 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 24 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(4-chlorobenzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccc(Cl)cc3)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.41 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000727 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 25 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2- ylidene)methyl)-3-(2-(trifluoromethyl)benzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3C(F)(F)F)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.13 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000728 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 26 3-(2-bromobenzyl)-2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4- oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3Br)=C4/Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.2 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000729 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 27 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(2-(methoxycarbonyl)benzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3C(=O)OC)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.17 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000730 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 28 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(2-methylbenzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3C)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.2 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000731 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 29 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(2-methoxybenzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3OC)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.12 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000732 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 30 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(2-((trifluoromethyl)thio)benzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3SC(F)(F)F)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.16 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000733 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 31 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(2-(trifluoromethoxy)benzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3OC(F)(F)F)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.12 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000734 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 32(JG-258) 3-benzyl-2-((Z)-((E)-3'-ethyl-3-methyl-4'-oxo-3',4,4',5-tetrahydro-2'H,3H-[2,5'-bithiazolylidene]- 2'-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/SCCN4C Benzothiazole Rhodacyanines derivative NA NA NA NA >20 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000735 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity JG-98 3-benzyl-2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 4.2 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000736 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 1 3-benzyl-2-((Z)-((E)-5-(6-bromo-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(Br)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 6.1 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000737 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 2 3-benzyl-2-((Z)-((E)-5-(5-bromo-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5ccc(Br)cc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.66 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000738 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 3 3-benzyl-2-((Z)-((E)-3-ethyl-5-(3-methyl-6-nitrobenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(ccc5N4C)[N+]([O-])=O Benzothiazole Rhodacyanines derivative NA NA NA NA 2.8 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000739 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 4 3-benzyl-2-((Z)-((E)-3-ethyl-5-(3-methyl-5-(methylsulfonyl)benzo[d]thiazol-2(3H)-ylidene)-4- oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5ccc(cc5N4C)[S](C)(=O)=O Benzothiazole Rhodacyanines derivative NA NA NA NA 2.5 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000740 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 5 3-benzyl-2-((Z)-((E)-3-ethyl-5-(3-methyl-6-(trifluoromethyl)benzo[d]thiazol-2(3H)-ylidene)-4- oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(ccc5N4C)C(F)(F)F Benzothiazole Rhodacyanines derivative NA NA NA NA 2.4 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000741 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 6 3-benzyl-2-((Z)-((E)-3-ethyl-5-(3-methyl-5-(trifluoromethoxy)benzo[d]thiazol-2(3H)-ylidene)- 4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5ccc(OC(F)(F)F)cc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.34 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000742 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 7 3-benzyl-2-((Z)-((E)-3-ethyl-5-(3-methyl-6-(trifluoromethoxy)benzo[d]thiazol-2(3H)-ylidene)- 4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(OC(F)(F)F)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 1.2 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000743 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 8 3-benzyl-2-((Z)-((E)-5-(3,5-dimethylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2- ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5ccc(C)cc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 1.3 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000744 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 9(JG-194) 3-benzyl-2-((Z)-((E)-5-(3,6-dimethylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2- ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(C)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 1.9 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000745 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 10 3-benzyl-2-((Z)-((E)-5-(3,4-dimethylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cccc(C)c5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 2.3 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000746 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 11 3-benzyl-2-((Z)-((E)-5-(3,7-dimethylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5c(C)cccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 1.6 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000747 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 12 3-benzyl-2-((Z)-((E)-3-ethyl-5-(6-ethyl-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(CC)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 1 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000748 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 13 3-benzyl-2-((Z)-((E)-3-ethyl-5-(5-methoxy-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazo lidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5ccc(OC)cc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 1 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000749 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 14 3-benzyl-2-((Z)-((E)-3-ethyl-5-(6-methoxy-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(OC)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 2 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000750 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 15 3-benzyl-2-((Z)-((E)-3-ethyl-5-(3-methyl-6-(methylthio)benzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(SC)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 1.7 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000751 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 16 2-((Z)-((E)-3-allyl-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)methyl)-3-benzylthiazol-3-ium chloride [Cl-].CN1C(\Sc2cc(Cl)ccc12)=C3/SC(=C\c4scc[n+]4Cc5ccccc5)/N(CC=C)C3=O Benzothiazole Rhodacyanines derivative NA NA NA NA 2.4 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000752 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 17 3-benzyl-2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-cyclopropyl-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CN1C(/Sc2cc(Cl)ccc12)=C3\S\C(=C/c4scc[n+]4Cc5ccccc5)N(C6CC6)C3=O Benzothiazole Rhodacyanines derivative NA NA NA NA 3.4 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000753 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 18 3-benzyl-2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-(3-methoxy-3-oxopropyl)-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].COC(=O)CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 4.9 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000754 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 19 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(2-fluorobenzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3F)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 1.2 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000755 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 20 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2- ylidene)methyl)-3-(3-fluorobenzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3cccc(F)c3)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 1 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000756 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 21 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(4-fluorobenzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccc(F)cc3)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 1.9 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000757 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 22 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(2-chlorobenzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3Cl)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.7 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000758 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 23 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(3-chlorobenzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3cccc(Cl)c3)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.69 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000759 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 24 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(4-chlorobenzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccc(Cl)cc3)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 3.1 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000760 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 25 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2- ylidene)methyl)-3-(2-(trifluoromethyl)benzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3C(F)(F)F)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 1.2 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000761 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 26 3-(2-bromobenzyl)-2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4- oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3Br)=C4/Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 1.6 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000762 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 27 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(2-(methoxycarbonyl)benzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3C(=O)OC)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 2.9 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000763 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 28 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(2-methylbenzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3C)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 1.6 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000764 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 29 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(2-methoxybenzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3OC)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 1.5 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000765 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 30 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(2-((trifluoromethyl)thio)benzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3SC(F)(F)F)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 3.7 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000766 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 31 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(2-(trifluoromethoxy)benzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3OC(F)(F)F)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 2.7 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000767 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 32(JG-258) 3-benzyl-2-((Z)-((E)-3'-ethyl-3-methyl-4'-oxo-3',4,4',5-tetrahydro-2'H,3H-[2,5'-bithiazolylidene]- 2'-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/SCCN4C Benzothiazole Rhodacyanines derivative NA NA NA NA >20 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000768 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 33 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(2,6-dichlorobenzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3c(Cl)cccc3Cl)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.16 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000769 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 34 3-((2-bromopyridin-3-yl)methyl)-2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(/S/C(C1=O)=C2/Sc3cc(Cl)ccc3N2C)=C/c4scc[n+]4Cc5cccnc5Br Benzothiazole Rhodacyanines derivative NA NA NA NA 1.5 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000770 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 35 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((2-chloropyridin-4-yl)methyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccnc(Cl)c3)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA >5 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000771 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 36 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((5-(trifluoromethyl)furan-2-yl)methyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3oc(cc3)C(F)(F)F)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.21 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000772 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 37 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((5-(methoxycarbonyl)furan-2-yl)methyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3oc(cc3)C(=O)OC)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 1.5 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000773 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 38 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((3-(methoxycarbonyl)furan-2-yl)methyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3occc3C(=O)OC)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.81 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000774 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 39 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(thiophen-3-ylmethyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3cscc3)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.73 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000775 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 40 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((2-(methoxycarbonyl)thiophen-3-yl)methyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccsc3C(=O)OC)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.16 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000776 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 41 3-((2-bromothiophen-3-yl)methyl)-2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccsc3Br)=C4/Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.52 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000777 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 42(JG-231) 3-((5-bromothiophen-2-yl)methyl)-2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3sc(Br)cc3)=C4/Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.12 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000778 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 43 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((2,5-dimethylthiophen-3-yl)methyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3cc(C)sc3C)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.098 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000779 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 44 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((2-methylthiazol-4-yl)methyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3csc(C)n3)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.96 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000780 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 45 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((2-chlorothiazol-5-yl)methyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3sc(Cl)nc3)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA >5 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000781 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 46 3-((2-acetamidothiazol-4-yl)methyl)-2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3csc(NC(C)=O)n3)=C4/Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA >5 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000782 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 47 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((3,5-dimethylisoxazol-4-yl)methyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3c(C)onc3C)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA >5 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000783 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 33 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(2,6-dichlorobenzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3c(Cl)cccc3Cl)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.16 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000784 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 34 3-((2-bromopyridin-3-yl)methyl)-2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(/S/C(C1=O)=C2/Sc3cc(Cl)ccc3N2C)=C/c4scc[n+]4Cc5cccnc5Br Benzothiazole Rhodacyanines derivative NA NA NA NA 1.6 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000785 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 35 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((2-chloropyridin-4-yl)methyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccnc(Cl)c3)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 7.2 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000786 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 36 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((5-(trifluoromethyl)furan-2-yl)methyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3oc(cc3)C(F)(F)F)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.12 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000787 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 37 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((5-(methoxycarbonyl)furan-2-yl)methyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3oc(cc3)C(=O)OC)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.97 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000788 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 38 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((3-(methoxycarbonyl)furan-2-yl)methyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3occc3C(=O)OC)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.13 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000789 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 39 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(thiophen-3-ylmethyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3cscc3)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.11 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000790 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 40 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((2-(methoxycarbonyl)thiophen-3-yl)methyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccsc3C(=O)OC)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.22 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000791 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 41 3-((2-bromothiophen-3-yl)methyl)-2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccsc3Br)=C4/Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.2 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000792 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 42(JG-231) 3-((5-bromothiophen-2-yl)methyl)-2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3sc(Br)cc3)=C4/Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.25 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000793 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 43 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((2,5-dimethylthiophen-3-yl)methyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3cc(C)sc3C)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.08 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000794 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 44 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((2-methylthiazol-4-yl)methyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3csc(C)n3)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.74 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000795 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 45 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((2-chlorothiazol-5-yl)methyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3sc(Cl)nc3)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 2.3 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000796 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 46 3-((2-acetamidothiazol-4-yl)methyl)-2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3csc(NC(C)=O)n3)=C4/Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA >20 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000797 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 47 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((3,5-dimethylisoxazol-4-yl)methyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3c(C)onc3C)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 10 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000798 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 33 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(2,6-dichlorobenzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3c(Cl)cccc3Cl)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 1.4 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000799 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 34 3-((2-bromopyridin-3-yl)methyl)-2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(/S/C(C1=O)=C2/Sc3cc(Cl)ccc3N2C)=C/c4scc[n+]4Cc5cccnc5Br Benzothiazole Rhodacyanines derivative NA NA NA NA 1.7 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000800 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 35 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((2-chloropyridin-4-yl)methyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccnc(Cl)c3)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA >5 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000801 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 36 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((5-(trifluoromethyl)furan-2-yl)methyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3oc(cc3)C(F)(F)F)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 5.5 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000802 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 37 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((5-(methoxycarbonyl)furan-2-yl)methyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3oc(cc3)C(=O)OC)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 2 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000803 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 38 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((3-(methoxycarbonyl)furan-2-yl)methyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3occc3C(=O)OC)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 2.7 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000804 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 39 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(thiophen-3-ylmethyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3cscc3)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 4.4 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000805 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 40 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((2-(methoxycarbonyl)thiophen-3-yl)methyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccsc3C(=O)OC)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 3.2 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000806 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 41 3-((2-bromothiophen-3-yl)methyl)-2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccsc3Br)=C4/Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 1.3 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000807 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 42(JG-231) 3-((5-bromothiophen-2-yl)methyl)-2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3sc(Br)cc3)=C4/Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 2.5 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000808 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 43 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((2,5-dimethylthiophen-3-yl)methyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3cc(C)sc3C)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 4.2 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000809 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 44 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((2-methylthiazol-4-yl)methyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3csc(C)n3)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 4.9 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000810 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 45 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((2-chlorothiazol-5-yl)methyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3sc(Cl)nc3)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 8.9 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000811 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 46 3-((2-acetamidothiazol-4-yl)methyl)-2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3csc(NC(C)=O)n3)=C4/Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 4.2 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000812 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 47 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((3,5-dimethylisoxazol-4-yl)methyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3c(C)onc3C)=C/4Sc5cc(Cl)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 7.6 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000813 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 48 2-((Z)-((E)-5-(3,5-dimethylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene) methyl)-3-(2-(trifluoromethoxy)benzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3OC(F)(F)F)=C/4Sc5ccc(C)cc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.089 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000814 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 49 2-((Z)-((E)-5-(3,6-dimethylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene) methyl)-3-(2-(trifluoromethoxy)benzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3OC(F)(F)F)=C/4Sc5cc(C)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.064 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000815 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 50 2-((Z)-((E)-3-ethyl-5-(5-methoxy-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2- ylidene)methyl)-3-(2-(trifluoromethoxy)benzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)C(/SC1=C\c2scc[n+]2Cc3ccccc3OC(F)(F)F)=C4\Sc5ccc(OC)cc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.16 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000816 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 51 2-((Z)-((E)-3-ethyl-5-(6-methoxy-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2- ylidene)methyl)-3-(2-(trifluoromethoxy)benzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)C(/SC1=C\c2scc[n+]2Cc3ccccc3OC(F)(F)F)=C4\Sc5cc(OC)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.07 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000817 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 52 2-((Z)-((E)-3-ethyl-5-(6-isopropyl-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2- ylidene)methyl)-3-(2-(trifluoromethoxy)benzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)C(/SC1=C\c2scc[n+]2Cc3ccccc3OC(F)(F)F)=C4\Sc5cc(ccc5N4C)C(C)C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.09 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000818 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 53 3-(2-chlorobenzyl)-2-((Z)-((E)-3-ethyl-5-(6-methoxy-3-methylbenzo[d]thiazol-2(3H)-ylidene)- 4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3Cl)=C4/Sc5cc(OC)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.048 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000819 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 54 3-(2-chlorobenzyl)-2-((Z)-((E)-3-ethyl-5-(3-methyl-6-(methylthio)benzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3Cl)=C4/Sc5cc(SC)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.15 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000820 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 55 2-((Z)-((E)-3-ethyl-5-(6-methoxy-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2- ylidene)methyl)-3-(2-methoxybenzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)C(/SC1=C\c2scc[n+]2Cc3ccccc3OC)=C4\Sc5cc(OC)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.076 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000821 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 56 2-((Z)-((E)-5-(3,6-dimethylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene) methyl)-3-(2-methoxybenzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3OC)=C/4Sc5cc(C)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.071 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000822 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 57(JG-345) 2-((Z)-((E)-3-ethyl-5-(6-ethyl-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)methyl)-3-(2-(methoxycarbonyl)benzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)C(/SC1=C\c2scc[n+]2Cc3ccccc3C(=O)OC)=C4\Sc5cc(CC)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.049 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000823 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 58 3-(2,6-dichlorobenzyl)-2-((Z)-((E)-5-(3,5-dimethylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4- oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3c(Cl)cccc3Cl)=C4/Sc5ccc(C)cc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.088 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000824 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 59 3-(2,6-dichlorobenzyl)-2-((Z)-((E)-3-ethyl-5-(6-ethyl-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4- oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3c(Cl)cccc3Cl)=C4/Sc5cc(CC)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.093 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000825 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 60(JG-294) 2-((Z)-((E)-5-(6-bromo-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((5-(trifluoromethyl)furan-2-yl)methyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3oc(cc3)C(F)(F)F)=C/4Sc5cc(Br)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.1 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000826 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 61 2-((Z)-((E)-3-ethyl-5-(6-ethyl-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)methyl)-3-((5-(trifluoromethyl)furan-2-yl)methyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)C(/SC1=C\c2scc[n+]2Cc3oc(cc3)C(F)(F)F)=C4\Sc5cc(CC)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.11 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000827 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 48 2-((Z)-((E)-5-(3,5-dimethylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene) methyl)-3-(2-(trifluoromethoxy)benzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3OC(F)(F)F)=C/4Sc5ccc(C)cc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.18 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000828 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 49 2-((Z)-((E)-5-(3,6-dimethylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene) methyl)-3-(2-(trifluoromethoxy)benzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3OC(F)(F)F)=C/4Sc5cc(C)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.077 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000829 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 50 2-((Z)-((E)-3-ethyl-5-(5-methoxy-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2- ylidene)methyl)-3-(2-(trifluoromethoxy)benzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)C(/SC1=C\c2scc[n+]2Cc3ccccc3OC(F)(F)F)=C4\Sc5ccc(OC)cc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.16 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000830 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 51 2-((Z)-((E)-3-ethyl-5-(6-methoxy-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2- ylidene)methyl)-3-(2-(trifluoromethoxy)benzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)C(/SC1=C\c2scc[n+]2Cc3ccccc3OC(F)(F)F)=C4\Sc5cc(OC)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.053 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000831 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 52 2-((Z)-((E)-3-ethyl-5-(6-isopropyl-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2- ylidene)methyl)-3-(2-(trifluoromethoxy)benzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)C(/SC1=C\c2scc[n+]2Cc3ccccc3OC(F)(F)F)=C4\Sc5cc(ccc5N4C)C(C)C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.21 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000832 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 53 3-(2-chlorobenzyl)-2-((Z)-((E)-3-ethyl-5-(6-methoxy-3-methylbenzo[d]thiazol-2(3H)-ylidene)- 4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3Cl)=C4/Sc5cc(OC)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.033 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000833 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 54 3-(2-chlorobenzyl)-2-((Z)-((E)-3-ethyl-5-(3-methyl-6-(methylthio)benzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3Cl)=C4/Sc5cc(SC)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.13 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000834 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 55 2-((Z)-((E)-3-ethyl-5-(6-methoxy-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2- ylidene)methyl)-3-(2-methoxybenzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)C(/SC1=C\c2scc[n+]2Cc3ccccc3OC)=C4\Sc5cc(OC)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.062 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000835 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 56 2-((Z)-((E)-5-(3,6-dimethylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene) methyl)-3-(2-methoxybenzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3OC)=C/4Sc5cc(C)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.082 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000836 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 57(JG-345) 2-((Z)-((E)-3-ethyl-5-(6-ethyl-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)methyl)-3-(2-(methoxycarbonyl)benzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)C(/SC1=C\c2scc[n+]2Cc3ccccc3C(=O)OC)=C4\Sc5cc(CC)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.046 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000837 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 58 3-(2,6-dichlorobenzyl)-2-((Z)-((E)-5-(3,5-dimethylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4- oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3c(Cl)cccc3Cl)=C4/Sc5ccc(C)cc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.054 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000838 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 59 3-(2,6-dichlorobenzyl)-2-((Z)-((E)-3-ethyl-5-(6-ethyl-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4- oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3c(Cl)cccc3Cl)=C4/Sc5cc(CC)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.1 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000839 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 60(JG-294) 2-((Z)-((E)-5-(6-bromo-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((5-(trifluoromethyl)furan-2-yl)methyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3oc(cc3)C(F)(F)F)=C/4Sc5cc(Br)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.18 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000840 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 61 2-((Z)-((E)-3-ethyl-5-(6-ethyl-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)methyl)-3-((5-(trifluoromethyl)furan-2-yl)methyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)C(/SC1=C\c2scc[n+]2Cc3oc(cc3)C(F)(F)F)=C4\Sc5cc(CC)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.1 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000841 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 48 2-((Z)-((E)-5-(3,5-dimethylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene) methyl)-3-(2-(trifluoromethoxy)benzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3OC(F)(F)F)=C/4Sc5ccc(C)cc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 1.4 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000842 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 49 2-((Z)-((E)-5-(3,6-dimethylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene) methyl)-3-(2-(trifluoromethoxy)benzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3OC(F)(F)F)=C/4Sc5cc(C)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.75 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000843 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 50 2-((Z)-((E)-3-ethyl-5-(5-methoxy-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2- ylidene)methyl)-3-(2-(trifluoromethoxy)benzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)C(/SC1=C\c2scc[n+]2Cc3ccccc3OC(F)(F)F)=C4\Sc5ccc(OC)cc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 2.2 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000844 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 51 2-((Z)-((E)-3-ethyl-5-(6-methoxy-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2- ylidene)methyl)-3-(2-(trifluoromethoxy)benzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)C(/SC1=C\c2scc[n+]2Cc3ccccc3OC(F)(F)F)=C4\Sc5cc(OC)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.7 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000845 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 52 2-((Z)-((E)-3-ethyl-5-(6-isopropyl-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2- ylidene)methyl)-3-(2-(trifluoromethoxy)benzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)C(/SC1=C\c2scc[n+]2Cc3ccccc3OC(F)(F)F)=C4\Sc5cc(ccc5N4C)C(C)C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.48 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000846 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 53 3-(2-chlorobenzyl)-2-((Z)-((E)-3-ethyl-5-(6-methoxy-3-methylbenzo[d]thiazol-2(3H)-ylidene)- 4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3Cl)=C4/Sc5cc(OC)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.66 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000847 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 54 3-(2-chlorobenzyl)-2-((Z)-((E)-3-ethyl-5-(3-methyl-6-(methylthio)benzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3Cl)=C4/Sc5cc(SC)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.75 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000848 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 55 2-((Z)-((E)-3-ethyl-5-(6-methoxy-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2- ylidene)methyl)-3-(2-methoxybenzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)C(/SC1=C\c2scc[n+]2Cc3ccccc3OC)=C4\Sc5cc(OC)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.77 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000849 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 56 2-((Z)-((E)-5-(3,6-dimethylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene) methyl)-3-(2-methoxybenzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3OC)=C/4Sc5cc(C)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.96 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000850 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 57(JG-345) 2-((Z)-((E)-3-ethyl-5-(6-ethyl-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)methyl)-3-(2-(methoxycarbonyl)benzyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)C(/SC1=C\c2scc[n+]2Cc3ccccc3C(=O)OC)=C4\Sc5cc(CC)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 1 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000851 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 58 3-(2,6-dichlorobenzyl)-2-((Z)-((E)-5-(3,5-dimethylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4- oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3c(Cl)cccc3Cl)=C4/Sc5ccc(C)cc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.55 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000852 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 59 3-(2,6-dichlorobenzyl)-2-((Z)-((E)-3-ethyl-5-(6-ethyl-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4- oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3c(Cl)cccc3Cl)=C4/Sc5cc(CC)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 0.3 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000853 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 60(JG-294) 2-((Z)-((E)-5-(6-bromo-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((5-(trifluoromethyl)furan-2-yl)methyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3oc(cc3)C(F)(F)F)=C/4Sc5cc(Br)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 3.5 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000854 29953808 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 61 2-((Z)-((E)-3-ethyl-5-(6-ethyl-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)methyl)-3-((5-(trifluoromethyl)furan-2-yl)methyl)thiazol-3-ium chloride [Cl-].CCN\1C(=O)C(/SC1=C\c2scc[n+]2Cc3oc(cc3)C(F)(F)F)=C4\Sc5cc(CC)ccc5N4C Benzothiazole Rhodacyanines derivative NA NA NA NA 1.4 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MEF Cancer HSPMDB000855 24548207 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 17a N-(6-Amino-2-((4,6-dimethoxy-2-(4-methylpiperazin-1-yl)pyrimidin-5-yl)thio)pyrimidin-4-yl)acrylamide COc1nc(nc(OC)c1Sc2nc(N)cc(NC(=O)C=C)n2)N3CCN(C)CC3 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 0.9 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA Kasumi-1 Cancer HSPMDB000856 24548207 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 17b N-(6-Amino-2-((4,6-dimethoxy-2-morpholinopyrimidin-5-yl)thio)pyrimidin-4-yl)acrylamide COc1nc(nc(OC)c1Sc2nc(N)cc(NC(=O)C=C)n2)N3CCOCC3 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 12.5 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA Kasumi-1 Cancer HSPMDB000857 24548207 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 17c N-(6-Amino-2-((4,6-dimethoxy-2-(piperidin-1-yl)pyrimidin-5-yl)thio)pyrimidin-4-yl)acrylamide COc1nc(nc(OC)c1Sc2nc(N)cc(NC(=O)C=C)n2)N3CCCCC3 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 17.1 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA Kasumi-1 Cancer HSPMDB000858 24548207 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 20a N-(6-Amino-2-((4,6-diethoxy-2-(4-methylpiperazin-1-yl)pyrimidin-5-yl)thio)pyrimidin-4-yl)acrylamide CCOc1nc(nc(OCC)c1Sc2nc(N)cc(NC(=O)C=C)n2)N3CCN(C)CC3 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 0.89 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA Kasumi-1 Cancer HSPMDB000859 24548207 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 20b N-(6-Amino-2-((4,6-diethoxy-2-morpholinopyrimidin-5-yl)thio)pyrimidin-4-yl)acrylamide CCOc1nc(nc(OCC)c1Sc2nc(N)cc(NC(=O)C=C)n2)N3CCOCC3 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 2.2 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA Kasumi-1 Cancer HSPMDB000860 24548207 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 20c N-(6-Amino-2-((4,6-diethoxy-2-(piperidin-1-yl)pyrimidin-5-yl)thio)pyrimidin-4-yl)acrylamide CCOc1nc(nc(OCC)c1Sc2nc(N)cc(NC(=O)C=C)n2)N3CCCCC3 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 4.5 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA Kasumi-1 Cancer HSPMDB000861 24548207 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 27a N-(2-((4,6-Dimethoxy-2-(4-methylpiperazin-1-yl)pyrimidin-5-yl)thio)pyrimidin-4-yl)acrylamide COc1nc(nc(OC)c1Sc2nccc(NC(=O)C=C)n2)N3CCN(C)CC3 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 1.25 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA Kasumi-1 Cancer HSPMDB000862 24548207 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 27b N-(2-((4,6-Dimethoxy-2-morpholinopyrimidin-5-yl)thio)pyrimidin-4-yl)acrylamide COc1nc(nc(OC)c1Sc2nccc(NC(=O)C=C)n2)N3CCOCC3 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 2 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA Kasumi-1 Cancer HSPMDB000863 24548207 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 27c N-(2-((4,6-Dimethoxy-2-(piperidin-1-yl)pyrimidin-5-yl)thio)pyrimidin-4-yl)acrylamide COc1nc(nc(OC)c1Sc2nccc(NC(=O)C=C)n2)N3CCCCC3 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 3.15 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA Kasumi-1 Cancer HSPMDB000864 24548207 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 27d N-(2-((4,6-Dimethoxy-2-(pyrrolidin-1-yl)pyrimidin-5-yl)thio)pyrimidin-4-yl)acrylamide COc1nc(nc(OC)c1Sc2nccc(NC(=O)C=C)n2)N3CCCC3 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 46.1 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA Kasumi-1 Cancer HSPMDB000865 24548207 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 28 4-(5-((4-Acrylamidopyrimidin-2-yl)thio)-4,6-dimethoxypyrimidin2-yl)-1-methylpiperazine 1-Oxide COc1nc(nc(OC)c1Sc2nccc(NC(=O)C=C)n2)N3CC[N+](C)([O-])CC3 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA >100 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA Kasumi-1 Cancer HSPMDB000866 24548207 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 31 N-(6-Amino-2-((2-amino-4,6-dimethoxypyrimidin-5-yl)thio)pyrimidin-4-yl)acrylamide COc1nc(N)nc(OC)c1Sc2nc(N)cc(NC(=O)C=C)n2 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 3.9 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA Kasumi-1 Cancer HSPMDB000867 24548207 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 36a N-(3-((4,6-Dimethoxy-2-(4-methylpiperazin-1-yl)pyrimidin-5-yl)thio)phenyl)acrylamide COc1nc(nc(OC)c1Sc2cccc(NC(=O)C=C)c2)N3CCN(C)CC3 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 7.8 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA Kasumi-1 Cancer HSPMDB000868 24548207 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 37 N-(3-((4,6-Dimethoxy-2-morpholinopyrimidin-5-yl)thio)phenyl)acrylamide COc1nc(nc(OC)c1Sc2cccc(NC(=O)C=C)c2)N3CCOCC3 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 46.5 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA Kasumi-1 Cancer HSPMDB000869 24548207 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 43 N-(2-((4,6-Dimethyl-2-morpholinopyrimidin-5-yl)thio)pyrimidin4-yl)acrylamide Cc1nc(nc(C)c1Sc2nccc(NC(=O)C=C)n2)N3CCOCC3 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 14.4 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA Kasumi-1 Cancer HSPMDB000870 24548207 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 44a N-(6-Amino-2-(2-(4-(2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)ethyl)piperazin-1-yl)-4,6- dimethoxypyrimidin-5-ylthio)pyrimidin-4-yl)acrylamide COc1nc(nc(OC)c1Sc2nc(N)cc(NC(=O)C=C)n2)N3CCN(CCOCCOCCOCCO)CC3 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 3.8 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA Kasumi-1 Cancer HSPMDB000871 24548207 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 45a N-(6-Amino-2-(4-(2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)ethoxy)-6-methoxy-2-(4- methylpiperazin-1-yl)pyrimidin-5-ylthio)pyrimidin-4-yl)acrylamide COc1nc(nc(OCCOCCOCCOCCO)c1Sc2nc(N)cc(NC(=O)C=C)n2)N3CCN(C)CC3 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 76.5 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA Kasumi-1 Cancer HSPMDB000872 24548207 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 17a N-(6-Amino-2-((4,6-dimethoxy-2-(4-methylpiperazin-1-yl)pyrimidin-5-yl)thio)pyrimidin-4-yl)acrylamide COc1nc(nc(OC)c1Sc2nc(N)cc(NC(=O)C=C)n2)N3CCN(C)CC3 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 0.8 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA SK-BR-3 Cancer HSPMDB000873 24548207 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 17c N-(6-Amino-2-((4,6-dimethoxy-2-(piperidin-1-yl)pyrimidin-5-yl)thio)pyrimidin-4-yl)acrylamide COc1nc(nc(OC)c1Sc2nc(N)cc(NC(=O)C=C)n2)N3CCCCC3 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 9 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA SK-BR-3 Cancer HSPMDB000874 24548207 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 20a N-(6-Amino-2-((4,6-diethoxy-2-(4-methylpiperazin-1-yl)pyrimidin-5-yl)thio)pyrimidin-4-yl)acrylamide CCOc1nc(nc(OCC)c1Sc2nc(N)cc(NC(=O)C=C)n2)N3CCN(C)CC3 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 1.1 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA SK-BR-3 Cancer HSPMDB000875 24548207 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 20c N-(6-Amino-2-((4,6-diethoxy-2-(piperidin-1-yl)pyrimidin-5-yl)thio)pyrimidin-4-yl)acrylamide CCOc1nc(nc(OCC)c1Sc2nc(N)cc(NC(=O)C=C)n2)N3CCCCC3 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 7 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA SK-BR-3 Cancer HSPMDB000876 24548207 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 27a N-(2-((4,6-Dimethoxy-2-(4-methylpiperazin-1-yl)pyrimidin-5-yl)thio)pyrimidin-4-yl)acrylamide COc1nc(nc(OC)c1Sc2nccc(NC(=O)C=C)n2)N3CCN(C)CC3 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 1.2 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA SK-BR-3 Cancer HSPMDB000877 24548207 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 27d N-(2-((4,6-Dimethoxy-2-(pyrrolidin-1-yl)pyrimidin-5-yl)thio)pyrimidin-4-yl)acrylamide COc1nc(nc(OC)c1Sc2nccc(NC(=O)C=C)n2)N3CCCC3 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 5 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA SK-BR-3 Cancer HSPMDB000878 24548207 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 31 N-(6-Amino-2-((2-amino-4,6-dimethoxypyrimidin-5-yl)thio)pyrimidin-4-yl)acrylamide COc1nc(N)nc(OC)c1Sc2nc(N)cc(NC(=O)C=C)n2 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 3.2 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA SK-BR-3 Cancer HSPMDB000879 24548207 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 37 N-(3-((4,6-Dimethoxy-2-morpholinopyrimidin-5-yl)thio)phenyl)acrylamide COc1nc(nc(OC)c1Sc2cccc(NC(=O)C=C)c2)N3CCOCC3 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 16.5 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA SK-BR-3 Cancer HSPMDB000880 24548207 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 42a N-(2-((4,6-Dimethyl-2-(4-methylpiperazin-1-yl)pyrimidin-5-yl)thio)pyrimidin-4-yl)acrylamide CN1CCN(CC1)c2nc(C)c(Sc3nccc(NC(=O)C=C)n3)c(C)n2 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 1.8 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA SK-BR-3 Cancer HSPMDB000881 24548207 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 42c N-(2-((4,6-Dimethyl-2-(4-methylpiperazin-1-yl)pyrimidin-5-yl)thio)pyrimidin-4-yl)methacrylamide  CC1=NC(=NC(=C1SC1=NC=CC(=N1)NC(C(=C)C)=O)C)N1CCN(CC1)C 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 16.7 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA SK-BR-3 Cancer HSPMDB000882 24548207 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 44a N-(6-Amino-2-(2-(4-(2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)ethyl)piperazin-1-yl)-4,6- dimethoxypyrimidin-5-ylthio)pyrimidin-4-yl)acrylamide COc1nc(nc(OC)c1Sc2nc(N)cc(NC(=O)C=C)n2)N3CCN(CCOCCOCCOCCO)CC3 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 7.5 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA SK-BR-3 Cancer HSPMDB000883 24548207 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 45a N-(6-Amino-2-(4-(2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)ethoxy)-6-methoxy-2-(4- methylpiperazin-1-yl)pyrimidin-5-ylthio)pyrimidin-4-yl)acrylamide COc1nc(nc(OCCOCCOCCOCCO)c1Sc2nc(N)cc(NC(=O)C=C)n2)N3CCN(C)CC3 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 50 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA SK-BR-3 Cancer HSPMDB000884 24548239 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 1a N-(6-amino-2-{[4,6-diethoxy-2-(4-methylpiperazin-1-yl)pyrimidin-5-yl]sulfanyl}pyrimidin-4-yl)prop-2-enamide CCOC1=NC(=NC(OCC)=C1SC1=NC(N)=CC(NC(=O)C=C)=N1)N1CCN(C)CC1 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 0.89 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA Kasumi-1 Cancer HSPMDB000885 24548239 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 3a N-(6-Amino-2-((4,6-diethoxy-2-(4-methylpiperazin-1-yl)-pyrimidin-5-yl)thio)pyrimidin-4-yl)propionamide NC1=CC(=NC(=N1)SC=1C(=NC(=NC1OCC)N1CCN(CC1)C)OCC)NC(CC)=O 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 51.4 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA Kasumi-1 Cancer HSPMDB000886 24548239 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 1b N-(2-{[4,6-dimethoxy-2-(4-methylpiperazin-1-yl)pyrimidin-5-yl]sulfanyl}pyrimidin-4-yl)prop-2-enamide COC1=NC(=NC(OC)=C1SC1=NC=CC(NC(=O)C=C)=N1)N1CCN(C)CC1 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 1.25 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA Kasumi-1 Cancer HSPMDB000887 24548239 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 1c N-(3-{[4,6-dimethoxy-2-(4-methylpiperazin-1-yl)pyrimidin-5-yl]sulfanyl}phenyl)prop-2-enamide COC1=NC(=NC(OC)=C1SC1=CC=CC(NC(=O)C=C)=C1)N1CCN(C)CC1 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 7.8 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA Kasumi-1 Cancer HSPMDB000888 24548239 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 4e N-(2-((4,6-Dimethyl-2-(4-methylpiperazin-1-yl)pyrimidin-5-yl)-thio)pyrimidin-4-yl)cyclopropanecarboxamide CC1=NC(=NC(=C1SC1=NC=CC(=N1)NC(=O)C1CC1)C)N1CCN(CC1)C 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 60.5 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA Kasumi-1 Cancer HSPMDB000889 24548239 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 7c 2-cyclobutyl-N-(3-{[4,6-dimethoxy-2-(4-methylpiperazin-1-yl)pyrimidin-5-yl]sulfanyl}phenyl)acetamide COC1=NC(=NC(OC)=C1SC1=CC=CC(NC(=O)CC2CCC2)=C1)N1CCN(C)CC1 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 47.2 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA Kasumi-1 Cancer HSPMDB000890 24548239 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 7e N-(3-{[4,6-dimethoxy-2-(4-methylpiperazin-1-yl)pyrimidin-5-yl]sulfanyl}phenyl)-2-phenylacetamide COC1=NC(=NC(OC)=C1SC1=CC=CC(NC(=O)CC2=CC=CC=C2)=C1)N1CCN(C)CC1 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 8.1 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA Kasumi-1 Cancer HSPMDB000891 24548239 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 4d N-(2-((4,6-Dimethyl-2-(4-methylpiperazin-1-yl)pyrimidin-5-yl)-thio)pyrimidin-4-yl)furan-2-carboxamide CN1CCN(CC1)c2nc(C)c(Sc3nccc(NC(=O)c4occc4)n3)c(C)n2 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 30.3 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA Kasumi-1 Cancer HSPMDB000892 24548239 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 7f 2-Amino-N-(3-((4,6-dimethoxy-2-(4-methylpiperazin-1-yl)-pyrimidin-5-yl)thio)phenyl)acetamide COc1nc(nc(OC)c1Sc2cccc(NC(=O)CN)c2)N3CCN(C)CC3 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 22.5 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA Kasumi-1 Cancer HSPMDB000893 24548239 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 9 N-(6-Amino-2-((4,6-dimethoxy-2-(4-methylpiperazin-1-yl)-pyrimidin-5-yl)thio)pyrimidin-4-yl)-3-(dimethylamino)propanamide COc1nc(nc(OC)c1Sc2nc(N)cc(NC(=O)CCN(C)C)n2)N3CCN(C)CC3 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 14.7 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA Kasumi-1 Cancer HSPMDB000894 24548239 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 7h 2-Amino-N-(3-((4-methoxy-2-(4-methylpiperazin-1-yl)pyrimidin-5-yl)thio)phenyl)acetamide COc1nc(ncc1Sc2cccc(NC(=O)CN)c2)N3CCN(C)CC3 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 25.2 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA Kasumi-1 Cancer HSPMDB000895 24548239 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 14b N-(2-((2-Methoxy-6-(4-methylpiperazin-1-yl)pyridin-3-yl)thio)-pyrimidin-4-yl)cyclopropanecarboxamide COc1nc(ccc1Sc2nccc(NC(=O)C3CC3)n2)N4CCN(C)CC4 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 58.5 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA Kasumi-1 Cancer HSPMDB000896 24548239 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 16b N-(3-((2-Methoxy-6-(4-methylpiperazin-1-yl)pyridin-3-yl)thio)-phenyl)cyclopropanecarboxamide COc1nc(ccc1Sc2cccc(NC(=O)C3CC3)c2)N4CCN(C)CC4 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 36.4 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA Kasumi-1 Cancer HSPMDB000897 24548239 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 16c N-(3-((2-Methoxy-6-(4-methylpiperazin-1-yl)pyridin-3-yl)thio)-phenyl)benzamide COc1nc(ccc1Sc2cccc(NC(=O)c3ccccc3)c2)N4CCN(C)CC4 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 4.7 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA Kasumi-1 Cancer HSPMDB000898 24548239 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 16d 2-Amino-N-(3-((2-methoxy-6-(4-methylpiperazin-1-yl)pyridin-3-yl)thio)phenyl)acetamide COc1nc(ccc1Sc2cccc(NC(=O)CN)c2)N3CCN(C)CC3 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 19.1 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA Kasumi-1 Cancer HSPMDB000899 24548239 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 27a N-(3-((4-(Benzyloxy)-2-(4-methylpiperazin-1-yl)pyrimidin-5-yl)-thio)phenyl)acetamide CN1CCN(CC1)c2ncc(Sc3cccc(NC(C)=O)c3)c(OCc4ccccc4)n2 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 5.2 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA Kasumi-1 Cancer HSPMDB000900 24548239 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 27b N-(3-((4-(Benzyloxy)-2-(4-methylpiperazin-1-yl)pyrimidin-5-yl)-thio)phenyl)benzamide CN1CCN(CC1)c2ncc(Sc3cccc(NC(=O)c4ccccc4)c3)c(OCc5ccccc5)n2 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 3.1 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA Kasumi-1 Cancer HSPMDB000901 24548239 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 27c 2-Amino-N-(3-((4-(benzyloxy)-2-(4-methylpiperazin-1-yl)-pyrimidin-5-yl)thio)phenyl)acetamide CN1CCN(CC1)c2ncc(Sc3cccc(NC(=O)CN)c3)c(OCc4ccccc4)n2 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 2.3 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA Kasumi-1 Cancer HSPMDB000902 24548239 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 27d 2-Amino-N-(3-((4-(benzyloxy)-2-(4-methylpiperazin-1-yl)-pyrimidin-5-yl)thio)phenyl)propanamide CC(N)C(=O)Nc1cccc(Sc2cnc(nc2OCc3ccccc3)N4CCN(C)CC4)c1 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 4.8r Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA Kasumi-1 Cancer HSPMDB000903 24548239 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 27e 2-Amino-N-(3-((4-(benzyloxy)-2-(4-methylpiperazin-1-yl)-pyrimidin-5-yl)thio)phenyl)-3-methylbutanamide CC(C)C(N)C(=O)Nc1cccc(Sc2cnc(nc2OCc3ccccc3)N4CCN(C)CC4)c1 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 3.1 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA Kasumi-1 Cancer HSPMDB000904 24548239 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 27f N-(3-((4-(Benzyloxy)-2-(4-methylpiperazin-1-yl)pyrimidin-5-yl)-thio)phenyl)pyrrolidine-2-carboxamide CN1CCN(CC1)c2ncc(Sc3cccc(NC(=O)C4CCCN4)c3)c(OCc5ccccc5)n2 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 2.9 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA Kasumi-1 Cancer HSPMDB000905 24548239 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 27g 2-Amino-N-(3-((2-(4-methylpiperazin-1-yl)-4-phenylpyrimidin-5-yl)thio)phenyl)acetamide CN1CCN(CC1)c2ncc(Sc3cccc(NC(=O)CN)c3)c(n2)c4ccccc4 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 20.8 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA Kasumi-1 Cancer HSPMDB000906 24548239 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 27h 2-amino-N-(3-{[2-(4-methylpiperazin-1-yl)-4-[(pyridin-4-yl)methoxy]pyrimidin-5-yl]sulfanyl}phenyl)acetamide CN1CCN(CC1)C1=NC=C(SC2=CC=CC(NC(=O)CN)=C2)C(OCC2=CC=NC=C2)=N1 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide NA NA NA NA NA NA NA 10.7 Nucleotide binding domain (allosteric site) NA NA Alamar Blue viability assay NA NA NA Kasumi-1 Cancer HSPMDB000907 27035072 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 6 (apoptozole) 4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)benzamide COc1ccc(cc1)c2nc(n(Cc3ccc(cc3)C(N)=O)c2c4ccc(OC)cc4)c5cc(cc(c5)C(F)(F)F)C(F)(F)F Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline NA NA NA NA NA NA NA 7 Nucleotide binding domain NA NA Resazurin based viability assay NA NA NA HCT116 Cancer HSPMDB000908 27035072 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 7a 2-Phenyl-1H-phenanthro[9,10-d]imidazole [nH]1c(nc2c1c3ccccc3c4ccccc24)c5ccccc5 Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline NA NA NA NA NA NA NA 7.6 NA NA NA Resazurin based viability assay NA NA NA HCT116 Cancer HSPMDB000909 27035072 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 7b 2-(4-Fluorophenyl)-1H-phenanthro[9,10-d]imidazole Fc1ccc(cc1)c2[nH]c3c4ccccc4c5ccccc5c3n2 Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline NA NA NA NA NA NA NA 6.7 NA NA NA Resazurin based viability assay NA NA NA HCT116 Cancer HSPMDB000910 27035072 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 7c 2-(4-Methoxyphenyl)-1H-phenanthro[9,10-d]imidazole COc1ccc(cc1)c2[nH]c3c4ccccc4c5ccccc5c3n2 Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline NA NA NA NA NA NA NA 3 NA NA NA Resazurin based viability assay NA NA NA HCT116 Cancer HSPMDB000911 27035072 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 7d 2-(3,5-Bis(trifluoromethyl)phenyl)-1H-phenanthro[9,10-d]imidazole FC(F)(F)c1cc(cc(c1)C(F)(F)F)c2[nH]c3c4ccccc4c5ccccc5c3n2 Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline NA NA NA NA NA NA NA 7.3 NA NA NA Resazurin based viability assay NA NA NA HCT116 Cancer HSPMDB000912 27035072 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 12 6,9-Dimethoxy-2-phenyl-1H-phenanthro[9,10-d]imidazole COc1ccc2c3[nH]c(nc3c4ccc(OC)cc4c2c1)c5ccccc5 Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline NA NA NA NA NA NA NA 7.8 NA NA NA Resazurin based viability assay NA NA NA HCT116 Cancer HSPMDB000913 27035072 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 13 2-(3,5-Bis(trifluoromethyl)phenyl)-6,9-dimethoxy-1H-phenanthro[9,10-d]imidazole COc1ccc2c3[nH]c(nc3c4ccc(OC)cc4c2c1)c5cc(cc(c5)C(F)(F)F)C(F)(F)F Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline NA NA NA NA NA NA NA 11.2 NA NA NA Resazurin based viability assay NA NA NA HCT116 Cancer HSPMDB000914 27035072 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 14 2-(4-Methoxyphenyl)-4,5-diphenyl-1H-imidazole COc1ccc(cc1)c2[nH]c(c3ccccc3)c(n2)c4ccccc4 Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline NA NA NA NA NA NA NA >20 NA NA NA Resazurin based viability assay NA NA NA HCT116 Cancer HSPMDB000915 27035072 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 15 2,4,5-Tri(4-methoxyphenyl)-1H-imidazole COc1ccc(cc1)c2[nH]c(c3ccc(OC)cc3)c(n2)c4ccc(OC)cc4 Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline NA NA NA NA NA NA NA 7.8 NA NA NA Resazurin based viability assay NA NA NA HCT116 Cancer HSPMDB000916 27035072 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 16 2,4,5-Tri(4-fluorophenyl)-1H-imidazole Fc1ccc(cc1)c2[nH]c(c3ccc(F)cc3)c(n2)c4ccc(F)cc4 Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline NA NA NA NA NA NA NA 9.5 NA NA NA Resazurin based viability assay NA NA NA HCT116 Cancer HSPMDB000917 27035072 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 18 1-Methyl-2-phenyl-1H-phenanthro[9,10-d]imidazole Cn1c(nc2c3ccccc3c4ccccc4c12)c5ccccc5 Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline NA NA NA NA NA NA NA 9.4 NA NA NA Resazurin based viability assay NA NA NA HCT116 Cancer HSPMDB000918 27035072 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 19 1-Benzyl-2-phenyl-1H-phenanthro[9,10-d]imidazole C(n1c(nc2c3ccccc3c4ccccc4c12)c5ccccc5)c6ccccc6 Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline NA NA NA NA NA NA NA 6.8 NA NA NA Resazurin based viability assay NA NA NA HCT116 Cancer HSPMDB000919 27035072 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 20 1-Benzyl-2-(3,5-bis(trifluoromethyl)phenyl)-1H-phenanthro-[9,10-d]imidazole FC(F)(F)c1cc(cc(c1)C(F)(F)F)c2nc3c4ccccc4c5ccccc5c3n2Cc6ccccc6 Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline NA NA NA NA NA NA NA >20 NA NA NA Resazurin based viability assay NA NA NA HCT116 Cancer HSPMDB000920 27035072 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 21 1-(4-Carboxamidobenzyl)-2-phenyl-1H-phenanthro[9,10-d]imidazole NC(=O)C1=CC=C(CN2C(=NC3=C2C2=C(C=CC=C2)C2=C3C=CC=C2)C2=CC=CC=C2)C=C1 Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline NA NA NA NA NA NA NA >20 NA NA NA Resazurin based viability assay NA NA NA HCT116 Cancer HSPMDB000921 27035072 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 22 1-(4-Carboxamidobenzyl)-2-(4-fluorophenyl)-1H-phenanthro-[9,10-d]imidazole NC(=O)C1=CC=C(CN2C(=NC3=C2C2=C(C=CC=C2)C2=C3C=CC=C2)C2=CC=C(F)C=C2)C=C1 Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline NA NA NA NA NA NA NA 5.9 NA NA NA Resazurin based viability assay NA NA NA HCT116 Cancer HSPMDB000922 27035072 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 23 1-(4-Carboxamidobenzyl)-2-(4-methoxyphenyl)-1H-phenanthro-[9,10-d]imidazole COC1=CC=C(C=C1)C1=NC2=C(N1CC1=CC=C(C=C1)C(N)=O)C1=C(C=CC=C1)C1=C2C=CC=C1 Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline NA NA NA NA NA NA NA 5.5 NA NA NA Resazurin based viability assay NA NA NA HCT116 Cancer HSPMDB000923 27035072 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 24 1-(4-Carboxamidobenzyl)-2-(3,5-bis(trifluoromethyl)phenyl)-1H-phenanthro[9,10-d]-imidazole NC(=O)C1=CC=C(CN2C(=NC3=C2C2=C(C=CC=C2)C2=C3C=CC=C2)C2=CC(=CC(=C2)C(F)(F)F)C(F)(F)F)C=C1 Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline NA NA NA NA NA NA NA >20 NA NA NA Resazurin based viability assay NA NA NA HCT116 Cancer HSPMDB000924 27035072 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 25 1-(4-Carboxamidobenzyl)-6,9-dimethoxy-2-phenyl-1H-phenanthro[9,10-d]imidazole COC1=CC2=C(C=C1)C1=C(N(CC3=CC=C(C=C3)C(N)=O)C(=N1)C1=CC=CC=C1)C1=C2C=C(OC)C=C1 Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline NA NA NA NA NA NA NA 3.4 NA NA NA Resazurin based viability assay NA NA NA HCT116 Cancer HSPMDB000925 27035072 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 28 2-Phenyl-1H-imidazo[4,5-f][1,10]phenanthroline [nH]1c(nc2c1c3cccnc3c4ncccc24)c5ccccc5 Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline NA NA NA NA NA NA NA 0.09 NA NA NA Resazurin based viability assay NA NA NA HCT116 Cancer HSPMDB000926 27035072 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 30 1-Methyl-2-phenyl-1H-imidazo[4,5-f ][1,10]phenanthroline Cn1c(nc2c3cccnc3c4ncccc4c12)c5ccccc5 Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline NA NA NA NA NA NA NA 2.6 NA NA NA Resazurin based viability assay NA NA NA HCT116 Cancer HSPMDB000927 27035072 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 31 1-Benzyl-2-(3,5-bis(trifluoromethyl)phenyl)-1H-imidazo[4,5-f ]-[1,10]phenanthroline FC(F)(F)c1cc(cc(c1)C(F)(F)F)c2nc3c4cccnc4c5ncccc5c3n2Cc6ccccc6 Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline NA NA NA NA NA NA NA 0.5 NA NA NA Resazurin based viability assay NA NA NA HCT116 Cancer HSPMDB000928 27035072 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 32 1-(4-Carboxamidobenzyl)-2-(3,5-bis(trifluoromethyl)phenyl)-1H-imidazo[4,5-f][1,10]-phenanthroline NC(=O)C1=CC=C(CN2C(=NC3=C2C2=C(N=CC=C2)C2=C3C=CC=N2)C2=CC(=CC(=C2)C(F)(F)F)C(F)(F)F)C=C1 Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline NA NA NA NA NA NA NA 0.7 NA NA NA Resazurin based viability assay NA NA NA HCT116 Cancer HSPMDB000929 27035072 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 7a 2-Phenyl-1H-phenanthro[9,10-d]imidazole [nH]1c(nc2c1c3ccccc3c4ccccc24)c5ccccc5 Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline NA NA NA NA NA NA NA >5 NA NA NA Resazurin based viability assay NA NA NA MCF7 Cancer HSPMDB000930 27035072 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 7c 2-(4-Methoxyphenyl)-1H-phenanthro[9,10-d]imidazole COc1ccc(cc1)c2[nH]c3c4ccccc4c5ccccc5c3n2 Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline NA NA NA NA NA NA NA 4 NA NA NA Resazurin based viability assay NA NA NA MCF7 Cancer HSPMDB000931 27035072 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 16 2,4,5-Tri(4-fluorophenyl)-1H-imidazole Fc1ccc(cc1)c2[nH]c(c3ccc(F)cc3)c(n2)c4ccc(F)cc4 Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline NA NA NA NA NA NA NA >10 NA NA NA Resazurin based viability assay NA NA NA MCF7 Cancer HSPMDB000932 27035072 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 22 1-(4-Carboxamidobenzyl)-2-(4-fluorophenyl)-1H-phenanthro-[9,10-d]imidazole NC(=O)C1=CC=C(CN2C(=NC3=C2C2=C(C=CC=C2)C2=C3C=CC=C2)C2=CC=C(F)C=C2)C=C1 Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline NA NA NA NA NA NA NA >10 NA NA NA Resazurin based viability assay NA NA NA MCF7 Cancer HSPMDB000933 27035072 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 23 1-(4-Carboxamidobenzyl)-2-(4-methoxyphenyl)-1H-phenanthro-[9,10-d]imidazole COC1=CC=C(C=C1)C1=NC2=C(N1CC1=CC=C(C=C1)C(N)=O)C1=C(C=CC=C1)C1=C2C=CC=C1 Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline NA NA NA NA NA NA NA >10 NA NA NA Resazurin based viability assay NA NA NA MCF7 Cancer HSPMDB000934 27035072 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 25 1-(4-Carboxamidobenzyl)-6,9-dimethoxy-2-phenyl-1H-phenanthro[9,10-d]imidazole COC1=CC2=C(C=C1)C1=C(N(CC3=CC=C(C=C3)C(N)=O)C(=N1)C1=CC=CC=C1)C1=C2C=C(OC)C=C1 Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline NA NA NA NA NA NA NA >10 NA NA NA Resazurin based viability assay NA NA NA MCF7 Cancer HSPMDB000935 27035072 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 28 2-Phenyl-1H-imidazo[4,5-f][1,10]phenanthroline [nH]1c(nc2c1c3cccnc3c4ncccc24)c5ccccc5 Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline NA NA NA NA NA NA NA 0.69 NA NA NA Resazurin based viability assay NA NA NA MCF7 Cancer HSPMDB000936 27035072 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 31 1-Benzyl-2-(3,5-bis(trifluoromethyl)phenyl)-1H-imidazo[4,5-f ]-[1,10]phenanthroline FC(F)(F)c1cc(cc(c1)C(F)(F)F)c2nc3c4cccnc4c5ncccc5c3n2Cc6ccccc6 Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline NA NA NA NA NA NA NA 2.8 NA NA NA Resazurin based viability assay NA NA NA MCF7 Cancer HSPMDB000937 27035072 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 32 1-(4-Carboxamidobenzyl)-2-(3,5-bis(trifluoromethyl)phenyl)-1H-imidazo[4,5-f][1,10]-phenanthroline NC(=O)C1=CC=C(CN2C(=NC3=C2C2=C(N=CC=C2)C2=C3C=CC=N2)C2=CC(=CC(=C2)C(F)(F)F)C(F)(F)F)C=C1 Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline NA NA NA NA NA NA NA 2.3 NA NA NA Resazurin based viability assay NA NA NA MCF7 Cancer HSPMDB000938 27035072 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 22 1-(4-Carboxamidobenzyl)-2-(4-fluorophenyl)-1H-phenanthro-[9,10-d]imidazole NC(=O)C1=CC=C(CN2C(=NC3=C2C2=C(C=CC=C2)C2=C3C=CC=C2)C2=CC=C(F)C=C2)C=C1 Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline NA NA NA NA NA NA NA >5 NA NA NA Resazurin based viability assay NA NA NA WM266.4 Cancer HSPMDB000939 27035072 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 23 1-(4-Carboxamidobenzyl)-2-(4-methoxyphenyl)-1H-phenanthro-[9,10-d]imidazole COC1=CC=C(C=C1)C1=NC2=C(N1CC1=CC=C(C=C1)C(N)=O)C1=C(C=CC=C1)C1=C2C=CC=C1 Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline NA NA NA NA NA NA NA >5 NA NA NA Resazurin based viability assay NA NA NA WM266.4 Cancer HSPMDB000940 27035072 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 25 1-(4-Carboxamidobenzyl)-6,9-dimethoxy-2-phenyl-1H-phenanthro[9,10-d]imidazole COC1=CC2=C(C=C1)C1=C(N(CC3=CC=C(C=C3)C(N)=O)C(=N1)C1=CC=CC=C1)C1=C2C=C(OC)C=C1 Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline NA NA NA NA NA NA NA >5 NA NA NA Resazurin based viability assay NA NA NA WM266.4 Cancer HSPMDB000941 27035072 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 28 2-Phenyl-1H-imidazo[4,5-f][1,10]phenanthroline [nH]1c(nc2c1c3cccnc3c4ncccc24)c5ccccc5 Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline NA NA NA NA NA NA NA 0.32 NA NA NA Resazurin based viability assay NA NA NA WM266.4 Cancer HSPMDB000942 27035072 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 31 1-Benzyl-2-(3,5-bis(trifluoromethyl)phenyl)-1H-imidazo[4,5-f ]-[1,10]phenanthroline FC(F)(F)c1cc(cc(c1)C(F)(F)F)c2nc3c4cccnc4c5ncccc5c3n2Cc6ccccc6 Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline NA NA NA NA NA NA NA 2.9 NA NA NA Resazurin based viability assay NA NA NA WM266.4 Cancer HSPMDB000943 27035072 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 32 1-(4-Carboxamidobenzyl)-2-(3,5-bis(trifluoromethyl)phenyl)-1H-imidazo[4,5-f][1,10]-phenanthroline NC(=O)C1=CC=C(CN2C(=NC3=C2C2=C(N=CC=C2)C2=C3C=CC=N2)C2=CC(=CC(=C2)C(F)(F)F)C(F)(F)F)C=C1 Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline NA NA NA NA NA NA NA 2.5 NA NA NA Resazurin based viability assay NA NA NA WM266.4 Cancer HSPMDB000944 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity MKT-077 1-ethyl-2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}pyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC=C2N1C)=C\C1=[N+](CC)C=CC=C1 Rhodacyanine NA NA NA NA 1.4 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000945 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity YM-01 2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC=C2N1C)=C\C1=[N+](C)C=CC=C1 Rhodacyanine derivative NA NA NA NA 2 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000946 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 1 2-{[(2Z)-3-ethyl-5-[(2E)-4-fluoro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC(F)=C2N1C)=C\C1=[N+](C)C=CC=C1 Rhodacyanine derivative NA NA NA NA 4 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000947 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 2 2-{[(2Z)-3-ethyl-5-[(2E)-5-fluoro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=C(F)C=C2N1C)=C\C1=[N+](C)C=CC=C1 Rhodacyanine derivative NA NA NA NA 7.7 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000948 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 3 2-{[(2Z)-3-ethyl-5-[(2E)-6-fluoro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC(F)=CC=C2N1C)=C\C1=[N+](C)C=CC=C1 Rhodacyanine derivative NA NA NA NA 5.6 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000949 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 4 2-{[(2Z)-3-ethyl-5-[(2E)-7-fluoro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=C(F)C=CC=C2N1C)=C\C1=[N+](C)C=CC=C1 Rhodacyanine derivative NA NA NA NA 6.2 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000950 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 5 1-ethyl-2-{[(2Z)-3-ethyl-5-[(2E)-4-fluoro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}pyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC(F)=C2N1C)=C\C1=[N+](CC)C=CC=C1 Rhodacyanine derivative NA NA NA NA 3.8 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000951 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 6 1-ethyl-2-{[(2Z)-3-ethyl-5-[(2E)-5-fluoro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}pyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=C(F)C=C2N1C)=C\C1=[N+](CC)C=CC=C1 Rhodacyanine derivative NA NA NA NA 13 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000952 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 7 1-ethyl-2-{[(2Z)-3-ethyl-5-[(2E)-6-fluoro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}pyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC(F)=CC=C2N1C)=C\C1=[N+](CC)C=CC=C1 Rhodacyanine derivative NA NA NA NA 8.3 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000953 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 8 1-ethyl-2-{[(2Z)-3-ethyl-5-[(2E)-7-fluoro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}pyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=C(F)C=CC=C2N1C)=C\C1=[N+](CC)C=CC=C1 Rhodacyanine derivative NA NA NA NA 2.8 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000954 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 9 2-{[(2Z)-5-[(2E)-4-chloro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-3-ethyl-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC(Cl)=C2N1C)=C\C1=[N+](C)C=CC=C1 Rhodacyanine derivative NA NA NA NA 4.4 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000955 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 10 2-{[(2Z)-5-[(2E)-5-chloro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-3-ethyl-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=C(Cl)C=C2N1C)=C\C1=[N+](C)C=CC=C1 Rhodacyanine derivative NA NA NA NA 4.6 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000956 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 11 2-{[(2Z)-5-[(2E)-6-chloro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-3-ethyl-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC(Cl)=CC=C2N1C)=C\C1=[N+](C)C=CC=C1 Rhodacyanine derivative NA NA NA NA 8.3 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000957 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 12 2-{[(2Z)-5-[(2E)-7-chloro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-3-ethyl-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=C(Cl)C=CC=C2N1C)=C\C1=[N+](C)C=CC=C1 Rhodacyanine derivative NA NA NA NA 4.1 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000958 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 13 2-{[(2Z)-3-ethyl-5-[(2E)-5-methoxy-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=C(OC)C=C2N1C)=C\C1=[N+](C)C=CC=C1 Rhodacyanine derivative NA NA NA NA 2.8 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000959 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 14 2-{[(2Z)-3-ethyl-5-[(2E)-6-methoxy-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC(OC)=CC=C2N1C)=C\C1=[N+](C)C=CC=C1 Rhodacyanine derivative NA NA NA NA 4 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000960 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 15 2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-5-(trifluoromethyl)-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=C(C=C2N1C)C(F)(F)F)=C\C1=[N+](C)C=CC=C1 Rhodacyanine derivative NA NA NA NA 21 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000961 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 16 2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-6-(trifluoromethyl)-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC(=CC=C2N1C)C(F)(F)F)=C\C1=[N+](C)C=CC=C1 Rhodacyanine derivative NA NA NA NA 19 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000962 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 17 1-methyl-2-{[(2Z)-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-3-(prop-2-en-1-yl)-1,3-thiazolidin-2-ylidene]methyl}pyridin-1-ium chloride [Cl-].CN1\C(SC2=CC=CC=C12)=C1/S\C(=C/C2=[N+](C)C=CC=C2)N(CC=C)C1=O Rhodacyanine derivative NA NA NA NA 3.6 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000963 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 18 2-{[(2Z)-3-benzyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CN1\C(SC2=CC=CC=C12)=C1/S\C(=C/C2=[N+](C)C=CC=C2)N(CC2=CC=CC=C2)C1=O Rhodacyanine derivative NA NA NA NA 1.8 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000964 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 19 2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-propylpyridin-1-ium chloride [Cl-].CCC[N+]1=C(\C=C2/S\C(C(=O)N2CC)=C2\SC3=CC=CC=C3N2C)C=CC=C1 Rhodacyanine derivative NA NA NA NA 1.6 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000965 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 20 1-benzyl-2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}pyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC=C2N1C)=C\C1=[N+](CC2=CC=CC=C2)C=CC=C1 Rhodacyanine derivative NA NA NA NA 1 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000966 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 21 2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-(2-hydroxyethyl)pyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC=C2N1C)=C\C1=[N+](CCO)C=CC=C1 Rhodacyanine derivative NA NA NA NA 24 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000967 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 22 4-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC=C2N1C)=C\C1=CC=[N+](C)C=C1 Rhodacyanine derivative NA NA NA NA 1.7 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000968 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 23 2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyrimidin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC=C2N1C)=C\C1=[N+](C)C=CC=N1 Rhodacyanine derivative NA NA NA NA 5.8 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000969 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 24 2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-3-methyl-1,3-thiazol-3-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC=C2N1C)=C\C1=[N+](C)C=CS1 Rhodacyanine derivative NA NA NA NA 5.1 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000970 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 25 3-ethyl-2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1,3-thiazol-3-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC=C2N1C)=C\C1=[N+](CC)C=CS1 Rhodacyanine derivative NA NA NA NA 2.2 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000971 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 26 3-benzyl-2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1,3-thiazol-3-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC=C2N1C)=C\C1=[N+](CC2=CC=CC=C2)C=CS1 Rhodacyanine derivative NA NA NA NA 0.5 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000972 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 27(JG-83) 3-benzyl-2-{[(2Z)-3-ethyl-5-[(2E)-4-fluoro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1,3-thiazol-3-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC(F)=C2N1C)=C\C1=[N+](CC2=CC=CC=C2)C=CS1 Rhodacyanine derivative NA NA NA NA 0.4 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000973 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 28(JG-84) 3-benzyl-2-{[(2Z)-5-[(2E)-4-chloro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-3-ethyl-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1,3-thiazol-3-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC(Cl)=C2N1C)=C\C1=[N+](CC2=CC=CC=C2)C=CS1 Rhodacyanine derivative NA NA NA NA 0.4 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000974 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 29 3-benzyl-2-{[(2Z)-5-[(2E)-5-chloro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-3-ethyl-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1,3-thiazol-3-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=C(Cl)C=C2N1C)=C\C1=[N+](CC2=CC=CC=C2)C=CS1 Rhodacyanine derivative NA NA NA NA 0.6 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000975 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 30(JG-98) 3-benzyl-2-{[(2Z)-5-[(2E)-6-chloro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-3-ethyl-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1,3-thiazol-3-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC(Cl)=CC=C2N1C)=C\C1=[N+](CC2=CC=CC=C2)C=CS1 Rhodacyanine derivative NA NA NA NA 0.4 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000976 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 31 3-benzyl-2-{[(2Z)-5-[(2E)-7-chloro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-3-ethyl-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1,3-thiazol-3-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=C(Cl)C=CC=C2N1C)=C\C1=[N+](CC2=CC=CC=C2)C=CS1 Rhodacyanine derivative NA NA NA NA 0.5 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MDA-MB-231 Cancer HSPMDB000977 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity MKT-077 1-ethyl-2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}pyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC=C2N1C)=C\C1=[N+](CC)C=CC=C1 Rhodacyanine derivative NA NA NA NA 2.2 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000978 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity YM-01 2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC=C2N1C)=C\C1=[N+](C)C=CC=C1 Rhodacyanine derivative NA NA NA NA 5.2 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000979 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 1 2-{[(2Z)-3-ethyl-5-[(2E)-4-fluoro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC(F)=C2N1C)=C\C1=[N+](C)C=CC=C1 Rhodacyanine derivative NA NA NA NA 2.2 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000980 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 2 2-{[(2Z)-3-ethyl-5-[(2E)-5-fluoro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=C(F)C=C2N1C)=C\C1=[N+](C)C=CC=C1 Rhodacyanine derivative NA NA NA NA 18 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000981 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 3 2-{[(2Z)-3-ethyl-5-[(2E)-6-fluoro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC(F)=CC=C2N1C)=C\C1=[N+](C)C=CC=C1 Rhodacyanine derivative NA NA NA NA 6.2 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000982 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 4 2-{[(2Z)-3-ethyl-5-[(2E)-7-fluoro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=C(F)C=CC=C2N1C)=C\C1=[N+](C)C=CC=C1 Rhodacyanine derivative NA NA NA NA 8.5 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000983 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 5 1-ethyl-2-{[(2Z)-3-ethyl-5-[(2E)-4-fluoro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}pyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC(F)=C2N1C)=C\C1=[N+](CC)C=CC=C1 Rhodacyanine derivative NA NA NA NA 1 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000984 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 6 1-ethyl-2-{[(2Z)-3-ethyl-5-[(2E)-5-fluoro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}pyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=C(F)C=C2N1C)=C\C1=[N+](CC)C=CC=C1 Rhodacyanine derivative NA NA NA NA 2.4 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000985 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 7 1-ethyl-2-{[(2Z)-3-ethyl-5-[(2E)-6-fluoro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}pyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC(F)=CC=C2N1C)=C\C1=[N+](CC)C=CC=C1 Rhodacyanine derivative NA NA NA NA 0.9 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000986 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 8 1-ethyl-2-{[(2Z)-3-ethyl-5-[(2E)-7-fluoro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}pyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=C(F)C=CC=C2N1C)=C\C1=[N+](CC)C=CC=C1 Rhodacyanine derivative NA NA NA NA 0.8 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000987 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 9 2-{[(2Z)-5-[(2E)-4-chloro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-3-ethyl-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC(Cl)=C2N1C)=C\C1=[N+](C)C=CC=C1 Rhodacyanine derivative NA NA NA NA 7.8 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000988 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 10 2-{[(2Z)-5-[(2E)-5-chloro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-3-ethyl-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=C(Cl)C=C2N1C)=C\C1=[N+](C)C=CC=C1 Rhodacyanine derivative NA NA NA NA 28 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000989 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 11 2-{[(2Z)-5-[(2E)-6-chloro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-3-ethyl-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC(Cl)=CC=C2N1C)=C\C1=[N+](C)C=CC=C1 Rhodacyanine derivative NA NA NA NA 9.5 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000990 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 12 2-{[(2Z)-5-[(2E)-7-chloro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-3-ethyl-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=C(Cl)C=CC=C2N1C)=C\C1=[N+](C)C=CC=C1 Rhodacyanine derivative NA NA NA NA 5.2 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000991 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 13 2-{[(2Z)-3-ethyl-5-[(2E)-5-methoxy-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=C(OC)C=C2N1C)=C\C1=[N+](C)C=CC=C1 Rhodacyanine derivative NA NA NA NA 14 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000992 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 14 2-{[(2Z)-3-ethyl-5-[(2E)-6-methoxy-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC(OC)=CC=C2N1C)=C\C1=[N+](C)C=CC=C1 Rhodacyanine derivative NA NA NA NA 11 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000993 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 15 2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-5-(trifluoromethyl)-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=C(C=C2N1C)C(F)(F)F)=C\C1=[N+](C)C=CC=C1 Rhodacyanine derivative NA NA NA NA >30 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000994 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 16 2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-6-(trifluoromethyl)-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC(=CC=C2N1C)C(F)(F)F)=C\C1=[N+](C)C=CC=C1 Rhodacyanine derivative NA NA NA NA >30 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000995 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 17 1-methyl-2-{[(2Z)-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-3-(prop-2-en-1-yl)-1,3-thiazolidin-2-ylidene]methyl}pyridin-1-ium chloride [Cl-].CN1\C(SC2=CC=CC=C12)=C1/S\C(=C/C2=[N+](C)C=CC=C2)N(CC=C)C1=O Rhodacyanine derivative NA NA NA NA 8.4 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000996 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 18 2-{[(2Z)-3-benzyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CN1\C(SC2=CC=CC=C12)=C1/S\C(=C/C2=[N+](C)C=CC=C2)N(CC2=CC=CC=C2)C1=O Rhodacyanine derivative NA NA NA NA 2.9 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000997 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 19 2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-propylpyridin-1-ium chloride [Cl-].CCC[N+]1=C(\C=C2/S\C(C(=O)N2CC)=C2\SC3=CC=CC=C3N2C)C=CC=C1 Rhodacyanine derivative NA NA NA NA 2.8 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000998 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 20 1-benzyl-2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}pyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC=C2N1C)=C\C1=[N+](CC2=CC=CC=C2)C=CC=C1 Rhodacyanine derivative NA NA NA NA 1.5 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB000999 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 21 2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-(2-hydroxyethyl)pyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC=C2N1C)=C\C1=[N+](CCO)C=CC=C1 Rhodacyanine derivative NA NA NA NA 6.9 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB001000 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 22 4-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC=C2N1C)=C\C1=CC=[N+](C)C=C1 Rhodacyanine derivative NA NA NA NA 19 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB001001 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 23 2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyrimidin-1-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC=C2N1C)=C\C1=[N+](C)C=CC=N1 Rhodacyanine derivative NA NA NA NA 9.1 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB001002 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 24 2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-3-methyl-1,3-thiazol-3-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC=C2N1C)=C\C1=[N+](C)C=CS1 Rhodacyanine derivative NA NA NA NA 0.7 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB001003 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 25 3-ethyl-2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1,3-thiazol-3-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC=C2N1C)=C\C1=[N+](CC)C=CS1 Rhodacyanine derivative NA NA NA NA 0.8 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB001004 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 26 3-benzyl-2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1,3-thiazol-3-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC=C2N1C)=C\C1=[N+](CC2=CC=CC=C2)C=CS1 Rhodacyanine derivative NA NA NA NA 0.6 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB001005 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 27(JG-83) 3-benzyl-2-{[(2Z)-3-ethyl-5-[(2E)-4-fluoro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1,3-thiazol-3-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC(F)=C2N1C)=C\C1=[N+](CC2=CC=CC=C2)C=CS1 Rhodacyanine derivative NA NA NA NA 1 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB001006 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 28(JG-84) 3-benzyl-2-{[(2Z)-5-[(2E)-4-chloro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-3-ethyl-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1,3-thiazol-3-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC(Cl)=C2N1C)=C\C1=[N+](CC2=CC=CC=C2)C=CS1 Rhodacyanine derivative NA NA NA NA 0.8 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB001007 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 29 3-benzyl-2-{[(2Z)-5-[(2E)-5-chloro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-3-ethyl-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1,3-thiazol-3-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=C(Cl)C=C2N1C)=C\C1=[N+](CC2=CC=CC=C2)C=CS1 Rhodacyanine derivative NA NA NA NA 0.8 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB001008 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 30(JG-98) 3-benzyl-2-{[(2Z)-5-[(2E)-6-chloro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-3-ethyl-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1,3-thiazol-3-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC(Cl)=CC=C2N1C)=C\C1=[N+](CC2=CC=CC=C2)C=CS1 Rhodacyanine derivative NA NA NA NA 0.7 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB001009 24312699 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 31 3-benzyl-2-{[(2Z)-5-[(2E)-7-chloro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-3-ethyl-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1,3-thiazol-3-ium chloride [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=C(Cl)C=CC=C2N1C)=C\C1=[N+](CC2=CC=CC=C2)C=CS1 Rhodacyanine derivative NA NA NA NA 1 NA NA NA Nucleotide binding domain (allosteric site) NA NA MTT viability assay NA NA NA MCF7 Cancer HSPMDB001010 25148104 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 2-phenylethyenesulfonamide (PES) 2-phenylethynesulfonamide C1=CC=C(C=C1)C#CS(=O)(=O)N NA NA NA NA NA NA NA NA NA C-terminal domain NA 90% at 10 uM MTT viability assay NA NA NA A875 Cancer HSPMDB001011 25148104 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity PET-16 triphenyl(phenylethynyl)phosphonium bromide [Br-].C1(=CC=CC=C1)[P+](C#CC1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1 2-phenylethyenesulfonamide (PES) derivative NA NA NA NA NA NA NA NA C-terminal domain NA 100% at 10 um MTT viability assay NA NA NA A875 Cancer HSPMDB001012 25148104 Hsp70 Hsp72 (HSPA1A) Human Cytosol and nucleus Binding affinity NA 2-phenylethyenesulfonamide (PES) 2-phenylethynesulfonamide C1=CC=C(C=C1)C#CS(=O)(=O)N NA NA 5.7 NA NA NA NA NA NA C-terminal domain Isothermal Titration Calorimetry (ITC) NA NA NA NA NA NA Cancer HSPMDB001013 25148104 Hsp70 Hsp72 (HSPA1A) Human Cytosol and nucleus Binding affinity NA PET-16 triphenyl(phenylethynyl)phosphonium bromide [Br-].C1(=CC=CC=C1)[P+](C#CC1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1 2-phenylethyenesulfonamide (PES) derivative NA 3.8 NA NA NA NA NA NA C-terminal domain Isothermal Titration Calorimetry (ITC) NA NA NA NA NA NA Cancer HSPMDB001014 25148104 Hsp70 DnaK Bacteria Cytosol and membrane Binding affinity NA PES 2-phenylethynesulfonamide C1=CC=C(C=C1)C#CS(=O)(=O)N NA NA 6.8 NA NA NA NA NA NA C-terminal domain Isothermal Titration Calorimetry (ITC) NA NA NA NA NA NA Bacterial infection HSPMDB001015 25148104 Hsp70 DnaK Bacteria Cytosol and membrane Binding affinity NA PET-16 triphenyl(phenylethynyl)phosphonium bromide [Br-].C1(=CC=CC=C1)[P+](C#CC1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1 2-phenylethyenesulfonamide (PES) derivative NA 6 NA NA NA NA NA NA C-terminal domain Isothermal Titration Calorimetry (ITC) NA NA NA NA NA NA Bacterial infection HSPMDB001016 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity Lapatinib 2-phenylethynesulfonamide C1=CC=C(C=C1)C#CS(=O)(=O)N Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 75.6 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001017 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 1 N-(3-Chlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3cccc(Cl)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 14.4 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001018 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 2 2-(((1-((2-Ethoxythiazol-5-yl)methyl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile CCOc1sc(CN2CCC(CC2)N(C)Cc3ccccc3C#N)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 17.6 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001019 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 3 N-(3,4-dichlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 62.9 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001020 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 4 4-(((1-((2-Ethoxythiazol-5-yl)methyl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile CCOc1sc(CN2CCC(CC2)N(C)Cc3ccc(cc3)C#N)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 61.7 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001021 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 5 N-(2-chloro-6-fluorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3c(F)cccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 54.4 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001022 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 6 N-(2-chlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3ccccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 10.1 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001023 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 7 1-((2-Ethoxythiazol-5-yl)methyl)-N-(4-fluorobenzyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3ccc(F)cc3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 36.4 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001024 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 8 N-(2,4-dichlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3ccc(Cl)cc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 70.3 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001025 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 9 N-(2,6-dichlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3c(Cl)cccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 38.2 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001026 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 10 N-(2,5-dichlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 5.6 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001027 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 11 N-methyl-N-(2-methylbenzyl)-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3ccccc3C)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 15.5 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001028 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 12 N-methyl-N-(4-methylbenzyl)-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(C)cc3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 68.3 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001029 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 13 N-(3-fluorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3cccc(F)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 26.3 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001030 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 14 N-(3-chlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3cccc(Cl)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 44.9 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001031 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 15 N-(4-fluorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(F)cc3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 54.4 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001032 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 16 N-(3,4-dichlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 62.6 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001033 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 17 N-(2-chloro-6-fluorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl) piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3c(F)cccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 49.5 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001034 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 18 N-(2,6-dichlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3c(Cl)cccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 54.9 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001035 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 19 N-(2,4-dichlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(Cl)cc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 70 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001036 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 20 N-(2,5-dichlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 42.3 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001037 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 21 2-(((1-((2-Chlorothiazol-5-yl)methyl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile CN(Cc1ccccc1C#N)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA -4.1 Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001038 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 22 4-(((1-((2-Chlorothiazol-5-yl)methyl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile CN(Cc1ccc(cc1)C#N)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 69.3 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001039 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 23 1-((2-Chlorothiazol-5-yl)methyl)-N-(4-fluorobenzyl)-N-methylpiperidin-4-amine CN(Cc1ccc(F)cc1)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 7.1 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001040 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 24 1-((2-Chlorothiazol-5-yl)methyl)-N-(3,4-dichlorobenzyl)-N-methylpiperidin-4-amine CN(Cc1ccc(Cl)c(Cl)c1)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 45.4 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001041 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 25 N-(3-chlorobenzyl)-1-((2-chlorothiazol-5-yl)methyl)-N-methylpiperidin-4-amine CN(Cc1cccc(Cl)c1)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 7.1 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001042 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 26 N-(2-chloro-6-fluorobenzyl)-1-((2-chlorothiazol-5-yl)methyl)-N-methylpiperidin-4-amine CN(Cc1c(F)cccc1Cl)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 10.6 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001043 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 27 1-((2-Chlorothiazol-5-yl)methyl)-N-(2,4-dichlorobenzyl)-N-methylpiperidin-4-amine CN(Cc1ccc(Cl)cc1Cl)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 64.1 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001044 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 28 1-((2-Chlorothiazol-5-yl)methyl)-N-methyl-N-(2-methylbenzyl)piperidin-4-amine CN(Cc1ccccc1C)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 1.5 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001045 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 29 1-((2-Chlorothiazol-5-yl)methyl)-N-methyl-N-(4-methylbenzyl)piperidin-4-amine CN(Cc1ccc(C)cc1)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 14.2 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001046 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 30 1-((2-Chlorothiazol-5-yl)methyl)-N-(3-fluorobenzyl)-N-methylpiperidin-4-amine CN(Cc1cccc(F)c1)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 2.4 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001047 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 31 1-((2-Chlorothiazol-5-yl)methyl)-N-(2,6-dichlorobenzyl)-N-methylpiperidin-4-amine CN(Cc1c(Cl)cccc1Cl)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 70 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001048 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 32 1-((2-Chlorothiazol-5-yl)methyl)-N-(3,4-dichlorobenzyl)piperidin-4-amine Clc1sc(CN2CCC(CC2)NCc3ccc(Cl)c(Cl)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 11 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001049 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 33 1-((2-Chlorothiazol-5-yl)methyl)-N-(4-fluorobenzyl)piperidin-4-amine Fc1ccc(CNC2CCN(CC2)Cc3sc(Cl)nc3)cc1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 70 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001050 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 34 N-(3-chlorobenzyl)-1-((2-chlorothiazol-5-yl)methyl)piperidin-4-amine Clc1sc(CN2CCC(CC2)NCc3cccc(Cl)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 3.8 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001051 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 35 N-(4-fluorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(F)cc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 40.5 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001052 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 36 4-((Methyl(1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-yl)amino)methyl) benzonitrile CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(cc3)C#N Piperidine derivative NA NA NA 1.41 NA NA NA NA Nucleotide binding domain (allosteric site) NA 75.5 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001053 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 37 N-(2-chloro-6-fluorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3c(F)cccc3Cl Piperidine derivative NA NA NA 1.04 NA NA NA NA Nucleotide binding domain (allosteric site) NA 75.5 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001054 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 38 N-(3,4-dichlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 39.5 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001055 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 39 N-(3-chlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3cccc(Cl)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 35.1 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001056 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 40 N-(2,4-dichlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(Cl)cc3Cl Piperidine derivative NA NA NA 1.62 NA NA NA NA Nucleotide binding domain (allosteric site) NA 74.2 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001057 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 41 2-((Methyl(1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-yl)amino)methyl) benzonitrile CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccccc3C#N Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 74.2 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001058 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 42 N-methyl-N-(4-methylbenzyl)-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(C)cc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 69.2 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001059 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 47 N-(2-chlorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 36.7 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001060 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 44 N-(2,5-dichlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 61 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001061 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 45 N-(3-fluorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3cccc(F)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 67.1 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001062 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 46 N-(2-chlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccccc3Cl Piperidine derivative NA NA NA 1.99 NA NA NA NA Nucleotide binding domain (allosteric site) NA 21.3 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001063 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 43 N-(2,6-dichlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3c(Cl)cccc3Cl Piperidine derivative NA NA NA 0.78 NA NA NA NA Nucleotide binding domain (allosteric site) NA 73.1 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001064 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 48 4-(((1-(2-Methoxypyrimidin-4-yl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(cc3)C#N Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 60.4 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001065 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 49 2-(((1-(2-Methoxypyrimidin-4-yl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccccc3C#N Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 71.6 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001066 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 50 1-(2-Methoxypyrimidin-4-yl)-N-methyl-N-(4-methylbenzyl)piperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(C)cc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 61.5 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001067 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 51 N-(2,5-dichlorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 27.5 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001068 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 52 N-(3,4-dichlorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 52.9 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001069 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 53 N-(2-chloro-6-fluorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3c(F)cccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 65.4 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001070 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 54 N-(3-chlorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3cccc(Cl)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 36.2 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001071 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 55 N-(3-fluorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3cccc(F)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 9.9 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001072 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 56 N-(4-fluorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(F)cc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 12.5 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001073 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 57 N-(2-chlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 27.7 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001074 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 58 1-(6-Methoxypyrimidin-4-yl)-N-methyl-N-(4-methylbenzyl)piperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccc(C)cc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 5 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001075 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 59 N-(2,6-dichlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3c(Cl)cccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 53.6 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001076 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 60 N-(3,4-dichlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 9.8 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001077 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 61 N-(4-fluorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccc(F)cc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 7.8 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001078 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 62 N-(3-chlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3cccc(Cl)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 11.9 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001079 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 63 N-(2-chloro-6-fluorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3c(F)cccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 45.9 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001080 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 64 2-(((1-(6-Methoxypyrimidin-4-yl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccccc3C#N Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 65.8 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001081 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 65 4-(((1-(6-Methoxypyrimidin-4-yl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccc(cc3)C#N Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 25.1 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001082 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 66 N-(2,5-dichlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 45.9 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001083 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 67 N-(2,5-dichlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 5.4 at 5 uM Luminescence based viability assay NA NA NA BT474 Cancer HSPMDB001084 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity Lapatinib N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 18 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001085 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 1 N-(3-Chlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3cccc(Cl)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 12.5 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001086 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 2 2-(((1-((2-Ethoxythiazol-5-yl)methyl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile CCOc1sc(CN2CCC(CC2)N(C)Cc3ccccc3C#N)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 19.4 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001087 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 3 N-(3,4-dichlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 67.4 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001088 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 4 4-(((1-((2-Ethoxythiazol-5-yl)methyl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile CCOc1sc(CN2CCC(CC2)N(C)Cc3ccc(cc3)C#N)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 66.1 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001089 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 5 N-(2-chloro-6-fluorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3c(F)cccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 50.5 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001090 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 6 N-(2-chlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3ccccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 13.3 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001091 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 7 1-((2-Ethoxythiazol-5-yl)methyl)-N-(4-fluorobenzyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3ccc(F)cc3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 20.7 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001092 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 8 N-(2,4-dichlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3ccc(Cl)cc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 65.9 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001093 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 9 N-(2,6-dichlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3c(Cl)cccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 25.6 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001094 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 10 N-(2,5-dichlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 9.6 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001095 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 11 N-methyl-N-(2-methylbenzyl)-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3ccccc3C)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 1.4 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001096 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 12 N-methyl-N-(4-methylbenzyl)-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(C)cc3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 66.7 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001097 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 13 N-(3-fluorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3cccc(F)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 19.8 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001098 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 14 N-(3-chlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3cccc(Cl)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 36.1 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001099 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 15 N-(4-fluorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(F)cc3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 50.5 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001100 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 16 N-(3,4-dichlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 67.1 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001101 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 17 N-(2-chloro-6-fluorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl) piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3c(F)cccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 59.9 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001102 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 18 N-(2,6-dichlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3c(Cl)cccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 54.9 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001103 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 19 N-(2,4-dichlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(Cl)cc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 66.3 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001104 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 20 N-(2,5-dichlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 34.4 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001105 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 21 2-(((1-((2-Chlorothiazol-5-yl)methyl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile CN(Cc1ccccc1C#N)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 4 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001106 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 22 4-(((1-((2-Chlorothiazol-5-yl)methyl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile CN(Cc1ccc(cc1)C#N)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 68.7 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001107 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 23 1-((2-Chlorothiazol-5-yl)methyl)-N-(4-fluorobenzyl)-N-methylpiperidin-4-amine CN(Cc1ccc(F)cc1)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 9 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001108 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 24 1-((2-Chlorothiazol-5-yl)methyl)-N-(3,4-dichlorobenzyl)-N-methylpiperidin-4-amine CN(Cc1ccc(Cl)c(Cl)c1)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 53.4 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001109 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 25 N-(3-chlorobenzyl)-1-((2-chlorothiazol-5-yl)methyl)-N-methylpiperidin-4-amine CN(Cc1cccc(Cl)c1)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 8.4 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001110 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 26 N-(2-chloro-6-fluorobenzyl)-1-((2-chlorothiazol-5-yl)methyl)-N-methylpiperidin-4-amine CN(Cc1c(F)cccc1Cl)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 3.2 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001111 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 27 1-((2-Chlorothiazol-5-yl)methyl)-N-(2,4-dichlorobenzyl)-N-methylpiperidin-4-amine CN(Cc1ccc(Cl)cc1Cl)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 61.8 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001112 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 28 1-((2-Chlorothiazol-5-yl)methyl)-N-methyl-N-(2-methylbenzyl)piperidin-4-amine CN(Cc1ccccc1C)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 4 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001113 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 29 1-((2-Chlorothiazol-5-yl)methyl)-N-methyl-N-(4-methylbenzyl)piperidin-4-amine CN(Cc1ccc(C)cc1)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 16 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001114 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 30 1-((2-Chlorothiazol-5-yl)methyl)-N-(3-fluorobenzyl)-N-methylpiperidin-4-amine CN(Cc1cccc(F)c1)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 5.7 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001115 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 31 1-((2-Chlorothiazol-5-yl)methyl)-N-(2,6-dichlorobenzyl)-N-methylpiperidin-4-amine CN(Cc1c(Cl)cccc1Cl)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 66.3 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001116 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 32 1-((2-Chlorothiazol-5-yl)methyl)-N-(3,4-dichlorobenzyl)piperidin-4-amine Clc1sc(CN2CCC(CC2)NCc3ccc(Cl)c(Cl)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 10.6 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001117 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 33 1-((2-Chlorothiazol-5-yl)methyl)-N-(4-fluorobenzyl)piperidin-4-amine Fc1ccc(CNC2CCN(CC2)Cc3sc(Cl)nc3)cc1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 66.3 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001118 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 34 N-(3-chlorobenzyl)-1-((2-chlorothiazol-5-yl)methyl)piperidin-4-amine Clc1sc(CN2CCC(CC2)NCc3cccc(Cl)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 7.2 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001119 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 35 N-(4-fluorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(F)cc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 44.7 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001120 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 36 4-((Methyl(1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-yl)amino)methyl) benzonitrile CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(cc3)C#N Piperidine derivative NA NA NA 1.47 NA NA NA NA Nucleotide binding domain (allosteric site) NA 76.2 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001121 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 37 N-(2-chloro-6-fluorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3c(F)cccc3Cl Piperidine derivative NA NA NA 0.94 NA NA NA NA Nucleotide binding domain (allosteric site) NA 70.7 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001122 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 38 N-(3,4-dichlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 29.9 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001123 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 39 N-(3-chlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3cccc(Cl)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 25.1 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001124 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 40 N-(2,4-dichlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(Cl)cc3Cl Piperidine derivative NA NA NA 1.68 NA NA NA NA Nucleotide binding domain (allosteric site) NA 68.1 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001125 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 41 2-((Methyl(1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-yl)amino)methyl) benzonitrile CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccccc3C#N Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 68.1 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001126 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 42 N-methyl-N-(4-methylbenzyl)-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(C)cc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 65.8 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001127 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 47 N-(2-chlorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 28.6 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001128 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 44 N-(2,5-dichlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 56.9 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001129 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 45 N-(3-fluorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3cccc(F)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 63.9 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001130 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 46 N-(2-chlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccccc3Cl Piperidine derivative NA NA NA 1.7 NA NA NA NA Nucleotide binding domain (allosteric site) NA 17.5 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001131 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 43 N-(2,6-dichlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3c(Cl)cccc3Cl Piperidine derivative NA NA NA 0.7 NA NA NA NA Nucleotide binding domain (allosteric site) NA 70 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001132 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 48 4-(((1-(2-Methoxypyrimidin-4-yl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(cc3)C#N Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 58.1 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001133 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 49 2-(((1-(2-Methoxypyrimidin-4-yl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccccc3C#N Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 72.7 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001134 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 50 1-(2-Methoxypyrimidin-4-yl)-N-methyl-N-(4-methylbenzyl)piperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(C)cc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 58.8 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001135 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 51 N-(2,5-dichlorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 22.7 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001136 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 52 N-(3,4-dichlorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 35.8 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001137 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 53 N-(2-chloro-6-fluorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3c(F)cccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 62.4 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001138 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 54 N-(3-chlorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3cccc(Cl)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 26.2 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001139 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 55 N-(3-fluorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3cccc(F)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 10.5 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001140 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 56 N-(4-fluorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(F)cc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 14.6 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001141 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 57 N-(2-chlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 18.9 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001142 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 58 1-(6-Methoxypyrimidin-4-yl)-N-methyl-N-(4-methylbenzyl)piperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccc(C)cc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 8 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001143 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 59 N-(2,6-dichlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3c(Cl)cccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 52.5 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001144 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 60 N-(3,4-dichlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 9.2 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001145 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 61 N-(4-fluorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccc(F)cc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 8.1 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001146 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 62 N-(3-chlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3cccc(Cl)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 9.4 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001147 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 63 N-(2-chloro-6-fluorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3c(F)cccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 48.5 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001148 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 64 2-(((1-(6-Methoxypyrimidin-4-yl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccccc3C#N Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 62.2 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001149 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 65 4-(((1-(6-Methoxypyrimidin-4-yl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccc(cc3)C#N Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 16.9 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001150 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 66 N-(2,5-dichlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 32.1 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001151 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 67 N-(2,5-dichlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 5.6 at 5 uM Luminescence based viability assay NA NA NA BT/LapR1.0 Cancer HSPMDB001152 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity Lapatinib N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 40.2 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001153 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 1 N-(3-Chlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3cccc(Cl)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 14.2 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001154 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 2 2-(((1-((2-Ethoxythiazol-5-yl)methyl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile CCOc1sc(CN2CCC(CC2)N(C)Cc3ccccc3C#N)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 12.3 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001155 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 3 N-(3,4-dichlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 35.8 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001156 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 4 4-(((1-((2-Ethoxythiazol-5-yl)methyl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile CCOc1sc(CN2CCC(CC2)N(C)Cc3ccc(cc3)C#N)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 51.3 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001157 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 5 N-(2-chloro-6-fluorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3c(F)cccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 32.8 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001158 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 6 N-(2-chlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3ccccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 33.3 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001159 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 7 1-((2-Ethoxythiazol-5-yl)methyl)-N-(4-fluorobenzyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3ccc(F)cc3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 24.2 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001160 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 8 N-(2,4-dichlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3ccc(Cl)cc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 49.2 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001161 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 9 N-(2,6-dichlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3c(Cl)cccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 24.5 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001162 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 10 N-(2,5-dichlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 25.3 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001163 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 11 N-methyl-N-(2-methylbenzyl)-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3ccccc3C)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 31.7 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001164 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 12 N-methyl-N-(4-methylbenzyl)-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(C)cc3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 38.3 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001165 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 13 N-(3-fluorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3cccc(F)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 31.7 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001166 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 14 N-(3-chlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3cccc(Cl)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 31.1 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001167 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 15 N-(4-fluorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(F)cc3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 32.8 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001168 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 16 N-(3,4-dichlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 42.1 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001169 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 17 N-(2-chloro-6-fluorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl) piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3c(F)cccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 47.2 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001170 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 18 N-(2,6-dichlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3c(Cl)cccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 45.2 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001171 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 19 N-(2,4-dichlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(Cl)cc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 36.3 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001172 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 20 N-(2,5-dichlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 25.4 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001173 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 21 2-(((1-((2-Chlorothiazol-5-yl)methyl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile CN(Cc1ccccc1C#N)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA -8.5 Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001174 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 22 4-(((1-((2-Chlorothiazol-5-yl)methyl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile CN(Cc1ccc(cc1)C#N)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 35.6 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001175 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 23 1-((2-Chlorothiazol-5-yl)methyl)-N-(4-fluorobenzyl)-N-methylpiperidin-4-amine CN(Cc1ccc(F)cc1)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA -1.3 Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001176 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 24 1-((2-Chlorothiazol-5-yl)methyl)-N-(3,4-dichlorobenzyl)-N-methylpiperidin-4-amine CN(Cc1ccc(Cl)c(Cl)c1)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 42.9 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001177 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 25 N-(3-chlorobenzyl)-1-((2-chlorothiazol-5-yl)methyl)-N-methylpiperidin-4-amine CN(Cc1cccc(Cl)c1)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 9.7 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001178 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 26 N-(2-chloro-6-fluorobenzyl)-1-((2-chlorothiazol-5-yl)methyl)-N-methylpiperidin-4-amine CN(Cc1c(F)cccc1Cl)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 10.4 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001179 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 27 1-((2-Chlorothiazol-5-yl)methyl)-N-(2,4-dichlorobenzyl)-N-methylpiperidin-4-amine CN(Cc1ccc(Cl)cc1Cl)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 30.1 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001180 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 28 1-((2-Chlorothiazol-5-yl)methyl)-N-methyl-N-(2-methylbenzyl)piperidin-4-amine CN(Cc1ccccc1C)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 4.4 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001181 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 29 1-((2-Chlorothiazol-5-yl)methyl)-N-methyl-N-(4-methylbenzyl)piperidin-4-amine CN(Cc1ccc(C)cc1)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 10.9 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001182 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 30 1-((2-Chlorothiazol-5-yl)methyl)-N-(3-fluorobenzyl)-N-methylpiperidin-4-amine CN(Cc1cccc(F)c1)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 3.2 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001183 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 31 1-((2-Chlorothiazol-5-yl)methyl)-N-(2,6-dichlorobenzyl)-N-methylpiperidin-4-amine CN(Cc1c(Cl)cccc1Cl)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 36.3 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001184 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 32 1-((2-Chlorothiazol-5-yl)methyl)-N-(3,4-dichlorobenzyl)piperidin-4-amine Clc1sc(CN2CCC(CC2)NCc3ccc(Cl)c(Cl)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 13.9 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001185 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 33 1-((2-Chlorothiazol-5-yl)methyl)-N-(4-fluorobenzyl)piperidin-4-amine Fc1ccc(CNC2CCN(CC2)Cc3sc(Cl)nc3)cc1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 36.3 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001186 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 34 N-(3-chlorobenzyl)-1-((2-chlorothiazol-5-yl)methyl)piperidin-4-amine Clc1sc(CN2CCC(CC2)NCc3cccc(Cl)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 3.2 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001187 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 35 N-(4-fluorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(F)cc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 46 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001188 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 36 4-((Methyl(1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-yl)amino)methyl) benzonitrile CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(cc3)C#N Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 46.9 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001189 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 37 N-(2-chloro-6-fluorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3c(F)cccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 55.9 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001190 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 38 N-(3,4-dichlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 29.5 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001191 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 39 N-(3-chlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3cccc(Cl)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 39.1 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001192 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 40 N-(2,4-dichlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(Cl)cc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 64.1 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001193 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 41 2-((Methyl(1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-yl)amino)methyl) benzonitrile CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccccc3C#N Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 64.1 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001194 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 42 N-methyl-N-(4-methylbenzyl)-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(C)cc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 55.7 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001195 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 47 N-(2-chlorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 45.1 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001196 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 44 N-(2,5-dichlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 45.7 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001197 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 45 N-(3-fluorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3cccc(F)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 50.4 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001198 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 46 N-(2-chlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 36.2 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001199 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 43 N-(2,6-dichlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3c(Cl)cccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 53.2 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001200 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 48 4-(((1-(2-Methoxypyrimidin-4-yl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(cc3)C#N Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 27.7 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001201 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 49 2-(((1-(2-Methoxypyrimidin-4-yl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccccc3C#N Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 53.3 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001202 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 50 1-(2-Methoxypyrimidin-4-yl)-N-methyl-N-(4-methylbenzyl)piperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(C)cc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 30.1 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001203 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 51 N-(2,5-dichlorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 22 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001204 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 52 N-(3,4-dichlorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 41.7 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001205 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 53 N-(2-chloro-6-fluorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3c(F)cccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 48.3 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001206 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 54 N-(3-chlorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3cccc(Cl)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 23.2 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001207 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 55 N-(3-fluorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3cccc(F)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 8.5 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001208 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 56 N-(4-fluorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(F)cc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 12.8 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001209 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 57 N-(2-chlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 20.3 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001210 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 58 1-(6-Methoxypyrimidin-4-yl)-N-methyl-N-(4-methylbenzyl)piperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccc(C)cc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 10.6 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001211 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 59 N-(2,6-dichlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3c(Cl)cccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 30.8 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001212 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 60 N-(3,4-dichlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 6.5 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001213 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 61 N-(4-fluorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccc(F)cc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 4.9 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001214 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 62 N-(3-chlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3cccc(Cl)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 25.6 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001215 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 63 N-(2-chloro-6-fluorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3c(F)cccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 39.6 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001216 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 64 2-(((1-(6-Methoxypyrimidin-4-yl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccccc3C#N Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 42.7 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001217 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 65 4-(((1-(6-Methoxypyrimidin-4-yl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccc(cc3)C#N Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 20.3 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001218 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 66 N-(2,5-dichlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 27.6 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001219 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 67 N-(2,5-dichlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 8.4 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-361 Cancer HSPMDB001220 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity Lapatinib N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 79 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001221 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 1 N-(3-Chlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3cccc(Cl)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 16.7 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001222 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 2 2-(((1-((2-Ethoxythiazol-5-yl)methyl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile CCOc1sc(CN2CCC(CC2)N(C)Cc3ccccc3C#N)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 13.6 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001223 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 3 N-(3,4-dichlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 41.2 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001224 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 4 4-(((1-((2-Ethoxythiazol-5-yl)methyl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile CCOc1sc(CN2CCC(CC2)N(C)Cc3ccc(cc3)C#N)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 45.5 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001225 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 5 N-(2-chloro-6-fluorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3c(F)cccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 40.9 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001226 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 6 N-(2-chlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3ccccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 12.6 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001227 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 7 1-((2-Ethoxythiazol-5-yl)methyl)-N-(4-fluorobenzyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3ccc(F)cc3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 26 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001228 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 8 N-(2,4-dichlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3ccc(Cl)cc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 41.6 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001229 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 9 N-(2,6-dichlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3c(Cl)cccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 17.9 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001230 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 10 N-(2,5-dichlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 9.4 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001231 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 11 N-methyl-N-(2-methylbenzyl)-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3ccccc3C)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 21.9 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001232 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 12 N-methyl-N-(4-methylbenzyl)-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(C)cc3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 49.6 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001233 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 13 N-(3-fluorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3cccc(F)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 19.5 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001234 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 14 N-(3-chlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3cccc(Cl)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 26.7 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001235 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 15 N-(4-fluorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(F)cc3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 40.9 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001236 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 16 N-(3,4-dichlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 42.4 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001237 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 17 N-(2-chloro-6-fluorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl) piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3c(F)cccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 9.2 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001238 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 18 N-(2,6-dichlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3c(Cl)cccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 24.3 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001239 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 19 N-(2,4-dichlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(Cl)cc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 37.8 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001240 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 20 N-(2,5-dichlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 23.3 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001241 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 21 2-(((1-((2-Chlorothiazol-5-yl)methyl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile CN(Cc1ccccc1C#N)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 7.3 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001242 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 22 4-(((1-((2-Chlorothiazol-5-yl)methyl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile CN(Cc1ccc(cc1)C#N)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 41.5 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001243 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 23 1-((2-Chlorothiazol-5-yl)methyl)-N-(4-fluorobenzyl)-N-methylpiperidin-4-amine CN(Cc1ccc(F)cc1)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 18.6 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001244 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 24 1-((2-Chlorothiazol-5-yl)methyl)-N-(3,4-dichlorobenzyl)-N-methylpiperidin-4-amine CN(Cc1ccc(Cl)c(Cl)c1)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 34.3 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001245 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 25 N-(3-chlorobenzyl)-1-((2-chlorothiazol-5-yl)methyl)-N-methylpiperidin-4-amine CN(Cc1cccc(Cl)c1)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 15.5 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001246 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 26 N-(2-chloro-6-fluorobenzyl)-1-((2-chlorothiazol-5-yl)methyl)-N-methylpiperidin-4-amine CN(Cc1c(F)cccc1Cl)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 9.8 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001247 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 27 1-((2-Chlorothiazol-5-yl)methyl)-N-(2,4-dichlorobenzyl)-N-methylpiperidin-4-amine CN(Cc1ccc(Cl)cc1Cl)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 47.1 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001248 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 28 1-((2-Chlorothiazol-5-yl)methyl)-N-methyl-N-(2-methylbenzyl)piperidin-4-amine CN(Cc1ccccc1C)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 9.7 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001249 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 29 1-((2-Chlorothiazol-5-yl)methyl)-N-methyl-N-(4-methylbenzyl)piperidin-4-amine CN(Cc1ccc(C)cc1)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 26.2 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001250 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 30 1-((2-Chlorothiazol-5-yl)methyl)-N-(3-fluorobenzyl)-N-methylpiperidin-4-amine CN(Cc1cccc(F)c1)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 4.2 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001251 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 31 1-((2-Chlorothiazol-5-yl)methyl)-N-(2,6-dichlorobenzyl)-N-methylpiperidin-4-amine CN(Cc1c(Cl)cccc1Cl)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 37.8 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001252 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 32 1-((2-Chlorothiazol-5-yl)methyl)-N-(3,4-dichlorobenzyl)piperidin-4-amine Clc1sc(CN2CCC(CC2)NCc3ccc(Cl)c(Cl)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 26.3 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001253 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 33 1-((2-Chlorothiazol-5-yl)methyl)-N-(4-fluorobenzyl)piperidin-4-amine Fc1ccc(CNC2CCN(CC2)Cc3sc(Cl)nc3)cc1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 37.8 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001254 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 34 N-(3-chlorobenzyl)-1-((2-chlorothiazol-5-yl)methyl)piperidin-4-amine Clc1sc(CN2CCC(CC2)NCc3cccc(Cl)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 17.9 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001255 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 35 N-(4-fluorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(F)cc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 31.5 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001256 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 36 4-((Methyl(1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-yl)amino)methyl) benzonitrile CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(cc3)C#N Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 83.4 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001257 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 37 N-(2-chloro-6-fluorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3c(F)cccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 78.9 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001258 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 38 N-(3,4-dichlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 30.1 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001259 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 39 N-(3-chlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3cccc(Cl)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 26.4 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001260 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 40 N-(2,4-dichlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(Cl)cc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 87.6 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001261 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 41 2-((Methyl(1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-yl)amino)methyl) benzonitrile CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccccc3C#N Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 87.6 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001262 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 42 N-methyl-N-(4-methylbenzyl)-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(C)cc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 38.9 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001263 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 47 N-(2-chlorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 41.4 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001264 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 44 N-(2,5-dichlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 19.3 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001265 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 45 N-(3-fluorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3cccc(F)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 32.6 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001266 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 46 N-(2-chlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 22.2 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001267 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 43 N-(2,6-dichlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3c(Cl)cccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 85.9 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001268 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 48 4-(((1-(2-Methoxypyrimidin-4-yl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(cc3)C#N Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 31.7 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001269 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 49 2-(((1-(2-Methoxypyrimidin-4-yl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccccc3C#N Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 86.5 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001270 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 50 1-(2-Methoxypyrimidin-4-yl)-N-methyl-N-(4-methylbenzyl)piperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(C)cc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 19.7 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001271 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 51 N-(2,5-dichlorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 24.7 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001272 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 52 N-(3,4-dichlorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 27.7 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001273 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 53 N-(2-chloro-6-fluorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3c(F)cccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 27.7 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001274 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 54 N-(3-chlorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3cccc(Cl)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 18.5 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001275 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 55 N-(3-fluorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3cccc(F)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 9.2 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001276 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 56 N-(4-fluorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(F)cc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 14.4 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001277 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 57 N-(2-chlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 13.5 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001278 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 58 1-(6-Methoxypyrimidin-4-yl)-N-methyl-N-(4-methylbenzyl)piperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccc(C)cc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 20.6 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001279 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 59 N-(2,6-dichlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3c(Cl)cccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 22.8 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001280 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 60 N-(3,4-dichlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 16.1 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001281 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 61 N-(4-fluorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccc(F)cc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 7.6 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001282 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 62 N-(3-chlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3cccc(Cl)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 12.6 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001283 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 63 N-(2-chloro-6-fluorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3c(F)cccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 15.5 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001284 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 64 2-(((1-(6-Methoxypyrimidin-4-yl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccccc3C#N Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 23.3 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001285 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 65 4-(((1-(6-Methoxypyrimidin-4-yl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccc(cc3)C#N Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 17.3 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001286 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 66 N-(2,5-dichlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 29.2 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001287 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 67 N-(2,5-dichlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 5.2 at 5 uM Luminescence based viability assay NA NA NA SK-BR-3 Cancer HSPMDB001288 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity Lapatinib N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 10.4 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001289 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 1 N-(3-Chlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3cccc(Cl)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 5.2 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001290 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 2 2-(((1-((2-Ethoxythiazol-5-yl)methyl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile CCOc1sc(CN2CCC(CC2)N(C)Cc3ccccc3C#N)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 7.2 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001291 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 3 N-(3,4-dichlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 13.1 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001292 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 4 4-(((1-((2-Ethoxythiazol-5-yl)methyl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile CCOc1sc(CN2CCC(CC2)N(C)Cc3ccc(cc3)C#N)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 6.7 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001293 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 5 N-(2-chloro-6-fluorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3c(F)cccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 11.7 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001294 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 6 N-(2-chlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3ccccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 0.6 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001295 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 7 1-((2-Ethoxythiazol-5-yl)methyl)-N-(4-fluorobenzyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3ccc(F)cc3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 25.1 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001296 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 8 N-(2,4-dichlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3ccc(Cl)cc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 12 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001297 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 9 N-(2,6-dichlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3c(Cl)cccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 5.1 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001298 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 10 N-(2,5-dichlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 5.2 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001299 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 11 N-methyl-N-(2-methylbenzyl)-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3ccccc3C)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 6.9 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001300 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 12 N-methyl-N-(4-methylbenzyl)-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(C)cc3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 12.1 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001301 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 13 N-(3-fluorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3cccc(F)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 2.1 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001302 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 14 N-(3-chlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3cccc(Cl)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 7.3 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001303 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 15 N-(4-fluorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(F)cc3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 11.7 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001304 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 16 N-(3,4-dichlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 10.1 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001305 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 17 N-(2-chloro-6-fluorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl) piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3c(F)cccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 4.5 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001306 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 18 N-(2,6-dichlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3c(Cl)cccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 26.8 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001307 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 19 N-(2,4-dichlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(Cl)cc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 40.4 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001308 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 20 N-(2,5-dichlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 11.4 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001309 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 21 2-(((1-((2-Chlorothiazol-5-yl)methyl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile CN(Cc1ccccc1C#N)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 4.2 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001310 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 22 4-(((1-((2-Chlorothiazol-5-yl)methyl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile CN(Cc1ccc(cc1)C#N)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 7.5 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001311 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 23 1-((2-Chlorothiazol-5-yl)methyl)-N-(4-fluorobenzyl)-N-methylpiperidin-4-amine CN(Cc1ccc(F)cc1)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA -0.1 Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001312 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 24 1-((2-Chlorothiazol-5-yl)methyl)-N-(3,4-dichlorobenzyl)-N-methylpiperidin-4-amine CN(Cc1ccc(Cl)c(Cl)c1)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 5.3 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001313 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 25 N-(3-chlorobenzyl)-1-((2-chlorothiazol-5-yl)methyl)-N-methylpiperidin-4-amine CN(Cc1cccc(Cl)c1)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 8.5 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001314 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 26 N-(2-chloro-6-fluorobenzyl)-1-((2-chlorothiazol-5-yl)methyl)-N-methylpiperidin-4-amine CN(Cc1c(F)cccc1Cl)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 1.5 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001315 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 27 1-((2-Chlorothiazol-5-yl)methyl)-N-(2,4-dichlorobenzyl)-N-methylpiperidin-4-amine CN(Cc1ccc(Cl)cc1Cl)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 11.4 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001316 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 28 1-((2-Chlorothiazol-5-yl)methyl)-N-methyl-N-(2-methylbenzyl)piperidin-4-amine CN(Cc1ccccc1C)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 5.1 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001317 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 29 1-((2-Chlorothiazol-5-yl)methyl)-N-methyl-N-(4-methylbenzyl)piperidin-4-amine CN(Cc1ccc(C)cc1)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 8.4 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001318 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 30 1-((2-Chlorothiazol-5-yl)methyl)-N-(3-fluorobenzyl)-N-methylpiperidin-4-amine CN(Cc1cccc(F)c1)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 1.3 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001319 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 31 1-((2-Chlorothiazol-5-yl)methyl)-N-(2,6-dichlorobenzyl)-N-methylpiperidin-4-amine CN(Cc1c(Cl)cccc1Cl)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 40.4 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001320 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 32 1-((2-Chlorothiazol-5-yl)methyl)-N-(3,4-dichlorobenzyl)piperidin-4-amine Clc1sc(CN2CCC(CC2)NCc3ccc(Cl)c(Cl)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 25.1 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001321 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 33 1-((2-Chlorothiazol-5-yl)methyl)-N-(4-fluorobenzyl)piperidin-4-amine Fc1ccc(CNC2CCN(CC2)Cc3sc(Cl)nc3)cc1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 40.4 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001322 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 34 N-(3-chlorobenzyl)-1-((2-chlorothiazol-5-yl)methyl)piperidin-4-amine Clc1sc(CN2CCC(CC2)NCc3cccc(Cl)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 4.1 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001323 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 35 N-(4-fluorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(F)cc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 30.9 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001324 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 36 4-((Methyl(1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-yl)amino)methyl) benzonitrile CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(cc3)C#N Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 86.1 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001325 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 37 N-(2-chloro-6-fluorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3c(F)cccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 78.3 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001326 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 38 N-(3,4-dichlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 12.9 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001327 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 39 N-(3-chlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3cccc(Cl)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 24.4 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001328 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 40 N-(2,4-dichlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(Cl)cc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 80.7 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001329 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 41 2-((Methyl(1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-yl)amino)methyl) benzonitrile CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccccc3C#N Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 80.7 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001330 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 42 N-methyl-N-(4-methylbenzyl)-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(C)cc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 42 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001331 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 47 N-(2-chlorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 35.8 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001332 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 44 N-(2,5-dichlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 29.4 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001333 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 45 N-(3-fluorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3cccc(F)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 35.2 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001334 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 46 N-(2-chlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 34.2 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001335 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 43 N-(2,6-dichlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3c(Cl)cccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 71 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001336 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 48 4-(((1-(2-Methoxypyrimidin-4-yl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(cc3)C#N Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 16.6 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001337 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 49 2-(((1-(2-Methoxypyrimidin-4-yl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccccc3C#N Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 74.3 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001338 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 50 1-(2-Methoxypyrimidin-4-yl)-N-methyl-N-(4-methylbenzyl)piperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(C)cc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 13.5 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001339 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 51 N-(2,5-dichlorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 11.7 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001340 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 52 N-(3,4-dichlorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 16.8 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001341 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 53 N-(2-chloro-6-fluorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3c(F)cccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 17.2 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001342 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 54 N-(3-chlorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3cccc(Cl)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 15.1 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001343 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 55 N-(3-fluorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3cccc(F)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 3.9 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001344 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 56 N-(4-fluorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(F)cc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 9 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001345 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 57 N-(2-chlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 29 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001346 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 58 1-(6-Methoxypyrimidin-4-yl)-N-methyl-N-(4-methylbenzyl)piperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccc(C)cc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 22 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001347 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 59 N-(2,6-dichlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3c(Cl)cccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 19.2 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001348 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 60 N-(3,4-dichlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 28 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001349 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 61 N-(4-fluorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccc(F)cc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 5.7 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001350 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 62 N-(3-chlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3cccc(Cl)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 24.8 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001351 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 63 N-(2-chloro-6-fluorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3c(F)cccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 16.6 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001352 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 64 2-(((1-(6-Methoxypyrimidin-4-yl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccccc3C#N Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 16.8 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001353 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 65 4-(((1-(6-Methoxypyrimidin-4-yl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccc(cc3)C#N Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 8.8 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001354 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 66 N-(2,5-dichlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 9.4 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001355 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 67 N-(2,5-dichlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 30.1 at 5 uM Luminescence based viability assay NA NA NA SK/ LapR1.0 Cancer HSPMDB001356 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity Lapatinib N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 42.6 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001357 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 1 N-(3-Chlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3cccc(Cl)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 41.2 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001358 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 2 2-(((1-((2-Ethoxythiazol-5-yl)methyl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile CCOc1sc(CN2CCC(CC2)N(C)Cc3ccccc3C#N)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 43.8 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001359 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 3 N-(3,4-dichlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 71.6 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001360 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 4 4-(((1-((2-Ethoxythiazol-5-yl)methyl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile CCOc1sc(CN2CCC(CC2)N(C)Cc3ccc(cc3)C#N)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 70.5 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001361 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 5 N-(2-chloro-6-fluorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3c(F)cccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 67.4 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001362 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 6 N-(2-chlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3ccccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 36.4 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001363 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 7 1-((2-Ethoxythiazol-5-yl)methyl)-N-(4-fluorobenzyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3ccc(F)cc3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 52.9 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001364 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 8 N-(2,4-dichlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3ccc(Cl)cc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 71.3 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001365 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 9 N-(2,6-dichlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3c(Cl)cccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 51.5 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001366 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 10 N-(2,5-dichlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 23.9 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001367 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 11 N-methyl-N-(2-methylbenzyl)-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3ccccc3C)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 35.1 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001368 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 12 N-methyl-N-(4-methylbenzyl)-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(C)cc3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 67.1 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001369 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 13 N-(3-fluorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3cccc(F)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 44.2 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001370 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 14 N-(3-chlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3cccc(Cl)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 62.3 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001371 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 15 N-(4-fluorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(F)cc3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 67.4 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001372 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 16 N-(3,4-dichlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 69.9 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001373 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 17 N-(2-chloro-6-fluorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl) piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3c(F)cccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 65.3 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001374 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 18 N-(2,6-dichlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3c(Cl)cccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 63.7 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001375 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 19 N-(2,4-dichlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(Cl)cc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 72.4 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001376 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 20 N-(2,5-dichlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 59.4 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001377 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 21 2-(((1-((2-Chlorothiazol-5-yl)methyl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile CN(Cc1ccccc1C#N)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 8.2 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001378 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 22 4-(((1-((2-Chlorothiazol-5-yl)methyl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile CN(Cc1ccc(cc1)C#N)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 68.5 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001379 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 23 1-((2-Chlorothiazol-5-yl)methyl)-N-(4-fluorobenzyl)-N-methylpiperidin-4-amine CN(Cc1ccc(F)cc1)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 11 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001380 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 24 1-((2-Chlorothiazol-5-yl)methyl)-N-(3,4-dichlorobenzyl)-N-methylpiperidin-4-amine CN(Cc1ccc(Cl)c(Cl)c1)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 63.8 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001381 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 25 N-(3-chlorobenzyl)-1-((2-chlorothiazol-5-yl)methyl)-N-methylpiperidin-4-amine CN(Cc1cccc(Cl)c1)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 12.6 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001382 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 26 N-(2-chloro-6-fluorobenzyl)-1-((2-chlorothiazol-5-yl)methyl)-N-methylpiperidin-4-amine CN(Cc1c(F)cccc1Cl)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 22.4 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001383 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 27 1-((2-Chlorothiazol-5-yl)methyl)-N-(2,4-dichlorobenzyl)-N-methylpiperidin-4-amine CN(Cc1ccc(Cl)cc1Cl)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 60.8 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001384 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 28 1-((2-Chlorothiazol-5-yl)methyl)-N-methyl-N-(2-methylbenzyl)piperidin-4-amine CN(Cc1ccccc1C)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 3.5 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001385 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 29 1-((2-Chlorothiazol-5-yl)methyl)-N-methyl-N-(4-methylbenzyl)piperidin-4-amine CN(Cc1ccc(C)cc1)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 29.6 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001386 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 30 1-((2-Chlorothiazol-5-yl)methyl)-N-(3-fluorobenzyl)-N-methylpiperidin-4-amine CN(Cc1cccc(F)c1)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 4.4 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001387 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 31 1-((2-Chlorothiazol-5-yl)methyl)-N-(2,6-dichlorobenzyl)-N-methylpiperidin-4-amine CN(Cc1c(Cl)cccc1Cl)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 72.4 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001388 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 32 1-((2-Chlorothiazol-5-yl)methyl)-N-(3,4-dichlorobenzyl)piperidin-4-amine Clc1sc(CN2CCC(CC2)NCc3ccc(Cl)c(Cl)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 32.9 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001389 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 33 1-((2-Chlorothiazol-5-yl)methyl)-N-(4-fluorobenzyl)piperidin-4-amine Fc1ccc(CNC2CCN(CC2)Cc3sc(Cl)nc3)cc1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 72.4 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001390 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 34 N-(3-chlorobenzyl)-1-((2-chlorothiazol-5-yl)methyl)piperidin-4-amine Clc1sc(CN2CCC(CC2)NCc3cccc(Cl)c3)cn1 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 2.4 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001391 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 35 N-(4-fluorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(F)cc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 82.3 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001392 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 36 4-((Methyl(1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-yl)amino)methyl) benzonitrile CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(cc3)C#N Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 82.4 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001393 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 37 N-(2-chloro-6-fluorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3c(F)cccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 84.2 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001394 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 38 N-(3,4-dichlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 60 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001395 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 39 N-(3-chlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3cccc(Cl)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 65.7 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001396 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 40 N-(2,4-dichlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(Cl)cc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 68.7 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001397 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 41 2-((Methyl(1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-yl)amino)methyl) benzonitrile CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccccc3C#N Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 68.7 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001398 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 42 N-methyl-N-(4-methylbenzyl)-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(C)cc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 66.6 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001399 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 47 N-(2-chlorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 60.8 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001400 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 44 N-(2,5-dichlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 69.3 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001401 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 45 N-(3-fluorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3cccc(F)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 66.2 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001402 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 46 N-(2-chlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 45.3 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001403 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 43 N-(2,6-dichlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3c(Cl)cccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 79.2 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001404 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 48 4-(((1-(2-Methoxypyrimidin-4-yl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(cc3)C#N Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 66.2 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001405 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 49 2-(((1-(2-Methoxypyrimidin-4-yl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccccc3C#N Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 79.5 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001406 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 50 1-(2-Methoxypyrimidin-4-yl)-N-methyl-N-(4-methylbenzyl)piperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(C)cc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 68.9 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001407 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 51 N-(2,5-dichlorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 50.6 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001408 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 52 N-(3,4-dichlorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 60.2 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001409 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 53 N-(2-chloro-6-fluorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3c(F)cccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 64.7 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001410 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 54 N-(3-chlorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3cccc(Cl)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 56.7 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001411 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 55 N-(3-fluorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3cccc(F)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 27.9 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001412 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 56 N-(4-fluorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(F)cc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 40.4 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001413 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 57 N-(2-chlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 46.7 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001414 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 58 1-(6-Methoxypyrimidin-4-yl)-N-methyl-N-(4-methylbenzyl)piperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccc(C)cc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 13.4 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001415 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 59 N-(2,6-dichlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3c(Cl)cccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 65.1 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001416 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 60 N-(3,4-dichlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 12.7 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001417 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 61 N-(4-fluorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccc(F)cc3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 5 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001418 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 62 N-(3-chlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3cccc(Cl)c3 Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 23.8 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001419 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 63 N-(2-chloro-6-fluorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3c(F)cccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 59.4 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001420 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 64 2-(((1-(6-Methoxypyrimidin-4-yl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccccc3C#N Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 66.1 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001421 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 65 4-(((1-(6-Methoxypyrimidin-4-yl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccc(cc3)C#N Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 46.1 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001422 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 66 N-(2,5-dichlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 61.1 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001423 25935385 Hsp70 Hsc70 (HSPA8) and Hsp72 (HSPA1A) Human Cytosol and nucleus NA Antiproliferative activity 67 N-(2,5-dichlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1cc(ncn1)N2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl Piperidine derivative NA NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) NA 9.4 at 5 uM Luminescence based viability assay NA NA NA MDA-MB-453 Cancer HSPMDB001424 25935385 Hsp70 Hsp70 Human Cytosol Binding affinity NA VER-155008 4-[[(2R,3S,4R,5R)-5-[6-amino-8-[(3,4-dichlorophenyl)methylamino]purin-9-yl]-3,4-dihydroxyoxolan-2-yl]methoxymethyl]benzonitrile Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc5ccc(Cl)c(Cl)c5)nc12 Piperidine derivative NA 0.206 NA NA NA NA NA NA Nucleotide binding domain (allosteric site) Surface plasmon resonance (SPR) NA NA NA NA NA NA Cancer HSPMDB001425 25935385 Hsp70 Hsp70 Human Cytosol Binding affinity NA 12 N-methyl-N-(4-methylbenzyl)-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(C)cc3)cn1 Piperidine derivative NA 0.1999 NA NA NA NA NA NA Nucleotide binding domain (allosteric site) Surface plasmon resonance (SPR) NA NA NA NA NA NA Cancer HSPMDB001426 25935385 Hsp70 Hsp70 Human Cytosol Binding affinity NA 14 N-(3-chlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3cccc(Cl)c3)cn1 Piperidine derivative NA 2.454 NA NA NA NA NA NA Nucleotide binding domain (allosteric site) Surface plasmon resonance (SPR) NA NA NA NA NA NA Cancer HSPMDB001427 25935385 Hsp70 Hsp70 Human Cytosol Binding affinity NA 35 N-(4-fluorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(F)cc3 Piperidine derivative NA 2.045 NA NA NA NA NA NA Nucleotide binding domain (allosteric site) Surface plasmon resonance (SPR) NA NA NA NA NA NA Cancer HSPMDB001428 25935385 Hsp70 Hsp70 Human Cytosol Binding affinity NA 36 4-((Methyl(1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-yl)amino)methyl) benzonitrile CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(cc3)C#N Piperidine derivative NA 0.2463 NA NA NA NA NA NA Nucleotide binding domain (allosteric site) Surface plasmon resonance (SPR) NA NA NA NA NA NA Cancer HSPMDB001429 25935385 Hsp70 Hsp70 Human Cytosol Binding affinity NA 56 N-(4-fluorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(F)cc3 Piperidine derivative NA 2.811 NA NA NA NA NA NA Nucleotide binding domain (allosteric site) Surface plasmon resonance (SPR) NA NA NA NA NA NA Cancer HSPMDB001430 25935385 Hsp70 DnaK:DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA 4 4-(((1-((2-Ethoxythiazol-5-yl)methyl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile CCOc1sc(CN2CCC(CC2)N(C)Cc3ccc(cc3)C#N)cn1 Piperidine derivative 5.49% at 200 uM NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) ATPase assay NA NA NA NA NA NA Bacterial infection HSPMDB001431 25935385 Hsp70 DnaK:DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA 8 N-(2,4-dichlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine CCOc1sc(CN2CCC(CC2)N(C)Cc3ccc(Cl)cc3Cl)cn1 Piperidine derivative 4.5% at 200 uM NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) ATPase assay NA NA NA NA NA NA Bacterial infection HSPMDB001432 25935385 Hsp70 DnaK:DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA 12 N-methyl-N-(4-methylbenzyl)-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(C)cc3)cn1 Piperidine derivative 10.59% at 200 uM NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) ATPase assay NA NA NA NA NA NA Bacterial infection HSPMDB001433 25935385 Hsp70 DnaK:DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA 16 N-(3,4-dichlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3)cn1 Piperidine derivative 10.74% at 200 uM NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) ATPase assay NA NA NA NA NA NA Bacterial infection HSPMDB001434 25935385 Hsp70 DnaK:DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA 19 N-(2,4-dichlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(Cl)cc3Cl)cn1 Piperidine derivative 6.21% at 200 uM NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) ATPase assay NA NA NA NA NA NA Bacterial infection HSPMDB001435 25935385 Hsp70 DnaK:DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA 22 4-(((1-((2-Chlorothiazol-5-yl)methyl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile CN(Cc1ccc(cc1)C#N)C2CCN(CC2)Cc3sc(Cl)nc3 Piperidine derivative 11.28% at 200 uM NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) ATPase assay NA NA NA NA NA NA Bacterial infection HSPMDB001436 25935385 Hsp70 DnaK:DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA 35 N-(4-fluorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(F)cc3 Piperidine derivative 7.73% at 200 uM NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) ATPase assay NA NA NA NA NA NA Bacterial infection HSPMDB001437 25935385 Hsp70 DnaK:DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA 36 4-((Methyl(1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-yl)amino)methyl) benzonitrile CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(cc3)C#N Piperidine derivative 8.14% at 200 uM NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) ATPase assay NA NA NA NA NA NA Bacterial infection HSPMDB001438 25935385 Hsp70 DnaK:DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA 37 N-(2-chloro-6-fluorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3c(F)cccc3Cl Piperidine derivative 20.39% at 200 uM NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) ATPase assay NA NA NA NA NA NA Bacterial infection HSPMDB001439 25935385 Hsp70 DnaK:DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA 40 N-(2,4-dichlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(Cl)cc3Cl Piperidine derivative 8.28% at 200 uM NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) ATPase assay NA NA NA NA NA NA Bacterial infection HSPMDB001440 25935385 Hsp70 DnaK:DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA 41 2-((Methyl(1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-yl)amino)methyl) benzonitrile CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccccc3C#N Piperidine derivative 16.67% at 200 uM NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) ATPase assay NA NA NA NA NA NA Bacterial infection HSPMDB001441 25935385 Hsp70 DnaK:DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA 43 N-(2,6-dichlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3c(Cl)cccc3Cl Piperidine derivative 12.81% at 200 uM NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) ATPase assay NA NA NA NA NA NA Bacterial infection HSPMDB001442 25935385 Hsp70 DnaK:DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA 46 N-(2-chlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccccc3Cl Piperidine derivative 11.63% at 200 uM NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) ATPase assay NA NA NA NA NA NA Bacterial infection HSPMDB001443 25935385 Hsp70 DnaK:DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity NA 47 N-(2-chlorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccccc3Cl Piperidine derivative 6.11% at 200 uM NA NA NA NA NA NA NA Nucleotide binding domain (allosteric site) ATPase assay NA NA NA NA NA NA Bacterial infection HSPMDB001444 28615625 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity Az 4-[[2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)imidazol-1-yl]methyl]benzamide COc1ccc(cc1)c2nc(n(Cc3ccc(cc3)C(N)=O)c2c4ccc(OC)cc4)c5cc(cc(c5)C(F)(F)F)C(F)(F)F Piperidine derivative NA NA NA 2.8 NA NA NA NA Nucleotide binding domain NA NA MTT viability assay NA NA NA HL60 Cancer HSPMDB001445 28615625 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity Az-GA (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-({2-[2-(2-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}ethoxy)ethoxy]ethyl}amino)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate CO[C@H]1C[C@H](C)CC2=C(NCCOCCOCCNC(=O)C3=CC=C(CN4C(=NC(=C4C4=CC=C(OC)C=C4)C4=CC=C(OC)C=C4)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C=C3)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O Hybrid of HSP70 and HSP90 inhibitor NA NA NA 0.73 NA NA NA NA Nucleotide binding domain NA NA MTT viability assay NA NA NA HL60 Cancer HSPMDB001446 28615625 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity Az-O3-GD (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-(16-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}-5,9,13-trioxa-1-azahexadecan-1-yl)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate CO[C@H]1C[C@H](C)CC2=C(NCCCOCCCOCCCOCCCNC(=O)C3=CC=C(CN4C(=NC(=C4C4=CC=C(OC)C=C4)C4=CC=C(OC)C=C4)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C=C3)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O Hybrid of HSP70 and HSP90 inhibitor NA NA NA 0.74 NA NA NA NA Nucleotide binding domain NA NA MTT viability assay NA NA NA HL60 Cancer HSPMDB001447 28615625 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity Az-amide-GD (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-[13-({2-[2-(2-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}ethoxy)ethoxy]ethyl}carbamoyl)-4,8,12-trioxa-1-azatridecan-1-yl]-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate CO[C@H]1C[C@H](C)CC2=C(NCCOCCCOCCCOCC(=O)NCCOCCOCCNC(=O)C3=CC=C(CN4C(=NC(=C4C4=CC=C(OC)C=C4)C4=CC=C(OC)C=C4)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C=C3)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O Hybrid of HSP70 and HSP90 inhibitor NA NA NA >10 NA NA NA NA Nucleotide binding domain NA NA MTT viability assay NA NA NA HL60 Cancer HSPMDB001448 28615625 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity Az-O3-Imatinib 4-{[4-(2-{[(2-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}ethoxy)methoxy]methoxy}ethyl)piperazin-1-yl]methyl}-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide COC1=CC=C(C=C1)C1=C(N(CC2=CC=C(C=C2)C(=O)NCCOCOCOCCN2CCN(CC3=CC=C(C=C3)C(=O)NC3=CC(NC4=NC(=CC=N4)C4=CC=CN=C4)=C(C)C=C3)CC2)C(=N1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)C1=CC=C(OC)C=C1 Hybrid of HSP70 and HSP90 inhibitor NA NA NA >10 NA NA NA NA Nucleotide binding domain NA NA MTT viability assay NA NA NA HL60 Cancer HSPMDB001449 28615625 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity Az-O4-Imatinib 4-{[4-(11-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}-3,5,7,9-tetraoxaundecan-1-yl)piperazin-1-yl]methyl}-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide COC1=CC=C(C=C1)C1=C(N(CC2=CC=C(C=C2)C(=O)NCCOCOCOCOCCN2CCN(CC3=CC=C(C=C3)C(=O)NC3=CC(NC4=NC(=CC=N4)C4=CC=CN=C4)=C(C)C=C3)CC2)C(=N1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)C1=CC=C(OC)C=C1 Hybrid of HSP70 and HSP90 inhibitor NA NA NA >10 NA NA NA NA Nucleotide binding domain NA NA MTT viability assay NA NA NA HL60 Cancer HSPMDB001450 28615625 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity Az 4-[[2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)imidazol-1-yl]methyl]benzamide COc1ccc(cc1)c2nc(n(Cc3ccc(cc3)C(N)=O)c2c4ccc(OC)cc4)c5cc(cc(c5)C(F)(F)F)C(F)(F)F Imidazole derivative NA NA NA 3.3 NA NA NA NA Nucleotide binding domain NA NA MTT viability assay NA NA NA KG-1 Cancer HSPMDB001451 28615625 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity Az-GA (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-({2-[2-(2-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}ethoxy)ethoxy]ethyl}amino)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate CO[C@H]1C[C@H](C)CC2=C(NCCOCCOCCNC(=O)C3=CC=C(CN4C(=NC(=C4C4=CC=C(OC)C=C4)C4=CC=C(OC)C=C4)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C=C3)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O Hybrid of HSP70 and HSP90 inhibitor NA NA NA 0.91 NA NA NA NA Nucleotide binding domain NA NA MTT viability assay NA NA NA KG-1 Cancer HSPMDB001452 28615625 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity Az-O3-GD (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-(16-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}-5,9,13-trioxa-1-azahexadecan-1-yl)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate CO[C@H]1C[C@H](C)CC2=C(NCCCOCCCOCCCOCCCNC(=O)C3=CC=C(CN4C(=NC(=C4C4=CC=C(OC)C=C4)C4=CC=C(OC)C=C4)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C=C3)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O Hybrid of HSP70 and HSP90 inhibitor NA NA NA 1.31 NA NA NA NA Nucleotide binding domain NA NA MTT viability assay NA NA NA KG-1 Cancer HSPMDB001453 28615625 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity Az-amide-GD (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-[13-({2-[2-(2-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}ethoxy)ethoxy]ethyl}carbamoyl)-4,8,12-trioxa-1-azatridecan-1-yl]-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate CO[C@H]1C[C@H](C)CC2=C(NCCOCCCOCCCOCC(=O)NCCOCCOCCNC(=O)C3=CC=C(CN4C(=NC(=C4C4=CC=C(OC)C=C4)C4=CC=C(OC)C=C4)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C=C3)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O Hybrid of HSP70 and HSP90 inhibitor NA NA NA >10 NA NA NA NA Nucleotide binding domain NA NA MTT viability assay NA NA NA KG-1 Cancer HSPMDB001454 28615625 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity Az-O3-Imatinib 4-{[4-(2-{[(2-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}ethoxy)methoxy]methoxy}ethyl)piperazin-1-yl]methyl}-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide COC1=CC=C(C=C1)C1=C(N(CC2=CC=C(C=C2)C(=O)NCCOCOCOCCN2CCN(CC3=CC=C(C=C3)C(=O)NC3=CC(NC4=NC(=CC=N4)C4=CC=CN=C4)=C(C)C=C3)CC2)C(=N1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)C1=CC=C(OC)C=C1 Hybrid of HSP70 and HSP90 inhibitor NA NA NA >10 NA NA NA NA Nucleotide binding domain NA NA MTT viability assay NA NA NA KG-1 Cancer HSPMDB001455 28615625 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity Az-O4-Imatinib 4-{[4-(11-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}-3,5,7,9-tetraoxaundecan-1-yl)piperazin-1-yl]methyl}-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide COC1=CC=C(C=C1)C1=C(N(CC2=CC=C(C=C2)C(=O)NCCOCOCOCOCCN2CCN(CC3=CC=C(C=C3)C(=O)NC3=CC(NC4=NC(=CC=N4)C4=CC=CN=C4)=C(C)C=C3)CC2)C(=N1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)C1=CC=C(OC)C=C1 Hybrid of HSP70 and HSP90 inhibitor NA NA NA >10 NA NA NA NA Nucleotide binding domain NA NA MTT viability assay NA NA NA KG-1 Cancer HSPMDB001456 28615625 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity Az 4-[[2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)imidazol-1-yl]methyl]benzamide COc1ccc(cc1)c2nc(n(Cc3ccc(cc3)C(N)=O)c2c4ccc(OC)cc4)c5cc(cc(c5)C(F)(F)F)C(F)(F)F Imidazole derivative NA NA NA 3.7 NA NA NA NA Nucleotide binding domain NA NA MTT viability assay NA NA NA THP1 Cancer HSPMDB001457 28615625 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity Az-GA (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-({2-[2-(2-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}ethoxy)ethoxy]ethyl}amino)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate CO[C@H]1C[C@H](C)CC2=C(NCCOCCOCCNC(=O)C3=CC=C(CN4C(=NC(=C4C4=CC=C(OC)C=C4)C4=CC=C(OC)C=C4)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C=C3)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O Hybrid of HSP70 and HSP90 inhibitor NA NA NA 0.36 NA NA NA NA Nucleotide binding domain NA NA MTT viability assay NA NA NA THP1 Cancer HSPMDB001458 28615625 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity Az-O3-GD (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-(16-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}-5,9,13-trioxa-1-azahexadecan-1-yl)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate CO[C@H]1C[C@H](C)CC2=C(NCCCOCCCOCCCOCCCNC(=O)C3=CC=C(CN4C(=NC(=C4C4=CC=C(OC)C=C4)C4=CC=C(OC)C=C4)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C=C3)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O Hybrid of HSP70 and HSP90 inhibitor NA NA NA 0.62 NA NA NA NA Nucleotide binding domain NA NA MTT viability assay NA NA NA THP1 Cancer HSPMDB001459 28615625 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity Az-amide-GD (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-[13-({2-[2-(2-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}ethoxy)ethoxy]ethyl}carbamoyl)-4,8,12-trioxa-1-azatridecan-1-yl]-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate CO[C@H]1C[C@H](C)CC2=C(NCCOCCCOCCCOCC(=O)NCCOCCOCCNC(=O)C3=CC=C(CN4C(=NC(=C4C4=CC=C(OC)C=C4)C4=CC=C(OC)C=C4)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C=C3)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O Hybrid of HSP70 and HSP90 inhibitor NA NA NA >10 NA NA NA NA Nucleotide binding domain NA NA MTT viability assay NA NA NA THP1 Cancer HSPMDB001460 28615625 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity Az-O3-Imatinib 4-{[4-(2-{[(2-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}ethoxy)methoxy]methoxy}ethyl)piperazin-1-yl]methyl}-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide COC1=CC=C(C=C1)C1=C(N(CC2=CC=C(C=C2)C(=O)NCCOCOCOCCN2CCN(CC3=CC=C(C=C3)C(=O)NC3=CC(NC4=NC(=CC=N4)C4=CC=CN=C4)=C(C)C=C3)CC2)C(=N1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)C1=CC=C(OC)C=C1 Hybrid of HSP70 and HSP90 inhibitor NA NA NA >10 NA NA NA NA Nucleotide binding domain NA NA MTT viability assay NA NA NA THP1 Cancer HSPMDB001461 28615625 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity Az-O4-Imatinib 4-{[4-(11-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}-3,5,7,9-tetraoxaundecan-1-yl)piperazin-1-yl]methyl}-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide COC1=CC=C(C=C1)C1=C(N(CC2=CC=C(C=C2)C(=O)NCCOCOCOCOCCN2CCN(CC3=CC=C(C=C3)C(=O)NC3=CC(NC4=NC(=CC=N4)C4=CC=CN=C4)=C(C)C=C3)CC2)C(=N1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)C1=CC=C(OC)C=C1 Hybrid of HSP70 and HSP90 inhibitor NA NA NA >10 NA NA NA NA Nucleotide binding domain NA NA MTT viability assay NA NA NA THP1 Cancer HSPMDB001462 28615625 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity Az 4-[[2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)imidazol-1-yl]methyl]benzamide COc1ccc(cc1)c2nc(n(Cc3ccc(cc3)C(N)=O)c2c4ccc(OC)cc4)c5cc(cc(c5)C(F)(F)F)C(F)(F)F Imidazole derivative NA NA NA 4.7 NA NA NA NA Nucleotide binding domain NA NA MTT viability assay NA NA NA U937 Cancer HSPMDB001463 28615625 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity Az-GA (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-({2-[2-(2-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}ethoxy)ethoxy]ethyl}amino)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate CO[C@H]1C[C@H](C)CC2=C(NCCOCCOCCNC(=O)C3=CC=C(CN4C(=NC(=C4C4=CC=C(OC)C=C4)C4=CC=C(OC)C=C4)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C=C3)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O Hybrid of HSP70 and HSP90 inhibitor NA NA NA 1.12 NA NA NA NA Nucleotide binding domain NA NA MTT viability assay NA NA NA U937 Cancer HSPMDB001464 28615625 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity Az-O3-GD (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-(16-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}-5,9,13-trioxa-1-azahexadecan-1-yl)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate CO[C@H]1C[C@H](C)CC2=C(NCCCOCCCOCCCOCCCNC(=O)C3=CC=C(CN4C(=NC(=C4C4=CC=C(OC)C=C4)C4=CC=C(OC)C=C4)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C=C3)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O Hybrid of HSP70 and HSP90 inhibitor NA NA NA 1.12 NA NA NA NA Nucleotide binding domain NA NA MTT viability assay NA NA NA U937 Cancer HSPMDB001465 28615625 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity Az-amide-GD (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-[13-({2-[2-(2-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}ethoxy)ethoxy]ethyl}carbamoyl)-4,8,12-trioxa-1-azatridecan-1-yl]-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate CO[C@H]1C[C@H](C)CC2=C(NCCOCCCOCCCOCC(=O)NCCOCCOCCNC(=O)C3=CC=C(CN4C(=NC(=C4C4=CC=C(OC)C=C4)C4=CC=C(OC)C=C4)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C=C3)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O Hybrid of HSP70 and HSP90 inhibitor NA NA NA >10 NA NA NA NA Nucleotide binding domain NA NA MTT viability assay NA NA NA U937 Cancer HSPMDB001466 28615625 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity Az-O3-Imatinib 4-{[4-(2-{[(2-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}ethoxy)methoxy]methoxy}ethyl)piperazin-1-yl]methyl}-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide COC1=CC=C(C=C1)C1=C(N(CC2=CC=C(C=C2)C(=O)NCCOCOCOCCN2CCN(CC3=CC=C(C=C3)C(=O)NC3=CC(NC4=NC(=CC=N4)C4=CC=CN=C4)=C(C)C=C3)CC2)C(=N1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)C1=CC=C(OC)C=C1 Hybrid of HSP70 and HSP90 inhibitor NA NA NA >10 NA NA NA NA Nucleotide binding domain NA NA MTT viability assay NA NA NA U937 Cancer HSPMDB001467 28615625 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity Az-O4-Imatinib 4-{[4-(11-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}-3,5,7,9-tetraoxaundecan-1-yl)piperazin-1-yl]methyl}-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide COC1=CC=C(C=C1)C1=C(N(CC2=CC=C(C=C2)C(=O)NCCOCOCOCOCCN2CCN(CC3=CC=C(C=C3)C(=O)NC3=CC(NC4=NC(=CC=N4)C4=CC=CN=C4)=C(C)C=C3)CC2)C(=N1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)C1=CC=C(OC)C=C1 Hybrid of HSP70 and HSP90 inhibitor NA NA NA >10 NA NA NA NA Nucleotide binding domain NA NA MTT viability assay NA NA NA U937 Cancer HSPMDB001468 28615625 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity Az 4-[[2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)imidazol-1-yl]methyl]benzamide COc1ccc(cc1)c2nc(n(Cc3ccc(cc3)C(N)=O)c2c4ccc(OC)cc4)c5cc(cc(c5)C(F)(F)F)C(F)(F)F Imidazole derivative NA NA NA 3.1 NA NA NA NA Nucleotide binding domain NA NA MTT viability assay NA NA NA Jurkat Cancer HSPMDB001469 28615625 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity Az-GA (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-({2-[2-(2-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}ethoxy)ethoxy]ethyl}amino)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate CO[C@H]1C[C@H](C)CC2=C(NCCOCCOCCNC(=O)C3=CC=C(CN4C(=NC(=C4C4=CC=C(OC)C=C4)C4=CC=C(OC)C=C4)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C=C3)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O Hybrid of HSP70 and HSP90 inhibitor NA NA NA 0.89 NA NA NA NA Nucleotide binding domain NA NA MTT viability assay NA NA NA Jurkat Cancer HSPMDB001470 28615625 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity Az-O3-GD (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-(16-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}-5,9,13-trioxa-1-azahexadecan-1-yl)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate CO[C@H]1C[C@H](C)CC2=C(NCCCOCCCOCCCOCCCNC(=O)C3=CC=C(CN4C(=NC(=C4C4=CC=C(OC)C=C4)C4=CC=C(OC)C=C4)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C=C3)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O Hybrid of HSP70 and HSP90 inhibitor NA NA NA 0.57 NA NA NA NA Nucleotide binding domain NA NA MTT viability assay NA NA NA Jurkat Cancer HSPMDB001471 28615625 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity Az-amide-GD (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-[13-({2-[2-(2-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}ethoxy)ethoxy]ethyl}carbamoyl)-4,8,12-trioxa-1-azatridecan-1-yl]-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate CO[C@H]1C[C@H](C)CC2=C(NCCOCCCOCCCOCC(=O)NCCOCCOCCNC(=O)C3=CC=C(CN4C(=NC(=C4C4=CC=C(OC)C=C4)C4=CC=C(OC)C=C4)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C=C3)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O Hybrid of HSP70 and HSP90 inhibitor NA NA NA >10 NA NA NA NA Nucleotide binding domain NA NA MTT viability assay NA NA NA Jurkat Cancer HSPMDB001472 28615625 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity Az-O3-Imatinib 4-{[4-(2-{[(2-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}ethoxy)methoxy]methoxy}ethyl)piperazin-1-yl]methyl}-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide COC1=CC=C(C=C1)C1=C(N(CC2=CC=C(C=C2)C(=O)NCCOCOCOCCN2CCN(CC3=CC=C(C=C3)C(=O)NC3=CC(NC4=NC(=CC=N4)C4=CC=CN=C4)=C(C)C=C3)CC2)C(=N1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)C1=CC=C(OC)C=C1 Hybrid of HSP70 and HSP90 inhibitor NA NA NA >10 NA NA NA NA Nucleotide binding domain NA NA MTT viability assay NA NA NA Jurkat Cancer HSPMDB001473 28615625 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity Az-O4-Imatinib 4-{[4-(11-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}-3,5,7,9-tetraoxaundecan-1-yl)piperazin-1-yl]methyl}-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide COC1=CC=C(C=C1)C1=C(N(CC2=CC=C(C=C2)C(=O)NCCOCOCOCOCCN2CCN(CC3=CC=C(C=C3)C(=O)NC3=CC(NC4=NC(=CC=N4)C4=CC=CN=C4)=C(C)C=C3)CC2)C(=N1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)C1=CC=C(OC)C=C1 Hybrid of HSP70 and HSP90 inhibitor NA NA NA >10 NA NA NA NA Nucleotide binding domain NA NA MTT viability assay NA NA NA Jurkat Cancer HSPMDB001474 28615625 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity Az 4-[[2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)imidazol-1-yl]methyl]benzamide COc1ccc(cc1)c2nc(n(Cc3ccc(cc3)C(N)=O)c2c4ccc(OC)cc4)c5cc(cc(c5)C(F)(F)F)C(F)(F)F Imidazole derivative NA NA NA 3.6 NA NA NA NA Nucleotide binding domain NA NA MTT viability assay NA NA NA K562 Cancer HSPMDB001475 28615625 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity Az-GA (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-({2-[2-(2-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}ethoxy)ethoxy]ethyl}amino)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate CO[C@H]1C[C@H](C)CC2=C(NCCOCCOCCNC(=O)C3=CC=C(CN4C(=NC(=C4C4=CC=C(OC)C=C4)C4=CC=C(OC)C=C4)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C=C3)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O Hybrid of HSP70 and HSP90 inhibitor NA NA NA 0.63 NA NA NA NA Nucleotide binding domain NA NA MTT viability assay NA NA NA K562 Cancer HSPMDB001476 28615625 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity Az-O3-GD (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-(16-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}-5,9,13-trioxa-1-azahexadecan-1-yl)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate CO[C@H]1C[C@H](C)CC2=C(NCCCOCCCOCCCOCCCNC(=O)C3=CC=C(CN4C(=NC(=C4C4=CC=C(OC)C=C4)C4=CC=C(OC)C=C4)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C=C3)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O Hybrid of HSP70 and HSP90 inhibitor NA NA NA 0.72 NA NA NA NA Nucleotide binding domain NA NA MTT viability assay NA NA NA K562 Cancer HSPMDB001477 28615625 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity Az-amide-GD (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-[13-({2-[2-(2-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}ethoxy)ethoxy]ethyl}carbamoyl)-4,8,12-trioxa-1-azatridecan-1-yl]-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate CO[C@H]1C[C@H](C)CC2=C(NCCOCCCOCCCOCC(=O)NCCOCCOCCNC(=O)C3=CC=C(CN4C(=NC(=C4C4=CC=C(OC)C=C4)C4=CC=C(OC)C=C4)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C=C3)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O Hybrid of HSP70 and HSP90 inhibitor NA NA NA >10 NA NA NA NA Nucleotide binding domain NA NA MTT viability assay NA NA NA K562 Cancer HSPMDB001478 28615625 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity Az-O3-Imatinib 4-{[4-(2-{[(2-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}ethoxy)methoxy]methoxy}ethyl)piperazin-1-yl]methyl}-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide COC1=CC=C(C=C1)C1=C(N(CC2=CC=C(C=C2)C(=O)NCCOCOCOCCN2CCN(CC3=CC=C(C=C3)C(=O)NC3=CC(NC4=NC(=CC=N4)C4=CC=CN=C4)=C(C)C=C3)CC2)C(=N1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)C1=CC=C(OC)C=C1 Hybrid of HSP70 and HSP90 inhibitor NA NA NA 4.3 NA NA NA NA Nucleotide binding domain NA NA MTT viability assay NA NA NA K562 Cancer HSPMDB001479 28615625 Hsp70 Hsc70 (HSPA8) Human Cytosol and nucleus NA Antiproliferative activity Az-O4-Imatinib 4-{[4-(11-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}-3,5,7,9-tetraoxaundecan-1-yl)piperazin-1-yl]methyl}-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide COC1=CC=C(C=C1)C1=C(N(CC2=CC=C(C=C2)C(=O)NCCOCOCOCOCCN2CCN(CC3=CC=C(C=C3)C(=O)NC3=CC(NC4=NC(=CC=N4)C4=CC=CN=C4)=C(C)C=C3)CC2)C(=N1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)C1=CC=C(OC)C=C1 Hybrid of HSP70 and HSP90 inhibitor NA NA NA 4.5 NA NA NA NA Nucleotide binding domain NA NA MTT viability assay NA NA NA K562 Cancer HSPMDB001480 20481474 Hsp70 DnaK (Full length) Bacteria Cytosol and membrane Activation of ATPase activity NA 115-7c 4-{5-[(benzyloxy)carbonyl]-4-(2,4-dichlorophenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-1-yl}butanoic acid CC1=C(C(NC(=O)N1CCCC(O)=O)C1=C(Cl)C=C(Cl)C=C1)C(=O)OCC1=CC=CC=C1 Dihydropyrimidine derivative 50% at 100 uM 220 NA NA NA NA NA NA Nucleotide binding domain ATPase assay NA NA NA NA NA NA NA HSPMDB001481 20481474 Hsp70 DnaK (NBD) Bacteria Cytosol and membrane Activation of ATPase activity NA 115-7c 4-{5-[(benzyloxy)carbonyl]-4-(2,4-dichlorophenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-1-yl}butanoic acid CC1=C(C(NC(=O)N1CCCC(O)=O)C1=C(Cl)C=C(Cl)C=C1)C(=O)OCC1=CC=CC=C1 Dihydropyrimidine derivative 2 fold at 100 uM 211 NA NA NA NA NA NA Nucleotide binding domain ATPase assay NA NA NA NA NA NA NA HSPMDB001482 20481474 Hsp70 DnaK Bacteria Cytosol and membrane Activation of chaperone activity NA 115-7c 4-{5-[(benzyloxy)carbonyl]-4-(2,4-dichlorophenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-1-yl}butanoic acid CC1=C(C(NC(=O)N1CCCC(O)=O)C1=C(Cl)C=C(Cl)C=C1)C(=O)OCC1=CC=CC=C1 Dihydropyrimidine derivative 2 fold at 1 uM NA NA NA NA NA NA NA Nucleotide binding domain Refolding assay (luciferase) NA NA NA NA NA NA NA HSPMDB001483 20481474 Hsp70 DnaK-DnaJ Bacteria Cytosol and membrane Inhibition of ATPase activity (DnaJ stimulated) NA 116-9e 6-{5-[(benzyloxy)carbonyl]-4-{[1,1'-biphenyl]-4-yl}-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-1-yl}hexanoic acid CC1=C(C(NC(=O)N1CCCCCC(O)=O)C1=CC=C(C=C1)C1=CC=CC=C1)C(=O)OCC1=CC=CC=C1 Dihydropyrimidine derivative 80% NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB010219 11036084 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (endogenous) NA NSC-630668-R/1 6-[5-(ethoxycarbonylcarbamoyl)-2,4-dioxopyrimidin-1-yl]hexyl N-[6-[6-[5-(ethoxycarbonylcarbamoyl)-2,4-dioxopyrimidin-1-yl]hexoxycarbonylamino]hexyl]carbamate C(C)OC(=O)NC(=O)C=1C(NC(N(C1)CCCCCCOC(=O)NCCCCCCNC(OCCCCCCN1C(NC(C(=C1)C(NC(=O)OCC)=O)=O)=O)=O)=O)=O DSG analogs 48% NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB010220 11036084 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity (DnaJ stimulated) NA NSC-630668-R/1 6-[5-(ethoxycarbonylcarbamoyl)-2,4-dioxopyrimidin-1-yl]hexyl N-[6-[6-[5-(ethoxycarbonylcarbamoyl)-2,4-dioxopyrimidin-1-yl]hexoxycarbonylamino]hexyl]carbamate C(C)OC(=O)NC(=O)C=1C(NC(N(C1)CCCCCCOC(=O)NCCCCCCNC(OCCCCCCN1C(NC(C(=C1)C(NC(=O)OCC)=O)=O)=O)=O)=O)=O DSG analogs 51% NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB010221 8939938 Hsp70 Ssa1p Yeast Cytosol Inhibition of ATPase activity NA N-ethylmaleimide 1-ethylpyrrole-2,5-dione CCN1C(=O)C=CC1=O NA 100% after 60 min NA NA NA NA NA NA NA NA ATPase assay NA NA NA NA NA NA NA HSPMDB010222 30452489 Hsp70 Hsp70-HDJ2 Human Cytosol NA Antiproliferative activity 116-9e in combination with Hydroxyurea 6-{5-[(benzyloxy)carbonyl]-4-{[1,1'-biphenyl]-4-yl}-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-1-yl}hexanoic acid CC1=C(C(NC(=O)N1CCCCCC(O)=O)C1=CC=C(C=C1)C1=CC=CC=C1)C(=O)OCC1=CC=CC=C1 Dihydropyrimidine derivative NA NA NA NA NA NA NA NA NA NA 60% at 40uM 116-9e and 100 uM Hydroxyurea Luminescence based viability assay NA NA NA HAP1 cells Cancer HSPMDB010223 30452489 Hsp70 Hsp70-HDJ2 Human Cytosol NA Antiproliferative activity 116-9e in combination with Triapine 6-{5-[(benzyloxy)carbonyl]-4-{[1,1'-biphenyl]-4-yl}-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-1-yl}hexanoic acid CC1=C(C(NC(=O)N1CCCCCC(O)=O)C1=CC=C(C=C1)C1=CC=CC=C1)C(=O)OCC1=CC=CC=C1 Dihydropyrimidine derivative NA NA NA NA NA NA NA NA NA NA 99% at 40uM 116-9e and 100 uM Triapine Luminescence based viability assay NA NA NA HAP1 cells Cancer